OBO_ID (LABEL):	CHEBI_17234 (glucose)

ARTICLE	ARTICLE DATE	SENTENCE NUM	SENTENCE	IGNORANCE CATEGORIES	NUM IGNORANCE CATEGORIES	OBO ID (LABEL)
BMJ_2012_Aug_30_345_e5605	8/2012	S9-BMJ_2012_Aug_30_345_e5605	['the rate of Glucose intolerance was also lower in the intervention arm: 21% (67/320) compared with 28% (100/352) of controls had a fasting Glucose of 5.1 mmol/l or greater or a 1 hour Glucose challenge test result of greater than 7.8 mmol/l (p=0.02).']	N/A	N/A	[('CHEBI_17234', 'glucose', 12, 'glucose'), ('CHEBI_17234', 'glucose', 139, 'glucose'), ('CHEBI_17234', 'glucose', 184, 'glucose')]
BMJ_2012_Aug_30_345_e5605	8/2012	S35-BMJ_2012_Aug_30_345_e5605	['fasting blood Glucose was measured and a mid upper Arm circumference recorded.']	N/A	N/A	[('CHEBI_17234', 'glucose', 14, 'glucose'), ('UBERON_0001460', 'arm', 51, 'arm')]
BMJ_2012_Aug_30_345_e5605	8/2012	S38-BMJ_2012_Aug_30_345_e5605	['at 28 weeks’ Gestation, repeat fasting Blood Glucose was measured and Glucose challenge testing one hour after a 50 g Glucose load was carried out.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 13, 'gestation'), ('UBERON_0000178', 'blood', 39, 'blood'), ('CHEBI_17234', 'glucose', 45, 'glucose'), ('CHEBI_17234', 'glucose', 70, 'glucose'), ('CHEBI_17234', 'glucose', 118, 'glucose')]
BMJ_2012_Aug_30_345_e5605	8/2012	S40-BMJ_2012_Aug_30_345_e5605	['Gestational diabetes was diagnosed when an abnormal Glucose challenge test was followed by two or more abnormal values on a three hour 100 g Glucose tolerance test using the carpenter and coustan criteria.23when Gestational diabetes was diagnosed, care continued in the multidisciplinary diabetic clinic.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_17234', 'glucose', 52, 'glucose'), ('CHEBI_17234', 'glucose', 141, 'glucose'), ('GO_0007565', 'female pregnancy', 212, 'gestational')]
BMJ_2012_Aug_30_345_e5605	8/2012	S68-BMJ_2012_Aug_30_345_e5605	['values are mean (sd) unless stated otherwisebaseline characteristicintervention group (n=383)control group (n=398)age (years)32.0 (4.2)32.0 (4.2)Gestational age at recruitment (weeks)13.0 (2.3)12.9 (2.2)weight (kg)73.8 (14.8)73.4 (13.7)height (cm)166.3 (6.4)168.9 (6.5)body mass index (kg/m2)26.8 (5.1)26.8 (4.8)mid upper Arm circumference (cm)29.5 (3.6)29.5 (3.4)fasting Glucose (mmol/l)4.5 (0.36)4.5 (0.38)previous Birth weight (g)4253 (261)4242 (236)no (%) smokers17 (4)12 (3)\n\nprimary outcome\nwe found no significant difference between the two groups in Birth weight at Delivery.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 145, 'Gestational'), ('UBERON_0001460', 'arm', 322, 'arm'), ('CHEBI_17234', 'glucose', 372, 'glucose'), ('GO_0007567', 'parturition', 417, 'birth'), ('GO_0007567', 'parturition', 558, 'birth'), ('GO_0007567', 'parturition', 574, 'delivery')]
BMJ_2012_Aug_30_345_e5605	8/2012	S72-BMJ_2012_Aug_30_345_e5605	['values are mean (sd) unless stated otherwiseoutcomeintervention group (n=372)control group (n=387)mean difference (95% ci)p valuebirth weight (g)4034 (510)4006 (497)28.6 (−45.6 to 102.8)0.449birthweight centile70.5 (25.6)72.8 (25.6)−1.6 (−5.39 to 2.2)0.409no (%) Birth weight >4000 g189 (51)199 (51)—0.88length at Birth (cm)52.9 (2.7)52.6 (2.1)0.263 (−0.13 to 0.655)0.189head circumference at Birth (cm)35.8 (1.3)35.7 (1.5)−0.00225 (−0.231 to 0.227)0.985ponderal index at birth2.76 (3.8)2.75 (0.33)0.011 (−0.36 to 0.39)0.95birthweight difference* from first Pregnancy (g)−214.2 (541)−250.8 (512)−36.6 (−120.15 to 46.95)0.507estimated fetal weight at 34 weeks (g)2631 (326)2616 (368)14.74 (−40.89 to 70.38)0.603fetal Abdominal circumference at 34 weeks (mm)315.8 (16.7)315.6 (19.2)−0.201 (−3.067 to 2.665)0.89fetal anterior Abdominal Wall width at 34 weeks (mm)5.0 (1.3)5.1 (1.2)−0.108 (−0.323 to 0.107)0.323fasting Glucose at 28 weeks (mmol/l)4.45 (0.4)4.51 (0.6)−0.058 (−0.146 to 0.03)0.198Glucose challenge test at 28 weeks (mmol/l)6.47 (1.4)6.67 (1.7)−0.205 (−0.44 to 0.031)0.088cord Blood Glucose (mmol/l)4.17 (1.1)4.16 (1.2)0.014 (−0.19 to 0.217)0.896weight gain at 24 weeks (kg)5.3 (2.7)5.5 (2.7)−0.244 (−0.786 to 0.299)0.378weight gain at 28 weeks (kg)7.1 (2.8)7.7 (3.0)−0.593 (−1.072 to −0.114)0.015weight gain at 34 weeks (kg)10.1 (3.7)10.9 (3.9)−0.83 (−1.48 to −0.182)0.012weight gain at 40 weeks (kg)12.2 (4.4)13.7 (4.9)−1.346 (−2.451 to −0.241)0.017\n*Birth weight in second Pregnancy minus Birth weight in first Pregnancy.']	N/A	N/A	[('GO_0007567', 'parturition', 263, 'birth'), ('GO_0007567', 'parturition', 314, 'birth'), ('GO_0007567', 'parturition', 393, 'birth'), ('GO_0007565', 'female pregnancy', 558, 'pregnancy'), ('UBERON_0000916', 'abdomen', 716, 'abdominal'), ('UBERON_0003697', 'abdominal wall', 823, 'abdominal wall'), ('CHEBI_17234', 'glucose', 915, 'glucose'), ('CHEBI_27415', "(+-)-2-(4'-isobutylphenyl)propionitrile", 988, '198Glucose'), ('UBERON_0000178', 'blood', 1087, 'blood'), ('CHEBI_17234', 'glucose', 1093, 'glucose'), ('GO_0007567', 'parturition', 1463, 'Birth'), ('GO_0007565', 'female pregnancy', 1486, 'pregnancy'), ('GO_0007567', 'parturition', 1502, 'birth'), ('GO_0007565', 'female pregnancy', 1524, 'pregnancy')]
BMJ_2012_Aug_30_345_e5605	8/2012	S80-BMJ_2012_Aug_30_345_e5605	['overall, a significantly higher proportion of women in the control group had a Glucose challenge test result of greater than 7.8 mmol/l at 28 weeks’ Gestation.']	N/A	N/A	[('CHEBI_17234', 'glucose', 79, 'glucose'), ('GO_0007565', 'female pregnancy', 149, 'gestation')]
BMJ_2012_Aug_30_345_e5605	8/2012	S81-BMJ_2012_Aug_30_345_e5605	['similarly, a higher proportion of women in the control arm than in the intervention had either a fasting Glucose at 28 weeks of 5.1 mmol/l or greater or a Glucose challenge test of greater than 7.8 mmol/l.']	N/A	N/A	[('CHEBI_17234', 'glucose', 105, 'glucose'), ('CHEBI_17234', 'glucose', 155, 'glucose')]
BMJ_2012_Aug_30_345_e5605	8/2012	S82-BMJ_2012_Aug_30_345_e5605	['an equal number of women in each arm had formal Glucose tolerance testing, and no significant difference existed in the incidence of Gestational diabetes according to either carpenter and coustan criteria (7 v 9) or the american diabetes association criteria (12 v 18).2328cord Blood Glucose was similar between the two groups (table 3).']	N/A	N/A	[('CHEBI_17234', 'glucose', 48, 'glucose'), ('GO_0007565', 'female pregnancy', 133, 'gestational'), ('UBERON_0000178', 'blood', 278, 'blood'), ('CHEBI_17234', 'glucose', 284, 'glucose')]
BMJ_2012_Aug_30_345_e5605	8/2012	S83-BMJ_2012_Aug_30_345_e5605	['caption (table-wrap): table 3\n\n\u2002comparison of maternal Glucose concentrations at 28 weeks’ Gestation in intervention and control groups.']	N/A	N/A	[('CHEBI_17234', 'glucose', 55, 'glucose'), ('GO_0007565', 'female pregnancy', 91, 'gestation')]
BMJ_2012_Aug_30_345_e5605	8/2012	S84-BMJ_2012_Aug_30_345_e5605	['values are numbers (percentages)measurementintervention groupcontrol group28 week fasting Glucose ≥5.1 mmol/l24/321 (7)41/352 (12)gct >7.8 mmol/l54/350 (15)79/371 (21)*28 week fasting Glucose ≥5.1 mmol/l or gct >7.8 mmol/l67/320 (21)100/352 (28)*gct >8.3 mmol/l42/350 (12)52/371 (14)Gestational diabetes (carpenter and coustan criteria)227/350 (2)9/371 (2)Gestational diabetes (american diabetes association criteria)2712/350 (3)18/371 (5)\ngct=Glucose challenge test (Serum Glucose measured 1 hour after 50 g Glucose load).']	N/A	N/A	[('CHEBI_17234', 'glucose', 90, 'glucose'), ('CHEBI_17234', 'glucose', 184, 'glucose'), ('GO_0007565', 'female pregnancy', 283, 'Gestational'), ('GO_0007565', 'female pregnancy', 356, 'Gestational'), ('CHEBI_17234', 'glucose', 444, 'glucose'), ('UBERON_0001977', 'blood serum', 468, 'serum'), ('CHEBI_17234', 'glucose', 474, 'glucose'), ('CHEBI_17234', 'glucose', 509, 'glucose')]
BMJ_2012_Aug_30_345_e5605	8/2012	S114-BMJ_2012_Aug_30_345_e5605	['a significantly higher proportion of women in the control arm had either a fasting Glucose concentration of 5.1 mmol/l or greater or a Glucose challenge test result of greater than 7.8 mmol/l at 28 weeks.']	N/A	N/A	[('CHEBI_17234', 'glucose', 83, 'glucose'), ('CHEBI_17234', 'glucose', 135, 'glucose')]
BMJ_2014_Feb_10_348_g1285	2/2014	S35-BMJ_2014_Feb_10_348_g1285	['prespecified secondary maternal outcomes included hypertension (systolic Blood pressure ≥140 mm hg and/or diastolic ≥90 mm hg on two occasions four or more hours apart) and pre-eclampsia27; Gestational diabetes (positive 75g Oral Glucose tolerance test result with fasting Blood Glucose ≥5.5 mmol/l or 2 hour ≥7.8 mmol/l)25; need for and length of antepartum hospital stay; antepartum haemorrhage requiring stay in hospital; preterm ruptured membranes before labour; term ruptured membranes before labour; chorioamnionitis requiring Antibiotics during labour; need for induction of labour; Antibiotic use during labour; caesarean section; Postpartum haemorrhage (>600 ml); Perineal trauma; wound infection; endometritis; Antibiotics Postpartum; Postpartum length of hospital stay; thromboembolic disease; and maternal death.']	N/A	N/A	[('UBERON_0000178', 'blood', 73, 'blood'), ('GO_0007565', 'female pregnancy', 190, 'gestational'), ('UBERON_0000165', 'mouth', 225, 'oral'), ('CHEBI_17234', 'glucose', 230, 'glucose'), ('UBERON_0000178', 'blood', 273, 'blood'), ('CHEBI_17234', 'glucose', 279, 'glucose'), ('CHEBI_33282', 'antibacterial agent', 533, 'antibiotics'), ('CHEBI_33282', 'antibacterial agent', 590, 'antibiotic'), ('GO_0007565', 'female pregnancy', 639, 'postpartum'), ('UBERON_0001977', 'blood serum', 673, 'perineal'), ('CHEBI_33282', 'antibacterial agent', 721, 'antibiotics'), ('GO_0007565', 'female pregnancy', 733, 'postpartum'), ('GO_0007565', 'female pregnancy', 745, 'postpartum')]
PMC1252725	10/2005	S88-PMC1252725	['in general Saletanol d5®Solution (Sodium Chloride 4.5 g, Glucose 50 g and Alcohol 50 g in 1000 ml Solution with a speed of 30-40 drops/min which means 0.19/bw/hour of Alcohol) or Ringer Lactate®Solution (Sodium Chloride 5.55 g, Potassium Chloride 0.3 g, Calcium Chloride 0.28 g, Magnesium Chloride 0.09 g, Sodium Lactate 5.04 g in 1000 ml with a speed of 120-150 drops/min) were used for this treatment.']	N/A	N/A	[('CHEBI_9011', 'salmeterol', 11, 'Saletanol'), ('CHEBI_75958', 'solution', 24, 'solution'), ('CHEBI_26710', 'sodium chloride', 34, 'sodium chloride'), ('CHEBI_17234', 'glucose', 57, 'glucose'), ('CHEBI_30879', 'alcohol', 74, 'alcohol'), ('CHEBI_75958', 'solution', 98, 'solution'), ('CHEBI_30879', 'alcohol', 167, 'alcohol'), ('CHEBI_8874', 'rivastigmine', 179, 'Ringer lactate'), ('CHEBI_75958', 'solution', 194, 'solution'), ('CHEBI_26710', 'sodium chloride', 204, 'sodium chloride'), ('CHEBI_63041', 'manganese(II) chloride', 228, 'potassium chloride'), ('CHEBI_3312', 'calcium dichloride', 254, 'calcium chloride'), ('CHEBI_6636', 'magnesium dichloride', 279, 'magnesium chloride'), ('CHEBI_75228', 'sodium lactate', 306, 'sodium lactate')]
PMC1852384	1/2007	S48-PMC1852384	['all routine follow-up appointments included nutritional counseling and those after 2\xa0weeks included laboratory studies [Serum electrolytes, Glucose, hba1c, calcium, albumin, Lipid profile, Liver function tests, complete Blood count, Platelets, Serum Insulin, iron, ferritin, Vitamin B12, 25-Oh Vitamin D, and Thiamine (Vitamin B1)].']	N/A	N/A	[('UBERON_0001977', 'blood serum', 120, 'serum'), ('CHEBI_17234', 'glucose', 140, 'glucose'), ('CHEBI_18059', 'lipid', 174, 'lipid'), ('UBERON_0002107', 'liver', 189, 'liver'), ('UBERON_0000178', 'blood', 220, 'blood'), ('CL_0000233', 'platelet', 233, 'platelets'), ('UBERON_0001977', 'blood serum', 244, 'serum'), ('PR_000045358', 'insulin family protein', 250, 'insulin'), ('CHEBI_33279', 'vitamin D5', 275, 'vitamin B12'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 283, 'B12'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 288, '25-OH'), ('CHEBI_27300', 'vitamin D', 294, 'vitamin D'), ('CHEBI_26948', 'vitamin B1', 309, 'thiamine'), ('PR_000004483', 'V-type proton ATPase subunit C 1', 319, 'vitamin B1')]
PMC2100429	9/2007	S37-PMC2100429	['a fasting Blood sample was collected, followed by a 1.75\xa0g/kg body weight oral anhydrous Glucose load and a further Blood sample 120\xa0min later.']	N/A	N/A	[('UBERON_0000178', 'blood', 10, 'blood'), ('CHEBI_17234', 'glucose', 89, 'glucose'), ('UBERON_0000178', 'blood', 116, 'blood')]
PMC2100429	9/2007	S43-PMC2100429	['Plasma Glucose was measured using an hitachi 911 automated analyser (hitachi, tokyo, japan) by the Glucose oxidase peroxidase method.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_17234', 'glucose', 7, 'glucose'), ('CHEBI_17234', 'glucose', 99, 'glucose')]
PMC2100429	9/2007	S45-PMC2100429	['Insulin resistance was calculated using the fasting Insulin and Glucose concentrations (Homeostatic model assessment of Insulin resistance [homa-r]) [15].']	N/A	N/A	[('PR_000045358', 'insulin family protein', 0, 'Insulin'), ('PR_000045358', 'insulin family protein', 52, 'insulin'), ('CHEBI_17234', 'glucose', 64, 'glucose'), ('GO_0042592', 'homeostatic process', 88, 'homeostatic'), ('PR_000045358', 'insulin family protein', 120, 'insulin')]
PMC2526009	10/2008	S86-PMC2526009	['hippocampal slices (0.4\u2009mm thick) were placed in cell strainers in 12-well cell culture clusters (10 slices per well) and incubated at 37°c for 1\u2009h in a physiological Salt Solution (pss) (in mm: 135 Nacl, 5 Kcl, 1 Cacl2, 0.75 Mgcl2, 10 Glucose, 10 Hepes, ph 7.4).']	N/A	N/A	[('CHEBI_24866', 'salt', 167, 'salt'), ('CHEBI_75958', 'solution', 172, 'solution'), ('CHEBI_26710', 'sodium chloride', 199, 'NaCl'), ('CHEBI_32588', 'potassium chloride', 207, 'KCl'), ('CHEBI_3312', 'calcium dichloride', 214, 'CaCl2'), ('CHEBI_6636', 'magnesium dichloride', 226, 'MgCl2'), ('CHEBI_17234', 'glucose', 236, 'glucose'), ('CHEBI_46756', 'HEPES', 248, 'HEPES')]
PMC2526009	10/2008	S88-PMC2526009	['the slices were then incubated at 37°c for 5\u2009min periods sequentially in a normal- (designated napss) and depolarizing- (designated kpss) Solution as follows napss/kpss/napss/kpss [napss (in mm), 135 Nacl, 5 Kcl, 1\u2009Cacl2, 0.75 Mgcl2, 10 Glucose, 10 Hepes, 0.02 Neostigmine Bromide, ph 7.4; kpss (in mm) 100 Nacl, 40 Kcl, 1 Cacl2, 0.75 Mgcl2, 10 Glucose, 10 Hepes, 0.02 Neostigmine Bromide, ph 7.4].']	N/A	N/A	[('CHEBI_75958', 'solution', 138, 'solution'), ('CHEBI_26710', 'sodium chloride', 200, 'NaCl'), ('CHEBI_32588', 'potassium chloride', 208, 'KCl'), ('CHEBI_3312', 'calcium dichloride', 215, 'CaCl2'), ('CHEBI_6636', 'magnesium dichloride', 227, 'MgCl2'), ('CHEBI_17234', 'glucose', 237, 'glucose'), ('CHEBI_46756', 'HEPES', 249, 'HEPES'), ('CHEBI_179557', 'neostigmine bromide', 261, 'neostigmine bromide'), ('CHEBI_26710', 'sodium chloride', 307, 'NaCl'), ('CHEBI_32588', 'potassium chloride', 316, 'KCl'), ('CHEBI_3312', 'calcium dichloride', 323, 'CaCl2'), ('CHEBI_6636', 'magnesium dichloride', 335, 'MgCl2'), ('CHEBI_17234', 'glucose', 345, 'glucose'), ('CHEBI_46756', 'HEPES', 357, 'HEPES'), ('CHEBI_179557', 'neostigmine bromide', 369, 'neostigmine bromide')]
PMC2529404	9/2008	S77-PMC2529404	['Glucose challenge\nMice were fasted for 21 hours.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('NCBITaxon_10088', 'Mus <genus>', 18, 'Mice')]
PMC2529404	9/2008	S78-PMC2529404	['Tail bleeds were used to sample Blood Glucose and measured using the accu-check active meter (roche).']	N/A	N/A	[('UBERON_0002415', 'tail', 0, 'Tail'), ('UBERON_0000178', 'blood', 32, 'blood'), ('CHEBI_17234', 'glucose', 38, 'glucose')]
PMC2529404	9/2008	S79-PMC2529404	['after a baseline fasting Glucose level was obtained, Mice were challenged with 2 g/kg Dextrose prepared in 0.9% saline and Blood Glucose checked at 30, 65 and 90 minutes.']	N/A	N/A	[('CHEBI_17234', 'glucose', 25, 'glucose'), ('NCBITaxon_10088', 'Mus <genus>', 53, 'mice'), ('CHEBI_23623', 'deoxyglucose', 86, 'dextrose'), ('UBERON_0000178', 'blood', 123, 'blood'), ('CHEBI_17234', 'glucose', 129, 'glucose')]
PMC2529404	9/2008	S118-PMC2529404	['following the concurrent choice test, we evaluated Glucose Metabolism in this cohort of Mice.']	N/A	N/A	[('CHEBI_17234', 'glucose', 51, 'glucose'), ('GO_0006006', 'glucose metabolic process', 51, 'glucose metabolism'), ('NCBITaxon_10088', 'Mus <genus>', 88, 'mice')]
PMC2529404	9/2008	S119-PMC2529404	['after 21 hours of fasting, there were no differences in weight between the groups (figure 3a; f(1,14)\u200a=\u200a.011, p\u200a=\u200a0.917) and no difference in either fasting Glucose levels (figure 3b; baseline, f(1,12)\u200a=\u200a.552, p\u200a=\u200a0.472) or response to Glucose challenge (figure 3b; group x timepoint, f(3,36)\u200a=\u200a1.15, p\u200a=\u200a0.340).']	N/A	N/A	[('CHEBI_17234', 'glucose', 157, 'glucose'), ('CHEBI_17234', 'glucose', 236, 'glucose')]
PMC2529404	9/2008	S121-PMC2529404	['(a) weights after a 21 hour fast and prior to Glucose challenge.']	N/A	N/A	[('CHEBI_17234', 'glucose', 46, 'glucose')]
PMC2529404	9/2008	S122-PMC2529404	['(b) blood Glucose levels at fasting baseline (timepoint 0) and following i.p.']	N/A	N/A	[('CHEBI_17234', 'glucose', 10, 'glucose')]
PMC2575191	10/2008	S24-PMC2575191	['at ~75 days of age control and experimental Animals were Food deprived overnight and fasting Glucose and Insulin levels were measured.']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 44, 'animals'), ('CHEBI_33290', 'food', 57, 'food'), ('CHEBI_17234', 'glucose', 93, 'glucose'), ('PR_000045358', 'insulin family protein', 105, 'insulin')]
PMC2575191	10/2008	S29-PMC2575191	['at ~75 days of age fasting Glucose and Insulin values were obtained from the f2 Rats as described.']	N/A	N/A	[('CHEBI_17234', 'glucose', 27, 'glucose'), ('PR_000045358', 'insulin family protein', 39, 'insulin'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 80, 'rats')]
PMC2575191	10/2008	S43-PMC2575191	['among f2 females, mean homa, Insulin and Glucose levels are all significantly (p < 0.05) higher than control values, with homa and Insulin values over 250 and 200 percent, respectively, compared to controls.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 29, 'insulin'), ('CHEBI_17234', 'glucose', 41, 'glucose'), ('PR_000045358', 'insulin family protein', 131, 'insulin')]
PMC2575191	10/2008	S47-PMC2575191	['caption (fig): figure 1\n\nhoma, fasting Glucose, and fasting Insulin .']	N/A	N/A	[('CHEBI_17234', 'glucose', 39, 'Glucose'), ('PR_000045358', 'insulin family protein', 60, 'Insulin')]
PMC2575191	10/2008	S48-PMC2575191	['homa, fasting Glucose, and fasting Insulin for female (a.)']	N/A	N/A	[('CHEBI_17234', 'glucose', 14, 'glucose'), ('PR_000045358', 'insulin family protein', 35, 'insulin')]
PMC2582131	11/2008	S22-PMC2582131	['in a cross-sectional study[24], Serum concentrations of 25-[Oh] D measured at the time of gdm screening test (24–28 weeks of Gestation) were significantly lower in gdm women than in normal Glucose tolerance Pregnant women (16.49 vs. 22.97, p \u200a=\u200a0.009).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 32, 'serum'), ('CHEBI_34300', '2-naphthoyl-CoA', 56, '25-[OH] D'), ('GO_0007565', 'female pregnancy', 125, 'gestation'), ('CHEBI_17234', 'glucose', 189, 'glucose'), ('GO_0007565', 'female pregnancy', 207, 'pregnant')]
PMC2582131	11/2008	S44-PMC2582131	['in our study settings, according to the recommendations from the american diabetes association (ada)[28], Pregnant women were screened at 24–28 weeks Gestation using a 50 gram 1-hour oral Glucose challenge test.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 106, 'pregnant'), ('GO_0007565', 'female pregnancy', 150, 'gestation'), ('CHEBI_17234', 'glucose', 188, 'glucose')]
PMC2582131	11/2008	S45-PMC2582131	['those patients who failed this screening test (Glucose≥7.8 mmol/l) were then followed-up within 1–2 weeks with a 100g, 3-h Oral Glucose tolerance test (ogtt).']	N/A	N/A	[('CHEBI_17234', 'glucose', 47, 'glucose'), ('UBERON_0000165', 'mouth', 123, 'oral'), ('CHEBI_17234', 'glucose', 128, 'glucose')]
PMC2582131	11/2008	S46-PMC2582131	["we also abstracted laboratory results from participants' 50 gram 1-hour Glucose challenge test and from the diagnostic 100 gram 3-hour ogtt."]	N/A	N/A	[('CHEBI_17234', 'glucose', 72, 'glucose')]
PMC2582131	11/2008	S47-PMC2582131	['women were diagnosed with gdm if two or more of the 100 gram ogtt Glucose levels exceeded the ada criteria[28]: fasting >5.3 mmol/l; 1-hour >10.0 mmol/l; 2-hour >8.6 mmol/l; 3-hour >7.8 mmol/l.']	N/A	N/A	[('CHEBI_17234', 'glucose', 66, 'glucose')]
PMC2582131	11/2008	S59-PMC2582131	['all reported confidence intervals were calculated at the 95% level and all reported p-values are two-tailed.10.1371/journal.pone.0003753.t001\n\ncaption (table-wrap): table 1\ncharacteristics of study participants according to Gestational diabetes (gdm) case-control status.characteristicsgdm casescontrolsp-value(n\u200a=\u200a57)(n\u200a=\u200a114)n (%)n (%)maternal age at interview (years)34.3±4.8133.1±3.90.09 <35 29 (50.9)72 (63.2)0.12 ≥35 28 (41.1)42 (36.8)maternal race/ethnicity white/non-hispanic 40 (70.2)96 (84.2)0.03 african american 2 (3.5)6 (5.3) others 15 (26.3)12 (10.5)nulliparous27 (47.4)62 (54.4)0.39consumed Prenatal vitamins49 (86.0)105 (92.1)0.21consumed≥2 servings of fish weekly27 (47.4)65 (57.0)0.23consumed≥1 glass of Milk daily22 (38.6)42 (36.8)0.82smoked during Pregnancy3 (5.3)7 (6.1)0.82family history of diabetes mellitus14 (24.6)15 (13.2)0.06physical inactivity during Pregnancy9 (15.8)9 (7.9)0.11pre-Pregnancy body mass index (kg/m2)26.7±7.2123.3±3.80.001pre-Pregnancy body mass index (kg/m2) <25 29 (50.9)84 (73.7)0.003 ≥25 28 (49.1)30 (26.3)Gestational age at Blood collection (weeks)16.3±2.1116.1±2.20.59gestational age at Glucose screening test (weeks)26.9±2.6126.4±2.50.25season of estimated time of conception* (march–may) spring 21 (36.8)42 (36.8)1.00 (june–august) summer 17 (29.8)34 (29.8) (september–november) autumn 13 (22.8)26 (22.8) (december–february) winter 6 (10.5)12 (10.5)Maternal Plasma 25-Hydroxyvitamin D concentrations (ng/ml) mean±sd 24.2±8.5130.1±9.7<0.001\nmean±sd (standard deviation).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 224, 'gestational'), ('GO_0007565', 'female pregnancy', 606, 'Prenatal'), ('UBERON_0001913', 'milk', 722, 'Milk'), ('GO_0007565', 'female pregnancy', 768, 'Pregnancy3'), ('GO_0007565', 'female pregnancy', 879, 'Pregnancy9'), ('GO_0007565', 'female pregnancy', 911, 'Pregnancy'), ('GO_0007565', 'female pregnancy', 970, 'Pregnancy'), ('GO_0007565', 'female pregnancy', 1054, 'Gestational'), ('UBERON_0000178', 'blood', 1073, 'Blood'), ('CHEBI_17234', 'glucose', 1137, 'Glucose'), ('UBERON_0000976', 'humerus', 1401, 'Maternal'), ('UBERON_0001969', 'blood plasma', 1410, 'Plasma'), ('CHEBI_27844', "2',3'-cyclic AMP", 1417, '25-Hydroxyvitamin D')]
PMC2646054	3/2009	S4-PMC2646054	['protein-restricted male offspring exhibited catch-up growth by 8 weeks of age and developed increased adiposity and Glucose intolerance by 32 weeks of age.']	N/A	N/A	[('CHEBI_17234', 'glucose', 116, 'glucose')]
PMC2646054	3/2009	S73-PMC2646054	['Glucose tolerance tests.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose')]
PMC2646054	3/2009	S74-PMC2646054	['Glucose tolerance tests were performed as previously described (29) on the low-protein and control offspring at 126 days (4 months) and 210 days (7 months) of age.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose')]
PMC2646054	3/2009	S76-PMC2646054	['the following morning, fasting Glucose was measured in Blood collected from Saphenous Vein puncture, after which 2 mg/g Glucose load was administered Intraperitoneally.']	N/A	N/A	[('CHEBI_17234', 'glucose', 31, 'glucose'), ('UBERON_0000178', 'blood', 55, 'blood'), ('UBERON_0007318', 'saphenous vein', 76, 'saphenous vein'), ('CHEBI_17234', 'glucose', 120, 'glucose'), ('UBERON_0000007', 'pituitary gland', 150, 'intraperitoneally')]
PMC2646054	3/2009	S77-PMC2646054	['serial Blood Glucose measurements were performed at 0.5-h intervals over the next 2 h from Saphenous Venipunctures.']	N/A	N/A	[('UBERON_0000178', 'blood', 7, 'blood'), ('CHEBI_17234', 'glucose', 13, 'glucose'), ('UBERON_0004110', 'midnasal cavity', 91, 'saphenous venipunctures')]
PMC2646054	3/2009	S78-PMC2646054	['the one touch ultra glucometer (lifescan) was used to measure whole-Blood Glucose concentrations (30).']	N/A	N/A	[('UBERON_0000178', 'blood', 68, 'blood'), ('CHEBI_17234', 'glucose', 74, 'glucose')]
PMC2646054	3/2009	S112-PMC2646054	['low-protein male offspring exhibited increased weight, adiposity, and Glucose intolerance.']	N/A	N/A	[('CHEBI_17234', 'glucose', 70, 'glucose')]
PMC2646054	3/2009	S117-PMC2646054	['1 e ) and a significantly higher ( p< 0.0001) area under the Glucose concentration curve (fig.']	N/A	N/A	[('CHEBI_17234', 'glucose', 61, 'glucose')]
PMC2646054	3/2009	S119-PMC2646054	['baseline Glucose concentrations and response to a Glucose load were not significantly different between low-protein and control female offspring at 32 weeks of age (data not shown).']	N/A	N/A	[('CHEBI_17234', 'glucose', 9, 'glucose'), ('CHEBI_17234', 'glucose', 50, 'glucose')]
PMC2646054	3/2009	S155-PMC2646054	['iugr low-protein females did not differ significantly from controls in Glucose tolerance and maintained a lower growth curve throughout.']	N/A	N/A	[('CHEBI_17234', 'glucose', 71, 'glucose')]
PMC2658734	4/2009	S62-PMC2658734	['caption (table-wrap): table\xa01\n\nvalidated and hypothetic Mirna targetsvalidated Mirna targets in type 2 diabetes and in the Endocrine systemmirnatargetfunctionreferencemir-375myotrophininhibition of Insulin secretion[69]mir-9onecut2 transcription factorinhibition of Glucose-stimulated Insulin Release[70]mir-192e-box repressorstgf-Beta-Induced Matrix Protein Collagen Col1A1 and -2[24]mir-143glut4, Hsl, Fatty Acid-Binding protein Ap2, Ppar-Μ2Adipocyte differentiation[49]hypothetic Mirna targets associated with type 2 diabetesmir-30 familyreceptor for advanced glycation end product, Immediate Early Response 3, Vimentin, Heat-Shock Protein-20Podocyte Apoptosis and Cytoskeletal structure[79,80]Mir-23Bhairy/Enhancer Of The Split Protein (Hes1)downstream target of activated Notch Signalling and Expressed in Nephron segments during development[81,84]mir-15, mir-16wnt and Β-Cateninnephron induction during Embryo Development[75,76]mir-7gy-boxnotch signalling[73,74]mir-4, mir-79Brd-boxmir-2, mir-11k-box\nBiogenesis Of Mirnas starts in the Nucleus (see figure3) where stretches of several kilobases long primary Mirnas (pri-Mirnas) are transcribed from the Genome, 3′- Polyadenylated [covalent Linkage Poly (a) tail of 3′ end of Mirna], 5′- capped [7-methyl guanylate (m7g) cap of 5′ end of Mirna].']	N/A	N/A	[('SO_0000276', 'miRNA', 56, 'miRNA'), ('SO_0000276', 'miRNA', 79, 'miRNA'), ('UBERON_0002049', 'vasculature', 123, 'endocrine'), ('PR_000045358', 'insulin family protein', 198, 'insulin'), ('CHEBI_17234', 'glucose', 266, 'glucose'), ('PR_000045358', 'insulin family protein', 285, 'insulin'), ('GO_0006260', 'DNA replication', 293, 'release'), ('PR_000004670', 'protein PTHB1', 330, '-beta-induced matrix protein collagen'), ('GO_0031012', 'extracellular matrix', 344, 'matrix'), ('PR_000003266', 'collagen type II alpha chain', 368, 'Col1a1'), ('PR_000010222', 'muscleblind-like protein 2', 380, '2'), ('PR_000008794', 'heat shock factor protein 5', 399, 'HSL'), ('CHEBI_35366', 'fatty acid', 404, 'fatty acid'), ('PR_000010000', 'lysozyme g-like protein 2', 414, '-binding'), ('PR_000004123', 'adenomatous polyposis coli protein 2', 431, 'aP2'), ('PR_000013031', 'periostin', 436, 'PPAR-μ2Adipocyte'), ('SO_0000276', 'miRNA', 483, 'miRNA'), ('PR_000000035', 'BMP receptor type-1A', 531, '-30'), ('PR_000008890', 'isocitrate dehydrogenase [NAD] subunit beta, mitochondrial', 586, 'immediate early response 3'), ('PR_000017283', 'vitamin D3 receptor', 614, 'vimentin'), ('PR_000005163', 'CD2-associated protein', 624, 'heat-shock protein-20Podocyte'), ('GO_0006915', 'apoptotic process', 654, 'apoptosis'), ('GO_0005856', 'cytoskeleton', 668, 'cytoskeletal'), ('PR_000002103', 'sodium channel protein type 8 subunit alpha', 697, 'miR-23bHairy'), ('PR_000006890', 'enhancer of mRNA-decapping protein 3', 710, 'enhancer of the split protein'), ('SO_0000165', 'enhancer', 710, 'enhancer'), ('PR_000008474', 'hematopoietic lineage cell-specific protein', 741, 'Hes1'), ('GO_0038189', 'neuropilin signaling pathway', 777, 'Notch signalling'), ('GO_0010467', 'gene expression', 798, 'expressed'), ('UBERON_0001285', 'nephron', 811, 'nephron'), ('PR_000002198', 'catenin beta-1', 875, 'β-cateninNephron'), ('GO_0009790', 'embryo development', 909, 'embryo development'), ('UBERON_0000922', 'embryo', 909, 'embryo'), ('PR_000011040', 'nuclear receptor coactivator 1', 979, '79Brd'), ('PR_000010222', 'muscleblind-like protein 2', 992, '2'), ('GO_0070277', 'iodide oxidation', 1007, 'Biogenesis of miRNAs'), ('SO_0000276', 'miRNA', 1021, 'miRNAs'), ('GO_0005634', 'nucleus', 1042, 'nucleus'), ('SO_0000276', 'miRNA', 1114, 'miRNAs'), ('SO_0000276', 'miRNA', 1126, 'miRNAs'), ('SO_0001026', 'genome', 1159, 'genome'), ('GO_0043651', 'linoleic acid metabolic process', 1171, 'polyadenylated'), ('SO_0000987', 'linear', 1196, 'linkage'), ('SO_0000610', 'polyA_sequence', 1204, 'poly'), ('SO_0000276', 'miRNA', 1231, 'miRNA'), ('SO_0000276', 'miRNA', 1293, 'miRNA')]
PMC2670501	4/2009	S77-PMC2670501	['Insulin sensitivity was assessed using the index quicki (quantitative Insulin Sensitivity Check Index) that was calculated as: quicki\u200a=\u200a1/(log (fasting Insulin)+log (fasting Glucose))[31].']	N/A	N/A	[('PR_000045358', 'insulin family protein', 0, 'Insulin'), ('PR_000001339', 'cytokine receptor common subunit beta', 70, 'insulin sensitivity check index'), ('PR_000045358', 'insulin family protein', 152, 'insulin'), ('CHEBI_17234', 'glucose', 174, 'glucose')]
PMC2670501	4/2009	S80-PMC2670501	['Glucose was measured immediately whereas samples for hormonal analysis were quickly centrifuged and Serum was separated and stored at −80° until analysis.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('UBERON_0001977', 'blood serum', 100, 'serum')]
PMC2671035	5/2009	S47-PMC2671035	['measurement of Glucose, hormones, and adipokines.']	N/A	N/A	[('CHEBI_17234', 'glucose', 15, 'glucose')]
PMC2671035	5/2009	S48-PMC2671035	['Fed Glucose was measured between 9:00a.m.and 11:00a.m.in Tail Vein Blood samples (ascensia elite; bayer, pittsburgh, pa) before Pentobarbital anesthesia (150 mg/kg i.p.)']	N/A	N/A	[('GO_0007631', 'feeding behavior', 0, 'Fed'), ('CHEBI_17234', 'glucose', 4, 'glucose'), ('UBERON_0003481', 'tail vein', 57, 'tail vein'), ('UBERON_0000178', 'blood', 67, 'blood'), ('CHEBI_7983', 'pentobarbital', 128, 'pentobarbital')]
PMC2671035	5/2009	S87-PMC2671035	['caption (table-wrap): table 1\n\ngrowth and hormonal data, age 3 weeksc-cc-uu-cu-ubirth weight (g)1.59 ± 0.011.56 ± 0.031.23 ± 0.05*1.09 ± 0.02*†body weight (g)16.4 ± 1.17.7 ± 0.8*‡17.8 ± 0.78.4 ± 0.9*‡body length (cm)7.8 ± 0.16.0 ± 0.2*‡7.7 ± 0.16.2 ± 0.2*‡Gonadal fat weight (g)0.18 ± 0.020.018 ± 0.004*‡0.25 ± 0.03§0.041 ± 0.005*‡Gonadal fat/body weight (%)1.1 ± 0.10.22 ± 0.04*‡1.4 ± 0.1§0.40 ± 0.04*‡sum of Fat Pad weights/body weight (%)#2.8 ± 0.20.5 ± 0.1*‡3.7 ± 0.3§1.2 ± 0.1§Blood Glucose (mmol/l)8.9 ± 0.25.5 ± 0.5§8.2 ± 0.36.1 ± 1.1§Corticosterone (ng/ml)151 ± 18234 ± 14167 ± 21341 ± 63‖¶Insulin (pmol/l)445 ± 70115 ± 35§545 ± 100275 ± 40§t4 (μg/dl)8.7 ± 0.77.1 ± 0.98.8 ± 0.86.1 ± 0.2*†T4 resin binding (%)40.8 ± 1.240.0 ± 1.641.5 ± 1.536.2 ± 1.6*†leptin (ng/dl)6.1 ± 0.40.8 ± 0.2*‡5.9 ± 0.42.0 ± 0.5*‡adiponectin (ng/ml)7.8 ± 1.213.3 ± 4.1*¶5.2 ± 0.98.9 ± 1.1resistin (ng/ml)2.6 ± 0.31.3 ± 0.1*2.0 ± 0.2§1.9 ± 0.3§Il-6 (pg/ml)4.0 ± 0.35.2 ± 0.94.8 ± 1.14.7 ± 0.5Mcp-1 (pg/ml)47 ± 460 ± 836 ± 649 ± 8Pai-1 (ng/ml)4.5 ± 0.45.9 ± 0.2§3.6 ± 0.34.4 ± 0.6Tnf-Α (pg/ml)9.5 ± 0.58.4 ± 0.49.1 ± 0.410.9 ± 1.2\ndata are means ± se.']	N/A	N/A	[('UBERON_0000991', 'gonad', 256, 'Gonadal'), ('UBERON_0000991', 'gonad', 331, 'Gonadal'), ('UBERON_0003916', 'fat pad', 410, 'fat pad'), ('UBERON_0000178', 'blood', 482, 'Blood'), ('CHEBI_17234', 'glucose', 488, 'glucose'), ('CHEBI_16827', 'corticosterone', 542, 'Corticosterone'), ('PR_000045358', 'insulin family protein', 598, 'Insulin'), ('PR_000016190', 'trichohyalin-like protein 1', 697, 'T4'), ('PR_000001470', 'interleukin-28B', 926, 'IL-6'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 973, '5MCP-1'), ('PR_000001890', 'mucin-1', 1010, '8PAI-1'), ('PR_000009167', 'involucrin', 1060, '6TNF-α')]
PMC2671035	5/2009	S88-PMC2671035	['growth data, Glucose Homeostasis, and hormonal data in male Mice, age 3 weeks.']	N/A	N/A	[('CHEBI_17234', 'glucose', 13, 'glucose'), ('GO_0042593', 'glucose homeostasis', 13, 'glucose homeostasis'), ('NCBITaxon_10088', 'Mus <genus>', 60, 'mice')]
PMC2671035	5/2009	S92-PMC2671035	['Glucose, Adipogenic hormones, and adipokines.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('CHEBI_59135', "4-isocyanato-4'-methyldiphenylmethane", 9, 'adipogenic'), ('GO_0060612', 'adipose tissue development', 9, 'adipogenic')]
PMC2671035	5/2009	S115-PMC2671035	['while growth data, Glucose levels, and hormonal analyses were similar to the entire cohort, Gonadal fat weight was not significantly different between u-c and c-c Mice in this subgroup (online appendixtable 2[available athttp://diabetes.diabetesjournals.org/cgi/content/full/db08–1266/dc1]).']	N/A	N/A	[('CHEBI_17234', 'glucose', 19, 'glucose'), ('UBERON_0000991', 'gonad', 92, 'gonadal'), ('NCBITaxon_10088', 'Mus <genus>', 163, 'mice')]
PMC2672462	4/2009	S30-PMC2672462	['this includes information regarding gdm, self-Monitoring of blood Glucose, dietary counseling, and advice regarding healthy lifestyle measures post-Partum.']	N/A	N/A	[('GO_0065007', 'biological regulation', 46, 'monitoring'), ('CHEBI_17234', 'glucose', 66, 'glucose'), ('GO_0007567', 'parturition', 148, 'partum')]
PMC2672462	4/2009	S33-PMC2672462	['Blood Glucose levels are usually monitored in the fasting state and 1–2 hours after meals.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('CHEBI_17234', 'glucose', 6, 'glucose')]
PMC2672462	4/2009	S41-PMC2672462	['when the fetal Abdominal circumference was <70th percentile, a higher Glucose threshold for initiating Insulin therapy did not result in an increase in fetal morbidity or macrosomia.26this protocol allowed more women to avoid Insulin therapy.']	N/A	N/A	[('UBERON_0000916', 'abdomen', 15, 'abdominal'), ('CHEBI_17234', 'glucose', 70, 'glucose'), ('PR_000045358', 'insulin family protein', 103, 'insulin'), ('PR_000045358', 'insulin family protein', 226, 'insulin')]
PMC2672462	4/2009	S68-PMC2672462	['a basal-bolus regimen of Insulin gives the most effective Glucose Control, and produces better fetal outcomes than a twice daily regime.34prandial fast-acting insulin is administered to control post-prandial hyperglycemia, and bedtime basal Insulin is given if there is fasting hyperglycemia.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 25, 'insulin'), ('CHEBI_17234', 'glucose', 58, 'glucose'), ('GO_0065007', 'biological regulation', 66, 'control'), ('PR_000045358', 'insulin family protein', 241, 'insulin')]
PMC2672462	4/2009	S108-PMC2672462	['the mig study randomized 751 women with gdm to treatment with Insulin or Metformin.72the women in the metformin arm were treated with supplemental Insulin if the maximal dose of Metformin, 2500 mg daily, failed to meet the Glucose targets.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 62, 'insulin'), ('CHEBI_6801', 'metformin', 73, 'metformin'), ('PR_000045358', 'insulin family protein', 147, 'insulin'), ('CHEBI_6801', 'metformin', 178, 'metformin'), ('CHEBI_17234', 'glucose', 223, 'glucose')]
PMC2672462	4/2009	S139-PMC2672462	['these subjects had a fasting Glucose up to 7.7 mmol/dl and a 2 hour level between 7.8 mmol/l and 11.1 mmol/dl.']	N/A	N/A	[('CHEBI_17234', 'glucose', 29, 'glucose')]
PMC2672462	4/2009	S140-PMC2672462	['they were randomized to receive treatment for gdm, including dietary advice, Blood Glucose monitoring, and Insulin as required, or standard Pregnancy care.']	N/A	N/A	[('UBERON_0000178', 'blood', 77, 'blood'), ('CHEBI_17234', 'glucose', 83, 'glucose'), ('PR_000045358', 'insulin family protein', 107, 'insulin'), ('GO_0007565', 'female pregnancy', 140, 'pregnancy')]
PMC2672462	4/2009	S142-PMC2672462	['in the treatment group, the aim was to maintain a fasting Glucose level of <5.5 mmol/l, and 2 hour post-prandial reading <7.0 mmol/l.']	N/A	N/A	[('CHEBI_17234', 'glucose', 58, 'glucose')]
PMC2672462	4/2009	S153-PMC2672462	['their Perinatal mortality rate was 2.3 times that of women with normal Glucose tolerance.']	N/A	N/A	[('GO_0036268', 'swimming', 6, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 6, 'perinatal'), ('CHEBI_17234', 'glucose', 71, 'glucose')]
PMC2672462	4/2009	S154-PMC2672462	['in the 1980s, with routine treatment for women with mild gdm, their outcomes were not different to women with normal Glucose tolerance.']	N/A	N/A	[('CHEBI_17234', 'glucose', 117, 'glucose')]
PMC2681032	6/2009	S12-PMC2681032	['Gestational diabetes mellitus (gdm) is defined as any degree of Glucose intolerance with onset or first recognition during Pregnancy (1).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_17234', 'glucose', 64, 'glucose'), ('GO_0007565', 'female pregnancy', 123, 'pregnancy')]
PMC2681032	6/2009	S25-PMC2681032	['unless indicated earlier, women have a 75-g Glucose tolerance test at the beginning of the third Trimester with Glucose samples taken after fasting and at 2 h. gdm is diagnosed if the fasting Glucose is ≥5.5 mmol/l (∼100 mg/dl) and/or the 2-h Glucose is ≥8.0 mmol/l (∼145 mg/dl) (9).']	N/A	N/A	[('CHEBI_17234', 'glucose', 44, 'glucose'), ('GO_0009294', 'DNA mediated transformation', 97, 'trimester'), ('UBERON_0002371', 'bone marrow', 97, 'trimester'), ('CHEBI_17234', 'glucose', 112, 'glucose'), ('CHEBI_17234', 'glucose', 192, 'glucose'), ('CHEBI_17234', 'glucose', 243, 'glucose')]
PMC2681032	6/2009	S52-PMC2681032	['to assist with achieving stable blood Glucose levels throughout the day, participants were advised to Consume three small meals and two to three snacks with a specified number of servings of chos.']	N/A	N/A	[('CHEBI_17234', 'glucose', 38, 'glucose'), ('GO_0007631', 'feeding behavior', 102, 'consume')]
PMC2681032	6/2009	S55-PMC2681032	['women were provided with a home Glucose meter (accu-check performa; roche) and were asked to test after fasting and 1 h after the start of each of their three major meals at least every second day.']	N/A	N/A	[('CHEBI_17234', 'glucose', 32, 'glucose')]
PMC2681032	6/2009	S61-PMC2681032	['Food intake data for the baseline visit, visit 2, visit 3, and the final visit for each participant were entered into a customized database incorporating the australian Food composition tables and published glycemic index values using the Glucose = 100 scale (foodworks professional, version 4 2005; xyris software, highgate hill, qld, australia).']	N/A	N/A	[('CHEBI_33290', 'food', 0, 'Food'), ('CHEBI_33290', 'food', 169, 'food'), ('CHEBI_17234', 'glucose', 239, 'glucose')]
PMC2681032	6/2009	S82-PMC2681032	['caption (table-wrap): table 1\n\nbaseline characteristics of the womenlow–glycemic index grouphigh–glycemic index group p value* n 3132age (years)30.8 ± 0.731.3 ± 0.80.68weight at enrollment (kg)83.1 ± 3.286.9 ± 3.60.43bmi at enrollment (kg/m2)32.0 ± 1.232.8 ± 1.40.68parity0.84 ± 0.170.78 ± 0.180.82oral Glucose tolerance test (mmol/l)†\u2003\u2003\u2003\u2003fasting Glucose4.6 ± 0.14.7 ± 0.10.49\u2003\u2003\u2003\u20032-h glucose8.4 ± 0.28.4 ± 0.10.83gestational age at entry to study (weeks)30.3 ± 0.229.9 ± 0.20.23\ndata are means ± sem.']	N/A	N/A	[('CHEBI_17234', 'glucose', 303, 'glucose'), ('CHEBI_24384', 'glycogens', 347, 'glucose4')]
PMC2681032	6/2009	S84-PMC2681032	['†2-h, 75-g Glucose load.']	N/A	N/A	[('CHEBI_17234', 'glucose', 11, 'glucose')]
PMC2682672	6/2009	S50-PMC2682672	['we repeated the analysis, with maternal Prepregnancy bmi; smoking; parity; and, in the efsoch study, maternal fasting Glucose included as additional covariates.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 40, 'prepregnancy'), ('CHEBI_17234', 'glucose', 118, 'glucose')]
PMC2687585	2/2006	S26-PMC2687585	['Plasma Glucose levels were measured immediately with an autoanalyzer using the hexokinase method (hitachi 747; roche, montclair, nj, usa).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_17234', 'glucose', 7, 'glucose')]
PMC2687585	2/2006	S34-PMC2687585	['the physiological characteristics (systolic Blood pressure, diastolic Blood pressure, total Cholesterol, Triglyceride, hdl-Cholesterol, ldl-Cholesterol, fasting Plasma Glucose, insulin, c-peptide, homa-ir, and Homa-Β) were adjusted using a general linear model; the covariates used were age, sex, height, weight, waist circumference, body fat percentage, and tanner stage.']	N/A	N/A	[('UBERON_0000178', 'blood', 44, 'blood'), ('UBERON_0000178', 'blood', 70, 'blood'), ('CHEBI_16113', 'cholesterol', 92, 'cholesterol'), ('CHEBI_17855', 'triglyceride', 105, 'triglyceride'), ('CHEBI_16113', 'cholesterol', 123, 'cholesterol'), ('CHEBI_16113', 'cholesterol', 140, 'cholesterol'), ('UBERON_0001969', 'blood plasma', 161, 'plasma'), ('CHEBI_17234', 'glucose', 168, 'glucose'), ('PR_000008689', 'homeobox protein Hox-A13', 210, 'HOMA-β')]
PMC2687585	2/2006	S42-PMC2687585	['Blood pressure, fasting Plasma Glucose, Insulin, c-peptide, homa-ir, and Homa-Β were not significantly different between males and females.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('UBERON_0001969', 'blood plasma', 24, 'plasma'), ('CHEBI_17234', 'glucose', 31, 'glucose'), ('PR_000045358', 'insulin family protein', 40, 'insulin'), ('PR_000008689', 'homeobox protein Hox-A13', 73, 'HOMA-β')]
PMC2704503	6/2007	S21-PMC2704503	['Cerebrospinal Fluid (csf) studies, including cytology, gram stain, culture, cryptococcus Antigen, and stain for Acid-fast bacilli, were normal (protein = 32; Glucose = 69; Leukocytes = 2; 92% Lymphocytes; Red Blood Cells [Rbc] = 1).']	N/A	N/A	[('UBERON_0001359', 'cerebrospinal fluid', 0, 'Cerebrospinal fluid'), ('CHEBI_59132', 'antigen', 89, 'antigen'), ('CHEBI_37527', 'acid', 112, 'acid'), ('CHEBI_17234', 'glucose', 158, 'glucose'), ('CL_0000738', 'leukocyte', 172, 'leukocytes'), ('CL_0000542', 'lymphocyte', 192, 'lymphocytes'), ('CL_0000232', 'erythrocyte', 205, 'red blood cells'), ('UBERON_0000178', 'blood', 209, 'blood'), ('CL_0000232', 'erythrocyte', 222, 'RBC')]
PMC2707610	7/2009	S6-PMC2707610	['Hypothalamic appetite regulators, and fuel (Glucose and Lipid) Metabolic markers were measured.']	N/A	N/A	[('UBERON_0001898', 'hypothalamus', 0, 'Hypothalamic'), ('CHEBI_17234', 'glucose', 44, 'glucose'), ('CHEBI_18059', 'lipid', 56, 'lipid'), ('GO_0008152', 'metabolic process', 63, 'metabolic')]
PMC2707610	7/2009	S24-PMC2707610	['they developed adiposity and impaired Glucose and Lipid Metabolism as early as Postnatal day 20[10],[11],[12], which were maintained until Adulthood[13].']	N/A	N/A	[('CHEBI_17234', 'glucose', 38, 'glucose'), ('GO_0007369', 'gastrulation', 38, 'glucose ...'), ('CHEBI_18059', 'lipid', 50, 'lipid'), ('GO_0006629', 'lipid metabolic process', 50, 'lipid metabolism'), ('GO_0007567', 'parturition', 79, 'postnatal'), ('UBERON_0000113', 'post-juvenile adult stage', 139, 'adulthood')]
PMC2707610	7/2009	S58-PMC2707610	['all the Adult offspring in each group were used to measure the body weight, energy Intake, Intraperitoneal Glucose tolerance test (ipgtt), Organ parameters at death, and Plasma hormones.']	N/A	N/A	[('UBERON_0007023', 'adult organism', 8, 'adult'), ('GO_0007631', 'feeding behavior', 83, 'intake'), ('UBERON_2001932', 'sensory canal tubular ossicle', 91, 'intraperitoneal'), ('CHEBI_17234', 'glucose', 107, 'glucose'), ('UBERON_0000062', 'organ', 139, 'organ'), ('UBERON_0001969', 'blood plasma', 170, 'plasma')]
PMC2707610	7/2009	S74-PMC2707610	['after the establishment of a baseline Glucose level (accu-chek®Glucose meter; roche diagnostics, nutley, usa) Rats were administered 2 g Glucose/kg (i.p.).']	N/A	N/A	[('CHEBI_17234', 'glucose', 38, 'glucose'), ('CHEBI_17234', 'glucose', 63, 'glucose'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 110, 'rats'), ('CHEBI_17234', 'glucose', 137, 'glucose')]
PMC2707610	7/2009	S75-PMC2707610	['Blood samples were taken at 15, 30, 60, and 90 minutes to monitor Glucose.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('CHEBI_17234', 'glucose', 66, 'glucose')]
PMC2707610	7/2009	S79-PMC2707610	['after measurement of Naso-Anal (n-a) length, Blood was collected by Cardiac puncture and Blood Glucose was measured immediately.']	N/A	N/A	[('UBERON_0000004', 'nose', 21, 'naso'), ('UBERON_0001245', 'anus', 26, 'anal'), ('UBERON_0000178', 'blood', 45, 'blood'), ('UBERON_0000948', 'heart', 68, 'cardiac'), ('UBERON_0000178', 'blood', 89, 'blood'), ('CHEBI_17234', 'glucose', 95, 'glucose')]
PMC2707610	7/2009	S93-PMC2707610	['the Insulin resistance index was estimated by homa: fasting Plasma Insulin (ng/ml) × fasting Plasma Glucose (mm)/(22.5×0.0417) (the greater the homa value, the greater the level of Insulin resistance[18],[19]), as well as leptin∶adiponectin ratio[20],[21].']	N/A	N/A	[('PR_000045358', 'insulin family protein', 4, 'insulin'), ('UBERON_0001969', 'blood plasma', 60, 'plasma'), ('PR_000045358', 'insulin family protein', 67, 'insulin'), ('UBERON_0001969', 'blood plasma', 93, 'plasma'), ('CHEBI_17234', 'glucose', 100, 'glucose'), ('PR_000045358', 'insulin family protein', 181, 'insulin')]
PMC2707610	7/2009	S155-PMC2707610	['Glucose Homeostasis in offspring\nfasting Blood Glucose was at similar higher levels in all hfd-Fed groups (p<0.001, hfd effect).']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('GO_0043062', 'extracellular structure organization', 0, 'Glucose homeostasis'), ('UBERON_0000178', 'blood', 41, 'blood'), ('CHEBI_17234', 'glucose', 47, 'glucose'), ('GO_0007631', 'feeding behavior', 95, 'fed')]
PMC2707610	7/2009	S161-PMC2707610	['3a,b).10.1371/journal.pone.0006259.g003\n\ncaption (fig): figure 3\nGlucose tolerance test and muscle Adipor1 mrna Expression.']	N/A	N/A	[('CHEBI_17234', 'glucose', 65, 'Glucose'), ('PR_000003679', 'actin, alpha cardiac muscle 1', 99, 'AdipoR1'), ('GO_0010467', 'gene expression', 112, 'expression')]
PMC2707610	7/2009	S162-PMC2707610	['(a) ip Glucose tolerance test, (b) area under the curve at 16 weeks (Glucose 2 g/kg, n\u200a=\u200a10–12 per group), and (c) muscle Adipor 1 mrna Expression (6–8 per group).']	N/A	N/A	[('CHEBI_17234', 'glucose', 7, 'glucose'), ('CHEBI_17234', 'glucose', 69, 'glucose'), ('PR_000003679', 'actin, alpha cardiac muscle 1', 122, 'AdipoR 1'), ('GO_0010467', 'gene expression', 136, 'expression')]
PMC2707610	7/2009	S180-PMC2707610	['3c).10.1371/journal.pone.0006259.t004\n\ncaption (table-wrap): table 4\neffects of maternal diet, Postnatal litter size adjustment and post-weaning diet on Plasma tg, Glucose, and hormones.postweaning diet maternal diet & litter sizechowhfdcncshnhscncshnhs(n\u200a=\u200a12)(n\u200a=\u200a12)(n\u200a=\u200a11)(n\u200a=\u200a10)(n\u200a=\u200a12)(n\u200a=\u200a12)(n\u200a=\u200a11)(n\u200a=\u200a10)Tg (mmol·l−1)0.35±0.050.53±0.070.46±0.090.50±0.060.62±0.06‡0.70±0.09‡1.15±0.21*‡1.37±0.20*‡Glucose (mmol·l−1)8.64±1.067.98±0.716.86±0.657.49±0.2511.3±0.70‡11.41±0.70‡11.15±0.74‡11.48±0.70‡Insulin (ng·ml−1)0.10±0.010.19±0.04†0.12±0.020.17±0.03†0.38±0.04‡0.40±0.06‡0.58±0.11*‡0.86±0.14*†‡homa0.94±0.191.63±0.310.95±0.221.37±0.244.56±0.51‡4.76±0.57‡7.30±1.74*‡10.37±1.57*‡leptin (ng·ml−1)1.34±0.181.77±0.251.26±0.152.03±0.329.13±1.24‡7.54±1.02‡13.84±2.63*‡16.53±1.45*‡adiponectin(ug·ml−1)2.31±0.132.83±0.262.57±0.232.56±0.163.79±0.20‡3.87±0.37‡4.76±0.33*‡5.25±0.33*‡adiponectin(ug·ml−1·g−1rp fat)0.86±0.090.36±0.04†0.71±0.09*0.35±0.04†0.62±0.05‡0.24±0.03†‡0.48±0.03*‡0.34±0.04*†‡leptin:adiponectin ratio0.60±0.082.25±0.3†0.61±0.082.14±0.3†0.52±0.08‡2.58±0.42†‡0.78±0.09*‡3.13±0.18*†‡\nresults are expressed as mean±sem.']	N/A	N/A	[('GO_0007567', 'parturition', 95, 'postnatal'), ('UBERON_0001969', 'blood plasma', 153, 'plasma'), ('CHEBI_17234', 'glucose', 164, 'glucose'), ('CHEBI_17855', 'triglyceride', 317, 'TG'), ('CHEBI_17234', 'glucose', 408, 'Glucose'), ('PR_000045358', 'insulin family protein', 505, 'Insulin')]
PMC2707610	7/2009	S258-PMC2707610	['any reduction of Metabolic rate in muscle would reduce Glucose utilization, thereby leading to hyperglycemia.']	N/A	N/A	[('GO_0008152', 'metabolic process', 17, 'metabolic'), ('CHEBI_17234', 'glucose', 55, 'glucose')]
PMC2707610	7/2009	S263-PMC2707610	['Glucose tolerance was reduced in Rats Consuming hfd, and more markedly in those from obese dams.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 33, 'rats'), ('GO_0007631', 'feeding behavior', 38, 'consuming')]
PMC2717130	7/2009	S2-PMC2717130	['methods\nblood Glucose was measured between 24 and 28 weeks Gestation after a 1-hr oral Glucose tolerance test (gtt) as part of routine Prenatal care.']	N/A	N/A	[('CHEBI_17234', 'glucose', 14, 'glucose'), ('GO_0007565', 'female pregnancy', 59, 'gestation'), ('CHEBI_17234', 'glucose', 87, 'glucose'), ('GO_0007565', 'female pregnancy', 135, 'prenatal')]
PMC2717130	7/2009	S23-PMC2717130	['Gestational diabetes (gd) occurs when resistance to circulating Insulin leads to hyperglycemia, and this impaired Glucose Metabolism is first detected during Pregnancy.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('PR_000045358', 'insulin family protein', 64, 'insulin'), ('CHEBI_17234', 'glucose', 114, 'glucose'), ('GO_0006006', 'glucose metabolic process', 114, 'glucose metabolism'), ('GO_0007565', 'female pregnancy', 158, 'pregnancy')]
PMC2717130	7/2009	S29-PMC2717130	['infants Born to mothers with impaired Glucose tolerance/gd are at increased risk of subsequent impaired Glucose tolerance and obesity.']	N/A	N/A	[('GO_0007567', 'parturition', 8, 'born'), ('CHEBI_17234', 'glucose', 38, 'glucose'), ('CHEBI_17234', 'glucose', 104, 'glucose')]
PMC2717130	7/2009	S52-PMC2717130	['participants who were missing information on Blood Arsenic ( n = 23) or Blood Glucose ( n = 34) were excluded, leaving a total of 532 women included in this analysis.']	N/A	N/A	[('UBERON_0000178', 'blood', 45, 'blood'), ('CHEBI_27563', 'arsenic atom', 51, 'arsenic'), ('UBERON_0000178', 'blood', 72, 'blood'), ('CHEBI_17234', 'glucose', 78, 'glucose')]
PMC2717130	7/2009	S75-PMC2717130	['maternal Blood (Plasma) Glucose was measured at a Prenatal visit between 24 and 28 weeks Gestation after a 1-hr, 50-g oral Glucose tolerance test (gtt) as part of routine Prenatal care (acog 2001), and results were obtained from the medical record.']	N/A	N/A	[('UBERON_0000178', 'blood', 9, 'blood'), ('UBERON_0001969', 'blood plasma', 16, 'plasma'), ('CHEBI_17234', 'glucose', 24, 'glucose'), ('GO_0007565', 'female pregnancy', 50, 'prenatal'), ('GO_0007565', 'female pregnancy', 89, 'gestation'), ('CHEBI_17234', 'glucose', 123, 'glucose'), ('GO_0007565', 'female pregnancy', 171, 'prenatal')]
PMC2717130	7/2009	S77-PMC2717130	['Glucose was measured in Plasma using the beckman coulter cx 9 (beckman coulter, inc. fullerton, ca) at the integris baptist clinical laboratory.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('UBERON_0001969', 'blood plasma', 24, 'plasma')]
PMC2717130	7/2009	S91-PMC2717130	['results\nmaternal characteristics and their bivariate associations with impaired Glucose tolerance are presented intable 1.']	N/A	N/A	[('CHEBI_17234', 'glucose', 80, 'glucose')]
PMC2717130	7/2009	S97-PMC2717130	['Hair Arsenic concentration, available on a subset of participants, ranged from 1.1 to 724.4 ng/g (ppb) ( n = 180; mean 27.4 ± 61.6) and was not significantly correlated with Blood Glucose level (spearman’s rho = 0.04; p = 0.6).']	N/A	N/A	[('UBERON_0001037', 'strand of hair', 0, 'Hair'), ('CHEBI_27563', 'arsenic atom', 5, 'arsenic'), ('UBERON_0000178', 'blood', 174, 'blood'), ('CHEBI_17234', 'glucose', 180, 'glucose')]
PMC2717130	7/2009	S99-PMC2717130	['one-hour Glucose levels ranged from 40 to 284 mg/dl (mean, 108.7 ± 29.5).']	N/A	N/A	[('CHEBI_17234', 'glucose', 9, 'glucose')]
PMC2717130	7/2009	S100-PMC2717130	['almost 12% of women participating had impaired gtts (blood Glucose > 140 mg/dl) at the 24- to 28-week Prenatal visit.']	N/A	N/A	[('CHEBI_17234', 'glucose', 59, 'glucose'), ('GO_0007565', 'female pregnancy', 102, 'prenatal')]
PMC2717130	7/2009	S101-PMC2717130	['using a more sensitive screening criterion (Blood Glucose > 130 mg/dl), > 20% had impaired gtt results.']	N/A	N/A	[('UBERON_0000178', 'blood', 44, 'blood'), ('CHEBI_17234', 'glucose', 50, 'glucose')]
PMC2722408	7/2009	S20-PMC2722408	['exposing fetal Rats to high levels of Glucocorticoids reduces Birth weight and results in Adults with high Blood levels of Insulin and Glucose.']	N/A	N/A	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 15, 'rats'), ('CHEBI_36597', 'phthalazine', 38, 'glucocorticoids'), ('GO_0007567', 'parturition', 62, 'birth'), ('UBERON_0007023', 'adult organism', 90, 'adults'), ('UBERON_0000178', 'blood', 107, 'blood'), ('PR_000045358', 'insulin family protein', 123, 'insulin'), ('CHEBI_17234', 'glucose', 135, 'glucose')]
PMC2749934	9/2009	S91-PMC2749934	['ns \u200a=\u200a not significant.10.1371/journal.pone.0007271.t002\n\ncaption (table-wrap): table 2\nphenotype data, day 110 male offspring.ad meanun meanadjusted p-valuebody weight (grams)511489nsbody length (mm)2382180.05total fat (%)27.835.60.05fat pad weight (% of body weight)1.452.140.05leptin (ng/ml)9.622.50.005insulin (ng/ml)0.2600.5020.001c-peptide (pg/ml)4667290.05plasma Glucose (mmol/l)7.07.2nsfree Fatty Acids (mmol/l)0.860.99nsliver weight (% body weight)2.922.78nsigf-1 (ng/ml)12361145ns\nphenotypic measurements relevant to Metabolic syndrome measured for each of the eight Animals in each treatment group at day 110.']	N/A	N/A	[('CHEBI_17234', 'glucose', 370, 'glucose'), ('CHEBI_35366', 'fatty acid', 399, 'Fatty Acids'), ('PR_000000037', 'BMP receptor type-2', 470, '-1'), ('GO_0008152', 'metabolic process', 527, 'metabolic'), ('NCBITaxon_33208', 'Metazoa', 577, 'animals')]
PMC2749934	9/2009	S136-PMC2749934	['(b) a summary of the Genes that are altered in signaling through the Igf-1 and Pi3K Signaling Pathways and their relevance to Glucose and fat Metabolism.']	N/A	N/A	[('SO_0000704', 'gene', 21, 'genes'), ('GO_0006260', 'DNA replication', 69, 'IGF- ...'), ('PR_000008929', 'interferon-related developmental regulator 1', 69, 'IGF-1'), ('GO_0035196', 'production of miRNAs involved in gene silencing by miRNA', 79, 'PI3K signaling pathways'), ('CHEBI_17234', 'glucose', 126, 'glucose'), ('GO_0006006', 'glucose metabolic process', 126, 'glucose ... metabolism')]
PMC2749934	9/2009	S156-PMC2749934	['its subsequent conversion to succinate is the only step in Glucose Catabolism that produces high-energy phosphate (gtp) directly, without the need for oxidative phosphorylation.']	N/A	N/A	[('CHEBI_17234', 'glucose', 59, 'glucose'), ('GO_0006007', 'glucose catabolic process', 59, 'glucose catabolism')]
PMC2756957	10/2009	S3-PMC2756957	['subsequent offspring remained on pasture until 1.5 years when all received Glucose and Insulin tolerance tests (gtt & itt) and body composition determination by dual energy x-ray absorptiometry (dxa).']	N/A	N/A	[('CHEBI_17234', 'glucose', 75, 'glucose'), ('PR_000045358', 'insulin family protein', 87, 'insulin')]
PMC2756957	10/2009	S41-PMC2756957	['Metabolic flexibility will be assessed in the lean and obese state (body composition determined by dual-energy x-ray absorptiometry) by measurement of Carbohydrate, fat and the protein Metabolite response to a Glucose tolerance test.']	N/A	N/A	[('GO_0008152', 'metabolic process', 0, 'Metabolic'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 151, 'carbohydrate'), ('CHEBI_39382', 'flufenoxuron', 185, 'metabolite'), ('CHEBI_17234', 'glucose', 210, 'glucose')]
PMC2756957	10/2009	S79-PMC2756957	['effects of Prenatal Nutrient restriction and Postnatal obesity on Glucose tolerance and Insulin sensitivity\n\nGlucose tolerance\nwhen lean, fasted Plasma Glucose concentrations were similar between dietary groups (ce, 3.65; lee, 3.95; lel, 3.70 mmol.l−1s.e.d.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 11, 'prenatal'), ('CHEBI_33284', 'nutrient', 20, 'nutrient'), ('GO_0007567', 'parturition', 45, 'postnatal'), ('CHEBI_17234', 'glucose', 66, 'glucose'), ('PR_000045358', 'insulin family protein', 88, 'insulin'), ('CHEBI_17234', 'glucose', 109, 'Glucose'), ('UBERON_0001969', 'blood plasma', 145, 'plasma'), ('CHEBI_17234', 'glucose', 152, 'glucose')]
PMC2756957	10/2009	S92-PMC2756957	['Glucose induced a significant rise in Plasma [Glucose] followed, ∼15–20 mins later, by a significant increment in Plasma [Insulin] (figure 1).']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'glucose'), ('UBERON_0001969', 'blood plasma', 38, 'plasma'), ('CHEBI_17234', 'glucose', 46, 'glucose'), ('UBERON_0001969', 'blood plasma', 114, 'plasma'), ('PR_000045358', 'insulin family protein', 122, 'insulin')]
PMC2756957	10/2009	S93-PMC2756957	['there were no treatment or gender related effects on Glucose tolerance (area under the Glucose response curve) or Insulin sensitivity (area under the Insulin response curve) when the Animals were lean.']	N/A	N/A	[('CHEBI_17234', 'glucose', 53, 'glucose'), ('CHEBI_17234', 'glucose', 87, 'glucose'), ('PR_000045358', 'insulin family protein', 114, 'insulin'), ('PR_000045358', 'insulin family protein', 150, 'insulin'), ('NCBITaxon_33208', 'Metazoa', 183, 'animals')]
PMC2756957	10/2009	S96-PMC2756957	['Glucose was administered i.v.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose')]
PMC2756957	10/2009	S97-PMC2756957	['(0.5 g.kg−1) and Blood samples collected for measurement of Plasma Glucose and Insulin (by elisa, seemethods).']	N/A	N/A	[('UBERON_0000178', 'blood', 17, 'blood'), ('UBERON_0001969', 'blood plasma', 60, 'plasma'), ('CHEBI_17234', 'glucose', 67, 'glucose'), ('PR_000045358', 'insulin family protein', 79, 'insulin')]
PMC2756957	10/2009	S98-PMC2756957	['statistics are *, p<0.05 lel vs. ce and lee for peak Insulin concentration.10.1371/journal.pone.0007393.g002\n\ncaption (fig): figure 2\npeak Plasma Insulin in lean and obese male and female Prenatally Nutrient restricted Adult Sheep during a Glucose tolerance test.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 53, 'insulin'), ('UBERON_0001969', 'blood plasma', 139, 'plasma'), ('PR_000045358', 'insulin family protein', 146, 'insulin'), ('GO_0019230', 'proprioception', 188, 'prenatally'), ('CHEBI_33284', 'nutrient', 199, 'nutrient'), ('UBERON_0007023', 'adult organism', 219, 'adult'), ('NCBITaxon_10088', 'Mus <genus>', 225, 'sheep'), ('CHEBI_17234', 'glucose', 240, 'glucose')]
PMC2756957	10/2009	S102-PMC2756957	['Insulin sensitivity\ninjection of Insulin reduced plasma Glucose by 0.92 (s.e.d.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 0, 'Insulin'), ('PR_000045358', 'insulin family protein', 33, 'insulin'), ('CHEBI_17234', 'glucose', 56, 'glucose')]
PMC2756957	10/2009	S120-PMC2756957	['change during the gtt\nfollowing injection of Glucose, Plasma nefa, Tag and Glycerol concentrations declined (p<0.01) in both lean and obese Animals.']	N/A	N/A	[('CHEBI_17234', 'glucose', 45, 'glucose'), ('UBERON_0001969', 'blood plasma', 54, 'plasma'), ('CHEBI_17855', 'triglyceride', 67, 'TAG'), ('CHEBI_17754', 'glycerol', 75, 'glycerol'), ('NCBITaxon_33208', 'Metazoa', 140, 'animals')]
PMC2756957	10/2009	S160-PMC2756957	['blunted first pass Insulin Metabolism and Insulin-induced suppression of Hepatic Glucose output).']	N/A	N/A	[('GO_1901142', 'insulin metabolic process', 19, 'insulin metabolism'), ('PR_000045358', 'insulin family protein', 19, 'insulin'), ('PR_000045358', 'insulin family protein', 42, 'insulin'), ('UBERON_0002107', 'liver', 73, 'hepatic'), ('CHEBI_17234', 'glucose', 81, 'glucose')]
PMC2756957	10/2009	S163-PMC2756957	['as a measure of Insulin-dependent peripheral Glucose Uptake).']	N/A	N/A	[('PR_000045358', 'insulin family protein', 16, 'insulin'), ('CHEBI_17234', 'glucose', 45, 'glucose'), ('GO_0046323', 'glucose import', 45, 'glucose uptake')]
PMC2756957	10/2009	S183-PMC2756957	['during hyperglycaemia, clearance is additionally coupled to mass-action passive Glucose Transfer Into Pancreatic and Hepatic Cells (via Glut2, which has a high kmfor Glucose;[36]).']	N/A	N/A	[('CHEBI_17234', 'glucose', 80, 'glucose'), ('GO_0045023', 'G0 to G1 transition', 80, 'glucose transfer into ...'), ('CL_0002351', 'progenitor cell of endocrine pancreas', 102, 'pancreatic ...'), ('UBERON_0001264', 'pancreas', 102, 'pancreatic'), ('CL_0000632', 'hepatic stellate cell', 117, 'hepatic cells'), ('UBERON_0002107', 'liver', 117, 'hepatic'), ('GO_0007567', 'parturition', 125, 'cells'), ('PR_000008011', 'glycerol kinase 2', 136, 'Glut2'), ('CHEBI_17234', 'glucose', 166, 'glucose')]
PMC2756957	10/2009	S213-PMC2756957	['the obese Individual, in response to elevated Blood Glucose, responded with markedly blunted excursions in Plasma Metabolites and biochemistry (table 3for Plasma biochemistry and supplementaryfigure s5for nefa).']	N/A	N/A	[('NCBITaxon_1', 'root', 10, 'individual'), ('UBERON_0000178', 'blood', 46, 'blood'), ('CHEBI_17234', 'glucose', 52, 'glucose'), ('UBERON_0001969', 'blood plasma', 107, 'plasma'), ('CHEBI_25212', 'metabolite', 114, 'metabolites'), ('UBERON_0001969', 'blood plasma', 155, 'plasma')]
PMC2756957	10/2009	S244-PMC2756957	['after two weeks, Sheep were weighed and a Jugular catheter inserted under local anaesthesia (0.5 ml Lignocaine Hydrochloride) and after 24 h fasting all Sheep were subjected, on separate days, to 1) a Glucose tolerance test (gtt), 2) an Insulin tolerance test (itt) and 3) body composition analysis by dual energy x-ray absorptiometry (dxa).']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 17, 'sheep'), ('UBERON_0004741', 'cleithrum', 42, 'jugular'), ('CHEBI_6475', 'Lindheimerine', 100, 'Lignocaine'), ('CHEBI_17883', 'hydrogen chloride', 111, 'hydrochloride'), ('NCBITaxon_10088', 'Mus <genus>', 153, 'sheep'), ('CHEBI_17234', 'glucose', 201, 'glucose'), ('PR_000045358', 'insulin family protein', 237, 'insulin')]
PMC2756957	10/2009	S250-PMC2756957	['experimental protocols\n\nGlucose tolerance test\nafter 24 h fasting, Blood (5 ml) was withdrawn into a K+edta Blood tube at −10 and −5 min relative to injection of a bolus dose of Glucose Solution (i.v.']	N/A	N/A	[('CHEBI_17234', 'glucose', 24, 'Glucose'), ('UBERON_0000178', 'blood', 67, 'blood'), ('CHEBI_52071', 'dextran', 101, 'K'), ('UBERON_0000178', 'blood', 108, 'blood'), ('CHEBI_17234', 'glucose', 178, 'glucose'), ('CHEBI_75958', 'solution', 186, 'solution')]
PMC2756957	10/2009	S255-PMC2756957	['the dose of Insulin given is designed to reduce resting Plasma Glucose by ∼1–1.5 mm over a 15–16 min period and from this the percentage decline in Blood Glucose concentration per minute (%min−1) from 4 to 16 min relative to baseline (0 and 2 mins) is calculated[60].']	N/A	N/A	[('PR_000045358', 'insulin family protein', 12, 'insulin'), ('UBERON_0001969', 'blood plasma', 56, 'plasma'), ('CHEBI_17234', 'glucose', 63, 'glucose'), ('UBERON_0000178', 'blood', 148, 'blood'), ('CHEBI_17234', 'glucose', 154, 'glucose')]
PMC2756957	10/2009	S272-PMC2756957	['assays of Blood and Plasma\n\nBlood biochemistry\nduring each gtt, baseline (−10 min) and +120 min whole Blood samples were auto-analysed for concentrations of Glucose, K+,Na+, Ca2+, Cl−(mmol.l−1) ph, p Co2, p O2, and Hco3−(mmhg; abl805-flex, radiometer, crawley, uk), subsequently, all gtt Plasma samples were assayed for concentrations (mmol.l−1) of Glucose, Urea, Triacylglycerides (Tag), Glycerol (µmol.l−1) and non-esterified Fatty Acids (nefas) whilst baseline samples were also analysed for concentrations of amino acids (nmoles.ml−1), Cholesterol, hdl, ldl, Glycerol (all mmol.l−1and by randox rx imola, co antrim, uk), haemoglobin (g/dl; osm3, radiometer, crawley, uk) and haematocrit (%).']	N/A	N/A	[('UBERON_0000178', 'blood', 10, 'blood'), ('UBERON_0001969', 'blood plasma', 20, 'plasma'), ('UBERON_0000178', 'blood', 28, 'Blood'), ('UBERON_0000178', 'blood', 102, 'blood'), ('CHEBI_17234', 'glucose', 157, 'glucose'), ('CHEBI_30050', 'gold(0)', 166, 'K+,'), ('CHEBI_26710', 'sodium chloride', 169, 'Na+,'), ('CHEBI_3312', 'calcium dichloride', 174, 'Ca2+,'), ('CHEBI_16236', 'ethanol', 180, 'Cl−('), ('CHEBI_16526', 'carbon dioxide', 200, 'CO2'), ('CHEBI_15379', 'dioxygen', 207, 'O2'), ('CHEBI_37566', 'S-beta-D-glucosyl-L-cysteine', 215, 'HCO3−('), ('UBERON_0001969', 'blood plasma', 288, 'plasma'), ('CHEBI_17234', 'glucose', 349, 'glucose'), ('CHEBI_16199', 'urea', 358, 'urea'), ('CHEBI_17855', 'triglyceride', 364, 'triacylglycerides'), ('CHEBI_17855', 'triglyceride', 383, 'TAG'), ('CHEBI_17754', 'glycerol', 389, 'glycerol'), ('CHEBI_35366', 'fatty acid', 428, 'fatty acids'), ('CHEBI_16113', 'cholesterol', 540, 'cholesterol'), ('CHEBI_17754', 'glycerol', 563, 'glycerol')]
PMC2756957	10/2009	S274-PMC2756957	['Plasma obtained during the itt was analysed for concentrations of Glucose, nefa, Glycerol and Tag (all mmol.l−1).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_17234', 'glucose', 66, 'glucose'), ('CHEBI_17754', 'glycerol', 81, 'glycerol'), ('CHEBI_17855', 'triglyceride', 94, 'TAG')]
PMC2756957	10/2009	S284-PMC2756957	['statistics\n\nunivariate analysis\nthe Glucose, Insulin, Tag, Glycerol and nefa data from each gtt were collated and baselines and the areas under the response curves (auc) calculated using the trapezoid rule (graphpad prism 5).']	N/A	N/A	[('CHEBI_17234', 'glucose', 36, 'glucose'), ('PR_000045358', 'insulin family protein', 45, 'insulin'), ('CHEBI_17855', 'triglyceride', 54, 'TAG'), ('CHEBI_17754', 'glycerol', 59, 'glycerol')]
PMC2756957	10/2009	S338-PMC2756957	['caption (supplementary-material): figure s3\n\nthe Lipid Metabolite response to a Glucose tolerance test in male and female lean and obese Sheep.']	N/A	N/A	[('CHEBI_18059', 'lipid', 49, 'lipid'), ('CHEBI_39382', 'flufenoxuron', 55, 'metabolite'), ('CHEBI_17234', 'glucose', 80, 'glucose'), ('NCBITaxon_10088', 'Mus <genus>', 137, 'sheep')]
PMC2756957	10/2009	S339-PMC2756957	['data are mean±sem for areas under the Glucose response curve (respective auc units).']	N/A	N/A	[('CHEBI_17234', 'glucose', 38, 'glucose')]
PMC2756957	10/2009	S346-PMC2756957	['caption (supplementary-material): figure s5\n\nthe Glucose, nefa and Triglyceride response of Prenatally Nutrient restricted Adult Sheep to an Insulin tolerance test when obese.']	N/A	N/A	[('CHEBI_17234', 'glucose', 49, 'glucose'), ('CHEBI_17855', 'triglyceride', 67, 'triglyceride'), ('GO_0019230', 'proprioception', 92, 'prenatally'), ('CHEBI_33284', 'nutrient', 103, 'nutrient'), ('UBERON_0007023', 'adult organism', 123, 'adult'), ('NCBITaxon_10088', 'Mus <genus>', 129, 'sheep'), ('PR_000045358', 'insulin family protein', 141, 'insulin')]
PMC2780862	12/2009	S57-PMC2780862	['glucokinase is a key enzyme in Hepatic Glucose Utilization, and its activity is decreased in the Liver of diabetic patients (35).']	N/A	N/A	[('UBERON_0002107', 'liver', 31, 'hepatic'), ('CHEBI_17234', 'glucose', 39, 'glucose'), ('GO_0006094', 'gluconeogenesis', 39, 'glucose utilization'), ('UBERON_0002107', 'liver', 97, 'liver')]
PMC2780862	12/2009	S70-PMC2780862	['the most well-characterized member, Sirt1, Regulates several Metabolic Pathways including Adipogenesis, Mitochondrial biogenesis, Glucose Utilization, fat oxidation, and Insulin secretion.']	N/A	N/A	[('PR_000014888', 'NAD-dependent protein deacetylase sirtuin-1', 36, 'SIRT1'), ('GO_0065007', 'biological regulation', 43, 'regulates'), ('GO_0009081', 'branched-chain amino acid metabolic process', 61, 'metabolic pathways'), ('GO_0060612', 'adipose tissue development', 90, 'adipogenesis'), ('GO_0005739', 'mitochondrion', 104, 'mitochondrial'), ('CHEBI_17234', 'glucose', 130, 'glucose'), ('GO_0006094', 'gluconeogenesis', 130, 'glucose utilization'), ('PR_000045358', 'insulin family protein', 170, 'insulin')]
PMC2780862	12/2009	S93-PMC2780862	['exercise induces the Expression of a number of Genes that Regulate Glucose Uptake in Skeletal muscle, including Glut Isoform 4 (Glut4), (68).']	N/A	N/A	[('GO_0010467', 'gene expression', 21, 'expression'), ('SO_0000704', 'gene', 47, 'genes'), ('GO_0065007', 'biological regulation', 58, 'regulate'), ('CHEBI_17234', 'glucose', 67, 'glucose'), ('GO_0046323', 'glucose import', 67, 'glucose uptake'), ('UBERON_0004288', 'skeleton', 85, 'skeletal'), ('PR_000002299', 'apoptosis regulator BAX isoform 1', 112, 'GLUT isoform 4'), ('SO_0001060', 'sequence_variant', 117, 'isoform'), ('PR_000015065', 'solute carrier family 2, facilitated glucose transporter member 3', 128, 'GLUT4')]
PMC2780862	12/2009	S153-PMC2780862	['these changes persist for 6 days during culture at normal Glucose levels.']	N/A	N/A	[('CHEBI_17234', 'glucose', 58, 'glucose')]
PMC2825514	1/2010	S47-PMC2825514	['biochemical assays\nPlasma tg, ffa and Glucose concentrations were analyzed with commercially available kits (roche diagnostic, basel, switzerland; wako chemicals, richmond, va and sigma, buchs, switzerland, respectively).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 19, 'Plasma'), ('CHEBI_17234', 'glucose', 38, 'glucose')]
PMC2825514	1/2010	S139-PMC2825514	['there were no significant differences in Plasma Glucose between groups at d21 (data not shown) and neither at d136 (10%-ala, 112.0 ± 3.3; 2.4%-ala, 110.0 ± 6.7 and 0.8%-ala group, 104.5 ± 4.6 mg.dl-1).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 41, 'plasma'), ('CHEBI_17234', 'glucose', 48, 'glucose')]
PMC2880107	5/2010	S44-PMC2880107	['Plasma Glucose was measured along with quality controls using commercial kits (roche diagnostics corp.; in, usa) on an auto-analyzer (roche/hitachi 9002 analyzer; hitachi, tokyo, japan).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_17234', 'glucose', 7, 'glucose')]
PMC2880107	5/2010	S59-PMC2880107	['differences in Plasma Glucose and Insulin concentrations were also evident between sexes and groups (table2).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 15, 'plasma'), ('CHEBI_17234', 'glucose', 22, 'glucose'), ('PR_000045358', 'insulin family protein', 34, 'insulin')]
PMC2880107	5/2010	S65-PMC2880107	['caption (table-wrap): table 2\n\nmature female and male Plasma Insulin and Glucose concentrations.Insulin (μg/l)Glucose (mmol/l)femalemalefemalemale mean ± semmean ± semmean ± semmean ± semchow Fed adad2.2 ± 0.4abx2.0 ± 0.6ax8.6 ± 0.3ax8.5 ± 0.4abxadun1.5 ± 0.4ax3.5 ± 0.5bcy8.3 ± 0.3ax8.8 ± 0.4abxunad1.6 ± 0.4ax2.5 ± 0.3aby9.1 ± 0.3ax8.1 ± 0.2ayhigh fat Fed adad2.9 ± 0.4Bcx4.0 ± 0.6Bcx8.7 ± 0.3ax9.1 ± 0.4bxadun3.1 ± 0.5Bcx3.1 ± 0.5abcx8.9 ± 0.3ax8.1 ± 0.3axunad3.6 ± 0.4Cx4.1 ± 0.3bcx10.2 ± 0.3bx9.4 b ± 0.2by\nInsulin and Glucose: female adad Chow (n = 9), adun Chow (n = 7), unad Chow (n = 6), adad high fat (n = 9), adun high fat (n = 6), unad high fat (n = 8); male adad Chow (n = 4), adun Chow (n = 5), unad Chow (n = 15), adad high fat (n = 4), adun high fat (n = 6), unad high fat (n = 14).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 54, 'plasma'), ('PR_000045358', 'insulin family protein', 61, 'insulin'), ('CHEBI_17234', 'glucose', 73, 'glucose'), ('PR_000045358', 'insulin family protein', 96, 'Insulin'), ('CHEBI_17234', 'glucose', 110, 'Glucose'), ('GO_0007631', 'feeding behavior', 192, 'fed'), ('GO_0007631', 'feeding behavior', 354, 'fed'), ('PR_000012552', 'pescadillo', 370, '4bcx4'), ('PR_000012509', 'PDZ and LIM domain protein 2', 382, '6bcx8'), ('PR_000011040', 'nuclear receptor coactivator 1', 420, '5bcx3'), ('PR_000007225', 'ETS translocation variant 3', 471, '4cx4'), ('PR_000045358', 'insulin family protein', 512, 'Insulin'), ('CHEBI_17234', 'glucose', 524, 'glucose'), ('CHEBI_33290', 'food', 545, 'chow'), ('CHEBI_33290', 'food', 564, 'chow'), ('CHEBI_33290', 'food', 583, 'chow'), ('CHEBI_33290', 'food', 676, 'chow'), ('CHEBI_33290', 'food', 695, 'chow'), ('CHEBI_33290', 'food', 714, 'chow')]
PMC2885310	5/2010	S22-PMC2885310	['we analyzed maternal Plasma Glucose concentrations 1 hour after a 50-gram Oral Glucose challenge as part of routine mid-Pregnancy screening for gdm.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 21, 'plasma'), ('CHEBI_17234', 'glucose', 28, 'glucose'), ('UBERON_0000165', 'mouth', 74, 'oral'), ('CHEBI_17234', 'glucose', 79, 'glucose'), ('GO_0007565', 'female pregnancy', 120, 'pregnancy')]
PMC2885310	5/2010	S49-PMC2885310	['in our study setting, according to the recommendations from the american diabetes association (ada) [25], all Pregnant women were screened at 24-28 weeks Gestation using a 50 gram 1-hour Oral Glucose challenge test.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 110, 'pregnant'), ('GO_0007565', 'female pregnancy', 154, 'gestation'), ('UBERON_0000165', 'mouth', 187, 'oral'), ('CHEBI_17234', 'glucose', 192, 'glucose')]
PMC2885310	5/2010	S50-PMC2885310	['those patients who failed this screening test (Glucose ≥ 140 mg/dl) were then followed-up within 1-2 weeks with a 100 gram, 3-hour oral Glucose tolerance test (ogtt).']	N/A	N/A	[('CHEBI_17234', 'glucose', 47, 'glucose'), ('CHEBI_17234', 'glucose', 136, 'glucose')]
PMC2885310	5/2010	S51-PMC2885310	["we abstracted laboratory results from participants' 50 gram 1-hour Glucose challenge test and from the diagnostic 100 gram 3-hour ogtt."]	N/A	N/A	[('CHEBI_17234', 'glucose', 67, 'glucose')]
PMC2885310	5/2010	S52-PMC2885310	['women were diagnosed with gdm if two or more of the 100 gram ogtt Glucose levels exceeded the ada criteria [28] as follows: fasting ≥ 95 mg/dl; 1-hour ≥ 180 mg/dl; 2-hour ≥ 155 mg/dl; 3-hour ≥ 140 mg/dl.']	N/A	N/A	[('CHEBI_17234', 'glucose', 66, 'glucose')]
PMC2885310	5/2010	S54-PMC2885310	['we assessed Glucose intolerance by analyzing results of the 1-hour Oral Glucose screening test results.']	N/A	N/A	[('CHEBI_17234', 'glucose', 12, 'glucose'), ('UBERON_0000165', 'mouth', 67, 'oral'), ('CHEBI_17234', 'glucose', 72, 'glucose')]
PMC2885310	5/2010	S55-PMC2885310	['linear regression procedures were used to estimate maternal mean 1-hour Glucose concentrations while adjusting for confounding by maternal age and race/ethnicity.']	N/A	N/A	[('CHEBI_17234', 'glucose', 72, 'glucose')]
PMC2885310	5/2010	S56-PMC2885310	['we fitted generalized linear models, using a log-link function, to derive relative risk (rr) and 95% confidence intervals (95% cis) [29,30] of the associations between Sleep duration and snoring variables with Glucose intolerance and gdm risk.']	N/A	N/A	[('GO_0030431', 'sleep', 168, 'sleep'), ('CHEBI_17234', 'glucose', 210, 'glucose')]
PMC2885310	5/2010	S80-PMC2885310	['maternal mean 1-hour Plasma Glucose concentrations, adjusted for age and race/ethnicity, were highest for women who reported habitual sleep duration ≤ 4 hours per night during early Pregnancy and lowest for those who reported sleeping 9 hours per night on average.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 21, 'plasma'), ('CHEBI_17234', 'glucose', 28, 'glucose'), ('GO_0007565', 'female pregnancy', 182, 'pregnancy')]
PMC2885310	5/2010	S81-PMC2885310	['mean Glucose concentrations 1-hour after a 50-gram oral Glucose challenge were 16.3 mg/dl higher in women who reported Sleeping ≤ 4 hours (95% ci 1.1-31.6, p = 0.04), 2.3 mg/dl higher for women who reported sleeping 5-8 hours (95% ci -1.8-6.3, p = 0.27), and 6.3 mg/dl higher for women who reported Sleeping ≥ 10 hours (95% ci -0.5-13.2, p = 0.07) compared with those who reported Sleeping 9 hours per night.']	N/A	N/A	[('CHEBI_17234', 'glucose', 5, 'glucose'), ('CHEBI_17234', 'glucose', 56, 'glucose'), ('GO_0034331', 'cell junction maintenance', 119, 'sleeping'), ('GO_0034331', 'cell junction maintenance', 299, 'sleeping'), ('GO_0034331', 'cell junction maintenance', 381, 'sleeping')]
PMC2885310	5/2010	S86-PMC2885310	['caption (fig): figure 1\n\nmaternal mean Plasma Glucose concentrations after a 50-g Glucose challenge .']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 39, 'plasma'), ('CHEBI_17234', 'glucose', 46, 'glucose'), ('CHEBI_17234', 'glucose', 82, 'glucose')]
PMC2885310	5/2010	S89-PMC2885310	['caption (fig): figure 2\n\nmaternal mean 1-hour Plasma Glucose concentrations after a 50-g oral Glucose challenge .']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 46, 'plasma'), ('CHEBI_17234', 'glucose', 53, 'glucose'), ('CHEBI_17234', 'glucose', 94, 'glucose')]
PMC2885310	5/2010	S91-PMC2885310	['proportion (%) of women with 1-hour Glucose concentrations ≥ 140 mg/dl (b).']	N/A	N/A	[('CHEBI_17234', 'glucose', 36, 'glucose')]
PMC2885310	5/2010	S109-PMC2885310	['additionally, Glucose concentrations were statistically significantly elevated among women who snored during Pregnancy; and the relative risk of gdm among overweight women who snored, compared to their non-snoring and lean counterparts was 6.91 (95% ci 2.87-16.6).']	N/A	N/A	[('CHEBI_17234', 'glucose', 14, 'glucose'), ('GO_0007565', 'female pregnancy', 109, 'pregnancy')]
PMC2885310	5/2010	S138-PMC2885310	['a total of 251 study subjects had a post-50 gram 1-hour Glucose concentration ≥ 140 mg/dl and thus required the follow-up diagnostic 100-gram Oral Glucose tolerance test (ogtt).']	N/A	N/A	[('CHEBI_17234', 'glucose', 56, 'glucose'), ('UBERON_0000165', 'mouth', 142, 'oral'), ('CHEBI_17234', 'glucose', 147, 'glucose')]
PMC2885310	5/2010	S143-PMC2885310	['sympathetic hyperactivity can alter Glucose Homeostasis and induce Insulin resistance by increasing Glycogen Breakdown and Gluconeogenesis.']	N/A	N/A	[('CHEBI_17234', 'glucose', 36, 'glucose'), ('GO_0042593', 'glucose homeostasis', 36, 'glucose homeostasis'), ('PR_000045358', 'insulin family protein', 67, 'insulin'), ('CHEBI_24384', 'glycogens', 100, 'glycogen'), ('GO_0005980', 'glycogen catabolic process', 100, 'glycogen breakdown'), ('GO_0006094', 'gluconeogenesis', 123, 'gluconeogenesis')]
PMC2888576	6/2010	S103-PMC2888576	['at 10 days of age lun Mice were hypoglycemic with non-fasted Blood Glucose levels of approximately 60 mg%, compared to Mice on a control diet (100 mg%).']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 22, 'mice'), ('UBERON_0000178', 'blood', 61, 'blood'), ('CHEBI_17234', 'glucose', 67, 'glucose'), ('NCBITaxon_10088', 'Mus <genus>', 119, 'mice')]
PMC2909243	6/2010	S94-PMC2909243	['Blood collection\nfasting Blood samples were taken from the Anterior Cubital Fossa for subsequent Glucose, Insulin, hba1c, hormonal, inflammatory and dna analyses.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('UBERON_0000178', 'blood', 25, 'blood'), ('UBERON_0003720', 'anterior cranial fossa', 59, 'anterior cubital fossa'), ('CHEBI_17234', 'glucose', 97, 'glucose'), ('PR_000045358', 'insulin family protein', 106, 'insulin')]
PMC2936567	9/2010	S85-PMC2936567	["for Glucose concentration analysis, proteins were precipitated by addition of 200 µl Hclo4(0.33n) to 20 µl Blood and concentration was determined by the Glucose oxidase method using trinder's Reagent (stanbio laboratory, texas, usa)."]	N/A	N/A	[('CHEBI_17234', 'glucose', 4, 'glucose'), ('CHEBI_63016', 'nonyl phenoxypolyethoxylethanol', 85, 'HClO4'), ('UBERON_0000178', 'blood', 107, 'blood'), ('CHEBI_17234', 'glucose', 153, 'glucose'), ('CHEBI_33893', 'reagent', 192, 'reagent')]
PMC2936567	9/2010	S91-PMC2936567	['Intraperitoneal Glucose tolerance test\nIntraperitoneal Glucose tolerance test (ipgtt) was performed after an overnight fast at 3 and 9 months in male offspring of c57bl6/j dams as well as at 6 months in male offspring of ldlr−/− dams.']	N/A	N/A	[('UBERON_0007158', 'lumen of anal canal', 0, 'Intraperitoneal'), ('CHEBI_17234', 'glucose', 16, 'Glucose'), ('UBERON_0007158', 'lumen of anal canal', 39, 'Intraperitoneal'), ('CHEBI_17234', 'glucose', 55, 'glucose')]
PMC2936567	9/2010	S92-PMC2936567	['Glucose was measured after a single Intraperitoneal bolus of Glucose (20% Glucose Solution, 2 g/kg) in samples collected by Tail bleeding after 0, 30, 60 and 120 minutes.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('UBERON_2001932', 'sensory canal tubular ossicle', 36, 'intraperitoneal'), ('CHEBI_17234', 'glucose', 61, 'glucose'), ('CHEBI_17234', 'glucose', 74, 'glucose'), ('CHEBI_75958', 'solution', 82, 'solution'), ('UBERON_0002415', 'tail', 124, 'tail')]
PMC2936567	9/2010	S93-PMC2936567	['Glucose concentration was determined with a Glucometer (ascencia contour, bayer health care, mishawak, in, usa).']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('CHEBI_24321', 'glutamo group', 44, 'glucometer')]
PMC2936567	9/2010	S113-PMC2936567	['Plasma Glucose concentration was significantly decreased in lp group compared to the c group (table 1).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_17234', 'glucose', 7, 'glucose')]
PMC2936567	9/2010	S218-PMC2936567	['in rodents, fetal exposure to excess Glucocorticoids via maternal stress (calorie restriction) or Drug treatment (Dexamethasone) lowered Birth weight, increased Glucose and Insulin levels and also increased Blood pressure in the Adult progeny[42].']	N/A	N/A	[('CHEBI_36597', 'phthalazine', 37, 'glucocorticoids'), ('CHEBI_23888', 'drug', 98, 'drug'), ('CHEBI_41879', 'dexamethasone', 114, 'dexamethasone'), ('GO_0007567', 'parturition', 137, 'birth'), ('CHEBI_17234', 'glucose', 161, 'glucose'), ('PR_000045358', 'insulin family protein', 173, 'insulin'), ('UBERON_0000178', 'blood', 207, 'blood'), ('UBERON_0007023', 'adult organism', 229, 'adult')]
PMC2939651	8/2010	S47-PMC2939651	['measurement of circulating parameters under Fed/fasting conditions, and calculation of the Homeostatic model assessment for Insulin resistance at different ages\nBlood Glucose concentration was measured by accu-chek glucometer (roche diagnostics, barcelona, spain).']	N/A	N/A	[('GO_0007631', 'feeding behavior', 44, 'fed'), ('GO_0042592', 'homeostatic process', 91, 'homeostatic'), ('PR_000045358', 'insulin family protein', 124, 'insulin'), ('UBERON_0000178', 'blood', 161, 'Blood'), ('CHEBI_17234', 'glucose', 167, 'glucose')]
PMC2939651	8/2010	S52-PMC2939651	['it was calculated from fasting Insulin and Glucose concentration using the formula of matthews et al [13]: homa-ir = fasting Glucose (mmol/liter) × fasting Insulin (mu/liter)/22.5.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 31, 'insulin'), ('CHEBI_17234', 'glucose', 43, 'glucose'), ('CHEBI_17234', 'glucose', 125, 'glucose'), ('PR_000045358', 'insulin family protein', 156, 'insulin')]
PMC2939651	8/2010	S98-PMC2939651	['circulating parameters under Fed and fasting conditions in the offspring\ncirculating Glucose, Insulin, leptin, Triglycerides and nefa levels were measured in control and cr male and female Animals under Fed and 14 h fasting conditions at the ages of 2, 4 and 5 months (table1).']	N/A	N/A	[('GO_0007631', 'feeding behavior', 29, 'fed'), ('CHEBI_17234', 'glucose', 85, 'glucose'), ('PR_000045358', 'insulin family protein', 94, 'insulin'), ('CHEBI_17855', 'triglyceride', 111, 'triglycerides'), ('NCBITaxon_33208', 'Metazoa', 189, 'animals'), ('GO_0007631', 'feeding behavior', 203, 'fed')]
PMC2939651	8/2010	S99-PMC2939651	['caption (table-wrap): table 1\n\nBlood parametersglucose(mg/dl)Insulin(μg/l)leptin(μg/l)Triglycerides(mg/ml)Nefa(μg/l)controlcrcontrolcrcontrolcrcontrolcrcontrolcrmalesad libitum98 ± 495 ± 40.774 ± 0.1661.44 ± 0.27#3.52 ± 0.433.38 ± 0.440.669 ± 0.1931.48 ± 0.20#0.447 ± 0.0540.895 ± 0.054#2 month-old14-h fasting65 ± 2+66 ± 3+0.115 ± 0.029+0.103 ± 0.026+0.832 ± 0.053+0.471 ± 0.086+0.447 ± 0.0651.30 ± 0.24#0.622 ± 0.0771.21 ± 0.03+ #anovafrxffrr,f ad libitum73 ± 277 ± 21.44 ± 0.242.29 ± 0.607.34 ± 0.749.48 ± 0.711.25 ± 0.251.57 ± 0.130.765 ± 0.0791.12 ± 0.164 month-old14-h fasting64 ± 3+72 ± 30.468 ± 0.094+1.15 ± 0.29+ #4.23 ± 0.31+4.82 ± 0.33+0.636 ± 0.153+1.12 ± 0.10+ #0.842 ± 0.1441.35 ± 0.11#anovafffr,fr ad libitum77 ± 580 ± 21.47 ± 0.412.69 ± 0.68#8.17 ± 1.2515.3 ± 1.6#1.06 ± 0.161.94 ± 0.23#1.27 ± 0.071.17 ± 0.145 month-old14-h fasting63 ± 3+65 ± 3+0.583 ± 0.147+1.43 ± 0.35+ #4.44 ± 0.78+6.17 ± 0.84+1.02 ± 0.211.31 ± 0.21+1.20 ± 0.101.26 ± 0.07 anovafr,frxfr femalesad libitum92 ± 3100 ± 50.657 ± 0.1151.55 ±0.35#3.38 ± 0.442.87 ± 0.320.373 ± 0.0630.946 ± 0.142#0.529 ± 0.0570.921 ± 0.047#2 month-old14-h fasting71 ± 2+71 ± 3+0.134 ± 0.019+0.134 ±0.014+0.448 ± 0.055+0.511 ± 0.129+0.516 ± 0.1480.633 ± 0.2170.657 ± 0.0851.28 ± 0.11+ #anovafrxffrr,f ad libitum84 ± 682 ± 21.27 ± 0.161.86 ±0.355.59 ± 0.266.31 ± 0.370.747 ± 0.1761.66 ± 0.38#0.715 ± 0.0901.35 ± 0.15#4 month-old14-h fasting67 ± 3+67 ± 1+0.246 ± 0.045+0.465 ±0.120+2.03 ± 0.17+2.09 ± 0.10+0.496 ± 0.119+0.693 ± 0.102+0.826 ± 0.1051.26 ± 0.08#anovafffr,fr ad libitum80 ± 181 ± 31.47 ± 0.192.34 ± 0.33#7.21 ± 0.676.21 ± 0.4490.909 ± 0.2901.44 ± 0.300.957 ± 0.0681.10 ± 0.095 month-old14-h fasting69 ± 2+60 ± 3+ #0.251 ± 0.033+0.476 ± 0.103+2.98 ± 0.20+3.25 ± 0.162+1.14 ± 0.321.19 ± 0.291.17 ± 0.091.30 ± 0.12 anovafr, ff\ncirculating Glucose, Insulin, leptin, Triacylglicerides and non-esterified Fatty Acid (nefa) in male and female offspring of controls and caloric restricted dams during Gestation (cr) at the ages of 2, 4 and 5 months, under ad libitum Feeding conditions and after 14 h fasting conditions.']	N/A	N/A	[('UBERON_0000178', 'blood', 31, 'Blood'), ('PR_000045358', 'insulin family protein', 61, 'Insulin'), ('CHEBI_17855', 'triglyceride', 86, 'Triglycerides'), ('CHEBI_13389', 'NAD', 106, 'NEFA'), ('CHEBI_17234', 'glucose', 1810, 'glucose'), ('PR_000045358', 'insulin family protein', 1819, 'insulin'), ('CHEBI_17855', 'triglyceride', 1836, 'triacylglicerides'), ('CHEBI_35366', 'fatty acid', 1873, 'fatty acid'), ('GO_0007565', 'female pregnancy', 1967, 'gestation'), ('GO_0007631', 'feeding behavior', 2033, 'feeding')]
PMC2945165	10/2010	S4-PMC2945165	['Plasma 8-Isoprostane, fasting Glucose, Insulin, leptin, and adiponectin levels were assessed in 12-month-old infants.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_35870', 'diarsenide', 7, '8-isoprostane'), ('CHEBI_17234', 'glucose', 30, 'glucose'), ('PR_000045358', 'insulin family protein', 39, 'insulin')]
PMC2945165	10/2010	S32-PMC2945165	['all women had normal fasting Glucose (<100 mg/dl) and a normal oral Glucose tolerance test (oral Intake of 75 g of Glucose) with 2-h blood Glucose ≤140 mg/dl during Pregnancy.']	N/A	N/A	[('CHEBI_17234', 'glucose', 29, 'glucose'), ('CHEBI_17234', 'glucose', 68, 'glucose'), ('GO_0007631', 'feeding behavior', 97, 'intake'), ('CHEBI_17234', 'glucose', 115, 'glucose'), ('CHEBI_17234', 'glucose', 139, 'glucose'), ('GO_0007565', 'female pregnancy', 165, 'pregnancy')]
PMC2945165	10/2010	S36-PMC2945165	['Blood samples were centrifuged, and aliquots of Plasma or Serum were used for Glucose and Insulin measurements by the hospital clinical laboratory or frozen (at −80°c) until assessed by the laboratory of experimental diabetes and Aging, the mount sinai school of medicine (new york, ny).']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('UBERON_0001969', 'blood plasma', 48, 'plasma'), ('UBERON_0001977', 'blood serum', 58, 'serum'), ('CHEBI_17234', 'glucose', 78, 'glucose'), ('PR_000045358', 'insulin family protein', 90, 'insulin'), ('GO_0007568', 'aging', 230, 'Aging')]
PMC2945165	10/2010	S39-PMC2945165	['Insulin resistance was calculated according to the homa index as fasting Insulin × fasting Glucose (millimoles per liter)/22.5 (13).']	N/A	N/A	[('PR_000045358', 'insulin family protein', 0, 'Insulin'), ('PR_000045358', 'insulin family protein', 73, 'insulin'), ('CHEBI_17234', 'glucose', 91, 'glucose')]
PMC2945165	10/2010	S85-PMC2945165	['infant Plasma Insulin and Glucose (or homa) levels were within the normal range at Birth and remained stable during the 1st year of Life (Insulin 5.4 ± 9, 3.2 ± 1.6, and 4.0 ± 3 units/ml; Glucose 82 ± 22, 85 ± 10, and 84 ± 8 mg/dl; and homa 1.12 ± 2.1, 0.69 ± 0.4, and 0.83 ± 0.6 at Birth, 6 months, and 12 months, respectively).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 7, 'plasma'), ('PR_000045358', 'insulin family protein', 14, 'insulin'), ('CHEBI_17234', 'glucose', 26, 'glucose'), ('GO_0007567', 'parturition', 83, 'birth'), ('UBERON_0000104', 'life cycle', 132, 'life'), ('PR_000045358', 'insulin family protein', 138, 'insulin'), ('CHEBI_17234', 'glucose', 188, 'glucose'), ('GO_0007567', 'parturition', 283, 'birth')]
PMC2992766	12/2010	S5-PMC2992766	['results\noffspring from dams Fed the western diet had significantly increased adiposity as early as 2 weeks of age as well as impaired Glucose tolerance compared with offspring of dams Fed a control diet.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 28, 'fed'), ('CHEBI_17234', 'glucose', 134, 'glucose'), ('GO_0007631', 'feeding behavior', 184, 'fed')]
PMC2992766	12/2010	S8-PMC2992766	['the addition of an antioxidant supplement decreased adiposity and normalized Glucose tolerance.']	N/A	N/A	[('CHEBI_17234', 'glucose', 77, 'glucose')]
PMC2992766	12/2010	S64-PMC2992766	['Glucose tolerance tests.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose')]
PMC2992766	12/2010	S67-PMC2992766	['at 0 min, Blood was obtained from the dorsal Tail Vein for measures of blood Glucose and plasma Insulin, and then an Intraperitoneal bolus of Glucose (2 mg Glucose per gram of body weight) was given and serial Blood Glucose measurements were done using the hemacue Glucose analyzer (angelholm, sweden).']	N/A	N/A	[('UBERON_0000178', 'blood', 10, 'blood'), ('UBERON_0003481', 'tail vein', 45, 'tail vein'), ('CHEBI_17234', 'glucose', 77, 'glucose'), ('PR_000045358', 'insulin family protein', 96, 'insulin'), ('UBERON_2001932', 'sensory canal tubular ossicle', 117, 'intraperitoneal'), ('CHEBI_17234', 'glucose', 142, 'glucose'), ('CHEBI_17234', 'glucose', 156, 'glucose'), ('UBERON_0000178', 'blood', 210, 'blood'), ('CHEBI_17234', 'glucose', 216, 'glucose'), ('CHEBI_17234', 'glucose', 265, 'glucose')]
PMC2992766	12/2010	S74-PMC2992766	['Embryos were harvested, incubated in invitrocare medium (ksom/aa medium containing 0.2 mmol/l Glucose, 0.2 mmol/l Pyruvate, and 10 mmol/l Lactate) 5% Co2In 95% air, 37°c, and then incubated for an additional hour in medium containing 10 μmol/l Dchfda, and then washed in fresh invitrocare medium before being placed on a glass slide and covered with a cover slip.']	N/A	N/A	[('UBERON_0000922', 'embryo', 0, 'Embryos'), ('CHEBI_17234', 'glucose', 94, 'glucose'), ('CHEBI_15361', 'pyruvate', 114, 'pyruvate'), ('CHEBI_24996', 'lactate', 138, 'lactate'), ('CHEBI_17029', 'chitin', 150, 'CO2in'), ('CHEBI_63557', 'Disperse Red 1', 244, 'DCHFDA')]
PMC2992766	12/2010	S104-PMC2992766	['caption (table-wrap): table 2\n\nEndocrine-Metabolic parameters in normal and western diet-Fed Pregnant Rats at day 21 Gestationcontrolcontrol+aoxwesternwestern+aoxleptin (ng/ml)1.00 ± 0.642.15 ± 0.424.97 ± 0.42*2.11 ± 0.38ffa (μeq/ml)925 ± 128854 ± 751,298 ± 101*877 ± 235blood Glucose (mg/dl)129 ± 14122 ± 15134 ± 15127 ± 10insulin (ng/ml)0.51 ± 0.020.53 ± 0.030.82 ± 0.03*0.60 ± 0.03total fat mass (% body mass)14.2 ± 2.515.8 ± 3.820.4 ± 1.8*20.7 ± 2.2*Food Consumption (g/100g body weight/day)#5.1 ± 1.25.3 ± 0.44.9 ± 1.54.8 ± 1.6\ndata are means ± se.']	N/A	N/A	[('GO_0009790', 'embryo development', 31, 'Endocrine ...'), ('GO_0008152', 'metabolic process', 41, 'metabolic'), ('GO_0007631', 'feeding behavior', 89, 'fed'), ('GO_0007565', 'female pregnancy', 93, 'pregnant'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 102, 'rats'), ('GO_0007281', 'germ cell development', 117, 'gestationControlControl'), ('CHEBI_17234', 'glucose', 277, 'glucose'), ('CHEBI_33290', 'food', 454, 'Food'), ('GO_0007631', 'feeding behavior', 454, 'Food consumption')]
PMC2992766	12/2010	S108-PMC2992766	['Glucose levels did not differ between groups.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose')]
PMC2992766	12/2010	S132-PMC2992766	['in the fetus (day 18 Gestation), there were no significant differences in Plasma levels of Glucose, Insulin, free Fatty Acids, or leptin among the four groups.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 21, 'gestation'), ('UBERON_0001969', 'blood plasma', 74, 'plasma'), ('CHEBI_17234', 'glucose', 91, 'glucose'), ('PR_000045358', 'insulin family protein', 100, 'insulin'), ('CHEBI_35366', 'fatty acid', 114, 'fatty acids')]
PMC2992766	12/2010	S138-PMC2992766	['caption (table-wrap): table 3\n\nEndocrine-Metabolic parameters in offspring of normal and western diet-Fed Pregnant Rats at Birthcontrolcontrol+aoxwesternwestern+aoxfetal d (18) ( n = 5 litters)\u2003\u2003\u2003\u2003leptin (ng/ml)2.2 ± 0.21.9 ± 0.22.1 ± 0.12.3 ± 0.2\u2003\u2003\u2003\u2003ffa (μeq/ml)35.3 ± 2.827.9 ± 3.133.2 ± 4.630.2 ± 4.9\u2003\u2003\u2003\u2003Blood Glucose (mg/dl)54.4 ± 6.757.9 ± 5.961.6 ± 7.758.14 ± 6.3\u2003\u2003\u2003\u2003Insulin (ng/ml)1.49 ± 0.071.51 ± 0.081.58 ± 0.091.55 ± 0.08birth ( n = 5 litters)\u2003\u2003\u2003\u2003leptin (ng/ml)2.8 ± 0.32.9 ± 0.23.8 ± 0.1*3.0 ± 0.3\u2003\u2003\u2003\u2003ffa (μeq/ml)64.8 ± 6.957.9 ± 5.1105.7 ± 9.9*76.6 ± 7.5\u2003\u2003\u2003\u2003Blood Glucose (mg/dl)88.2 ± 8.877.4 ± 9.481.0 ± 8.386.6 ± 9.4\u2003\u2003\u2003\u2003Insulin (ng/ml)0.47 ± 0.060.49 ± 0.060.68 ± 0.07*0.47 ± 0.072 weeks ( n = 5 litters)\u2003\u2003\u2003\u2003leptin (ng/ml)4.2 ± 0.63.9 ± 0.77.8 ± 0.9*4.1 ± 0.8\u2003\u2003\u2003\u2003ffa (μeq/ml)38.5 ± 4.241 ± 4.352.5 ± 5.5*43 ± 5.6\u2003\u2003\u2003\u2003Blood Glucose (mg/dl)93.6 ± 10.497.2 ± 11.5104.4 ± 9.795.4 ± 9.5\u2003\u2003\u2003\u2003Insulin (ng/ml)0.81 ± 0.050.84 ± 0.041.9 ± 0.02*0.92 ± 0.012 months ( n = 8)\u2003\u2003\u2003\u2003leptin (ng/ml)14.7 ± 1.513.2 ± 2.525 ± 1.9*14.5 ± 1.9\u2003\u2003\u2003\u2003ffa (μeq/ml)15.7 ± 1.312.4 ± 1.413.4 ± 1.612.9 ± 1.5\u2003\u2003\u2003\u2003Blood Glucose (mg/dl)118.8 ± 10.8117 ± 11.9120.6 ± 14.0122.0 ± 14.4\u2003\u2003\u2003\u2003Insulin (ng/ml)1.4 ± 0.061.8 ± 0.042.9 ± 0.09*1.9 ± 0.05\ndata are means ± se.']	N/A	N/A	[('GO_0006897', 'endocytosis', 31, 'Endocrine ... metabolic'), ('GO_0007631', 'feeding behavior', 102, 'fed'), ('GO_0007565', 'female pregnancy', 106, 'pregnant'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 115, 'rats'), ('GO_0044582', 'butyryl-CoA catabolic process to butanol', 123, 'birthControlControl'), ('UBERON_0000178', 'blood', 307, 'Blood'), ('CHEBI_17234', 'glucose', 313, 'glucose'), ('PR_000045358', 'insulin family protein', 373, 'Insulin'), ('UBERON_0000178', 'blood', 571, 'Blood'), ('CHEBI_17234', 'glucose', 577, 'glucose'), ('PR_000045358', 'insulin family protein', 636, 'Insulin'), ('UBERON_0000178', 'blood', 832, 'Blood'), ('CHEBI_17234', 'glucose', 838, 'glucose'), ('PR_000045358', 'insulin family protein', 900, 'Insulin'), ('UBERON_0000178', 'blood', 1093, 'Blood'), ('CHEBI_17234', 'glucose', 1099, 'glucose'), ('PR_000045358', 'insulin family protein', 1164, 'Insulin')]
PMC2992766	12/2010	S143-PMC2992766	['maternal antioxidant supplement improves Glucose tolerance in 2-month-old offspring of western diet-Fed Rats.']	N/A	N/A	[('CHEBI_17234', 'glucose', 41, 'glucose'), ('GO_0007631', 'feeding behavior', 100, 'fed'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 104, 'rats')]
PMC2992766	12/2010	S144-PMC2992766	['at 2 months of age, offspring were given 2 g Glucose/kg Intraperitoneally and Glucose was measured 15, 30, 60, and 120 min after injection.']	N/A	N/A	[('CHEBI_17234', 'glucose', 45, 'glucose'), ('UBERON_0000007', 'pituitary gland', 56, 'intraperitoneally'), ('CHEBI_17234', 'glucose', 78, 'glucose')]
PMC2992766	12/2010	S146-PMC2992766	['the western+aox Animals demonstrated marked improvement in Glucose Homeostasis (table 3andfig.']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 16, 'animals'), ('CHEBI_17234', 'glucose', 59, 'glucose'), ('GO_0042593', 'glucose homeostasis', 59, 'glucose homeostasis')]
PMC3001618	1/2011	S64-PMC3001618	['the Glucocorticoid Receptor and 11Β Hydroxysteroid Dehydrogenase ( Hsd ) Type 2) and Glucose (i.e.']	N/A	N/A	[('CHEBI_24261', 'glucocorticoid', 4, 'glucocorticoid'), ('PR_000001594', 'leukotriene B4 receptor 1', 4, 'glucocorticoid receptor'), ('CHEBI_36858', '2alpha-hydroxy steroid', 32, '11β hydroxysteroid'), ('PR_000003770', 'all-trans-retinol dehydrogenase [NAD(+)] ADH4', 32, '11β hydroxysteroid dehydrogenase ...'), ('PR_000008430', 'E3 ubiquitin-protein ligase HACE1', 67, 'HSD ... type 2'), ('CHEBI_17234', 'glucose', 85, 'glucose')]
PMC3001618	1/2011	S106-PMC3001618	['all obese Sheep exhibited raised Expression of Glucose-sensitive Genes including Gr ( Nr3C1 ), Pck2 and Glucokinase Iv.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 10, 'sheep'), ('GO_0010467', 'gene expression', 33, 'expression'), ('CHEBI_17234', 'glucose', 47, 'glucose'), ('SO_0000704', 'gene', 65, 'genes'), ('PR_000008290', 'eukaryotic peptide chain release factor GTP-binding subunit ERF3A', 81, 'GR'), ('PR_000011403', 'photoreceptor-specific nuclear receptor', 86, 'NR3C1'), ('PR_000012422', 'PEST proteolytic signal-containing nuclear protein', 95, 'PCK2'), ('PR_000007997', 'gap junction beta-1 protein', 104, 'glucokinase IV')]
PMC3001618	1/2011	S114-PMC3001618	['2009), which would be predicted to decrease Glucose conversion into Glycogen for storage (melania et al .']	N/A	N/A	[('CHEBI_17234', 'glucose', 44, 'glucose'), ('CHEBI_24384', 'glycogens', 68, 'glycogen')]
PMC3028350	2/2011	S77-PMC3028350	['Glucose and Insulin tolerance tests (subgroup b).']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('PR_000045358', 'insulin family protein', 12, 'insulin')]
PMC3028350	2/2011	S78-PMC3028350	['in a set of Animals in which no other determinations/experiments were performed and after a 5-h fast, Rats were injected Intraperitoneally with a 50% Glucose Solution (2 g/kg) for the Glucose tolerance test.']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 12, 'animals'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 102, 'rats'), ('UBERON_0000007', 'pituitary gland', 121, 'intraperitoneally'), ('CHEBI_17234', 'glucose', 150, 'glucose'), ('CHEBI_75958', 'solution', 158, 'solution'), ('CHEBI_17234', 'glucose', 184, 'glucose')]
PMC3028350	2/2011	S79-PMC3028350	['Glucose Plasma concentrations were determined using an accu-chek advantage Glucose meter (roche diagnostics) using Blood collected from the Tail in fasting conditions and after Glucose injection (at 15, 30, 60, 90, and 120 min).']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('UBERON_0001969', 'blood plasma', 8, 'plasma'), ('CHEBI_17234', 'glucose', 75, 'glucose'), ('UBERON_0000178', 'blood', 115, 'blood'), ('UBERON_0002415', 'tail', 140, 'tail'), ('CHEBI_17234', 'glucose', 177, 'glucose')]
PMC3028350	2/2011	S81-PMC3028350	['as described above, blood Glucose from the Tail was measured at baseline and after Insulin injection (at 15, 30, 60, 90, and 120 min).']	N/A	N/A	[('CHEBI_17234', 'glucose', 26, 'glucose'), ('UBERON_0002415', 'tail', 43, 'tail'), ('PR_000045358', 'insulin family protein', 83, 'insulin')]
PMC3028350	2/2011	S146-PMC3028350	['caption (table-wrap): table 1\n\ncirculating concentrations of Glucose and adipokine in control and iugr Rats Fed lf and hf dietslf diethf diettwo-way anovacontroliugrcontroliugriugrdietintglucose (mmol/l)5.1 ± 0.245.2 ± 0.185.4 ± 0.175.6 ± 0.24insulin (miu/l)48.1 ± 5.442.0 ± 4.959.6 ± 6.590.5 ± 7.3†***homa index11.0 ± 1.210.4 ± 1.414.0 ± 1.222.7 ± 2.3†***leptin (pg/ml)4.03 ± 0.414.36 ± 0.659.10 ± 1.312.9 ± 1.2†**adiponectin (μg/ml)2.74 ± 0.222.90 ± 0.173.06 ± 0.183.10 ± 0.17il-1Β (pg/ml)145.0 ± 43.9112.7 ± 47.2230.8 ± 45.9181.6 ± 56.2il-6 (pg/ml)46.2 ± 7.547.2 ± 7.847.7 ± 6.235.2 ± 8.6\ndata are means ± sem.']	N/A	N/A	[('CHEBI_17234', 'glucose', 61, 'glucose'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 103, 'rats'), ('GO_0007631', 'feeding behavior', 108, 'fed'), ('PR_000003778', 'adiponectin receptor protein 1', 481, '1β'), ('PR_000000035', 'BMP receptor type-1A', 541, '-6')]
PMC3028350	2/2011	S149-PMC3028350	['† p< 0.05 vs. controls on the same diet after a bonferroni post hoc test ( n = 6 for Glucose and n = 10 for hormone and adipokine determinations).']	N/A	N/A	[('CHEBI_17234', 'glucose', 85, 'glucose')]
PMC3028350	2/2011	S167-PMC3028350	['effect of iugr on Glucose tolerance test ( a and b ) and Insulin tolerance test ( c and d ) in offspring Fed a lf diet (10% fat, 3.85 kcal/g) or hf diet (45% fat, 4.73 kcal/g).']	N/A	N/A	[('CHEBI_17234', 'glucose', 18, 'glucose'), ('PR_000045358', 'insulin family protein', 57, 'insulin'), ('GO_0007631', 'feeding behavior', 105, 'fed')]
PMC3028350	2/2011	S221-PMC3028350	['iugr, hf diet, and impaired Glucose Metabolism.']	N/A	N/A	[('CHEBI_17234', 'glucose', 28, 'glucose'), ('GO_0006006', 'glucose metabolic process', 28, 'glucose metabolism')]
PMC3032617	5/2010	S0-PMC3032617	['regular Vitamin C supplementation during Pregnancy reduces hospitalization: outcomes of a ugandan rural cohort study\n\nabstract:executive-summary\n\nbackground\nvitamin c or Ascorbic Acid is a hydro-soluble Lactone (synthesized from Glucose) essential to Human body and available from diet.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 8, 'vitamin C'), ('GO_0007565', 'female pregnancy', 41, 'pregnancy'), ('CHEBI_22652', 'ascorbic acid', 170, 'ascorbic acid'), ('CHEBI_25000', 'lactone', 203, 'lactone'), ('CHEBI_17234', 'glucose', 229, 'glucose'), ('NCBITaxon_9606', 'Homo sapiens', 251, 'human')]
PMC3032617	5/2010	S9-PMC3032617	['background\nvitamin c or Ascorbic Acid is a hydro-soluble Lactone (synthesized from Glucose) essential to Human body for several functions.']	N/A	N/A	[('CHEBI_22652', 'ascorbic acid', 24, 'ascorbic acid'), ('CHEBI_25000', 'lactone', 57, 'lactone'), ('CHEBI_17234', 'glucose', 83, 'glucose'), ('NCBITaxon_9606', 'Homo sapiens', 105, 'human')]
PMC3052301	3/2011	S8-PMC3052301	['we determined Glucose-tolerance and measured Cardiovascular parameters using a tip-catheter.']	N/A	N/A	[('CHEBI_17234', 'glucose', 14, 'glucose'), ('UBERON_0004535', 'cardiovascular system', 45, 'cardiovascular')]
PMC3052301	3/2011	S45-PMC3052301	['Glucose tolerance test\nat day 150, Mice (n≥7 per group) were starved for 12 h. they were Fed a Glucose Solution (1 g/kg body weight; concentration of Glucose Solution: 200 mg/ml) via oral gavage.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('NCBITaxon_10088', 'Mus <genus>', 35, 'mice'), ('GO_0007631', 'feeding behavior', 89, 'fed'), ('CHEBI_17234', 'glucose', 95, 'glucose'), ('CHEBI_75958', 'solution', 103, 'solution'), ('CHEBI_17234', 'glucose', 150, 'glucose'), ('CHEBI_75958', 'solution', 158, 'solution')]
PMC3052301	3/2011	S47-PMC3052301	['Blood Glucose measurement was performed with a glucometer (bayer ascensia elite®).']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('CHEBI_17234', 'glucose', 6, 'glucose')]
PMC3052301	3/2011	S48-PMC3052301	['values were taken 30 min before Feeding (fasted value) and again 5, 10, 15, 30, 60, 120, 180, 240, 300 and 360 min post Glucose challenge.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 32, 'feeding'), ('CHEBI_17234', 'glucose', 120, 'glucose')]
PMC3052301	3/2011	S94-PMC3052301	['( a ) body weight at day 180; ( b ) oral Glucose tolerance test at day 150 (c-c: n\u200a=\u200a10; hp-c: n\u200a=\u200a7; c-hp: n\u200a=\u200a8); ( c ) kaplan meier curve from weaning until end of experiment (d360); ( d ) Cardiovascular characterization of Mice at day 360 via tip-catheter (c-c: n\u200a=\u200a8; hp-c: n\u200a=\u200a7; c-hp: n\u200a=\u200a7).']	N/A	N/A	[('CHEBI_17234', 'glucose', 41, 'glucose'), ('UBERON_0004535', 'cardiovascular system', 192, 'Cardiovascular'), ('NCBITaxon_10088', 'Mus <genus>', 227, 'mice')]
PMC3052301	3/2011	S98-PMC3052301	['fasting Blood Glucose levels under basal conditions were not significantly altered in either the c-hp or hp-c Mice.']	N/A	N/A	[('UBERON_0000178', 'blood', 8, 'blood'), ('CHEBI_17234', 'glucose', 14, 'glucose'), ('NCBITaxon_10088', 'Mus <genus>', 110, 'mice')]
PMC3066640	12/2011	S74-PMC3066640	['in addition, we did not find any significant difference in Plasma Glucose levels between the sga and aga groups.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 59, 'plasma'), ('CHEBI_17234', 'glucose', 66, 'glucose')]
PMC3076295	3/2011	S14-PMC3076295	['trial registration\nclinicaltrials.gov:nct01102530\n\nbackground\nGestational diabetes mellitus (gdm), defined as Glucose intolerance that begins or is first detected during Pregnancy [1], occurs in 3-5% of Pregnancies in the united states (us), [2] and carries a 7-12 fold lifetime risk for the subsequent development of type 2 diabetes [3].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 62, 'Gestational'), ('CHEBI_17234', 'glucose', 110, 'glucose'), ('GO_0007565', 'female pregnancy', 170, 'pregnancy'), ('GO_0007565', 'female pregnancy', 203, 'pregnancies')]
PMC3081498	7/2006	S16-PMC3081498	['[5]\nnormal Glucose Regulation during Pregnancy: Metabolic changes occur in normal Pregnancy in response to the increase in Nutrient needs of the foetus and the mother.']	N/A	N/A	[('CHEBI_17234', 'glucose', 11, 'Glucose'), ('GO_0000006', 'high-affinity zinc transmembrane transporter activity', 11, 'Glucose Regulation'), ('GO_0007565', 'female pregnancy', 37, 'Pregnancy'), ('GO_0008152', 'metabolic process', 48, 'Metabolic'), ('GO_0007565', 'female pregnancy', 82, 'pregnancy'), ('CHEBI_33284', 'nutrient', 123, 'nutrient')]
PMC3081498	7/2006	S21-PMC3081498	['as a result, circulating Glucose levels are kept within normal.']	N/A	N/A	[('CHEBI_17234', 'glucose', 25, 'glucose')]
PMC3081498	7/2006	S22-PMC3081498	['if there is maternal defect in Insulin secretion and in Glucose utilisation, then gdm will occur as the Diabetogenic hormones rise to their peak levels.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 31, 'insulin'), ('CHEBI_17234', 'glucose', 56, 'glucose'), ('CHEBI_50905', 'teratogenic agent', 104, 'diabetogenic')]
PMC3081498	7/2006	S66-PMC3081498	['pre-prandial Glucose level < 5.5 mmol/l (<95mg/dl), and postprandial level Glucose <7.8 mmol/ l (<140mg/dl).']	N/A	N/A	[('CHEBI_17234', 'glucose', 13, 'glucose'), ('CHEBI_17234', 'glucose', 75, 'glucose')]
PMC3081498	7/2006	S73-PMC3081498	['the aim is to achieve Blood Glucose as near normal as possible without excessive risk of hypoglycaemia.']	N/A	N/A	[('UBERON_0000178', 'blood', 22, 'blood'), ('CHEBI_17234', 'glucose', 28, 'glucose')]
PMC3081498	7/2006	S116-PMC3081498	['management of Labour and Delivery:\nGlucose Control during labour.']	N/A	N/A	[('GO_0007612', 'learning', 14, 'labour'), ('GO_0007567', 'parturition', 25, 'delivery'), ('CHEBI_17234', 'glucose', 35, 'Glucose'), ('GO_0065007', 'biological regulation', 43, 'control')]
PMC3081498	7/2006	S128-PMC3081498	['Gestational diabetes mellitus: gdm is defined as a Glucose intolerance that begins or is first detected during Pregnancy.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_17234', 'glucose', 51, 'glucose'), ('GO_0007565', 'female pregnancy', 111, 'pregnancy')]
PMC3081498	7/2006	S150-PMC3081498	['[23]\n\ncaption (table-wrap): table 7\n\nreclassification of Glucose tolerance status post-Partum 75-g Oral Glucose tolerance testfasting Plasma Glucose2-hour ogttnormal6.1 mmol/1 [<110mg/dl]< 7.8mmol/l [140mg/dl]impaired5.6–6.9mmol/1 [100–125mg/dl] impaired fasting Glucose7.8–11mmol/l [140–199mg/dl] impaired Glucose tolerancediabetes>7mmol/l [126mg/dl]> 11.1mmol/l [200mg/dl]\n\npubmed central:']	N/A	N/A	[('CHEBI_17234', 'glucose', 57, 'glucose'), ('GO_0007567', 'parturition', 87, 'partum'), ('UBERON_0000165', 'mouth', 99, 'oral'), ('CHEBI_17234', 'glucose', 104, 'glucose'), ('UBERON_0001969', 'blood plasma', 134, 'Plasma'), ('CHEBI_80751', 'Goitrin', 141, 'Glucose2'), ('CHEBI_28087', 'glycogen', 263, 'glucose7'), ('CHEBI_17234', 'glucose', 307, 'glucose')]
PMC3095978	4/2011	S27-PMC3095978	['the panel describes ms as the presence of any three of the following: Abdominal obesity, dislipidemia (high levels of Triglycerides, low hdl), increased Blood pressure, and elevated fasting Glucose.']	N/A	N/A	[('UBERON_0000916', 'abdomen', 70, 'abdominal'), ('CHEBI_17855', 'triglyceride', 118, 'triglycerides'), ('UBERON_0000178', 'blood', 153, 'blood'), ('CHEBI_17234', 'glucose', 190, 'glucose')]
PMC3095978	4/2011	S65-PMC3095978	['Plasma Glucose concentration was determined by the Glucose oxidase-peroxidase method (vitalab selectra-2, merck, germany).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_17234', 'glucose', 7, 'glucose'), ('CHEBI_17234', 'glucose', 51, 'glucose')]
PMC3095978	4/2011	S66-PMC3095978	['the diagnosis of diabetes was defined by either casual Plasma Glucose ≥ 200\u2009mg·dl−1associated with symptoms of diabetes and on fasting samples—Plasma Glucose ≥ 126\u2009mg·dl−1.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 55, 'plasma'), ('CHEBI_17234', 'glucose', 62, 'glucose'), ('UBERON_0001969', 'blood plasma', 143, 'plasma'), ('CHEBI_17234', 'glucose', 150, 'glucose')]
PMC3095978	4/2011	S211-PMC3095978	['there was also a high level of Blood Glucose.']	N/A	N/A	[('UBERON_0000178', 'blood', 31, 'blood'), ('CHEBI_17234', 'glucose', 37, 'glucose')]
PMC3098253	5/2011	S4-PMC3098253	['fasting Serum Glucose, fasting Plasma total Cholesterol (tc), high-density lipoprotein (hdl) Cholesterol, and Triglycerides (tg) were assessed using automatic biochemistry analyzer.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 8, 'serum'), ('CHEBI_17234', 'glucose', 14, 'glucose'), ('UBERON_0001969', 'blood plasma', 31, 'plasma'), ('CHEBI_16113', 'cholesterol', 44, 'cholesterol'), ('CHEBI_16113', 'cholesterol', 93, 'cholesterol'), ('CHEBI_17855', 'triglyceride', 110, 'triglycerides')]
PMC3098253	5/2011	S8-PMC3098253	['at all bmis, chinese males had significantly higher fasting Glucose levels (chinese: 5.7±1.0 mmol/l vs.']	N/A	N/A	[('CHEBI_17234', 'glucose', 60, 'glucose')]
PMC3098253	5/2011	S60-PMC3098253	['fasting Glucose (fg), fasting Plasma total Cholesterol (tc), high-density lipoprotein (hdl) - Cholesterol, and Triglycerides (tg) were assayed by the same medical staff, using an automatic biochemistry analyzer (hitachi 7600-020, hitachi high-technologies corporation, tokyo, japan).']	N/A	N/A	[('CHEBI_17234', 'glucose', 8, 'glucose'), ('UBERON_0001969', 'blood plasma', 30, 'plasma'), ('CHEBI_16113', 'cholesterol', 43, 'cholesterol'), ('CHEBI_16113', 'cholesterol', 94, 'cholesterol'), ('CHEBI_17855', 'triglyceride', 111, 'triglycerides')]
PMC3098253	5/2011	S79-PMC3098253	['bmi, body mass index; sbp, systolic Blood pressure; dbp, diastolic Blood pressure; fg, fasting Glucose; tc, total Cholesterol; tg, Triglyceride; hdl, high-density lipoprotein.']	N/A	N/A	[('UBERON_0000178', 'blood', 36, 'blood'), ('UBERON_0000178', 'blood', 67, 'blood'), ('CHEBI_17234', 'glucose', 95, 'glucose'), ('CHEBI_16113', 'cholesterol', 114, 'cholesterol'), ('CHEBI_17855', 'triglyceride', 131, 'triglyceride')]
PMC3111740	5/2011	S6-PMC3111740	['the rate at which each Carbohydrate raises Blood Glucose levels after Ingestion, can be measured via the dietary Glycemic index (gi).']	N/A	N/A	[('CHEBI_16730', 'chloramphenicol 3-acetate', 23, 'carbohydrate'), ('UBERON_0000178', 'blood', 43, 'blood'), ('CHEBI_17234', 'glucose', 49, 'glucose'), ('GO_0007631', 'feeding behavior', 70, 'ingestion'), ('GO_0006096', 'glycolytic process', 113, 'glycemic')]
PMC3111740	5/2011	S52-PMC3111740	['indeed, maternal obesity is a risk factor for the development of maternal Gdm and strongly predisposes the offspring to obesity, Glucose intolerance and ir in successive generations [31].']	N/A	N/A	[('GO_0070477', 'endospore core', 74, 'GDM'), ('CHEBI_17234', 'glucose', 129, 'glucose')]
PMC3111740	5/2011	S56-PMC3111740	['rich in fat, Sugar and Salt) produces Rat offspring with increased adiposity, raised circulating Glucose, Insulin, Triglyceride and Cholesterol by the end of adolescence in comparison with the offspring of mothers Feeding on a balanced Chow diet during Pregnancy and Lactation.']	N/A	N/A	[('CHEBI_24870', 'ion', 13, 'sugar'), ('CHEBI_24866', 'salt', 23, 'salt'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 38, 'rat'), ('CHEBI_17234', 'glucose', 97, 'glucose'), ('PR_000045358', 'insulin family protein', 106, 'insulin'), ('CHEBI_17855', 'triglyceride', 115, 'triglyceride'), ('CHEBI_16113', 'cholesterol', 132, 'cholesterol'), ('GO_0007631', 'feeding behavior', 214, 'feeding'), ('CHEBI_33290', 'food', 236, 'chow'), ('GO_0007565', 'female pregnancy', 253, 'pregnancy'), ('GO_0007595', 'lactation', 267, 'lactation')]
PMC3111740	5/2011	S62-PMC3111740	['also, the process of slowing Glucose Uptake Into maternal Tissues serves to provide Nutrients to the fetus.']	N/A	N/A	[('CHEBI_17234', 'glucose', 29, 'glucose'), ('GO_0046630', 'gamma-delta T cell proliferation', 29, 'glucose uptake into ... tissues'), ('UBERON_0000479', 'tissue', 58, 'tissues'), ('CHEBI_33284', 'nutrient', 84, 'nutrients')]
PMC3111740	5/2011	S65-PMC3111740	['the Glucose-stimulated Insulin secretion of the fetus is down-regulated by constant hyperglycemia, but enhanced by pulsatile hyperglycemia [34-37].']	N/A	N/A	[('CHEBI_17234', 'glucose', 4, 'glucose'), ('PR_000045358', 'insulin family protein', 23, 'insulin')]
PMC3111740	5/2011	S89-PMC3111740	['the gi is defined as the area under the curve of the Glucose responses to a Carbohydrate-containing Food compared to either a specific Glucose dose or a specific amount of white bread [65,66].']	N/A	N/A	[('CHEBI_17234', 'glucose', 53, 'glucose'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 76, 'carbohydrate'), ('CHEBI_33290', 'food', 100, 'food'), ('CHEBI_17234', 'glucose', 135, 'glucose')]
PMC3111740	5/2011	S90-PMC3111740	['the greater the particle size, the lower the Glucose and Insulin response.']	N/A	N/A	[('CHEBI_17234', 'glucose', 45, 'glucose'), ('PR_000045358', 'insulin family protein', 57, 'insulin')]
PMC3111740	5/2011	S91-PMC3111740	['the greater the level of processing and refining, the higher the Glucose response of a particular Carbohydrate (table 1 ).']	N/A	N/A	[('CHEBI_17234', 'glucose', 65, 'glucose'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 98, 'carbohydrate')]
PMC3111740	5/2011	S100-PMC3111740	["the sme represents a meal's ability (Carbohydrate content and quality) to diminish the Glucose response (reduction of glycemia) to Carbohydrates eaten during the following meal."]	N/A	N/A	[('CHEBI_16730', 'chloramphenicol 3-acetate', 37, 'carbohydrate'), ('CHEBI_17234', 'glucose', 87, 'glucose'), ('GO_0040007', 'growth', 87, 'glucose'), ('CHEBI_16646', 'carbohydrate', 131, 'carbohydrates')]
PMC3111740	5/2011	S112-PMC3111740	['in Rats, differences in Amniotic Fluid concentrations of Glucose, Uric Acid and Urea nitrogen respond to differing amounts of Carbohydrate in the maternal diet [84].']	N/A	N/A	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 3, 'rats'), ('UBERON_0000173', 'amniotic fluid', 24, 'amniotic fluid'), ('CHEBI_17234', 'glucose', 57, 'glucose'), ('CHEBI_27226', 'uric acid', 66, 'uric acid'), ('CHEBI_16199', 'urea', 80, 'urea'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 126, 'carbohydrate')]
PMC3111740	5/2011	S132-PMC3111740	['a number of different whole grain foods and grain fiber sources were beneficial in ir reduction and improvement in Glucose tolerance all characterized by a low gi.']	N/A	N/A	[('CHEBI_17234', 'glucose', 115, 'glucose')]
PMC3120169	7/2011	S37-PMC3120169	['studies in iron-overload states demonstrate an improvement in Glucose Metabolism with either of these modalities (2,14).']	N/A	N/A	[('CHEBI_17234', 'glucose', 62, 'glucose'), ('GO_0006006', 'glucose metabolic process', 62, 'glucose metabolism')]
PMC3120183	7/2011	S11-PMC3120183	['Gestational diabetes mellitus (gdm) is Glucose intolerance with onset or first diagnosis during Pregnancy (1).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_17234', 'glucose', 39, 'glucose'), ('GO_0007565', 'female pregnancy', 96, 'pregnancy')]
PMC3120183	7/2011	S83-PMC3120183	['no differences in baseline characteristics were observed between women in the intervention and usual care conditions except that the 1-h Glucose value from the diagnostic 100-g oral Glucose tolerance test was lower among women in the intervention condition compared with women in the usual care condition and small differences in smoking and employment status (table 1).']	N/A	N/A	[('CHEBI_17234', 'glucose', 137, 'glucose'), ('CHEBI_17234', 'glucose', 182, 'glucose')]
PMC3120183	7/2011	S85-PMC3120183	['caption (table-wrap): table 1\n\nbaseline characteristics of women with gdm by randomization condition, kpnc, 2005–2008lifestyle interventionusual care p value* n 96101age (years)0.88\u200321–243.14.0\u200325–2918.820.8\u200330+78.175.3race/ethnicity0.89\u2003non-hispanic white19.818.8\u2003black/african american5.24.0\u2003asian or pacific islander49.054.5\u2003hispanic origin18.818.8\u2003other4.22.0\u2003missing3.12.0education0.09\u2003high school or less16.76.9\u2003some college24.023.8\u2003college graduate31.330.7\u2003postgraduate24.036.6\u2003missing4.22.0marriage status0.51\u2003married86.584.2\u2003not married, living with partner7.36.9\u2003never married1.05.0\u2003divorced/separated1.02.0\u2003missing4.22.0employment0.14\u2003full time40.655.4\u2003part time21.917.8\u2003not employed33.324.8\u2003missing4.22.0parity0.98\u2003039.641.6\u2003141.740.6\u2003215.613.9\u20033+3.14.0first-degree family history of diabetes0.67\u2003yes47.348.3\u2003no37.443.8\u2003missing15.47.9smoking before Pregnancy (≥7 cigarettes/week)0.12\u2003yes18.89.9\u2003no7.35.0\u2003never smoke69.883.2\u2003missing4.22.0alcohol consumption before Pregnancy (≥1 drink/week)0.51\u2003yes24.028.7\u2003no71.969.3\u2003missing4.22.0prepregnancy bmi (kg/m2)0.90\u200317–2440.643.6\u200325–2924.021.8\u200330+35.434.7bmi at baseline (kg/m2)\u200320–2415.614.9\u200325–2927.132.7\u200330+57.352.5therapy during Pregnancy after gdm diagnosis0.50\u2003diet66.760.4\u2003Glyburide28.135.6\u2003Insulin5.24.0infant Birth weight (g)0.51\u2003<2,5004.64.2\u20032,500–4,00079.385.4\u2003>4,00016.110.5mean (sd)mean (sd) p valueplasma Glucose levels after 50-g Glucose challenge (mg/dl)165.5 (21.8)166.1 (21.7)0.85diagnostic test (100-g ogtt)\u2003fasting Plasma Glucose92.1 (12.2)91.7 (13.6)0.85\u20031-h Plasma Glucose196.4 (22.6)206.6 (22.7)0.002\u20032-h Plasma Glucose176.6 (18.9)180.4 (26.2)0.27\u20033-h Plasma Glucose125.6 (35.0)129.6 (34.4)0.42gestation age at baseline (weeks)31.8 (5.6)31.0 (6.1)0.34gestational weight gain at baseline (kg)8.5 (5.4)8.6 (5.4)0.93percent of calories from dietary fat at baseline37.3 (6.7)37.6 (7.6)0.81moderate or vigorous physical activity at baseline (min/week)333.6 (295)334.1 (326)0.99number of visits to health care providers11.1 (5.9)11.0 (6.1)0.86\ndata are % unless otherwise indicated.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 861, 'pregnancy'), ('GO_0007565', 'female pregnancy', 976, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1188, 'pregnancy'), ('CHEBI_52746', 'hemo red 720', 1235, 'Glyburide28'), ('PR_000045358', 'insulin family protein', 1253, 'Insulin5'), ('GO_0007567', 'parturition', 1273, 'birth'), ('CHEBI_17234', 'glucose', 1374, 'glucose'), ('CHEBI_17234', 'glucose', 1400, 'glucose'), ('UBERON_0001969', 'blood plasma', 1490, 'plasma'), ('CHEBI_79107', 'icas#21', 1497, 'glucose92'), ('UBERON_0001969', 'blood plasma', 1535, 'plasma'), ('CHEBI_53741', 'N-acetyltyrosine-4-azobenzenearsonic acid', 1542, 'glucose196'), ('UBERON_0001969', 'blood plasma', 1583, 'plasma'), ('CHEBI_67984', 'Pseudoginsenoside RT1 methyl ester', 1590, 'glucose176'), ('UBERON_0001969', 'blood plasma', 1630, 'plasma'), ('CHEBI_79320', '4-O-(p-hydroxybenzoyl)ascaroside', 1637, 'glucose125')]
PMC3120183	7/2011	S86-PMC3120183	['ogtt, oral Glucose tolerance test.']	N/A	N/A	[('CHEBI_17234', 'glucose', 11, 'glucose')]
PMC3120183	7/2011	S90-PMC3120183	['similar results were obtained after adjusting for 1-h Glucose levels and in subgroup analyses where women were stratified by smoking or employment status (data not shown).']	N/A	N/A	[('CHEBI_17234', 'glucose', 54, 'glucose')]
PMC3120196	7/2011	S35-PMC3120196	['of 93 responders who confirmed a singleton Pregnancy during this period, 83% reported a Glucose loading test, and 100% reported frequent Urine screening in Pregnancy (13).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 43, 'pregnancy'), ('CHEBI_17234', 'glucose', 88, 'glucose'), ('UBERON_0001088', 'urine', 137, 'urine'), ('GO_0007565', 'female pregnancy', 156, 'pregnancy')]
PMC3120196	7/2011	S99-PMC3120196	['Pregnancy-related Metabolic challenges unmask a predisposition to Glucose Metabolic disorders in some women.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnancy'), ('GO_0008152', 'metabolic process', 18, 'metabolic'), ('CHEBI_17234', 'glucose', 66, 'glucose'), ('GO_0008152', 'metabolic process', 74, 'metabolic')]
PMC3120197	7/2011	S57-PMC3120197	['those who failed this screening test (≥7.8 mmol/l) were then followed-up within 1–2 weeks with a 100-g 3-h Oral Glucose tolerance test (ogtt).']	N/A	N/A	[('UBERON_0000165', 'mouth', 107, 'oral'), ('CHEBI_17234', 'glucose', 112, 'glucose')]
PMC3120197	7/2011	S58-PMC3120197	['we also abstracted laboratory results from participants’ 50-g 1-h Glucose challenge test and from the diagnostic 100-g 3-h ogtt.']	N/A	N/A	[('CHEBI_17234', 'glucose', 66, 'glucose')]
PMC3120197	7/2011	S59-PMC3120197	['women were diagnosed with gdm if two or more of the 100-g ogtt Glucose concentrations exceeded american diabetes association criteria (19) (fasting ≥5.3 mmol/l, 1-h postchallenge ≥10.0 mmol/l, 2-h postchallenge ≥8.6 mmol/l, and 3-h postchallenge ≥7.8 mmol/l).']	N/A	N/A	[('CHEBI_17234', 'glucose', 63, 'glucose')]
PMC3120197	7/2011	S143-PMC3120197	['third, universal Glucose tolerance testing in early Pregnancy is not part of standard obstetric care.']	N/A	N/A	[('CHEBI_17234', 'glucose', 17, 'glucose'), ('GO_0007565', 'female pregnancy', 52, 'pregnancy')]
PMC3131279	7/2011	S6-PMC3131279	['pr offspring showed altered fasting Glucose Homeostasis and changes in Phosphoenolpyruvate carboxykinase Promoter methylation and Expression in all three generations.']	N/A	N/A	[('CHEBI_17234', 'glucose', 36, 'glucose'), ('GO_0042593', 'glucose homeostasis', 36, 'glucose homeostasis'), ('CHEBI_18021', 'phosphoenolpyruvate', 71, 'phosphoenolpyruvate'), ('SO_0000167', 'promoter', 105, 'promoter'), ('GO_0010467', 'gene expression', 130, 'expression')]
PMC3131279	7/2011	S13-PMC3131279	['for example, maternal dietary protein restriction in Rats induces hypertension, dyslipidaemia and impaired Glucose tolerance in the Adult offspring[2].']	N/A	N/A	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 53, 'rats'), ('CHEBI_17234', 'glucose', 107, 'glucose'), ('UBERON_0007023', 'adult organism', 132, 'adult')]
PMC3131279	7/2011	S57-PMC3131279	['no other Genes were among the twenty most altered Genes in more than one generation.10.1371/journal.pone.0021668.t001\n\ncaption (table-Wrap): table 1\nHepatic Genes showing the greatest difference between pr and ps offspring.difference between ps and pr offspring (fold differences between pr and ps)f1f2f3up-regulateddown-regulatedup-regulateddown-regulatedup-regulateddown-regulatedcytochrome P450, 3,A nm_153312 (69.4)Transmembrane Protein 27 nm_020976 (174.3) Trefoil Factor 2 nm_053844 (13.9) Olfactory receptor 144 nm_001000164 (15.3)Surfactant associated protein c nm_017342 (25.1)Pancreatic Lipase Related Protein 1 nm_032081 (47.5)α2μ globulin nm_001024248 (40.2)Uromodulin nm_017082 (105.3)Hyaluronan mediated motility receptor nm_012964 (12.9)Egf-Like Domain 7 nm_139104 (14) Lymphocyte-Activation Gene 3 nm_212513 (17.4) Pancreatic lipase nm_013161 (39.6)α2μ globulin Pgcl4 nm_147215 (38.3)Cytochrome P450 (11B) nm_012537 (104.9)Sarcolipin nm_001013247 (10.0)Type i keratin Ka11 nm_001008750 (7.1)Caveolin 3 nm_019155 (11.2) Pancreatic Amylase 2 nm_031502 (39.4)Lymphocyte-Activation Gene 3 nm_212513 (35.9) Chromogranin B nm_012526 (98.8)Cathepsin R nm_001017509 (7.9)T-Cell receptor Β-Chain mrna v-region m23885 (6.6)Telethonin xm_001081394 (9.9)Glycoprotein 2 nm_134418 (38.5)Α2Μ Globulin Pgcl3 nm_147212 (29.1)Chloride channel kb nm_173103 (98.1)Threonyl-Trna Synthetase-Like 2 nm_001014020 (7.6)Stathmin-Like 3 nm_024346 (5.5)Bile Acid Coenzyme A: amino acid n-acyltransferasexm_001055067 (9.7)Cationic Trypsinogen nm_173127 (34.4)α2μ globulin Pgcl1 nm_147214 (16.4)Solute Carrier Family 7 (y+ system) member 13 nm_001012100 (92.6) Lymphocyte-Activation Gene 3 nm_212513 (7.5) Myelin-Associated Basic Protein-99 X89638 (5.2)riken nm_001039686 (7.9)Serine Protease-2 nm_012729 (26.0)myosin ixb xm_346173 (15.2)Defensin Β1 nm_031810 (81.4)C-Myc Promoter binding protein xr_009072 (7.3)Cystatin nm_133566 (5.0)Myosin, Light Polypeptide 3 nm_012606 (7.9)Pancreatic Trypsin 1 nm_012635 (24.8)α2μ globulin Pgcl5 nm_147213 (12.8)Solute Carrier Family 26 (4) nm_019214 (80.1)Gastrokine 1 Xm_001074955 (6.4)Socs Box-Containing Protein 3 Xm_344277 (4.5)Immunoglobulin variable region z93370 (7.8)Pancreatic lipase-related Protein-2 nm_057206 (22.5)Caldesmon 1 nm_013146 (12.3)Protein Phosphatase 1, Regulatory Subunit 1A nm_022676 (76.6)Membrane-associated dhhc17 zinc finger protein nm_001039340 (5.8)Fun14 Domain Containing-1 nm_001025027 (4.5)Pancreatitis-Associated Protein nm_053289 (7.8)Ribonuclease A nm_001029904 (19.8)Major Urinary Protein 5 nm_203325 (11.3)Solute Carrier Family 3 nm_017216 (71.0)unknown af433878 (5.3)arachidonate 5-lipoxygenase nm_012822 (4.5)Actin-Α Cardiac- 1 nm_019183 (7.7)Chymotrypsin C nm_001077649 (19.1)Cytochrome P450 (2C13) nm_138514 (10.4)Kidney Androgen Regulated Protein nm_052802 (67.6)Glycosylation Dependent Cell Adhesion Molecule 1 nm_012794 (5.2)Protocadherin-Α nm_201422 (4.5)Ec1-V2R Pheromone Receptor Xm_236825 (7.0)Pancreatic Elastase-1 nm_012552 (18.9)α2μ globulin (l type) nm_001003409 (10.1)Deoxyribonuclease 1 nm_013097 (60.8)Actin Α Cardiac 1 nm_019183 (5.2)Thioesterase Superfamily Member 4 (Them4), mrna nm_001025017 (4.4)S100 Calcium Binding protein g nm_012521 (7.0)Chymotrypsin-Like nm_054009 (17.0)Kpl2 protein nm_022620 (10.0)Degenerative Spermatocyte Homolog 2 nm_001017457 (58.0)serine dehydratase x13119 (5.0)Endothelial differentiation, Sphingolipid G-Protein-Coupled Receptor, 8 nm_021775 (4.3) Trefoil Factor 2 nm_053844 (6.9) Carboxypeptidase B1 nm_012533 (16.5)Cytochrome P450 (iic) nm_019184 (8.1)solute carrier family 5 (Sodium/Glucose co-Transporter), nm_022590 (57.6)phosphodiesterase 4d interacting protein nm_022382 (4.9)Olfactory Receptor 74 nm_001000134 (4.3)Type i keratin Ka15 nm_001004022 (6.9)Trypsin 10 nm_001004097 (16.5)protein tyrosine kinase c-yes xm_343644 (7.5)Tonin nm_012677 (49.7)Olfactory receptor 1250 nm_001000806 (4.8)Olfactory Receptor 821 nm_001000842 (4.3)Topoisomerase -2Α nm_022183 (6.7)chymotrypsinogen b nm_012536 (15.1)Diamine Acetyltransferase 1 Xm_228448 (7.0)myosin, heavy polypeptide 7 nm_017240 (48.1)pparγ1 co-activator 1α nm_031347 (4.6)Kiss1 receptor nm_023992 (4.2)cleavage and Polyadenylation specificity Factor 3 Xr_005746 (6.3)Elastase 2 nm_012553 (11.9) Pancreatic Amylase 2 nm_031502 (6.8) Cadherin 16 nm_001012055 (47.6)Olfactory receptor 1467 nm_001000025 (4.6)Calmodulin-sensitive Plasma Membrane Ca2+-Transporting atpase j05087 (4.2)atp-binding Cassette (Sub-Family B, Member 11) xm_579531 (6.2)Pancreatic colipase nm_013139 (10.6)absent 1 Isoform b xm_232591 (6.8)Solute Carrier Family 7 (y+ system), member 12 nm_001017465 (47.1)Cysteine And Tyrosine-Rich Protein 1 nm_001013980 (4.6)Seminal Vesicle Protein 4 nm_012662 (4.1)Annexin A8 nm_001031654 (6.1)syncollin nm_139086 (9.4)Glandular Kallikrein 11 nm_001003977 (5.5)Hydroxyacid Oxidase-2 nm_032082 (45.1)Neurogenic Differentiation- 2 nm_019326 (4.6)Rt1 class ib Gene nm_012646 (4.1)Olfactory receptor 272 nm_001000230 (6.0)serpin x99773 (9.2)Rab3A nm_013018 (5.5)Solute Carrier Family 12, Member 1 nm_019134 (41.9)Rt1 Class Ii, locus dob nm_001008846 (4.3)Dual Oxidase 1 nm_153739 (4.1)lectin, Galactose binding, soluble 4 nm_012975 (5.8)Carboxyl Ester lipase nm_016997 (9.2)\nGenes which were among the twenty most different between pr and ps offspring in more than one generation are in bold font.']	N/A	N/A	[('SO_0000704', 'gene', 9, 'genes'), ('SO_0000704', 'gene', 50, 'genes'), ('PR_000017453', 'protein Wnt-9b', 134, 'WRAP'), ('UBERON_0002107', 'liver', 149, 'Hepatic'), ('SO_0000704', 'gene', 157, 'genes'), ('CHEBI_8102', 'phenylmethanesulfonyl fluoride', 393, 'P450'), ('PR_000013139', "serine/threonine-protein phosphatase 2A regulatory subunit B'' subunit alpha", 393, 'P450, 3,a'), ('GO_0032588', 'trans-Golgi network membrane', 419, 'Transmembrane'), ('PR_000029823', 'E3 ubiquitin ligase TRIM40', 419, 'Transmembrane protein 27'), ('PR_000016470', 'transmembrane and ubiquitin-like domain-containing protein 1', 462, 'Trefoil factor 2'), ('GO_0007608', 'sensory perception of smell', 496, 'Olfactory'), ('CHEBI_35195', 'surfactant', 538, 'Surfactant'), ('PR_000012527', 'Na(+)/H(+) exchange regulatory cofactor NHE-RF4', 586, 'Pancreatic lipase related protein 1'), ('UBERON_0001264', 'pancreas', 586, 'Pancreatic'), ('PR_000004483', 'V-type proton ATPase subunit C 1', 670, 'Uromodulin'), ('CHEBI_5828', 'Hymexazol O-glucoside', 698, 'Hyaluronan'), ('PR_000006911', 'selenocysteine-specific elongation factor', 752, 'EGF-like domain 7'), ('SO_0000417', 'polypeptide_domain', 761, 'domain'), ('CL_0000824', 'mature natural killer cell', 785, 'Lymphocyte'), ('GO_0036364', 'transforming growth factor beta1 activation', 785, 'Lymphocyte-activation'), ('PR_000009658', 'laminin subunit gamma-1', 785, 'Lymphocyte-activation gene 3'), ('SO_0000704', 'gene', 807, 'gene'), ('UBERON_0001264', 'pancreas', 831, 'Pancreatic'), ('PR_000012388', 'protocadherin gamma-A10', 878, 'PGCL4'), ('CHEBI_4056', 'cytochrome', 900, 'Cytochrome'), ('PR_000006137', 'cytochrome P450 4B1', 900, 'Cytochrome P450'), ('PR_000008777', '17-beta-hydroxysteroid dehydrogenase 13', 917, '11B'), ('PR_000000364', 'smad2', 939, 'Sarcolipin'), ('PR_000016580', 'tropomyosin beta chain', 969, 'Type'), ('PR_000009255', 'potassium voltage-gated channel subfamily E member 1', 984, 'KA11'), ('PR_000004967', 'calbindin', 1007, 'Caveolin 3'), ('PR_000012527', 'Na(+)/H(+) exchange regulatory cofactor NHE-RF4', 1035, 'Pancreatic amylase 2'), ('UBERON_0001264', 'pancreas', 1035, 'Pancreatic'), ('CL_0000824', 'mature natural killer cell', 1072, 'Lymphocyte'), ('GO_0036364', 'transforming growth factor beta1 activation', 1072, 'Lymphocyte-activation'), ('PR_000009658', 'laminin subunit gamma-1', 1072, 'Lymphocyte-activation gene 3'), ('SO_0000704', 'gene', 1094, 'gene'), ('CHEBI_68805', 'chaetomugilin A', 1118, 'Chromogranin B'), ('PR_000001204', 'C-C chemokine receptor type 8', 1149, 'Cathepsin R'), ('CL_0000084', 'T cell', 1179, 'T-cell'), ('PR_000003676', 'actin, cytoplasmic 1', 1195, 'β-chain'), ('PR_000016393', 'transmembrane channel-like protein 2', 1229, 'Telethonin'), ('CHEBI_17089', 'glycoprotein', 1258, 'Glycoprotein'), ('PR_000007898', 'glutamate--cysteine ligase regulatory subunit', 1258, 'Glycoprotein 2'), ('PR_000001990', 'C-C motif chemokine 18', 1289, 'α2μ'), ('CHEBI_5386', 'globin', 1293, 'globulin'), ('PR_000012591', 'pepsin A-5', 1302, 'PGCL3'), ('CHEBI_17996', 'chloride', 1324, 'Chloride'), ('PR_000016296', 'protein-glutamine gamma-glutamyltransferase 5', 1360, 'Threonyl-tRNA synthetase-like 2'), ('PR_000015293', 'sphingomyelin phosphodiesterase 2', 1410, 'Stathmin-like 3'), ('CHEBI_3098', 'bile acid', 1441, 'Bile acid'), ('UBERON_0001970', 'bile', 1441, 'Bile'), ('CHEBI_15346', 'coenzyme A', 1451, 'Coenzyme A'), ('CHEBI_36916', 'cation', 1509, 'Cationic'), ('PR_000016770', 'testis-specific serine/threonine-protein kinase 1', 1518, 'trypsinogen'), ('PR_000013059', 'peroxisome proliferator-activated receptor gamma coactivator 1-alpha', 1559, 'PGCL1'), ('PR_000015439', 'nuclear body protein SP140-like protein', 1581, 'Solute carrier family 7 ...'), ('CL_0000824', 'mature natural killer cell', 1647, 'Lymphocyte'), ('PR_000004680', 'breast carcinoma-amplified sequence 3', 1657, '-activation gene 3'), ('SO_0000704', 'gene', 1669, 'gene'), ('PR_000029266', 'alkylglycerol monooxygenase', 1692, 'Myelin-associated Basic Protein-99 X89638'), ('UBERON_0000345', 'myelin', 1692, 'Myelin'), ('PR_000014506', 'secretoglobin family 1D member 1', 1763, 'Serine protease-2'), ('PR_000006525', 'delta-like protein 4', 1824, 'Defensin β1'), ('PR_000000084', 'c-myc protein', 1852, 'C-myc'), ('SO_0000167', 'promoter', 1858, 'promoter'), ('PR_000005890', 'crooked neck-like protein 1', 1898, 'Cystatin'), ('PR_000010876', 'myoferlin', 1922, 'Myosin, light polypeptide 3'), ('PR_000014709', 'neuroserpin', 1965, 'Pancreatic'), ('UBERON_0001264', 'pancreas', 1965, 'Pancreatic'), ('PR_000027795', 'trypsin', 1976, 'trypsin 1'), ('PR_000012388', 'protocadherin gamma-A10', 2015, 'PGCL5'), ('PR_000015229', 'solute carrier organic anion transporter family member 4A1', 2037, 'Solute carrier family 26'), ('PR_000007220', 'ethanolamine kinase 2', 2082, 'Gastrokine 1 XM_001074955'), ('PR_000029264', 'AT-hook DNA-binding motif-containing protein 1', 2113, 'SOCS box-containing protein 3 XM_344277'), ('GO_0019815', 'B cell receptor complex', 2158, 'Immunoglobulin'), ('UBERON_0001264', 'pancreas', 2201, 'Pancreatic'), ('PR_000014700', 'serpin B9', 2227, 'protein-2'), ('PR_000002199', 'cytochrome c protein', 2253, 'Caldesmon 1'), ('PR_000013086', 'peptidyl-prolyl cis-trans isomerase-like 4', 2281, 'Protein phosphatase 1, regulatory subunit 1A'), ('GO_0065007', 'biological regulation', 2304, 'regulatory'), ('GO_0016020', 'membrane', 2342, 'Membrane'), ('PR_000007693', 'ferritin, mitochondrial', 2407, 'FUN14 domain containing-1'), ('SO_0000417', 'polypeptide_domain', 2413, 'domain'), ('PR_000013199', 'prolargin', 2451, 'Pancreatitis-associated protein'), ('PR_000023799', 'ribonuclease R', 2498, 'Ribonuclease A'), ('PR_000010045', 'transcription factor Maf', 2532, 'Major urinary protein 5'), ('UBERON_0001088', 'urine', 2538, 'urinary'), ('PR_000015399', 'superoxide dismutase [Cu-Zn]', 2572, 'Solute carrier family 3'), ('PR_000003666', 'acyl-coenzyme A synthetase ACSM2B, mitochondrial', 2677, 'Actin-α cardiac- 1'), ('UBERON_0000948', 'heart', 2685, 'cardiac'), ('PR_000006022', 'lysosomal protective protein', 2711, 'Chymotrypsin C'), ('CHEBI_4056', 'cytochrome', 2745, 'Cytochrome'), ('PR_000006137', 'cytochrome P450 4B1', 2745, 'Cytochrome P450'), ('PR_000005173', 'CD59 glycoprotein', 2762, '2c13'), ('PR_000009204', 'lysine-specific demethylase 5A', 2784, 'Kidney androgen regulated protein'), ('UBERON_0002113', 'kidney', 2784, 'Kidney'), ('CHEBI_50113', 'androgen', 2791, 'androgen'), ('GO_0065007', 'biological regulation', 2800, 'regulated'), ('GO_0006277', 'DNA amplification', 2834, 'Glycosylation'), ('PR_000007775', 'gamma-aminobutyric acid receptor subunit delta', 2834, 'Glycosylation dependent cell adhesion molecule 1'), ('CHEBI_36357', 'polyatomic entity', 2872, 'molecule'), ('PR_000012194', 'P2X purinoceptor 7', 2898, 'Protocadherin-α'), ('PR_000006897', 'endothelin-1', 2929, 'EC1-'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 2933, 'V2R pheromone receptor XM_236825'), ('PR_000012529', 'PDZK1-interacting protein 1', 2971, 'Pancreatic elastase-1'), ('UBERON_0001264', 'pancreas', 2971, 'Pancreatic'), ('PR_000006605', 'dynamin-binding protein', 3050, 'Deoxyribonuclease 1'), ('PR_000003564', 'ATP-binding cassette sub-family C member 9', 3086, 'Actin α cardiac 1'), ('UBERON_0000948', 'heart', 3094, 'cardiac'), ('PR_000016139', 'TATA box-binding protein-like 2', 3119, 'Thioesterase superfamily member 4'), ('PR_000016329', 'T-lymphoma invasion and metastasis-inducing protein 2', 3154, 'Them4'), ('PR_000014411', 'protein S100-A4', 3185, 'S100 calcium binding'), ('PR_000005875', 'cysteine-rich protein 3', 3231, 'Chymotrypsin-like'), ('PR_000009329', 'killer cell immunoglobulin-like receptor 2DL3', 3265, 'KPL2'), ('PR_000006460', 'dihydroorotate dehydrogenase (quinone), mitochondrial', 3294, 'Degenerative spermatocyte homolog 2'), ('CL_0000017', 'spermatocyte', 3307, 'spermatocyte'), ('SO_0000853', 'homologous_region', 3320, 'homolog'), ('UBERON_0001986', 'endothelium', 3380, 'Endothelial'), ('CHEBI_26739', 'sphingolipid', 3409, 'sphingolipid'), ('PR_000001703', 'mas-related G-protein coupled receptor X2', 3409, 'sphingolipid G-protein-coupled receptor, 8'), ('PR_000016470', 'transmembrane and ubiquitin-like domain-containing protein 1', 3468, 'Trefoil factor 2'), ('PR_000005347', 'centrosome-associated protein CEP250', 3501, 'Carboxypeptidase B1'), ('CHEBI_4056', 'cytochrome', 3537, 'Cytochrome'), ('PR_000006137', 'cytochrome P450 4B1', 3537, 'Cytochrome P450'), ('CHEBI_52632', 'potassium-39 atom', 3599, 'sodium'), ('CHEBI_17234', 'glucose', 3606, 'glucose'), ('PR_000014938', 'urea transporter 1', 3617, 'transporter'), ('GO_0007608', 'sensory perception of smell', 3703, 'Olfactory'), ('PR_000014368', 'RuvB-like 1', 3713, 'receptor'), ('PR_000016580', 'tropomyosin beta chain', 3743, 'Type'), ('PR_000009486', 'keratin, type II cytoskeletal 71', 3758, 'KA15'), ('PR_000016869', 'thioredoxin-like protein 4A', 3781, 'Trypsin 10'), ('PR_000016331', 'tigger transposable element-derived protein 1', 3856, 'Tonin'), ('GO_0007608', 'sensory perception of smell', 3878, 'Olfactory'), ('GO_0007608', 'sensory perception of smell', 3920, 'Olfactory'), ('PR_000029714', 'roquin-2', 3930, 'receptor 821'), ('PR_000016842', 'trafficking regulator of GLUT4 1', 3961, 'Topoisomerase -2α'), ('CHEBI_4514', 'dicyclomine', 4029, 'Diamine'), ('PR_000029427', 'DnaJ homolog subfamily C member 7', 4029, 'Diamine acetyltransferase 1 XM_228448'), ('PR_000009329', 'killer cell immunoglobulin-like receptor 2DL3', 4154, 'KISS1'), ('GO_0043631', 'RNA polyadenylation', 4197, 'polyadenylation'), ('PR_000049700', 'protein Wnt-9b, signal peptide removed form (human)', 4225, 'factor 3 XR_005746'), ('PR_000007002', 'eukaryotic translation initiation factor 5', 4249, 'Elastase 2'), ('PR_000012527', 'Na(+)/H(+) exchange regulatory cofactor NHE-RF4', 4277, 'Pancreatic amylase 2'), ('UBERON_0001264', 'pancreas', 4277, 'Pancreatic'), ('PR_000004968', 'calretinin', 4314, 'Cadherin 16'), ('GO_0007608', 'sensory perception of smell', 4345, 'Olfactory'), ('PR_000004967', 'calbindin', 4387, 'Calmodulin'), ('GO_0005886', 'plasma membrane', 4408, 'plasma membrane'), ('CHEBI_81233', 'Schizonepetoside B', 4424, 'Ca2+-'), ('GO_0016554', 'cytidine to uridine editing', 4424, 'Ca2+-transporting'), ('SO_0005853', 'gene_cassette', 4473, 'cassette'), ('PR_000015900', 'putative synaptotagmin-14-like protein', 4483, 'sub-family B, member 11'), ('UBERON_0001264', 'pancreas', 4523, 'Pancreatic'), ('SO_0001060', 'sequence_variant', 4568, 'isoform'), ('PR_000015439', 'nuclear body protein SP140-like protein', 4593, 'Solute carrier family 7 ...'), ('PR_000005866', 'cAMP-responsive element modulator', 4659, 'Cysteine and tyrosine-rich protein 1'), ('PR_000014892', 'NAD-dependent protein deacetylase sirtuin-6', 4714, 'Seminal vesicle protein 4'), ('UBERON_0000997', 'mammalian vulva', 4714, 'Seminal'), ('PR_000004080', 'annexin A7', 4755, 'Annexin A8'), ('UBERON_0002530', 'gland', 4809, 'Glandular'), ('PR_000009309', 'kinesin-like protein KIF2B', 4819, 'kallikrein 11'), ('CHEBI_16240', 'hydrogen peroxide', 4851, 'Hydroxyacid'), ('PR_000008453', 'hepatitis A virus cellular receptor 1', 4851, 'Hydroxyacid oxidase-2'), ('GO_0001822', 'kidney development', 4889, 'Neurogenic'), ('PR_000011461', 'endonuclease III-like protein 1', 4889, 'Neurogenic differentiation- 2'), ('PR_000012993', 'DNA-directed RNA polymerase II subunit RPB7', 4934, 'RT1'), ('SO_0000704', 'gene', 4947, 'gene'), ('GO_0007608', 'sensory perception of smell', 4967, 'Olfactory'), ('PR_000013610', 'Ras-related protein Rab-34', 5027, 'RAB3A'), ('PR_000015229', 'solute carrier organic anion transporter family member 4A1', 5048, 'Solute carrier family 12, member 1'), ('PR_000014373', 'retinoic acid receptor RXR-beta', 5099, 'RT1 class II'), ('PR_000006745', 'dual specificity protein phosphatase 19', 5141, 'Dual oxidase 1'), ('CHEBI_28260', 'galactose', 5179, 'galactose'), ('CHEBI_3385', 'carbachol', 5223, 'Carboxyl ester'), ('SO_0000704', 'gene', 5261, 'Genes')]
PMC3131279	7/2011	S122-PMC3131279	['for example, Feeding a pr diet during f0 Pregnancy induced impaired Glucose Homeostasis in male f1 offspring which was exacerbated in f2, but then fell to a level below control offspring in f3[13].']	N/A	N/A	[('GO_0007631', 'feeding behavior', 13, 'feeding'), ('GO_0007565', 'female pregnancy', 41, 'pregnancy'), ('CHEBI_17234', 'glucose', 68, 'glucose'), ('GO_0042593', 'glucose homeostasis', 68, 'glucose homeostasis')]
PMC3131279	7/2011	S174-PMC3131279	['Plasma was separated by centrifugation and stored at −80°c.10.1371/journal.pone.0021668.t003\n\ncaption (table-wrap): table 3\ndiet composition.Pregnancy dietslactation dietmaintenance dietps (all generations)pr (f0 generation)ain-93gain-93mcasein (g/kg)18.392200140cornstarch (g/kg)420482397466sucrose (g/kg)213243100100choline (g/kg)2.82.82.52.5Methionine (g/kg)9.77.45.23.6crude fibre (g/kg)50505050oil (g/kg)1001007040total Metabolisable energy (mj/kg)17.217.416.415.78\n\nmeasurement of fasting Plasma Glucose concentration\nPlasma Glucose concentration was measured by an automated colorimetric method as described[34].']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('GO_0007565', 'female pregnancy', 141, 'Pregnancy'), ('CHEBI_68613', 'aurothiomalate(2-)', 343, '5Methionine'), ('GO_0008152', 'metabolic process', 425, 'metabolisable'), ('UBERON_0001969', 'blood plasma', 495, 'plasma'), ('CHEBI_17234', 'glucose', 502, 'glucose'), ('UBERON_0001969', 'blood plasma', 524, 'Plasma'), ('CHEBI_17234', 'glucose', 531, 'glucose')]
PMC3131279	7/2011	S202-PMC3131279	['within assay precision was between 0·8 and 1·7% depending on cpg, and detection limits were 2–5% methylation.10.1371/journal.pone.0021668.t005\n\ncaption (table-wrap): table 5\npyrosequencing Primers and Phosphoenolpyruvate carboxykinase cpg identifiers.real time rtpcrprimer location (Bp relative to Transcription Start Site)Forward Primer (5′→3′)Reverse Primer (3′→5′)pcr Primers−658 to −405 aggggttagtatgtatatagagtgatt  atcaaaacaccacaactataaaatatc −417 to −56 gtggtgttttgataattagtagtgatt  cccctcaactaaacctaaaaactc −373 to −44 gttagtagtatatgaagtttaaga  cccctattaaccaaaaatatattcc −658 to −405 aggggttagtatgtatatagagtgatt  atcaaaacaccacaactataaaatatc −417 to −56 gtggtgttttgataattagtagtgatt  cccctcaactaaacctaaaaactc −373 to −44 gttagtagtatatgaagtttaaga  cccctattaaccaaaaatatattcc sequencing Primers gtgattattttatattaggtattg  agaggatttagtagatatttagtg  taaatattaaaaaacctcaaaccc  ttattatttttttaaagtttattg cpg locationscpg location relative to Transcription Start Site (Bp)chromosome 3 coordinate (Bp)−606164,012,404−508164,012,502−440164,012,570−248164,012,762−218164,012,792−129164,012,881−100164,012,910−90164,012,920−81164,012,929\n\nstatistical analysis\nfor analysis of Glucose concentration, and pepck methylation and Expression, values are shown as mean ± 1 sd.']	N/A	N/A	[('SO_0000112', 'primer', 189, 'primers'), ('CHEBI_18021', 'phosphoenolpyruvate', 201, 'phosphoenolpyruvate'), ('SO_0000028', 'base_pair', 283, 'bp'), ('SO_0000315', 'TSS', 298, 'transcription start site'), ('SO_0000121', 'forward_primer', 323, 'Forward Primer'), ('SO_0000132', 'reverse_primer', 345, 'Reverse Primer'), ('SO_0000112', 'primer', 371, 'primers'), ('SO_0000112', 'primer', 789, 'primers'), ('SO_0000315', 'TSS', 938, 'transcription start site'), ('SO_0000028', 'base_pair', 964, 'bp'), ('SO_0000028', 'base_pair', 992, 'bp'), ('CHEBI_17234', 'glucose', 1167, 'glucose'), ('GO_0010467', 'gene expression', 1216, 'expression')]
PMC3192058	10/2011	S2-PMC3192058	['Glucose tolerance test and Insulin tolerance test(itt) in vivo and Glucose stimulated Insulin secretion(gsis) test in vitro were performed at different stages in iugr and normal groups.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('PR_000045358', 'insulin family protein', 27, 'insulin'), ('CHEBI_17234', 'glucose', 67, 'glucose'), ('PR_000045358', 'insulin family protein', 86, 'insulin')]
PMC3192058	10/2011	S5-PMC3192058	['in the newborns, the fasting Glucose and Insulin levels of iugr Rats were both lower than those of controls, whereas Glucose levels at 120 and 180 min after Glucose load were significantly higher in iugr group.']	N/A	N/A	[('CHEBI_17234', 'glucose', 29, 'glucose'), ('PR_000045358', 'insulin family protein', 41, 'insulin'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 64, 'rats'), ('CHEBI_17234', 'glucose', 117, 'glucose'), ('CHEBI_17234', 'glucose', 157, 'glucose')]
PMC3192058	10/2011	S6-PMC3192058	['between 3 and 15 weeks of age, both the fasting Glucose and Insulin levels were elevated and the Glucose tolerance was impaired with time in iugr Rats.']	N/A	N/A	[('CHEBI_17234', 'glucose', 48, 'glucose'), ('PR_000045358', 'insulin family protein', 60, 'insulin'), ('CHEBI_17234', 'glucose', 97, 'glucose'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 146, 'rats')]
PMC3192058	10/2011	S7-PMC3192058	['at age 15 weeks, the area under curve of Insulin(auci) after Glucose load in iugr Rats elevated markedly.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 41, 'insulin'), ('CHEBI_17234', 'glucose', 61, 'glucose'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 82, 'rats')]
PMC3192058	10/2011	S19-PMC3192058	['in Human, sga (small for Gestational age) fetus was hypoinsulinemic and hypoglycemic[16],[17]and a Glucose challenge in utero provoked only a small Insulin secretory response[18]which persisted neonatally[19].']	N/A	N/A	[('NCBITaxon_9606', 'Homo sapiens', 3, 'human'), ('GO_0007565', 'female pregnancy', 25, 'gestational'), ('CHEBI_17234', 'glucose', 99, 'glucose'), ('PR_000045358', 'insulin family protein', 148, 'insulin')]
PMC3192058	10/2011	S23-PMC3192058	['Intraperitoneal Glucose tolerance test (ipgtt) in vivo and Glucose stimulated Insulin secretion (gsis) test in vitro were performed to evaluate Islet Β Cell function, meanwhile Insulin tolerance test (itt) were executed to Learn Insulin sensitivity.']	N/A	N/A	[('UBERON_0007158', 'lumen of anal canal', 0, 'Intraperitoneal'), ('CHEBI_17234', 'glucose', 16, 'glucose'), ('CHEBI_17234', 'glucose', 59, 'glucose'), ('PR_000045358', 'insulin family protein', 78, 'insulin'), ('CL_0000214', 'synovial cell', 144, 'islet β cell'), ('PR_000045358', 'insulin family protein', 177, 'insulin'), ('GO_0007612', 'learning', 223, 'learn'), ('PR_000045358', 'insulin family protein', 229, 'insulin')]
PMC3192058	10/2011	S35-PMC3192058	['Intraperitoneal Glucose tolerance test (ipgtt) and Insulin releasing test (irt)\nthe neonatal pups from iugr and normal group were fasted for 12 hours and then injected Glucose (2 g/kg) Intraperitoneally.']	N/A	N/A	[('UBERON_0007158', 'lumen of anal canal', 0, 'Intraperitoneal'), ('CHEBI_17234', 'glucose', 16, 'glucose'), ('PR_000045358', 'insulin family protein', 51, 'insulin'), ('CHEBI_17234', 'glucose', 168, 'glucose'), ('UBERON_0000007', 'pituitary gland', 185, 'intraperitoneally')]
PMC3192058	10/2011	S36-PMC3192058	['Blood samples were collected from Fossa Orbitalis to determine Blood Glucose by an automatic glucometer (roche, germany) at 0, 30, 60, 120 and 180 min after the Glucose load.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('UBERON_3000802', 'fossa glenoidalis', 34, 'fossa orbitalis'), ('UBERON_0000178', 'blood', 63, 'blood'), ('CHEBI_17234', 'glucose', 69, 'glucose'), ('CHEBI_17234', 'glucose', 161, 'glucose')]
PMC3192058	10/2011	S39-PMC3192058	['two groups of male Rats at 3, 7, 10, 15 weeks of age were fasted overnight for 12 hours, and in the morning of the next day, Blood samples were taken for determination of Blood Glucose and Serum Insulin.']	N/A	N/A	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 19, 'rats'), ('UBERON_0000178', 'blood', 125, 'blood'), ('UBERON_0000178', 'blood', 171, 'blood'), ('CHEBI_17234', 'glucose', 177, 'glucose'), ('UBERON_0001977', 'blood serum', 189, 'serum'), ('PR_000045358', 'insulin family protein', 195, 'insulin')]
PMC3192058	10/2011	S40-PMC3192058	['Glucose (2 g/kg) was injected Intraperitoneally in Rats.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('UBERON_0000007', 'pituitary gland', 30, 'intraperitoneally'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 51, 'rats')]
PMC3192058	10/2011	S41-PMC3192058	['Blood samples were collected from Fossa Orbitalis sequentially before and 15, 30, 60, 120 min after Glucose administration.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('UBERON_3000802', 'fossa glenoidalis', 34, 'fossa orbitalis'), ('CHEBI_17234', 'glucose', 100, 'glucose')]
PMC3192058	10/2011	S42-PMC3192058	['Blood Glucose was measured using an automatic Glucometer (roche, germany).']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('CHEBI_17234', 'glucose', 6, 'glucose'), ('CHEBI_24321', 'glutamo group', 46, 'glucometer')]
PMC3192058	10/2011	S59-PMC3192058	['Glucose stimulated Insulin secretion (gsis) test\nIslets were randomly hand-picked (200∼250 um in diameter) into milicell (milipore, american, 20islets/well) which was placed in 24 wells plate beforehand, and preincubated in 0.5 ml basic medium, rpmi 1640 with 3.3 mmol/l Glucose (sigma, american) at 37°c (air:Co2 95∶5) for 30 minutes.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('PR_000045358', 'insulin family protein', 19, 'insulin'), ('CL_0000034', 'stem cell', 49, 'Islets'), ('UBERON_0012356', 'pedal acropodium region', 49, 'Islets'), ('CHEBI_17234', 'glucose', 271, 'glucose'), ('CHEBI_16526', 'carbon dioxide', 310, 'CO2')]
PMC3192058	10/2011	S60-PMC3192058	['after discarding the supernatants, each well was filled with 0.4 ml basic medium supplemented with 3.3 mmol/l Glucose and incubated for 1 hour at 37°c (air:Co2 95∶5).']	N/A	N/A	[('CHEBI_17234', 'glucose', 110, 'glucose'), ('CHEBI_16526', 'carbon dioxide', 156, 'CO2')]
PMC3192058	10/2011	S61-PMC3192058	['the supernatants were harvested, and each well was filled with 0.4 ml stimulation medium, rpmi 1640 supplemented with 16.7 mmol/l Glucose.']	N/A	N/A	[('CHEBI_17234', 'glucose', 130, 'glucose')]
PMC3192058	10/2011	S66-PMC3192058	['stimulating index was calculated as Insulin concentration in the 16.7 mmol/l Glucose stimulation samples divided by Insulin concentration in the 3.3 mmol/l Glucose stimulation samples.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 36, 'insulin'), ('CHEBI_17234', 'glucose', 77, 'glucose'), ('PR_000045358', 'insulin family protein', 116, 'insulin'), ('CHEBI_17234', 'glucose', 156, 'glucose')]
PMC3192058	10/2011	S69-PMC3192058	['Blood samples were collected via Tail Vein at 0, 20, 40, 60, and 90 min subsequently to measure Glucose concentrations.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('UBERON_0003481', 'tail vein', 33, 'tail vein'), ('CHEBI_17234', 'glucose', 96, 'glucose')]
PMC3192058	10/2011	S88-PMC3192058	['in the newborns, the fasting Glucose and Insulin levels of iugr pups were both lower than those of normal ones (4.17±0.41 mmol/l vs 4.36±0.41 mmol/l; 0.20±0.02 ng/ml vs 0.25±0.07 ng/ml), whereas Glucose levels at 120 and 180 min after Glucose load were significantly higher in iugr group ( p<0.05) (fig.']	N/A	N/A	[('CHEBI_17234', 'glucose', 29, 'glucose'), ('PR_000045358', 'insulin family protein', 41, 'insulin'), ('CHEBI_17234', 'glucose', 195, 'glucose'), ('CHEBI_17234', 'glucose', 235, 'glucose')]
PMC3192058	10/2011	S89-PMC3192058	['3).10.1371/journal.pone.0025167.g003\n\ncaption (fig): figure 3\nBlood Glucose levels during an Intraperitoneal Glucose tolerance test in newborn pups in iugr (△) and control (•) Rats.']	N/A	N/A	[('UBERON_0000178', 'blood', 62, 'Blood'), ('CHEBI_17234', 'glucose', 68, 'glucose'), ('UBERON_2001932', 'sensory canal tubular ossicle', 93, 'intraperitoneal'), ('CHEBI_17234', 'glucose', 109, 'glucose'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 176, 'rats')]
PMC3192058	10/2011	S92-PMC3192058	['compared with the normal control group, both the fasting Glucose and Insulin levels were elevated, and the Glucose tolerance was impaired with time in iugr Rats from 3 to 15 weeks of age.']	N/A	N/A	[('CHEBI_17234', 'glucose', 57, 'glucose'), ('PR_000045358', 'insulin family protein', 69, 'insulin'), ('CHEBI_17234', 'glucose', 107, 'glucose'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 156, 'rats')]
PMC3192058	10/2011	S93-PMC3192058	['early in Life, Glucose intolerance was mild; however, as age Grew, iugr Rats showed a progressive loss in the ability to handle a Glucose load.']	N/A	N/A	[('UBERON_0000104', 'life cycle', 9, 'life'), ('CHEBI_17234', 'glucose', 15, 'glucose'), ('GO_0040007', 'growth', 61, 'grew'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 72, 'rats'), ('CHEBI_17234', 'glucose', 130, 'glucose')]
PMC3192058	10/2011	S94-PMC3192058	['at age 15 weeks, Glucose levels of iugr group at 15, 30, 60 and 120 min were significantly higher than those of control group (16.97±1.13 mmol/l vs 15.06±1.30 mmol/l; 12.61±1.38 mmol/l vs 10.96±0.92 mmol/l; 9.59±1.37 mmol/l vs 7.88±0.67 mmol/l; 8.59±1.56 mmol/l vs 7.12±0.30 mmol/l, p<0.05) (fig.']	N/A	N/A	[('CHEBI_17234', 'glucose', 17, 'glucose')]
PMC3192058	10/2011	S95-PMC3192058	['4a–d).10.1371/journal.pone.0025167.g004\n\ncaption (fig): figure 4\nBlood Glucose levels during an Intraperitoneal Glucose tolerance test at 3 weeks (a), 7 weeks (b), 10 weeks (c) and 15 weeks (d) of age in iugr (△) and control (•) Rats.']	N/A	N/A	[('UBERON_0000178', 'blood', 65, 'Blood'), ('CHEBI_17234', 'glucose', 71, 'glucose'), ('UBERON_2001932', 'sensory canal tubular ossicle', 96, 'intraperitoneal'), ('CHEBI_17234', 'glucose', 112, 'glucose'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 229, 'rats')]
PMC3192058	10/2011	S98-PMC3192058	['in addition, Insulin Release was detected in response to Glucose load at 3, 7, 10 and 15 weeks of age.']	N/A	N/A	[('GO_0006880', 'intracellular sequestering of iron ion', 13, 'insulin release'), ('PR_000045358', 'insulin family protein', 13, 'insulin'), ('CHEBI_17234', 'glucose', 57, 'glucose')]
PMC3192058	10/2011	S110-PMC3192058	['a significant reduction of Insulin Release response to stimulation of 16.7 mmol/l Glucose was seen in Islets isolated from iugr Rats at 15 weeks of age.']	N/A	N/A	[('GO_0006880', 'intracellular sequestering of iron ion', 27, 'insulin release'), ('PR_000045358', 'insulin family protein', 27, 'insulin'), ('CHEBI_17234', 'glucose', 82, 'glucose'), ('UBERON_0000029', 'lymph node', 102, 'islets'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 128, 'rats')]
PMC3192058	10/2011	S119-PMC3192058	['in iugr Rats, at 15 weeks, the Glycemic Response to exogenous Insulin was a 40% drop in Glucose levels after 60 min of Insulin load.']	N/A	N/A	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 8, 'rats'), ('GO_0006096', 'glycolytic process', 31, 'glycemic response'), ('PR_000045358', 'insulin family protein', 62, 'insulin'), ('CHEBI_17234', 'glucose', 88, 'glucose'), ('PR_000045358', 'insulin family protein', 119, 'insulin')]
PMC3192058	10/2011	S152-PMC3192058	['however, impaired Glucose tolerance progressed to overt diabetes in iugr Rat because of the ultimate inability of Β Cell and gradually diminished Β Cell mass.']	N/A	N/A	[('CHEBI_17234', 'glucose', 18, 'glucose'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 73, 'rat'), ('CL_0000570', 'parafollicular cell', 114, 'β cell'), ('CL_0000570', 'parafollicular cell', 146, 'β cell')]
PMC3192420	7/2011	S56-PMC3192420	['in addition, Glucose tolerance tests were undertaken on all offspring at 8 and 17 months of age after on overnight fast and the area under the curve (auc) calculated (10).']	N/A	N/A	[('CHEBI_17234', 'glucose', 13, 'glucose')]
PMC3192420	7/2011	S64-PMC3192420	['laboratory analysis\n\nPlasma Metabolite and hormones\nGlucose, nonesterified Fatty Acid and Triacylglycerol concentrations were determined by colorimetric assays (randox, crumlin, uk).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 21, 'Plasma'), ('CHEBI_39382', 'flufenoxuron', 28, 'metabolite'), ('CHEBI_17234', 'glucose', 52, 'Glucose'), ('CHEBI_35366', 'fatty acid', 75, 'fatty acid'), ('CHEBI_17515', 'L-gamma-glutamyl-L-cysteine', 90, 'triacylglycerol')]
PMC3192420	7/2011	S127-PMC3192420	[')838.3 ± 1064.0 ± 1132.6 ± 6.9<0.05<0.051653.1 ± 15107 ± 3791.1 ± 47<0.05—auc Glucose (a.u.']	N/A	N/A	[('CHEBI_17234', 'glucose', 78, 'glucose')]
PMC3192420	7/2011	S155-PMC3192420	['Agrp , Agouti-Related Peptide; Dnmt1 , Dinucleotide Methyl Transferase 1; Ghsr , Ghrelin Receptor; Glut1 , Glucose Transporter 1; Ir , Insulin Receptor; Socs3 , suppressor of Cytokine Signalling.']	N/A	N/A	[('PR_000003580', 'ABI gene family member 3', 0, 'AgRP'), ('PR_000004268', 'AT-rich interactive domain-containing protein 4B', 7, 'Agouti-related peptide'), ('PR_000006564', 'dynein heavy chain 5, axonemal', 31, 'DNMT1'), ('PR_000006279', 'death-associated protein-like 1', 39, 'dinucleotide methyl transferase 1'), ('PR_000007939', 'glial fibrillary acidic protein', 74, 'GHSR'), ('PR_000001593', 'leucine-rich repeat-containing G-protein coupled receptor 6', 81, 'ghrelin receptor'), ('PR_000015065', 'solute carrier family 2, facilitated glucose transporter member 3', 99, 'GLUT1'), ('CHEBI_17234', 'glucose', 107, 'glucose'), ('PR_000015064', 'solute carrier family 2, facilitated glucose transporter member 2', 107, 'glucose transporter 1'), ('PR_000002050', 'interferon regulatory factor 8', 130, 'IR'), ('PR_000001365', 'interleukin-10 receptor subunit alpha', 135, 'insulin receptor'), ('PR_000015399', 'superoxide dismutase [Cu-Zn]', 153, 'SOCS3'), ('GO_0019221', 'cytokine-mediated signaling pathway', 175, 'cytokine signalling')]
PMC3198285	11/2011	S9-PMC3198285	['Gestational diabetes mellitus (gdm) is commonly defined as any degree of Glucose intolerance with onset or first recognition during Pregnancy (1).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_17234', 'glucose', 73, 'glucose'), ('GO_0007565', 'female pregnancy', 132, 'pregnancy')]
PMC3198285	11/2011	S29-PMC3198285	['subject recruitment, randomization, and stratification\nwomen aged 18–45 years diagnosed with gdm by a 75-g oral Glucose tolerance test at 20–32 weeks’ Gestation, with an otherwise healthy singleton Pregnancy, were eligible for the study.']	N/A	N/A	[('CHEBI_17234', 'glucose', 112, 'glucose'), ('GO_0007565', 'female pregnancy', 151, 'gestation'), ('GO_0007565', 'female pregnancy', 198, 'pregnancy')]
PMC3198285	11/2011	S30-PMC3198285	['gdm diagnosis was based on the modified australasian diabetes in Pregnancy society (adips) criteria: fasting Blood Glucose level (bgl) ≥5.5 mmol/l, 1-h bgl ≥10.0 mmol/l, or 2-h bgl ≥8.0 mmol/l.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 65, 'Pregnancy'), ('UBERON_0000178', 'blood', 109, 'blood'), ('CHEBI_17234', 'glucose', 115, 'glucose')]
PMC3198285	11/2011	S80-PMC3198285	['at baseline, subjects in the lgi group had significantly higher 2-h postload Blood Glucose levels (lgi 8.6 ± 1.2 mmol/l vs. hf 8.0 ± 1.3 mmol/l; p = 0.024) but were otherwise similar to those in the hf group.']	N/A	N/A	[('UBERON_0000178', 'blood', 77, 'blood'), ('CHEBI_17234', 'glucose', 83, 'glucose')]
PMC3198285	11/2011	S87-PMC3198285	['ogtt, oral Glucose tolerance test.']	N/A	N/A	[('CHEBI_17234', 'glucose', 11, 'glucose')]
PMC3198285	11/2011	S98-PMC3198285	['additional analyses with adjustments for ethnicity (asian vs. caucasian), bmi; oral Glucose tolerance test results; baseline characteristics including daily intakes of energy, monounsaturated fatty Acid, polyunsaturated Fatty Acid, and Sodium; fasting bgl; fasting Insulin; Homeostasis model assessment of Insulin resistance; and total Cholesterol did not change the lack of significance of the between-group comparisons.']	N/A	N/A	[('CHEBI_17234', 'glucose', 84, 'glucose'), ('CHEBI_37527', 'acid', 198, 'acid'), ('CHEBI_35366', 'fatty acid', 220, 'fatty acid'), ('CHEBI_52632', 'potassium-39 atom', 236, 'sodium'), ('PR_000045358', 'insulin family protein', 265, 'insulin'), ('GO_0042592', 'homeostatic process', 274, 'homeostasis'), ('PR_000045358', 'insulin family protein', 306, 'insulin'), ('CHEBI_16113', 'cholesterol', 336, 'cholesterol')]
PMC3202114	10/2011	S20-PMC3202114	['in Adult pima indians with normal Glucose tolerance and who had been exposed to an Intrauterine diabetic environment, acute Insulin response to i.v.']	N/A	N/A	[('UBERON_0007023', 'adult organism', 3, 'adult'), ('CHEBI_17234', 'glucose', 34, 'glucose'), ('UBERON_0022293', 'reproductive gland secretion', 83, 'intrauterine'), ('PR_000045358', 'insulin family protein', 124, 'insulin')]
PMC3202114	10/2011	S56-PMC3202114	['maternal Glucose infusions limited to the last Trimester of Pregnancy result in hyperglycemia and hyperinsulinemia and do not mimic the relative Insulin deficiency of Gestational diabetes [38].']	N/A	N/A	[('CHEBI_17234', 'glucose', 9, 'glucose'), ('GO_0009294', 'DNA mediated transformation', 47, 'trimester'), ('GO_0007565', 'female pregnancy', 60, 'pregnancy'), ('PR_000045358', 'insulin family protein', 145, 'insulin'), ('GO_0007565', 'female pregnancy', 167, 'gestational')]
PMC3202114	10/2011	S74-PMC3202114	['female offspring only develop hyperinsulinemia and impaired Glucose tolerance at a much later age (21 months) [54].']	N/A	N/A	[('CHEBI_17234', 'glucose', 60, 'glucose')]
PMC3202114	10/2011	S78-PMC3202114	['fetal upi Rats have decreased levels of Glucose, Insulin, Igf1, amino acids, and oxygen [63–65].']	N/A	N/A	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 10, 'rats'), ('CHEBI_17234', 'glucose', 40, 'glucose'), ('PR_000045358', 'insulin family protein', 49, 'insulin'), ('PR_000008954', 'insulin-like growth factor-binding protein-like 1', 58, 'IGF1')]
PMC3202114	10/2011	S81-PMC3202114	['high-fat diet Consumption by female Rats malprograms the male offspring for Glucose intolerance and increased body weight in Adulthood [70].']	N/A	N/A	[('GO_0007631', 'feeding behavior', 14, 'consumption'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 36, 'rats'), ('CHEBI_17234', 'glucose', 76, 'glucose'), ('UBERON_0000113', 'post-juvenile adult stage', 125, 'adulthood')]
PMC3202114	10/2011	S90-PMC3202114	['at Adult age while maintained on normal diet, Genetically normal, Adult female offspring of ay-positive mothers exhibited reduced Glucose-induced Insulin secretion in vivo [81].']	N/A	N/A	[('UBERON_0007023', 'adult organism', 3, 'adult'), ('SO_0000704', 'gene', 46, 'genetically'), ('UBERON_0007023', 'adult organism', 66, 'adult'), ('CHEBI_17234', 'glucose', 130, 'glucose'), ('PR_000045358', 'insulin family protein', 146, 'insulin')]
PMC3202114	10/2011	S94-PMC3202114	['relative to controls, their female offspring had an early onset of impaired Insulin secretion and Glucose tolerance that worsened with time and normal adiposity.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 76, 'insulin'), ('CHEBI_17234', 'glucose', 98, 'glucose')]
PMC3202114	10/2011	S114-PMC3202114	['the low-protein diet significantly reduced Insulin and essential amino acid levels and increased Glucose levels within maternal Serum by day 4 of development.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 43, 'insulin'), ('CHEBI_17234', 'glucose', 97, 'glucose'), ('UBERON_0001977', 'blood serum', 128, 'serum')]
PMC3202114	10/2011	S176-PMC3202114	['f1 Gestational diabetes per se is an inducing factor for impaired Glucose tolerance and Gestational diabetes again in the next female generation (f2).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 3, 'gestational'), ('CHEBI_17234', 'glucose', 66, 'glucose'), ('GO_0007565', 'female pregnancy', 88, 'gestational')]
PMC3208550	11/2011	S48-PMC3208550	['biochemical analysis\nSerum Glucose was determined with a hexokinase assay (thermo Electron, melbourne, australia), Triglyceride and Cholesterol were measured using an olympus au400 analyzer with enzymatic Reagents (olympus america, new york, usa).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 21, 'Serum'), ('CHEBI_17234', 'glucose', 27, 'glucose'), ('CHEBI_10545', 'electron', 82, 'Electron'), ('CHEBI_17855', 'triglyceride', 115, 'triglyceride'), ('CHEBI_16113', 'cholesterol', 132, 'cholesterol'), ('CHEBI_33893', 'reagent', 205, 'reagents')]
PMC3208550	11/2011	S51-PMC3208550	['Intraperitoneal Glucose tolerance test measurement\nthe Intraperitoneal Glucose tolerance test (ipgtt) was performed as previously described[26].']	N/A	N/A	[('UBERON_0007158', 'lumen of anal canal', 0, 'Intraperitoneal'), ('CHEBI_17234', 'glucose', 16, 'glucose'), ('UBERON_2001932', 'sensory canal tubular ossicle', 55, 'intraperitoneal'), ('CHEBI_17234', 'glucose', 71, 'glucose')]
PMC3208550	11/2011	S53-PMC3208550	['thereafter, Blood samples were drawn at 30-, 60- and 120-min intervals after the Glucose injection, and Glucose levels were measured by a Glucose meter (accu-chek; roche, mannheim, germany).']	N/A	N/A	[('UBERON_0000178', 'blood', 12, 'blood'), ('CHEBI_17234', 'glucose', 81, 'glucose'), ('CHEBI_17234', 'glucose', 104, 'glucose'), ('CHEBI_17234', 'glucose', 138, 'glucose')]
PMC3208550	11/2011	S80-PMC3208550	["Serum Glucose during Ipgtt was analyzed using repeated-measures anova followed by fisher's test."]	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_17234', 'glucose', 6, 'glucose'), ('GO_0003099', 'positive regulation of the force of heart contraction by chemical signal', 21, 'IPGTT')]
PMC3208550	11/2011	S106-PMC3208550	['effect of Postnatal overfeeding on biochemical measurements\nthere were no differences in Serum Glucose, Triglyceride and Cholesterol levels from w3 to w16 (data not shown).']	N/A	N/A	[('GO_0007567', 'parturition', 10, 'postnatal'), ('UBERON_0001977', 'blood serum', 89, 'serum'), ('CHEBI_17234', 'glucose', 95, 'glucose'), ('CHEBI_17855', 'triglyceride', 104, 'triglyceride'), ('CHEBI_16113', 'cholesterol', 121, 'cholesterol')]
PMC3208550	11/2011	S107-PMC3208550	['Insulin levels at w16 were higher in sl Rats compared to nl Rats (108.65±4.88 vs. 87.06±6.48 pmol/l, p<0.05), and the Insulin-to-Glucose ratio was higher in sl Rats than in nl Rats (15.62±1.43 vs. 12.5±1.08, p<0.05).']	N/A	N/A	[('PR_000045358', 'insulin family protein', 0, 'Insulin'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 40, 'rats'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 60, 'rats'), ('PR_000045358', 'insulin family protein', 118, 'insulin'), ('CHEBI_17234', 'glucose', 129, 'glucose'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 160, 'rats'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 176, 'rats')]
PMC3208550	11/2011	S109-PMC3208550	['3).10.1371/journal.pone.0025726.g003\n\ncaption (fig): figure 3\nIntraperitoneal Glucose tolerance test at w16 (2.0 g Glucose/kg) in sl and nl Rats.']	N/A	N/A	[('UBERON_0007158', 'lumen of anal canal', 62, 'Intraperitoneal'), ('CHEBI_17234', 'glucose', 78, 'glucose'), ('CHEBI_17234', 'glucose', 115, 'glucose'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 140, 'rats')]
PMC3227644	11/2011	S5-PMC3227644	['on Gestational day 8, fasting Plasma Glucose concentration was higher and β-Hydroxybutyrate lower in f0 and f1 dams than f2 dams.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 3, 'gestational'), ('UBERON_0001969', 'blood plasma', 30, 'plasma'), ('CHEBI_17234', 'glucose', 37, 'glucose'), ('CHEBI_35944', 'thiosulfite(1-)', 76, 'hydroxybutyrate')]
PMC3227644	11/2011	S52-PMC3227644	['gr (generation f(3.9,0.2) 16.5, p<0.0001), Pparα (f(5.9,0.1) 43.8, p<0.0001), Carnitine Palmitoy1 Transferase (Cpt)-1 (f(15.1,0.2) 65.1, p<0.0001), Glucose-6-phosphatase (g6pase) (f(12.1,0.1) 97.4, p<0.0001) and Phosphoenolpyruvate carboxykinase (pepck) (f(1.3,0.3) 4.3, p\u200a=\u200a0.001) mrna Expression was increased in f2 compared to f0 and f1 dams.']	N/A	N/A	[('PR_000013057', 'peroxisome proliferator-activated receptor delta', 43, 'PPARα'), ('CHEBI_76918', '(R)-nisoldipine', 78, 'carnitine palmitoy1'), ('PR_000005844', 'cellular retinoic acid-binding protein 2', 78, 'carnitine palmitoy1 transferase ...'), ('PR_000005855', 'cyclic AMP-responsive element-binding protein 3', 111, 'CPT ... 1'), ('CHEBI_17234', 'glucose', 148, 'glucose'), ('CHEBI_18021', 'phosphoenolpyruvate', 212, 'phosphoenolpyruvate'), ('GO_0010467', 'gene expression', 287, 'expression')]
PMC3227644	11/2011	S56-PMC3227644	['Plasma fasting Glucose and β-Hydroxybutyrate concentrations.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_17234', 'glucose', 15, 'glucose'), ('CHEBI_35944', 'thiosulfite(1-)', 29, 'hydroxybutyrate')]
PMC3227644	11/2011	S57-PMC3227644	['Hepatic Pparα, Carnitine Palmitoyltransferase-1 (Cpt-1), Glucocorticoid receptor (gr), Phosphoenolpyruvate carboxykinase (pepck), (g) Glucose-6-phosphatase (g-6-pase) mrna Expression.']	N/A	N/A	[('UBERON_0002107', 'liver', 0, 'Hepatic'), ('PR_000013057', 'peroxisome proliferator-activated receptor delta', 8, 'PPARα'), ('CHEBI_17126', 'carnitine', 15, 'carnitine'), ('PR_000005848', 'protein crumbs homolog 1', 15, 'carnitine palmitoyltransferase-1'), ('PR_000005855', 'cyclic AMP-responsive element-binding protein 3', 49, 'CPT-1'), ('CHEBI_24261', 'glucocorticoid', 57, 'glucocorticoid'), ('CHEBI_18021', 'phosphoenolpyruvate', 87, 'phosphoenolpyruvate'), ('CHEBI_17234', 'glucose', 134, 'glucose'), ('GO_0010467', 'gene expression', 172, 'expression')]
PMC3227644	11/2011	S72-PMC3227644	['change in offspring body weight on day 70 compared to weaning, offspring energy Intake on day 70, fasting Glucose and β-Hydroxybutyrate concentrations on Postnatal day 70.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 80, 'intake'), ('CHEBI_17234', 'glucose', 106, 'glucose'), ('CHEBI_35944', 'thiosulfite(1-)', 120, 'hydroxybutyrate'), ('GO_0007567', 'parturition', 154, 'postnatal')]
PMC3227644	11/2011	S73-PMC3227644	['Hepatic Pparα, Carnitine Palmitoyltransferase-1 (Cpt-1), Glucocorticoid receptor (gr), Phosphoenolpyruvate carboxykinase (pepck), (i) Glucose-6-phosphatase (g-6-pase) mrna Expression.']	N/A	N/A	[('UBERON_0002107', 'liver', 0, 'Hepatic'), ('PR_000013057', 'peroxisome proliferator-activated receptor delta', 8, 'PPARα'), ('CHEBI_17126', 'carnitine', 15, 'carnitine'), ('PR_000005848', 'protein crumbs homolog 1', 15, 'carnitine palmitoyltransferase-1'), ('PR_000005855', 'cyclic AMP-responsive element-binding protein 3', 49, 'CPT-1'), ('CHEBI_24261', 'glucocorticoid', 57, 'glucocorticoid'), ('CHEBI_18021', 'phosphoenolpyruvate', 87, 'phosphoenolpyruvate'), ('CHEBI_17234', 'glucose', 134, 'glucose'), ('GO_0010467', 'gene expression', 172, 'expression')]
PMC3227644	11/2011	S165-PMC3227644	['measurements of Metabolites in Blood\nβhb and Glucose concentrations in Plasma were measured as described using a konelab 20[36].']	N/A	N/A	[('CHEBI_25212', 'metabolite', 16, 'metabolites'), ('UBERON_0000178', 'blood', 31, 'blood'), ('CHEBI_17234', 'glucose', 45, 'glucose'), ('UBERON_0001969', 'blood plasma', 71, 'plasma')]
PMC3237352	4/2011	S36-PMC3237352	['case presentation\nthe case mother was a 26-year-old african-american woman (case mother) with three reported past Pregnancies and one living child; she had no significant past medical history and negative Prenatal laboratory testing for hepatitis b, syphilis, group b streptococcus, and Glucose intolerance.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 114, 'pregnancies'), ('GO_0007565', 'female pregnancy', 205, 'prenatal'), ('CHEBI_17234', 'glucose', 287, 'glucose')]
PMC3240629	12/2011	S20-PMC3240629	['in the Sheep, reductions in Maternal Food Intake, or Feeding of diets deficient in b Vitamins and methionine during the Periconceptional period (between 60 days Preconception to 31 days Gestational age), elevates fetal Blood pressure, induces Cardiovascular and Renal abnormalities, impairs Glucose tolerance and Insulin resistance and increases adiposity in Adult offspring[18],[19],[20],[21].']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 7, 'sheep'), ('GO_0007618', 'mating', 28, 'maternal'), ('CHEBI_33290', 'food', 37, 'food'), ('GO_0007631', 'feeding behavior', 37, 'food intake'), ('GO_0007631', 'feeding behavior', 53, 'feeding'), ('CHEBI_33277', 'gamma-tocotrienol', 85, 'vitamins'), ('GO_0007565', 'female pregnancy', 120, 'periconceptional'), ('GO_0007565', 'female pregnancy', 161, 'preconception'), ('GO_0007565', 'female pregnancy', 186, 'gestational'), ('UBERON_0000178', 'blood', 219, 'blood'), ('UBERON_0004535', 'cardiovascular system', 243, 'cardiovascular'), ('UBERON_0002113', 'kidney', 262, 'renal'), ('CHEBI_17234', 'glucose', 291, 'glucose'), ('PR_000045358', 'insulin family protein', 313, 'insulin'), ('UBERON_0007023', 'adult organism', 359, 'adult')]
PMC3240629	12/2011	S54-PMC3240629	["Serum Glucose and Insulin measurements\nSerum Glucose concentrations were measured using the infinity™ Glucose oxidase liquid stable Reagent kit (thermo) according to manufacturer's instructions."]	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_17234', 'glucose', 6, 'glucose'), ('PR_000045358', 'insulin family protein', 18, 'insulin'), ('UBERON_0001977', 'blood serum', 39, 'Serum'), ('CHEBI_17234', 'glucose', 45, 'glucose'), ('CHEBI_17234', 'glucose', 102, 'Glucose'), ('CHEBI_33893', 'reagent', 132, 'Reagent')]
PMC3240629	12/2011	S69-PMC3240629	['genorm software[28]was used to determine these to be the most stable reference Genes in the Adult Mouse Fat Tissues[29].10.1371/journal.pone.0028745.t005\n\ncaption (table-Wrap): table 5\nreal-time pcr Primer details for Gene Expression studies.Gene namegene symbolaccession numberprimer sequencesamplicon lengthprimer efficiencyforward Primerreverse Primeruncoupling Protein 1 (Mitochondrial, Proton Carrier) Ucp1 nm_009463.2 ggcctctacgactcagtcca  taagccggctgagatcttgt 841.99insulin Receptor insr nm_010568.1 ggattattgtctcaaagggctgaa  gagtcgtcatactcactctgattgtg 1021.93adrenergic Receptor, Beta 3 Adrb3 nm_013462.3 cagccagccctgttgaag  ccttcatagccatcaaacctg 611.99insulin-Like Growth Factor I Receptor igf1r nm_010513.2 ccagaagtggagcagaataatc  gccatgccatctgcaatct 891.98succinate Dehydrogenase Complex, Subunit A, Flavoprotein Sdha nm_023281 tgttcagttccaccccaca  tctccacgacacccttctgt 661.99phosphoglycerate Kinase 1 Pgk1 nm_008828 tacctgctggctggatgg  cacagcctcggcatatttct 651.99tata Box Binding Protein Tbp nm_013684.3 gggagaatcatggaccagaa  gatgggaattccaggagtca 901.94peptidylprolyl isomerase b Ppib nm_011149 ttcttcataaccacagtcaagacc  accttccgtaccacatccat 921.95\n\nstatistical analyses\nall data (Postnatal weights, Sbp, Organ allometry, Serum Insulin and Glucose levels and Fat Pad Gene Expression) were analysed using a multilevel random effects regression model (spss version 18) as described previously[30],[31].']	N/A	N/A	[('SO_0000704', 'gene', 79, 'genes'), ('UBERON_0007023', 'adult organism', 92, 'adult'), ('NCBITaxon_10088', 'Mus <genus>', 98, 'mouse'), ('UBERON_0000947', 'aorta', 104, 'fat tissues'), ('PR_000017453', 'protein Wnt-9b', 170, 'WRAP'), ('SO_0000112', 'primer', 199, 'primer'), ('GO_0010467', 'gene expression', 218, 'gene expression'), ('SO_0000704', 'gene', 218, 'gene'), ('SO_0000704', 'gene', 242, 'Gene'), ('SO_0001424', 'pyrosequenced_read', 334, 'PrimerReverse'), ('SO_0000112', 'primer', 348, 'PrimerUncoupling'), ('PR_000006745', 'dual specificity protein phosphatase 19', 365, 'protein 1'), ('GO_0005739', 'mitochondrion', 376, 'mitochondrial'), ('PR_000010705', 'metallothionein-3', 376, 'mitochondrial'), ('CHEBI_51219', 'zinc tetrapyrrole', 391, 'proton carrier'), ('PR_000016970', 'ubiquitin-conjugating enzyme E2 D4', 407, 'Ucp1'), ('PR_000014368', 'RuvB-like 1', 481, 'receptor'), ('PR_000013708', 'GTP-binding nuclear protein Ran', 578, 'receptor, beta 3'), ('PR_000003719', 'disintegrin and metalloproteinase domain-containing protein 23', 595, 'Adrb3'), ('PR_000000035', 'BMP receptor type-1A', 668, '-like growth factor I receptor'), ('GO_0044776', 'DNA polymerase III, core complex', 777, 'dehydrogenase complex'), ('PR_000012975', 'DNA polymerase eta', 777, 'dehydrogenase complex, subunit A'), ('CHEBI_5086', 'flavoprotein', 811, 'flavoprotein'), ('PR_000002092', 'signal transducer and activator of transcription 5b', 824, 'Sdha'), ('PR_000009211', 'lysine-specific demethylase 3A', 904, 'kinase 1'), ('PR_000012564', 'peroxisomal biogenesis factor 3', 913, 'Pgk1'), ('PR_000004770', 'Polycomb complex protein BMI-1', 980, 'box binding protein'), ('SO_0000620', 'B_box', 980, 'box'), ('PR_000016193', 'T-cell leukemia/lymphoma protein 1A', 1000, 'Tbp'), ('PR_000013350', 'pregnancy-specific beta-1-glycoprotein 2', 1092, 'Ppib'), ('GO_0007567', 'parturition', 1193, 'postnatal'), ('UBERON_0012176', 'comb', 1212, 'SBP'), ('UBERON_0000062', 'organ', 1217, 'organ'), ('UBERON_0001977', 'blood serum', 1234, 'serum'), ('PR_000045358', 'insulin family protein', 1240, 'insulin'), ('CHEBI_17234', 'glucose', 1252, 'glucose'), ('UBERON_0003916', 'fat pad', 1271, 'fat pad'), ('GO_0010467', 'gene expression', 1279, 'gene expression'), ('SO_0000704', 'gene', 1279, 'gene')]
PMC3240629	12/2011	S91-PMC3240629	['Serum Glucose and Insulin levels\nno differences were observed between egg-npd and egg-lpd offspring, or between npd, lpd and emb-lpd offspring in mean Serum Glucose or Insulin levels (table 6).10.1371/journal.pone.0028745.t006\n\ncaption (table-wrap): table 6\nfasted offspring Serum Insulin and Glucose concentrations.npdlpdemb-lpdegg-npdegg-lpd meansemmeansemmeansemmeansemmeanseminsulin (ug/l) males2.4000.1902.1600.1612.5460.1531.9900.0882.2020.115females2.0040.1551.8420.0561.9720.1351.9910.1221.8820.051 Glucose (mg/dl) males174.76721.51214.50119.031169.88718.523166.63412.341156.18712.626females153.6658.989149.367.317162.56117.852150.8819.386151.3418.937\nvalues are means ± sem for 9–13, 11–12, 9–12, 8–10 and 9–11 Egg-npd, Egg-lpd, npd, lpd and emb-lpd males and females respectively.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_17234', 'glucose', 6, 'glucose'), ('PR_000045358', 'insulin family protein', 18, 'insulin'), ('UBERON_0001977', 'blood serum', 151, 'serum'), ('CHEBI_17234', 'glucose', 157, 'glucose'), ('PR_000045358', 'insulin family protein', 168, 'insulin'), ('UBERON_0001977', 'blood serum', 275, 'serum'), ('PR_000045358', 'insulin family protein', 281, 'insulin'), ('CHEBI_17234', 'glucose', 293, 'glucose'), ('CHEBI_17234', 'glucose', 507, 'Glucose'), ('CL_0002322', 'embryonic stem cell', 720, 'Egg'), ('CL_0002322', 'embryonic stem cell', 729, 'Egg')]
PMC3240629	12/2011	S137-PMC3240629	['stimulation of the Insulin ( Insr ) and Igf-1 ( igf1r ) receptors induces Glucose Transporter translocation, increasing Intracellular Glucose levels.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 19, 'insulin'), ('PR_000009167', 'involucrin', 29, 'Insr'), ('PR_000008929', 'interferon-related developmental regulator 1', 40, 'IGF-1'), ('CHEBI_17234', 'glucose', 74, 'glucose'), ('GO_0006094', 'gluconeogenesis', 74, 'glucose transporter'), ('GO_0005622', 'intracellular anatomical structure', 120, 'intracellular'), ('CHEBI_17234', 'glucose', 134, 'glucose')]
PMC3260090	12/2011	S15-PMC3260090	['background\nGestational diabetes mellitus (gdm) is defined as "any degree of Glucose intolerance with onset or first recognition during Pregnancy" [1].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 11, 'Gestational'), ('CHEBI_17234', 'glucose', 76, 'glucose'), ('GO_0007565', 'female pregnancy', 135, 'pregnancy')]
PMC3260090	12/2011	S52-PMC3260090	['the following key words in the titles and abstracts and subsequent mesh headings will be searched:\nPregnan* or Antenatal or Prenatal, or neonatal or newborn or infan* or fetal or fetus or foetal or foetus\nand diabet* or hyperglyc?mi* or Glucose intoleran* or obes* (or Gestational diabet*)\nand aborigin* or indigen* or native* or first nation*\nsee table1for a full search tree in medline.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 99, 'pregnan'), ('GO_0007567', 'parturition', 111, 'antenatal'), ('GO_0007565', 'female pregnancy', 124, 'prenatal'), ('CHEBI_17234', 'glucose', 237, 'glucose'), ('GO_0007565', 'female pregnancy', 269, 'gestational')]
PMC3260090	12/2011	S76-PMC3260090	['Glucose intoleran*.mp.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'glucose')]
PMC3260090	12/2011	S77-PMC3260090	['[mp = title, original title, abstract, name of substance word, subject heading word, unique identifier]27. exp Glucose intolerance/or exp Glucose tolerance test/28.']	N/A	N/A	[('CHEBI_17234', 'glucose', 111, 'Glucose'), ('CHEBI_17234', 'glucose', 138, 'Glucose')]
PMC3263630	1/2012	S102-PMC3263630	['in the mothers with preexisting t2dm in the manitoba oji-cree, 25% of their children eligible for Blood Glucose screening (>7 years old) had t2dm and 43% of those >10 years old had t2dm [3].']	N/A	N/A	[('UBERON_0000178', 'blood', 98, 'blood'), ('CHEBI_17234', 'glucose', 104, 'glucose')]
PMC3263630	1/2012	S115-PMC3263630	['Glucose intolerance would be avoided in children and Adults who continued to be malnourished because they preprogrammed their Metabolism to deal with lifelong malnutrition.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('UBERON_0007023', 'adult organism', 53, 'adults'), ('GO_0008152', 'metabolic process', 126, 'metabolism')]
PMC3263848	7/2011	S10-PMC3263848	['other variables with significantly increased compliance using the team-based method were compliance with checking a Blood Glucose value, diagnosing gerd, and prescribing Medication such as Analgesics and multivitamins.']	N/A	N/A	[('UBERON_0000178', 'blood', 116, 'blood'), ('CHEBI_17234', 'glucose', 122, 'glucose'), ('CHEBI_60211', 'compound Z', 170, 'medication'), ('CHEBI_35480', 'analgesic', 189, 'analgesics')]
PMC3263848	7/2011	S56-PMC3263848	['for Blood Glucose value checked, 132 (42%) patients were tested with the team-based approach and 9 (5.9%) patients were tested with the traditional method, p = 0.000.']	N/A	N/A	[('UBERON_0000178', 'blood', 4, 'blood'), ('CHEBI_17234', 'glucose', 10, 'glucose')]
PMC3268605	8/2011	S40-PMC3268605	['directly after weaning of the pups, the dams were placed in Metabolic cages without Food but with access to Water with 2% Glucose and 24-h Urine was collected on Antibiotic/Antimycotic Solution (sigma-aldrich) to prevent degradation of No Metabolites.']	N/A	N/A	[('GO_0008152', 'metabolic process', 60, 'metabolic'), ('CHEBI_33290', 'food', 84, 'food'), ('CHEBI_15377', 'water', 108, 'water'), ('CHEBI_17234', 'glucose', 122, 'glucose'), ('UBERON_0001088', 'urine', 139, 'urine'), ('CHEBI_33282', 'antibacterial agent', 162, 'antibiotic'), ('CHEBI_15369', 'actinomycin', 173, 'antimycotic'), ('CHEBI_75958', 'solution', 185, 'solution'), ('CHEBI_16382', 'iodide', 236, 'NO'), ('CHEBI_25212', 'metabolite', 239, 'metabolites')]
PMC3273459	2/2012	S8-PMC3273459	['fasted Plasma Glucose, Insulin and leptin concentrations were unchanged.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 7, 'plasma'), ('CHEBI_17234', 'glucose', 14, 'glucose'), ('PR_000045358', 'insulin family protein', 23, 'insulin')]
PMC3273459	2/2012	S66-PMC3273459	['tubes containing f-edta (s-monovette, 1.2 g edta/l Blood, 1 g Fluoride/l Blood; sarstedt ag & co, nümbrecht, germany) were used for the analysis of Glucose, Triacylglycerol (tg), non-esterified Fatty Acids (nefa), total Cholesterol (c), low density Lipoprotein Cholesterol (ldlc), high density Lipoprotein Cholesterol (hdlc), and Insulin-Like Growth Factor-I (Igf-I) concentrations.']	N/A	N/A	[('UBERON_0000178', 'blood', 51, 'blood'), ('CHEBI_17051', 'fluoride', 62, 'fluoride'), ('UBERON_0000178', 'blood', 73, 'blood'), ('CHEBI_17234', 'glucose', 148, 'glucose'), ('CHEBI_17515', 'L-gamma-glutamyl-L-cysteine', 157, 'triacylglycerol'), ('CHEBI_35366', 'fatty acid', 194, 'fatty acids'), ('CHEBI_16113', 'cholesterol', 220, 'cholesterol'), ('CHEBI_24911', 'isopiperitenol', 249, 'lipoprotein cholesterol'), ('CHEBI_39015', 'apolipoprotein', 294, 'lipoprotein'), ('CHEBI_16113', 'cholesterol', 306, 'cholesterol'), ('PR_000008959', 'immunoglobulin heavy constant gamma 1', 330, 'insulin-like growth factor-I'), ('PR_000008919', 'interferon alpha-6', 360, 'IGF-I')]
PMC3273459	2/2012	S68-PMC3273459	['Metabolite and hormone analyses\nPlasma Metabolites (Glucose, Urea, tg, nefa, c) were analyzed by the klinik für rinder (stiftung tierärztliche hochschule hannover, germany) using the following kits: Glucose (no.']	N/A	N/A	[('GO_0008152', 'metabolic process', 0, 'Metabolite'), ('UBERON_0001969', 'blood plasma', 32, 'Plasma'), ('CHEBI_25212', 'metabolite', 39, 'metabolites'), ('CHEBI_17234', 'glucose', 52, 'glucose'), ('CHEBI_16199', 'urea', 61, 'urea'), ('CHEBI_17234', 'glucose', 199, 'glucose')]
PMC3273459	2/2012	S92-PMC3273459	['the Insulin∶Glucose ratio was calculated as the Insulin concentration in pmol/l divided by the Glucose concentration in mmol/l.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 4, 'insulin'), ('PR_000007591', 'protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha', 11, '∶'), ('CHEBI_17234', 'glucose', 12, 'glucose'), ('PR_000045358', 'insulin family protein', 48, 'insulin'), ('CHEBI_17234', 'glucose', 95, 'glucose')]
PMC3273459	2/2012	S108-PMC3273459	['the factor time during Pregnancy was significant for Plasma Glucose, nefa, tg, c, hdlc, %hdlc, Urea, and Serum protein concentrations.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 23, 'pregnancy'), ('UBERON_0001969', 'blood plasma', 53, 'plasma'), ('CHEBI_17234', 'glucose', 60, 'glucose'), ('CHEBI_16199', 'urea', 95, 'urea'), ('UBERON_0001977', 'blood serum', 105, 'serum')]
PMC3273459	2/2012	S137-PMC3273459	['of animals161715insulin, µu/ml−510.31.69.51.79.41.90.753<0.0010.1090.1230.441247.11.59.41.69.81.6664.41.58.61.66.51.61089.21.57.91.67.91.6glucagon, pg/ml−5104.86.297.76.5103.36.80.0420.051<0.0010.5040.2652469.65.764.06.083.86.26660.25.769.55.973.36.410870.15.766.96.483.86.5ratiosglucagon to Insulin, nmol/nmol(13)(13)−50.60.62.10.60.50.60.1770.3800.7340.2190.225240.50.52.30.50.40.5660.60.50.90.60.50.61080.80.50.30.61.20.6insulin to Glucose, pmol/mmol(15)(14)(13)−517.32.314.42.317.22.60.2510.0050.0940.2460.2132412.32.010.92.217.32.1668.22.014.42.311.92.310813.32.213.32.313.22.2\nsows were Fed isoenergetic diets with low protein∶high Carbohydrate (6.5% crude protein, lp), adequate protein∶Carbohydrate (12.1% crude protein, ap), and high protein∶low Carbohydrate (30% crude protein, hp) ratios throughout Pregnancy (Exp1).']	N/A	N/A	[('PR_000045358', 'insulin family protein', 292, 'Insulin'), ('CHEBI_17234', 'glucose', 435, 'Glucose'), ('GO_0007631', 'feeding behavior', 593, 'fed'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 638, 'carbohydrate'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 694, 'carbohydrate'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 755, 'carbohydrate'), ('GO_0007565', 'female pregnancy', 810, 'pregnancy'), ('PR_000007209', 'steroid hormone receptor ERR2', 821, 'EXP1')]
PMC3273459	2/2012	S158-PMC3273459	['Plasma c concentrations were higher in lp than in ap ( p<0.01) and hp sows ( p<0.001) ( figure 2c ).10.1371/journal.pone.0031390.g001\n\ncaption (fig): figure 1\ndiurnal Plasma Glucose and Urea concentrations at 92 dpc.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('UBERON_0001969', 'blood plasma', 167, 'plasma'), ('CHEBI_17234', 'glucose', 174, 'glucose'), ('CHEBI_16199', 'urea', 186, 'urea')]
PMC3273459	2/2012	S161-PMC3273459	['panel a, Glucose; panel b, Urea; values are least square means ± se, n\u200a=\u200a9 per group.']	N/A	N/A	[('CHEBI_17234', 'glucose', 9, 'glucose'), ('CHEBI_16199', 'urea', 27, 'urea')]
PMC3273459	2/2012	S169-PMC3273459	['concentrations: c, total Cholesterol; cs, Cortisol; g, Glucose; gg/i, glucagon to Insulin ratio; i, Insulin; i/g, Insulin to Glucose ratio; Igf, Insulin Like Growth Factor-I; ldlc, low density lipoprotein Cholesterol; nefa, non-esterified Fatty Acid; p4, Progesterone; sp, Serum protein.']	N/A	N/A	[('CHEBI_16113', 'cholesterol', 25, 'cholesterol'), ('CHEBI_17650', 'cortisol', 42, 'cortisol'), ('CHEBI_17234', 'glucose', 55, 'glucose'), ('PR_000045358', 'insulin family protein', 82, 'insulin'), ('PR_000045358', 'insulin family protein', 100, 'insulin'), ('PR_000045358', 'insulin family protein', 114, 'insulin'), ('CHEBI_17234', 'glucose', 125, 'glucose'), ('PR_000008989', 'interleukin-1 family member 7', 140, 'IGF'), ('PR_000008959', 'immunoglobulin heavy constant gamma 1', 145, 'insulin like growth factor-I'), ('CHEBI_16113', 'cholesterol', 205, 'cholesterol'), ('CHEBI_35366', 'fatty acid', 239, 'fatty acid'), ('CHEBI_17026', 'progesterone', 255, 'progesterone'), ('UBERON_0001977', 'blood serum', 273, 'serum')]
PMC3273459	2/2012	S196-PMC3273459	['in Rats, prandial Plasma Glucose and Insulin were reported to be lower when a high protein diet was Fed[26].']	N/A	N/A	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 3, 'rats'), ('UBERON_0001969', 'blood plasma', 18, 'plasma'), ('CHEBI_17234', 'glucose', 25, 'glucose'), ('PR_000045358', 'insulin family protein', 37, 'insulin'), ('GO_0007631', 'feeding behavior', 100, 'fed')]
PMC3316748	10/2011	S70-PMC3316748	['Plasma Glucose, total Cholesterol, hdl Cholesterol, ldl Cholesterol, and Triacylglycerol (Tag) concentrations were measured by standard colorimetric assay using a vitalab flexor biochemical analyzer.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_17234', 'glucose', 7, 'glucose'), ('CHEBI_16113', 'cholesterol', 22, 'cholesterol'), ('CHEBI_16113', 'cholesterol', 39, 'cholesterol'), ('CHEBI_16113', 'cholesterol', 56, 'cholesterol'), ('CHEBI_17515', 'L-gamma-glutamyl-L-cysteine', 73, 'triacylglycerol'), ('CHEBI_17855', 'triglyceride', 90, 'TAG')]
PMC3321448	3/2012	S42-PMC3321448	['the Heart was rapidly excised and cannulated via the Aorta to langendorff perfusion apparatus within 90 seconds (ad instruments, oxford, uk) and perfused with krebs henseleit buffer (118\u2009mm Nacl, 4.7\u2009mm Kcl, 1.2\u2009mm Kh2Po4, 1.2\u2009mm Mgso4, 25\u2009mm Nahco3, 11\u2009mm Glucose, and 1.25\u2009mm Cacl2(ph 7.4)) bubbled with O2-Co2(95\u2009:\u20095, v/v) in a Coronary retrograde fashion.']	N/A	N/A	[('UBERON_0000948', 'heart', 4, 'heart'), ('UBERON_0000947', 'aorta', 53, 'aorta'), ('CHEBI_26710', 'sodium chloride', 190, 'NaCl'), ('CHEBI_32588', 'potassium chloride', 203, 'KCl'), ('CHEBI_63036', 'potassium dihydrogen phosphate', 215, 'KH2PO4'), ('CHEBI_32599', 'magnesium sulfate', 230, 'MgSO4'), ('CHEBI_32139', 'sodium hydrogencarbonate', 243, 'NaHCO3'), ('CHEBI_17234', 'glucose', 257, 'glucose'), ('CHEBI_3312', 'calcium dichloride', 278, 'CaCl2'), ('CHEBI_15379', 'dioxygen', 306, 'O2'), ('CHEBI_16526', 'carbon dioxide', 309, 'CO2'), ('UBERON_0005985', 'coronary vessel', 331, 'coronary')]
PMC3325178	4/2012	S79-PMC3325178	['the Adult transcriptional response to starvation promotes a switch from Glucose to Fatty Acid and Ketone body utilisation.']	N/A	N/A	[('UBERON_0007023', 'adult organism', 4, 'adult'), ('CHEBI_17234', 'glucose', 72, 'glucose'), ('CHEBI_35366', 'fatty acid', 83, 'fatty acid'), ('CHEBI_17087', 'ketone', 98, 'ketone')]
PMC3350070	1/2011	S78-PMC3350070	['bradycardia, mild breathing difficulties, and low normal Glucose levels prompted admission to the special care nursery, but no intubation or active intervention was required.']	N/A	N/A	[('CHEBI_17234', 'glucose', 57, 'glucose')]
PMC3350953	4/2012	S28-PMC3350953	['women with gdm were helped to achieve good Metabolic Control: fasting Plasma Glucose (fpg) <5.3\u2009mm and 2\u2009h Postprandial Plasma Glucose (ppg) <6.7\u2009mm.']	N/A	N/A	[('GO_0051238', 'sequestering of metal ion', 43, 'metabolic control'), ('UBERON_0001969', 'blood plasma', 70, 'plasma'), ('CHEBI_17234', 'glucose', 77, 'glucose'), ('GO_0007567', 'parturition', 107, 'postprandial'), ('UBERON_0001969', 'blood plasma', 120, 'plasma'), ('CHEBI_17234', 'glucose', 127, 'glucose')]
PMC3350953	4/2012	S29-PMC3350953	['patients were given dietary advice about the nutritional requirements of Pregnancy [1], and nurse educators showed them how to self-monitor Blood Glucose.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 73, 'pregnancy'), ('UBERON_0000178', 'blood', 140, 'blood'), ('CHEBI_17234', 'glucose', 146, 'glucose')]
PMC3350953	4/2012	S56-PMC3350953	['difficulties related to diabetes monitoring\na considerable number of respondents claimed that they had experienced some difficulties in following the dietary advice, home blood Glucose, and physical activity recommendations.']	N/A	N/A	[('CHEBI_17234', 'glucose', 177, 'glucose')]
PMC3357266	6/2012	S7-PMC3357266	['we conclude that iugr resulted in obesity without Insulin resistance and energy Metabolic perturbations prior to development of Glucose intolerance and t2dm.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 50, 'insulin'), ('GO_0008152', 'metabolic process', 80, 'metabolic'), ('CHEBI_17234', 'glucose', 128, 'glucose')]
PMC3357266	6/2012	S10-PMC3357266	['disruption of Tissue-specific Insulin-Signaling pathways during the fetal and Postnatal stages of development perturbs the whole-body Glucose Homeostasis, with concomitant Insulin resistance in Skeletal muscle and White Adipose Tissue (Wat) of the Adult (1–3).']	N/A	N/A	[('UBERON_0000479', 'tissue', 14, 'tissue'), ('GO_0060494', 'inductive mesenchymal-endodermal cell signaling', 30, 'insulin-signaling'), ('PR_000045358', 'insulin family protein', 30, 'insulin'), ('GO_0007567', 'parturition', 78, 'postnatal'), ('CHEBI_17234', 'glucose', 134, 'glucose'), ('GO_0042593', 'glucose homeostasis', 134, 'glucose homeostasis'), ('PR_000045358', 'insulin family protein', 172, 'insulin'), ('UBERON_0004288', 'skeleton', 194, 'skeletal'), ('UBERON_0001347', 'white adipose tissue', 214, 'white adipose tissue'), ('UBERON_0006337', 'distal early tubule', 236, 'WAT'), ('UBERON_0007023', 'adult organism', 248, 'adult')]
PMC3357266	6/2012	S67-PMC3357266	['Intravenous Glucose tolerance tests.']	N/A	N/A	[('UBERON_3000713', 'epichordal', 0, 'Intravenous'), ('CHEBI_17234', 'glucose', 12, 'glucose')]
PMC3357266	6/2012	S68-PMC3357266	['Adult awake 10-month-old male Animals received 0.5 g/kg Glucose via the Tail Vein, and Blood was obtained at 0, 5, 15, 30, 60, and 120 min subsequently to measure plasma Glucose and Insulin concentrations.']	N/A	N/A	[('UBERON_0007023', 'adult organism', 0, 'Adult'), ('NCBITaxon_33208', 'Metazoa', 30, 'animals'), ('CHEBI_17234', 'glucose', 56, 'glucose'), ('UBERON_0003481', 'tail vein', 72, 'tail vein'), ('UBERON_0000178', 'blood', 87, 'blood'), ('CHEBI_17234', 'glucose', 170, 'glucose'), ('PR_000045358', 'insulin family protein', 182, 'insulin')]
PMC3357266	6/2012	S69-PMC3357266	['the Insulin concentrations measured at 5 min following the intravenous Glucose challenge reflected the first phase and were used to determine the Glucose-Stimulated Insulin Release (gsir).']	N/A	N/A	[('PR_000045358', 'insulin family protein', 4, 'insulin'), ('CHEBI_17234', 'glucose', 71, 'glucose'), ('CHEBI_17234', 'glucose', 146, 'glucose'), ('GO_0031588', 'nucleotide-activated protein kinase complex', 154, 'stimulated'), ('GO_0006880', 'intracellular sequestering of iron ion', 165, 'insulin release'), ('PR_000045358', 'insulin family protein', 165, 'insulin')]
PMC3357266	6/2012	S76-PMC3357266	['all Animals were subjected to an overnight fast for ∼16 h prior to the clamp to standardize Liver Glycogen and Hepatic Glucose output.']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 4, 'animals'), ('UBERON_0002107', 'liver', 92, 'liver'), ('CHEBI_24384', 'glycogens', 98, 'glycogen'), ('UBERON_0002107', 'liver', 111, 'hepatic'), ('CHEBI_17234', 'glucose', 119, 'glucose')]
PMC3357266	6/2012	S81-PMC3357266	['a variable infusion of 50% Glucose Solution was started at the beginning of the hyperinsulinemic clamp and adjusted to maintain the Plasma Glucose concentration at 100–120 mg/dl (euglycemia).']	N/A	N/A	[('CHEBI_17234', 'glucose', 27, 'glucose'), ('CHEBI_75958', 'solution', 35, 'solution'), ('UBERON_0001969', 'blood plasma', 132, 'plasma'), ('CHEBI_17234', 'glucose', 139, 'glucose')]
PMC3357266	6/2012	S82-PMC3357266	['Insulin-stimulated Tissue Glucose Uptake was simultaneously estimated by the concomitant administration of an Intravenous bolus of the nonmetabolizable 2-Deoxy-d-[1-14C]Glucose (10 μci; perkin elmer).']	N/A	N/A	[('PR_000045358', 'insulin family protein', 0, 'Insulin'), ('UBERON_0000479', 'tissue', 19, 'tissue'), ('CHEBI_17234', 'glucose', 26, 'glucose'), ('GO_0046323', 'glucose import', 26, 'glucose uptake'), ('UBERON_0034986', 'sacral nerve plexus', 110, 'intravenous'), ('CHEBI_42485', 'formyl group', 152, '2-deoxy'), ('CHEBI_36927', 'carbon-14 atom', 165, '14C'), ('CHEBI_17234', 'glucose', 169, 'glucose')]
PMC3357266	6/2012	S86-PMC3357266	['total-body Glucose kinetics.']	N/A	N/A	[('CHEBI_17234', 'glucose', 11, 'glucose')]
PMC3357266	6/2012	S87-PMC3357266	['Plasma samples were analyzed for Glucose concentration by a hemocue Glucose 201 analyzer (hemocue, cypress, ca).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_17234', 'glucose', 33, 'glucose'), ('CHEBI_17234', 'glucose', 68, 'glucose')]
PMC3357266	6/2012	S88-PMC3357266	['[3-3H]Glucose specific radioactivity was assessed in the supernatant of Barium Hydroxide–Zinc Sulfate–precipitated Plasma samples after overnight elimination of tritiated Water (somogyi method) by evaporating to dryness.']	N/A	N/A	[('CHEBI_76777', 'poly(inosinic acid)', 1, '3-'), ('CHEBI_29238', 'tritium atom', 3, '3H'), ('CHEBI_17234', 'glucose', 6, 'glucose'), ('CHEBI_35112', 'barium monohydroxide', 72, 'barium hydroxide'), ('CHEBI_32313', 'Zinc undecylenate', 89, 'zinc sulfate'), ('UBERON_0001969', 'blood plasma', 115, 'plasma'), ('CHEBI_15377', 'water', 171, 'water')]
PMC3357266	6/2012	S89-PMC3357266	['in steady state, the raof Glucose, which equals rd, was calculated by dividing the infusion rate of labeled Glucose by the specific activity at the same time point.']	N/A	N/A	[('CHEBI_17234', 'glucose', 26, 'glucose'), ('CHEBI_17234', 'glucose', 108, 'glucose')]
PMC3357266	6/2012	S90-PMC3357266	['endogenous hgp was calculated by subtracting the unlabeled Glucose infusion rate (gir) from rd.']	N/A	N/A	[('CHEBI_17234', 'glucose', 59, 'glucose')]
PMC3357266	6/2012	S91-PMC3357266	['Tissue Glucose Uptake.']	N/A	N/A	[('UBERON_0000479', 'tissue', 0, 'Tissue'), ('CHEBI_17234', 'glucose', 7, 'glucose'), ('GO_0046323', 'glucose import', 7, 'glucose uptake')]
PMC3357266	6/2012	S97-PMC3357266	['Plasma was separated, and aliquots were prepared for measurement of Glucose by the Glucose oxidase method (sigma diagnostics, st. louis, mo) (sensitivity = 0.1 mmol/l).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_17234', 'glucose', 68, 'glucose'), ('CHEBI_17234', 'glucose', 83, 'glucose')]
PMC3357266	6/2012	S106-PMC3357266	['results\n\nanthropometric measurements, Food and Water Intake, Plasma Glucose, and hormone concentrations.']	N/A	N/A	[('CHEBI_33290', 'food', 38, 'food'), ('GO_0007631', 'feeding behavior', 38, 'food ... intake'), ('CHEBI_15377', 'water', 47, 'water'), ('UBERON_0001969', 'blood plasma', 61, 'plasma'), ('CHEBI_17234', 'glucose', 68, 'glucose')]
PMC3357266	6/2012	S179-PMC3357266	['Glucose tolerance test and gsir.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose')]
PMC3357266	6/2012	S180-PMC3357266	['Plasma Glucose and Glucose area under the curve (auc) in iugr, ipgr, and pngr were not different from con (fig.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_17234', 'glucose', 7, 'glucose'), ('CHEBI_17234', 'glucose', 19, 'glucose')]
PMC3357266	6/2012	S182-PMC3357266	['gsir at 5 min after a Glucose challenge in ipgr was significantly higher than in con ( p< 0.03), iugr ( p< 0.005), and pngr ( p< 0.003) (fig.']	N/A	N/A	[('CHEBI_17234', 'glucose', 22, 'glucose')]
PMC3357266	6/2012	S188-PMC3357266	['a : Plasma Glucose concentrations at baseline and 5, 15, 30, 45, 60, and 120 min after an intravenous Glucose challenge are shown in con, iugr, pngr, and ipgr ( n = 7 each in all groups).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 4, 'Plasma'), ('CHEBI_17234', 'glucose', 11, 'glucose'), ('CHEBI_17234', 'glucose', 102, 'glucose')]
PMC3357266	6/2012	S189-PMC3357266	['b : auc for Plasma Glucose concentration during the Glucose tolerance test for con, iugr, pngr, and ipgr.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 12, 'plasma'), ('CHEBI_17234', 'glucose', 19, 'glucose'), ('CHEBI_17234', 'glucose', 52, 'glucose')]
PMC3357266	6/2012	S190-PMC3357266	['c : Plasma Insulin concentrations at baseline and 5, 15, 30, 45, 60, and 120 min after an intravenous Glucose challenge are shown in con, iugr, pngr, and ipgr ( n = 7 each in all groups).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 4, 'Plasma'), ('PR_000045358', 'insulin family protein', 11, 'insulin'), ('CHEBI_17234', 'glucose', 102, 'glucose')]
PMC3357266	6/2012	S192-PMC3357266	['d : the auc for Plasma Insulin concentrations during the Glucose tolerance test for con, iugr, pngr, and ipgr; ‡ p< 0.01 ipgr vs. pngr.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 16, 'plasma'), ('PR_000045358', 'insulin family protein', 23, 'insulin'), ('CHEBI_17234', 'glucose', 57, 'glucose')]
PMC3357266	6/2012	S199-PMC3357266	['the gir and 2-Deoxyglucose uptake in Skeletal muscle (skm) (Soleus; oxidative type) were significantly increased in ipgr and pngr compared with con and iugr ( p< 0.05), supporting increased skm Insulin sensitivity and Insulin-induced Glucose Uptake by Oxidative Muscle Fibers (fig.']	N/A	N/A	[('CHEBI_33980', 'quinovose', 12, '2-deoxyglucose'), ('UBERON_0004288', 'skeleton', 37, 'skeletal'), ('UBERON_0001389', 'soleus muscle', 60, 'soleus'), ('PR_000045358', 'insulin family protein', 194, 'insulin'), ('PR_000045358', 'insulin family protein', 218, 'insulin'), ('CHEBI_17234', 'glucose', 234, 'glucose'), ('GO_0046323', 'glucose import', 234, 'glucose uptake'), ('CL_0002210', 'red muscle cell', 252, 'oxidative muscle fibers')]
PMC3357266	6/2012	S202-PMC3357266	['there were no intergroup differences observed in the Insulin-induced Glucose Uptake by the Extensor Digitorum Longus Muscle (Glycolytic type), Gastrocnemius (mixed type), Liver, or Wat (fig.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 53, 'insulin'), ('CHEBI_17234', 'glucose', 69, 'glucose'), ('GO_0046323', 'glucose import', 69, 'glucose uptake'), ('UBERON_0001386', 'extensor digitorum longus', 91, 'extensor digitorum longus muscle'), ('GO_0006096', 'glycolytic process', 125, 'glycolytic'), ('UBERON_0001388', 'gastrocnemius', 143, 'gastrocnemius'), ('UBERON_0002107', 'liver', 171, 'liver'), ('UBERON_0006337', 'distal early tubule', 181, 'WAT')]
PMC3357266	6/2012	S212-PMC3357266	['d : Insulin-stimulated Glucose Uptake in Skeletal muscles, Liver (liv), and Wat in all groups is shown ( n = 6 each in all groups).']	N/A	N/A	[('PR_000045358', 'insulin family protein', 4, 'Insulin'), ('CHEBI_17234', 'glucose', 23, 'glucose'), ('GO_0046323', 'glucose import', 23, 'glucose uptake'), ('UBERON_0004288', 'skeleton', 41, 'skeletal'), ('UBERON_0002107', 'liver', 59, 'liver'), ('UBERON_0006337', 'distal early tubule', 76, 'WAT')]
PMC3357266	6/2012	S248-PMC3357266	['additionally, there was no hyperglycemia or hyperinsulinemia by Intravenous Glucose tolerance test.']	N/A	N/A	[('UBERON_0034986', 'sacral nerve plexus', 64, 'intravenous'), ('CHEBI_17234', 'glucose', 76, 'glucose')]
PMC3382418	6/2012	S89-PMC3382418	['assays\n\nhormones and Plasma parameter determination\nPlasma Glucose, Cholesterol, and Triglycerides were measured by kits using enzymatic methods (biomérieux, marcy l’etoile, france).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 21, 'plasma'), ('UBERON_0001969', 'blood plasma', 52, 'Plasma'), ('CHEBI_17234', 'glucose', 59, 'glucose'), ('CHEBI_16113', 'cholesterol', 68, 'cholesterol'), ('CHEBI_17855', 'triglyceride', 85, 'triglycerides')]
PMC3382418	6/2012	S93-PMC3382418	['an Insulin sensitivity index (isi) was calculated as plasma Insulin (ng/ml) divided by plasma Glucose (mmol/l).']	N/A	N/A	[('PR_000045358', 'insulin family protein', 3, 'insulin'), ('PR_000045358', 'insulin family protein', 60, 'insulin'), ('CHEBI_17234', 'glucose', 94, 'glucose')]
PMC3382418	6/2012	S133-PMC3382418	['Plasma parameters variations in offspring\nplasma concentrations of Glucose, Triglycerides, Cholesterol, and hormones are shown in table5.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_17234', 'glucose', 67, 'glucose'), ('CHEBI_17855', 'triglyceride', 76, 'triglycerides'), ('CHEBI_16113', 'cholesterol', 91, 'cholesterol')]
PMC3382418	6/2012	S139-PMC3382418	['caption (table-wrap): table 5\n\nBlood Glucose and Plasma concentrations of Triglycerides, Cholesterol, immunoreactive Insulin, and Ghrelin (mean\u2009±\u2009sem) in offspring from dams Fed either a Gestational Control diet (ca group) ad libitum , or a restricted control (cr group), a high-fat (hf group), or a high-Carbohydrate (hc group) diet ad libitum for 6\u2009h during the light period, in addition to two normal meals given during the dark period .timegroup of ratscacrhfhc weaning Blood Glucose (mmol/l)7.8\u2009±\u20090.17.8\u2009±\u20090.37.6\u2009±\u20090.47.7\u2009±\u20090.5triglycerides (mmol/l)1.2\u2009±\u20090.11.3\u2009±\u20090.21.1\u2009±\u20090.11.5\u2009±\u20090.3Cholesterol (mmol/l)3.0\u2009±\u20090.33.1\u2009±\u20090.22.9\u2009±\u20090.13.1\u2009±\u20090.2insulin (ng/ml)3.1\u2009±\u20090.34.0\u2009±\u20090.43.2\u2009±\u20090.52.8\u2009±\u20090.6 postnatal week 20 Blood Glucose (mmol/l)8.3\u2009±\u20090.39.1\u2009±\u20090.38.9\u2009±\u20090.29.6\u2009±\u20090.3**Triglycerides (mmol/l)3.5\u2009±\u20090.23.5\u2009±\u20090.33.3\u2009±\u20090.23.3\u2009±\u20090.2cholesterol (mmol/l)2.8\u2009±\u20090.12.6\u2009±\u20090.12.6\u2009±\u20090.12.8\u2009±\u20090.1insulin (ng/ml)15.1\u2009±\u20091.415.5\u2009±\u20091.112.8\u2009±\u20090.819.8\u2009±\u20091.7* § ###Ghrelin (pg/ml)810\u2009±\u200958667\u2009±\u200950761\u2009±\u200951681\u2009±\u200949\n* p \u2009<\u20090.05 and ** p \u2009<\u20090.01 vs ca;§p \u2009<\u20090.05 vs Cr;###p \u2009<\u20090.001 vs hf .']	N/A	N/A	[('UBERON_0000178', 'blood', 31, 'Blood'), ('CHEBI_17234', 'glucose', 37, 'glucose'), ('UBERON_0001969', 'blood plasma', 49, 'plasma'), ('CHEBI_17855', 'triglyceride', 74, 'triglycerides'), ('CHEBI_16113', 'cholesterol', 89, 'cholesterol'), ('PR_000045358', 'insulin family protein', 117, 'insulin'), ('PR_000007988', 'gastric inhibitory polypeptide receptor', 130, 'ghrelin'), ('GO_0007631', 'feeding behavior', 174, 'fed'), ('GO_0007530', 'sex determination', 187, 'gestational control'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 305, 'carbohydrate'), ('UBERON_0000178', 'blood', 474, 'Blood'), ('CHEBI_17234', 'glucose', 480, 'glucose'), ('CHEBI_16933', 'ergosterol', 589, '3Cholesterol'), ('UBERON_0000178', 'blood', 716, 'Blood'), ('CHEBI_17234', 'glucose', 722, 'glucose'), ('CHEBI_17855', 'triglyceride', 776, 'Triglycerides'), ('PR_000008031', 'GLIPR1-like protein 1', 952, 'Ghrelin'), ('CHEBI_37987', 'Cy3 dye', 1049, 'Cr')]
PMC3401547	7/2012	S51-PMC3401547	['in addition, since Uteroplacental oxygen and Glucose consumption rates per gram of Tissue remain within normal limits, the decrease in leucine utilization is not due to the general decline in Metabolic rate [42].']	N/A	N/A	[('UBERON_0012469', 'external anal region', 19, 'uteroplacental'), ('CHEBI_17234', 'glucose', 45, 'glucose'), ('UBERON_0000479', 'tissue', 83, 'tissue'), ('GO_0008152', 'metabolic process', 192, 'metabolic')]
PMC3433666	8/2012	S65-PMC3433666	['the offspring from these dams are hyperphagic, Insulin resistant, Glucose intolerant and hypertensive [41,42].']	N/A	N/A	[('PR_000045358', 'insulin family protein', 47, 'insulin'), ('CHEBI_17234', 'glucose', 66, 'glucose')]
PMC3436647	4/2012	S221-PMC3436647	['items of particular interest include specific clinical tests or results in mothers (for example, type of ultrasound, Blood pressure, Blood Glucose levels) and newborns (for example, oxygen saturation values, fetal Heart rate tracings, newborn screening results) and details regarding indications and dates for procedures and Medications.']	N/A	N/A	[('UBERON_0000178', 'blood', 117, 'blood'), ('UBERON_0000178', 'blood', 133, 'blood'), ('CHEBI_17234', 'glucose', 139, 'glucose'), ('UBERON_0000948', 'heart', 214, 'heart'), ('CHEBI_25441', 'mycothiols', 325, 'medications')]
PMC3463445	9/2012	S15-PMC3463445	['the electrical stimulation of the Ventromedial Hypothalamic Nucleus induces the immediate activation of Hepatic Glycogenolysis [10], whereas the stimulation of the Lateral Hypothalamus leads to a prompt enhancement of Glycogen Synthesis that allows an increase in Blood Glucose levels [11].']	N/A	N/A	[('UBERON_0001925', 'ventral lateral nucleus of thalamus', 34, 'ventromedial hypothalamic nucleus'), ('UBERON_0002107', 'liver', 104, 'hepatic'), ('GO_0005981', 'regulation of glycogen catabolic process', 112, 'glycogenolysis'), ('UBERON_0002736', 'lateral nuclear group of thalamus', 164, 'lateral hypothalamus'), ('CHEBI_24384', 'glycogens', 218, 'glycogen'), ('GO_0005978', 'glycogen biosynthetic process', 218, 'glycogen synthesis'), ('UBERON_0000178', 'blood', 264, 'blood'), ('CHEBI_17234', 'glucose', 270, 'glucose')]
PMC3463445	9/2012	S17-PMC3463445	['the Hepatic Vagus Nerve senses Glucose Production in the Liver and sends signals to the Central Nervous System, which integrates this Message to Control the Metabolism [13].']	N/A	N/A	[('UBERON_0001148', 'median nerve', 4, 'hepatic vagus nerve'), ('CHEBI_17234', 'glucose', 31, 'glucose'), ('GO_0006094', 'gluconeogenesis', 31, 'glucose production'), ('UBERON_0002107', 'liver', 57, 'liver'), ('UBERON_0001017', 'central nervous system', 88, 'central nervous system'), ('CHEBI_33695', 'information biomacromolecule', 134, 'message'), ('GO_0065007', 'biological regulation', 145, 'control'), ('GO_0008152', 'metabolic process', 157, 'metabolism')]
PMC3463445	9/2012	S23-PMC3463445	['Postprandial hyperglycemia induces an increase in the Pns activity, which, throughout the Vagal ends, potentiates Glucose-induced Insulin Release From the Pancreatic Β-Cells.']	N/A	N/A	[('GO_0008283', 'cell proliferation', 0, 'Postprandial'), ('UBERON_0000010', 'peripheral nervous system', 54, 'PNS'), ('UBERON_0001155', 'colon', 90, 'vagal'), ('CHEBI_17234', 'glucose', 114, 'glucose'), ('GO_0097577', 'sequestering of iron ion', 130, 'insulin release from'), ('PR_000045358', 'insulin family protein', 130, 'insulin'), ('CL_0000173', 'pancreatic D cell', 155, 'pancreatic β-cells'), ('UBERON_0001264', 'pancreas', 155, 'pancreatic'), ('GO_0007567', 'parturition', 168, 'cells')]
PMC3463445	9/2012	S58-PMC3463445	['these programmed Rats can no longer Secrete as much Insulin as the rising Blood Glucose levels demand [8].']	N/A	N/A	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 17, 'rats'), ('GO_0046903', 'secretion', 36, 'secrete'), ('PR_000045358', 'insulin family protein', 52, 'insulin'), ('UBERON_0000178', 'blood', 74, 'blood'), ('CHEBI_17234', 'glucose', 80, 'glucose')]
PMC3463445	9/2012	S61-PMC3463445	['Pancreatic Islets isolated from programmed lean Adult Rats show low Glucose Insulin tropic responses [52-54].']	N/A	N/A	[('CL_0002079', 'pancreatic ductal cell', 0, 'Pancreatic islets'), ('UBERON_0000426', 'extravillous trophoblast', 0, 'Pancreatic islets'), ('UBERON_0007023', 'adult organism', 48, 'adult'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 54, 'rats'), ('CHEBI_17234', 'glucose', 68, 'glucose'), ('PR_000045358', 'insulin family protein', 76, 'insulin')]
PMC3463445	9/2012	S87-PMC3463445	['programmed Metabolism and Insulin tropic effects of neurotransmitters\nInsulin Release is Modulated by non-Nutrient secretagogues, such as neurotransmitters, which enhance or inhibit Glucose-stimulated insulin secretion.']	N/A	N/A	[('GO_0008152', 'metabolic process', 11, 'metabolism'), ('PR_000045358', 'insulin family protein', 26, 'insulin'), ('GO_0006880', 'intracellular sequestering of iron ion', 70, 'Insulin release'), ('PR_000045358', 'insulin family protein', 70, 'Insulin'), ('GO_0065007', 'biological regulation', 89, 'modulated'), ('CHEBI_33284', 'nutrient', 106, 'nutrient'), ('CHEBI_17234', 'glucose', 182, 'glucose')]
PMC3463445	9/2012	S90-PMC3463445	['during Blood Glucose level oscillations, the Β-Cells receive inputs from the Parasympathetic and Sympathetic systems to participate in Glycemic Regulation.']	N/A	N/A	[('UBERON_0000178', 'blood', 7, 'blood'), ('CHEBI_17234', 'glucose', 13, 'glucose'), ('CL_0002200', 'oxyphil cell of thyroid', 45, 'β-cells'), ('UBERON_0004148', 'cardiac vein', 77, 'parasympathetic'), ('UBERON_0000402', 'nasal vestibule', 97, 'sympathetic'), ('GO_0006094', 'gluconeogenesis', 135, 'glycemic regulation')]
PMC3463445	9/2012	S91-PMC3463445	['overall, Acetylcholine promotes the potentiation of Glucose-induced Insulin secretion, whereas Noradrenaline and Adrenaline inhibit this response [19].']	N/A	N/A	[('CHEBI_15355', 'acetylcholine', 9, 'acetylcholine'), ('CHEBI_17234', 'glucose', 52, 'glucose'), ('PR_000045358', 'insulin family protein', 68, 'insulin'), ('CHEBI_7621', 'norajmaline', 95, 'noradrenaline'), ('CHEBI_2436', 'acronycidine', 113, 'adrenaline')]
PMC3463445	9/2012	S105-PMC3463445	['fasting normoglycemia and hypoinsulinemia, Glucose intolerance and low Plasma Glucose and Insulin concentrations during an intravenous Glucose tolerance test were observed in the Adult offspring of malnourished mothers [53].']	N/A	N/A	[('CHEBI_17234', 'glucose', 43, 'glucose'), ('UBERON_0001969', 'blood plasma', 71, 'plasma'), ('CHEBI_17234', 'glucose', 78, 'glucose'), ('PR_000045358', 'insulin family protein', 90, 'insulin'), ('CHEBI_17234', 'glucose', 135, 'glucose'), ('UBERON_0007023', 'adult organism', 179, 'adult')]
PMC3463445	9/2012	S107-PMC3463445	['in addition, Islets from Postnatally malnourished Animals exhibited decreased Insulin secretion in response to low Glucose and Carbachol.']	N/A	N/A	[('CL_0000125', 'glial cell', 13, 'islets'), ('UBERON_0000029', 'lymph node', 13, 'islets'), ('GO_0007565', 'female pregnancy', 25, 'postnatally'), ('NCBITaxon_33208', 'Metazoa', 50, 'animals'), ('PR_000045358', 'insulin family protein', 78, 'insulin'), ('CHEBI_17234', 'glucose', 115, 'glucose'), ('CHEBI_3385', 'carbachol', 127, 'carbachol')]
PMC3470091	9/2012	S27-PMC3470091	['Gestational diabetes mellitus was diagnosed by performing oral Glucose (50 g and 100 g) tolerance test (gtt) at 24-28thweek of Gestation.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_17234', 'glucose', 63, 'glucose'), ('GO_0007565', 'female pregnancy', 127, 'gestation')]
PMC3470091	9/2012	S28-PMC3470091	['the patients had gdm if 50 g resulted in a Glucose Serum concentration of 7.2 mmol/lit, and if 100 g gtt test was disturbed on the basis of carpenter and coustan criteria.25the study inclusion criteria were the absence of Thyroid, Kidney and Liver diseases as well as malabsorption.']	N/A	N/A	[('CHEBI_17234', 'glucose', 43, 'glucose'), ('UBERON_0001977', 'blood serum', 51, 'serum'), ('UBERON_0002046', 'thyroid gland', 222, 'thyroid'), ('UBERON_0002113', 'kidney', 231, 'kidney'), ('UBERON_0002107', 'liver', 242, 'liver')]
PMC3478561	11/2012	S4-PMC3478561	['body weight, body composition, and Glucose tolerance were measured at weaning and in Adulthood.']	N/A	N/A	[('CHEBI_17234', 'glucose', 35, 'glucose'), ('UBERON_0000113', 'post-juvenile adult stage', 85, 'adulthood')]
PMC3478561	11/2012	S7-PMC3478561	['Postnatal hf pups had greater adiposity, higher Plasma leptin concentration, impaired Glucose tolerance, and reduced phosphorylated Stat3 in response to leptin in the Arcuate nucleus at weaning.']	N/A	N/A	[('GO_0007567', 'parturition', 0, 'Postnatal'), ('UBERON_0001969', 'blood plasma', 48, 'plasma'), ('CHEBI_17234', 'glucose', 86, 'glucose'), ('PR_000015700', 'alpha-2,8-sialyltransferase 8F', 132, 'STAT3'), ('UBERON_0001876', 'amygdala', 167, 'arcuate')]
PMC3478561	11/2012	S9-PMC3478561	['Postnatal hf diet during Suckling continued to impair Glucose tolerance in male and female offspring in Adulthood.']	N/A	N/A	[('GO_0007567', 'parturition', 0, 'Postnatal'), ('GO_0001967', 'suckling behavior', 25, 'suckling'), ('CHEBI_17234', 'glucose', 54, 'glucose'), ('UBERON_0000113', 'post-juvenile adult stage', 104, 'adulthood')]
PMC3478561	11/2012	S29-PMC3478561	['we measured offspring’s body weight, body composition, and tested Glucose tolerance at weaning and in Adulthood and assessed leptin sensitivity on pnd10 and 21.']	N/A	N/A	[('CHEBI_17234', 'glucose', 66, 'glucose'), ('UBERON_0000113', 'post-juvenile adult stage', 102, 'adulthood')]
PMC3478561	11/2012	S58-PMC3478561	['Glucose tolerance test and endocrine assays.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose')]
PMC3478561	11/2012	S61-PMC3478561	['baseline fasted Blood Glucose was determined at the same time by a handheld freestyle Glucose meter (therasense, alameda, ca).']	N/A	N/A	[('UBERON_0000178', 'blood', 16, 'blood'), ('CHEBI_17234', 'glucose', 22, 'glucose'), ('CHEBI_17234', 'glucose', 86, 'glucose')]
PMC3478561	11/2012	S62-PMC3478561	['an oral gavage of Glucose (2.0 g/kg body weight, 20% Glucose in sterile Water Solution) was administered.']	N/A	N/A	[('CHEBI_17234', 'glucose', 18, 'glucose'), ('CHEBI_17234', 'glucose', 53, 'glucose'), ('CHEBI_15377', 'water', 72, 'water'), ('CHEBI_75958', 'solution', 78, 'solution')]
PMC3478561	11/2012	S63-PMC3478561	['Blood samples were collected at 15, 30, 45, 60, and 120 min after Glucose gavage to determine plasma Insulin levels.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('CHEBI_17234', 'glucose', 66, 'glucose'), ('PR_000045358', 'insulin family protein', 101, 'insulin')]
PMC3478561	11/2012	S64-PMC3478561	['Blood Glucose was determined at each interval using the Glucometer.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('CHEBI_17234', 'glucose', 6, 'glucose'), ('CHEBI_24321', 'glutamo group', 56, 'glucometer')]
PMC3478561	11/2012	S120-PMC3478561	['caption (table-wrap): table 2\n\nPlasma leptin concentration (ng/ml) in pnd10 and pnd21 offspring\n\nGlucose tolerance test.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 31, 'Plasma'), ('CHEBI_17234', 'glucose', 97, 'Glucose')]
PMC3478561	11/2012	S121-PMC3478561	['at weaning, hf-chow males had significantly lower baseline Blood Glucose and plasma Insulin compared with the chow-chow males ( p< 0.05;fig.']	N/A	N/A	[('UBERON_0000178', 'blood', 59, 'blood'), ('CHEBI_17234', 'glucose', 65, 'glucose'), ('PR_000045358', 'insulin family protein', 84, 'insulin')]
PMC3478561	11/2012	S123-PMC3478561	['Postnatal hf-diet male pups had significantly higher Glucose levels at 45, 60, and 120 min ( p< 0.01).']	N/A	N/A	[('GO_0007567', 'parturition', 0, 'Postnatal'), ('CHEBI_17234', 'glucose', 53, 'glucose')]
PMC3478561	11/2012	S124-PMC3478561	['the overall Glucose area under the curve (auc;fig.']	N/A	N/A	[('CHEBI_17234', 'glucose', 12, 'glucose')]
PMC3478561	11/2012	S134-PMC3478561	['Glucose tolerance test (2.0 g/kg, oral gavage) results for male ( a and c ) and female ( b and d ) offspring on pnd23.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose')]
PMC3478561	11/2012	S135-PMC3478561	['Blood Glucose ( a and b ) and Plasma Insulin ( c and d ) were determined for 2 h after oral administration of Glucose.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('CHEBI_17234', 'glucose', 6, 'glucose'), ('UBERON_0001969', 'blood plasma', 30, 'plasma'), ('PR_000045358', 'insulin family protein', 37, 'insulin'), ('CHEBI_17234', 'glucose', 110, 'glucose')]
PMC3478561	11/2012	S136-PMC3478561	['the integrated auc ( inset ) was determined for Glucose and Insulin using the trapezoidal method.']	N/A	N/A	[('CHEBI_17234', 'glucose', 48, 'glucose'), ('PR_000045358', 'insulin family protein', 60, 'insulin')]
PMC3478561	11/2012	S140-PMC3478561	['Glucose tolerance data for females pups are presented infigs.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose')]
PMC3478561	11/2012	S142-PMC3478561	['female pups cross-fostered to dams Fed the hf diet had higher Glucose and Insulin levels at 45, 60, and 120 min ( p< 0.05) and higher Glucose and Insulin auc ( p< 0.05).']	N/A	N/A	[('GO_0007631', 'feeding behavior', 35, 'fed'), ('CHEBI_17234', 'glucose', 62, 'glucose'), ('PR_000045358', 'insulin family protein', 74, 'insulin'), ('CHEBI_17234', 'glucose', 134, 'glucose'), ('PR_000045358', 'insulin family protein', 146, 'insulin')]
PMC3478561	11/2012	S191-PMC3478561	['there were no differences among the groups in Glucose clearance in the Glucose tolerance test in 10-week-old males (fig.']	N/A	N/A	[('CHEBI_17234', 'glucose', 46, 'glucose'), ('CHEBI_17234', 'glucose', 71, 'glucose')]
PMC3478561	11/2012	S195-PMC3478561	['among the females, offspring from Postnatal hf dams had no significant differences in Glucose auc (fig.']	N/A	N/A	[('GO_0007567', 'parturition', 34, 'postnatal'), ('CHEBI_17234', 'glucose', 86, 'glucose')]
PMC3478561	11/2012	S200-PMC3478561	['Glucose tolerance test in males ( a and c) and females ( b and d ) at age 10 weeks.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose')]
PMC3478561	11/2012	S201-PMC3478561	['Blood Glucose ( a and b ) and Plasma Insulin ( c and d ) were determined for 2 h after oral administration of Glucose.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('CHEBI_17234', 'glucose', 6, 'glucose'), ('UBERON_0001969', 'blood plasma', 30, 'plasma'), ('PR_000045358', 'insulin family protein', 37, 'insulin'), ('CHEBI_17234', 'glucose', 110, 'glucose')]
PMC3478561	11/2012	S202-PMC3478561	['the integrated auc ( inset ) was determined for Glucose and Insulin using the trapezoidal method.']	N/A	N/A	[('CHEBI_17234', 'glucose', 48, 'glucose'), ('PR_000045358', 'insulin family protein', 60, 'insulin')]
PMC3533960	10/2012	S86-PMC3533960	['during Prenatal visits, doctors record obstetric history, morbidity, workload, depression, vital signs, anthropometric measurements, hemoglobin values, urinalysis results, Blood Glucose and collect Venous Blood (for the first and second Pregnancy semesters).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 7, 'prenatal'), ('UBERON_0000178', 'blood', 172, 'blood'), ('CHEBI_17234', 'glucose', 178, 'glucose'), ('UBERON_0001638', 'vein', 198, 'venous'), ('UBERON_0000178', 'blood', 205, 'blood'), ('GO_0007565', 'female pregnancy', 237, 'pregnancy')]
PMC3533960	10/2012	S100-PMC3533960	['caption (table-wrap): table 2\n\ndata collection and measurementsmeasurementspre-pregnancypregnancybirthpost-Partum \xa0\xa0 6-12 weeks23-28 weeks30-36 weeks \xa0\xa0 maternal \xa0\xa0\xa0\xa0\xa0\xa0demographics, ses status√\xa0\xa0\xa0\xa0\xa0obgyn history√\xa0\xa0\xa0\xa0\xa0Food frequency questionnaire√\xa0\xa0\xa0\xa0\xa0helminthic infections√\xa0\xa0\xa0\xa0\xa0mental health√√√√\xa0√morbidity\xa0√√√\xa0√periodontitis screening\xa0√√√\xa0\xa0workload\xa0√√√\xa0\xa0Blood pressure√√√√\xa0\xa0anthropometry√√√√\xa0√hematological measures\xa0\xa0\xa0\xa0\xa0\xa0Hemoglobin√√√√\xa0√Serum ferritin√√√\xa0\xa0√Transferrin Receptor√√√\xa0\xa0√infection indicators (crp, agp)√√√\xa0\xa0√other biological indicators\xa0\xa0\xa0\xa0\xa0\xa0Vitamin A√√√\xa0\xa0√Blood Glucose\xa0√√\xa0\xa0\xa0Urine protein\xa0√√√\xa0\xa0 Fetal Development (ultrasound) \xa0√√√\xa0\xa0 Birth information \xa0\xa0\xa0\xa0√\xa0 child measurement \xa0\xa0\xa0\xa0\xa0\xa0Gestational age\xa0\xa0\xa0\xa0√\xa0anthropometry\xa0\xa0\xa0\xa0√√hematological measures\xa0\xa0\xa0\xa0\xa0\xa0hemoglobin\xa0\xa0\xa0\xa0\xa0√Serum ferritin\xa0\xa0\xa0\xa0√\xa0Transferrin Receptor\xa0\xa0\xa0\xa0√\xa0infant Feeding practices\xa0\xa0\xa0\xa0\xa0√ supplement information \xa0\xa0\xa0\xa0\xa0\xa0supplement consumption√√√√\xa0\xa0side effects√√√√\xa0\xa0\n\nmeasurement of key outcomes\nBirth size : infant anthropometry is measured as early as possible within seven days after Birth and at one and three months Postpartum using standard procedures [34,35].']	N/A	N/A	[('GO_0007567', 'parturition', 107, 'partum'), ('UBERON_0001013', 'adipose tissue', 107, 'partum'), ('CHEBI_33290', 'food', 217, 'Food'), ('GO_0007596', 'blood coagulation', 355, 'Blood'), ('UBERON_0000178', 'blood', 355, 'Blood'), ('CHEBI_5679', 'herniarin', 422, 'Hemoglobin'), ('UBERON_0001977', 'blood serum', 438, 'Serum'), ('PR_000001703', 'mas-related G-protein coupled receptor X2', 458, 'Transferrin receptor'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 554, 'Vitamin A'), ('CHEBI_33290', 'food', 569, 'Blood'), ('UBERON_0000178', 'blood', 569, 'Blood'), ('CHEBI_17234', 'glucose', 575, 'Glucose'), ('UBERON_0001088', 'urine', 588, 'Urine'), ('GO_0060132', 'prolactin secreting cell development', 608, 'Fetal development'), ('GO_0007567', 'parturition', 646, 'Birth'), ('GO_0007565', 'female pregnancy', 695, 'Gestational'), ('UBERON_0001977', 'blood serum', 779, 'Serum'), ('PR_000001703', 'mas-related G-protein coupled receptor X2', 799, 'Transferrin receptor'), ('GO_0007631', 'feeding behavior', 832, 'feeding'), ('GO_0007567', 'parturition', 961, 'Birth'), ('GO_0007567', 'parturition', 1052, 'birth'), ('GO_0007565', 'female pregnancy', 1086, 'postpartum')]
PMC3533960	10/2012	S135-PMC3533960	['other information collected in the three Prenatal visits includes symptoms of Preeclampsia (Blood pressure, edema, albumin in Urine) and fasting Blood Glucose in the first and second Trimester.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 41, 'prenatal'), ('GO_0007128', 'meiotic prophase I', 78, 'preeclampsia'), ('UBERON_0000178', 'blood', 92, 'blood'), ('UBERON_0001088', 'urine', 126, 'urine'), ('UBERON_0000178', 'blood', 145, 'blood'), ('CHEBI_17234', 'glucose', 151, 'glucose'), ('GO_0009294', 'DNA mediated transformation', 183, 'trimester')]
PMC3538633	1/2013	S72-PMC3538633	['vascular studies\nthe Mesenteric Bed was removed and placed in a dissecting dish containing physiological salt Solution (pss) (119 mm Nacl, 4.7 Kcl, 2.5 Cacl2, 24 Nahco3, 1.18 Kh2Po4, 1.2 Mgso4, 0.01 edta, 5.5 Glucose) on ice.']	N/A	N/A	[('UBERON_0012332', 'broad ligament of uterus', 21, 'mesenteric bed'), ('CHEBI_75958', 'solution', 110, 'solution'), ('CHEBI_26710', 'sodium chloride', 133, 'NaCl'), ('CHEBI_32588', 'potassium chloride', 143, 'KCl'), ('CHEBI_3312', 'calcium dichloride', 152, 'CaCl2'), ('CHEBI_32139', 'sodium hydrogencarbonate', 162, 'NaHCO3'), ('CHEBI_63036', 'potassium dihydrogen phosphate', 175, 'KH2PO4'), ('CHEBI_32599', 'magnesium sulfate', 187, 'MgSO4'), ('CHEBI_17234', 'glucose', 209, 'glucose')]
PMC3556301	1/2013	S1-PMC3556301	['methods\nPlasma Glucose, Lipids, homa –ir (Homeostasis model assessment of Insulin resistance) and aasi, as obtained from 24-hour ambulatory Blood pressure monitoring in Third Trimester Pregnancy and at three months Postpartum, were measured in three groups of women: controls (n = 32), women with gdm on diet (n = 42) and women with gdm requiring insulin treatment (n = 10).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 8, 'Plasma'), ('CHEBI_17234', 'glucose', 15, 'glucose'), ('CHEBI_18059', 'lipid', 24, 'lipids'), ('GO_0042592', 'homeostatic process', 42, 'homeostasis'), ('PR_000045358', 'insulin family protein', 74, 'insulin'), ('UBERON_0000178', 'blood', 140, 'blood'), ('GO_0042793', 'plastid transcription', 169, 'third trimester'), ('GO_0007565', 'female pregnancy', 185, 'pregnancy'), ('GO_0007565', 'female pregnancy', 215, 'postpartum')]
PMC3556301	1/2013	S6-PMC3556301	['background\nGestational diabetes mellitus (gdm) is defined as Glucose intolerance with its onset or first recognition during Pregnancy and it occurs in 3–6% of all Pregnancies [1].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 11, 'Gestational'), ('CHEBI_17234', 'glucose', 61, 'glucose'), ('GO_0007565', 'female pregnancy', 124, 'pregnancy'), ('GO_0007565', 'female pregnancy', 163, 'pregnancies')]
PMC3556301	1/2013	S32-PMC3556301	['a total of 10 women in the gdm group needed Insulin to maintain the target Glucose values but the others achieved adequate Glycemic Control through dietary measures.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 44, 'insulin'), ('CHEBI_17234', 'glucose', 75, 'glucose'), ('GO_0006094', 'gluconeogenesis', 123, 'glycemic control')]
PMC3556301	1/2013	S37-PMC3556301	['Gestational diabetes was determined as an abnormal 75 g Oral Glucose tolerance test (ogtt) [normal Capillary Plasma values after 12 h of fasting being lower than 4.8-11.2-9.9 mmol/l (fasting -1h-2h)].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('UBERON_0000165', 'mouth', 56, 'oral'), ('CHEBI_17234', 'glucose', 61, 'glucose'), ('UBERON_0001982', 'capillary', 99, 'capillary'), ('UBERON_0001969', 'blood plasma', 109, 'plasma')]
PMC3556301	1/2013	S40-PMC3556301	['Plasma Glucose levels were determined by the hexokinase method (konelab 60i clinical chemistry analyzer, thermo Electron co, finland).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_17234', 'glucose', 7, 'glucose'), ('CHEBI_10545', 'electron', 112, 'Electron')]
PMC3556301	1/2013	S42-PMC3556301	['of the gdm group, 91.7% had fasting Glucose higher than the reference value, 27.7% had the 1-h value and 4.3% had the 2-h value higher than the reference value.']	N/A	N/A	[('CHEBI_17234', 'glucose', 36, 'glucose')]
PMC3556301	1/2013	S43-PMC3556301	['women with gdm received structured dietary and exercise advice and were taught home Blood Glucose monitoring by a diabetes specialist nurse.']	N/A	N/A	[('UBERON_0000178', 'blood', 84, 'blood'), ('CHEBI_17234', 'glucose', 90, 'glucose')]
PMC3556301	1/2013	S62-PMC3556301	['the homeostasis model assessment of Insulin resistance (homa-ir) was used to estimate the levels of Insulin resistance with the equation: homa-ir= fasting Insulin (mu/l × fasting Glucose (mmol/l)/22.5 [27].']	N/A	N/A	[('PR_000045358', 'insulin family protein', 36, 'insulin'), ('PR_000045358', 'insulin family protein', 100, 'insulin'), ('PR_000045358', 'insulin family protein', 155, 'insulin'), ('CHEBI_17234', 'glucose', 179, 'glucose')]
PMC3556301	1/2013	S75-PMC3556301	['the mean maternal weight, Glucose and homa-ir levels were significantly higher in both gdm groups than in the controls (p = 0.000- 0.013) (figure\u20091a).']	N/A	N/A	[('CHEBI_17234', 'glucose', 26, 'glucose')]
PMC3556301	1/2013	S86-PMC3556301	['three months after Delivery, there were statistically significant differences between the control group and Insulin-using gdm group in all Serum Lipids and Glucose; i.e.']	N/A	N/A	[('GO_0007567', 'parturition', 19, 'delivery'), ('PR_000045358', 'insulin family protein', 108, 'insulin'), ('UBERON_0001977', 'blood serum', 139, 'serum'), ('CHEBI_18059', 'lipid', 145, 'lipids'), ('CHEBI_17234', 'glucose', 156, 'glucose')]
PMC3556301	1/2013	S88-PMC3556301	['in women with gdm on diet, the levels of fasting Glucose, ldl, Triglycerides, and homa-ir were significantly higher than in controls (figure\u20091b).']	N/A	N/A	[('CHEBI_17234', 'glucose', 49, 'glucose'), ('CHEBI_17855', 'triglyceride', 63, 'triglycerides')]
PMC3556301	1/2013	S93-PMC3556301	['in the comparison between the women Controlling gdm by diet and with Insulin, there were significant differences in fasting Glucose levels during Pregnancy (p = 0.011) and homa-ir:s during and after Pregnancy (p = 0.018, p = 0.044, respectively.)']	N/A	N/A	[('GO_0065007', 'biological regulation', 36, 'controlling'), ('PR_000045358', 'insulin family protein', 69, 'insulin'), ('CHEBI_17234', 'glucose', 124, 'glucose'), ('GO_0007565', 'female pregnancy', 146, 'pregnancy'), ('GO_0007565', 'female pregnancy', 199, 'pregnancy')]
PMC3556301	1/2013	S119-PMC3556301	['there was no correlation between aasi values and 2-hour Glucose test measurement results.']	N/A	N/A	[('CHEBI_17234', 'glucose', 56, 'glucose')]
PMC3556301	1/2013	S170-PMC3556301	['abbreviations\naasi: ambulatory Arterial stiffness index; gdm: Gestational diabetes mellitus; fmd: flow mediated dilation; bp: Blood pressure; homa-ir: Homeostasis model assessment of Insulin resistance; ldl: low density lipoprotein; hdl: high density lipoprotein; bmi: body mass index; ogtt: oral Glucose tolerance test.']	N/A	N/A	[('UBERON_0001637', 'artery', 31, 'arterial'), ('GO_0007565', 'female pregnancy', 62, 'Gestational'), ('UBERON_0000178', 'blood', 126, 'Blood'), ('GO_0042592', 'homeostatic process', 151, 'Homeostasis'), ('PR_000045358', 'insulin family protein', 183, 'insulin'), ('CHEBI_17234', 'glucose', 297, 'glucose')]
PMC3559868	1/2013	S33-PMC3559868	['phase i consisted of standardized interviews and examinations, and Glucose tolerance testing.']	N/A	N/A	[('CHEBI_17234', 'glucose', 67, 'glucose')]
PMC3559868	1/2013	S38-PMC3559868	['a 75 g oral Glucose tolerance test was then performed between 24 and 30 weeks of Pregnancy.']	N/A	N/A	[('CHEBI_17234', 'glucose', 12, 'glucose'), ('GO_0007565', 'female pregnancy', 81, 'pregnancy')]
PMC3559868	1/2013	S39-PMC3559868	['Gestational diabetes was defined as blood Glucose greater than or equal to 140 mg/dl two hours after Intake, according to who criteria[17].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_17234', 'glucose', 42, 'glucose'), ('GO_0007631', 'feeding behavior', 101, 'intake')]
PMC3561108	9/2012	S205-PMC3561108	['husbands and partners provided the most support and supported the women in terms of accompanying them on walks for exercise and encouraging them to adhere to the gdm diet as well as providing encouragement and emotional support when the woman was Learning to take blood Glucose levels and administer Insulin.']	N/A	N/A	[('GO_0007612', 'learning', 247, 'learning'), ('CHEBI_17234', 'glucose', 270, 'glucose'), ('PR_000045358', 'insulin family protein', 300, 'insulin')]
PMC3561108	9/2012	S256-PMC3561108	['this manifested in the discomfort they endured by Eating less than they desired, Eating foods they did not enjoy, doing Blood Glucose levels and administering Insulin, and trying to meet with exercise requirements.']	N/A	N/A	[('GO_0051318', 'G1 phase', 50, 'eating'), ('GO_0051318', 'G1 phase', 81, 'eating'), ('UBERON_0000178', 'blood', 120, 'blood'), ('CHEBI_17234', 'glucose', 126, 'glucose'), ('CHEBI_66075', 'inflexin', 159, 'insulin'), ('PR_000045358', 'insulin family protein', 159, 'insulin')]
PMC3571634	12/2012	S10-PMC3571634	['introduction\nGlucose that comes from the mother provides fuel for fetal growth [1].']	N/A	N/A	[('CHEBI_17234', 'glucose', 13, 'Glucose')]
PMC3571634	12/2012	S30-PMC3571634	['anthropometry and self Blood Glucose monitoring (sbgm)\nsubjects were weighed at the first study session in light clothing and with shoes off, and their height was obtained from their electronic medical record.']	N/A	N/A	[('UBERON_0000178', 'blood', 23, 'Blood'), ('CHEBI_17234', 'glucose', 29, 'Glucose')]
PMC3571634	12/2012	S38-PMC3571634	['the composition and nutritional content of the two test meals (table 1) were analysed with foodworks professional (version 2009, xyris software, brisbane, australia), using ausnut2007 as the source of nutrition composition [15].Nutrients-05-00001-t001_table 1\n\ncaption (table-wrap): table 1\n\ncomposition and nutritional analysis of the test meals.aburgen fruit and muesli bread;bflora mono-sun Margarine;cdevondale light dairy Blend;dbenefibre fibre Supplement;etip top sunblest wholemeal;flucozade orange flavour.low gihigh gifoods included70 g fruit breada60 g wholemeal breade3 g margarineb134 g fizzy Glucose drinkf3 g light dairy blendc1 hardboiled egg200 ml skim milk1.7 g fibre supplementdnutritional analyses energy (kcal)328328protein (% kcal)18.918.3fat (% kcal)22.124.7carbohydrates (% kcal)54.552.1dietary fibre (g)4.23.9glycemic index4582glycemic load2136\n\n2.4.']	N/A	N/A	[('CHEBI_33284', 'nutrient', 228, 'nutrients'), ('CHEBI_6784', 'mestranol', 394, 'margarine'), ('CHEBI_46707', 'gypsogenin 3-O-rhamnosylglucosiduronic acid', 427, 'blend'), ('CHEBI_16158', 'steroid sulfate', 450, 'supplement'), ('CHEBI_17234', 'glucose', 605, 'glucose')]
PMC3571634	12/2012	S39-PMC3571634	['quantification of fasting and Postprandial Blood Glucose levels\nFinger prick Blood samples were collected before the start of the meal, and at 15, 30, 45, 60, 75, 90 and 120 min after the start of the meal.']	N/A	N/A	[('GO_0008283', 'cell proliferation', 30, 'Postprandial'), ('UBERON_0000178', 'blood', 43, 'Blood'), ('CHEBI_17234', 'glucose', 49, 'Glucose'), ('UBERON_0002046', 'thyroid gland', 64, 'Finger'), ('UBERON_0000178', 'blood', 77, 'blood')]
PMC3571634	12/2012	S40-PMC3571634	['the Blood samples were analysed immediately after collection using a portable Blood analyser (hemocue Glucose analyzer 201, hemocue australia pty ltd., wamberal, australia).']	N/A	N/A	[('UBERON_0000178', 'blood', 4, 'blood'), ('UBERON_0000178', 'blood', 78, 'blood'), ('CHEBI_17234', 'glucose', 102, 'Glucose')]
PMC3571634	12/2012	S46-PMC3571634	['mean ± sem bgl for all subjects (figure 1), as well as that of the individual subjects (figure 2) were plotted against time to obtain Postprandial Blood Glucose curves, and the incremental area under the Glucose curve (iaucglucose) was calculated by the trapezoidal rule.']	N/A	N/A	[('GO_0007567', 'parturition', 134, 'postprandial'), ('UBERON_0000178', 'blood', 147, 'blood'), ('CHEBI_17234', 'glucose', 153, 'glucose'), ('CHEBI_17234', 'glucose', 204, 'glucose')]
PMC3571634	12/2012	S49-PMC3571634	['the time point with the highest mean Blood Glucose level was deemed as the time of peak pbgl for the overall analysis (figure 1), and the peak pbgl time for individual subjects were also identified (figure 2).']	N/A	N/A	[('UBERON_0000178', 'blood', 37, 'blood'), ('CHEBI_17234', 'glucose', 43, 'glucose')]
PMC3571634	12/2012	S50-PMC3571634	['caption (fig): figure 1\n\nmean ± sem Postprandial Blood Glucose level of the 10 subjects.']	N/A	N/A	[('GO_0007567', 'parturition', 36, 'postprandial'), ('UBERON_0000178', 'blood', 49, 'blood'), ('CHEBI_17234', 'glucose', 55, 'glucose')]
PMC3571634	12/2012	S53-PMC3571634	['peak Blood Glucose levels were circled.']	N/A	N/A	[('UBERON_0000178', 'blood', 5, 'blood'), ('CHEBI_17234', 'glucose', 11, 'glucose')]
PMC3574039	1/2013	S5-PMC3574039	['the fasting Serum Glucose was similar among the groups.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 12, 'serum'), ('CHEBI_17234', 'glucose', 18, 'glucose')]
PMC3574039	1/2013	S6-PMC3574039	['the area under the Glucose curve was higher in the lo and co Rats than in the lc and cc Rats.']	N/A	N/A	[('CHEBI_17234', 'glucose', 19, 'glucose'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 61, 'rats'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 88, 'rats')]
PMC3574039	1/2013	S40-PMC3574039	['at 90 d of age, the Animals were euthanized with Co2After fasting 12 h. Blood samples were collected, and Serum was obtained by centrifugation to determine the Lipid profile (Triglycerides, total Cholesterol, ldl Cholesterol and hdl), blood Glucose and Insulin.']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 20, 'animals'), ('CHEBI_87163', 'dihydroisopentenyldehydrorhodopin', 49, 'CO2after'), ('UBERON_0000178', 'blood', 72, 'Blood'), ('UBERON_0001977', 'blood serum', 106, 'serum'), ('CHEBI_18059', 'lipid', 160, 'lipid'), ('CHEBI_17855', 'triglyceride', 175, 'triglycerides'), ('CHEBI_16113', 'cholesterol', 196, 'cholesterol'), ('CHEBI_16113', 'cholesterol', 213, 'cholesterol'), ('CHEBI_17234', 'glucose', 241, 'glucose'), ('PR_000045358', 'insulin family protein', 253, 'insulin')]
PMC3574039	1/2013	S67-PMC3574039	['the homa-ir was calculated from the fasting Glucose and the fasting Insulin concentrations using the following formula:\nhoma-ir=fastinginsulinpmo1/1×fastingglucosemmo1/1/22.5\n\nIntraperitoneal Glucose-tolerance test\nafter a 12 h fast, Glucose (200 g/l) was administered Intraperitoneally at a dose of 2 g/kg body weight.']	N/A	N/A	[('CHEBI_17234', 'glucose', 44, 'glucose'), ('PR_000045358', 'insulin family protein', 68, 'insulin'), ('UBERON_0007158', 'lumen of anal canal', 176, 'Intraperitoneal'), ('CHEBI_17234', 'glucose', 192, 'glucose'), ('CHEBI_17234', 'glucose', 234, 'glucose'), ('UBERON_0000007', 'pituitary gland', 269, 'intraperitoneally')]
PMC3574039	1/2013	S68-PMC3574039	['Blood samples were obtained from the cut Tip Of the Tail 0, 30, 60 and 120 min later to determine Serum Glucose and Insulin concentrations.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('UBERON_0010162', 'post-anal tail tip', 41, 'tip of ... tail'), ('UBERON_0001977', 'blood serum', 98, 'serum'), ('CHEBI_17234', 'glucose', 104, 'glucose'), ('PR_000045358', 'insulin family protein', 116, 'insulin')]
PMC3574039	1/2013	S69-PMC3574039	['the Glucose and Insulin responses during the Intraperitoneal Glucose tolerance tests were calculated by estimating the total area under the Glucose curves, using the trapezoidal method [20].']	N/A	N/A	[('CHEBI_17234', 'glucose', 4, 'glucose'), ('PR_000045358', 'insulin family protein', 16, 'insulin'), ('UBERON_2001932', 'sensory canal tubular ossicle', 45, 'intraperitoneal'), ('CHEBI_17234', 'glucose', 61, 'glucose'), ('CHEBI_17234', 'glucose', 140, 'glucose')]
PMC3574039	1/2013	S72-PMC3574039	['Blood samples were obtained from the cut Tip Of the Tail 0, 5, 10 and 15 min later to measure Glucose levels.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('UBERON_0010162', 'post-anal tail tip', 41, 'tip of ... tail'), ('CHEBI_17234', 'glucose', 94, 'glucose')]
PMC3574039	1/2013	S73-PMC3574039	['the rate constant for the Elimination Of Serum Glucose was calculated using the formula 0.693/ t 1=2, where t 1=2 is half-Life.']	N/A	N/A	[('GO_0021706', 'locus ceruleus maturation', 26, 'elimination of ... glucose'), ('UBERON_0001977', 'blood serum', 41, 'serum'), ('CHEBI_17234', 'glucose', 47, 'glucose'), ('UBERON_0000104', 'life cycle', 122, 'life')]
PMC3574039	1/2013	S74-PMC3574039	['the Serum Glucose half-life was calculated from the slope of a least-square analysis of the Serum Glucose concentrations from 0–15 min after the subcutaneous injection of Insulin, when the Serum Glucose concentrations declined linearly [21].']	N/A	N/A	[('UBERON_0001977', 'blood serum', 4, 'serum'), ('CHEBI_17234', 'glucose', 10, 'glucose'), ('UBERON_0001977', 'blood serum', 92, 'serum'), ('CHEBI_17234', 'glucose', 98, 'glucose'), ('PR_000045358', 'insulin family protein', 171, 'insulin'), ('UBERON_0001977', 'blood serum', 189, 'serum'), ('CHEBI_17234', 'glucose', 195, 'glucose')]
PMC3574039	1/2013	S133-PMC3574039	['the total area under the Glucose curve for the co and lo Rats was higher than for the cc and lc Rats (f1,21=13.25, p<0.01).']	N/A	N/A	[('CHEBI_17234', 'glucose', 25, 'glucose'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 57, 'rats'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 96, 'rats')]
PMC3574039	1/2013	S135-PMC3574039	['caption (table-wrap): table 6\n\nfasting Serum Glucose and Insulin concentration, total area under the Glucose (aug) and Insulin (aui) curves, Glucose disappearance ratio (Kitt) obtained from the Intraperitoneal Insulin tolerance test and homa-ir of Rats maintained with the control (cc and lc) or overfeeding diets (co and lo)variables \xa0 groups \xa0\xa0\xa0 cccolclo \xa0 nmeansemnmeansemnmeansemnmeansem basal Glucose (mmol/l)77.00.177.10.136.80.067.00.1basal Insulin (pmol/l)714.8b0.8735.3a2.3334.6a1.363.3c0.7aug (mmol/l.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 39, 'serum'), ('CHEBI_17234', 'glucose', 45, 'glucose'), ('PR_000045358', 'insulin family protein', 57, 'insulin'), ('CHEBI_17234', 'glucose', 101, 'glucose'), ('PR_000045358', 'insulin family protein', 119, 'insulin'), ('CHEBI_17234', 'glucose', 141, 'glucose'), ('PR_000009211', 'lysine-specific demethylase 3A', 170, 'Kitt'), ('UBERON_2001932', 'sensory canal tubular ossicle', 194, 'intraperitoneal'), ('PR_000045358', 'insulin family protein', 210, 'insulin'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 248, 'rats'), ('CHEBI_17234', 'glucose', 398, 'glucose'), ('PR_000045358', 'insulin family protein', 448, 'insulin')]
PMC3574039	1/2013	S172-PMC3574039	['independent of Prenatal nutrition, Postnatal overfeeding resulted in impaired Glucose tolerance.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 15, 'prenatal'), ('GO_0007567', 'parturition', 35, 'postnatal'), ('CHEBI_17234', 'glucose', 78, 'glucose')]
PMC3574039	1/2013	S187-PMC3574039	['when Postnatal overfeeding was combined with normal Intrauterine nutrition, impaired Glucose tolerance resulted from Insulin resistance.']	N/A	N/A	[('GO_0007567', 'parturition', 5, 'postnatal'), ('UBERON_0022293', 'reproductive gland secretion', 52, 'intrauterine'), ('CHEBI_17234', 'glucose', 85, 'glucose'), ('PR_000045358', 'insulin family protein', 117, 'insulin')]
PMC3574039	1/2013	S189-PMC3574039	['abbreviations\nauc: area under the curve; ain: american institute of nutrition; bw: body weight; cc: offspring Born from mothers Fed a control diet whose litter was adjusted by eight pups during Lactation; co: offspring Born from mothers Fed a control diet whose litter was adjusted by four pups during Lactation; ee: energy expenditure; Ewat: Epididymal White Adipose Tissue; ffa: Free Fatty Acid; hdl: high-density lipoprotein; igtt: Intraperitoneal Glucose tolerance test; Ibat: Interscapular Brown Tissue; kitt: Glucose disappearance ratio; lc: offspring Born from mothers Fed a low protein diet whose litter was adjusted by eight pups during Lactation; ldl: low-density lipoprotein; lo: offspring Born from mothers Fed a low protein diet whose litter was adjusted by four pups during Lactation; nal: Naso-Anal length; ria: radioimmunoassay; rq: respiratory quotient; Rwat: retroperitoneal white adipose tissue; tc: total Cholesterol; vco2: Carbon Dioxide Production; vo2: oxygen consumption; δ g : total area under the Glucose curve; δ i: total area under the insulin curve; 11Β- Hsd1: 11Β-Hidroxysteroid Dehydrogenase Type 1.']	N/A	N/A	[('GO_0007567', 'parturition', 110, 'born'), ('GO_0007631', 'feeding behavior', 128, 'fed'), ('GO_0007595', 'lactation', 194, 'lactation'), ('GO_0007567', 'parturition', 219, 'born'), ('GO_0007631', 'feeding behavior', 237, 'fed'), ('GO_0007595', 'lactation', 302, 'lactation'), ('UBERON_0007376', 'outer epithelium', 337, 'EWAT'), ('UBERON_0004360', 'cauda epididymis', 343, 'Epididymal white adipose tissue'), ('CHEBI_30823', 'oleate', 381, 'Free'), ('CHEBI_35366', 'fatty acid', 386, 'fatty acid'), ('UBERON_0007158', 'lumen of anal canal', 435, 'Intraperitoneal'), ('CHEBI_17234', 'glucose', 451, 'glucose'), ('UBERON_0001348', 'brown adipose tissue', 475, 'IBAT'), ('UBERON_0013765', 'digestive system element', 481, 'Interscapular brown'), ('UBERON_0000479', 'tissue', 501, 'tissue'), ('CHEBI_17234', 'glucose', 515, 'Glucose'), ('GO_0007567', 'parturition', 558, 'born'), ('GO_0007631', 'feeding behavior', 576, 'fed'), ('GO_0007595', 'lactation', 646, 'lactation'), ('GO_0007567', 'parturition', 701, 'born'), ('GO_0007631', 'feeding behavior', 719, 'fed'), ('GO_0007595', 'lactation', 788, 'lactation'), ('UBERON_0001091', 'calcareous tooth', 804, 'Naso'), ('UBERON_0001245', 'anus', 809, 'anal'), ('UBERON_0013641', 'external cheek pouch', 871, 'RWAT'), ('CHEBI_16113', 'cholesterol', 925, 'cholesterol'), ('CHEBI_16526', 'carbon dioxide', 944, 'Carbon dioxide'), ('GO_0010143', 'cutin biosynthetic process', 944, 'Carbon dioxide production'), ('CHEBI_17234', 'glucose', 1023, 'glucose'), ('PR_000008777', '17-beta-hydroxysteroid dehydrogenase 13', 1079, '11β- HSD1'), ('PR_000008777', '17-beta-hydroxysteroid dehydrogenase 13', 1090, '11β-'), ('PR_000008446', 'hyaluronan and proteoglycan link protein 3', 1094, 'Hidroxysteroid dehydrogenase type 1')]
PMC3575022	2/2013	S10-PMC3575022	['exposure to a maternal diet rich in Sucrose led to obesity and Glucose intolerance in female Mice offspring, and hypertension in both sexes.']	N/A	N/A	[('CHEBI_17992', 'sucrose', 36, 'sucrose'), ('CHEBI_17234', 'glucose', 63, 'glucose'), ('NCBITaxon_10088', 'Mus <genus>', 93, 'mice')]
PMC3575022	2/2013	S56-PMC3575022	['Glucose tolerance test\nat 3 months of age, Glucose tolerance was assessed after a single bolus of Glucose (1 g/kg; i.p.)']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('CHEBI_17234', 'glucose', 43, 'glucose'), ('CHEBI_17234', 'glucose', 98, 'glucose')]
PMC3575022	2/2013	S58-PMC3575022	['the Glucose concentration of samples of Blood from the Tail Vein was measured at 0, 15, 30, 60, 90, and 120 min in conscious, semi restrained Animals (glucomen sensor, a. menarini diagnostics, it).']	N/A	N/A	[('CHEBI_17234', 'glucose', 4, 'glucose'), ('UBERON_0000178', 'blood', 40, 'blood'), ('UBERON_0003481', 'tail vein', 55, 'tail vein'), ('NCBITaxon_33208', 'Metazoa', 142, 'animals')]
PMC3575022	2/2013	S65-PMC3575022	['biochemical determinations\nsamples from dams and their 3 month old offspring were analysed by autoanalyser (lx20, beckman coulter, mijdrecht, netherlands; with beckman coulter kits: Glucose; uv-hexokinase; nr.']	N/A	N/A	[('CHEBI_17234', 'glucose', 182, 'Glucose')]
PMC3575022	2/2013	S89-PMC3575022	['caption (table-wrap): table 1\n\nmaternal fasting Serum Cholesterol, Triglyceride, Glucose, Insulin, and leptin concentrations at weaning in dams Fed either control ( n = 8) or a Sucrose rich diet ( n = 6) .groupcholesterol (mmol/l)Triglyceride (mmol/l)Glucose (μmol/l)Insulin (pmol/l)leptin (ng/ml) c1.52 ± 0.110.81 ± 0.117.0 ± 0.488.1 ± 8.33.7 ± 0.6sf1.89 ± 0.170.97 ± 0.155.3 ± 0.4*475.4 ± 14.5†3.0 ± 0.4\np < 0.05;\np < 0.001 vs. offspring of control dams (two-tailed t-test).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 48, 'serum'), ('CHEBI_16113', 'cholesterol', 54, 'cholesterol'), ('CHEBI_17855', 'triglyceride', 67, 'triglyceride'), ('CHEBI_17234', 'glucose', 81, 'glucose'), ('PR_000045358', 'insulin family protein', 90, 'insulin'), ('GO_0007631', 'feeding behavior', 144, 'fed'), ('CHEBI_17992', 'sucrose', 177, 'sucrose'), ('CHEBI_17855', 'triglyceride', 230, 'Triglyceride'), ('CHEBI_17234', 'glucose', 251, 'Glucose'), ('PR_000045358', 'insulin family protein', 267, 'Insulin')]
PMC3575022	2/2013	S104-PMC3575022	['at 3 months of age, Glucose intolerance was evident in female osf vs. oc, with a prolonged recovery phase in the Glucose tolerance test (figures3a,b) and a greater area under the Glucose concentration curve (Glucose [mmol/l min] osf, 1437 ± 124 vs. oc, 1077 ± 84, p< 0.05, n = 6).']	N/A	N/A	[('CHEBI_17234', 'glucose', 20, 'glucose'), ('CHEBI_17234', 'glucose', 113, 'glucose'), ('CHEBI_17234', 'glucose', 179, 'glucose'), ('CHEBI_17234', 'glucose', 208, 'glucose')]
PMC3575022	2/2013	S109-PMC3575022	['caption (table-wrap): table 3\n\nSerum Cholesterol, Triglyceride, Glucose, Insulin, and leptin concentrations at 3 months old offspring of control ( n = 8) or Sucrose Fed dams ( n = 6) .sex/groupcholesterol (mmol/l)Triglyceride (mmol/l)Glucose (umol/l)Insulin (pmol/l)leptin (ng/ml)male oc1.71 ± 0.270.37 ± 0.107.9 ± 0.939.3 ± 5.20.97 ± 0.02osf1.66 ± 0.220.30 ± 0.067.9 ± 0.568.9 ± 10.21.20 ± 0.10 female oc0.82 ± 0.120.34 ± 0.086.9 ± 0.820.3 ± 1.81.34 ± 0.26osf1.23 ± 0.200.49 ± 0.11*7.6 ± 0.8200.3 ± 16.1†3.82 ± 0.39*\np < 0.05;\np < 0.001 vs. offspring of control dams (two-tailed t-test).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 31, 'Serum'), ('CHEBI_16113', 'cholesterol', 37, 'cholesterol'), ('CHEBI_17855', 'triglyceride', 50, 'triglyceride'), ('CHEBI_17234', 'glucose', 64, 'glucose'), ('PR_000045358', 'insulin family protein', 73, 'insulin'), ('CHEBI_17992', 'sucrose', 157, 'sucrose'), ('GO_0007631', 'feeding behavior', 165, 'fed'), ('CHEBI_17855', 'triglyceride', 213, 'Triglyceride'), ('CHEBI_17234', 'glucose', 234, 'Glucose'), ('PR_000045358', 'insulin family protein', 250, 'Insulin')]
PMC3575022	2/2013	S112-PMC3575022	['caption (fig): figure 3\n\nGlucose tolerance tests at 3 months.']	N/A	N/A	[('CHEBI_17234', 'glucose', 25, 'Glucose')]
PMC3575022	2/2013	S113-PMC3575022	['Blood Glucose concentrations after administration of a bolus dose of Glucose (1 g/kg, i.p.)']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('CHEBI_17234', 'glucose', 6, 'glucose'), ('CHEBI_17234', 'glucose', 69, 'glucose')]
PMC3575022	2/2013	S129-PMC3575022	['a Sugar-rich diet in utero and during the Suckling period led to profound hyperinsulinaemia, increased adiposity and impaired Glucose tolerance in the female offspring.']	N/A	N/A	[('CHEBI_24870', 'ion', 2, 'sugar'), ('GO_0001967', 'suckling behavior', 42, 'suckling'), ('CHEBI_17234', 'glucose', 126, 'glucose')]
PMC3581200	3/2013	S2-PMC3581200	['Dogs ( n = 7 per group) that were nonpregnant (n), normal Pregnant (p), or Pregnant with igt/gdm (Pregnant Dogs Fed a high-fat and -Fructose diet [p-hff]) underwent a hyperinsulinemic-hyperglycemic clamp with intraportal Glucose infusion.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 0, 'Dogs'), ('GO_0007565', 'female pregnancy', 58, 'pregnant'), ('GO_0007565', 'female pregnancy', 75, 'pregnant'), ('GO_0007565', 'female pregnancy', 98, 'pregnant'), ('NCBITaxon_33208', 'Metazoa', 107, 'dogs'), ('GO_0007631', 'feeding behavior', 112, 'fed'), ('CHEBI_28757', 'fructose', 132, 'fructose'), ('CHEBI_17234', 'glucose', 221, 'glucose')]
PMC3581200	3/2013	S3-PMC3581200	['clamp period Insulin, glucagon, and Glucose concentrations and Hepatic Glucose loads did not differ among groups.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 13, 'insulin'), ('CHEBI_17234', 'glucose', 36, 'glucose'), ('UBERON_0002107', 'liver', 63, 'hepatic'), ('CHEBI_17234', 'glucose', 71, 'glucose')]
PMC3581200	3/2013	S11-PMC3581200	['net Hepatic Glucose balance is the sum of two processes, Hepatic Glucose output (hgo) and Hepatic Glucose Uptake (hgu), which often occur simultaneously.']	N/A	N/A	[('UBERON_0002107', 'liver', 4, 'hepatic'), ('CHEBI_17234', 'glucose', 12, 'glucose'), ('UBERON_0002107', 'liver', 57, 'hepatic'), ('CHEBI_17234', 'glucose', 65, 'glucose'), ('UBERON_0002107', 'liver', 90, 'hepatic'), ('CHEBI_17234', 'glucose', 98, 'glucose'), ('GO_0046323', 'glucose import', 98, 'glucose uptake')]
PMC3581200	3/2013	S30-PMC3581200	['approximately 16 days before the experiment, sampling catheters were inserted in the Femoral Artery and the Hepatic Portal, left Common Hepatic and Common Iliac Veins; infusion catheters were placed in Jejunal and Splenic Veins for Delivery Of Glucose and Hormones into the Portal Circulation; and ultrasonic Blood flow cuffs (transonic systems, ithaca, ny) were positioned around the Hepatic Artery, Portal Vein, and External Iliac Vein as previously described (10,11).']	N/A	N/A	[('UBERON_0002060', 'femoral artery', 85, 'femoral artery'), ('UBERON_0001594', 'azygos vein', 108, 'hepatic portal'), ('UBERON_0013201', 'olfactory pathway', 129, 'common hepatic ...'), ('UBERON_0001139', 'common iliac vein', 148, 'common iliac veins'), ('UBERON_0001947', 'red nucleus', 202, 'jejunal ...'), ('UBERON_0001213', 'intestinal villus', 214, 'splenic veins'), ('GO_0009887', 'animal organ morphogenesis', 232, 'delivery of glucose ... hormones'), ('CHEBI_17234', 'glucose', 244, 'glucose'), ('UBERON_0002630', 'body of caudate nucleus', 274, 'portal circulation'), ('UBERON_0000178', 'blood', 309, 'blood'), ('UBERON_0001193', 'hepatic artery', 385, 'hepatic artery'), ('UBERON_0002017', 'portal vein', 401, 'portal vein'), ('UBERON_0001316', 'external iliac vein', 418, 'external iliac vein')]
PMC3581200	3/2013	S35-PMC3581200	['each experiment started with a primed (777 kbq) constant (7.8 kbq/min) Peripheral Venous (intravenous) infusion of [3-3H]Glucose.']	N/A	N/A	[('UBERON_0012101', 'perinatal stage', 71, 'peripheral'), ('UBERON_0001638', 'vein', 82, 'venous'), ('CHEBI_76777', 'poly(inosinic acid)', 116, '3-'), ('CHEBI_29238', 'tritium atom', 118, '3H'), ('CHEBI_17234', 'glucose', 121, 'glucose')]
PMC3581200	3/2013	S40-PMC3581200	['Glucose 21.7 ± 0.11 µmol⋅kg–1⋅min−1mixed with P -Aminohippuric Acid 0.4 mg⋅kg–1⋅min−1was infused intraportally, and additional Glucose was infused intravenously as needed to maintain the Hepatic Glucose load at twofold basal.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('CHEBI_35697', 'trans-cinnamic acid', 46, 'p -aminohippuric acid'), ('CHEBI_17234', 'glucose', 127, 'glucose'), ('UBERON_0002107', 'liver', 187, 'hepatic'), ('CHEBI_17234', 'glucose', 195, 'glucose')]
PMC3581200	3/2013	S43-PMC3581200	['analysis of Blood Lactate, Glycerol, and alanine levels; plasma Glucose, Insulin, glucagon, Cortisol, and nonesterified fatty acid (nefa) levels; specific radioactivity of [3H]Glucose; and Hepatic Glycogen were carried out as described previously (7,10,15,16).']	N/A	N/A	[('UBERON_0000178', 'blood', 12, 'blood'), ('CHEBI_24996', 'lactate', 18, 'lactate'), ('CHEBI_17754', 'glycerol', 27, 'glycerol'), ('CHEBI_17234', 'glucose', 64, 'glucose'), ('PR_000045358', 'insulin family protein', 73, 'insulin'), ('CHEBI_17650', 'cortisol', 92, 'cortisol'), ('CHEBI_29238', 'tritium atom', 173, '3H'), ('CHEBI_17234', 'glucose', 176, 'glucose'), ('UBERON_0002107', 'liver', 189, 'hepatic'), ('CHEBI_24384', 'glycogens', 197, 'glycogen')]
PMC3581200	3/2013	S45-PMC3581200	['Hepatic Glycogen synthase (gs) activity was determined by measuring incorporation of [14C]Glucose from uridine diphosphate (udp)-[14C]Glucose into Glycogen at low (160 μmol/l) or high (6.7 mmol/l) Glucose-6-Phosphate (g6p) concentrations with low Udp-Glucose (134 μmol/l) (17).']	N/A	N/A	[('UBERON_0002107', 'liver', 0, 'Hepatic'), ('CHEBI_24384', 'glycogens', 8, 'glycogen'), ('CHEBI_36927', 'carbon-14 atom', 86, '14C'), ('CHEBI_17234', 'glucose', 90, 'glucose'), ('CHEBI_36927', 'carbon-14 atom', 130, '14C'), ('CHEBI_17234', 'glucose', 134, 'glucose'), ('CHEBI_24384', 'glycogens', 147, 'glycogen'), ('CHEBI_14314', 'D-glucose 6-phosphate', 197, 'glucose-6-phosphate'), ('CHEBI_17983', 'UDP-L-arabinose', 247, 'UDP-glucose')]
PMC3581200	3/2013	S55-PMC3581200	['mixing of the Glucose infusate in the Hepatic circulation was evaluated by recovery of P -Aminohippuric Acid in the Portal and Hepatic Vein Blood, using predefined exclusion criteria (15).']	N/A	N/A	[('CHEBI_17234', 'glucose', 14, 'glucose'), ('UBERON_0002107', 'liver', 38, 'hepatic'), ('CHEBI_35697', 'trans-cinnamic acid', 87, 'p -aminohippuric acid'), ('UBERON_0010166', 'coat of hair', 116, 'portal ...'), ('UBERON_0001143', 'hepatic vein', 127, 'hepatic vein'), ('UBERON_0000178', 'blood', 140, 'blood')]
PMC3581200	3/2013	S58-PMC3581200	['net Hepatic balance of Glucose was calculated with both a direct and an indirect method to minimize the impact of any error introduced by streaming of the Glucose infusate in the Portal Vein (15).']	N/A	N/A	[('UBERON_0002107', 'liver', 4, 'hepatic'), ('CHEBI_17234', 'glucose', 23, 'glucose'), ('CHEBI_17234', 'glucose', 155, 'glucose'), ('UBERON_0002017', 'portal vein', 179, 'portal vein')]
PMC3581200	3/2013	S64-PMC3581200	['the rate of Glucose appearance was calculated with [3H]Glucose using a two-compartment model (22) with Dog parameters (23).']	N/A	N/A	[('CHEBI_17234', 'glucose', 12, 'glucose'), ('CHEBI_29238', 'tritium atom', 52, '3H'), ('CHEBI_17234', 'glucose', 55, 'glucose'), ('NCBITaxon_33208', 'Metazoa', 103, 'dog')]
PMC3581200	3/2013	S65-PMC3581200	['direct pathway Hepatic Glycogen Synthesis was estimated as the3h disintegrations per minute in Hepatic Glycogen divided by the inflowing [3H]Glucose-specific radioactivity.']	N/A	N/A	[('GO_0007568', 'aging', 15, 'hepatic'), ('UBERON_0002107', 'liver', 15, 'hepatic'), ('CHEBI_24384', 'glycogens', 23, 'glycogen'), ('GO_0005978', 'glycogen biosynthetic process', 23, 'glycogen synthesis'), ('UBERON_0002107', 'liver', 95, 'hepatic'), ('CHEBI_24384', 'glycogens', 103, 'glycogen'), ('CHEBI_29238', 'tritium atom', 138, '3H'), ('CHEBI_17234', 'glucose', 141, 'glucose')]
PMC3581200	3/2013	S66-PMC3581200	['net Hepatic Carbon retention, an index of Glycogen Synthesis, and nonhepatic Glucose Uptake (non-hgu) were calculated as previously described (24).']	N/A	N/A	[('UBERON_0002107', 'liver', 4, 'hepatic'), ('CHEBI_33306', 'carbon group element atom', 12, 'carbon'), ('CHEBI_24384', 'glycogens', 42, 'glycogen'), ('GO_0005978', 'glycogen biosynthetic process', 42, 'glycogen synthesis'), ('CHEBI_17234', 'glucose', 77, 'glucose'), ('GO_0046323', 'glucose import', 77, 'glucose uptake')]
PMC3581200	3/2013	S79-PMC3581200	['caption (table-wrap): table 2\n\nHepatic Blood flow\n\nGlucose Metabolism.']	N/A	N/A	[('UBERON_0002107', 'liver', 31, 'Hepatic'), ('UBERON_0000178', 'blood', 39, 'blood'), ('CHEBI_17234', 'glucose', 51, 'Glucose'), ('GO_0006006', 'glucose metabolic process', 51, 'Glucose metabolism')]
PMC3581200	3/2013	S80-PMC3581200	['the Blood Glucose concentrations were significantly higher in n than in p under basal conditions, whereas the Glucose concentrations in p-hff did not differ from those in p (fig.']	N/A	N/A	[('UBERON_0000178', 'blood', 4, 'blood'), ('CHEBI_17234', 'glucose', 10, 'glucose'), ('CHEBI_17234', 'glucose', 110, 'glucose')]
PMC3581200	3/2013	S82-PMC3581200	['during the experimental period, the Glucose concentrations (Artery 8.8 ± 0.1, 8.7 ± 0.1, and 8.8 ± 0.1 mmol/l and Portal Vein 9.9 ± 0.1, 9.5 ± 0.1, and 9.6 ± 0.1 mmol/l in n, p, and p-hff, respectively) (fig.']	N/A	N/A	[('CHEBI_17234', 'glucose', 36, 'glucose'), ('UBERON_0001637', 'artery', 60, 'artery'), ('UBERON_0002017', 'portal vein', 114, 'portal vein')]
PMC3581200	3/2013	S83-PMC3581200	['1 a and b ) and the Hepatic Glucose loads were clamped at the same levels in all groups (fig.']	N/A	N/A	[('UBERON_0002107', 'liver', 20, 'hepatic'), ('CHEBI_17234', 'glucose', 28, 'glucose')]
PMC3581200	3/2013	S87-PMC3581200	['Arterial ( a ) and Portal Vein ( b ) Plasma Glucose concentrations and Hepatic Glucose loads ( c ) in the n, p, and p-hff groups were well matched during the hyperinsulinemic-hyperglycemic clamp period in the presence of the portal Glucose signal.']	N/A	N/A	[('UBERON_0001637', 'artery', 0, 'Arterial'), ('UBERON_0002017', 'portal vein', 19, 'portal vein'), ('UBERON_0001969', 'blood plasma', 37, 'plasma'), ('CHEBI_17234', 'glucose', 44, 'glucose'), ('UBERON_0002107', 'liver', 71, 'hepatic'), ('CHEBI_17234', 'glucose', 79, 'glucose'), ('CHEBI_17234', 'glucose', 232, 'glucose')]
PMC3581200	3/2013	S98-PMC3581200	['the rate of endogenous Glucose appearance during the basal period was not significantly different between n and p or between p and p-hff (63 ± 8, 65 ± 6, and 77 ± 8 µmol⋅100 g Liver−1⋅min−1in n, p, and p-Hff, respectively), and it declined similarly to 33 ± 11, 35 ± 31, and 44 ± 21 µmol⋅100 g Liver−1⋅min−1during the last hour of the experimental period.']	N/A	N/A	[('CHEBI_17234', 'glucose', 23, 'glucose'), ('UBERON_0002107', 'liver', 176, 'liver'), ('PR_000008530', 'hairy/enhancer-of-split related with YRPW motif-like protein', 204, 'HFF'), ('UBERON_0002107', 'liver', 294, 'liver')]
PMC3581200	3/2013	S103-PMC3581200	['total (portal plus peripheral) Glucose infusion rate ( a ), non-hgu ( b ), and Hindlimb Glucose Uptake ( c ) during a hyperinsulinemic-hyperglycemic clamp in the presence of the portal Glucose signal in the n, p, and p-hff groups.']	N/A	N/A	[('CHEBI_17234', 'glucose', 31, 'glucose'), ('UBERON_0002103', 'hindlimb', 79, 'hindlimb'), ('CHEBI_17234', 'glucose', 88, 'glucose'), ('GO_0046323', 'glucose import', 88, 'glucose uptake'), ('CHEBI_17234', 'glucose', 185, 'glucose')]
PMC3581200	3/2013	S145-PMC3581200	['Hepatic Glycogen Synthesis from [3H]Glucose did not differ between n and p. in p-hff, Hepatic Glycogen concentrations, total Glycogen Synthetic rate, and Glycogen Synthesis from [3H]Glucose were reduced ∼35% ( p ns), 56% ( p< 0.05), and 53% ( p< 0.05), respectively, compared with p.\n\ncaption (fig): fig.']	N/A	N/A	[('GO_0000237', 'leptotene', 0, 'Hepatic'), ('UBERON_0002107', 'liver', 0, 'Hepatic'), ('CHEBI_24384', 'glycogens', 8, 'glycogen'), ('GO_0005978', 'glycogen biosynthetic process', 8, 'glycogen synthesis'), ('CHEBI_29238', 'tritium atom', 33, '3H'), ('CHEBI_17234', 'glucose', 36, 'glucose'), ('UBERON_0002107', 'liver', 86, 'hepatic'), ('CHEBI_24384', 'glycogens', 94, 'glycogen'), ('CHEBI_24384', 'glycogens', 125, 'glycogen'), ('GO_0005978', 'glycogen biosynthetic process', 125, 'glycogen synthetic'), ('CHEBI_24384', 'glycogens', 154, 'glycogen'), ('GO_0005978', 'glycogen biosynthetic process', 154, 'glycogen synthesis'), ('CHEBI_29238', 'tritium atom', 179, '3H'), ('CHEBI_17234', 'glucose', 182, 'glucose')]
PMC3581200	3/2013	S148-PMC3581200	['Glycogen concentrations at the end of study ( a ); net Glycogen Synthesis ( b ) (cold indicates the area under the curve of net Hepatic carbon retention during the clamp, and3h depos[deposition] indicates incorporation of3h from Glucose into Hepatic Glycogen, i.e., synthesis through the direct pathway); Gk protein Expressed relative to Β-Actin ( c ); catalytic gk activity ( d ) at near half-maximal and maximal velocity (in the presence of 8 mmol/l [solid bars] and 100 mmol/l [open bars] Glucose, respectively); Akt ( e ) and Gsk3Β ( f ) phosphorylation, expressed relative to total Akt and Gsk3Β protein, respectively; and activity ratios of gs ( g ), gp ( h ), and gs/gp ( i ) at the end of a 4-h hyperinsulinemic-hyperglycemic clamp in the presence of the portal signal.']	N/A	N/A	[('CHEBI_28087', 'glycogen', 0, 'Glycogen'), ('CHEBI_24384', 'glycogens', 55, 'glycogen'), ('GO_0005978', 'glycogen biosynthetic process', 55, 'glycogen synthesis'), ('UBERON_0002107', 'liver', 128, 'hepatic'), ('CHEBI_17234', 'glucose', 229, 'glucose'), ('UBERON_0002107', 'liver', 242, 'hepatic'), ('CHEBI_24384', 'glycogens', 250, 'glycogen'), ('PR_000008000', 'gap junction beta-4 protein', 305, 'GK'), ('GO_0010467', 'gene expression', 316, 'expressed'), ('PR_000003676', 'actin, cytoplasmic 1', 338, 'β-actin'), ('CHEBI_17234', 'glucose', 492, 'glucose'), ('PR_000003908', 'aflatoxin B1 aldehyde reductase member 2', 516, 'Akt'), ('PR_000008288', 'glycogen synthase kinase-3 beta', 530, 'GSK3β'), ('PR_000003908', 'aflatoxin B1 aldehyde reductase member 2', 587, 'Akt'), ('PR_000008288', 'glycogen synthase kinase-3 beta', 595, 'GSK3β')]
PMC3581200	3/2013	S188-PMC3581200	['Hepatic gk catalyzes the rate-determining step in Regulation Of Hepatic Glucose Metabolism (35).']	N/A	N/A	[('UBERON_0002107', 'liver', 0, 'Hepatic'), ('GO_0010906', 'regulation of glucose metabolic process', 50, 'regulation of ... glucose metabolism'), ('UBERON_0002107', 'liver', 64, 'hepatic'), ('CHEBI_17234', 'glucose', 72, 'glucose')]
PMC3581200	3/2013	S202-PMC3581200	['the male Dogs exhibited marked reduction of nhgu in response to hyperinsulinemia and hyperglycemia induced by peripheral Glucose infusion, and the presence of the portal signal did not enhance nhgu.']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 9, 'dogs'), ('CHEBI_17234', 'glucose', 121, 'glucose')]
PMC3581200	3/2013	S226-PMC3581200	['the Liver’s response to hyperinsulinemia, hyperglycemia, and portal Glucose Delivery was delayed and blunted during the third Trimester of normal Pregnancy.']	N/A	N/A	[('UBERON_0002107', 'liver', 4, 'liver'), ('CHEBI_17234', 'glucose', 68, 'glucose'), ('GO_0007567', 'parturition', 76, 'delivery'), ('GO_0009294', 'DNA mediated transformation', 126, 'trimester'), ('GO_0007565', 'female pregnancy', 146, 'pregnancy')]
PMC3585827	1/2013	S4-PMC3585827	['they also undergo a provocative test to diagnose impaired Glucose tolerance and Gestational diabetes.']	N/A	N/A	[('CHEBI_17234', 'glucose', 58, 'glucose'), ('GO_0007565', 'female pregnancy', 80, 'gestational')]
PMC3585827	1/2013	S21-PMC3585827	['further, south asians have more Adipose Tissue and develop abnormal Glucose, Lipids, and Blood pressure at a significantly lower body mass index (bmi) compared to white caucasians [13].']	N/A	N/A	[('UBERON_0001013', 'adipose tissue', 32, 'adipose tissue'), ('CHEBI_17234', 'glucose', 68, 'glucose'), ('CHEBI_18059', 'lipid', 77, 'lipids'), ('UBERON_0000178', 'blood', 89, 'blood')]
PMC3585827	1/2013	S26-PMC3585827	['increased Glucose, abnormal Lipids and elevated Blood pressure) [15].']	N/A	N/A	[('CHEBI_17234', 'glucose', 10, 'glucose'), ('CHEBI_18059', 'lipid', 28, 'lipids'), ('UBERON_0000178', 'blood', 48, 'blood')]
PMC3585827	1/2013	S38-PMC3585827	['furthermore, south asians in canada had higher fasting levels of Glucose and Insulin and were significantly more “Insulin resistant”, as assessed by the Homeostasis model assessment index [13].']	N/A	N/A	[('CHEBI_17234', 'glucose', 65, 'glucose'), ('PR_000045358', 'insulin family protein', 77, 'insulin'), ('PR_000045358', 'insulin family protein', 114, 'insulin'), ('GO_0042592', 'homeostatic process', 153, 'homeostasis')]
PMC3585827	1/2013	S61-PMC3585827	['abnormal Gestational Glucose tolerance, Pregnancy-induced hypertension, preterm births, and newborn small and large-for-Gestational age Birth weight) across diverse environments on newborn’s body composition, Birth weight and length.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 9, 'gestational'), ('CHEBI_17234', 'glucose', 21, 'glucose'), ('GO_0007565', 'female pregnancy', 40, 'pregnancy'), ('GO_0007565', 'female pregnancy', 120, 'gestational'), ('GO_0007567', 'parturition', 136, 'birth'), ('GO_0007567', 'parturition', 209, 'birth')]
PMC3585827	1/2013	S81-PMC3585827	['anthropometric measurements (height, weight, Skinfold thickness), Blood pressure, Urine sample, and a fasting Blood sample for Glucose, Insulin, Micronutrients (i.e.']	N/A	N/A	[('UBERON_0009007', 'superficial inguinal lymph node', 45, 'skinfold'), ('UBERON_0000178', 'blood', 66, 'blood'), ('UBERON_0001088', 'urine', 82, 'urine'), ('UBERON_0000178', 'blood', 110, 'blood'), ('CHEBI_17234', 'glucose', 127, 'glucose'), ('PR_000045358', 'insulin family protein', 136, 'insulin'), ('CHEBI_33839', 'macromolecule', 145, 'micronutrients')]
PMC3585827	1/2013	S121-PMC3585827	['Midarm muscle area (mama) will be calculated using the following equation:mama=muac-3.14159*tsf24*3.14159\n\nmaternal Glucose status\nthe diagnosis of maternal Glycemic status is made using standardized methods at similar time point in Pregnancy across the 3 cohorts.']	N/A	N/A	[('UBERON_0001005', 'respiratory airway', 0, 'Midarm'), ('CHEBI_17234', 'glucose', 116, 'glucose'), ('GO_0006096', 'glycolytic process', 157, 'glycemic'), ('GO_0007565', 'female pregnancy', 233, 'pregnancy')]
PMC3585827	1/2013	S122-PMC3585827	['all non-diabetic mothers undergo the 75 oral Glucose tolerance test between 24-28 weeks of Gestational age.']	N/A	N/A	[('CHEBI_17234', 'glucose', 45, 'glucose'), ('GO_0007565', 'female pregnancy', 91, 'gestational')]
PMC3585827	1/2013	S123-PMC3585827	['this test is chosen to avoid the high false negative rate using the 50 gram Glucose challenge test among south asians.']	N/A	N/A	[('CHEBI_17234', 'glucose', 76, 'Glucose')]
PMC3585827	1/2013	S216-PMC3585827	['in canada samples from the three recruiting hospitals will be periodically shipped to the central storage at the clinical trials clinical research laboratory, hamilton health sciences, where they will be stored in liquid nitrogen for later measurement of Lipids, Insulin, and Glucose and for Genetic testing.']	N/A	N/A	[('CHEBI_18059', 'lipid', 255, 'lipids'), ('PR_000045358', 'insulin family protein', 263, 'insulin'), ('CHEBI_17234', 'glucose', 276, 'glucose'), ('SO_0000704', 'gene', 292, 'genetic')]
PMC3585827	1/2013	S224-PMC3585827	['caption (table-wrap): table 2\n\ntiming and type of measurement in start canada and indiameasuresantenatal visit (m)Birth (m, b)first year (m, b)12 month (m, b)24 month (m, b)36 month (m, f, b) \xa0 t1t2t3 \xa0 3 mth6 mth9 mth \xa0\xa0\xa0 demographics \xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0ageic\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0expected Delivery dateic\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0medical and obstetric history\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0gravidaic\xa0c (m)\xa0\xa0\xa0\xa0\xa0\xa0current Gestational diabetesic\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0current increased Blood pressureic\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0increased Cholesterolic\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0other major medical conditions checklistic\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0family historyic\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0medications usedic\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0past Pregnancy history\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0Live Birthsic\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0Still Birthsic\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0Abortions (therapeutic and spontaneous)ic\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0past Gestational diabetesic\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0pre-eclampsiaii/c\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0Multivitamin useii/c\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 social determinants \xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0self-reported ethnicity - for self, parents and grandparentsi\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0mother tongueic\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0religious denominationic\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0years in canada\xa0c\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0place immigrated fromic\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0place of birthic\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0annual household incomeic\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0occupationic\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0marital statusic\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0educationic\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0social supportic\xa0\xa0\xa0\xa0\xa0i/c (m)\xa0\xa0social status-mccarthur\xa0\xa0\xa0\xa0\xa0\xa0\xa0i/c\xa0\xa0acculturation\xa0\xa0\xa0\xa0\xa0\xa0\xa0c (m)\xa0\xa0Alcohol and tobacco use\xa0c\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0maternal depression\xa0i/c\xa0\xa0\xa0(m)\xa0i/c (m)\xa0\xa0intimate partner violence\xa0\xa0\xa0\xa0\xa0\xa0\xa0c(m)\xa0\xa0home environment and parenting\xa0\xa0\xa0\xa0\xa0\xa0\xa0i/c (m)\xa0\xa0infant temperament\xa0\xa0\xa0\xa0\xa0\xa0\xa0i/ci/ci/csleep patterns\xa0\xa0\xa0\xa0cc\xa0i/c\xa0\xa0 diet \xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0ffq\xa0i (mf)/c (m)\xa0i (b)\xa0\xa0\xa0i/c (m)\xa0i/c (m)24 hour recalli (m)ii(m)\xa0ii (m)ii/c (m)\xa0i/c (mother for baby)infant Feeding questions\xa0\xa0\xa0ii/ci/c\xa0i/c\xa0i/cphysical activityii/ci\xa0\xa0\xa0\xa0i/c (m)c (m)i/c (m) anthropometric measures \xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0Blood pressureii/cii/c (b)\xa0\xa0\xa0i/ci/ci/cheight/Lengthii/cii/c (b)i/c (b)\xa0ii/c\xa0i/cweightii/cii/c (b)i/c (b)i/c (b)1ii/ci/ci/Cwaist and Hip circumferenceii/ci\xa0\xa0\xa0\xa0i/ci/ci/cskin foldsii/cii/c (b)i\xa0ii/c (b)i/c (b)i/c (b, m)Head circumference\xa0\xa0\xa0i/c (b)i/ci/cii/c (b)\xa0i/c (b)Chest, mid upper Arm circumference\xa0\xa0\xa0i/c (b)iiii/c (b)\xa0i/c (b)fetal ultrasound\xa0i/c (m)i/c (m)i (b)\xa0\xa0\xa0i (b)i (b)i (b)dlw\xa0\xa0\xa0\xa0\xa0\xa0\xa0ii\xa0bia\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0i/c (b)Blood specimens\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0hemoglobini (m)c (m)\xa0i/c (b)\xa0\xa0\xa0i/c (m)\xa0i/c (m, f)fasting Glucose\xa0i/c (m)ii/c (b)\xa0\xa0\xa0i/c (b)i/c (b)i/c (b)75 g ogtt\xa0i/c (m)\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0Insulin\xa0i/c (m)ii/c (b)\xa0\xa0\xa0i/c (b)i/c (b)i/c (b)Lipids\xa0i/c (m)ii/c (b)\xa0\xa0\xa0i/c\xa0i/calt\xa0i/c (m)\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0Micronutrients (b12 Folate)\xa0i/ci\xa0\xa0\xa0\xa0\xa0\xa0\xa0dna/long term storage (Urine sample)\xa0\xa0\xa0i/c (m)\xa0\xa0\xa0\xa0\xa0\xa0Birth visit\xa0\xa0\xa0i/c (m)\xa0\xa0\xa0\xa0\xa0\xa0type of Delivery\xa0\xa0\xa0i/c (m)\xa0\xa0\xa0\xa0\xa0\xa0Pregnancy weight gain\xa0\xa0\xa0i/c (m)\xa0\xa0\xa0\xa0\xa0\xa0duration of labour\xa0\xa0\xa0i/c (m)\xa0\xa0\xa0\xa0\xa0\xa0low Birth weight\xa0\xa0\xa0i/c (b)\xa0\xa0\xa0\xa0\xa0\xa0Premature Delivery\xa0\xa0\xa0i/c (b)\xa0\xa0\xa0\xa0\xa0\xa0Premature labour\xa0\xa0\xa0i/c (m)\xa0\xa0\xa0\xa0\xa0\xa0Blood loss\xa0\xa0\xa0i/c (m)\xa0\xa0\xa0\xa0\xa0\xa0Epidural\xa0\xa0\xa0i/c (b)\xa0\xa0\xa0\xa0\xa0\xa0Birth weight\xa0\xa0\xa0i/c (b)\xa0\xa0\xa0\xa0\xa0\xa0apgar scores (1 min & 5 min)\xa0\xa0\xa0i/c (b)\xa0\xa0\xa0\xa0\xa0\xa0Vitamin K given\xa0\xa0\xa0i/c (b)\xa0\xa0\xa0\xa0\xa0\xa0adverse outcomes\xa0\xa0\xa0i/c\xa0\xa0\xa0\xa0\xa0\xa0Placenta\xa0\xa0\xa0i/c\xa0\xa0\xa0\xa0\xa0\xa0Cord Blood\xa0\xa0\xa0i/c (b)\xa0\xa0\xa0\xa0\xa0\xa0\nlegend: i india, c canada, b baby, m mother.']	N/A	N/A	[('GO_0007567', 'parturition', 114, 'Birth'), ('GO_0007586', 'digestion', 268, 'Delivery'), ('GO_0007565', 'female pregnancy', 359, 'gestational'), ('UBERON_0000178', 'blood', 407, 'blood'), ('CHEBI_62415', 'propanoyl-AMP', 441, 'cholesterolIC'), ('GO_0007565', 'female pregnancy', 567, 'Pregnancy'), ('GO_0019668', 'anaerobic catabolism of pairs of amino acids', 594, 'Live BirthsIC'), ('GO_0034209', 'sterol acetylation', 615, 'Still BirthsIC'), ('GO_0006915', 'apoptotic process', 637, 'Abortions'), ('GO_0007565', 'female pregnancy', 691, 'Gestational'), ('CHEBI_7025', 'mupirocin', 746, 'Multivitamin'), ('CHEBI_30879', 'alcohol', 1198, 'Alcohol'), ('GO_0007631', 'feeding behavior', 1538, 'Feeding'), ('UBERON_0000178', 'blood', 1653, 'Blood'), ('PR_000009651', 'laminin subunit alpha-2', 1698, 'LengthII'), ('UBERON_0007356', 'crop', 1774, 'CWaist'), ('UBERON_0006337', 'distal early tubule', 1785, 'Hip'), ('UBERON_0000033', 'head', 1869, 'Head'), ('UBERON_0012131', 'centrale', 1919, 'Chest'), ('UBERON_0001460', 'arm', 1936, 'arm'), ('UBERON_0000178', 'blood', 2067, 'Blood'), ('CHEBI_17234', 'glucose', 2149, 'Glucose'), ('PR_000045358', 'insulin family protein', 2221, 'Insulin'), ('CHEBI_18059', 'lipid', 2268, 'Lipids'), ('CHEBI_34850', 'milrinone lactate', 2319, 'Micronutrients'), ('CHEBI_81245', 'Vulpecholate', 2339, 'Folate'), ('UBERON_0001088', 'urine', 2381, 'urine'), ('GO_0007567', 'parturition', 2410, 'Birth'), ('GO_0007586', 'digestion', 2445, 'Delivery'), ('GO_0007565', 'female pregnancy', 2469, 'Pregnancy'), ('GO_0007567', 'parturition', 2544, 'Birth'), ('GO_0007129', 'homologous chromosome pairing at meiosis', 2572, 'Premature'), ('GO_0007586', 'digestion', 2582, 'Delivery'), ('GO_0007129', 'homologous chromosome pairing at meiosis', 2606, 'Premature'), ('UBERON_0000178', 'blood', 2638, 'Blood'), ('UBERON_2000660', 'epural', 2664, 'Epidural'), ('GO_0007567', 'parturition', 2688, 'Birth'), ('CHEBI_28384', 'vitamin K', 2760, 'Vitamin K'), ('UBERON_0001987', 'placenta', 2819, 'Placenta'), ('UBERON_0000948', 'heart', 2839, 'Cord'), ('UBERON_0000178', 'blood', 2844, 'Blood')]
PMC3586494	2/2013	S9-PMC3586494	['a consensus group for the international diabetes federation defines Metabolic syndrome as central obesity, plus any two of the following: raised Triglycerides, reduced high-density lipoprotein (hdl) Cholesterol, raised fasting Plasma Glucose, and raised Blood pressure [2].']	N/A	N/A	[('GO_0008152', 'metabolic process', 68, 'metabolic'), ('CHEBI_17855', 'triglyceride', 145, 'triglycerides'), ('CHEBI_16113', 'cholesterol', 199, 'cholesterol'), ('UBERON_0001969', 'blood plasma', 227, 'plasma'), ('CHEBI_17234', 'glucose', 234, 'glucose'), ('UBERON_0000178', 'blood', 254, 'blood')]
PMC3586494	2/2013	S22-PMC3586494	['in this study Metabolic syndrome was defined as impaired Glucose tolerance, hypertension, and elevated Triglycerides.']	N/A	N/A	[('GO_0008152', 'metabolic process', 14, 'metabolic'), ('CHEBI_17234', 'glucose', 57, 'glucose'), ('CHEBI_17855', 'triglyceride', 103, 'triglycerides')]
PMC3586494	2/2013	S77-PMC3586494	['it is this peripheral Insulin resistance that ensures that adequate amounts of Glucose are delivered to essential Organs such as the Brain with subsequent reduced delivery to nonessential Tissues such as Skeletal muscle.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 22, 'insulin'), ('CHEBI_17234', 'glucose', 79, 'glucose'), ('UBERON_0000062', 'organ', 114, 'organs'), ('UBERON_0000955', 'brain', 133, 'brain'), ('UBERON_0000479', 'tissue', 188, 'tissues'), ('UBERON_0004288', 'skeleton', 204, 'skeletal')]
PMC3586494	2/2013	S94-PMC3586494	['as a group, the young Adults in the study who had impaired Glucose tolerance or diabetes were overweight.']	N/A	N/A	[('UBERON_0007023', 'adult organism', 22, 'adults'), ('CHEBI_17234', 'glucose', 59, 'glucose')]
PMC3586494	2/2013	S201-PMC3586494	['weanling (26-day-old) Rats exposed to low protein during Gestation and Lactation were smaller and had reduced Serum Insulin and increased Serum Glucose and Triglycerides [87].']	N/A	N/A	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 22, 'rats'), ('GO_0007565', 'female pregnancy', 57, 'gestation'), ('GO_0007595', 'lactation', 71, 'lactation'), ('UBERON_0001977', 'blood serum', 110, 'serum'), ('PR_000045358', 'insulin family protein', 116, 'insulin'), ('UBERON_0001977', 'blood serum', 138, 'serum'), ('CHEBI_17234', 'glucose', 144, 'glucose'), ('CHEBI_17855', 'triglyceride', 156, 'triglycerides')]
PMC3586494	2/2013	S217-PMC3586494	['Carbohydrates\nall dietary Carbohydrates can be converted into Glucose [90].']	N/A	N/A	[('CHEBI_16646', 'carbohydrate', 0, 'Carbohydrates'), ('CHEBI_16646', 'carbohydrate', 26, 'carbohydrates'), ('CHEBI_17234', 'glucose', 62, 'glucose')]
PMC3586494	2/2013	S225-PMC3586494	['Triglycerides, free Fatty Acids, overall Glucose tolerance, and the Insulin sensitivity of Adipose Tissue were comparable in both groups [92].']	N/A	N/A	[('CHEBI_17855', 'triglyceride', 0, 'Triglycerides'), ('CHEBI_35366', 'fatty acid', 20, 'fatty acids'), ('CHEBI_17234', 'glucose', 41, 'glucose'), ('PR_000045358', 'insulin family protein', 68, 'insulin'), ('UBERON_0001013', 'adipose tissue', 91, 'adipose tissue')]
PMC3586494	2/2013	S229-PMC3586494	['Pregnancies complicated by maternal diabetes, in any form, place the offspring at risk for developing obesity and Glucose intolerance [29,96].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnancies'), ('CHEBI_17234', 'glucose', 114, 'glucose')]
PMC3586494	2/2013	S232-PMC3586494	['offspring risk of the Metabolic syndrome increased significantly with increasing maternal fasting Blood Glucose as well as 2-hour Blood Glucose following an oral Glucose load.']	N/A	N/A	[('GO_0008152', 'metabolic process', 22, 'metabolic'), ('UBERON_0000178', 'blood', 98, 'blood'), ('CHEBI_17234', 'glucose', 104, 'glucose'), ('UBERON_0000178', 'blood', 130, 'blood'), ('CHEBI_17234', 'glucose', 136, 'glucose'), ('CHEBI_17234', 'glucose', 162, 'glucose')]
PMC3599191	1/2013	S56-PMC3599191	['type 2 diabetes\nfifteen percent of Pregnant women develop impaired Glucose tolerance and more than 5% of these develop diabetes [25].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 35, 'pregnant'), ('CHEBI_17234', 'glucose', 67, 'glucose')]
PMC3599191	1/2013	S72-PMC3599191	['prolonged fetal exposure to elevated Glucose levels results in chronic fetal hyperinsulinemia, with a consequent trigger to increased oxygen consumption and Metabolism, leading to chronic Intrauterine Tissue hypoxia [31].']	N/A	N/A	[('CHEBI_17234', 'glucose', 37, 'glucose'), ('GO_0008152', 'metabolic process', 157, 'metabolism'), ('UBERON_0022293', 'reproductive gland secretion', 188, 'intrauterine'), ('UBERON_0000479', 'tissue', 201, 'tissue')]
PMC3607807	3/2013	S329-PMC3607807	["breakfast\nthe level of Glucose Metabolism in children's Brains increases from Birth until 4 years of age, reaching twice that of the Adults' Metabolic rate."]	N/A	N/A	[('CHEBI_17234', 'glucose', 23, 'glucose'), ('GO_0006006', 'glucose metabolic process', 23, 'glucose metabolism'), ('UBERON_0000955', 'brain', 56, 'brains'), ('GO_0007567', 'parturition', 78, 'birth'), ('UBERON_0007023', 'adult organism', 133, 'adults'), ('GO_0008152', 'metabolic process', 141, 'metabolic')]
PMC3607807	3/2013	S330-PMC3607807	['this rate of Glucose Metabolism in children remains elevated until 9–10 years of age, before it declines to the Adult level by late Adolescence (chugani,1998).']	N/A	N/A	[('CHEBI_17234', 'glucose', 13, 'glucose'), ('GO_0006006', 'glucose metabolic process', 13, 'glucose metabolism'), ('UBERON_0007023', 'adult organism', 112, 'adult'), ('GO_0048848', 'neurohypophysis morphogenesis', 132, 'adolescence')]
PMC3613945	2/2013	S114-PMC3613945	['in the cited study, homa(r) was calculated as [the fasting Plasma Glucose concentration (mg/dl)]\u2009×\u2009[fasting Plasma Insulin concentration (μu/ml)]/40568.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 59, 'plasma'), ('CHEBI_17234', 'glucose', 66, 'glucose'), ('UBERON_0001969', 'blood plasma', 108, 'plasma'), ('PR_000045358', 'insulin family protein', 115, 'insulin')]
PMC3613945	2/2013	S123-PMC3613945	['in a japanese study group, composed of 47 males and 35 females with normal Glucose tolerance, carriers of gc1s-2 and gc1s-1s had significantly higher fasting Plasma Insulin levels than homozygotes for gc1f ( p \u2009<\u20090.01 and p \u2009<\u20090.03, respectively)68.']	N/A	N/A	[('CHEBI_17234', 'glucose', 75, 'glucose'), ('UBERON_0001969', 'blood plasma', 158, 'plasma'), ('PR_000045358', 'insulin family protein', 165, 'insulin')]
PMC3613945	2/2013	S127-PMC3613945	['specifically, Individuals homozygous for gc1f had the highest increment in Glucose concentration at 30 and 60\u2009min and the lowest Glucose concentration at 180\u2009min.']	N/A	N/A	[('NCBITaxon_1', 'root', 14, 'individuals'), ('CHEBI_17234', 'glucose', 75, 'glucose'), ('CHEBI_17234', 'glucose', 129, 'glucose')]
PMC3613945	2/2013	S128-PMC3613945	['moreover, carriers homozygous for Gc2 had significantly lower mean incremental Glucose concentrations at 60 and 120\u2009min70.']	N/A	N/A	[('PR_000007894', 'GTP cyclohydrolase 1 feedback regulatory protein', 34, 'Gc2'), ('CHEBI_17234', 'glucose', 79, 'glucose')]
PMC3614838	9/2011	S2-PMC3614838	['circulating fasting Glucose, Insulin and glucagon concentrations were determined in dams and their neonatal offspring.']	N/A	N/A	[('CHEBI_17234', 'glucose', 20, 'glucose'), ('PR_000045358', 'insulin family protein', 29, 'insulin')]
PMC3614838	9/2011	S14-PMC3614838	['circulating ffa increase Hepatic Glucose output by increasing Gluconeogenesis or Glycogenolysis (8).']	N/A	N/A	[('UBERON_0002107', 'liver', 25, 'hepatic'), ('CHEBI_17234', 'glucose', 33, 'glucose'), ('GO_0006094', 'gluconeogenesis', 62, 'gluconeogenesis'), ('GO_0005981', 'regulation of glycogen catabolic process', 81, 'glycogenolysis')]
PMC3614838	9/2011	S18-PMC3614838	['Glucose Sensing units are present in different locations of the body and their integrated functions participate in the Adaptation Of an Organism to new Metabolic demands (10).']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('GO_0007601', 'visual perception', 8, 'sensing'), ('GO_0051866', 'general adaptation syndrome', 119, 'adaptation of ... organism'), ('NCBITaxon_1', 'root', 136, 'organism'), ('GO_0008152', 'metabolic process', 152, 'metabolic')]
PMC3614838	9/2011	S19-PMC3614838	['Glucose Transporter 2 (Glut2) and glucokinase (gk) represent Glucose sensors that are functional in the Liver, Pancreatic Beta Cells, Kidneys and Brain.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('PR_000015060', 'solute carrier family 2, facilitated glucose transporter member 11', 0, 'Glucose transporter 2'), ('PR_000015065', 'solute carrier family 2, facilitated glucose transporter member 3', 23, 'GLUT2'), ('CHEBI_17234', 'glucose', 61, 'glucose'), ('UBERON_0002107', 'liver', 104, 'liver'), ('CL_0000169', 'type B pancreatic cell', 111, 'pancreatic beta cells'), ('UBERON_0001264', 'pancreas', 111, 'pancreatic'), ('UBERON_0002113', 'kidney', 134, 'kidneys'), ('UBERON_0000955', 'brain', 146, 'brain')]
PMC3614838	9/2011	S23-PMC3614838	['further, maternal Food Intake, body weight, Organ weights (Liver, Pancreas, Heart and Retroperitoneal fat), circulating Glucose, Insulin and glucagon concentrations were also measured.']	N/A	N/A	[('CHEBI_33290', 'food', 18, 'food'), ('GO_0007631', 'feeding behavior', 18, 'food intake'), ('UBERON_0000062', 'organ', 44, 'organ'), ('UBERON_0002107', 'liver', 59, 'liver'), ('UBERON_0001264', 'pancreas', 66, 'pancreas'), ('UBERON_0000948', 'heart', 76, 'heart'), ('UBERON_0003693', 'retroperitoneal space', 86, 'retroperitoneal'), ('CHEBI_17234', 'glucose', 120, 'glucose'), ('PR_000045358', 'insulin family protein', 129, 'insulin')]
PMC3614838	9/2011	S32-PMC3614838	['after 3 h of fasting, Blood was collected prior to Mating and on days 7, 14 and 20 of Gestation to measure Blood Glucose concentrations.']	N/A	N/A	[('UBERON_0000178', 'blood', 22, 'blood'), ('GO_0007618', 'mating', 51, 'mating'), ('GO_0007565', 'female pregnancy', 86, 'gestation'), ('UBERON_0000178', 'blood', 107, 'blood'), ('CHEBI_17234', 'glucose', 113, 'glucose')]
PMC3614838	9/2011	S33-PMC3614838	['on the day of Delivery, Blood Glucose, Serum Insulin and Serum glucagon concentrations were determined.']	N/A	N/A	[('GO_0007567', 'parturition', 14, 'delivery'), ('UBERON_0000178', 'blood', 24, 'blood'), ('CHEBI_17234', 'glucose', 30, 'glucose'), ('UBERON_0001977', 'blood serum', 39, 'serum'), ('PR_000045358', 'insulin family protein', 45, 'insulin'), ('UBERON_0001977', 'blood serum', 57, 'serum')]
PMC3614838	9/2011	S40-PMC3614838	['Blood was collected from individual neonates for the determination of Glucose concentrations (n=38-56 per group).']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('CHEBI_17234', 'glucose', 70, 'glucose')]
PMC3614838	9/2011	S45-PMC3614838	['determination of Blood Glucose, Serum Insulin, Glucagon, Triglyceride and ffa concentrations\nin mothers and neonates, Blood Glucose concentrations were determined with a glucometer (precision qd, medisense inc, oxfordshire, uk) employing the oxidase method.']	N/A	N/A	[('UBERON_0000178', 'blood', 17, 'blood'), ('CHEBI_17234', 'glucose', 23, 'glucose'), ('UBERON_0001977', 'blood serum', 32, 'serum'), ('PR_000045358', 'insulin family protein', 38, 'insulin'), ('CHEBI_17754', 'glycerol', 47, 'glucagon'), ('CHEBI_17855', 'triglyceride', 57, 'triglyceride'), ('UBERON_0000178', 'blood', 118, 'blood'), ('CHEBI_17234', 'glucose', 124, 'glucose')]
PMC3614838	9/2011	S96-PMC3614838	['maternal Blood Glucose, Serum Insulin and Serum glucagon concentrations\nthere were no differences in maternal Blood Glucose concentrations before Gestation, during Gestation or on the day of delivery (fig.1a).']	N/A	N/A	[('UBERON_0000178', 'blood', 9, 'blood'), ('CHEBI_17234', 'glucose', 15, 'glucose'), ('UBERON_0001977', 'blood serum', 24, 'serum'), ('PR_000045358', 'insulin family protein', 30, 'insulin'), ('UBERON_0001977', 'blood serum', 42, 'serum'), ('UBERON_0000178', 'blood', 110, 'blood'), ('CHEBI_17234', 'glucose', 116, 'glucose'), ('GO_0007565', 'female pregnancy', 146, 'gestation'), ('GO_0007565', 'female pregnancy', 164, 'gestation')]
PMC3614838	9/2011	S98-PMC3614838	['caption (fig): figure 1\n\nmaternal Blood Glucose, Serum Insulin and Serum glucagon concentrations.']	N/A	N/A	[('UBERON_0000178', 'blood', 34, 'blood'), ('CHEBI_17234', 'glucose', 40, 'glucose'), ('UBERON_0001977', 'blood serum', 49, 'serum'), ('PR_000045358', 'insulin family protein', 55, 'insulin'), ('UBERON_0001977', 'blood serum', 67, 'serum')]
PMC3614838	9/2011	S99-PMC3614838	['(a), maternal Blood Glucose concentrations during Pregnancy; (b), maternal Serum Insulin concentrations on the day of Delivery; (c), maternal Serum glucagon concentrations on the day of Delivery.']	N/A	N/A	[('UBERON_0000178', 'blood', 14, 'blood'), ('CHEBI_17234', 'glucose', 20, 'glucose'), ('GO_0007565', 'female pregnancy', 50, 'pregnancy'), ('UBERON_0001977', 'blood serum', 75, 'serum'), ('PR_000045358', 'insulin family protein', 81, 'insulin'), ('GO_0007567', 'parturition', 118, 'delivery'), ('UBERON_0001977', 'blood serum', 142, 'serum'), ('GO_0007567', 'parturition', 186, 'delivery')]
PMC3614838	9/2011	S115-PMC3614838	['neonatal Blood Glucose, Serum Insulin, Glucagon, Triglyceride and ffa concentrations\nthe 20f neonates displayed elevated Blood Glucose concentrations compared to control neonates (fig.2a).']	N/A	N/A	[('UBERON_0000178', 'blood', 9, 'blood'), ('CHEBI_17234', 'glucose', 15, 'glucose'), ('UBERON_0001977', 'blood serum', 24, 'serum'), ('PR_000045358', 'insulin family protein', 30, 'insulin'), ('CHEBI_17754', 'glycerol', 39, 'glucagon'), ('CHEBI_17855', 'triglyceride', 49, 'triglyceride'), ('UBERON_0000178', 'blood', 121, 'blood'), ('CHEBI_17234', 'glucose', 127, 'glucose')]
PMC3614838	9/2011	S117-PMC3614838	['caption (fig): figure 2\n\nneonatal Blood Glucose, Serum Insulin and Serum glucagon concentrations.']	N/A	N/A	[('UBERON_0000178', 'blood', 34, 'blood'), ('CHEBI_17234', 'glucose', 40, 'glucose'), ('UBERON_0001977', 'blood serum', 49, 'serum'), ('PR_000045358', 'insulin family protein', 55, 'insulin'), ('UBERON_0001977', 'blood serum', 67, 'serum')]
PMC3614838	9/2011	S118-PMC3614838	['(a), neonatal Blood Glucose concentrations; (b), neonatal Serum Insulin concentrations; (c), neonatal Serum Glucagon concentrations.']	N/A	N/A	[('UBERON_0000178', 'blood', 14, 'blood'), ('CHEBI_17234', 'glucose', 20, 'glucose'), ('UBERON_0001977', 'blood serum', 58, 'serum'), ('PR_000045358', 'insulin family protein', 64, 'insulin'), ('UBERON_0001977', 'blood serum', 102, 'serum'), ('CHEBI_17754', 'glycerol', 108, 'glucagon')]
PMC3614838	9/2011	S120-PMC3614838	['n=53 for control, 38 for 20f, 53 for 30f and 52 for 40f for Glucose concentrations; n=4 for Insulin and glucagon concentrations.']	N/A	N/A	[('CHEBI_17234', 'glucose', 60, 'glucose'), ('PR_000045358', 'insulin family protein', 92, 'insulin')]
PMC3650171	2/2013	S28-PMC3650171	['thrifty genotype confers a survival advantage in a poor Food environment by reducing Glucose Uptake and limiting body growth.']	N/A	N/A	[('CHEBI_33290', 'food', 56, 'food'), ('CHEBI_17234', 'glucose', 85, 'glucose'), ('GO_0046323', 'glucose import', 85, 'glucose uptake')]
PMC3650171	2/2013	S42-PMC3650171	['the offspring of women exposed to famine in mid- and late Gestation were Born smaller than unexposed babies and had an increased risk of impaired Glucose tolerance as adults [28,29].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 58, 'gestation'), ('GO_0007567', 'parturition', 73, 'born'), ('CHEBI_17234', 'glucose', 146, 'glucose')]
PMC3650171	2/2013	S48-PMC3650171	['[6]\xa0age 50\xa0years2-h Glucose levels were elevated after a Glucose loadravelli et al.']	N/A	N/A	[('CHEBI_17234', 'glucose', 20, 'glucose'), ('CHEBI_17234', 'glucose', 57, 'glucose')]
PMC3650171	2/2013	S50-PMC3650171	['[26]\xa0age 58\xa0years2-h Glucose levels were elevated after a Glucose loadde rooij sr et al.']	N/A	N/A	[('CHEBI_17234', 'glucose', 21, 'glucose'), ('CHEBI_17234', 'glucose', 58, 'glucose')]
PMC3650171	2/2013	S51-PMC3650171	['[127]impaired Insulin secretion after a Glucose loadde rooij sr et al.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 14, 'insulin'), ('CHEBI_17234', 'glucose', 40, 'glucose')]
PMC3650171	2/2013	S52-PMC3650171	['[128]Glucose intolerance was differed by Ppar-Gamma 2 genotypede rooij sr et al.']	N/A	N/A	[('CHEBI_17234', 'glucose', 5, 'Glucose'), ('PR_000013057', 'peroxisome proliferator-activated receptor delta', 41, 'PPAR-gamma')]
PMC3650171	2/2013	S84-PMC3650171	['offspring of Rat dams given Dexamethasone during Pregnancy have reduced Birth weight and increased Blood pressure and Glucose intolerance in Adulthood [46,47].']	N/A	N/A	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 13, 'rat'), ('CHEBI_41879', 'dexamethasone', 28, 'dexamethasone'), ('GO_0007565', 'female pregnancy', 49, 'pregnancy'), ('GO_0007567', 'parturition', 72, 'birth'), ('UBERON_0000178', 'blood', 99, 'blood'), ('CHEBI_17234', 'glucose', 118, 'glucose'), ('UBERON_0000113', 'post-juvenile adult stage', 141, 'adulthood')]
PMC3650171	2/2013	S130-PMC3650171	['in addition, Individuals from dutch hunger winter families also had lower Dna Methylation of the Imprinted Ins-Igf2 ( Insigf ) Gene, but increased Dna Methylation of the guanine nucleotide-binding protein ( gnasas ), Maternally Expressed 3 ( Meg3 ), Interleukin-10 ( Il10 ), atp-binding Cassette a1 ( Abca1 ), and leptin ( lep) Genes in parallel with impaired Glucose tolerance compared with their unexposed same-sex siblings [85].']	N/A	N/A	[('NCBITaxon_1', 'root', 13, 'individuals'), ('GO_0006306', 'DNA methylation', 74, 'DNA methylation'), ('GO_0071514', 'genetic imprinting', 97, 'imprinted'), ('PR_000009033', 'inhibitor of growth protein 1', 107, 'INS-'), ('PR_000008989', 'interleukin-1 family member 7', 111, 'IGF2'), ('PR_000009020', "Golgi-resident adenosine 3',5'-bisphosphate 3'-phosphatase", 118, 'INSIGF'), ('SO_0000704', 'gene', 127, 'gene'), ('GO_0006306', 'DNA methylation', 147, 'DNA methylation'), ('PR_000010393', 'melanoma-derived growth regulatory protein', 217, 'maternally expressed 3'), ('GO_0010467', 'gene expression', 228, 'expressed'), ('PR_000010330', 'talin rod domain-containing protein 1', 242, 'MEG3'), ('PR_000001470', 'interleukin-28B', 250, 'interleukin-10'), ('PR_000001470', 'interleukin-28B', 267, 'IL10'), ('SO_0005853', 'gene_cassette', 287, 'cassette'), ('PR_000003555', 'ATP-binding cassette sub-family C member 10', 301, 'ABCA1'), ('SO_0000704', 'gene', 328, 'genes'), ('CHEBI_17234', 'glucose', 360, 'glucose')]
PMC3650171	2/2013	S179-PMC3650171	['[168]\xa0ratsbpaperinatal exposure led to impaired Glucose tolerancewei et al.']	N/A	N/A	[('CHEBI_17234', 'glucose', 48, 'glucose')]
PMC3653849	5/2013	S147-PMC3653849	['Primers specific for the control region of Mitochondrial Dna were used for the quantification of the mtdna Molecules, whereas Primers specific for the Glucose-6-phosphatase Nuclear Gene were used for standardization (table 4).']	N/A	N/A	[('SO_0000112', 'primer', 0, 'Primers'), ('GO_0005739', 'mitochondrion', 43, 'mitochondrial'), ('SO_0001032', 'mitochondrial_DNA', 43, 'mitochondrial DNA'), ('CHEBI_36357', 'polyatomic entity', 107, 'molecules'), ('SO_0000112', 'primer', 126, 'primers'), ('CHEBI_17234', 'glucose', 151, 'glucose'), ('GO_0005634', 'nucleus', 173, 'nuclear'), ('SO_0000704', 'gene', 181, 'gene')]
PMC3664621	5/2013	S8-PMC3664621	['we report the proportion of mothers with pathological Glucose tolerance at 26–28 weeks’ Gestation, the mother’s Gestational weight gain (gwg) and newborn anthropometry.']	N/A	N/A	[('CHEBI_17234', 'glucose', 54, 'glucose'), ('GO_0007565', 'female pregnancy', 88, 'gestation'), ('GO_0007565', 'female pregnancy', 112, 'gestational')]
PMC3664621	5/2013	S38-PMC3664621	['in the follow-up of the hapo study, Glucose levels during Pregnancy were not found to correlate significantly with offspring’s weight gain until two years of age [34].']	N/A	N/A	[('CHEBI_17234', 'glucose', 36, 'glucose'), ('GO_0007565', 'female pregnancy', 58, 'pregnancy')]
PMC3664621	5/2013	S50-PMC3664621	['in finland this group of mothers is routinely offered an oral Glucose tolerance test (ogtt) when 26–28 weeks Pregnant.']	N/A	N/A	[('CHEBI_17234', 'glucose', 62, 'glucose'), ('GO_0007565', 'female pregnancy', 109, 'pregnant')]
PMC3664621	5/2013	S82-PMC3664621	['the ogtt was performed with a 75 gram Glucose load.']	N/A	N/A	[('CHEBI_17234', 'glucose', 38, 'glucose')]
PMC3664621	5/2013	S83-PMC3664621	['the Plasma Glucose values were analysed from capillary Plasma samples at vaasa central hospital laboratory.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 4, 'plasma'), ('CHEBI_17234', 'glucose', 11, 'glucose'), ('UBERON_0001969', 'blood plasma', 55, 'plasma')]
PMC3664621	5/2013	S84-PMC3664621	['the following ogtt cut-off levels were used for Capillary Plasma Glucose: 0 h\u2009≥\u20095.3 or 1 h\u2009≥\u200911.0 or 2 h\u2009≥\u20099.6 mmol/l [42].']	N/A	N/A	[('UBERON_0001982', 'capillary', 48, 'capillary'), ('UBERON_0001969', 'blood plasma', 58, 'plasma'), ('CHEBI_17234', 'glucose', 65, 'glucose')]
PMC3664621	5/2013	S123-PMC3664621	['caption (table-wrap): table 2\n\nsecondary maternal and neonatal outcomes in the trial groups (mean or frequency and 95% ci)\xa0 interventioncontrolp valuemissing (n in groups) n9689\xa0\xa0 maternal \xa0\xa0\xa0\xa0first trimester\xa0\xa0\xa0\xa0\u2003\u2009systolic Blood pressure (mmhg)119.1 (116.9 to 121.2)116.5 (114.3 to 118.7)0.10a4, 5\u2003\u2009diastolic Blood pressure (mmhg)73.9 (72.4 to 75.4)72.1 (70.0 to 74.1)0.14a4, 5second trimester\xa0\xa0\xa0\xa0\u2003\u2009systolic Blood pressure (mmhg)116.8 (114.7 to 119.0)117.7 (115.4 to 119.9)0.59a2, 6\u2003\u2009diastolic Blood pressure (mmhg)71.7 (70.1 to 73.3)70.5 (68.5 to 72.5)0.33a2, 6\u2003\u2009physical exercise (h/week)*4.2 (3.6 to 4.7)4.5 (3.6 to 5.4)0.62b2, 5ogtt (Gestational weeks 26–28)\xa0\xa0\xa0\xa0\u2003\u2009fasting-0 h (mmol/l)4.8 (4.7 to 4.8)4.9 (4.8 to 5.0)0.12b-\u2003\u20091 h (mmol/l)8.7 (8.4 to 9.0)9.0 (8.7 to 9.4)0.21a-\u2003\u20092 h (mmol/l)6.8 (6.6 to 7.1)6.9 (6.6 to 7.1)0.77a-\u2003\u2009pathological ogtt result (cp)14.6% (8.9% to 23.0%)29.2% (20.8% to 39.4%)0.016c\xa0third Trimester\xa0\xa0\xa0\xa0\u2003\u2009systolic Blood pressure (mmhg)122.4 (120.1 to 124.6)122.5 (120.0 to 125.0)0.79b3, 4\u2003\u2009diastolic Blood pressure (mmhg)77.8 (76.1 to 79.5)75.2 (73.2 to 77.3)0.052a3, 4\u2003\u2009physical exercise (h/week)*3.4 (3.0 to 3.8)3.2 (2.5 to 3.9)0.11b4, 4\u2003\u2009Gestational weight gain until 37 gw (kg)11.4 (10.4 to 12.5)12.7 (11.5 to 14.0)0.11a2, 0\u2003\u2009min – max−4.9 to 27.2−1.0 to 34.7\xa0\xa0 Neonatal \xa0\xa0\xa0\xa0non-complicated Vaginal delivery77.1% (67.7% to 84.4%)75.3% (65.4% to 83.1%)0.77c-Gestational age at birth39.8 (39.4 to 40.1)39.4 (39.2 to 39.7)0.084b-sex of the newborn (boy)51.0% (41.2% to 60.8%)50.6% (40.4% to 60.7%)0.95c-Birth weight (grams)3509 (3404 to 3615)3507 (3417 to 3596)0.97a-ponderal index (weight, kg/length, m3)27.4 (26.9 to 27.9)27.5 (27.0 to 27.9)0.89a-large for Gestational age7.3% (3.6% to 14.3%)5.6% (2.4% to 12.5%)0.64c-small for Gestational age13.5% (8.1% to 21.8%)6.7% (3.1% to 13.9%)0.13c-exclusive breastfeeding (months)3.0 (2.5 to 3.4)2.8 (2.3 to 3.2)0.52b8, 0\naindependent samples t -test,bmann-whitney u -test,cchi-square test,dfisher’s exact test; ogtt, oral Glucose tolerance test (75 g Glucose load, 2-hour); cp\u2009=\u2009capillary Plasma Glucose; ci, confidence interval; *level of at least slightly out of Breath; gw, Gestational weeks.']	N/A	N/A	[('UBERON_0000178', 'blood', 223, 'blood'), ('UBERON_0000178', 'blood', 309, 'blood'), ('UBERON_0000178', 'blood', 408, 'blood'), ('UBERON_0000178', 'blood', 494, 'blood'), ('GO_0007565', 'female pregnancy', 638, 'Gestational'), ('GO_0009294', 'DNA mediated transformation', 917, 'trimester'), ('UBERON_0000178', 'blood', 941, 'blood'), ('UBERON_0000178', 'blood', 1027, 'blood'), ('GO_0007565', 'female pregnancy', 1168, 'Gestational'), ('GO_0007569', 'cell aging', 1293, 'Neonatal'), ('GO_0007601', 'visual perception', 1322, 'vaginal'), ('UBERON_0001987', 'placenta', 1322, 'vaginal'), ('GO_0007565', 'female pregnancy', 1388, 'Gestational'), ('GO_0007567', 'parturition', 1531, 'Birth'), ('GO_0007565', 'female pregnancy', 1687, 'gestational'), ('GO_0007565', 'female pregnancy', 1758, 'gestational'), ('CHEBI_17234', 'glucose', 1995, 'glucose'), ('CHEBI_17234', 'glucose', 2024, 'glucose'), ('UBERON_0001969', 'blood plasma', 2062, 'plasma'), ('CHEBI_17234', 'glucose', 2069, 'glucose'), ('UBERON_0000310', 'breast', 2138, 'breath'), ('GO_0007565', 'female pregnancy', 2150, 'gestational')]
PMC3664621	5/2013	S184-PMC3664621	['all mothers with gdm are given dietary advice contributing to better Glucose balance and a Glucose meter to monitor their Glucose values at home.']	N/A	N/A	[('CHEBI_17234', 'glucose', 69, 'glucose'), ('CHEBI_17234', 'glucose', 91, 'glucose'), ('CHEBI_17234', 'glucose', 122, 'glucose')]
PMC3664621	5/2013	S185-PMC3664621	['Insulin treatment is initiated if the target Glucose balance is not achieved by these means.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 0, 'Insulin'), ('CHEBI_17234', 'glucose', 45, 'glucose')]
PMC3664621	5/2013	S227-PMC3664621	['abbreviations\ngwg: Gestational weight gain; sds: standard deviation score; gdm: Gestational diabetes mellitus; bmi: body mass index; ogtt: oral Glucose tolerance test; phn: public health nurse; bp: Blood pressure; ci: confidence interval.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 19, 'Gestational'), ('GO_0007565', 'female pregnancy', 80, 'Gestational'), ('CHEBI_17234', 'glucose', 144, 'glucose'), ('UBERON_0000178', 'blood', 198, 'Blood')]
PMC3669365	5/2013	S18-PMC3669365	['ampk acts as an efficient sensor of cellular energy states Regulating Glucose and Lipid Metabolism[15],[16],[17].']	N/A	N/A	[('GO_0065007', 'biological regulation', 59, 'regulating'), ('CHEBI_17234', 'glucose', 70, 'glucose'), ('GO_0007369', 'gastrulation', 70, 'glucose ...'), ('CHEBI_18059', 'lipid', 82, 'lipid'), ('GO_0006629', 'lipid metabolic process', 82, 'lipid metabolism')]
PMC3669365	5/2013	S69-PMC3669365	['measurement of Plasma levels of Triglycerides, Free Fatty Acids (ffas), Ketone bodies, and Glucose\nat the time of decapitation, Trunk Blood was collected for measurement of Triglycerides, ffas, and Ketone body levels.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 15, 'Plasma'), ('CHEBI_17855', 'triglyceride', 32, 'Triglycerides'), ('CHEBI_26590', 'sabinol', 47, 'Free Fatty Acids'), ('CHEBI_17087', 'ketone', 72, 'Ketone'), ('CHEBI_17234', 'glucose', 91, 'Glucose'), ('UBERON_0002100', 'trunk', 128, 'trunk'), ('UBERON_0000178', 'blood', 134, 'blood'), ('CHEBI_17855', 'triglyceride', 173, 'triglycerides'), ('CHEBI_17087', 'ketone', 198, 'ketone')]
PMC3669365	5/2013	S72-PMC3669365	['Glucose was detected from Tail Blood by a Glucose biosensor (lifescan, inc., milpitas, ca, usa).']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('UBERON_0002415', 'tail', 26, 'tail'), ('UBERON_0000178', 'blood', 31, 'blood'), ('CHEBI_17234', 'glucose', 42, 'glucose')]
PMC3669365	5/2013	S73-PMC3669365	['in vivo Metabolic testing\nGlucose tolerance was assessed after Glucose Intraperitoneal (i.p.)']	N/A	N/A	[('GO_0008152', 'metabolic process', 8, 'Metabolic'), ('CHEBI_17234', 'glucose', 26, 'Glucose'), ('CHEBI_17234', 'glucose', 63, 'glucose'), ('UBERON_2001932', 'sensory canal tubular ossicle', 71, 'intraperitoneal')]
PMC3669365	5/2013	S94-PMC3669365	['the results of behavioral tests, real-time rt-pcr, Blood Glucose, and measurements of Plasma substances were analyzed by mann-whitney u test.']	N/A	N/A	[('UBERON_0000178', 'blood', 51, 'blood'), ('CHEBI_17234', 'glucose', 57, 'glucose'), ('UBERON_0001969', 'blood plasma', 86, 'plasma')]
PMC3669365	5/2013	S97-PMC3669365	['dr female Mice displayed a marked decrease in Blood Glucose (figure s1b).']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 10, 'mice'), ('UBERON_0000178', 'blood', 46, 'blood'), ('CHEBI_17234', 'glucose', 52, 'glucose')]
PMC3669365	5/2013	S145-PMC3669365	['at Gestation day 17, the fetuses of dr Mice showed a marked decrease in Blood Glucose (figure 5a).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 3, 'gestation'), ('NCBITaxon_10088', 'Mus <genus>', 39, 'mice'), ('UBERON_0000178', 'blood', 72, 'blood'), ('CHEBI_17234', 'glucose', 78, 'glucose')]
PMC3669365	5/2013	S155-PMC3669365	['furthermore, there were no significant differences in the Glucose tolerance test (gtt) or the Insulin tolerance test (itt) between the two groups (figure 6f, g).']	N/A	N/A	[('CHEBI_17234', 'glucose', 58, 'glucose'), ('PR_000045358', 'insulin family protein', 94, 'insulin')]
PMC3669365	5/2013	S159-PMC3669365	['also, there were no significant differences in the mrna Expression of various Glucose Metabolism-related enzymes, transporters, or receptors in the Hypothalamus (figure s7b).10.1371/journal.pone.0064263.g006\n\ncaption (fig): figure 6\nMetabolic state in Adulthood (8–9 weeks).']	N/A	N/A	[('GO_0010467', 'gene expression', 56, 'expression'), ('CHEBI_17234', 'glucose', 78, 'glucose'), ('GO_0006006', 'glucose metabolic process', 78, 'glucose metabolism'), ('UBERON_0001898', 'hypothalamus', 148, 'hypothalamus'), ('GO_0008152', 'metabolic process', 233, 'Metabolic'), ('UBERON_0000113', 'post-juvenile adult stage', 252, 'adulthood')]
PMC3669365	5/2013	S161-PMC3669365	['Glucose tolerance test (gtt; f) and Insulin tolerance test (itt; g) in Adulthood.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('PR_000045358', 'insulin family protein', 36, 'insulin'), ('UBERON_0000113', 'post-juvenile adult stage', 71, 'adulthood')]
PMC3669365	5/2013	S226-PMC3669365	['maternal Blood Glucose concentration (b) on Gestation day 17.']	N/A	N/A	[('UBERON_0000178', 'blood', 9, 'blood'), ('CHEBI_17234', 'glucose', 15, 'glucose'), ('GO_0007565', 'female pregnancy', 44, 'gestation')]
PMC3669365	5/2013	S274-PMC3669365	['caption (supplementary-material): figure s7\n\nGene Expression related to the Feeding Regulation (a) and the Regulation Of Glucose Metabolism (b) such as hexokinase 1 (Hk1, encoded by Hk1 ), Hexokinase 2 (Hk2, encoded by Hk2 ), Phosphofructokinase, Muscle (Pfkm, encoded by Pfkm ), solute carrier family 2, Member 1 (Slc2A1, encoded by slc2a1 ), Solute Carrier Family 2, Member 3 (Slc2A3, encoded by slc2a3 ), Lactate dehydrogenase a (ldha, encoded by Ldha ), and Lactate dehydrogenase b (Ldhb, encoded by Ldhb ) in the Hypothalamus.']	N/A	N/A	[('GO_0010467', 'gene expression', 45, 'Gene expression'), ('SO_0000704', 'gene', 45, 'Gene'), ('GO_0007631', 'feeding behavior', 76, 'feeding'), ('GO_0065007', 'biological regulation', 84, 'regulation'), ('GO_0010906', 'regulation of glucose metabolic process', 107, 'regulation of glucose metabolism'), ('CHEBI_17234', 'glucose', 121, 'glucose'), ('PR_000003770', 'all-trans-retinol dehydrogenase [NAD(+)] ADH4', 163, '1'), ('PR_000008608', 'hexokinase-1', 166, 'HK1'), ('PR_000008608', 'hexokinase-1', 182, 'Hk1'), ('PR_000008609', 'hexokinase-2', 189, 'hexokinase 2'), ('PR_000008608', 'hexokinase-1', 203, 'HK2'), ('PR_000008608', 'hexokinase-1', 219, 'Hk2'), ('PR_000012582', 'ATP-dependent 6-phosphofructokinase, liver type', 226, 'phosphofructokinase, muscle'), ('PR_000012572', 'prefoldin subunit 1', 255, 'PFKM'), ('PR_000012774', 'polycystic kidney disease 2-like 1 protein', 272, 'Pfkm'), ('PR_000010283', 'mediator of RNA polymerase II transcription subunit 12-like protein', 302, '2, member 1'), ('PR_000015219', 'sodium/hydrogen exchanger 7', 315, 'SLC2A1'), ('PR_000015229', 'solute carrier organic anion transporter family member 4A1', 344, 'solute carrier family 2, member 3'), ('PR_000015199', 'cationic amino acid transporter 3', 379, 'SLC2A3'), ('CHEBI_24996', 'lactate', 408, 'lactate'), ('PR_000009751', 'lymphoid enhancer-binding factor 1', 450, 'Ldha'), ('CHEBI_24996', 'lactate', 462, 'lactate'), ('PR_000009751', 'lymphoid enhancer-binding factor 1', 487, 'LDHB'), ('PR_000009651', 'laminin subunit alpha-2', 504, 'Ldhb'), ('UBERON_0001898', 'hypothalamus', 518, 'hypothalamus')]
PMC3674738	5/2013	S161-PMC3674738	['Glucose Transporter I deficiency has emerged as the leading Metabolic indication for the Ketogenic diet, a dietary therapy that replaces Glucose with Ketone bodies as the primary biochemical energy source.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('PR_000015060', 'solute carrier family 2, facilitated glucose transporter member 11', 0, 'Glucose transporter I'), ('GO_0008152', 'metabolic process', 60, 'metabolic'), ('CHEBI_75715', "dUMP 3'-end residue", 89, 'ketogenic'), ('GO_0000241', 'diakinesis', 89, 'ketogenic'), ('CHEBI_17234', 'glucose', 137, 'glucose'), ('CHEBI_17087', 'ketone', 150, 'ketone')]
PMC3675032	6/2013	S126-PMC3675032	['at 6-months of age, the hchf Lambs had become obese (>30% fat in soft Tissue), and had impaired Glucose-stimulated secretion of Insulin.']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 29, 'lambs'), ('UBERON_0000479', 'tissue', 70, 'tissue'), ('CHEBI_17234', 'glucose', 96, 'glucose'), ('PR_000045358', 'insulin family protein', 128, 'insulin')]
PMC3675032	6/2013	S131-PMC3675032	['there were no gender specific effects for any of those indicators of Glucose-Insulin axis function in the 6-months old Animals, where both male and female lambs were studied.']	N/A	N/A	[('CHEBI_17234', 'glucose', 69, 'glucose'), ('PR_000045358', 'insulin family protein', 77, 'insulin'), ('NCBITaxon_33208', 'Metazoa', 119, 'animals')]
PMC3675032	6/2013	S139-PMC3675032	['panel a, Insulin Receptor-Β Subunit ( Insrβ ); panel b, Protein Kinase Zeta ( Pkcζ ); panel c, Glucose Transporter 4 ( Glut4 ).']	N/A	N/A	[('PR_000001379', 'interleukin-2', 9, 'insulin receptor-β subunit'), ('PR_000009020', "Golgi-resident adenosine 3',5'-bisphosphate 3'-phosphatase", 38, 'INSRβ'), ('PR_000012270', 'pappalysin-1', 56, 'protein kinase zeta'), ('PR_000003059', 'protein kinase C beta type', 78, 'PKCζ'), ('CHEBI_17234', 'glucose', 95, 'glucose'), ('PR_000015064', 'solute carrier family 2, facilitated glucose transporter member 2', 95, 'glucose transporter 4'), ('PR_000015065', 'solute carrier family 2, facilitated glucose transporter member 3', 119, 'GLUT4')]
PMC3675032	6/2013	S155-PMC3675032	['thus, in ld, the Hchf diet enhanced Expression of a range of Genes involved in Regulation Of Glucose Uptake, Insulin Signalling and Fatty Acid Oxidation: Insrβ, ( p\u200a=\u200a 0.06), Irs1 ( p\u200a=\u200a 0.02), Glut4 ( p\u200a=\u200a 0.02), Cpt1 ( p< 0.0001), Uncoupling Protein 3 ( Ucp3 , p\u200a=\u200a 0.07), and Peroxisome Proliferator-Activated Receptor Alpha ( Pparα , p\u200a=\u200a 0.04) (figure 2a).']	N/A	N/A	[('CHEBI_17883', 'hydrogen chloride', 17, 'HCHF'), ('GO_0010467', 'gene expression', 36, 'expression'), ('SO_0000704', 'gene', 61, 'genes'), ('GO_0046324', 'regulation of glucose import', 79, 'regulation of glucose uptake'), ('CHEBI_17234', 'glucose', 93, 'glucose'), ('GO_0031129', 'inductive cell-cell signaling', 109, 'insulin signalling'), ('PR_000045358', 'insulin family protein', 109, 'insulin'), ('CHEBI_35366', 'fatty acid', 132, 'fatty acid'), ('GO_0019395', 'fatty acid oxidation', 132, 'fatty acid oxidation'), ('PR_000009020', "Golgi-resident adenosine 3',5'-bisphosphate 3'-phosphatase", 154, 'INSRβ'), ('PR_000009158', 'inositol 1,4,5-trisphosphate receptor type 1', 175, 'IRS1'), ('PR_000015065', 'solute carrier family 2, facilitated glucose transporter member 3', 194, 'GLUT4'), ('PR_000005850', 'protein crumbs homolog 3', 214, 'CPT1'), ('PR_000017116', 'uroplakin-3b', 233, 'uncoupling protein 3'), ('PR_000017025', 'ubiquitin carboxyl-terminal hydrolase isozyme L3', 256, 'UCP3'), ('GO_0005777', 'peroxisome', 279, 'peroxisome'), ('PR_000013354', 'pregnancy-specific beta-1-glycoprotein 6', 279, 'peroxisome proliferator-activated receptor alpha'), ('PR_000013057', 'peroxisome proliferator-activated receptor delta', 330, 'PPARα')]
PMC3675032	6/2013	S157-PMC3675032	['the mrna Expression of the following Genes are shown: Insulin Receptor-Beta Subunit ( Insrβ ), Insulin Receptor Substrate 1 ( Irs1 ), Glucose Transporter 4 ( Glut4 ), Carnitine Palmitoyltransferase I ( Cpt1 ), Uncoupling Protein 3 ( Ucp3 ), and Peroxisome Proliferator-Activated Receptor Alpha ( Pparα ).']	N/A	N/A	[('GO_0010467', 'gene expression', 9, 'expression'), ('SO_0000704', 'gene', 37, 'genes'), ('PR_000009000', 'interleukin-22 receptor subunit alpha-2', 54, 'insulin receptor-beta subunit'), ('PR_000009020', "Golgi-resident adenosine 3',5'-bisphosphate 3'-phosphatase", 86, 'INSRβ'), ('PR_000008959', 'immunoglobulin heavy constant gamma 1', 95, 'insulin receptor substrate 1'), ('PR_000009158', 'inositol 1,4,5-trisphosphate receptor type 1', 126, 'IRS1'), ('CHEBI_17234', 'glucose', 134, 'glucose'), ('PR_000015064', 'solute carrier family 2, facilitated glucose transporter member 2', 134, 'glucose transporter 4'), ('PR_000015065', 'solute carrier family 2, facilitated glucose transporter member 3', 158, 'GLUT4'), ('CHEBI_17126', 'carnitine', 167, 'carnitine'), ('PR_000005848', 'protein crumbs homolog 1', 167, 'carnitine palmitoyltransferase I'), ('PR_000005850', 'protein crumbs homolog 3', 202, 'CPT1'), ('PR_000017116', 'uroplakin-3b', 210, 'uncoupling protein 3'), ('PR_000017025', 'ubiquitin carboxyl-terminal hydrolase isozyme L3', 233, 'UCP3'), ('GO_0005777', 'peroxisome', 245, 'peroxisome'), ('PR_000013354', 'pregnancy-specific beta-1-glycoprotein 6', 245, 'peroxisome proliferator-activated receptor alpha'), ('PR_000013057', 'peroxisome proliferator-activated receptor delta', 296, 'PPARα')]
PMC3675032	6/2013	S320-PMC3675032	['target proteins are Insulin Receptor-Beta Subunit ( Insre ), Protein Kinase Zeta ( Pkcζ ), and Glucose Transporter 4 ( Glut4 ).']	N/A	N/A	[('PR_000009000', 'interleukin-22 receptor subunit alpha-2', 20, 'insulin receptor-beta subunit'), ('PR_000009020', "Golgi-resident adenosine 3',5'-bisphosphate 3'-phosphatase", 52, 'INSRe'), ('PR_000012270', 'pappalysin-1', 61, 'protein kinase zeta'), ('PR_000003059', 'protein kinase C beta type', 83, 'PKCζ'), ('CHEBI_17234', 'glucose', 95, 'glucose'), ('PR_000015064', 'solute carrier family 2, facilitated glucose transporter member 2', 95, 'glucose transporter 4'), ('PR_000015065', 'solute carrier family 2, facilitated glucose transporter member 3', 119, 'GLUT4')]
PMC3675032	6/2013	S324-PMC3675032	['target proteins are Insulin Receptor-Beta Subunit ( Insrβ ), Protein Kinase Zeta ( Pkcζ ), and Glucose Transporter 4 ( Glut4 ).']	N/A	N/A	[('PR_000009000', 'interleukin-22 receptor subunit alpha-2', 20, 'insulin receptor-beta subunit'), ('PR_000009020', "Golgi-resident adenosine 3',5'-bisphosphate 3'-phosphatase", 52, 'INSRβ'), ('PR_000012270', 'pappalysin-1', 61, 'protein kinase zeta'), ('PR_000003059', 'protein kinase C beta type', 83, 'PKCζ'), ('CHEBI_17234', 'glucose', 95, 'glucose'), ('PR_000015064', 'solute carrier family 2, facilitated glucose transporter member 2', 95, 'glucose transporter 4'), ('PR_000015065', 'solute carrier family 2, facilitated glucose transporter member 3', 119, 'GLUT4')]
PMC3675032	6/2013	S328-PMC3675032	['target proteins are Insulin Receptor-Beta Subunit ( Insrβ ), Protein Kinase Zeta ( Pkcζ ), and Glucose Transporter 4 ( Glut4 ).']	N/A	N/A	[('PR_000009000', 'interleukin-22 receptor subunit alpha-2', 20, 'insulin receptor-beta subunit'), ('PR_000009020', "Golgi-resident adenosine 3',5'-bisphosphate 3'-phosphatase", 52, 'INSRβ'), ('PR_000012270', 'pappalysin-1', 61, 'protein kinase zeta'), ('PR_000003059', 'protein kinase C beta type', 83, 'PKCζ'), ('CHEBI_17234', 'glucose', 95, 'glucose'), ('PR_000015064', 'solute carrier family 2, facilitated glucose transporter member 2', 95, 'glucose transporter 4'), ('PR_000015065', 'solute carrier family 2, facilitated glucose transporter member 3', 119, 'GLUT4')]
PMC3685567	5/2013	S45-PMC3685567	['body weight, blood Glucose and β −Ketones ( β − hydroxybutyrate ) were measured weekly, using an abbott “precision xtra” Glucometer which required a relatively minute Blood volume of 0.6-1.5 μ l/test [15] drawn from the Tail Vein.']	N/A	N/A	[('CHEBI_17234', 'glucose', 19, 'glucose'), ('CHEBI_17087', 'ketone', 34, 'ketones'), ('CHEBI_24321', 'glutamo group', 121, 'glucometer'), ('UBERON_0000178', 'blood', 167, 'blood'), ('UBERON_0003481', 'tail vein', 220, 'tail vein')]
PMC3685567	5/2013	S68-PMC3685567	['results\n\nMetabolic status of pre-Mated female Mice\naverage body weight and Blood Glucose of kd female Mice did not statistically differ from those of sd female Mice (p > 0.1) prior to Mating.']	N/A	N/A	[('GO_0008152', 'metabolic process', 9, 'Metabolic'), ('GO_0007618', 'mating', 33, 'mated'), ('NCBITaxon_10088', 'Mus <genus>', 46, 'mice'), ('UBERON_0000178', 'blood', 75, 'blood'), ('CHEBI_17234', 'glucose', 81, 'glucose'), ('NCBITaxon_10088', 'Mus <genus>', 102, 'mice'), ('NCBITaxon_10088', 'Mus <genus>', 160, 'mice'), ('GO_0007618', 'mating', 184, 'mating')]
PMC3686716	6/2013	S14-PMC3686716	['for instance, in comparison to their non-low-Birth-weight term-Born peers, vlbw subjects have higher Blood pressure[7]–[10]as well as impaired Glucose Regulation[11],[12].']	N/A	N/A	[('GO_0007567', 'parturition', 45, 'birth'), ('GO_0007567', 'parturition', 63, 'born'), ('UBERON_0000178', 'blood', 101, 'blood'), ('CHEBI_17234', 'glucose', 143, 'glucose'), ('GO_0006094', 'gluconeogenesis', 143, 'glucose regulation')]
PMC3686716	6/2013	S33-PMC3686716	['the examination included, e.g., height and weight measurement based on which body mass index (bmi) was calculated (weight in kilograms divided by height in meters squared), and a 2-hour oral Glucose tolerance test.']	N/A	N/A	[('CHEBI_17234', 'glucose', 191, 'glucose')]
PMC3687314	7/2013	S94-PMC3687314	['consumption of a high-protein diet for 6 months in healthy Individuals induced a higher Glucose-stimulated Insulin secretion due to reduced Glucose threshold of the endocrine β-Cells, increased endogenous Glucose output and Plasma glucagon level, and enhanced Gluconeogenesis (30).']	N/A	N/A	[('NCBITaxon_1', 'root', 59, 'individuals'), ('CHEBI_17234', 'glucose', 88, 'glucose'), ('PR_000045358', 'insulin family protein', 107, 'insulin'), ('CHEBI_17234', 'glucose', 140, 'glucose'), ('CL_0000622', 'acinar cell', 176, '-cells'), ('CHEBI_17234', 'glucose', 205, 'glucose'), ('GO_0040007', 'growth', 205, 'glucose'), ('UBERON_0001969', 'blood plasma', 224, 'plasma'), ('GO_0006094', 'gluconeogenesis', 260, 'gluconeogenesis')]
PMC3691177	6/2013	S29-PMC3691177	['eligible participants were women presenting at 27 weeks Gestation for routine Glucose challenge test from the following ethnic groups: asian, middle eastern, black and white.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 56, 'gestation'), ('CHEBI_17234', 'glucose', 78, 'glucose')]
PMC3698442	7/2013	S17-PMC3698442	['in rodents, Feeding a high-saturated fat diet during Pregnancy and/or Pregnancy and Lactation induced in the offspring vascular dysfunction[5,6]and impaired Control Of Lipid and Glucose Metabolism[7–14].']	N/A	N/A	[('GO_0007631', 'feeding behavior', 12, 'feeding'), ('GO_0007565', 'female pregnancy', 53, 'pregnancy'), ('GO_0007565', 'female pregnancy', 70, 'pregnancy'), ('GO_0007595', 'lactation', 84, 'lactation'), ('GO_0046939', 'nucleotide phosphorylation', 157, 'control of lipid ... glucose metabolism'), ('CHEBI_18059', 'lipid', 168, 'lipid'), ('CHEBI_17234', 'glucose', 178, 'glucose')]
PMC3698442	7/2013	S18-PMC3698442	['furthermore, the offspring of Mice Fed a diet enriched in trans Fatty Acids during Pregnancy and Lactation showed growth retardation and impaired Glucose Homeostasis[15].']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 30, 'mice'), ('GO_0007631', 'feeding behavior', 35, 'fed'), ('CHEBI_35366', 'fatty acid', 64, 'fatty acids'), ('GO_0007565', 'female pregnancy', 83, 'pregnancy'), ('GO_0007595', 'lactation', 97, 'lactation'), ('CHEBI_17234', 'glucose', 146, 'glucose'), ('GO_0042593', 'glucose homeostasis', 146, 'glucose homeostasis')]
PMC3700139	2/2011	S91-PMC3700139	['maternal obesity and diabetes result in maternal hyperglycemia [54], and as Glucose can readily pass through the Blood-Placenta barrier, it is transferred to the fetus.']	N/A	N/A	[('CHEBI_17234', 'glucose', 76, 'glucose'), ('UBERON_0000178', 'blood', 113, 'blood'), ('UBERON_0001987', 'placenta', 119, 'placenta')]
PMC3700139	2/2011	S94-PMC3700139	['administering Insulin to Rats during the last term of Gestation produces obesity in the offspring [6,56] and administering Insulin to the Hypothalamus of Rat pups during the time that projects from the arh to the pvh results in elevations in body weight, Insulin level, impaired Glucose tolerance, and increased vulnerability to diabetes [57].']	N/A	N/A	[('CHEBI_66075', 'inflexin', 14, 'insulin'), ('PR_000045358', 'insulin family protein', 14, 'insulin'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 25, 'rats'), ('GO_0007565', 'female pregnancy', 54, 'gestation'), ('PR_000045358', 'insulin family protein', 123, 'insulin'), ('UBERON_0001898', 'hypothalamus', 138, 'hypothalamus'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 154, 'rat'), ('PR_000045358', 'insulin family protein', 255, 'insulin'), ('CHEBI_17234', 'glucose', 279, 'glucose')]
PMC3702421	6/2013	S3-PMC3702421	['key details of environment and health including Maternal nutrition, Glucose tolerance, physical activity, and weight gain will be collected.']	N/A	N/A	[('GO_0007618', 'mating', 48, 'maternal'), ('CHEBI_17234', 'glucose', 68, 'glucose')]
PMC3702421	6/2013	S16-PMC3702421	['abnormal Glucose, Insulin, Blood pressure, and Lipids) in aboriginal People, we propose to recruit and follow prospectively aboriginal Pregnant mothers and their offspring from the six Nations reserve near brantford, ontario and surrounding areas.']	N/A	N/A	[('CHEBI_17234', 'glucose', 9, 'glucose'), ('PR_000045358', 'insulin family protein', 18, 'insulin'), ('UBERON_0000178', 'blood', 27, 'blood'), ('CHEBI_18059', 'lipid', 47, 'lipids'), ('NCBITaxon_10088', 'Mus <genus>', 69, 'people'), ('GO_0007565', 'female pregnancy', 135, 'pregnant'), ('UBERON_0000979', 'tibia', 185, 'Nations')]
PMC3702421	6/2013	S87-PMC3702421	['dmx\xa0\xa0\xa0\xa0\xa0pre-eclampsiax\xa0\xa0\xa0\xa0\xa0low Birth weightx\xa0\xa0\xa0\xa0\xa0premature birthx\xa0\xa0\xa0\xa0\xa0 social determinants x\xa0\xa0\xa0\xa0\xa0years living on the reservex\xa0\xa0\xa0\xa0\xa0place of Birthx\xa0\xa0\xa0\xa0\xa0religious practicesx\xa0\xa0\xa0\xa0\xa0annual household incomex\xa0\xa0x1x1x1occupationx\xa0\xa0x1x1x1marital statusx\xa0\xa0x1x1x1educationx\xa0\xa0\xa0\xa0xsocial supportx\xa0\xa0x1x1x1domestic violencex\xa0\xa0x1x1x1depressionx\xa0x1x1x1x1health behaviours \xa0\xa0\xa0\xa0\xa0\xa0cigarette exposurex\xa0\xa0xxxdiet/infant feedingx\xa0x3x3x3x3activity/sedentary behavioursx\xa0x3x3x3x3physical exam x\xa0\xa0xxxblood pressurexx2\xa0x3x3x1,3height/lengthxx2x3x3x3x1,3weightxx2x3x1,3x1,3x1,3waist and hip circumferencexx2\xa0x3x3x1,3skin foldsxx2\xa0x3x3x1,3head circumference (baby only)\xa0x2xxxxfetal ultrasoundx\xa0\xa0\xa0\xa0\xa0 Blood analysis x\xa0\xa0\xa0\xa0\xa0Hemoglobinx\xa0\xa0\xa0\xa0\xa0Glucose\xa0x2\xa0x3x3x375\xa0g ogtt (0, 60, 120\xa0min)x\xa0\xa0\xa0\xa0\xa0Insulinxx2\xa0x3x3x3adiponectinxx\xa0xxxleptinxx2\xa0xxxlipid profilexx2\xa0x3x3x3cbc\xa0x2\xa0x3x3x3aliquots for future analysisxx2\xa0x3x3x3dna long-term storagexx2\xa0\xa0\xa0\xa0 Birth visit \xa0\xa0\xa0\xa0\xa0\xa0type of delivery\xa0x\xa0\xa0\xa0\xa0duration of labour\xa0x\xa0\xa0\xa0\xa0Premature labour\xa0x\xa0\xa0\xa0\xa0Blood loss\xa0x\xa0\xa0\xa0\xa0Birth weight\xa0x\xa0\xa0\xa0\xa0apgar scores (1 and 5\xa0min)\xa0x\xa0\xa0\xa0\xa0adverse outcomes\xa0x\xa0\xa0\xa0\xa0Placenta & Cord blood\xa0x\xa0\xa0\xa0\xa0Stool\xa0\xa0\xa0X3\xa0\xa0Breastmilk\xa0X4\xa0\xa0\xa0\xa0\n1: all measurements taken in the mother,2: measurements taken in newborn at Birth,3measurements taken in infant,4: collected from mother at 6\xa0weeks.']	N/A	N/A	[('GO_0007567', 'parturition', 31, 'Birth'), ('GO_0042633', 'hair cycle', 139, 'BirthX'), ('UBERON_0000178', 'blood', 665, 'Blood'), ('CHEBI_5646', 'Hellicoside', 686, 'HemoglobinX'), ('CHEBI_17234', 'glucose', 702, 'Glucose'), ('PR_000008919', 'interferon alpha-6', 751, 'InsulinXX2'), ('GO_0007567', 'parturition', 901, 'Birth'), ('GO_0007129', 'homologous chromosome pairing at meiosis', 965, 'Premature'), ('UBERON_0000178', 'blood', 987, 'Blood'), ('GO_0007567', 'parturition', 1003, 'Birth'), ('UBERON_0001987', 'placenta', 1075, 'Placenta'), ('UBERON_0000948', 'heart', 1086, 'Cord'), ('UBERON_0001988', 'feces', 1102, 'Stool'), ('UBERON_0012353', 'fin skeleton', 1110, 'X3'), ('UBERON_0013538', 'Brodmann (1909) area 7', 1114, 'Breastmilk'), ('UBERON_2002112', 'preural 3 vertebra', 1125, 'X4'), ('GO_0007567', 'parturition', 1208, 'birth')]
PMC3702421	6/2013	S99-PMC3702421	['all non-diabetic mothers will undergo the 75-gram Oral Glucose tolerance test (ogtt) between 24–28\xa0weeks of Gestation.']	N/A	N/A	[('UBERON_0000165', 'mouth', 50, 'oral'), ('CHEBI_17234', 'glucose', 55, 'glucose'), ('GO_0007565', 'female pregnancy', 108, 'gestation')]
PMC3702421	6/2013	S100-PMC3702421	['this test is chosen to avoid the high false negative rate using the 50\xa0gram Glucose challenge test among some non-white populations [28].']	N/A	N/A	[('CHEBI_17234', 'glucose', 76, 'glucose')]
PMC3702421	6/2013	S116-PMC3702421	['an annual Blood sample will be collected from the infant to measure the complete Blood count to screen for iron deficiency anemia, and for analysis of Glucose, Insulin, and Lipids.']	N/A	N/A	[('UBERON_0000178', 'blood', 10, 'blood'), ('UBERON_0000178', 'blood', 81, 'blood'), ('CHEBI_17234', 'glucose', 151, 'glucose'), ('PR_000045358', 'insulin family protein', 160, 'insulin'), ('CHEBI_18059', 'lipid', 173, 'lipids')]
PMC3702421	6/2013	S153-PMC3702421	['there is also sufficient power to detect an absolute difference of 3.24% body fat between top and bottom quartile group extremes (e.g., maternal Glucose values or dietary factors).']	N/A	N/A	[('CHEBI_17234', 'glucose', 145, 'glucose')]
PMC3718280	6/2013	S31-PMC3718280	['measurements in maternal and Cord Blood\nmaternal Blood was collected at 24-28 weeks of Gestation, after an 8-14 hour fast, one hour after Ingestion of a 50g Glucose drink.']	N/A	N/A	[('UBERON_0002240', 'spinal cord', 29, 'cord'), ('UBERON_0000178', 'blood', 34, 'blood'), ('UBERON_0000178', 'blood', 49, 'blood'), ('GO_0007565', 'female pregnancy', 87, 'gestation'), ('GO_0007631', 'feeding behavior', 138, 'ingestion'), ('CHEBI_17234', 'glucose', 157, 'glucose')]
PMC3720837	7/2013	S75-PMC3720837	["parameters related to the Metabolism Of Glucose and Lipids (Triglycerides, total Cholesterol, high-density lipoproteins Cholesterol [Hdl-C] and low-density lipoproteins Cholesterol [Ldl-C]) were measured in maternal and foetal Plasma and Allantoic and Amniotic Fluids with a clinical chemistry analyzer (screen point, hospitex diagnostics, sesto fiorentino, italy), according to the manufacturer's instructions."]	N/A	N/A	[('GO_0009554', 'megasporogenesis', 26, 'metabolism of glucose'), ('CHEBI_17234', 'glucose', 40, 'glucose'), ('CHEBI_18059', 'lipid', 52, 'lipids'), ('GO_0008610', 'lipid biosynthetic process', 52, 'lipids'), ('CHEBI_17855', 'triglyceride', 60, 'triglycerides'), ('CHEBI_16113', 'cholesterol', 81, 'cholesterol'), ('CHEBI_16113', 'cholesterol', 120, 'cholesterol'), ('PR_000008530', 'hairy/enhancer-of-split related with YRPW motif-like protein', 133, 'HDL-c'), ('CHEBI_16113', 'cholesterol', 169, 'cholesterol'), ('PR_000009791', 'LIM/homeobox protein Lhx1', 182, 'LDL-c'), ('UBERON_0001969', 'blood plasma', 227, 'plasma'), ('UBERON_0010898', 'gastralium', 238, 'allantoic ...'), ('UBERON_0000053', 'macula lutea', 252, 'amniotic fluids')]
PMC3720837	7/2013	S112-PMC3720837	['parameters related to Glucose and Lipid Metabolism in foetal Plasma are described intables 2and3.']	N/A	N/A	[('CHEBI_17234', 'glucose', 22, 'glucose'), ('GO_0007369', 'gastrulation', 22, 'glucose ...'), ('CHEBI_18059', 'lipid', 34, 'lipid'), ('GO_0006629', 'lipid metabolic process', 34, 'lipid metabolism'), ('UBERON_0001969', 'blood plasma', 61, 'plasma')]
PMC3720837	7/2013	S116-PMC3720837	['Glucose concentrations in Plasma and Allantoic and Amniotic Fluids of iberian purebred and lean crossbreed foetuses.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'glucose'), ('UBERON_0001969', 'blood plasma', 26, 'plasma'), ('UBERON_0010898', 'gastralium', 37, 'allantoic ...'), ('UBERON_0000053', 'macula lutea', 51, 'amniotic fluids')]
PMC3734354	7/2013	S13-PMC3734354	['most fundamentally, and throughout Life, energy to fuel the Brain comes from dietary Intake, mainly in the form of Glucose.']	N/A	N/A	[('UBERON_0000104', 'life cycle', 35, 'life'), ('UBERON_0000955', 'brain', 60, 'brain'), ('GO_0007631', 'feeding behavior', 85, 'intake'), ('CHEBI_17234', 'glucose', 115, 'glucose')]
PMC3736889	11/2010	S26-PMC3736889	['the control Chow diet contained proteins, 23.2%; fiber, 3.8%; Starch, 39.5%; Glucose, 0.29%; Fructose, 0.34%; Sucrose, 3.38%; ash, 6.6% and 5% fat (agribrands purina inc, on, canada).']	N/A	N/A	[('CHEBI_33290', 'food', 12, 'chow'), ('CHEBI_28017', 'starch', 62, 'starch'), ('CHEBI_17234', 'glucose', 77, 'glucose'), ('CHEBI_28757', 'fructose', 93, 'fructose'), ('CHEBI_17992', 'sucrose', 110, 'sucrose')]
PMC3736889	11/2010	S34-PMC3736889	['Blood Glucose concentrations were measured using a commercially available Glucometer (lifescan inc, ca, usa) in the fasted Animals from the Tail Blood at the time of sacrificing the Animals.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('CHEBI_17234', 'glucose', 6, 'glucose'), ('CHEBI_24321', 'glutamo group', 74, 'glucometer'), ('NCBITaxon_33208', 'Metazoa', 123, 'animals'), ('UBERON_0002415', 'tail', 140, 'tail'), ('UBERON_0000178', 'blood', 145, 'blood'), ('NCBITaxon_33208', 'Metazoa', 182, 'animals')]
PMC3736889	11/2010	S57-PMC3736889	['no differences were found among the offspring for either fasting Plasma Glucose or nefa concentrations (table 2).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 65, 'plasma'), ('CHEBI_17234', 'glucose', 72, 'glucose')]
PMC3740243	8/2013	S89-PMC3740243	['dietary factors such as Pufas and Glucose, as well as changes in the Gut microbiota, are able to trigger a chronic low-grade inflammatory profile initially in White Adipose Tissue (Wat).']	N/A	N/A	[('CHEBI_86926', 'S a S b S', 24, 'PUFAs'), ('CHEBI_17234', 'glucose', 34, 'glucose'), ('UBERON_0001555', 'digestive tract', 69, 'gut'), ('UBERON_0001347', 'white adipose tissue', 159, 'white adipose tissue'), ('UBERON_0006337', 'distal early tubule', 181, 'WAT')]
PMC3742769	8/2013	S45-PMC3742769	['from these samples, we measured partial pressures of Carbon Dioxide and oxygen, ph, and Blood Lactate and Glucose levels with a radiometer abl 800 Blood gas analyzer (radiometer, copenhagen, denmark).']	N/A	N/A	[('CHEBI_16526', 'carbon dioxide', 53, 'carbon dioxide'), ('UBERON_0000178', 'blood', 88, 'blood'), ('CHEBI_24996', 'lactate', 94, 'lactate'), ('CHEBI_17234', 'glucose', 106, 'glucose'), ('UBERON_0000178', 'blood', 147, 'blood')]
PMC3742769	8/2013	S117-PMC3742769	['a: ph; b: paco2; c: pao2; d: Blood Lactate concentration; e: Blood Glucose concentration.']	N/A	N/A	[('UBERON_0000178', 'blood', 29, 'Blood'), ('CHEBI_24996', 'lactate', 35, 'lactate'), ('UBERON_0000178', 'blood', 61, 'Blood'), ('CHEBI_17234', 'glucose', 67, 'glucose')]
PMC3742769	8/2013	S119-PMC3742769	['sevo treatment could decrease ph (a) due to hypercarbia (b) and increase the Blood Glucose concentration; n\u200a=\u200a3 at each time.']	N/A	N/A	[('UBERON_0000178', 'blood', 77, 'blood'), ('CHEBI_17234', 'glucose', 83, 'glucose')]
PMC3743371	7/2013	S9-PMC3743371	['[1]\nmaternal hyperglycemia causes a greater Transfer Of Glucose to the fetus, causing fetal hyperinsulinemia and an overgrowth of Insulin-sensitive (mainly Adipose) Tissues, with excessive fetal growth, resulting in more trauma at Birth, Shoulder dystocia and Perinatal deaths.']	N/A	N/A	[('GO_0006098', 'pentose-phosphate shunt', 44, 'transfer of glucose'), ('CHEBI_17234', 'glucose', 56, 'glucose'), ('PR_000045358', 'insulin family protein', 130, 'insulin'), ('UBERON_2000251', 'adipose fin', 156, 'adipose'), ('UBERON_0000479', 'tissue', 165, 'tissues'), ('GO_0007567', 'parturition', 231, 'birth'), ('UBERON_0001467', 'shoulder', 238, 'shoulder'), ('GO_0036268', 'swimming', 260, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 260, 'perinatal')]
PMC3743371	7/2013	S11-PMC3743371	['[3] Carbohydrates Intake with a low-Glycemic index (gi) result in smaller increase in Postprandial Glucose concentration than after high gi diet in normal and also type 2 diabetic patients.']	N/A	N/A	[('CHEBI_16646', 'carbohydrate', 4, 'Carbohydrates'), ('GO_0007631', 'feeding behavior', 18, 'intake'), ('GO_0006096', 'glycolytic process', 36, 'glycemic'), ('GO_0007567', 'parturition', 86, 'postprandial'), ('CHEBI_17234', 'glucose', 99, 'glucose')]
PMC3743371	7/2013	S20-PMC3743371	['fasting Plasma Glucose 92 mg/dl\none-hour Plasma Glucose 180 mg/dl\ntwo-hour Plasma Glucose 153 mg/dlthe monitoring criteria for gdm considered as fasting Plasma Glucose ≤ 90 mg/dl and 2 hr pp Plasma Glucose ≤ 120 mg/dl.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 8, 'plasma'), ('CHEBI_17234', 'glucose', 15, 'glucose'), ('UBERON_0001969', 'blood plasma', 41, 'plasma'), ('CHEBI_17234', 'glucose', 48, 'glucose'), ('UBERON_0001969', 'blood plasma', 75, 'plasma'), ('CHEBI_17234', 'glucose', 82, 'glucose'), ('UBERON_0001969', 'blood plasma', 153, 'plasma'), ('CHEBI_17234', 'glucose', 160, 'glucose'), ('UBERON_0001969', 'blood plasma', 191, 'plasma'), ('CHEBI_17234', 'glucose', 198, 'glucose')]
PMC3743371	7/2013	S21-PMC3743371	['[8]\npatients were either ifg (fbs > 92, impaired fasting Glucose) or igt (fbs < 92; igt 1 h, 2 h > 180, 153 mg/dl; impaired Glucose tolerance).']	N/A	N/A	[('CHEBI_17234', 'glucose', 57, 'glucose'), ('CHEBI_17234', 'glucose', 124, 'glucose')]
PMC3743371	7/2013	S33-PMC3743371	['after two weeks women who achieved fbs and bs 2 hr pp Blood Glucose Control continued their diet, otherwise commenced Insulin treatment\n\ncaption (table-wrap): table 1\n\ncomposition of low glycemic load diet with 1800 kcal administrated to diabetics patients*\n\nstatistical analysis\ndata are reported as mean ± sd.']	N/A	N/A	[('UBERON_0000178', 'blood', 54, 'blood'), ('CHEBI_17234', 'glucose', 60, 'glucose'), ('GO_0065007', 'biological regulation', 68, 'control'), ('PR_000045358', 'insulin family protein', 118, 'insulin')]
PMC3743371	7/2013	S34-PMC3743371	['Blood Glucose data were analyzed by independent sample t -test and chi-square test to compare Blood Glucose concentration before and after intervention and between two groups of “fiber” and “without fiber”.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('CHEBI_17234', 'glucose', 6, 'glucose'), ('UBERON_0000178', 'blood', 94, 'blood'), ('CHEBI_17234', 'glucose', 100, 'glucose')]
PMC3743371	7/2013	S35-PMC3743371	['Blood Glucose monitoring\nafter two weeks dietary intervention Plasma Blood Glucose monitored using fasting Blood Glucose and 2 hours Postprandial Plasma Blood Glucose.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('CHEBI_17234', 'glucose', 6, 'glucose'), ('UBERON_0001969', 'blood plasma', 62, 'plasma'), ('UBERON_0000178', 'blood', 69, 'blood'), ('CHEBI_17234', 'glucose', 75, 'glucose'), ('UBERON_0000178', 'blood', 107, 'blood'), ('CHEBI_17234', 'glucose', 113, 'glucose'), ('GO_0007567', 'parturition', 133, 'postprandial'), ('UBERON_0001969', 'blood plasma', 146, 'plasma'), ('UBERON_0000178', 'blood', 153, 'blood'), ('CHEBI_17234', 'glucose', 159, 'glucose')]
PMC3743371	7/2013	S40-PMC3743371	['based on diagnosis of gdm all participated subjects were diabetes without significant differences in fasting Blood Glucose of two groups at the beginning of the study (100.4 ± 16.3 and 108.0 ± 20.3 in “fiber” and “without fiber” groups respectively, p = 0.2).']	N/A	N/A	[('UBERON_0000178', 'blood', 109, 'blood'), ('CHEBI_17234', 'glucose', 115, 'glucose')]
PMC3743371	7/2013	S41-PMC3743371	['in “fiber” group fasting Blood Glucose concentration before intervention and after intervention were 100.4 ± 16.3 and 86.3 ± 11.3 respectively which resulted in 14% (14 mlg/dl) reduction ( p = 0.001).']	N/A	N/A	[('UBERON_0000178', 'blood', 25, 'blood'), ('CHEBI_17234', 'glucose', 31, 'glucose')]
PMC3743371	7/2013	S45-PMC3743371	['caption (table-wrap): table 2\n\ncomparison of Blood Glucose concentration between “fiber” and “without fiber” groups\nthe Postprandial Blood Glucose in two groups of “fiber” and “without fiber” after intervention were 115.1 ± 18.1 and 136.9 ± 18.7 respectively, which the difference was significant ( p = 0.003) [table 2].']	N/A	N/A	[('UBERON_0000178', 'blood', 45, 'blood'), ('CHEBI_17234', 'glucose', 51, 'glucose'), ('GO_0007567', 'parturition', 120, 'postprandial'), ('UBERON_0000178', 'blood', 133, 'blood'), ('CHEBI_17234', 'glucose', 139, 'glucose')]
PMC3743371	7/2013	S46-PMC3743371	["regarding to Blood Glucose Control based our study's criteria, 11 (61.1%) patients in “fiber” group and 3 (23.1%) patients in “without fiber” groups achieved Blood Glucose Control (chi-square, p = 0.04) [table 3]."]	N/A	N/A	[('UBERON_0000178', 'blood', 13, 'blood'), ('CHEBI_17234', 'glucose', 19, 'glucose'), ('GO_0046323', 'glucose import', 19, 'glucose control'), ('UBERON_0000178', 'blood', 158, 'blood'), ('CHEBI_17234', 'glucose', 164, 'glucose'), ('GO_0065007', 'biological regulation', 172, 'control')]
PMC3743371	7/2013	S63-PMC3743371	['the mechanism behind the fact that the lgl diet plus fiber Intake was more effective in Blood Glucose of gdm subjects is that fiber slows Carbohydrate absorption and reducing gi of meal.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 59, 'intake'), ('UBERON_0000178', 'blood', 88, 'blood'), ('CHEBI_17234', 'glucose', 94, 'glucose'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 138, 'carbohydrate')]
PMC3751294	8/2013	S139-PMC3751294	['fructose\nfructose, an Isomer of Glucose, is a natural Sugar found in many fruits.']	N/A	N/A	[('SO_0001017', 'silent_mutation', 22, 'isomer'), ('CHEBI_17234', 'glucose', 32, 'glucose'), ('CHEBI_24870', 'ion', 54, 'sugar')]
PMC3751294	8/2013	S156-PMC3751294	['additionally, Fructose does not directly stimulate Insulin secretion and has a low Glycemic index, which results in smaller increments in Plasma Glucose levels in healthy Individuals and those with t2d [99].']	N/A	N/A	[('CHEBI_28757', 'fructose', 14, 'fructose'), ('PR_000045358', 'insulin family protein', 51, 'insulin'), ('GO_0006096', 'glycolytic process', 83, 'glycemic'), ('UBERON_0001969', 'blood plasma', 138, 'plasma'), ('CHEBI_17234', 'glucose', 145, 'glucose'), ('NCBITaxon_1', 'root', 171, 'individuals')]
PMC3751294	8/2013	S173-PMC3751294	['in addition, added Fructose (< 50\xa0g/day) has no deleterious effect on Triglyceride levels, Glucose Control, or Insulin resistance.']	N/A	N/A	[('CHEBI_28757', 'fructose', 19, 'fructose'), ('CHEBI_17855', 'triglyceride', 70, 'triglyceride'), ('CHEBI_17234', 'glucose', 91, 'glucose'), ('GO_0046323', 'glucose import', 91, 'glucose control'), ('PR_000045358', 'insulin family protein', 111, 'insulin')]
PMC3751294	8/2013	S176-PMC3751294	['diets high in added-Sugars promote Visceral adiposity, dyslipidemia, and Insulin resistance/Glucose intolerance [28,91,108-111]—all components of the mets [112].']	N/A	N/A	[('CHEBI_26822', 'sulfide', 20, 'sugars'), ('UBERON_0002075', 'viscus', 35, 'visceral'), ('PR_000045358', 'insulin family protein', 73, 'insulin'), ('CHEBI_17234', 'glucose', 92, 'glucose')]
PMC3751294	8/2013	S202-PMC3751294	['total Sugars were defined as the sum of three free Monosaccharides (Glucose, Fructose, and Galactose) and three free Disaccharides (Sucrose, Lactose, and Maltose).']	N/A	N/A	[('CHEBI_26822', 'sulfide', 6, 'sugars'), ('CHEBI_35381', 'monosaccharide', 51, 'monosaccharides'), ('CHEBI_17234', 'glucose', 68, 'glucose'), ('CHEBI_28757', 'fructose', 77, 'fructose'), ('CHEBI_28260', 'galactose', 91, 'galactose'), ('CHEBI_36649', 'tellurium hydride', 117, 'disaccharides'), ('CHEBI_17992', 'sucrose', 132, 'sucrose'), ('CHEBI_17716', 'lactose', 141, 'lactose'), ('CHEBI_30981', 'digitoxose', 154, 'maltose')]
PMC3756974	8/2013	S142-PMC3756974	['for example, fetal malnutrition was an early-Life inducer of Glucose intolerance and obesity [30–32].']	N/A	N/A	[('UBERON_0000104', 'life cycle', 45, 'life'), ('CHEBI_17234', 'glucose', 61, 'glucose')]
PMC3759332	9/2013	S66-PMC3759332	['to examine circulating Sugars in offspring, we extracted Hemolymph from wl3 males and measured Glucose and Trehalose content.']	N/A	N/A	[('CHEBI_26822', 'sulfide', 23, 'sugars'), ('UBERON_0001011', 'hemolymph', 57, 'hemolymph'), ('CHEBI_17234', 'glucose', 95, 'glucose'), ('CHEBI_27081', 'transition element atom', 107, 'trehalose')]
PMC3759332	9/2013	S67-PMC3759332	['both Hemolymph Glucose and Hemolymph Trehalose were significantly increased in hs-ls when compared with control ls-ls Animals (fig.']	N/A	N/A	[('UBERON_0001011', 'hemolymph', 5, 'hemolymph'), ('CHEBI_17234', 'glucose', 15, 'glucose'), ('UBERON_0001011', 'hemolymph', 27, 'hemolymph'), ('CHEBI_27081', 'transition element atom', 37, 'trehalose'), ('NCBITaxon_33208', 'Metazoa', 118, 'animals')]
PMC3759332	9/2013	S77-PMC3759332	['(b) Hemolymph Glucose and Trehalose concentrations from wl3 offspring.']	N/A	N/A	[('UBERON_0001011', 'hemolymph', 4, 'Hemolymph'), ('CHEBI_17234', 'glucose', 14, 'glucose'), ('CHEBI_27081', 'transition element atom', 26, 'trehalose')]
PMC3759332	9/2013	S83-PMC3759332	['3a) and Glucose (fig.']	N/A	N/A	[('CHEBI_17234', 'glucose', 8, 'glucose')]
PMC3759332	9/2013	S89-PMC3759332	['in offspring from ls-Fed maternal Flies, an hs diet (ls-hs) elicited a further reduction in weight and Glucose (fig.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 21, 'fed'), ('NCBITaxon_10088', 'Mus <genus>', 34, 'flies'), ('CHEBI_17234', 'glucose', 103, 'glucose')]
PMC3759332	9/2013	S93-PMC3759332	['specifically, an hs diet caused a greater reduction in Glucose in hs-hs offspring than that seen in ls-hs (fig.']	N/A	N/A	[('CHEBI_17234', 'glucose', 55, 'glucose')]
PMC3759332	9/2013	S120-PMC3759332	['(a,b) qrt-pcr analysis of mrna from ml3 male offspring for Genes involved in Lipid Metabolism ( cg17191 , Lip3 , Fas , dacc , Cpt1 , dfoxo ) and Carbohydrate Metabolism [ cg4797 (Glucose transporter), pyk , Eno , Pgi , Tps1 , Pdk , cg15400 (Glucose-6-phosphatase), dhr38].']	N/A	N/A	[('SO_0000704', 'gene', 59, 'genes'), ('CHEBI_18059', 'lipid', 77, 'lipid'), ('GO_0006629', 'lipid metabolic process', 77, 'lipid metabolism'), ('PR_000010000', 'lysozyme g-like protein 2', 106, 'Lip3'), ('PR_000007706', '3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase FUT3', 113, 'Fas'), ('PR_000004970', 'calcium-binding and coiled-coil domain-containing protein 1', 126, 'Cpt1'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 145, 'carbohydrate'), ('GO_0005975', 'carbohydrate metabolic process', 145, 'carbohydrate metabolism'), ('CHEBI_17234', 'glucose', 179, 'glucose'), ('PR_000007020', 'ETS-related transcription factor Elf-1', 207, 'Eno'), ('PR_000012270', 'pappalysin-1', 213, 'Pgi'), ('PR_000016880', '5,6-dihydroxyindole-2-carboxylic acid oxidase', 219, 'Tps1'), ('PR_000012224', 'glycodelin', 226, 'Pdk'), ('CHEBI_17234', 'glucose', 241, 'glucose')]
PMC3759332	9/2013	S153-PMC3759332	['Transcripts of Gene involved in Lipid Metabolism: cg17191 (lipase), Fas , Cpt1, Lip3 , Dfoxo ; and Carbohydrate Metabolism: cg4797 (Glucose transporter), pyk , eno and dhr38 .']	N/A	N/A	[('SO_0000673', 'transcript', 0, 'Transcripts'), ('SO_0000704', 'gene', 15, 'gene'), ('CHEBI_18059', 'lipid', 32, 'lipid'), ('GO_0006629', 'lipid metabolic process', 32, 'lipid metabolism'), ('PR_000007706', '3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase FUT3', 68, 'Fas'), ('PR_000004970', 'calcium-binding and coiled-coil domain-containing protein 1', 74, 'Cpt1'), ('PR_000010000', 'lysozyme g-like protein 2', 80, 'Lip3'), ('PR_000006460', 'dihydroorotate dehydrogenase (quinone), mitochondrial', 87, 'dFOXO'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 99, 'carbohydrate'), ('GO_0005975', 'carbohydrate metabolic process', 99, 'carbohydrate metabolism'), ('CHEBI_17234', 'glucose', 132, 'glucose')]
PMC3759332	9/2013	S175-PMC3759332	['wl3 total body composition of f2generation male offspring (a–c) [(a) Glucose, (b) Trehalose, (c) Tag] and females (d–f) [(d) Glucose, (e) Trehalose, (f) Tag].']	N/A	N/A	[('CHEBI_17234', 'glucose', 69, 'glucose'), ('CHEBI_27081', 'transition element atom', 82, 'trehalose'), ('CHEBI_17855', 'triglyceride', 97, 'TAG'), ('CHEBI_17234', 'glucose', 125, 'glucose'), ('CHEBI_27081', 'transition element atom', 138, 'trehalose'), ('CHEBI_17855', 'triglyceride', 153, 'TAG')]
PMC3759332	9/2013	S182-PMC3759332	['specifically, we found that wl3 offspring exhibited increased Whole Body and Hemolymph Glucose and Trehalose, and modest reductions in Glycogen and Cholesterol.']	N/A	N/A	[('UBERON_0000468', 'multicellular organism', 62, 'whole body'), ('UBERON_0001011', 'hemolymph', 77, 'hemolymph'), ('CHEBI_17234', 'glucose', 87, 'glucose'), ('CHEBI_27081', 'transition element atom', 99, 'trehalose'), ('CHEBI_24384', 'glycogens', 135, 'glycogen'), ('CHEBI_16113', 'cholesterol', 148, 'cholesterol')]
PMC3759332	9/2013	S183-PMC3759332	['increased whole body Glucose and Trehalose persisted in the f2generation offspring.']	N/A	N/A	[('CHEBI_17234', 'glucose', 21, 'glucose'), ('CHEBI_27081', 'transition element atom', 33, 'trehalose')]
PMC3759332	9/2013	S267-PMC3759332	['whole body Glucose, Trehalose and Glycogen content were determined by homogenizing pooled groups of six wl3 or eight Adult Animals in pbs or pbs + 0.1% Tween.']	N/A	N/A	[('CHEBI_17234', 'glucose', 11, 'glucose'), ('CHEBI_27081', 'transition element atom', 20, 'trehalose'), ('CHEBI_24384', 'glycogens', 34, 'glycogen'), ('UBERON_0007023', 'adult organism', 117, 'adult'), ('NCBITaxon_33208', 'Metazoa', 123, 'animals'), ('CHEBI_53422', 'polysorbate', 152, 'Tween')]
PMC3759332	9/2013	S269-PMC3759332	['for Glucose measurements, 2 μl of homogenate was combined with 98 μl of infinity™ Glucose hexokinase liquid stable Reagent (fisher) and incubated at 37°c for 15 minutes.']	N/A	N/A	[('CHEBI_17234', 'glucose', 4, 'glucose'), ('CHEBI_17234', 'glucose', 82, 'Glucose'), ('CHEBI_33893', 'reagent', 115, 'Reagent')]
PMC3759332	9/2013	S277-PMC3759332	['hemolymph Glucose and Trehalose measurements\nhemolymph was pooled from ten Larvae to obtain ∼1 μl for assays.']	N/A	N/A	[('CHEBI_17234', 'glucose', 10, 'glucose'), ('CHEBI_27081', 'transition element atom', 22, 'trehalose'), ('UBERON_0002548', 'larva', 75, 'larvae')]
PMC3760821	9/2013	S53-PMC3760821	['exclusion criteria for the control subjects were as follows: presence of Glucose intolerance on routine screening[24], previous Gestational diabetes mellitus, or a first-degree relative with diabetes mellitus.']	N/A	N/A	[('CHEBI_17234', 'glucose', 73, 'glucose'), ('GO_0007565', 'female pregnancy', 128, 'gestational')]
PMC3794936	10/2013	S184-PMC3794936	['body weight (b) Blood Glucose (c) Serum Triglyceride (d) Liver Triglyceride of Gcn2;db dko ( Gcn2 −/−; db/db ) and db/db ( Gcn2+/+;db/db ) Mice (mean ± sem, n\u200a=\u200a4, *p<0.05, Gcn2;db dko versus db/d b Mice).']	N/A	N/A	[('UBERON_0000178', 'blood', 16, 'Blood'), ('CHEBI_17234', 'glucose', 22, 'glucose'), ('UBERON_0001977', 'blood serum', 34, 'Serum'), ('CHEBI_17855', 'triglyceride', 40, 'triglyceride'), ('UBERON_0002107', 'liver', 57, 'Liver'), ('CHEBI_17855', 'triglyceride', 63, 'triglyceride'), ('PR_000007759', 'gamma-aminobutyric acid receptor-associated protein-like 2', 79, 'Gcn2'), ('PR_000007759', 'gamma-aminobutyric acid receptor-associated protein-like 2', 93, 'Gcn2'), ('PR_000007759', 'gamma-aminobutyric acid receptor-associated protein-like 2', 123, 'Gcn2'), ('NCBITaxon_10088', 'Mus <genus>', 139, 'mice'), ('PR_000007759', 'gamma-aminobutyric acid receptor-associated protein-like 2', 173, 'Gcn2'), ('NCBITaxon_10088', 'Mus <genus>', 199, 'mice')]
PMC3794936	10/2013	S343-PMC3794936	['aspects of Glucose and Fat Metabolism are coordinated by both afferent and Efferent signaling through the Hepatic branch of the Vagus Nerve[62],[63].']	N/A	N/A	[('CHEBI_17234', 'glucose', 11, 'glucose'), ('GO_0006006', 'glucose metabolic process', 11, 'glucose ... fat metabolism'), ('UBERON_0006798', 'efferent nerve', 75, 'efferent'), ('UBERON_0002107', 'liver', 106, 'hepatic'), ('UBERON_0001759', 'vagus nerve', 128, 'vagus nerve')]
PMC3809191	1/2013	S1-PMC3809191	['methodology: Gestational diabetes was diagnosed with 75 gram oral Glucose tolerance test.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 13, 'Gestational'), ('CHEBI_17234', 'glucose', 66, 'glucose')]
PMC3809191	1/2013	S8-PMC3809191	['there was no significant association between Vitamin D levels and fasting Glucose, Insulin and hba1c.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('CHEBI_17234', 'glucose', 74, 'glucose'), ('PR_000045358', 'insulin family protein', 83, 'insulin')]
PMC3809191	1/2013	S13-PMC3809191	['the diagnosis of Gestational diabetes was determined by the guidelines proposed by the international association of diabetes and Pregnancy study groups (iadpsg) with a 75-gr 2 hour oral Glucose tolerance test at 24-32 weeks’ Gestation.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 17, 'gestational'), ('GO_0007565', 'female pregnancy', 129, 'Pregnancy'), ('CHEBI_17234', 'glucose', 186, 'glucose'), ('GO_0007565', 'female pregnancy', 225, 'gestation')]
PMC3809191	1/2013	S14-PMC3809191	['gdm is diagnosed when the fasting Serum Glucose is 92\xa0mg/dl or greater, or the 1-hour value is 180\xa0mg/dl or greater or when the 2-hour value is 153\xa0mg/dl or greater.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 34, 'serum'), ('CHEBI_17234', 'glucose', 40, 'glucose')]
PMC3809191	1/2013	S22-PMC3809191	['Serum Glucose was measured by using an enzymatic in vitro test.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_17234', 'glucose', 6, 'glucose')]
PMC3809191	1/2013	S24-PMC3809191	['Serum Ca, p, Mg, (alp) and Glucose levels were measured using the enzymatic colorimetric method\xa0 (roche integra 800), while\xa0 Serum 25 Hydroxy Vitamin D 25(Oh) D levels were measured during the fall and the winter with a chemiluminescent immunassay method (cmia) (architect i1000 system, abbott, usa) normal ranges were between (na): 15.7-60.3ng/ml (summer), 8.8-46.3ng/ml (winter).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_32588', 'potassium chloride', 6, 'Ca'), ('CHEBI_34829', 'Medrysone', 13, 'Mg'), ('CHEBI_17234', 'glucose', 27, 'glucose'), ('UBERON_0001977', 'blood serum', 125, 'serum'), ('CHEBI_72760', 'tryprostatin B', 131, '25 hydroxy vitamin'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 150, 'D'), ('PR_000004270', 'AT-rich interactive domain-containing protein 5B', 150, 'D 25(OH) D'), ('CHEBI_71657', 'versiconol acetate', 152, '25(OH) D')]
PMC3809191	1/2013	S31-PMC3809191	['intra and inter-assay coefficients of variation were 0.5-0.6%, and 0.5-0.3% for Ca; 0.5-0.5% and 0.3-0.6% for p. Serum Glucose measured with enzymatic colorimetric assay (c8000 system, abbott, usa) intra and interassay coefficients of variation were 1.98-0.65% and 0.84-0.93% respectively.']	N/A	N/A	[('CHEBI_32588', 'potassium chloride', 80, 'Ca'), ('UBERON_0001977', 'blood serum', 113, 'Serum'), ('CHEBI_17234', 'glucose', 119, 'glucose')]
PMC3809191	1/2013	S42-PMC3809191	['there was no significant difference between Serum Vitamin D and Serum fasting Glucose, Insulin and hba1c levels (table-iii).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 44, 'serum'), ('CHEBI_28384', 'vitamin K', 50, 'Vitamin D'), ('UBERON_0001977', 'blood serum', 64, 'serum'), ('CHEBI_17234', 'glucose', 78, 'glucose'), ('PR_000045358', 'insulin family protein', 87, 'insulin')]
PMC3813450	10/2013	S67-PMC3813450	['Glucose and Fructosamine were measured by means of a clinical chemistry analyzer (saturno 300 plus, crony instruments s.r.l., rome, italy) whilst Insulin was determined by means of a porcine Insulin elisa kit (mercodia ab, uppsala, sweden).']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('CHEBI_24111', 'fructoside', 12, 'fructosamine'), ('PR_000045358', 'insulin family protein', 146, 'insulin'), ('PR_000045358', 'insulin family protein', 191, 'Insulin')]
PMC3813450	10/2013	S69-PMC3813450	['possible changes in beta cell function and Insulin resistance (ir) were assessed by the homeostasis model assessment (homa), using the equations homa-ir = (fins x fpg)/22.5 to assess Insulin resistance [14] and Homa-Β = (20 x fins)/(fpg-3.5) to assess beta cell function [15]; fins is fasting Plasma Insulin concentration in u/l and fpg is fasting Plasma Glucose concentration in mmol/l.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 43, 'insulin'), ('PR_000045358', 'insulin family protein', 183, 'insulin'), ('PR_000008689', 'homeobox protein Hox-A13', 211, 'HOMA-β'), ('UBERON_0001969', 'blood plasma', 293, 'plasma'), ('PR_000045358', 'insulin family protein', 300, 'insulin'), ('UBERON_0001969', 'blood plasma', 348, 'plasma'), ('CHEBI_17234', 'glucose', 355, 'glucose')]
PMC3813450	10/2013	S141-PMC3813450	['for Glucose and Fructosamine, and values for Insulin and homa indexes, in male and female Pigs Born from sows Fed, during the entire Pregnancy, with a diet fulfilling 100% (control), 160% (overfed) or 50% of daily maintenance requirements for Gestation (underfed).']	N/A	N/A	[('CHEBI_17234', 'glucose', 4, 'glucose'), ('CHEBI_24111', 'fructoside', 16, 'fructosamine'), ('PR_000045358', 'insulin family protein', 45, 'insulin'), ('NCBITaxon_10088', 'Mus <genus>', 90, 'pigs'), ('GO_0007567', 'parturition', 95, 'born'), ('GO_0007631', 'feeding behavior', 110, 'fed'), ('GO_0007565', 'female pregnancy', 133, 'pregnancy'), ('GO_0007565', 'female pregnancy', 243, 'gestation')]
PMC3813450	10/2013	S188-PMC3813450	['indexes of Carbohydrates and Lipids Metabolism at Adulthood\nassessment of Plasma indexes of Carbohydrates Metabolism showed, overall, higher values of Glucose in overfed Pigs (p<0.005) than in the underfed and late-underfed groups (table 6).']	N/A	N/A	[('CHEBI_16646', 'carbohydrate', 11, 'carbohydrates'), ('CHEBI_18059', 'lipid', 29, 'lipids'), ('GO_0006629', 'lipid metabolic process', 29, 'lipids metabolism'), ('UBERON_0000113', 'post-juvenile adult stage', 50, 'adulthood'), ('UBERON_0001969', 'blood plasma', 74, 'plasma'), ('CHEBI_16646', 'carbohydrate', 92, 'carbohydrates'), ('GO_0005975', 'carbohydrate metabolic process', 92, 'carbohydrates metabolism'), ('CHEBI_17234', 'glucose', 151, 'glucose'), ('NCBITaxon_10088', 'Mus <genus>', 170, 'pigs')]
PMC3813450	10/2013	S191-PMC3813450	['for Glucose, Fructosamine, Triglycerides, total Cholesterol, hdl-Cholesterol and ldl-Cholesterol in male and female Pigs Born from sows Fed, during the entire Pregnancy, with a diet fulfilling 100% (control), 160% (overfed) or 50% of daily maintenance requirements for Gestation (underfed).']	N/A	N/A	[('CHEBI_17234', 'glucose', 4, 'glucose'), ('CHEBI_24111', 'fructoside', 13, 'fructosamine'), ('CHEBI_17855', 'triglyceride', 27, 'triglycerides'), ('CHEBI_16113', 'cholesterol', 48, 'cholesterol'), ('CHEBI_16113', 'cholesterol', 65, 'cholesterol'), ('CHEBI_16113', 'cholesterol', 85, 'cholesterol'), ('NCBITaxon_10088', 'Mus <genus>', 116, 'pigs'), ('GO_0007567', 'parturition', 121, 'born'), ('GO_0007631', 'feeding behavior', 136, 'fed'), ('GO_0007565', 'female pregnancy', 159, 'pregnancy'), ('GO_0007565', 'female pregnancy', 269, 'gestation')]
PMC3813450	10/2013	S242-PMC3813450	['the syndrome is characterized by the presence of at least three of five symptoms: central obesity, impaired Glucose Regulation, Insulin resistance, dyslipidemia (increased Triglyceridemia and low Plasma Hdl-C), and hypertension [44–47].']	N/A	N/A	[('CHEBI_17234', 'glucose', 108, 'glucose'), ('GO_0006094', 'gluconeogenesis', 108, 'glucose regulation'), ('PR_000045358', 'insulin family protein', 128, 'insulin'), ('CHEBI_9675', 'triazolealanine', 172, 'triglyceridemia'), ('UBERON_0001969', 'blood plasma', 196, 'plasma'), ('PR_000008530', 'hairy/enhancer-of-split related with YRPW motif-like protein', 203, 'HDL-c')]
PMC3817352	10/2013	S72-PMC3817352	['gdm was diagnosed on the basis of a 50-g 1-hour Glucose challenge test (gct) and a 75-g 2-hour oral Glucose tolerance test (ogtt) using who criteria [28].']	N/A	N/A	[('CHEBI_17234', 'glucose', 48, 'glucose'), ('CHEBI_17234', 'glucose', 100, 'glucose')]
PMC3818269	11/2013	S51-PMC3818269	['determination of body weight and Plasma Glucose\nat Birth, each littermate from all groups Fed with experimental diets, was weighed and an average Birth weight assigned to each of the three groups.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 33, 'plasma'), ('CHEBI_17234', 'glucose', 40, 'glucose'), ('GO_0007567', 'parturition', 51, 'birth'), ('GO_0007631', 'feeding behavior', 90, 'fed'), ('GO_0007567', 'parturition', 146, 'birth')]
PMC3818269	11/2013	S53-PMC3818269	['after 21 days of Lactation, the male offspring were weighed and Blood Glucose taken, after which they were forced to fast overnight (20:00–09:00).']	N/A	N/A	[('GO_0007595', 'lactation', 17, 'lactation'), ('UBERON_0000178', 'blood', 64, 'blood'), ('CHEBI_17234', 'glucose', 70, 'glucose')]
PMC3818269	11/2013	S54-PMC3818269	['prior to euthanization the following day, Glucose tolerance tests of 2\xa0g/kg Glucose load were performed on the fasted Animals.']	N/A	N/A	[('CHEBI_17234', 'glucose', 42, 'glucose'), ('CHEBI_17234', 'glucose', 76, 'glucose'), ('NCBITaxon_33208', 'Metazoa', 118, 'animals')]
PMC3818269	11/2013	S55-PMC3818269	['Blood samples were drawn from the Tip Of the Tail at 0, 30, 60, 90 and 120\xa0min after administration of the Glucose load.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('UBERON_0010162', 'post-anal tail tip', 34, 'tip of ... tail'), ('CHEBI_17234', 'glucose', 107, 'glucose')]
PMC3818269	11/2013	S56-PMC3818269	['Blood Glucose concentrations were measured with a Glucometer (accu-check active; roche diagnostics, mannheim, germany).']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('CHEBI_17234', 'glucose', 6, 'glucose'), ('CHEBI_24321', 'glutamo group', 50, 'glucometer')]
PMC3818269	11/2013	S155-PMC3818269	['lower Carbohydrate contents causes suppression of Postprandial Glucose increase.']	N/A	N/A	[('CHEBI_16730', 'chloramphenicol 3-acetate', 6, 'carbohydrate'), ('GO_0007567', 'parturition', 50, 'postprandial'), ('CHEBI_17234', 'glucose', 63, 'glucose')]
PMC3818269	11/2013	S161-PMC3818269	['lower Carbohydrate Intake results in lower Postprandial increase in Blood Glucose level, resulting in lower Postprandial Insulin secretion and suppression of Igf-1 Signaling Pathway.']	N/A	N/A	[('CHEBI_16730', 'chloramphenicol 3-acetate', 6, 'carbohydrate'), ('GO_0007631', 'feeding behavior', 19, 'intake'), ('GO_0007567', 'parturition', 43, 'postprandial'), ('UBERON_0000178', 'blood', 68, 'blood'), ('CHEBI_17234', 'glucose', 74, 'glucose'), ('GO_0007567', 'parturition', 108, 'postprandial'), ('PR_000045358', 'insulin family protein', 121, 'insulin'), ('GO_0038100', 'nodal binding', 158, 'IGF-1 signaling pathway'), ('PR_000008929', 'interferon-related developmental regulator 1', 158, 'IGF-1')]
PMC3820434	12/2012	S56-PMC3820434	['administration of recombinant Il-33 to Genetically obese diabetic (ob/ob) Mice led to reduced adiposity and fasting Glucose and increased Glucose tolerance and Insulin sensitivity.']	N/A	N/A	[('PR_000001470', 'interleukin-28B', 30, 'Il-33'), ('SO_0000704', 'gene', 39, 'genetically'), ('NCBITaxon_10088', 'Mus <genus>', 74, 'mice'), ('CHEBI_17234', 'glucose', 116, 'glucose'), ('CHEBI_17234', 'glucose', 138, 'glucose'), ('PR_000045358', 'insulin family protein', 160, 'insulin')]
PMC3820434	12/2012	S64-PMC3820434	['inflamed cls+ obese subjects displayed higher Plasma Insulin, homeostasis model assessment (homa), Triglycerides, Glucose, Blood pressure, High sensitive C-Reactive Protein (Hs-Crp) and lower hdl-Cholesterol, and Brachial Artery flow-mediated dilation compared with lean subjects.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 46, 'plasma'), ('PR_000045358', 'insulin family protein', 53, 'insulin'), ('CHEBI_17855', 'triglyceride', 99, 'triglycerides'), ('CHEBI_17234', 'glucose', 114, 'glucose'), ('UBERON_0000178', 'blood', 123, 'blood'), ('PR_000008550', '3-hydroxyisobutyryl-CoA hydrolase, mitochondrial', 139, 'high'), ('PR_000005890', 'crooked neck-like protein 1', 154, 'C-reactive protein'), ('PR_000006060', 'CWF19-like protein 1', 174, 'hs-CRP'), ('CHEBI_16113', 'cholesterol', 196, 'cholesterol'), ('UBERON_0001398', 'brachial artery', 213, 'brachial artery')]
PMC3820434	12/2012	S84-PMC3820434	['it defined mets components as (1) waist circumference ≥102\u2009cm in men and ≥88\u2009cm in women; (2) fasting Triglycerides ≥150\u2009mg/dl (1.70\u2009mmol/l); (3) hdl-Cholesterol <40\u2009mg/dl (1.03\u2009mmol/l) in men and <50\u2009mg/dl (1.29\u2009mmol/l) in women; (4) Blood pressure ≥130/85\u2009mmhg; (5) fasting-Glucose ≥100\u2009mg/dl (5.55\u2009mmol/l).']	N/A	N/A	[('CHEBI_17855', 'triglyceride', 102, 'triglycerides'), ('CHEBI_16113', 'cholesterol', 150, 'cholesterol'), ('UBERON_0000178', 'blood', 235, 'blood'), ('CHEBI_17234', 'glucose', 276, 'glucose')]
PMC3820434	12/2012	S164-PMC3820434	['mechanistically, exercise training significantly increased the Expression of the Glucose-transporter- (Glut-) 4 [75] and of the Insulin-Receptor-substrate- (Irs-) 1 and the posttranscriptional Regulation Of the Pi3-Kinase Expression [76].']	N/A	N/A	[('GO_0010467', 'gene expression', 63, 'expression'), ('CHEBI_17234', 'glucose', 81, 'glucose'), ('PR_000015069', 'solute carrier family 2, facilitated glucose transporter member 6', 103, 'GLUT'), ('PR_000017527', 'YEATS domain-containing protein 4', 110, '4'), ('PR_000045358', 'insulin family protein', 128, 'insulin'), ('PR_000014368', 'RuvB-like 1', 136, 'receptor'), ('PR_000010220', 'mannose-binding protein C', 156, '('), ('PR_000009159', 'inositol 1,4,5-trisphosphate receptor type 2', 157, 'IRS-) 1'), ('GO_0010468', 'regulation of gene expression', 193, 'regulation of ... expression'), ('PR_000012771', 'polycystic kidney disease protein 1-like 2', 211, 'PI3-kinase')]
PMC3820434	12/2012	S360-PMC3820434	['prolonged therapy with Etanercept, which blocks the action of Tnf- Α , improved fasting Glucose, increased the ratio of high molecular weight to total adiponectin, and decreased Soluble-Intercellular-Adhesion-Molecule- (Sicam-) 1 in obese subjects with abnormal Glucose Homeostasis and significant subclinical inflammation [174].']	N/A	N/A	[('CHEBI_4785', 'enalapril maleate', 23, 'etanercept'), ('PR_000000134', 'tumor necrosis factor alpha', 62, 'TNF- α'), ('CHEBI_17234', 'glucose', 88, 'glucose'), ('PR_000001944', 'transcription factor PU.1', 178, 'soluble-intercellular-adhesion-molecule- ...'), ('GO_0030424', 'axon', 200, 'adhesion'), ('CHEBI_36357', 'polyatomic entity', 209, 'molecule'), ('PR_000014701', 'heparin cofactor 2', 220, 'sICAM-) 1'), ('CHEBI_17234', 'glucose', 262, 'glucose'), ('GO_0042593', 'glucose homeostasis', 262, 'glucose homeostasis')]
PMC3829207	11/2013	S142-PMC3829207	['this syndrome is biochemically characterized by hypophosphatemia, hypomagnesemia, hypokalemia, Glucose intolerance, Fluid overload, and Thiamine deficiency.']	N/A	N/A	[('CHEBI_17234', 'glucose', 95, 'glucose'), ('UBERON_0006314', 'bodily fluid', 116, 'fluid'), ('CHEBI_26948', 'vitamin B1', 136, 'thiamine')]
PMC3850030	9/2013	S38-PMC3850030	['disorders with at least 5% prevalence among Adults included diabetes mellitus, impaired fasting Glucose, impaired Glucose tolerance, obesity, Metabolic syndrome, osteoporosis, osteopenia, mild-moderate hypovitaminosis d, erectile dysfunction, dyslipidemia, and thyroiditis.']	N/A	N/A	[('UBERON_0007023', 'adult organism', 44, 'adults'), ('CHEBI_17234', 'glucose', 96, 'glucose'), ('CHEBI_17234', 'glucose', 114, 'glucose'), ('GO_0008152', 'metabolic process', 142, 'metabolic')]
PMC3850030	9/2013	S469-PMC3850030	['abbreviations\na-dmrs: chronological age; aeds: Antiepileptic Drugs; afc: antral follicle count; amh: antimullerian hormone; apap: Acetaminophen (Paracetamol); ap-dmrs: age-related phenotypes; ar: Androgen receptor; Bm: Bone Marrow; Bpa: Bisphenol A; ccrk: Cell Cycle-related kinase; cdc: centers for disease control; Cns: Central Nervous System; cpgs: Cytosine-phosphate-guanine; ct: computerized tomography; Cxcr4+: C-x-C Chemokine Receptor Type 4; dmrs: differentially methylated regions; edstac: endocrine disruptor screening and testing advisory committee; facs: fluorescence activated cell sorting; fda: Food and Drug administration; Dha: Docosahexaenoic Acid; dna: Deoxyribonucleic Acid; dsm: diagnostic and statistical manual of mental disorders; Edcs: Endocrine-disrupting chemicals; ets: environmental tobacco smoke; f1-cd: control diet; f1-lpd: low-protein-diet; ffq: Food frequency questionnaire; fmri: functional magnetic resonance imaging; gh/igh: Growth Hormone/Insulin-Like Growth Factor 1; gr: glucocorticoid receptor; Hat: Histone Acetylases; hcc: hepatocellular carcinoma; hdac: Histone deacetylases; hfd: high-fat-diet; hpaa: Hypothalamic-Pituitary-Adrenal axis; Hsc: Hematopoietic Stem Cells; ictp: trimeric carboxyterminal telopeptide; infanib: infant Neurological international battery; iq: intelligence quotient; lbw: low-birthweight; lt-hsc: Long-Term Repopulation Of Hematopoietic Stem Cells; lys: lysine; Mgso4: Magnesium Sulfate; Mirna: micro-Ribonucleic Acid; mri: magnetic resonance imaging; Nac: N-Acetylcysteine; nhanes: national health and nutritional examination survey; nhis: national health interview survey; oc: Osteocalcin; O-Glcnac: O-Glcnacylation; ogtt: oral Glucose tolerance test; or: odds ratio; otc: over the counter; pbdes: polybrominated diphenyl ethers; pcos: polycystic Ovary syndrome; pet: positron emission tomography; pfcs: Perfluorinated Compounds; pp: precocious pubarche; psa: Prostate Specific Antigen; rna: Ribonucleic Acid; rt-pcr: reverse transcriptase polymerase chain reaction; scls: Salivary Cotinine levels; Sdf-1: Stromal-Cell-Derived-Factor-1; ses: socio-economic status; Sirnas: short inhibitory ribonucleic Acids; tcf: T-Cell factor; tcscs: Tissue-committed Stem Cells; tedx: the Endocrine disruption exchange; uspstf: u.s. preventive services task force; Vcam-1: Vascular Cell Adhesion Protein 1.']	N/A	N/A	[('CHEBI_35218', 'anthocyanin cation', 47, 'Antiepileptic drugs'), ('CHEBI_2404', 'acetosyringone', 130, 'Acetaminophen'), ('CHEBI_46195', 'paracetamol', 145, 'paracetamol'), ('CHEBI_50113', 'androgen', 196, 'Androgen'), ('UBERON_0005401', 'cerebral hemisphere gray matter', 215, 'BM'), ('UBERON_0002371', 'bone marrow', 219, 'Bone marrow'), ('CHEBI_34018', '(S)-AMPA', 232, 'BPA'), ('CHEBI_33216', 'bisphenol A', 237, 'Bisphenol A'), ('GO_0007049', 'cell cycle', 256, 'Cell cycle'), ('UBERON_0001017', 'central nervous system', 317, 'CNS'), ('UBERON_0001017', 'central nervous system', 322, 'Central nervous system'), ('CHEBI_4056', 'cytochrome', 352, 'Cytosine'), ('PR_000001209', 'C-X-C chemokine receptor type 5', 409, 'CXCR4'), ('CHEBI_51686', 'haematoxylin', 417, 'C-'), ('PR_000005920', 'lambda-crystallin', 417, 'C-'), ('PR_000001215', 'atypical chemokine receptor 2', 420, '-C chemokine receptor type 4'), ('CHEBI_33290', 'food', 609, 'Food'), ('CHEBI_23888', 'drug', 618, 'Drug'), ('CHEBI_17874', 'dihydrozeatin', 639, 'DHA'), ('CHEBI_78869', 'octacosapentaenoic acid', 644, 'Docosahexaenoic acid'), ('CHEBI_86026', 'tRNA threonylcarbamoyladenosine', 671, 'Deoxyribonucleic acid'), ('CL_0002364', 'cortical thymic epithelial cell', 754, 'EDCs'), ('GO_0009790', 'embryo development', 760, 'Endocrine'), ('CHEBI_33290', 'food', 878, 'Food'), ('CHEBI_5542', 'grayanotoxin I', 961, 'Growth Hormone'), ('PR_000008959', 'immunoglobulin heavy constant gamma 1', 976, 'Insulin-like growth factor 1'), ('PR_000008443', 'huntingtin-associated protein 1', 1035, 'HAT'), ('CHEBI_15358', 'histone', 1040, 'Histone'), ('PR_000008454', 'hepatitis A virus cellular receptor 2', 1040, 'Histone acetylases'), ('CHEBI_15358', 'histone', 1097, 'Histone'), ('PR_000027594', 'histone H3', 1097, 'Histone'), ('UBERON_0001898', 'hypothalamus', 1145, 'Hypothalamic'), ('UBERON_0002109', 'pair of nares', 1158, 'pituitary'), ('UBERON_0002369', 'adrenal gland', 1168, 'adrenal'), ('CL_0000037', 'hematopoietic stem cell', 1182, 'HSC'), ('CL_0000037', 'hematopoietic stem cell', 1187, 'Hematopoietic stem cells'), ('GO_0030097', 'hemopoiesis', 1187, 'Hematopoietic'), ('UBERON_0001016', 'nervous system', 1273, 'Neurological'), ('GO_0006099', 'tricarboxylic acid cycle', 1366, 'Long-term'), ('GO_0009450', 'gamma-aminobutyric acid catabolic process', 1376, 'repopulation of'), ('CL_0000037', 'hematopoietic stem cell', 1392, 'hematopoietic stem cells'), ('GO_0016476', 'regulation of embryonic cell shape', 1392, 'hematopoietic stem cells'), ('CHEBI_32599', 'magnesium sulfate', 1431, 'MgSO4'), ('CHEBI_31795', 'magnesium sulfate heptahydrate', 1438, 'Magnesium sulfate'), ('SO_0000276', 'miRNA', 1457, 'miRNA'), ('CHEBI_15986', 'polynucleotide', 1470, 'ribonucleic acid'), ('CHEBI_7421', 'NAC', 1521, 'NAC'), ('CHEBI_70981', '6-formylpterin', 1526, 'N-acetylcysteine'), ('PR_000011634', 'oxidized low-density lipoprotein receptor 1', 1648, 'Osteocalcin'), ('CHEBI_63103', 'NSDB 211', 1661, 'O-GlcNAc'), ('CHEBI_52846', 'cycloalkane ring', 1671, 'O-GlcNAcylation'), ('CHEBI_17234', 'glucose', 1699, 'glucose'), ('UBERON_0000992', 'ovary', 1818, 'ovary'), ('CHEBI_86922', 'Pinoresinol biphenyl', 1875, 'Perfluorinated'), ('CHEBI_36357', 'polyatomic entity', 1890, 'compounds'), ('PR_000001908', 'platelet glycoprotein Ib beta chain', 1931, 'Prostate specific antigen'), ('CHEBI_59132', 'antigen', 1949, 'antigen'), ('CHEBI_15986', 'polynucleotide', 1963, 'Ribonucleic acid'), ('UBERON_0001836', 'saliva', 2044, 'Salivary'), ('CHEBI_18123', 'N-methylnicotinate', 2053, 'cotinine'), ('PR_000014762', 'serine/arginine-rich splicing factor 5', 2070, 'SDF-1'), ('CL_0000810', 'CD4-positive, alpha-beta thymocyte', 2077, 'Stromal-cell'), ('PR_000015629', 'SRSF protein kinase 1', 2077, 'Stromal-cell-derived-factor-1'), ('UBERON_0003891', 'stroma', 2077, 'Stromal'), ('SO_0000646', 'siRNA', 2136, 'siRNAs'), ('CHEBI_37527', 'acid', 2173, 'acids'), ('CL_0000084', 'T cell', 2185, 'T-cell'), ('CL_0000895', 'naive thymus-derived CD4-positive, alpha-beta T cell', 2207, 'Tissue ...'), ('UBERON_0000479', 'tissue', 2207, 'Tissue'), ('CL_0000034', 'stem cell', 2224, 'stem cells'), ('GO_0009790', 'embryo development', 2246, 'Endocrine'), ('PR_000001970', 'vascular cell adhesion protein 1', 2322, 'VCAM-1'), ('CL_0000635', "Deiter's cell", 2330, 'Vascular cell'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 2330, 'Vascular cell adhesion protein 1')]
PMC3855580	10/2013	S5-PMC3855580	['neonatal anthropometry was recorded, and the children’s Glucose and Insulin concentrations were measured at 5, 9.5 and 13.5\xa0years of age.']	N/A	N/A	[('CHEBI_17234', 'glucose', 56, 'glucose'), ('PR_000045358', 'insulin family protein', 68, 'insulin')]
PMC3855580	10/2013	S37-PMC3855580	['Glucose, Insulin and fasting Lipid concentrations were measured at 5 and 9.5\xa0years from a 2\xa0h ogtt [11,14].']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('PR_000045358', 'insulin family protein', 9, 'insulin'), ('CHEBI_18059', 'lipid', 29, 'lipid')]
PMC3855580	10/2013	S38-PMC3855580	['at 13.5\xa0years of age, Glucose, Insulin and Lipid concentrations were measured using fasting Blood samples.']	N/A	N/A	[('CHEBI_17234', 'glucose', 22, 'glucose'), ('PR_000045358', 'insulin family protein', 31, 'insulin'), ('CHEBI_18059', 'lipid', 43, 'lipid'), ('UBERON_0000178', 'blood', 92, 'blood')]
PMC3855580	10/2013	S41-PMC3855580	['Plasma Glucose and Lipid concentrations were measured by standard enzymatic methods (hitachi-902; roche diagnostics, mannheim, germany).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_17234', 'glucose', 7, 'glucose'), ('CHEBI_18059', 'lipid', 19, 'lipid')]
PMC3859677	7/2013	S26-PMC3859677	['full details of the study methodology have been previously reported.27women were recruited at their oral Glucose tolerance test (ogtt) appointment; all women booked for Delivery in bradford are offered a 75\u2005g ogtt at around 26–28\u2005weeks Gestation.']	N/A	N/A	[('CHEBI_17234', 'glucose', 105, 'glucose'), ('GO_0007567', 'parturition', 169, 'delivery'), ('GO_0007565', 'female pregnancy', 236, 'gestation')]
PMC3859677	7/2013	S49-PMC3859677	["maternal weight (seca digital scales) and height (leicester height measure) were measured in light clothing and unshod.27fasting and postload Glucose and fasting Insulin were obtained from the ogtt samples which were assayed immediately after sampling at the biochemistry department of bradford royal infirmary using the Glucose oxidase method on siemen's advia 2400 chemistry autoanalysers and siemen's advia centaur assay."]	N/A	N/A	[('CHEBI_17234', 'glucose', 142, 'glucose'), ('PR_000045358', 'insulin family protein', 162, 'insulin'), ('CHEBI_17234', 'glucose', 321, 'glucose')]
PMC3859677	7/2013	S70-PMC3859677	['smoking, maternal fasting Glucose, parity and living with a partner all masked some of the difference.']	N/A	N/A	[('CHEBI_17234', 'glucose', 26, 'glucose')]
PMC3859677	7/2013	S73-PMC3859677	['caption (fig): figure\xa02\n\nunadjusted and adjustedamean difference in Birth weight (95% ci) between pakistani and white british infants.aadjusted for smoking; alcohol; maternal age; maternal hypertension; maternal fasting Glucose; maternal height; maternal body mass index; parity; Gestation; sex; socioeconomic position (maternal education, housing tenure, receipt of means tested benefits); and living with partner.']	N/A	N/A	[('GO_0007567', 'parturition', 68, 'birth'), ('CHEBI_17234', 'glucose', 220, 'glucose'), ('GO_0007565', 'female pregnancy', 280, 'gestation')]
PMC3859677	7/2013	S79-PMC3859677	['caption (fig): figure\xa03\n\nunadjusted and Adjustedamean difference in Subscapular Skinfold between pakistani and white british infants.aadjusted for smoking; Alcohol; maternal age; maternal hypertension; maternal fasting Glucose; maternal height; maternal body mass index; parity; Gestation; sex; socioeconomic position (maternal education, housing tenure, receipt of means tested benefits); and living with partner.']	N/A	N/A	[('UBERON_0001707', 'nasal cavity', 40, 'adjustedamean'), ('UBERON_0007191', 'anterior paracentral gyrus', 68, 'subscapular skinfold'), ('CHEBI_30879', 'alcohol', 156, 'alcohol'), ('CHEBI_17234', 'glucose', 219, 'glucose'), ('GO_0007565', 'female pregnancy', 279, 'gestation')]
PMC3859677	7/2013	S82-PMC3859677	['caption (fig): figure\xa04\n\nunadjusted and Adjustedamean difference in Triceps Skinfold between pakistani and white british infants.aadjusted for smoking; Alcohol; maternal age; maternal hypertension; maternal fasting Glucose; maternal height; maternal body mass index; parity; Gestation; sex; socioeconomic position (maternal education, housing tenure, receipt of means tested benefits); and living with partner.']	N/A	N/A	[('UBERON_0001707', 'nasal cavity', 40, 'adjustedamean'), ('UBERON_0005299', 'prepuce of clitoris', 68, 'triceps skinfold'), ('CHEBI_30879', 'alcohol', 152, 'alcohol'), ('CHEBI_17234', 'glucose', 215, 'glucose'), ('GO_0007565', 'female pregnancy', 275, 'gestation')]
PMC3859677	7/2013	S88-PMC3859677	['caption (table-wrap): table\xa01\n\nadjusted mean z-score differences in pakistani relative to white british infantsadjusted* mean difference (95% ci) in z-scores for pakistani infants relative to white british infantspakistani subgroups defined by place of Birth of parents†all pakistani Births, n=4649pakistani: both parents uk born, n=492pakistani: mum only uk born, n=1192pakistani: dad only uk born, n=1104pakistani: both parents south asian born, n=1411pakistani: other, n=450birth weight, n=7342−0.52 (−0.58 to −0.47)−0.49 (−0.59 to −0.39)−0.56 (−0.63 to −0.49)−0.52 (−0.60 to −0.45)−0.51 (−0.58 to −0.44)−0.48 (−0.58 to −0.38)Subscapular Skinfold thickness, n=5228−0.27 (−0.34 to −0.20)−0.20 (−0.33 to −0.08)−0.27 (−0.36 to −0.17)−0.33 (−0.43 to −0.23)−0.26 (−0.35 to −0.17)−0.26 (−0.40 to −0.14)Triceps Skinfold thickness, n=5243−0.23 (−0.30 to −0.16)−0.23 (−0.36 to −0.11)−0.21 (−0.30 to −0.12)−0.30 (−0.40 to −0.20)−0.21 (−0.32 to −0.14)−0.22 (−0.34 to −0.09)\n* adjusted for smoking; Alcohol; maternal age; maternal hypertension; maternal fasting Glucose; maternal height; maternal bmi; parity; Gestation; sex; socioeconomic position (maternal education, housing tenure, receipt of means tested benefits); and living with partner.']	N/A	N/A	[('GO_0007567', 'parturition', 253, 'birth'), ('GO_0007567', 'parturition', 284, 'births'), ('UBERON_0012295', "Guérin's valve", 629, 'Subscapular skinfold'), ('UBERON_0001509', 'triceps brachii', 799, 'Triceps'), ('UBERON_0009007', 'superficial inguinal lymph node', 807, 'skinfold'), ('CHEBI_30879', 'alcohol', 990, 'alcohol'), ('CHEBI_17234', 'glucose', 1053, 'glucose'), ('GO_0007565', 'female pregnancy', 1101, 'gestation')]
PMC3859677	7/2013	S92-PMC3859677	['caption (table-wrap): table\xa02\n\nadjusted mean z-score differences in pakistani relative to white british infants with adjustment for Birth weightadjusted* mean difference (95% ci) in z-scores for pakistani infants relative to white british infants including adjustment for Birth weightpakistani subgroups defined by place of Birth of parents†all pakistani Births, n=4649pakistani: both parents uk born, n=492pakistani: mum only uk born, n=1192pakistani: dad only uk born, n=1104pakistani: both parents south asian born, n=1411pakistani: other, n=450subscapular Skinfold thickness, n=5228–0.01 (−0.08 to 0.05)0.04 (−0.07 to 0.15)0.00 (−0.09 to 0.08)−0.08 (−0.17 to 0.01)−0.01 (−0.09 to 0.07)0.00 (−0.11 to 0.11)Triceps Skinfold thickness, n=52430.03 (−0.03 to 0.09)0.02 (−0.09 to 0.13)0.06 (−0.02 to 0.14)−0.04 (−0.13 to 0.05)0.03 (−0.05 to 0.11)0.05 (−0.06 to 0.16)\n* adjusted for smoking; Alcohol; maternal age; maternal hypertension; maternal fasting Glucose; maternal height; maternal bmi; parity; Gestation; sex; socioeconomic position (maternal education, housing tenure, receipt of means tested benefits); living with partner; and Birth weight.']	N/A	N/A	[('GO_0007567', 'parturition', 132, 'birth'), ('GO_0007567', 'parturition', 272, 'birth'), ('GO_0007567', 'parturition', 324, 'birth'), ('GO_0007567', 'parturition', 355, 'births'), ('UBERON_0009007', 'superficial inguinal lymph node', 560, 'skinfold'), ('UBERON_0001509', 'triceps brachii', 709, 'Triceps'), ('UBERON_0009007', 'superficial inguinal lymph node', 717, 'skinfold'), ('CHEBI_30879', 'alcohol', 889, 'alcohol'), ('CHEBI_17234', 'glucose', 952, 'glucose'), ('GO_0007565', 'female pregnancy', 1000, 'gestation'), ('GO_0007567', 'parturition', 1136, 'birth')]
PMC3859677	7/2013	S100-PMC3859677	['‡to maintain statistical power, only those covariables that had an effect were included in the final model: smoking; maternal fasting Glucose; maternal postload Glucose; maternal fasting Insulin; maternal bmi; and living with a partner.']	N/A	N/A	[('CHEBI_17234', 'glucose', 134, 'glucose'), ('CHEBI_17234', 'glucose', 161, 'glucose'), ('PR_000045358', 'insulin family protein', 187, 'insulin')]
PMC3860105	7/2013	S67-PMC3860105	['in hematology analysis, 81% had a normal fasting Glucose, 65% had a normal hematocrit and 31% had a normal hemoglobin level.']	N/A	N/A	[('CHEBI_17234', 'glucose', 49, 'glucose')]
PMC3876120	12/2013	S90-PMC3876120	['Plasma analysis\nPlasma Glucose (hk-cp kit; abx diagnostics, montpellier, france), total Cholesterol (Cholesterol-cp; abx diagnostics, montpellier, france), hdl Cholesterol (hdl direct-cp; abx diagnostics, montpellier, france), Triglycerides (Triglycerides; randox laboratories ltd, crumlin, uk), free fatty acids (ffa) (Nefa-Hr-2 kit; wako chemicals gmbh, neuss, germany) and Homocysteine levels (Homocysteine enzymatic assays; demeditec diagnosis, kiel, germany) were measured using an automated abx pentra c200 equipment (horiba abx diagnostics, montpellier, france).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('UBERON_0001969', 'blood plasma', 16, 'Plasma'), ('CHEBI_17234', 'glucose', 23, 'glucose'), ('CHEBI_16113', 'cholesterol', 88, 'cholesterol'), ('CHEBI_16113', 'cholesterol', 101, 'Cholesterol'), ('CHEBI_16113', 'cholesterol', 160, 'cholesterol'), ('CHEBI_17855', 'triglyceride', 227, 'triglycerides'), ('CHEBI_17855', 'triglyceride', 242, 'Triglycerides'), ('PR_000011111', 'N-terminal EF-hand calcium-binding protein 3', 320, 'NEFA'), ('PR_000001164', '5-hydroxytryptamine receptor 1E', 325, 'HR-2'), ('CHEBI_17088', 'monoacyl-sn-glycerol 3-phosphate', 376, 'homocysteine'), ('CHEBI_5759', 'Honokiol', 397, 'Homocysteine')]
PMC3877972	12/2013	S66-PMC3877972	['Gestational diabetes mellitus (gdm): gdm refers to various degrees of abnormal Glucose tolerance occurring or found for the first time during Pregnancy.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_17234', 'glucose', 79, 'glucose'), ('GO_0007565', 'female pregnancy', 142, 'pregnancy')]
PMC3877972	12/2013	S67-PMC3877972	['Blood Glucose threshold values for fasting ogtt and at 1\xa0h, 2\xa0h, were 5.1, 10.0, 8.5\xa0mmol/l (92, 180, 153\xa0mg/dl), respectively.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('CHEBI_17234', 'glucose', 6, 'glucose')]
PMC3898607	1/2014	S202-PMC3898607	['10\xa0μl were then transferred to 100\xa0μl of Glucose assay Reagent (sigma) or protein quantification kit – rapid (sigma).']	N/A	N/A	[('CHEBI_17234', 'glucose', 41, 'glucose'), ('CHEBI_33893', 'reagent', 55, 'reagent')]
PMC3914197	7/2012	S17-PMC3914197	['laboratory studies revealed a Serum Sodium of 171\u2009meq/l, potassium 4.1\u2009meq/l, Chloride 138\u2009meq/l, bicarbonate 21\u2009meq/l, Glucose 197\u2009mg/dl, bun 49\u2009mg/dl, creatinine 3.2\u2009mg/dl, calcium 7.8\u2009meq/l, total protein 5.4\u2009gm/dl, Albumin 1.6\u2009gm/dl, alkaline phosphatase 576\u2009units/l, ast 391\u2009units/l, and alt 443\u2009units/l.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 30, 'serum'), ('CHEBI_52632', 'potassium-39 atom', 36, 'sodium'), ('CHEBI_17996', 'chloride', 78, 'chloride'), ('CHEBI_17234', 'glucose', 120, 'glucose'), ('PR_000005908', 'alpha-crystallin B chain', 219, 'albumin')]
PMC3914197	7/2012	S24-PMC3914197	['laboratory evaluation of the infant showed Serum Sodium of 177\u2009meq/l, potassium 4.4\u2009meq/l, Chloride 140\u2009meq/l, bicarbonate 14\u2009meq/l, bun 49\u2009meq/l, creatinine 3.2\u2009mg/dl, Glucose 30\u2009mg/dl, and calcium 8.3\u2009meq/l.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 43, 'serum'), ('CHEBI_52632', 'potassium-39 atom', 49, 'sodium'), ('CHEBI_17996', 'chloride', 91, 'chloride'), ('CHEBI_17234', 'glucose', 169, 'glucose')]
PMC3914269	6/2012	S23-PMC3914269	['the presence of pih or pet or both were combined in “hypertensive disease.” gdm was defined according to the international association of diabetes in Pregnancy study groups (iadpsg) criteria (75\u2009g oral Glucose tolerance test (ogtt) results fasting Glucose levels >5.1\u2009mmol/l or 1\u2009hr >10\u2009mmol/l or 2\u2009hr >8.5\u2009mmol/l) and 100\u2009g ogtt test were recalculated [4].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 150, 'Pregnancy'), ('CHEBI_17234', 'glucose', 202, 'glucose'), ('CHEBI_17234', 'glucose', 248, 'glucose')]
PMC3925765	9/2013	S10-PMC3925765	['before breeding, mo elevated f0 Glucose, Insulin, Triglycerides, Cholesterol, leptin, fat and oxidative stress.']	N/A	N/A	[('CHEBI_17234', 'glucose', 32, 'glucose'), ('PR_000045358', 'insulin family protein', 41, 'insulin'), ('CHEBI_17855', 'triglyceride', 50, 'triglycerides'), ('CHEBI_16113', 'cholesterol', 65, 'cholesterol')]
PMC3925765	9/2013	S11-PMC3925765	['exercise completely prevented the Triglyceride rise and partially Glucose, Insulin, Cholesterol and oxidative stress increases.']	N/A	N/A	[('CHEBI_17855', 'triglyceride', 34, 'triglyceride'), ('CHEBI_17234', 'glucose', 66, 'glucose'), ('PR_000045358', 'insulin family protein', 75, 'insulin'), ('CHEBI_16113', 'cholesterol', 84, 'cholesterol')]
PMC3925765	9/2013	S69-PMC3925765	['Blood measurements\nGlucose, Triglycerides, Cholesterol enzymatically by synchron cx auto analyser (beckman coulter, co.), Insulin, leptin, Corticosterone, Testosterone and Estradiol were determined by ria(19–21).']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('CHEBI_17234', 'glucose', 19, 'Glucose'), ('CHEBI_17855', 'triglyceride', 28, 'triglycerides'), ('CHEBI_16113', 'cholesterol', 43, 'cholesterol'), ('PR_000045358', 'insulin family protein', 122, 'insulin'), ('CHEBI_16827', 'corticosterone', 139, 'corticosterone'), ('CHEBI_17347', 'testosterone', 155, 'testosterone'), ('CHEBI_23965', 'estradiol', 172, 'estradiol')]
PMC3925765	9/2013	S70-PMC3925765	['Homeostasis model assessment (homa) was calculated from homa=Glucose (mmol/l) × Insulin (µu/ml).22.5−1(19).']	N/A	N/A	[('GO_0042592', 'homeostatic process', 0, 'Homeostasis'), ('CHEBI_17234', 'glucose', 61, 'glucose'), ('PR_000045358', 'insulin family protein', 80, 'insulin')]
PMC3925765	9/2013	S104-PMC3925765	['f0 Metabolic parameters before breeding\nmo increased maternal Insulin, Glucose, homa, leptin, Triglycerides, Cholesterol and Retroperitoneal fat before breeding (fig 2 a–g).']	N/A	N/A	[('GO_0008152', 'metabolic process', 3, 'Metabolic'), ('PR_000045358', 'insulin family protein', 62, 'insulin'), ('CHEBI_17234', 'glucose', 71, 'glucose'), ('CHEBI_17855', 'triglyceride', 94, 'triglycerides'), ('CHEBI_16113', 'cholesterol', 109, 'cholesterol'), ('UBERON_0003693', 'retroperitoneal space', 125, 'retroperitoneal')]
PMC3925765	9/2013	S108-PMC3925765	['Maternal Metabolism at the end of Lactation\nat the end of Lactation maternal Insulin, Glucose, homa, leptin, Triglycerides and Cholesterol were elevated in mo (fig 3a–f).']	N/A	N/A	[('GO_0007618', 'mating', 0, 'Maternal'), ('GO_0008152', 'metabolic process', 9, 'metabolism'), ('GO_0007595', 'lactation', 34, 'lactation'), ('GO_0007595', 'lactation', 58, 'lactation'), ('PR_000045358', 'insulin family protein', 77, 'insulin'), ('CHEBI_17234', 'glucose', 86, 'glucose'), ('CHEBI_17855', 'triglyceride', 109, 'triglycerides'), ('CHEBI_16113', 'cholesterol', 127, 'cholesterol')]
PMC3925765	9/2013	S127-PMC3925765	['maternal exercise in c reduced male and female f1 offspring Glucose and male homa (fig 6b, c, h, i).']	N/A	N/A	[('CHEBI_17234', 'glucose', 60, 'glucose')]
PMC3925765	9/2013	S137-PMC3925765	['exposure of non-Pregnant females to the mo diet from weaning to breeding established a dysfunctional Metabolic phenotype (elevated Glucose, Insulin and homa), increased ros and Rns Production and elevated Corticosterone.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 16, 'pregnant'), ('GO_0008152', 'metabolic process', 101, 'metabolic'), ('CHEBI_17234', 'glucose', 131, 'glucose'), ('PR_000045358', 'insulin family protein', 140, 'insulin'), ('GO_0006302', 'double-strand break repair', 177, 'RNS production'), ('CHEBI_16827', 'corticosterone', 205, 'corticosterone')]
PMC3946277	3/2014	S85-PMC3946277	['experimental protocol\nat 1.5 and 2.5 years of age, a Glucose tolerance test (gtt) was performed following an overnight fast (16.00 h–09.00 h).']	N/A	N/A	[('CHEBI_17234', 'glucose', 53, 'glucose')]
PMC3946277	3/2014	S86-PMC3946277	['Glucose (0.5 g.kg body weight−1) was administered as an intravenous bolus over 3 minutes and Arterial Blood samples (3 ml into chilled edta tubes) were collected immediately before (0 min) and at 10, 20, 30, 60, and 120 min after the start of the Glucose administration (time 0).']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('UBERON_0001637', 'artery', 93, 'arterial'), ('UBERON_0000178', 'blood', 102, 'blood'), ('CHEBI_17234', 'glucose', 247, 'glucose')]
PMC3946277	3/2014	S140-PMC3946277	['(a) Plasma non-esterified Fatty Acid (nefa) concentrations relative to baseline in male and female Sheep combined during a Glucose tolerance test at 2.5 years.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 4, 'Plasma'), ('CHEBI_35366', 'fatty acid', 26, 'fatty acid'), ('NCBITaxon_10088', 'Mus <genus>', 99, 'sheep'), ('CHEBI_17234', 'glucose', 123, 'glucose')]
PMC3946277	3/2014	S141-PMC3946277	['Glucose (0.5 g.kg−1) was given at time 0.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose')]
PMC3946277	3/2014	S170-PMC3946277	['messenger rna levels (normalised to geometric mean of Β Actin, gapdh and Rpl-19) of Glucocorticoid Receptor (Gr; a), Insulin Receptor (ir; b), Phosphoenolpyruvate carboxykinase (pepck; c) and Glucose-6-phosphatase (g6pase; d) in Left and right Liver Lobes of control (c, n \u200a=\u200a8), early Gestation undernutrition (e, n \u200a=\u200a9) and late Gestation undernutrition (l, n \u200a=\u200a6) fetuses (males and females combined).']	N/A	N/A	[('PR_000003676', 'actin, cytoplasmic 1', 54, 'β actin'), ('PR_000014170', 'replication protein A 70 kDa DNA-binding subunit', 73, 'RPL-19'), ('CHEBI_24261', 'glucocorticoid', 84, 'glucocorticoid'), ('PR_000001594', 'leukotriene B4 receptor 1', 84, 'glucocorticoid receptor'), ('PR_000008290', 'eukaryotic peptide chain release factor GTP-binding subunit ERF3A', 109, 'GR'), ('PR_000001365', 'interleukin-10 receptor subunit alpha', 117, 'insulin receptor'), ('CHEBI_18021', 'phosphoenolpyruvate', 143, 'phosphoenolpyruvate'), ('CHEBI_17234', 'glucose', 192, 'glucose'), ('UBERON_0013698', 'strand of pubic hair', 229, 'left'), ('UBERON_0001113', 'lobe of liver', 244, 'liver lobes'), ('GO_0007565', 'female pregnancy', 286, 'gestation'), ('GO_0007565', 'female pregnancy', 332, 'gestation')]
PMC3946277	3/2014	S179-PMC3946277	['messenger rna levels (normalised to Β Actin and gapdh) of Insulin Receptor (Ir) and Glucose Transporter 4 (Glut4) from male (a, c) and female (b, d) Sheep (cc: male, n \u200a=\u200a13, female, n \u200a=\u200a8; cu: male, n \u200a=\u200a7, female n \u200a=\u200a7; uc: male, n \u200a=\u200a6, female, n \u200a=\u200a7; uu: male, n \u200a=\u200a11, female, n \u200a=\u200a10).']	N/A	N/A	[('PR_000003676', 'actin, cytoplasmic 1', 36, 'β actin'), ('PR_000001365', 'interleukin-10 receptor subunit alpha', 58, 'insulin receptor'), ('PR_000002050', 'interferon regulatory factor 8', 76, 'IR'), ('CHEBI_17234', 'glucose', 84, 'glucose'), ('PR_000015064', 'solute carrier family 2, facilitated glucose transporter member 2', 84, 'glucose transporter 4'), ('PR_000015065', 'solute carrier family 2, facilitated glucose transporter member 3', 107, 'GLUT4'), ('NCBITaxon_10088', 'Mus <genus>', 149, 'sheep')]
PMC3946277	3/2014	S269-PMC3946277	['in conclusion, Undernutrition during development induces changes in mechanisms of Lipid and Glucose Metabolism which differ between Tissues and sexes contingent on the period of nutritional restriction.']	N/A	N/A	[('GO_0019653', 'anaerobic purine nucleobase catabolic process', 15, 'undernutrition'), ('CHEBI_18059', 'lipid', 82, 'lipid'), ('GO_0006266', 'DNA ligation', 82, 'lipid ...'), ('CHEBI_17234', 'glucose', 92, 'glucose'), ('GO_0006006', 'glucose metabolic process', 92, 'glucose metabolism'), ('UBERON_0000479', 'tissue', 132, 'tissues')]
PMC3973835	3/2014	S7-PMC3973835	['an oral Glucose tolerance test is offered to all participants.']	N/A	N/A	[('CHEBI_17234', 'glucose', 8, 'glucose')]
PMC3973835	3/2014	S79-PMC3973835	['moreover, women are motivated to participate in a standardised two hour oral Glucose tolerance test (ogtt) between the 24thand 28thweek of Gestation, and an appointment for the ogtt is fixed.']	N/A	N/A	[('CHEBI_17234', 'glucose', 77, 'glucose'), ('GO_0007565', 'female pregnancy', 139, 'gestation')]
PMC3973835	3/2014	S116-PMC3973835	['ogtt and hba1c\nto test for Gestational diabetes mellitus (gdm), a standardised two-hour oral Glucose tolerance test (ogtt) is offered to all participants between the 24thand 28thweek of Gestation.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 27, 'gestational'), ('CHEBI_17234', 'glucose', 93, 'glucose'), ('GO_0007565', 'female pregnancy', 186, 'gestation')]
PMC3973835	3/2014	S118-PMC3973835	['after an overnight fast, Serum Glucose level is measured before, one and two hours after Intake of 75 grams Glucose (dextro®ogt, roche, mannheim).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 25, 'serum'), ('CHEBI_17234', 'glucose', 31, 'glucose'), ('GO_0007631', 'feeding behavior', 89, 'intake'), ('CHEBI_17234', 'glucose', 108, 'glucose')]
PMC3994935	5/2014	S3-PMC3994935	['research design and methods\nusing a randomized, crossover design, we provided 16 gdm women (bmi 34 ± 1 kg/m2) with two 3-day isocaloric diets at 31 ± 0.5 weeks (washout between diets) and performed continuous Glucose monitoring.']	N/A	N/A	[('CHEBI_17234', 'glucose', 209, 'glucose')]
PMC3994935	5/2014	S4-PMC3994935	['on day 4 of each diet, we determined postprandial (5 h) Glucose, Insulin, Triglycerides (tgs), and free Fatty Acids (ffas) following a controlled breakfast meal.']	N/A	N/A	[('CHEBI_17234', 'glucose', 56, 'glucose'), ('PR_000045358', 'insulin family protein', 65, 'insulin'), ('CHEBI_17855', 'triglyceride', 74, 'triglycerides'), ('CHEBI_35366', 'fatty acid', 104, 'fatty acids')]
PMC3994935	5/2014	S5-PMC3994935	['results\nthere were no between-diet differences for fasting or mean nocturnal Glucose, but 24-h auc was slightly higher (∼6%) on the hcc/lf choice diet ( p = 0.02).']	N/A	N/A	[('CHEBI_17234', 'glucose', 77, 'glucose')]
PMC3994935	5/2014	S7-PMC3994935	['after breakfast, 5-h Glucose and Insulin aucs were slightly higher ( p< 0.05), tg auc was no different, but the ffa auc was significantly lower (∼19%; p ≤ 0.01) on the choice diet.']	N/A	N/A	[('CHEBI_17234', 'glucose', 21, 'glucose'), ('PR_000045358', 'insulin family protein', 33, 'insulin')]
PMC3994935	5/2014	S33-PMC3994935	['on day 3, subjects reported to the ctrc, where a continuous Glucose monitoring system (cgms) was placed before breakfast, and they began the first random diet assignment (lc/conv or hcc/lf choice) to be followed for 72 h as an outpatient.']	N/A	N/A	[('CHEBI_17234', 'glucose', 60, 'glucose')]
PMC3994935	5/2014	S57-PMC3994935	['Blood measures\nPlasma Glucose was measured using hexokinase (beckman coulter, brea, ca).']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('UBERON_0001969', 'blood plasma', 15, 'Plasma'), ('CHEBI_17234', 'glucose', 22, 'glucose')]
PMC3994935	5/2014	S63-PMC3994935	['Homeostasis model assessment of Insulin resistance was calculated as (fasting Insulin [µu/ml]) × (fasting Glucose [mg/dl] × 0.05551) / 22.5.']	N/A	N/A	[('GO_0042592', 'homeostatic process', 0, 'Homeostasis'), ('PR_000045358', 'insulin family protein', 32, 'insulin'), ('PR_000045358', 'insulin family protein', 78, 'insulin'), ('CHEBI_17234', 'glucose', 106, 'glucose')]
PMC3994935	5/2014	S65-PMC3994935	['cgms\nthe cgms (medtronic minimed) was used to monitor Interstitial Glucose every 5 min during the randomized diet assignments.']	N/A	N/A	[('UBERON_0005169', 'interstitial tissue', 54, 'interstitial'), ('CHEBI_17234', 'glucose', 67, 'glucose')]
PMC3994935	5/2014	S66-PMC3994935	['women were blinded to cgms Glucose concentrations.']	N/A	N/A	[('CHEBI_17234', 'glucose', 27, 'glucose')]
PMC3994935	5/2014	S67-PMC3994935	['identical glucometers were provided by the investigators (onetouch, Lifescan inc., milpitas, ca); Postprandial Glucose was measured either 1 or 2 h after meals as per obstetrician preference, with the accepted targets of <140 mg/dl at 1 h and <120 mg/dl at 2 h (1).']	N/A	N/A	[('UBERON_0000104', 'life cycle', 68, 'LifeScan'), ('GO_0007567', 'parturition', 98, 'postprandial'), ('CHEBI_17234', 'glucose', 111, 'glucose')]
PMC3994935	5/2014	S68-PMC3994935	['Preprandial Glucose via glucometer four times daily was also measured for calibration of the cgms sensor data (correlation between Interstitial and meter Glucose, r = 0.732; p< 0.0001; n = 840 measures).']	N/A	N/A	[('GO_0007128', 'meiotic prophase I', 0, 'Preprandial'), ('CHEBI_17234', 'glucose', 12, 'glucose'), ('UBERON_0005169', 'interstitial tissue', 131, 'interstitial'), ('CHEBI_17234', 'glucose', 154, 'glucose')]
PMC3994935	5/2014	S69-PMC3994935	['women recorded meter Glucose and meal start times.']	N/A	N/A	[('CHEBI_17234', 'glucose', 21, 'glucose')]
PMC3994935	5/2014	S73-PMC3994935	['the mean of Interstitial Glucose data from the two sensors was used for analysis in these cases.']	N/A	N/A	[('UBERON_0005169', 'interstitial tissue', 12, 'interstitial'), ('CHEBI_17234', 'glucose', 25, 'glucose')]
PMC3994935	5/2014	S74-PMC3994935	['cgms Glucose variables were extracted and represent the mean over 48 h as we have described in detail previously (20,21).']	N/A	N/A	[('CHEBI_17234', 'glucose', 5, 'glucose')]
PMC3994935	5/2014	S81-PMC3994935	['Blood was sampled hourly for 5 h to measure Postprandial tg, ffa, Glucose, c-peptide, and Insulin.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('GO_0007567', 'parturition', 44, 'postprandial'), ('CHEBI_17234', 'glucose', 66, 'glucose'), ('PR_000045358', 'insulin family protein', 90, 'insulin')]
PMC3994935	5/2014	S86-PMC3994935	['sample size determination and statistical methods\nthe a priori primary outcome was the difference in maternal 24-h Glucose auc between the two diet treatments (lc/conv versus hcc/lf) within gdm subjects.']	N/A	N/A	[('CHEBI_17234', 'glucose', 115, 'glucose')]
PMC3994935	5/2014	S89-PMC3994935	['using a one-sample, two-sided t test with α at 0.05, a sample size of 16 was predicted to achieve 81% power to detect a statistically significant difference in auc Glucose between the diets.']	N/A	N/A	[('CHEBI_17234', 'glucose', 164, 'glucose')]
PMC3994935	5/2014	S90-PMC3994935	['Glucose auc was calculated using the trapezoid method to capture all potential Glucose/substrate exposure to the fetus in the designated time periods (24 h, daytime, nocturnal, and Postprandial).']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('CHEBI_17234', 'glucose', 79, 'glucose'), ('GO_0007567', 'parturition', 181, 'postprandial')]
PMC3994935	5/2014	S109-PMC3994935	['when meals were considered individually, the 1-h Postprandial Glucose was higher on the choice diet for lunch only (hcc/lf 115 ± 3 vs. lc/conv 101 ± 3 mg/dl; p ≤ 0.001) (fig.']	N/A	N/A	[('GO_0007567', 'parturition', 49, 'postprandial'), ('CHEBI_17234', 'glucose', 62, 'glucose')]
PMC3994935	5/2014	S111-PMC3994935	['the 2-h Postprandial Glucose was higher on choice for breakfast (hcc/lf 111 ± 4 vs. lc/conv 99 ± 3 mg/dl; p ≤ 0.01) (fig.']	N/A	N/A	[('GO_0007567', 'parturition', 8, 'postprandial'), ('CHEBI_17234', 'glucose', 21, 'glucose')]
PMC3994935	5/2014	S115-PMC3994935	['when meals were considered together as a mean across three meals, both 1- and 2-h Postprandial Glucose were modestly higher on the choice diet (1 h, hcc/lf 115 ± 2 vs. lc/conv 107 ± 3 mg/dl, p ≤ 0.01; 2 h, hcc/lf 106 ± 3 vs. lc/conv 97 ± 3 mg/dl, p = 0.001) (fig.']	N/A	N/A	[('GO_0007567', 'parturition', 82, 'postprandial'), ('CHEBI_17234', 'glucose', 95, 'glucose')]
PMC3994935	5/2014	S117-PMC3994935	['the 2-h Postprandial Glucose auc was moderately higher for breakfast and lunch on choice (hcc/lf 13,597 ± 346 vs. lc/conv 12,894 ± 306 breakfast, p = 0.03 [fig.']	N/A	N/A	[('GO_0007567', 'parturition', 8, 'postprandial'), ('CHEBI_17234', 'glucose', 21, 'glucose')]
PMC3994935	5/2014	S121-PMC3994935	['the 2-h Postprandial Glucose auc across meals was modestly higher on choice versus the lc/conv diet (hcc/lf 12,780 ± 337 vs. 12,086 ± 325 mg·min/dl; p = 0.009) (fig.']	N/A	N/A	[('GO_0007567', 'parturition', 8, 'postprandial'), ('CHEBI_17234', 'glucose', 21, 'glucose')]
PMC3994935	5/2014	S123-PMC3994935	['there was no significant difference in the time to Postprandial Glucose peak between the diets.']	N/A	N/A	[('GO_0007567', 'parturition', 51, 'postprandial'), ('CHEBI_17234', 'glucose', 64, 'glucose')]
PMC3994935	5/2014	S124-PMC3994935	['caption (table-wrap): table 2\n\ncgms-derived Glucose variables within 16 women during 3 days each of diet treatment (lc/conv vs. hcc/lf choice, in random order)\n\ncaption (fig): figure 1\n\ncgms data portraying patterns of glycemia within 16 Pregnant women with gdm during 3 days each of diet treatment (lc/conv [gray] vs. hcc/lf choice [black]).']	N/A	N/A	[('CHEBI_17234', 'glucose', 44, 'glucose'), ('GO_0007565', 'female pregnancy', 238, 'pregnant')]
PMC3994935	5/2014	S125-PMC3994935	['two-hour Postprandial Glucose response for ( a ) breakfast, ( b ) lunch, and ( c ) dinner and ( d ) average of three meals (mean over 2 days).']	N/A	N/A	[('GO_0007567', 'parturition', 9, 'postprandial'), ('CHEBI_17234', 'glucose', 22, 'glucose')]
PMC3994935	5/2014	S127-PMC3994935	['( e and f ) twenty-four-hour pattern of glycemia and Glucose auc with difference between diets.']	N/A	N/A	[('CHEBI_17234', 'glucose', 53, 'glucose')]
PMC3994935	5/2014	S131-PMC3994935	['we additionally used the cgms to derive mean Glucose measures and total auc.']	N/A	N/A	[('CHEBI_17234', 'glucose', 45, 'glucose')]
PMC3994935	5/2014	S137-PMC3994935	['Postprandial Plasma/Serum\nin response to breakfast, Glucose (fig.']	N/A	N/A	[('GO_0008283', 'cell proliferation', 0, 'Postprandial'), ('UBERON_0001969', 'blood plasma', 13, 'Plasma'), ('UBERON_0001977', 'blood serum', 20, 'Serum'), ('CHEBI_17234', 'glucose', 52, 'glucose')]
PMC3994935	5/2014	S139-PMC3994935	['2 b ) auc were significantly higher on choice compared with lc/conv (Glucose, 30,000 ± 574 vs. 27,323 ± 602 mg·min/dl, p ≤ 0.001; c-peptide, 2,121 ± 132 vs. 1,709 ± 93 ng·min/dl, p ≤ 0.001; Insulin, 29,374 ± 2,973 vs. 20,713 ± 2,344 µu·min/ml, p = 0.0001; respectively).']	N/A	N/A	[('CHEBI_17234', 'glucose', 69, 'glucose'), ('PR_000045358', 'insulin family protein', 190, 'insulin')]
PMC3994935	5/2014	S158-PMC3994935	['by a cgms across meals, choice compared with the lc/conv diet resulted in slightly higher 1- and 2-h Postprandial Glucose (115 vs. 107 mg/dl [rounded] at 1 h and 106 vs. 97 mg/dl at 2 h, respectively, [table 2]), but values on both diets were well within the recommended Postprandial targets of <140 mg/dl (1 h) and <120 mg/dl (2 h) (1) (fig.']	N/A	N/A	[('GO_0007567', 'parturition', 101, 'postprandial'), ('CHEBI_17234', 'glucose', 114, 'glucose'), ('GO_0007567', 'parturition', 271, 'postprandial')]
PMC3996361	4/2014	S7-PMC3996361	['these include changes in Hypothalamic-Pituitary-Adrenal axis function, body composition, Glucose Metabolism, and Cardiovascular function.']	N/A	N/A	[('UBERON_0001898', 'hypothalamus', 25, 'hypothalamic'), ('UBERON_0002109', 'pair of nares', 38, 'pituitary'), ('UBERON_0002369', 'adrenal gland', 48, 'adrenal'), ('CHEBI_17234', 'glucose', 89, 'glucose'), ('GO_0006006', 'glucose metabolic process', 89, 'glucose metabolism'), ('UBERON_0004535', 'cardiovascular system', 113, 'cardiovascular')]
PMC3996361	4/2014	S78-PMC3996361	['higher rates of Glucose intolerance, atherogenic Lipid profile, altered Coagulation profile, obesity in women, altered stress sensitivity and response, Coronary Heart disease, schizophrenia, addiction, and Breast cancer are observed in this cohort [65–77].']	N/A	N/A	[('CHEBI_17234', 'glucose', 16, 'glucose'), ('CHEBI_18059', 'lipid', 49, 'lipid'), ('GO_0050817', 'coagulation', 72, 'coagulation'), ('UBERON_0004151', 'cardiac chamber', 152, 'coronary heart'), ('UBERON_0000310', 'breast', 206, 'breast')]
PMC3996361	4/2014	S80-PMC3996361	['the cohort exposed to famine in mid and late Gestation was smaller at Birth and had reduced Glucose tolerance and higher rates of obstructive Airways disease and microalbuminuria [65,75,76,78,79].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 45, 'gestation'), ('GO_0007567', 'parturition', 70, 'birth'), ('CHEBI_17234', 'glucose', 92, 'glucose'), ('UBERON_0001005', 'respiratory airway', 142, 'airways')]
PMC3996361	4/2014	S153-PMC3996361	['altered Gestational Glucose exposure and Metabolism\nInsulin resistance is a normal adaptation to Pregnancy, allowing for greater availability of Glucose to the fetus [98].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 8, 'Gestational'), ('CHEBI_17234', 'glucose', 20, 'Glucose'), ('GO_0060206', 'estrous cycle phase', 20, 'Glucose'), ('GO_0008152', 'metabolic process', 41, 'Metabolism'), ('PR_000045358', 'insulin family protein', 52, 'Insulin'), ('GO_0007565', 'female pregnancy', 97, 'pregnancy'), ('CHEBI_17234', 'glucose', 145, 'glucose')]
PMC3996361	4/2014	S156-PMC3996361	['altered Insulin response to Glucose is evident in late Gestation [36], and at 10 weeks Postnatally [38], with greater Insulin response following Glucose challenge compared to controls [36].']	N/A	N/A	[('PR_000045358', 'insulin family protein', 8, 'insulin'), ('CHEBI_17234', 'glucose', 28, 'glucose'), ('GO_0007565', 'female pregnancy', 55, 'gestation'), ('GO_0007565', 'female pregnancy', 87, 'postnatally'), ('PR_000045358', 'insulin family protein', 118, 'insulin'), ('CHEBI_17234', 'glucose', 145, 'glucose')]
PMC3996361	4/2014	S160-PMC3996361	['impaired Adult Glucose tolerance\nin Adult offspring, Periconceptional Undernutrition in normal weight ewes results in impaired Glucose tolerance [40].']	N/A	N/A	[('UBERON_0007023', 'adult organism', 9, 'Adult'), ('CHEBI_17234', 'glucose', 15, 'Glucose'), ('UBERON_0007023', 'adult organism', 36, 'adult'), ('GO_0007565', 'female pregnancy', 53, 'periconceptional'), ('GO_0019653', 'anaerobic purine nucleobase catabolic process', 70, 'undernutrition'), ('CHEBI_17234', 'glucose', 127, 'glucose')]
PMC4002571	12/2013	S3-PMC4002571	['Blood samples were collected before and after chronic stress, and Serum acth, Corticosterone, Glucose, Insulin, total Cholesterol, Triglyceride and Free Fatty Acids levels were measured.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('UBERON_0001977', 'blood serum', 66, 'serum'), ('CHEBI_16827', 'corticosterone', 78, 'corticosterone'), ('CHEBI_17234', 'glucose', 94, 'glucose'), ('PR_000045358', 'insulin family protein', 103, 'insulin'), ('CHEBI_16113', 'cholesterol', 118, 'cholesterol'), ('CHEBI_17855', 'triglyceride', 131, 'triglyceride'), ('CHEBI_37958', 'dye', 148, 'free'), ('CHEBI_35366', 'fatty acid', 153, 'fatty acids')]
PMC4002571	12/2013	S5-PMC4002571	['results:\nucs significantly increased the Serum acth, Corticosterone and Insulin levels as well as the Insulin resistant index without changing the Serum Glucose, Total Cholesterol, Triglyceride and free Fatty Acids levels in Adult offspring Rats without pne.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 41, 'serum'), ('CHEBI_16827', 'corticosterone', 53, 'corticosterone'), ('PR_000045358', 'insulin family protein', 72, 'insulin'), ('PR_000045358', 'insulin family protein', 102, 'insulin'), ('UBERON_0001977', 'blood serum', 147, 'serum'), ('CHEBI_17234', 'glucose', 153, 'glucose'), ('CHEBI_66254', 'topopyrone C', 162, 'total cholesterol'), ('CHEBI_17855', 'triglyceride', 181, 'triglyceride'), ('CHEBI_35366', 'fatty acid', 203, 'fatty acids'), ('UBERON_0007023', 'adult organism', 225, 'adult'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 241, 'rats')]
PMC4002571	12/2013	S28-PMC4002571	['after Birth and the initiation of a normal diet, the iugr offspring induced by pne showed low basal activity but an enhanced sensitivity of the hpa axis to chronic stress, as well as gc-dependent phenotypic alterations of the Blood Glucose and Lipid Metabolism14.']	N/A	N/A	[('GO_0007567', 'parturition', 6, 'birth'), ('UBERON_0000178', 'blood', 226, 'blood'), ('CHEBI_17234', 'glucose', 232, 'glucose'), ('GO_0007369', 'gastrulation', 232, 'glucose ...'), ('CHEBI_18059', 'lipid', 244, 'lipid'), ('GO_0090452', 'lithium ion transmembrane transport', 244, 'lipid metabolism14')]
PMC4002571	12/2013	S39-PMC4002571	['a Glucose oxidase assay kit was provided by mind bioengineering co, ltd (shanghai, china).']	N/A	N/A	[('CHEBI_17234', 'glucose', 2, 'glucose')]
PMC4002571	12/2013	S61-PMC4002571	['at pw16, the Animals were fasted for 12 h, and Blood was taken via the Vena Caudalis within 3 min to measure levels of acth, cort, Glucose, Insulin, tch, tg and ffa.']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 13, 'animals'), ('UBERON_0000178', 'blood', 47, 'blood'), ('UBERON_0005486', 'venous dural sinus', 71, 'vena caudalis'), ('CHEBI_17234', 'glucose', 131, 'glucose'), ('PR_000045358', 'insulin family protein', 140, 'insulin')]
PMC4002571	12/2013	S67-PMC4002571	['Blood samples were collected via the Vena Caudalis within 5 min before and after chronic stress, and the Serum was prepared by centrifugation at 17 205× g for 15 min at 4 °c and then stored at −80 °c until it was used to measure the levels of acth, cort, Glucose, insulin, tch, tg, and ffa.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('UBERON_0005486', 'venous dural sinus', 37, 'vena caudalis'), ('UBERON_0001977', 'blood serum', 105, 'serum'), ('CHEBI_17234', 'glucose', 255, 'glucose')]
PMC4002571	12/2013	S71-PMC4002571	["the levels of Serum Glucose, tch, tg and ffa were detected using biochemical assay kits following the manufacturer's protocol."]	N/A	N/A	[('UBERON_0001977', 'blood serum', 14, 'serum'), ('CHEBI_17234', 'glucose', 20, 'glucose')]
PMC4002571	12/2013	S91-PMC4002571	['Serum Glucose and Insulin concentration alterations before and after chronic stress\nbefore chronic stress, the fasting Serum Glucose concentrations (figures 4aand4d) were the same in the pne and control groups.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_17234', 'glucose', 6, 'glucose'), ('PR_000045358', 'insulin family protein', 18, 'insulin'), ('UBERON_0001977', 'blood serum', 119, 'serum'), ('CHEBI_17234', 'glucose', 125, 'glucose')]
PMC4002571	12/2013	S92-PMC4002571	['after chronic stress, the Serum Glucose concentrations of the pne Rats were significantly increased from baseline ( p<0.01,figure 4a) and were significantly higher than those of the controls ( p<0.05,figure 4a) in males, but no change was observed in the female offspring (figure 4d).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 26, 'serum'), ('CHEBI_17234', 'glucose', 32, 'glucose'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 66, 'rats')]
PMC4006733	5/2014	S7-PMC4006733	['Glucose promotes resistance against cellular stress and neurodegeneration in parental and descendent progeny, while reducing Lifespan only in the parental generation.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('UBERON_0000104', 'life cycle', 125, 'lifespan')]
PMC4006733	5/2014	S22-PMC4006733	['Glucose promotes resistance against cellular stress and neurodegeneration in parental and descendent progeny, while reducing Lifespan in the parental generation only.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('UBERON_0000104', 'life cycle', 125, 'lifespan')]
PMC4006733	5/2014	S37-PMC4006733	['finally, we examined hif-1 , the c. elegans Orthologue of Mammalian Hypoxia Induced Factor 1 (Hif1)[12], a protein that Regulates Glucose Metabolism and the Cellular Response to low oxygen conditions and observed that ge continued to reduce progeny numbers in the p0 and f1 generation of hif-1 mutants.']	N/A	N/A	[('SO_0000855', 'orthologous_region', 44, 'orthologue'), ('NCBITaxon_40674', 'Mammalia', 58, 'mammalian'), ('PR_000008479', 'polyamine deacetylase HDAC10', 68, 'hypoxia induced factor 1'), ('PR_000008532', 'hemojuvelin', 94, 'HIF1'), ('GO_0065007', 'biological regulation', 120, 'regulates'), ('CHEBI_17234', 'glucose', 130, 'glucose'), ('GO_0006006', 'glucose metabolic process', 130, 'glucose metabolism'), ('GO_0051716', 'cellular response to stimulus', 157, 'cellular response')]
PMC4006733	5/2014	S38-PMC4006733	["exposure to high dietary Glucose reduces the Lifespan of wild type n2 worms, as well as the long-lived phenotype of worms with hypomorphic mutations in the Gene encoding the worm's sole Insulin/Igf-like receptor Daf-2[5]–[7]."]	N/A	N/A	[('CHEBI_17234', 'glucose', 25, 'glucose'), ('UBERON_0000104', 'life cycle', 45, 'lifespan'), ('SO_0000704', 'gene', 156, 'gene'), ('PR_000045358', 'insulin family protein', 186, 'Insulin'), ('PR_000008989', 'interleukin-1 family member 7', 194, 'IGF'), ('PR_000006282', 'aspartate--tRNA ligase, mitochondrial', 212, 'DAF-2')]
PMC4006733	5/2014	S44-PMC4006733	['Glucose-mediated resistance against oxidative stress was not transmitted further since the f2 generation of n2 worms was sensitive to Juglone (figure 2a).']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('CHEBI_15794', 'juglone', 134, 'juglone')]
PMC4006733	5/2014	S62-PMC4006733	['c. elegans Expressing mutant Tdp-43 in Motor Neurons show Adult onset, age-dependent paralysis and neurodegeneration phenotypes that are diminished by treatment with Glucose[5].']	N/A	N/A	[('GO_0010467', 'gene expression', 11, 'expressing'), ('PR_000016755', 'tetraspanin-9', 29, 'TDP-43'), ('CL_0000100', 'motor neuron', 39, 'motor neurons'), ('UBERON_0007023', 'adult organism', 58, 'adult'), ('CHEBI_17234', 'glucose', 166, 'glucose')]
PMC4006733	5/2014	S78-PMC4006733	['we further investigated the Genetic requirements of set-2 and wdr-5.1 for the transmission of Glucose-mediated phenotypes.']	N/A	N/A	[('SO_0000704', 'gene', 28, 'genetic'), ('CHEBI_17234', 'glucose', 94, 'glucose')]
PMC4006733	5/2014	S88-PMC4006733	['the germline is required for transmission of Glucose protection\nthe transgenerational inheritance of longevity requires a functional germline[23].']	N/A	N/A	[('CHEBI_17234', 'glucose', 45, 'glucose')]
PMC4006733	5/2014	S91-PMC4006733	['(a–b) Glucose increased stress resistance in p0 and f1 generation of fem-3(e2006) mutants at 15°c, but failed in the f1 generation at 25°c.']	N/A	N/A	[('CHEBI_17234', 'glucose', 6, 'Glucose')]
PMC4006733	5/2014	S92-PMC4006733	['(c–d) Glucose increased resistance to juglone in p0 and f1 generation of pgl-1(bn102) mutants at 15°c but failed in the f1 generation at 25°c.']	N/A	N/A	[('CHEBI_17234', 'glucose', 6, 'Glucose')]
PMC4006733	5/2014	S132-PMC4006733	['for the paralysis tests worms were Grown on ngm or ngm +2% Glucose and transferred to ngm-fudr or ngm-fudr +2% Glucose.']	N/A	N/A	[('GO_0040007', 'growth', 35, 'grown'), ('CHEBI_17234', 'glucose', 59, 'glucose'), ('CHEBI_17234', 'glucose', 111, 'glucose')]
PMC4006733	5/2014	S133-PMC4006733	['for the f1 generation, l4 Animals were transferred from ngm +2% Glucose to ngm and their progeny used as the f1 generation.']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 26, 'animals'), ('CHEBI_17234', 'glucose', 64, 'glucose')]
PMC4006733	5/2014	S140-PMC4006733	['stress assays\nfor oxidative stress tests, Worms were Grown on ngm or ngm with a dietary supplement (Glucose, Oleic Acid or methionine) and transferred to ngm plates +240 µm Juglone at Adult day 1.']	N/A	N/A	[('CL_0000561', 'amacrine cell', 42, 'worms'), ('GO_0040007', 'growth', 53, 'grown'), ('CHEBI_17234', 'glucose', 100, 'glucose'), ('CHEBI_30814', 'digallic acid', 109, 'oleic acid'), ('CHEBI_15794', 'juglone', 173, 'juglone'), ('UBERON_0007023', 'adult organism', 184, 'adult')]
PMC4006733	5/2014	S141-PMC4006733	['for the f1, l4 worms from ngm +2% Glucose plates were transferred on ngm and their progeny used as f1 generation.']	N/A	N/A	[('CHEBI_17234', 'glucose', 34, 'glucose')]
PMC4006733	5/2014	S148-PMC4006733	['lifespan assays\nworms were Grown on ngm or ngm +4% Glucose and transferred on ngm-fudr or ngm-fudr + Glucose.']	N/A	N/A	[('GO_0040007', 'growth', 27, 'grown'), ('CHEBI_17234', 'glucose', 51, 'glucose'), ('CHEBI_17234', 'glucose', 101, 'glucose')]
PMC4006733	5/2014	S149-PMC4006733	['for the f1 generation, l4 Animals from the ngm +4% Glucose plates were transferred to ngm plates and progeny used as the f1 generation on ngm-fudr.']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 26, 'animals'), ('CHEBI_17234', 'glucose', 51, 'glucose')]
PMC4006733	5/2014	S153-PMC4006733	['progeny tests\nfor scoring progeny, 10 l4 worms were Grown on ngm or ngm +2% Glucose and placed at 20°c.']	N/A	N/A	[('GO_0040007', 'growth', 52, 'grown'), ('CHEBI_17234', 'glucose', 76, 'glucose')]
PMC4006733	5/2014	S155-PMC4006733	['for the f1 generation, 10 l4 Larvae from the p0 were transferred to new ngm plates without Glucose and this process was repeated for the f2 and f3 generations.']	N/A	N/A	[('UBERON_0002548', 'larva', 29, 'larvae'), ('CHEBI_17234', 'glucose', 91, 'glucose')]
PMC4006733	5/2014	S169-PMC4006733	['worms were Grown on either ngm or ngm +2% Glucose both enriched with 1 mm Isopropyl-B-D-Thiogalactopyranoside (Iptg).']	N/A	N/A	[('GO_0040007', 'growth', 11, 'grown'), ('CHEBI_17234', 'glucose', 42, 'glucose'), ('CHEBI_81454', 'gamma-L-Glutamyl-4-amino-2-hydroxybutyryl-[acp]', 74, 'Isopropyl-b-D-thiogalactopyranoside'), ('CHEBI_61448', 'isopropyl beta-D-thiogalactopyranoside', 111, 'IPTG')]
PMC4006733	5/2014	S171-PMC4006733	['supporting information\n\ncaption (supplementary-material): figure s1\n\nLifespan reduction by Glucose is not transmitted over generation.']	N/A	N/A	[('UBERON_0000104', 'life cycle', 69, 'Lifespan'), ('CHEBI_17234', 'glucose', 91, 'glucose')]
PMC4006733	5/2014	S175-PMC4006733	['caption (supplementary-material): figure s2\n\nGlucose protection is independent of a hormetic increase of oxidative stress.']	N/A	N/A	[('CHEBI_17234', 'glucose', 45, 'Glucose')]
PMC4006733	5/2014	S179-PMC4006733	['n2 worms do not show increased fluorescence after treatment with Glucose.']	N/A	N/A	[('CHEBI_17234', 'glucose', 65, 'glucose')]
PMC4006733	5/2014	S183-PMC4006733	['caption (supplementary-material): figure s3\n\ncompass Genes are required for methylation increase by Glucose.']	N/A	N/A	[('SO_0000704', 'gene', 53, 'genes'), ('CHEBI_17234', 'glucose', 100, 'glucose')]
PMC4006733	5/2014	S184-PMC4006733	['(a) Glucose failed to increase the methylation H3K4Me3 mark in set-2(ok952) and wdr-5.1(ok1417) mutated Animals (related tofigure 4).']	N/A	N/A	[('CHEBI_17234', 'glucose', 4, 'Glucose'), ('GO_0006909', 'phagocytosis', 47, 'H3K4me3'), ('SO_0001734', 'H3K4_methylation_site', 47, 'H3K4me3'), ('NCBITaxon_33208', 'Metazoa', 104, 'animals')]
PMC4006733	5/2014	S185-PMC4006733	['(b) Glucose enrichment reduced Axonal degeneration in mtdp-43; set-2(ok952) (p<0.001) and mtdp-43; wdr-5.1(ok1417) (p<0.0001) p0 Animals but failed to rescue the phenotype in the f1 generation.']	N/A	N/A	[('CHEBI_17234', 'glucose', 4, 'Glucose'), ('GO_0030424', 'axon', 31, 'axonal'), ('NCBITaxon_33208', 'Metazoa', 129, 'animals')]
PMC4029895	5/2014	S94-PMC4029895	['caption (table-wrap): table 1\n\nlist of quality of care indicators\xa0 part a. accepted indicators \xa0\xa0 initiation and number of Antenatal visits \xa0 1 percentage of Pregnant women who began anc during the first Trimester of Gestation\xa0 2 percentage of women with low risk Pregnancy†who at the end of the Pregnancy had at least four anc visits\xa0\xa0 health education \xa0 3 percentage of Pregnant women who had documented educational activities provided by the maternity nurse or social worker\xa0 4 percentage of overweight/obese (pre-Pregnancy bmi ≥ 25 kg/m2) Pregnant women who had documented nutritional counselling provided by the nutrition service\xa0\xa0 screening \xa0 5 percentage of Pregnant women who were referred to or had documented Rh and Blood group test\xa0 6 percentage of Pregnant women who were referred to haemoglobin test during the first two anc visits\xa0 7 percentage of Pregnant women who were referred to fasting Plasma Glucose test during the first two anc visits and between weeks 24 and 28 of Gestation\xa0 8 percentage of Pregnant women who were referred to obstetric ultrasound between weeks 18 and 22 of Gestation\xa0 9 percentage of Pregnant women who were referred to vdrl test (syphilis screening) during the first two anc visits\xa0\xa0 nutritional supplementation \xa0 10 percentage of Pregnant women who had prescription of Folic Acid during the first Trimester of Gestation\xa0\xa0 treatment and referrals to the obstetrician-gynecologist \xa0 11 percentage of Pregnant women diagnosed with bacterial vaginosis or trichomoniasis, who had Vaginal Metronidazol prescription in adequate doses and duration\xa0 12 percentage of Pregnant women with systolic Blood pressure ≥ 140 mmhg, or diastolic Blood pressure ≥ 90 mmhg who was referred to the second or third level of care\xa0 13 percentage of Pregnant women with pre-existing degenerative chronic disease (diabetes, hypertension, lupus, Heart disease) who were referred to the second or third level of care\xa0 14 percentage of Pregnant women between 20–32 weeks with Symphysis-Fundal height 4 cm less than indicated by their Gestational age, who were referred to ultrasound or another level of care\xa0\xa0 part b. discarded indicatorsreasons of elimination 1.']	N/A	N/A	[('GO_0007567', 'parturition', 123, 'antenatal'), ('GO_0007565', 'female pregnancy', 158, 'pregnant'), ('GO_0009294', 'DNA mediated transformation', 204, 'trimester'), ('GO_0007565', 'female pregnancy', 217, 'gestation'), ('GO_0007565', 'female pregnancy', 264, 'pregnancy'), ('GO_0007565', 'female pregnancy', 296, 'pregnancy'), ('GO_0007565', 'female pregnancy', 372, 'pregnant'), ('GO_0007565', 'female pregnancy', 517, 'pregnancy'), ('GO_0007565', 'female pregnancy', 543, 'pregnant'), ('GO_0007565', 'female pregnancy', 665, 'pregnant'), ('PR_000013773', 'retinoblastoma-associated protein', 719, 'Rh'), ('UBERON_0000178', 'blood', 726, 'blood'), ('GO_0007565', 'female pregnancy', 760, 'pregnant'), ('GO_0007565', 'female pregnancy', 862, 'pregnant'), ('UBERON_0001969', 'blood plasma', 906, 'plasma'), ('CHEBI_17234', 'glucose', 913, 'glucose'), ('GO_0007565', 'female pregnancy', 989, 'gestation'), ('GO_0007565', 'female pregnancy', 1016, 'pregnant'), ('GO_0007565', 'female pregnancy', 1100, 'gestation'), ('GO_0007565', 'female pregnancy', 1127, 'pregnant'), ('GO_0007565', 'female pregnancy', 1275, 'pregnant'), ('CHEBI_30751', 'formic acid', 1314, 'folic acid'), ('GO_0009294', 'DNA mediated transformation', 1342, 'trimester'), ('GO_0007565', 'female pregnancy', 1355, 'gestation'), ('GO_0007565', 'female pregnancy', 1443, 'pregnant'), ('UBERON_0001987', 'placenta', 1520, 'vaginal'), ('CHEBI_81835', 'Glyphosate-monoammonium', 1528, 'metronidazol'), ('GO_0007565', 'female pregnancy', 1603, 'pregnant'), ('UBERON_0000178', 'blood', 1632, 'blood'), ('UBERON_0000178', 'blood', 1672, 'blood'), ('GO_0007565', 'female pregnancy', 1769, 'pregnant'), ('UBERON_0000948', 'heart', 1863, 'heart'), ('GO_0007565', 'female pregnancy', 1951, 'pregnant'), ('UBERON_0002216', 'symphysis', 1991, 'symphysis'), ('UBERON_0003631', 'pedal digit 1', 2001, 'fundal'), ('GO_0007565', 'female pregnancy', 2049, 'gestational')]
PMC4029895	5/2014	S140-PMC4029895	['caption (table-wrap): table 4\n\nquality of careindicators%initiation and number of Antenatal visits \xa0pregnant women who began anc during the first Trimester of Gestation n\u2009=\u20095342 40.6women with low risk Pregnancy† who at the end of the Pregnancy had at least 4 anc visits n\u2009=\u20094300 63.5 education for health \xa0pregnant women with documented educational activities provided by the maternity nurse or social worker n\u2009=\u20095342 20.7overweight/obese (pre-Pregnancy bmi\u2009≥\u200925\xa0kg/m2) Pregnant women who had documented nutritional counseling provided by the nutrition service n\u2009=\u20091754 26.0 screeningn\u2009=\u20095342 Pregnant women referred to or had documented rh and Blood group test23.9pregnant women referred to hemoglobin test during the first 2 anc visits41.9pregnant women referred to fasting Plasma Glucose test during the first 2 anc visits and between weeks 24 and 28 of Gestation41.1pregnant women referred to obstetric ultrasound between weeks 18 and 22 of Gestation4.4pregnant women referred to vdrl test (syphilis screening) during the first 2 anc visits40.1 supplementationn\u2009=\u20092169 pregnant women prescribed Folic Acid during the first Trimester of Gestation64.6 treatment and references to the obstetrician-gynecologists consultation at the second level of care \xa0pregnant women diagnosed with bacterial vaginosis or trichomoniasis who had Vaginal Metronidazol prescription n\u2009=\u200995 45.3pregnant women with systolic Blood pressure ≥140\xa0mmhg, or diastolic\u2009≥\u200990\xa0mmhg referred to the second or third level of care n\u2009=\u2009291 69.1pregnant women with pre-existing degenerative chronic disease (diabetes, hypertension, lupus, Heart disease) referred to the second or third level of care n\u2009=\u200954 92.6pregnant women between 20–32 weeks with Symphysis-Fundal height 4\xa0cm less than indicated by their Gestational age, referred to ultrasound or another level of care n\u2009=\u20091445 60.3 percentage of recommended care††,mean (standard deviation) 32.7 (22.2)\nn: indicates the number of women eligible for the evaluated indicator; †low risk Pregnancy: <4 points at the obstetric risk scored system of ehr;††proportion of Antenatal Care procedures that a woman received relative the total number of indicators for which she was eligible.']	N/A	N/A	[('GO_0007567', 'parturition', 82, 'antenatal'), ('GO_0009294', 'DNA mediated transformation', 146, 'trimester'), ('GO_0007565', 'female pregnancy', 159, 'gestation'), ('GO_0007565', 'female pregnancy', 202, 'pregnancy'), ('GO_0007565', 'female pregnancy', 235, 'pregnancy'), ('GO_0007565', 'female pregnancy', 445, 'pregnancy'), ('GO_0007565', 'female pregnancy', 471, 'pregnant'), ('GO_0007565', 'female pregnancy', 594, 'Pregnant'), ('UBERON_0000178', 'blood', 646, 'blood'), ('UBERON_0001969', 'blood plasma', 777, 'plasma'), ('CHEBI_17234', 'glucose', 784, 'glucose'), ('GO_0007565', 'female pregnancy', 858, 'gestation41'), ('GO_0007565', 'female pregnancy', 946, 'gestation4'), ('CHEBI_30751', 'formic acid', 1100, 'folic acid'), ('GO_0009294', 'DNA mediated transformation', 1128, 'trimester'), ('GO_0007565', 'female pregnancy', 1141, 'gestation64'), ('UBERON_0001987', 'placenta', 1332, 'vaginal'), ('CHEBI_81835', 'Glyphosate-monoammonium', 1340, 'metronidazol'), ('UBERON_0000178', 'blood', 1406, 'blood'), ('UBERON_0000948', 'heart', 1607, 'heart'), ('UBERON_0002216', 'symphysis', 1719, 'symphysis'), ('UBERON_0003631', 'pedal digit 1', 1729, 'fundal'), ('GO_0007565', 'female pregnancy', 1777, 'gestational'), ('GO_0007565', 'female pregnancy', 2008, 'pregnancy'), ('GO_0007608', 'sensory perception of smell', 2088, 'antenatal care')]
PMC4077117	6/2014	S55-PMC4077117	['in the gambia, no differences were found in Blood pressure, Plasma Glucose and Lipids, or other Cardiovascular risk factors between People Born in the ‘Hungry’ or ‘harvest’ seasons [20].']	N/A	N/A	[('UBERON_0000178', 'blood', 44, 'blood'), ('UBERON_0001969', 'blood plasma', 60, 'plasma'), ('CHEBI_17234', 'glucose', 67, 'glucose'), ('CHEBI_18059', 'lipid', 79, 'lipids'), ('UBERON_0004535', 'cardiovascular system', 96, 'cardiovascular'), ('NCBITaxon_10088', 'Mus <genus>', 132, 'people'), ('GO_0007567', 'parturition', 139, 'born'), ('GO_0007605', 'sensory perception of sound', 152, 'hungry')]
PMC4113768	7/2014	S1380-PMC4113768	['results: our study population comprised 92 overweight, non-diabetic Individuals with no history of Cardiovascular disease—mean age 56 years (range 40–77 years), 64% males, 36% females, body mass index 30.9 kg/m2(range 26.4–36.9 kg/m2), fasting Plasma Glucose 5.8 mmol/l (range 4.9–7.0 mmol/l).']	N/A	N/A	[('NCBITaxon_1', 'root', 68, 'individuals'), ('UBERON_0004535', 'cardiovascular system', 99, 'cardiovascular'), ('UBERON_0001969', 'blood plasma', 244, 'plasma'), ('CHEBI_17234', 'glucose', 251, 'glucose')]
PMC4113768	7/2014	S2185-PMC4113768	['office and 24 h Ambulatory Blood pressure, Glucose and Cholesterol were measured at baseline, 2, 4 and 6 months; Left Ventricular mass index was measured by Cardiac magnetic resonance imaging on a subgroup at baseline and 6 months.']	N/A	N/A	[('GO_0040011', 'locomotion', 16, 'ambulatory'), ('UBERON_0000178', 'blood', 27, 'blood'), ('CHEBI_17234', 'glucose', 43, 'glucose'), ('CHEBI_16113', 'cholesterol', 55, 'cholesterol'), ('UBERON_0002084', 'heart left ventricle', 113, 'left ventricular'), ('UBERON_0000948', 'heart', 157, 'cardiac')]
PMC4113768	7/2014	S2191-PMC4113768	['there was no significant change in Cholesterol or Glucose levels.']	N/A	N/A	[('CHEBI_16113', 'cholesterol', 35, 'cholesterol'), ('CHEBI_17234', 'glucose', 50, 'glucose')]
PMC4113768	7/2014	S2321-PMC4113768	['anthropometrics, Glucose, Lipid profile and 25-Hydroxy Vitamin D (25-Ohvitd) were measured at baseline, 6 and 12 months.']	N/A	N/A	[('CHEBI_17234', 'glucose', 17, 'glucose'), ('CHEBI_18059', 'lipid', 26, 'lipid'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 44, '25-hydroxy vitamin D'), ('CHEBI_72659', 'epoxyoctadecenoic acid', 66, '25-OHVitD')]
PMC4113768	7/2014	S2324-PMC4113768	['no significant changes were observed in the bmi and Glucose in any of the dmt2 groups.']	N/A	N/A	[('CHEBI_17234', 'glucose', 52, 'glucose')]
PMC4113768	7/2014	S2362-PMC4113768	['fasting Blood Glucose, corrected calcium and Lipid profiles were measured routinely.']	N/A	N/A	[('UBERON_0000178', 'blood', 8, 'blood'), ('CHEBI_17234', 'glucose', 14, 'glucose'), ('CHEBI_18059', 'lipid', 45, 'lipid')]
PMC4113768	7/2014	S3062-PMC4113768	['no improvement in Glucose Metabolism and Cardiovascular risk factors after 1 year of supplementation of high-Dose Vitamin D. 1 year results from a double blinded randomized clinical trial in subjects with prediabetes\n\nsollid, s.t.']	N/A	N/A	[('CHEBI_17234', 'glucose', 18, 'Glucose'), ('GO_0006006', 'glucose metabolic process', 18, 'Glucose Metabolism'), ('UBERON_0004535', 'cardiovascular system', 41, 'Cardiovascular'), ('CHEBI_18130', '(-)-5-oxo-1,2-campholide', 109, 'Dose'), ('CHEBI_28384', 'vitamin K', 114, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 114, 'Vitamin D')]
PMC4113768	7/2014	S3067-PMC4113768	['methods: 556 Individuals with impaired fasting Glucose and/or impaired Glucose tolerance were randomly assigned to 20,000 iu of Vitamin D3/week ( n = 278) or placebo ( n = 278).']	N/A	N/A	[('NCBITaxon_1', 'root', 13, 'individuals'), ('CHEBI_17234', 'glucose', 47, 'glucose'), ('CHEBI_17234', 'glucose', 71, 'glucose'), ('CHEBI_33279', 'vitamin D5', 128, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 128, 'vitamin D3')]
PMC4113768	7/2014	S3068-PMC4113768	['Oral Glucose tolerance tests (ogtt) have been performed annually with the main outcome after 1 year being changes in Glucose tolerance.']	N/A	N/A	[('UBERON_0000978', 'leg', 0, 'Oral'), ('CHEBI_17234', 'glucose', 5, 'glucose'), ('CHEBI_17234', 'glucose', 117, 'glucose')]
PMC4113768	7/2014	S3070-PMC4113768	['there were no differences between the groups regarding fasting blood Glucose, 2 h blood Glucose after oggt, hba1c levels, Insulin secretion and sensitivity and development of type 2 diabetes after 1 year.']	N/A	N/A	[('CHEBI_17234', 'glucose', 69, 'glucose'), ('CHEBI_17234', 'glucose', 88, 'glucose'), ('PR_000045358', 'insulin family protein', 122, 'insulin')]
PMC4113771	7/2014	S20-PMC4113771	['the primary outcome was reduction in rates of macrosomia while the secondary outcomes were a reduction in excess Gestational weight gain and attenuation of the normal Pregnancy-related increase Glucose intolerance [4].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 113, 'gestational'), ('GO_0007565', 'female pregnancy', 167, 'pregnancy'), ('CHEBI_17234', 'glucose', 194, 'glucose')]
PMC4113771	7/2014	S24-PMC4113771	['gi is used to classify different Carbohydrate Foods according to Glycaemic response gi is defined as “the incremental area under the Blood Glucose response curve of a test Food containing 50 g available Carbohydrate expressed as a percentage of the response to the same amount of available Carbohydrate from a reference Food”, the reference Food usually being Glucose or white bread [10].']	N/A	N/A	[('CHEBI_16730', 'chloramphenicol 3-acetate', 33, 'carbohydrate'), ('CHEBI_33290', 'food', 46, 'foods'), ('GO_0006096', 'glycolytic process', 65, 'glycaemic'), ('UBERON_0000178', 'blood', 133, 'blood'), ('CHEBI_17234', 'glucose', 139, 'glucose'), ('CHEBI_33290', 'food', 172, 'food'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 203, 'carbohydrate'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 290, 'carbohydrate'), ('CHEBI_33290', 'food', 320, 'food'), ('CHEBI_33290', 'food', 341, 'food'), ('CHEBI_17234', 'glucose', 360, 'glucose')]
PMC4120194	7/2014	S91-PMC4120194	['caption (table-wrap): table 7\n\nconsiderations for baseline laboratory investigations (as needed based on patient’s presenting symptoms)basic lab tests • complete blood count• fasting Glucose• fasting Lipid profile (tc, vldl, ldl, hdl, tg)• Thyroid-Stimulating Hormone• electrolytes• Liver enzymes if warranted • Urine toxicology for substance use\nadapted from references [32,53].']	N/A	N/A	[('CHEBI_17234', 'glucose', 183, 'glucose'), ('CHEBI_18059', 'lipid', 200, 'lipid'), ('CHEBI_81565', 'resolvin D2', 240, 'Thyroid-stimulating hormone'), ('UBERON_0002107', 'liver', 283, 'Liver'), ('UBERON_0001088', 'urine', 312, 'Urine')]
PMC4122175	8/2014	S153-PMC4122175	['Adult offspring of all generations and crosses were tested in a Glucose tolerance test (gtt).']	N/A	N/A	[('UBERON_0007023', 'adult organism', 0, 'Adult'), ('CHEBI_17234', 'glucose', 64, 'glucose')]
PMC4122175	8/2014	S163-PMC4122175	['(a) Adult sprague dawley (ss f1) male and female Rats exposed to Alcohol in utero showed hyperglycemic Glucose responses in the Glucose tolerance test (gtt).']	N/A	N/A	[('UBERON_0007023', 'adult organism', 4, 'Adult'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 49, 'rats'), ('CHEBI_30879', 'alcohol', 65, 'alcohol'), ('CHEBI_17234', 'glucose', 103, 'glucose'), ('CHEBI_17234', 'glucose', 128, 'glucose')]
PMC4122175	8/2014	S167-PMC4122175	['Glucose levels were measured in duplicates by stanbio Glucose liquicolor kit.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('CHEBI_17234', 'glucose', 54, 'glucose')]
PMC4122175	8/2014	S168-PMC4122175	['there were no sex differences in the Glucose response to gtt of ss f1 offspring; therefore, male and female data were combined.']	N/A	N/A	[('CHEBI_17234', 'glucose', 37, 'glucose')]
PMC4124499	8/2014	S69-PMC4124499	['oral Glucose challenge test (gct)\nat 28\xa0weeks Gestation, fasting Glucose was measured and a Glucose challenge test (gct) measuring Serum Glucose one hour post 50\xa0g Glucose load was performed.']	N/A	N/A	[('CHEBI_17234', 'glucose', 5, 'glucose'), ('GO_0007565', 'female pregnancy', 46, 'gestation'), ('CHEBI_17234', 'glucose', 65, 'glucose'), ('CHEBI_17234', 'glucose', 92, 'glucose'), ('UBERON_0001977', 'blood serum', 131, 'serum'), ('CHEBI_17234', 'glucose', 137, 'glucose'), ('CHEBI_17234', 'glucose', 164, 'glucose')]
PMC4124499	8/2014	S70-PMC4124499	['Postprandial Blood Glucose levels were recorded with results ≥7.8\xa0mmol/l categorised as Glucose intolerance [42,43].']	N/A	N/A	[('GO_0008283', 'cell proliferation', 0, 'Postprandial'), ('UBERON_0000178', 'blood', 13, 'blood'), ('CHEBI_17234', 'glucose', 19, 'glucose'), ('CHEBI_17234', 'glucose', 88, 'glucose')]
PMC4124499	8/2014	S72-PMC4124499	['if women have a blood Glucose level of\u2009>\u20098.3\xa0mmol/l 1\xa0hour post gct, formal Glucose tolerance testing is carried out on a different day to rule out Gestational diabetes.']	N/A	N/A	[('CHEBI_17234', 'glucose', 22, 'glucose'), ('CHEBI_17234', 'glucose', 76, 'glucose'), ('GO_0007565', 'female pregnancy', 148, 'gestational')]
PMC4124499	8/2014	S89-PMC4124499	['maternal characteristics did not differ between the control and intervention groups except for Gestational weight gain [25,27], Glucose intolerance and Maternal well-Being score [29] as previously described.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 95, 'gestational'), ('CHEBI_17234', 'glucose', 128, 'glucose'), ('GO_0007618', 'mating', 152, 'maternal'), ('GO_0016441', 'posttranscriptional gene silencing', 165, '-being')]
PMC4124499	8/2014	S94-PMC4124499	['caption (table-wrap): table 1\n\ngeneral maternal characteristics during Pregnancy, neonatal anthropometry and comparison of control and intervention (low glycaemic index diet) groups\xa0 ninterventioncontroltotalp-value mother age (yrs)54232.83\u2009±\u20093.9732.91\u2009±\u20093.9132.87\u2009±\u20093.930.824mother height (cm)542165.58\u2009±\u200912.29165.03\u2009±\u200911.54165.27\u2009±\u200911.860.591mother weight (kg)54272.45\u2009±\u200912.9572.32\u2009±\u200912.9772.38\u2009±\u200912.940.905mother bmi1(kg/m2)54226.19\u2009±\u20094.3526.38\u2009±\u20094.4226.30\u2009±\u20094.380.616gestational weight gain (kg)27312.48\u2009±\u20094.4014.13\u2009±\u20094.5513.39\u2009±\u20094.550.003postprandial Glucose*5376.47\u2009±\u20091.426.77\u2009±\u20091.776.64\u2009±\u20091.630.031mother well-being% score50856.37\u2009±\u200915.3860.21\u2009±\u200915.1958.48\u2009±\u200915.370.005days per week walking ≥30\xa0min24263.55\u2009±\u20091.863.44\u2009±\u20091.743.48\u2009±\u20091.790.527moderate activity (min per week)30870.80\u2009±\u200949.7061.80\u2009±\u200936.6466.20\u2009±\u200943.460.066t1 energy intake (kcal/d)5211828.25\u2009±\u2009407.981874.02\u2009±\u2009474.101854.47\u2009±\u2009446.120.245t2 energy intake (kcal/d)5291803.43\u2009±\u2009440.821943.24\u2009±\u2009476.751883.50\u2009±\u2009467.540.001t3 energy intake (kcal/d)5411832.55\u2009±\u2009424.021932.42\u2009±\u2009472.561889.62\u2009±\u2009454.910.011t1 protein intake (%te)52117.23\u2009±\u20093.0416.80\u2009±\u20093.1016.98\u2009±\u20093.080.114t2 protein intake (%te)52917.79\u2009±\u20093.1616.75\u2009±\u20092.9217.21\u2009±\u20093.07<0.001t3 protein intake (%te)54117.62\u2009±\u20093.1816.69\u2009±\u20092.9617.10\u2009±\u20093.09<0.001t1 Carbohydrate intake (%te)52150.31\u2009±\u20096.6550.32\u2009±\u20096.3550.31\u2009±\u20096.470.996t2 Carbohydrate intake (%te)52948.99\u2009±\u20095.9149.88\u2009±\u20095.9449.48\u2009±\u20095.940.089t3 Carbohydrate intake (%te)54149.05\u2009±\u20095.5049.96\u2009±\u20096.0949.57\u2009±\u20095.850.072t1total fat intake (%te)52135.47\u2009±\u20095.9235.83\u2009±\u20095.4535.68\u2009±\u20095.660.471t2 total fat intake (%te)52936.11\u2009±\u20095.3536.30\u2009±\u20095.4336.22\u2009±\u20095.390.673t3 total fat intake (%te)54136.19\u2009±\u20095.2636.20\u2009±\u20095.4036.19\u2009±\u20095.330.978t1 sfa3intake (%te)52113.35\u2009±\u20093.0013.76\u2009±\u20092.9313.57\u2009±\u20092.970.119t2 sfa3intake (%te)52913.45\u2009±\u20093.0013.95\u2009±\u20093.0013.72\u2009±\u20093.020.055t3 sfa3intake (%te)54114.00\u2009±\u20093.1713.90\u2009±\u20093.1013.93\u2009±\u20093.140.721t1 mufa4intake (%te)52111.09\u2009±\u20092.5511.38\u2009±\u20092.4011.26\u2009±\u20092.470.184t2 mufa4intake (%te)52911.41\u2009±\u20092.3711.49\u2009±\u20092.2611.46\u2009±\u20092.310.695t3 mufa4intake (%te)54111.25\u2009±\u20092.2911.38\u2009±\u20092.2111.33\u2009±\u20092.240.497t1 pufa5intake (%te)5215.99\u2009±\u20092.105.81\u2009±\u20092.115.90\u2009±\u20092.120.347t2 pufa5intake (%te)5296.07\u2009±\u20091.765.78\u2009±\u20091.805.91\u2009±\u20091.800.066t3 pufa5intake (%te)5415.79\u2009±\u20091.815.72\u2009±\u20091.875.76\u2009±\u20091.850.672t1 glycaemic index52157.38\u2009±\u20094.2457.71\u2009±\u20094.0357.56\u2009±\u20094.120.365t2 glycaemic index52956.26\u2009±\u20094.0457.83\u2009±\u20093.7157.13\u2009±\u20093.93<0.001t3 Glycaemic index54156.12\u2009±\u20093.8857.70\u2009±\u20093.8857.00\u2009±\u20093.96<0.001t1 Glycaemic load521132.40\u2009±\u200932.79136.45\u2009±\u200938.70134.69\u2009±\u200936.210.209t2 Glycaemic load529123.34\u2009±\u200931.42140.26\u2009±\u200936.90132.93\u2009±\u200935.62<0.001t3 glycaemic load541126.49\u2009±\u200930.03139.81\u2009±\u200937.22134.10\u2009±\u200934.96<0.001neonatal weight (kg)5424.05\u2009±\u20090.474.01\u2009±\u20090.454.02\u2009±\u20090.460.274neonatal length (cm)54253.01\u2009±\u20092.4052.48\u2009±\u20092.6852.73\u2009±\u20092.560.160neonatal Abdominal circ6(cm)22233.24\u2009±\u20092.2933.54\u2009±\u20091.9633.40\u2009±\u20092.110.303neonatal waist circ6:height ratio1820.63\u2009±\u20090.040.64\u2009±\u20090.050.64\u2009±\u20090.050.013neonatal sosf7(mm)18628.66\u2009±\u20095.6028.52\u2009±\u20094.8828.58\u2009±\u20095.180.848neonatal sum tsf8and ssf9(mm)18613.87\u2009±\u20092.8313.92\u2009±\u20092.6013.90\u2009±\u20092.690.906neonatal tsf8:ssf9ratio1861.01\u2009±\u20090.191.00\u2009±\u20090.181.00\u2009±\u20090.190.489neonatal Waist:hip circ6ratio2210.99\u2009±\u20090.061.00\u2009±\u20090.051.00\u2009±\u20090.060.192\n“n” denotes number, %te denotes percentage of total energy, p\u2009<\u20090.05 was considered statistically significant (2-tailed significance generated from anova or t-tests as appropriate).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 71, 'pregnancy'), ('CHEBI_17234', 'glucose', 556, 'glucose'), ('CHEBI_16646', 'carbohydrate', 1275, 'Carbohydrate'), ('CHEBI_16646', 'carbohydrate', 1347, 'Carbohydrate'), ('CHEBI_16646', 'carbohydrate', 1419, 'Carbohydrate'), ('GO_0006281', 'DNA repair', 2386, 'Glycaemic'), ('GO_0006281', 'DNA repair', 2449, 'Glycaemic'), ('GO_0006281', 'DNA repair', 2516, 'Glycaemic'), ('UBERON_0000916', 'abdomen', 2783, 'Abdominal'), ('UBERON_0000088', 'trophoblast', 3128, 'Waist')]
PMC4124499	8/2014	S95-PMC4124499	['*1\xa0hour post 50\xa0g Glucose challenge test.']	N/A	N/A	[('CHEBI_17234', 'glucose', 18, 'glucose')]
PMC4129499	8/2014	S146-PMC4129499	['this includes fasting morning labs of Lactate, Pyruvate, Carnitine (free and total), Acyl Carnitine panel, quantitative Plasma amino acids, ubiquinone, Ammonia, ck, ast/alt, Co2, and Glucose (44).']	N/A	N/A	[('CHEBI_24996', 'lactate', 38, 'lactate'), ('CHEBI_15361', 'pyruvate', 47, 'pyruvate'), ('CHEBI_17126', 'carnitine', 57, 'carnitine'), ('CHEBI_17387', 'O-acylcarnitine', 85, 'acyl carnitine'), ('UBERON_0001969', 'blood plasma', 120, 'plasma'), ('CHEBI_16134', 'ammonia', 152, 'ammonia'), ('CHEBI_16526', 'carbon dioxide', 174, 'CO2'), ('CHEBI_17234', 'glucose', 183, 'glucose')]
PMC4132016	8/2014	S46-PMC4132016	['measurement of Metabolites and hormones\nthe Plasma Glucose concentration was measured by using a Glucose Reagent strip and a glucometer (glucotouch, lifescan, milpitas, ca).']	N/A	N/A	[('CHEBI_25212', 'metabolite', 15, 'metabolites'), ('UBERON_0001969', 'blood plasma', 44, 'plasma'), ('CHEBI_17234', 'glucose', 51, 'glucose'), ('CHEBI_17234', 'glucose', 97, 'glucose'), ('CHEBI_33893', 'reagent', 105, 'reagent')]
PMC4132016	8/2014	S98-PMC4132016	['Glucose, Insulin and Triglycerides levels are significantly decreased in Plasma of f1-lpd Mice.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('PR_000045358', 'insulin family protein', 9, 'insulin'), ('CHEBI_17855', 'triglyceride', 21, 'triglycerides'), ('UBERON_0001969', 'blood plasma', 73, 'plasma'), ('NCBITaxon_10088', 'Mus <genus>', 90, 'mice')]
PMC4132016	8/2014	S100-PMC4132016	['the body weight gain per unit of energy consumed) as well as Glucose and Lipid Homeostasis.']	N/A	N/A	[('CHEBI_17234', 'glucose', 61, 'glucose'), ('GO_0007369', 'gastrulation', 61, 'glucose ...'), ('CHEBI_18059', 'lipid', 73, 'lipid'), ('GO_0055088', 'lipid homeostasis', 73, 'lipid homeostasis')]
PMC4132016	8/2014	S126-PMC4132016	['*p≤0.05.10.1371/journal.pone.0104896.t001\n\ncaption (table-wrap): table 1\nphysiological parameters.f1-Cdf1-lpdp-valueglucose (mg/dl)89.13±9.0763.57±8.990.026insulin (ng/ml)0.463±0.0340.167±0.0067.6×10−09tg (mm)0.564±0.0240.381±0.0231.43×10−06cholesterol (mm)3.376±0.0123.431±0.0120.0023cholesterol-hdl (mm)0.752±0.0190.78±0.024ns\nPlasma Metabolites and hormones parameters of 7-mo-old male f1-cd and f1-lpd Mice were measured in Plasma of over-night starved Animals and are expressed as means ±semfor n\u200a=\u200a10 (Glucose) or n\u200a=\u200a25 (Insulin, tg, Cholesterol, Cholesterol-hdl).']	N/A	N/A	[('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 101, 'CDF1'), ('UBERON_0001969', 'blood plasma', 329, 'Plasma'), ('CHEBI_25212', 'metabolite', 336, 'metabolites'), ('NCBITaxon_10088', 'Mus <genus>', 406, 'mice'), ('UBERON_0001969', 'blood plasma', 428, 'plasma'), ('NCBITaxon_33208', 'Metazoa', 457, 'animals'), ('CHEBI_17234', 'glucose', 508, 'Glucose'), ('PR_000045358', 'insulin family protein', 528, 'Insulin'), ('CHEBI_16113', 'cholesterol', 541, 'Cholesterol'), ('CHEBI_16113', 'cholesterol', 554, 'Cholesterol')]
PMC4141279	8/2014	S58-PMC4141279	['Metabolic Regulation\nGlucose tolerance test (gtt) .']	N/A	N/A	[('GO_0045729', 'respiratory burst at fertilization', 0, 'Metabolic regulation'), ('CHEBI_17234', 'glucose', 21, 'Glucose')]
PMC4141279	8/2014	S60-PMC4141279	['Animals were intra-Peritoneally (ip) loaded with 2 g/kg body weight D-Glucose (10% D Glucose Solution; sigma, st. louis, mo, usa) (satapathy et al.,2011).']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 0, 'Animals'), ('UBERON_0001179', 'peritoneal cavity', 19, 'peritoneally'), ('CHEBI_17634', 'D-glucose', 68, 'D-glucose'), ('CHEBI_17234', 'glucose', 83, 'D glucose'), ('CHEBI_75958', 'solution', 93, 'solution')]
PMC4141279	8/2014	S61-PMC4141279	['Blood was collected from the Tail Vein at 0 (baseline), 30, 60, 120 and 180 min (ranieri et al.,2010) following ip injection and glycemia (blood Glucose concentration) was measured using a commercial glucometer (statstrip xpress-i, nova biomedical, a. menarini diagnostic) (titta et al.,2010).']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('UBERON_0003481', 'tail vein', 29, 'tail vein'), ('CHEBI_17234', 'glucose', 145, 'glucose')]
PMC4141279	8/2014	S140-PMC4141279	['Metabolic Regulation\nGlucose tolerance test (gtt) .']	N/A	N/A	[('GO_0045729', 'respiratory burst at fertilization', 0, 'Metabolic regulation'), ('CHEBI_17234', 'glucose', 21, 'Glucose')]
PMC4141279	8/2014	S154-PMC4141279	['Glucose tolerance assessment in wt and ko male (a) and female (b) offspring Fed cd or hfd.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('GO_0007631', 'feeding behavior', 76, 'fed')]
PMC4141279	8/2014	S222-PMC4141279	['in particular, ko Mice show a greater resistance toward Glucose challenge compared to wt.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 18, 'mice'), ('CHEBI_17234', 'glucose', 56, 'glucose')]
PMC4143751	8/2014	S83-PMC4143751	['maternal Folic Acid supplementation along with a high fat diet increased Glucose intolerance and Insulin resistance in male Mice offspring (huang et al.,2014).']	N/A	N/A	[('CHEBI_30751', 'formic acid', 9, 'folic acid'), ('CHEBI_17234', 'glucose', 73, 'glucose'), ('PR_000045358', 'insulin family protein', 97, 'insulin'), ('NCBITaxon_10088', 'Mus <genus>', 124, 'mice')]
PMC4155824	8/2014	S140-PMC4155824	['a knock-out mutant of the wele Gene, encoding the priming Glycosyltransferase, is completely devoid of the long Galactose-rich eps but shows a higher concentration of short Glucose-rich eps [62].']	N/A	N/A	[('SO_0000704', 'gene', 31, 'gene'), ('CHEBI_24405', 'glycosylglucose', 58, 'glycosyltransferase'), ('CHEBI_28260', 'galactose', 112, 'galactose'), ('CHEBI_17234', 'glucose', 173, 'glucose')]
PMC4161944	9/2014	S160-PMC4161944	['in utero exposure to famine resulted in lower Birth weights, later increased rates of mental illness (schizophrenia and antisocial personality disorder), congenital neural defects, obstructive Airway disease, Coronary Heart disease, altered Renal function, fivefold increases in Breast cancer risk among women and reduced Glucose and Insulin tolerance (124).']	N/A	N/A	[('GO_0007567', 'parturition', 46, 'birth'), ('UBERON_0001005', 'respiratory airway', 193, 'airway'), ('UBERON_0004151', 'cardiac chamber', 209, 'coronary heart'), ('UBERON_0002113', 'kidney', 241, 'renal'), ('UBERON_0000310', 'breast', 279, 'breast'), ('CHEBI_17234', 'glucose', 322, 'glucose'), ('PR_000045358', 'insulin family protein', 334, 'insulin')]
PMC4162567	9/2014	S51-PMC4162567	['we sent an additional questionnaire to participants who reported probable new onset gdm, requesting their written confirmation and date of the diagnosis of either gdm, a previous diagnosis of diabetes, their highest fasting Glucose value, their first glycated haemoglobin during Pregnancy, whether they had ever undergone an oral Glucose tolerance test and its results, and the use during Pregnancy of Insulin.']	N/A	N/A	[('CHEBI_17234', 'glucose', 224, 'glucose'), ('GO_0007565', 'female pregnancy', 279, 'pregnancy'), ('CHEBI_17234', 'glucose', 330, 'glucose'), ('GO_0007565', 'female pregnancy', 389, 'pregnancy'), ('CHEBI_66075', 'inflexin', 402, 'insulin'), ('PR_000045358', 'insulin family protein', 402, 'insulin')]
PMC4162567	9/2014	S59-PMC4162567	['the usual diagnosis criteria for gdm in spain were those with 100-g oral Glucose tolerance test with the cut-off points of carpenter and coustan[27]or the cut-off points from the national diabetes data group[28]after a positive 50-g Glucose challenge test.']	N/A	N/A	[('CHEBI_17234', 'glucose', 73, 'glucose'), ('CHEBI_17234', 'glucose', 233, 'glucose')]
PMC4166817	10/2014	S22-PMC4166817	['[8] in zucker diabetic fatty Rats, drinking Water containing 63% Watermelon pomace Juice for 4 weeks increased Serum concentrations of arginine; reduced-fat accretion; lowered the Serum concentrations of Glucose, free Fatty Acids, Homocysteine, and dimethylarginine; enhanced guanosine triphosphate cyclohydrolase-i activity and Tetrahydrobiopterin concentrations in the heart; and improved Acetylcholine-induced vascular relaxation.']	N/A	N/A	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 29, 'rats'), ('CHEBI_15377', 'water', 44, 'water'), ('CHEBI_10032', 'Warburganal', 65, 'watermelon'), ('CHEBI_37958', 'dye', 83, 'juice'), ('UBERON_0001977', 'blood serum', 111, 'serum'), ('UBERON_0001977', 'blood serum', 180, 'serum'), ('CHEBI_17234', 'glucose', 204, 'glucose'), ('CHEBI_35366', 'fatty acid', 218, 'fatty acids'), ('CHEBI_17088', 'monoacyl-sn-glycerol 3-phosphate', 231, 'homocysteine'), ('CHEBI_26914', 'tetrahydromethanopterin', 329, 'tetrahydrobiopterin'), ('CHEBI_15355', 'acetylcholine', 391, 'acetylcholine')]
PMC4183922	6/2014	S19-PMC4183922	['Hypothalamic Neurons are exquisitely sensitive to changes in Extracellular Glucose-levels (16) and disturbance of their ability to respond appropriately leads to dysfunctional maintenance of whole body Glucose Homeostasis (17).']	N/A	N/A	[('CL_0000743', 'hypertrophic chondrocyte', 0, 'Hypothalamic neurons'), ('UBERON_0001898', 'hypothalamus', 0, 'Hypothalamic'), ('GO_0005576', 'extracellular region', 61, 'extracellular'), ('CHEBI_17234', 'glucose', 75, 'glucose'), ('CHEBI_17234', 'glucose', 202, 'glucose'), ('GO_0042593', 'glucose homeostasis', 202, 'glucose homeostasis')]
PMC4183922	6/2014	S29-PMC4183922	['weight, Food Intake, and ambient Glucose measurements\nweight and Blood Glucose measurements were collected from dams every two days between 10:00 and 11:00 am.']	N/A	N/A	[('CHEBI_33290', 'food', 8, 'food'), ('GO_0007631', 'feeding behavior', 8, 'food intake'), ('CHEBI_17234', 'glucose', 33, 'glucose'), ('UBERON_0000178', 'blood', 65, 'blood'), ('CHEBI_17234', 'glucose', 71, 'glucose')]
PMC4183922	6/2014	S30-PMC4183922	['circulating Blood Glucose measurements were collected from a Tail tip using a one touch ultra handheld Glucose meter (lifescan, inc).']	N/A	N/A	[('UBERON_0000178', 'blood', 12, 'blood'), ('CHEBI_17234', 'glucose', 18, 'glucose'), ('UBERON_0002415', 'tail', 61, 'tail'), ('CHEBI_17234', 'glucose', 103, 'glucose')]
PMC4183922	6/2014	S34-PMC4183922	['fasting Glucose\nMice were single caged and fasted for 6 hours with access to Water.']	N/A	N/A	[('CHEBI_17234', 'glucose', 8, 'glucose'), ('NCBITaxon_10088', 'Mus <genus>', 16, 'Mice'), ('CHEBI_15377', 'water', 77, 'water')]
PMC4183922	6/2014	S35-PMC4183922	['Blood Glucose measurements were collected by Tail tip at the start and end of the fast.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('CHEBI_17234', 'glucose', 6, 'glucose'), ('UBERON_0002415', 'tail', 45, 'tail')]
PMC4183922	6/2014	S36-PMC4183922	['Glucose tolerance test\nMice were fasted for 6 hours and injected Intraperitoneally (ip) with a 20% (wt/vol) Glucose Solution at 2g/kg body weight.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('NCBITaxon_10088', 'Mus <genus>', 23, 'Mice'), ('UBERON_0000007', 'pituitary gland', 65, 'intraperitoneally'), ('CHEBI_17234', 'glucose', 108, 'glucose'), ('CHEBI_75958', 'solution', 116, 'solution')]
PMC4183922	6/2014	S37-PMC4183922	['Blood Glucose levels were measured before and 15, 30, 45, 60, 90, and 120 minutes after Glucose injection.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('CHEBI_17234', 'glucose', 6, 'glucose'), ('CHEBI_17234', 'glucose', 88, 'glucose')]
PMC4183922	6/2014	S38-PMC4183922	['for measurement of Insulin Release in response to Glucose, Animals were killed at 0, 30, or 60 minutes after Glucose injection and Truncal Blood collected for further analysis.']	N/A	N/A	[('GO_0006880', 'intracellular sequestering of iron ion', 19, 'insulin release'), ('PR_000045358', 'insulin family protein', 19, 'insulin'), ('CHEBI_17234', 'glucose', 50, 'glucose'), ('NCBITaxon_33208', 'Metazoa', 59, 'animals'), ('CHEBI_17234', 'glucose', 109, 'glucose'), ('UBERON_0002061', 'truncus arteriosus', 131, 'truncal'), ('UBERON_0000178', 'blood', 139, 'blood')]
PMC4183922	6/2014	S40-PMC4183922	['Blood Glucose levels were measured before and 15, 30, 45, 60, 75, and 90 minutes after Insulin injection.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('CHEBI_17234', 'glucose', 6, 'glucose'), ('PR_000045358', 'insulin family protein', 87, 'insulin')]
PMC4183922	6/2014	S47-PMC4183922	['after 1 hour, Blood Glucose levels were ascertained to be below 2.5 mm and Animals culled by overdose of Anesthetic (euthatal).']	N/A	N/A	[('UBERON_0000178', 'blood', 14, 'blood'), ('CHEBI_17234', 'glucose', 20, 'glucose'), ('NCBITaxon_33208', 'Metazoa', 75, 'animals'), ('CHEBI_38867', 'anaesthetic', 105, 'anesthetic')]
PMC4183922	6/2014	S56-PMC4183922	['Glucose-sensitive Hypothalamic Gene Expression Modulation.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('UBERON_0001898', 'hypothalamus', 18, 'hypothalamic'), ('GO_0010468', 'regulation of gene expression', 31, 'gene expression modulation'), ('SO_0000704', 'gene', 31, 'gene')]
PMC4183922	6/2014	S58-PMC4183922	['b, arc Glut3, Irs2, Crh, and kir6.2 mrna Expression (taqman probe and multiplexing against 18S Rrna) was measured in male cd1 Mice 60 minutes after either a saline injection (sal) or Insulin-induced hypoglycemia (<2.5 mm blood Glucose; hypo) (n = 5–9; *, p< .05; **, p< .01; ***, p< .001 t -test for individual Genes).']	N/A	N/A	[('PR_000008011', 'glycerol kinase 2', 7, 'Glut3'), ('PR_000009158', 'inositol 1,4,5-trisphosphate receptor type 1', 14, 'Irs2'), ('PR_000005904', 'cone-rod homeobox protein', 20, 'Crh'), ('GO_0010467', 'gene expression', 41, 'expression'), ('SO_0000407', 'cytosolic_18S_rRNA', 91, '18S rRNA'), ('NCBITaxon_10088', 'Mus <genus>', 126, 'mice'), ('PR_000045358', 'insulin family protein', 183, 'insulin'), ('CHEBI_17234', 'glucose', 227, 'glucose'), ('SO_0000704', 'gene', 311, 'genes')]
PMC4183922	6/2014	S74-PMC4183922	['b, body weight and c, blood Glucose of Chow- and hfd-Fed dams during Pregnancy and Lactation (n = 8; **, p< .01; *, p< .05, 2-way repeated measures anova).']	N/A	N/A	[('CHEBI_17234', 'glucose', 28, 'glucose'), ('CHEBI_33290', 'food', 39, 'chow'), ('GO_0007631', 'feeding behavior', 53, 'fed'), ('GO_0007565', 'female pregnancy', 69, 'pregnancy'), ('GO_0007595', 'lactation', 83, 'lactation')]
PMC4183922	6/2014	S77-PMC4183922	['female offspring of hfd-Fed dams is more vulnerable to Metabolic disturbance than males\nat p4 no difference in body weight or Blood Glucose was noted between unsexed offc and offhfd (figure 3a).']	N/A	N/A	[('GO_0007631', 'feeding behavior', 24, 'fed'), ('GO_0008152', 'metabolic process', 55, 'metabolic'), ('UBERON_0000178', 'blood', 126, 'blood'), ('CHEBI_17234', 'glucose', 132, 'glucose')]
PMC4183922	6/2014	S78-PMC4183922	['at p21 both female and male offhfd pups had significantly increased weight and Blood Glucose (figure 3b).']	N/A	N/A	[('UBERON_0000178', 'blood', 79, 'blood'), ('CHEBI_17234', 'glucose', 85, 'glucose')]
PMC4183922	6/2014	S80-PMC4183922	['male offhfd body weight normalized within a week of weaning; Blood Glucose levels also returned to normal within 3 days (figure 3d).']	N/A	N/A	[('UBERON_0000178', 'blood', 61, 'blood'), ('CHEBI_17234', 'glucose', 67, 'glucose')]
PMC4183922	6/2014	S84-PMC4183922	['a, body weight and Blood Glucose of (unsexed) p4 offspring from Chow-Fed (offc) or hfd-Fed (offhfd) dams (n = 15).']	N/A	N/A	[('UBERON_0000178', 'blood', 19, 'blood'), ('CHEBI_17234', 'glucose', 25, 'glucose'), ('CHEBI_33290', 'food', 64, 'chow'), ('GO_0007631', 'feeding behavior', 69, 'fed'), ('GO_0007631', 'feeding behavior', 87, 'fed')]
PMC4183922	6/2014	S85-PMC4183922	['b, female and male offc and offhfd body weight and Blood Glucose at p21/weaning (n = 33–42; **, p< .01; ***, p< .001; 1-way anova).']	N/A	N/A	[('UBERON_0000178', 'blood', 51, 'blood'), ('CHEBI_17234', 'glucose', 57, 'glucose')]
PMC4183922	6/2014	S86-PMC4183922	['c, female body weight and Blood Glucose curves after weaning until 8 weeks of age.']	N/A	N/A	[('UBERON_0000178', 'blood', 26, 'blood'), ('CHEBI_17234', 'glucose', 32, 'glucose')]
PMC4183922	6/2014	S87-PMC4183922	['d, male body weight and blood Glucose curves after weaning until 8 weeks of age (n = 14–24; **, p< .01; *, p< .05; 2-way repeated measures anova).']	N/A	N/A	[('CHEBI_17234', 'glucose', 30, 'glucose')]
PMC4183922	6/2014	S92-PMC4183922	['Adult female offspring of hfd-Fed dams have dysfunctional Glucose Homeostasis.']	N/A	N/A	[('UBERON_0007023', 'adult organism', 0, 'Adult'), ('GO_0007631', 'feeding behavior', 30, 'fed'), ('CHEBI_17234', 'glucose', 58, 'glucose'), ('GO_0042593', 'glucose homeostasis', 58, 'glucose homeostasis')]
PMC4183922	6/2014	S95-PMC4183922	['c, 8-week-old female and male offc and offhfd were fasted at 9:00 am for 6 hours and Blood Glucose measured at 1 and 6 hours (n = 13–15; *, p< .05; 2-way repeated measures anova).']	N/A	N/A	[('UBERON_0000178', 'blood', 85, 'blood'), ('CHEBI_17234', 'glucose', 91, 'glucose')]
PMC4183922	6/2014	S96-PMC4183922	['d, Glucose tolerance test (2g/kg) in 8-week-old female and male offc and offhfd (n = 8–11; **, p< .01; 2-way repeated measures anova).']	N/A	N/A	[('CHEBI_17234', 'glucose', 3, 'Glucose')]
PMC4183922	6/2014	S100-PMC4183922	['male offhfd Insulin responses to the Glucose tolerance test are comparable to offc (supplemental figure 3b).']	N/A	N/A	[('PR_000045358', 'insulin family protein', 12, 'insulin'), ('CHEBI_17234', 'glucose', 37, 'glucose')]
PMC4183922	6/2014	S107-PMC4183922	['sexual dimorphism in pvh Glucose- and maternal-diet-sensitive Gene Expression Regulation.']	N/A	N/A	[('CHEBI_17234', 'glucose', 25, 'glucose'), ('GO_0010468', 'regulation of gene expression', 62, 'gene expression regulation'), ('SO_0000704', 'gene', 62, 'gene')]
PMC4183922	6/2014	S109-PMC4183922	['to further analyze this sexual dimorphism in Glucose-responsive Pvh Gene Expression, Pvh Gene Expression was plotted against Blood Glucose levels for all Adult male and female offc Mice (figure 6).']	N/A	N/A	[('CHEBI_17234', 'glucose', 45, 'glucose'), ('PR_000013502', 'parvalbumin alpha', 64, 'PVH'), ('GO_0010467', 'gene expression', 68, 'gene expression'), ('SO_0000704', 'gene', 68, 'gene'), ('PR_000013502', 'parvalbumin alpha', 85, 'PVH'), ('GO_0010467', 'gene expression', 89, 'gene expression'), ('SO_0000704', 'gene', 89, 'gene'), ('UBERON_0000178', 'blood', 125, 'blood'), ('CHEBI_17234', 'glucose', 131, 'glucose'), ('UBERON_0007023', 'adult organism', 154, 'adult'), ('NCBITaxon_10088', 'Mus <genus>', 181, 'mice')]
PMC4183922	6/2014	S119-PMC4183922	['Glucose homeostasis dysregulation in female offspring of hfd-Fed dams is programmed in utero.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('GO_0007631', 'feeding behavior', 61, 'fed')]
PMC4183922	6/2014	S124-PMC4183922	['Blood Glucose drop is expressed as %prefast (n = 10–14; **, p< .01; *, p< .05; 2-way repeated measures anova).']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('CHEBI_17234', 'glucose', 6, 'glucose')]
PMC4194375	10/2014	S24-PMC4194375	['dietary Glycaemic index (gi) was developed as a tool for Individuals with diabetes [18], ranking the post-prandial Glycaemic response to Ingested Carbohydrates against a reference of either pure Glucose or white bread, and the Glycaemic load (gl) is the product of the Glycaemic index and the amount of dietary Carbohydrate [19].']	N/A	N/A	[('GO_0006096', 'glycolytic process', 8, 'glycaemic'), ('NCBITaxon_1', 'root', 57, 'individuals'), ('GO_0006096', 'glycolytic process', 115, 'glycaemic'), ('GO_0007631', 'feeding behavior', 137, 'ingested'), ('CHEBI_16646', 'carbohydrate', 146, 'carbohydrates'), ('CHEBI_17234', 'glucose', 195, 'glucose'), ('GO_0006096', 'glycolytic process', 227, 'glycaemic'), ('GO_0006096', 'glycolytic process', 269, 'glycaemic'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 311, 'carbohydrate')]
PMC4196482	11/2014	S97-PMC4196482	['at 27–33 wk, we repeated the hemoglobin measurement and performed an oral-Glucose-tolerance test (who protocol) (19).']	N/A	N/A	[('CHEBI_17234', 'glucose', 74, 'glucose')]
PMC4196482	11/2014	S173-PMC4196482	['gtt, Glucose tolerance test; lmp, last Menstrual Period; ref, reference group.']	N/A	N/A	[('CHEBI_17234', 'glucose', 5, 'glucose'), ('GO_0007613', 'memory', 39, 'menstrual'), ('UBERON_0006505', 'palmar interosseous muscle of manus', 39, 'menstrual period')]
PMC4196482	11/2014	S219-PMC4196482	['strengths and limitations\nstrengths of the study were the individual random assignment, supervised supplementation, Menstrual Period monitoring combined with ultrasound to date Pregnancies, and standardized measurements of Glucose tolerance during Pregnancy.']	N/A	N/A	[('GO_0007613', 'memory', 116, 'menstrual'), ('UBERON_0006505', 'palmar interosseous muscle of manus', 116, 'menstrual period'), ('GO_0007565', 'female pregnancy', 177, 'pregnancies'), ('CHEBI_17234', 'glucose', 223, 'glucose'), ('GO_0007565', 'female pregnancy', 248, 'pregnancy')]
PMC4202338	10/2014	S168-PMC4202338	['the second pathway is the Synthesis Of Free Fatty Acids from substrates such as Glucose provided by the mother [52].']	N/A	N/A	[('GO_0019629', 'propionate catabolic process, 2-methylcitrate cycle', 26, 'synthesis of free fatty acids'), ('CHEBI_35366', 'fatty acid', 44, 'fatty acids'), ('CHEBI_17234', 'glucose', 80, 'glucose')]
PMC4210519	10/2014	S63-PMC4210519	['following the incubation period, the medium was removed and used for spectrophotometric measurement of Glucose (hexokinase/Glucose-6-Phosphate dehydrogenase assay; D-Glucose assay kit; r-biopharm, boehringer, mannheim, germany; sensitivity 0.4 mg/l) and Glycerol (Glycerol-3-Phosphate oxidase (gpo) method; free Glycerol assay kit; sensitivity 0.03 mmol/l) concentrations in triplicate.']	N/A	N/A	[('CHEBI_17234', 'glucose', 103, 'glucose'), ('CHEBI_14314', 'D-glucose 6-phosphate', 123, 'glucose-6-phosphate'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 164, 'D'), ('CHEBI_17234', 'glucose', 166, 'glucose'), ('CHEBI_17754', 'glycerol', 254, 'glycerol'), ('CHEBI_17270', 'glycerol 2-phosphate', 264, 'glycerol-3-phosphate'), ('CHEBI_17754', 'glycerol', 312, 'glycerol')]
PMC4210519	10/2014	S64-PMC4210519	['Insulin-stimulated Glucose Uptake assay\nTissue samples were incubated for 2.5 h in dmem supplemented with 1% bsa and Glucose to a concentration of 0.225 g/l with or without Insulin (10 mu/ml; recombinant Human Insulin, sigma).']	N/A	N/A	[('PR_000045358', 'insulin family protein', 0, 'Insulin'), ('CHEBI_17234', 'glucose', 19, 'glucose'), ('GO_0046323', 'glucose import', 19, 'glucose uptake'), ('UBERON_0000479', 'tissue', 40, 'Tissue'), ('CHEBI_17234', 'glucose', 117, 'glucose'), ('PR_000045358', 'insulin family protein', 173, 'insulin'), ('NCBITaxon_9606', 'Homo sapiens', 204, 'human'), ('PR_000045358', 'insulin family protein', 210, 'insulin')]
PMC4210519	10/2014	S66-PMC4210519	['post-incubation medium was collected and Glucose concentration measured.']	N/A	N/A	[('CHEBI_17234', 'glucose', 41, 'glucose')]
PMC4210519	10/2014	S67-PMC4210519	['the decrease in medium Glucose concentration in control and Insulin-supplemented incubations was considered equal to the Glucose Uptake by the Adipose Tissue (0.225 g/l before incubation – × g/l after incubation\u2009=\u2009Glucose Uptake).']	N/A	N/A	[('CHEBI_17234', 'glucose', 23, 'glucose'), ('PR_000045358', 'insulin family protein', 60, 'insulin'), ('CHEBI_17234', 'glucose', 121, 'glucose'), ('GO_0046323', 'glucose import', 121, 'glucose uptake'), ('UBERON_0001013', 'adipose tissue', 143, 'adipose tissue'), ('CHEBI_17234', 'glucose', 214, 'glucose'), ('GO_0046323', 'glucose import', 214, 'glucose uptake')]
PMC4210519	10/2014	S68-PMC4210519	['Glucose Uptake was then corrected for Adipose Tissue weight (final Glucose Uptake rate in μg/mg/2.5h).']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('GO_0042352', 'GDP-L-fucose salvage', 0, 'Glucose uptake'), ('UBERON_0001013', 'adipose tissue', 38, 'adipose tissue'), ('CHEBI_17234', 'glucose', 67, 'glucose'), ('GO_0046323', 'glucose import', 67, 'glucose uptake')]
PMC4210519	10/2014	S73-PMC4210519	['Blood sample analyses\nPlasma Glucose concentration was measured by the spectrometric Glucose oxidase/peroxidase-anti-peroxidase method (mtidiagnostics, idstein, germany; sensitivity 0.11 mmol/l)), and Plasma Triglyceride concentration by the spectrometric gpo method (wak-chemie, steinbach, germany, sensitivity 0.05 mmol/l).']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('UBERON_0001969', 'blood plasma', 22, 'Plasma'), ('CHEBI_17234', 'glucose', 29, 'glucose'), ('CHEBI_17234', 'glucose', 85, 'glucose'), ('UBERON_0001969', 'blood plasma', 201, 'plasma'), ('CHEBI_17855', 'triglyceride', 208, 'triglyceride')]
PMC4210519	10/2014	S92-PMC4210519	['linear relationships between body weight and variables of Glucose Metabolism were detected by linear regression analysis.']	N/A	N/A	[('CHEBI_17234', 'glucose', 58, 'glucose'), ('GO_0006006', 'glucose metabolic process', 58, 'glucose metabolism')]
PMC4210519	10/2014	S100-PMC4210519	['Plasma Glucose concentrations did not differ between the two groups.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_17234', 'glucose', 7, 'glucose')]
PMC4210519	10/2014	S120-PMC4210519	['Glucose Disposal in different Adipose Tissue depots in ad and un offspring\nresults of the Glucose Uptake in ex vivo Adipose Tissue explants are shown in figure\xa03a-c.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('GO_0000024', 'maltose biosynthetic process', 0, 'Glucose disposal'), ('UBERON_0001013', 'adipose tissue', 30, 'adipose tissue'), ('CHEBI_17234', 'glucose', 90, 'glucose'), ('GO_0046323', 'glucose import', 90, 'glucose uptake'), ('UBERON_0001013', 'adipose tissue', 116, 'adipose tissue')]
PMC4210519	10/2014	S123-PMC4210519	['the Insulin-dependent increase in Glucose Uptake in Adipose Tissue explants was lower in rpat compared with scat, with the un group rpat showing clearly and significantly reduced response (figure\xa03c).']	N/A	N/A	[('PR_000045358', 'insulin family protein', 4, 'insulin'), ('CHEBI_17234', 'glucose', 34, 'glucose'), ('GO_0046323', 'glucose import', 34, 'glucose uptake'), ('UBERON_0001013', 'adipose tissue', 52, 'adipose tissue')]
PMC4210519	10/2014	S124-PMC4210519	['caption (fig): figure 3\n\nInsulin-stimulated Glucose Uptake in subcutaneous (scat; a) and Retroperitoneal (rpat; b)ex vivoadipose Tissue explants.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 25, 'Insulin'), ('CHEBI_17234', 'glucose', 44, 'glucose'), ('GO_0046323', 'glucose import', 44, 'glucose uptake'), ('UBERON_0003693', 'retroperitoneal space', 89, 'retroperitoneal'), ('UBERON_0000479', 'tissue', 129, 'tissue')]
PMC4210519	10/2014	S125-PMC4210519	['c shows the Insulin-dependent increase in Glucose Uptake in Adipose Tissue explants.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 12, 'insulin'), ('CHEBI_17234', 'glucose', 42, 'glucose'), ('GO_0046323', 'glucose import', 42, 'glucose uptake'), ('UBERON_0001013', 'adipose tissue', 60, 'adipose tissue')]
PMC4210519	10/2014	S173-PMC4210519	['Insulin responsiveness of Adipose Tissues\nin the ex vivo studies, the basal Glucose Uptake in Rpat was similar in both ad and un offspring.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 0, 'Insulin'), ('UBERON_0001013', 'adipose tissue', 26, 'adipose tissues'), ('CHEBI_17234', 'glucose', 76, 'glucose'), ('GO_0046323', 'glucose import', 76, 'glucose uptake'), ('PR_000012999', 'DNA-directed RNA polymerases I, II, and III subunit RPABC5', 94, 'RpAT')]
PMC4210519	10/2014	S180-PMC4210519	['in the Scat explants, basal Glucose Uptake and Expression of markers of the Insulin Signalling Cascade were similar in both ad and un offspring.']	N/A	N/A	[('PR_000014450', 'histone deacetylase complex subunit SAP30L', 7, 'ScAT'), ('CHEBI_17234', 'glucose', 28, 'glucose'), ('GO_0046323', 'glucose import', 28, 'glucose uptake'), ('GO_0010467', 'gene expression', 47, 'expression'), ('GO_0014051', 'gamma-aminobutyric acid secretion', 76, 'insulin signalling cascade'), ('PR_000045358', 'insulin family protein', 76, 'insulin')]
PMC4210519	10/2014	S185-PMC4210519	['stored Lipids within the Vacuole stem from both de novo Fatty Acid Synthesis from Glucose and Plasma Fatty Acids, which are taken up by the Adipocyte.']	N/A	N/A	[('CHEBI_18059', 'lipid', 7, 'lipids'), ('GO_0005773', 'vacuole', 25, 'vacuole'), ('CHEBI_35366', 'fatty acid', 56, 'fatty acid'), ('GO_0006633', 'fatty acid biosynthetic process', 56, 'fatty acid synthesis'), ('CHEBI_17234', 'glucose', 82, 'glucose'), ('UBERON_0001969', 'blood plasma', 94, 'plasma'), ('CHEBI_35366', 'fatty acid', 101, 'fatty acids'), ('GO_0019401', 'alditol biosynthetic process', 107, 'acids'), ('CL_0000136', 'fat cell', 140, 'adipocyte')]
PMC4210519	10/2014	S203-PMC4210519	['in this setting, any excess Glucose would be utilised for increased Hepatic de Novo Synthesis Of Fatty Acids.']	N/A	N/A	[('CHEBI_17234', 'glucose', 28, 'glucose'), ('UBERON_0002107', 'liver', 68, 'hepatic'), ('GO_0007567', 'parturition', 79, 'novo'), ('GO_0019626', 'short-chain fatty acid catabolic process', 84, 'synthesis of fatty acids'), ('CHEBI_35366', 'fatty acid', 97, 'fatty acids')]
PMC4210914	10/2014	S51-PMC4210914	['the cells were seeded at a density of 2 × 105cells/ml in tc25 culture flasks containing 10 ml of Proliferation medium (dulbecco’s modified eagle medium (dmem-f12), 1% Antibiotic Solution (pen strep), 200 mml-glutamine, 33 mmd-Glucose, 2% b27, 20 ng/ml Epidermal Growth Factor (Egf) and 20 ng/ml Basic Fibroblast Growth Factor (Bfgf); all purchased from life technologies, carlsbad, ca, usa).']	N/A	N/A	[('GO_0008283', 'cell proliferation', 97, 'proliferation'), ('CHEBI_33282', 'antibacterial agent', 167, 'antibiotic'), ('CHEBI_75958', 'solution', 178, 'solution'), ('CHEBI_17234', 'glucose', 226, 'glucose'), ('PR_000006890', 'enhancer of mRNA-decapping protein 3', 252, 'epidermal growth factor'), ('UBERON_0007376', 'outer epithelium', 252, 'epidermal'), ('PR_000006901', 'early endosome antigen 1', 277, 'EGF'), ('PR_000004693', 'Bcl-2-like protein 10', 295, 'basic fibroblast growth factor'), ('CL_0000057', 'fibroblast', 301, 'fibroblast'), ('PR_000006910', 'elongation factor 2 kinase', 327, 'bFGF')]
PMC4231349	10/2013	S5-PMC4231349	['maternal Metabolic status was also tracked during Lactation, by following their body weight, Blood Glucose, Ketone, Cholesterol, and Triglyceride concentrations.']	N/A	N/A	[('GO_0008152', 'metabolic process', 9, 'metabolic'), ('GO_0007595', 'lactation', 50, 'lactation'), ('UBERON_0000178', 'blood', 93, 'blood'), ('CHEBI_17234', 'glucose', 99, 'glucose'), ('CHEBI_17087', 'ketone', 108, 'ketone'), ('CHEBI_16113', 'cholesterol', 116, 'cholesterol'), ('CHEBI_17855', 'triglyceride', 133, 'triglyceride')]
PMC4231349	10/2013	S59-PMC4231349	['during Lactation, and between p2.5 and p20.5, maternal body weight, Blood Glucose and β −Ketones ( β − hydroxybutyrate ) were measured every other day.']	N/A	N/A	[('GO_0007595', 'lactation', 7, 'lactation'), ('UBERON_0000178', 'blood', 68, 'blood'), ('CHEBI_17234', 'glucose', 74, 'glucose'), ('CHEBI_17087', 'ketone', 89, 'ketones')]
PMC4231349	10/2013	S60-PMC4231349	['Glucose and Ketone concentrations were measured with an abbott “precision xtra” Glucometer which required 0.6-1.5 μ l of whole-Blood per test [20], drawn from the Tail Vein.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('CHEBI_17087', 'ketone', 12, 'ketone'), ('CHEBI_24321', 'glutamo group', 80, 'glucometer'), ('UBERON_0000178', 'blood', 127, 'blood'), ('UBERON_0003481', 'tail vein', 163, 'tail vein')]
PMC4231349	10/2013	S131-PMC4231349	['further, their Blood Glucose concentration stabilized by p6.5-8.5, and did not continue to increase past the normal range exhibited by the sd control dams.']	N/A	N/A	[('UBERON_0000178', 'blood', 15, 'blood'), ('CHEBI_17234', 'glucose', 21, 'glucose')]
PMC4231349	10/2013	S133-PMC4231349	['caption (fig): figure 4\n\nBlood Glucose and Ketone concentration over time in kd and sd dams following separation from their litters at p2.5, and until p20.5.']	N/A	N/A	[('UBERON_0000178', 'blood', 25, 'Blood'), ('CHEBI_17234', 'glucose', 31, 'glucose'), ('CHEBI_17087', 'ketone', 43, 'ketone')]
PMC4231349	10/2013	S170-PMC4231349	['the elevated maternal Serum Ketone along with the statistically lower Serum Glucose concentration, as measured at p2.5, were the early signs of Ketoacidosis and an indication of physiological strain due to Lactation.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 22, 'serum'), ('CHEBI_17087', 'ketone', 28, 'ketone'), ('UBERON_0001977', 'blood serum', 70, 'serum'), ('CHEBI_17234', 'glucose', 76, 'glucose'), ('GO_0044813', 'glycolytic fermentation via PFOR pathway', 144, 'ketoacidosis'), ('GO_0007595', 'lactation', 206, 'lactation')]
PMC4231349	10/2013	S173-PMC4231349	['their elevated Ketone concentration at p2.5 dropped to below ∼2mmol/l, and their below-normal p2.5 Glucose concentration increased to ∼6mmol/l, both of which were within the normal stable-Ketosis values [38].']	N/A	N/A	[('CHEBI_17087', 'ketone', 15, 'ketone'), ('CHEBI_17234', 'glucose', 99, 'glucose'), ('GO_0001818', 'negative regulation of cytokine production', 188, 'ketosis')]
PMC4243771	8/2014	S30-PMC4243771	['maternal Plasma hdl concentrations were raised in the hf group compared to controls, whereas Plasma ldl, Triglycerides and Glucose were unaffected.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 9, 'plasma'), ('UBERON_0001969', 'blood plasma', 93, 'plasma'), ('CHEBI_17855', 'triglyceride', 105, 'triglycerides'), ('CHEBI_17234', 'glucose', 123, 'glucose')]
PMC4243771	8/2014	S61-PMC4243771	['caption (fig): figure 5\n\nmrna abundance of Enolase 3 (Eno3), Phosphoglycerate mutase 2 (Pgam2), Glucose Transporter 1 (Glut1), Fatty Acid translocase (Fat/Cd36) and lipoprotein Lipase (lpl) in thebicep femorisof 7-day-old offspring exposed to a control (white; n\u2009=\u20097) or high fat (black; n\u2009=\u20097) maternal diet throughout Gestation as determined by real time pcr.']	N/A	N/A	[('PR_000007070', 'homeobox protein engrailed-1', 43, 'Enolase 3'), ('PR_000007070', 'homeobox protein engrailed-1', 54, 'ENO3'), ('CHEBI_18122', 'peptidylamidoglycolate', 61, 'Phosphoglycerate'), ('PR_000012572', 'prefoldin subunit 1', 88, 'PGAM2'), ('CHEBI_17234', 'glucose', 96, 'Glucose'), ('PR_000015043', 'testis anion transporter 1', 96, 'Glucose transporter 1'), ('PR_000015065', 'solute carrier family 2, facilitated glucose transporter member 3', 119, 'GLUT1'), ('CHEBI_35366', 'fatty acid', 127, 'Fatty acid'), ('PR_000007355', 'Fas-binding factor 1', 151, 'FAT'), ('PR_000002060', 'lysosome-associated membrane glycoprotein 1', 155, 'CD36'), ('PR_000009875', 'E3 ubiquitin-protein ligase LNX', 177, 'lipase'), ('GO_0007565', 'female pregnancy', 320, 'gestation')]
PMC4243771	8/2014	S82-PMC4243771	['additionally, the increase in mrna Expression of Genes for proteins involved in Glycolysis, such as Eno3 and Pgam2, together with greater Glut-1 (which is independent of Insulin) and ldh enzymatic activity are all indicative of greater Glucose consumption [47].']	N/A	N/A	[('GO_0010467', 'gene expression', 35, 'expression'), ('SO_0000704', 'gene', 49, 'genes'), ('GO_0006096', 'glycolytic process', 80, 'glycolysis'), ('PR_000007070', 'homeobox protein engrailed-1', 100, 'ENO3'), ('PR_000012572', 'prefoldin subunit 1', 109, 'PGAM2'), ('PR_000015065', 'solute carrier family 2, facilitated glucose transporter member 3', 138, 'GLUT-1'), ('PR_000045358', 'insulin family protein', 170, 'insulin'), ('CHEBI_17234', 'glucose', 236, 'glucose')]
PMC4243771	8/2014	S115-PMC4243771	['laboratory procedures\n\nPlasma and Milk analysis\nPlasma high-density lipoprotein (hdl), low-density lipoprotein (ldl) and Glucose were determined by colorimetric assays and measured using an imola rx automated apparatus (randox laboratories ltd. co, antrim, uk).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 23, 'Plasma'), ('UBERON_0001913', 'milk', 34, 'milk'), ('UBERON_0001969', 'blood plasma', 48, 'Plasma'), ('CHEBI_17234', 'glucose', 121, 'glucose')]
PMC4243771	8/2014	S131-PMC4243771	['the concentration of Glucose released from this reaction was determined by a colorimetric commercial assay (randox ltd., county antrim, uk) and the results were expressed as a concentration of milligrams of Glycogen per gram of Tissue dissected.']	N/A	N/A	[('CHEBI_17234', 'glucose', 21, 'glucose'), ('CHEBI_24384', 'glycogens', 207, 'glycogen'), ('UBERON_0000479', 'tissue', 228, 'tissue')]
PMC4246417	11/2014	S227-PMC4246417	['participants had been asked to fast overnight before the clinic visit and underwent a standard Glucose tolerance test with a 75-mg oral Glucose challenge.']	N/A	N/A	[('CHEBI_17234', 'glucose', 95, 'glucose'), ('CHEBI_17234', 'glucose', 136, 'glucose')]
PMC4246417	11/2014	S228-PMC4246417	['Glucose was assayed in promptly separated Serum by the hexokinase reaction on a modular p800 (roche, boehringer mannheim, germany); the interassay coefficient of variation was 1.3–1.8%.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('UBERON_0001977', 'blood serum', 42, 'serum')]
PMC4246417	11/2014	S325-PMC4246417	['cell culture and (transient) Transfections\nhek293 cells originally acquired form atcc were cultured in dulbecco’s modified eagle’s medium (+4.5\u2009g\u2009l−1d-Glucose,l-glutamate, Pyruvate) (gibco) with 10% fetal Calf Serum (gibco) and 1% Penicillin/Streptomycin (gibco) at 37\u2009°c and 5% Co2.']	N/A	N/A	[('GO_0009294', 'DNA mediated transformation', 29, 'transfections'), ('CHEBI_17234', 'glucose', 151, 'glucose'), ('CHEBI_15361', 'pyruvate', 172, 'pyruvate'), ('NCBITaxon_33208', 'Metazoa', 205, 'calf'), ('UBERON_0001977', 'blood serum', 210, 'serum'), ('CHEBI_17334', 'penicillin', 231, 'penicillin'), ('CHEBI_17076', 'streptomycin', 242, 'streptomycin'), ('CHEBI_16526', 'carbon dioxide', 279, 'CO2')]
PMC4264037	9/2014	S77-PMC4264037	['Ventromedial Hypothalamus\nsituated lateral to the Arc, the vmh is the other major constituent of the Mediobasal Hypothalamus, and a key node in the Circuits that Govern Reproduction, Feeding, and Glucose Homeostasis.']	N/A	N/A	[('UBERON_2000324', 'caudal periventricular hypothalamus', 0, 'Ventromedial hypothalamus'), ('UBERON_0004356', 'apical ectodermal ridge', 50, 'ARC'), ('UBERON_0013159', 'epithalamus mantle layer', 101, 'mediobasal hypothalamus'), ('UBERON_0024914', 'circuit part of central nervous system', 148, 'circuits'), ('GO_0065007', 'biological regulation', 162, 'govern'), ('GO_0000003', 'reproduction', 169, 'reproduction'), ('GO_0007631', 'feeding behavior', 183, 'feeding'), ('CHEBI_17234', 'glucose', 196, 'glucose'), ('GO_0042593', 'glucose homeostasis', 196, 'glucose homeostasis')]
PMC4277409	12/2014	S4-PMC4277409	['Human Omental Adipose Tissue and Skeletal muscle were obtained from normal Glucose tolerant (ngt) women and bmi-matched women with diet-control gdm at the time of caesarean section.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 0, 'Human'), ('UBERON_0001431', 'distal carpal bone 2', 6, 'omental adipose tissue'), ('UBERON_0004288', 'skeleton', 33, 'skeletal'), ('CHEBI_17234', 'glucose', 75, 'glucose')]
PMC4277409	12/2014	S21-PMC4277409	['in vivo , increased Gsk3 activity is an early event in the development of Insulin resistance where Glycogen Synthesis is impaired in type 2 diabetes[25]and inhibition of Gsk3 in zucker diabetic fatty Rats leads to an improvement in both Insulin action and Glucose Uptake[26].']	N/A	N/A	[('PR_000008288', 'glycogen synthase kinase-3 beta', 20, 'GSK3'), ('PR_000045358', 'insulin family protein', 74, 'insulin'), ('CHEBI_24384', 'glycogens', 99, 'glycogen'), ('GO_0005978', 'glycogen biosynthetic process', 99, 'glycogen synthesis'), ('PR_000008288', 'glycogen synthase kinase-3 beta', 170, 'GSK3'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 200, 'rats'), ('PR_000045358', 'insulin family protein', 237, 'insulin'), ('CHEBI_17234', 'glucose', 256, 'glucose'), ('GO_0046323', 'glucose import', 256, 'glucose uptake')]
PMC4277409	12/2014	S38-PMC4277409	['Omental Adipose Tissue (n\u200a=\u200a24 patients) and Skeletal muscle (n\u200a=\u200a24 patients) was obtained from normal Glucose tolerant (ngt) women and bmi-matched women with gdm.']	N/A	N/A	[('UBERON_0008834', 'prostomium', 0, 'Omental adipose tissue'), ('UBERON_0004288', 'skeleton', 45, 'skeletal'), ('CHEBI_17234', 'glucose', 104, 'glucose')]
PMC4277409	12/2014	S41-PMC4277409	['women with gdm were diagnosed according to the criteria of the australasian diabetes in Pregnancy society (adips) by either a fasting Venous Plasma Glucose concentrations of ≥5.5 mmol/l Glucose, and/or ≥8.0 mmol/l Glucose 2 h after a 75 g oral Glucose load at approximately 28 weeks Gestation.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 88, 'Pregnancy'), ('UBERON_0001638', 'vein', 134, 'venous'), ('UBERON_0001969', 'blood plasma', 141, 'plasma'), ('CHEBI_17234', 'glucose', 148, 'glucose'), ('CHEBI_17234', 'glucose', 186, 'glucose'), ('CHEBI_17234', 'glucose', 214, 'glucose'), ('CHEBI_17234', 'glucose', 244, 'glucose'), ('GO_0007565', 'female pregnancy', 283, 'gestation')]
PMC4277409	12/2014	S45-PMC4277409	['dissected fragments were stored at −80°c until assayed as detailed below.10.1371/journal.pone.0115854.t001\n\ncaption (table-wrap): table 1\nclinical characteristics of the Adipose Tissue study group.ngt (n\u200a=\u200a12)gdm-diet (n\u200a=\u200a12)maternal age (years)31.8±1.734.9±1.5maternal bmi at ∼12 wks (kg/m2)33.3±3.430.6±2.1maternal bmi at Delivery (kg/m2)36.8±2.933.1±1.6gestational weight gain (kg)9.4±1.86.7±2.5gestational age at Birth (weeks)38.6±0.138.6±0.2fetal Birth weight (g)3761±1863277±153fetal gender6 female; 6 male7 female; 5 malematernal ogtt at ∼28 weeks Gestation…fasting Plasma ogtt (mmol/l)4.5±0.15.3±0.2*§…1 hour Plasma ogtt (mmol/l)7.5±0.610.3±0.3*…2 hour Plasma ogtt (mmol/l)5.9±0.48.8±0.5*\nogtt, oral Glucose tolerance test.']	N/A	N/A	[('UBERON_0001013', 'adipose tissue', 170, 'adipose tissue'), ('GO_0007567', 'parturition', 325, 'delivery'), ('GO_0007567', 'parturition', 418, 'birth'), ('GO_0007567', 'parturition', 453, 'birth'), ('GO_0007565', 'female pregnancy', 556, 'gestation'), ('UBERON_0001969', 'blood plasma', 574, 'plasma'), ('UBERON_0001969', 'blood plasma', 618, 'plasma'), ('UBERON_0001969', 'blood plasma', 662, 'plasma'), ('CHEBI_17234', 'glucose', 709, 'glucose')]
PMC4277409	12/2014	S47-PMC4277409	['* p<0.05 vs. ngt.10.1371/journal.pone.0115854.t002\n\ncaption (table-wrap): table 2\nclinical characteristics of the Skeletal muscle study group.ngt (n\u200a=\u200a12)gdm-diet (n\u200a=\u200a12)maternal age (years)32.7±1.432.3±1.6pre-Pregnancy bmi (kg/m2)32.6±3.533.8±2.6maternal bmi at Delivery (kg/m2)36.4±2.936.4±2.7gestational weight gain (kg)10.3±2.56.3±1.4gestational age at Birth (weeks)38.7±0.338.5±0.2fetal Birth weight (g)3606±1163414±129fetal gender6 female; 6 male6 female; 6 malematernal ogtt at ∼28 weeks Gestation…fasting Plasma ogtt (mmol/l)4.4±0.15.4±0.1*…1 hour Plasma ogtt (mmol/l)5.6±0.411.0±0.3*…2 hour Plasma ogtt (mmol/l)4.9±0.39.4±0.5*\nogtt, oral Glucose tolerance test.']	N/A	N/A	[('UBERON_0004288', 'skeleton', 114, 'skeletal'), ('GO_0007565', 'female pregnancy', 211, 'pregnancy'), ('GO_0007567', 'parturition', 264, 'delivery'), ('GO_0007567', 'parturition', 358, 'birth'), ('GO_0007567', 'parturition', 393, 'birth'), ('GO_0007565', 'female pregnancy', 496, 'gestation'), ('UBERON_0001969', 'blood plasma', 514, 'plasma'), ('UBERON_0001969', 'blood plasma', 557, 'plasma'), ('UBERON_0001969', 'blood plasma', 601, 'plasma'), ('CHEBI_17234', 'glucose', 648, 'glucose')]
PMC4277409	12/2014	S159-PMC4277409	['fasting, one hour and two hour plasma Glucose during the Antenatal ogtt were significantly higher in women with gdm when compared to ngt Pregnant women.']	N/A	N/A	[('CHEBI_17234', 'glucose', 38, 'glucose'), ('GO_0007567', 'parturition', 57, 'antenatal'), ('GO_0007565', 'female pregnancy', 137, 'pregnant')]
PMC4292443	1/2015	S8-PMC4292443	['weight changes and Glucose Metabolism were unaffected by the early Life experience.']	N/A	N/A	[('CHEBI_17234', 'glucose', 19, 'glucose'), ('GO_0006006', 'glucose metabolic process', 19, 'glucose metabolism'), ('UBERON_0000104', 'life cycle', 67, 'life')]
PMC4292443	1/2015	S48-PMC4292443	['Glucose tolerance test (gtt).']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'glucose'), ('GO_0040007', 'growth', 0, 'glucose')]
PMC4292443	1/2015	S49-PMC4292443	['Rats were fasted for 3–4 h prior to testing to standardize basal Glucose levels.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 0, 'Rats'), ('CHEBI_17234', 'glucose', 65, 'glucose')]
PMC4292443	1/2015	S53-PMC4292443	['we also measured basal Glucose levels at this time using an accu-chek performa Blood Glucose meter (roche diagnostics; castle hill, nsw, au).']	N/A	N/A	[('CHEBI_17234', 'glucose', 23, 'glucose'), ('UBERON_0000178', 'blood', 79, 'blood'), ('CHEBI_17234', 'glucose', 85, 'glucose')]
PMC4292443	1/2015	S54-PMC4292443	['we then injected each Rat with 1.5 g/kg Glucose and measured Glucose levels at 15, 30, 45, 60, and 90 min after injection.']	N/A	N/A	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 22, 'rat'), ('CHEBI_17234', 'glucose', 40, 'glucose'), ('CHEBI_17234', 'glucose', 61, 'glucose')]
PMC4292443	1/2015	S98-PMC4292443	['we also included time (min) as a repeated measure in analysis of Plasma Glucose concentrations.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 65, 'plasma'), ('CHEBI_17234', 'glucose', 72, 'glucose')]
PMC4292443	1/2015	S150-PMC4292443	['Glucose concentrations (a,c) and incremental area under the curve (iauc) responses (b,d) to an i.p.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose')]
PMC4292443	1/2015	S151-PMC4292443	['Glucose tolerance test after 3 day (3d) and 3 week (3w) high fat diet or Chow (Ch) in male (a,b) and female (c,d) Adult Rats that were raised in control (cl) and small (sl) litters.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'glucose'), ('CHEBI_33290', 'food', 73, 'chow'), ('CHEBI_17996', 'chloride', 79, 'CH'), ('UBERON_0007023', 'adult organism', 114, 'adult'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 120, 'rats')]
PMC4292819	1/2015	S98-PMC4292819	['quantitative Insulin sensitivity check index (quicki) was calculated as 1/(ln(S-Insulin)(mu/l)\u2009+\u2009ln(P-Glucose)(mmol/l)) [20].']	N/A	N/A	[('PR_000045358', 'insulin family protein', 13, 'insulin'), ('PR_000002125', 'C-C motif chemokine 7', 78, 's-insulin'), ('CHEBI_76777', 'poly(inosinic acid)', 100, 'p-'), ('CHEBI_17234', 'glucose', 102, 'glucose')]
PMC4302093	1/2015	S21-PMC4302093	['basically, there are five major pathways, that activate mtorc1: 1) the presence of growth factors such as Insulin and Igf-1 [3,6,7,11,12], 2) sufficient cellular energy (Glucose, atp) [31,32], 3) the availability of amino acids, predominantly essential Branched-Chain Amino Acids (Bcaas) such as leucine [5-10,33], 4) the presence of glutamine for cellular leucine Uptake and Glutaminolysis-mediated activation of mtorc1 [34-36], and 5) the availability of Saturated Fatty Acids, especially Palmitic Acid [37].']	N/A	N/A	[('PR_000045358', 'insulin family protein', 106, 'insulin'), ('PR_000008929', 'interferon-related developmental regulator 1', 118, 'IGF-1'), ('CHEBI_17234', 'glucose', 170, 'glucose'), ('CHEBI_22918', 'branched-chain amino acid', 253, 'branched-chain amino acids'), ('CHEBI_22918', 'branched-chain amino acid', 281, 'BCAAs'), ('GO_0098657', 'import into cell', 365, 'uptake'), ('GO_0006096', 'glycolytic process', 376, 'glutaminolysis'), ('CHEBI_26604', 'santonin', 457, 'saturated fatty acids'), ('CHEBI_15756', 'hexadecanoic acid', 491, 'palmitic acid')]
PMC4302093	1/2015	S33-PMC4302093	['Hpl via Stat5/Socs signaling as well as increased Milk-mediated Mtorc1/S6K1 Signaling induce Insulin resistance enhancing the Glucose gradient to the fetus.']	N/A	N/A	[('UBERON_0009889', 'secondary heart field', 0, 'HPL'), ('PR_000015700', 'alpha-2,8-sialyltransferase 8F', 8, 'STAT5'), ('PR_000015399', 'superoxide dismutase [Cu-Zn]', 14, 'SOCS'), ('UBERON_0001913', 'milk', 50, 'milk'), ('GO_0038179', 'neurotrophin signaling pathway', 64, 'mTORC1 ... S6K1 signaling'), ('PR_000000124', 'ribosomal protein S6 kinase beta-2', 71, 'S6K1'), ('PR_000045358', 'insulin family protein', 93, 'insulin'), ('CHEBI_17234', 'glucose', 126, 'glucose')]
PMC4302093	1/2015	S35-PMC4302093	['Milk Consumption during Pregnancy exaggerates Glucose transfer to the fetus.']	N/A	N/A	[('GO_0001774', 'microglial cell activation', 0, 'Milk consumption'), ('GO_0007565', 'female pregnancy', 24, 'pregnancy'), ('CHEBI_17234', 'glucose', 46, 'glucose')]
PMC4302093	1/2015	S111-PMC4302093	['Milk Intake and maternal Insulin resistance\nmaternal Insulin resistance is a physiologic Adaptation of Pregnancy that limits maternal Glucose Uptake to ensure an adequate supply of Glucose that is shunted to the Growing fetus.']	N/A	N/A	[('GO_0006266', 'DNA ligation', 0, 'Milk intake'), ('UBERON_0001913', 'milk', 0, 'Milk'), ('PR_000045358', 'insulin family protein', 25, 'insulin'), ('PR_000045358', 'insulin family protein', 53, 'insulin'), ('GO_1990603', 'dark adaptation', 89, 'adaptation'), ('GO_0007565', 'female pregnancy', 103, 'pregnancy'), ('CHEBI_17234', 'glucose', 134, 'glucose'), ('GO_0046323', 'glucose import', 134, 'glucose uptake'), ('CHEBI_17234', 'glucose', 181, 'glucose'), ('GO_0040007', 'growth', 212, 'growing')]
PMC4302093	1/2015	S138-PMC4302093	['Glut1 is the primary Glucose transporter Isoform in the Human Placenta that increases its Expression over Gestation [133].']	N/A	N/A	[('PR_000015065', 'solute carrier family 2, facilitated glucose transporter member 3', 0, 'GLUT1'), ('CHEBI_17234', 'glucose', 21, 'glucose'), ('SO_0001060', 'sequence_variant', 41, 'isoform'), ('NCBITaxon_9606', 'Homo sapiens', 56, 'human'), ('UBERON_0001987', 'placenta', 62, 'placenta'), ('GO_0010467', 'gene expression', 90, 'expression'), ('GO_0007565', 'female pregnancy', 106, 'gestation')]
PMC4302093	1/2015	S197-PMC4302093	['accordingly, fetal cells obtain an excessive supply of Glucose and Bcaas.']	N/A	N/A	[('CHEBI_17234', 'glucose', 55, 'glucose'), ('CHEBI_22918', 'branched-chain amino acid', 67, 'BCAAs')]
PMC4309881	2/2015	S47-PMC4309881	['prior to Mating, body weight, Blood Glucose and β −Ketones ( β − hydroxybutyrate ) were measured in randomly chosen Animals from both groups.']	N/A	N/A	[('GO_0007618', 'mating', 9, 'mating'), ('UBERON_0000178', 'blood', 30, 'blood'), ('CHEBI_17234', 'glucose', 36, 'glucose'), ('CHEBI_17087', 'ketone', 51, 'ketones'), ('NCBITaxon_33208', 'Metazoa', 116, 'animals')]
PMC4309881	2/2015	S56-PMC4309881	['of the Mice that did not undergo the neurobehavioral tests, a subset was randomly selected to undergo weight, Blood Glucose, and Blood Ketone measurements at 8-weeks of age.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 7, 'mice'), ('UBERON_0000178', 'blood', 110, 'blood'), ('CHEBI_17234', 'glucose', 116, 'glucose'), ('UBERON_0000178', 'blood', 129, 'blood'), ('CHEBI_17087', 'ketone', 135, 'ketone')]
PMC4309881	2/2015	S136-PMC4309881	['caption (table-wrap): table 1\n\nbody weight, Blood Glucose, Blood Ketones, and Brain volume for Adult male and female Mice (mean ± stdv)sd femalessd maleskd femaleskd malesbody weight (g)29.2 ± 2.937.3 ± 3.427.9 ± 3.236.5 ± 4.4blood Glucose (mmol/l)5.9 ± 1.37.4 ± 1.04.8 ± 1.15.1 ± 1.0blood Ketones (mmol/l)0.3 ± 0.10.4 ± 0.10.4 ± 0.20.4 ± 0.1brain volume (mm)527.6 ± 60.5511.5 ± 54.5\nsd, standard diet; kd, Ketogenic diet.']	N/A	N/A	[('UBERON_0000178', 'blood', 44, 'blood'), ('CHEBI_17234', 'glucose', 50, 'glucose'), ('UBERON_0000178', 'blood', 59, 'blood'), ('CHEBI_17087', 'ketone', 65, 'ketones'), ('UBERON_0000955', 'brain', 78, 'brain'), ('UBERON_0007023', 'adult organism', 95, 'adult'), ('NCBITaxon_10088', 'Mus <genus>', 117, 'mice'), ('CHEBI_17234', 'glucose', 232, 'glucose'), ('CHEBI_17087', 'ketone', 290, 'ketones'), ('CHEBI_75715', "dUMP 3'-end residue", 407, 'ketogenic'), ('GO_0000241', 'diakinesis', 407, 'ketogenic')]
PMC4309881	2/2015	S205-PMC4309881	['Adult male kd Mice were also found to have reduced Blood Glucose concentration compared with sd males.']	N/A	N/A	[('UBERON_0007023', 'adult organism', 0, 'Adult'), ('NCBITaxon_10088', 'Mus <genus>', 14, 'mice'), ('UBERON_0000178', 'blood', 51, 'blood'), ('CHEBI_17234', 'glucose', 57, 'glucose')]
PMC4311629	1/2015	S54-PMC4311629	['in addition to using Lipids, Bat also displays a very high rate of Glucose Uptake, particularly under sympathetic activation (cannon and nedergaard,2004).']	N/A	N/A	[('CHEBI_18059', 'lipid', 21, 'lipids'), ('UBERON_0001348', 'brown adipose tissue', 29, 'BAT'), ('CHEBI_17234', 'glucose', 67, 'glucose'), ('GO_0046323', 'glucose import', 67, 'glucose uptake')]
PMC4311629	1/2015	S56-PMC4311629	['this Tissue also responds to Insulin with a 5-fold increase in Glucose Uptake, without any change in Blood flow (orava et al.,2011), while under cold exposure, Glucose Uptake increases by 12-folds, dissipating energy as a function of increased Blood flow (orava et al.,2011).']	N/A	N/A	[('UBERON_0000479', 'tissue', 5, 'tissue'), ('PR_000045358', 'insulin family protein', 29, 'insulin'), ('CHEBI_17234', 'glucose', 63, 'glucose'), ('GO_0046323', 'glucose import', 63, 'glucose uptake'), ('UBERON_0000178', 'blood', 101, 'blood'), ('CHEBI_17234', 'glucose', 160, 'glucose'), ('GO_0046323', 'glucose import', 160, 'glucose uptake'), ('UBERON_0000178', 'blood', 244, 'blood')]
PMC4311629	1/2015	S57-PMC4311629	['regarding the fate of Glucose in Brown Adipocytes under anabolic conditions characterized by high Insulin levels, it is essentially Metabolized to provide Glycerol-3-Phosphate for Triglyceride Synthesis or Acetyl- Coa for de novo Fatty Acid Synthesis (cannon and nedergaard,2004).']	N/A	N/A	[('CHEBI_17234', 'glucose', 22, 'glucose'), ('CL_0000449', 'brown fat cell', 33, 'brown adipocytes'), ('UBERON_0010308', 'os opticus', 39, 'adipocytes'), ('PR_000045358', 'insulin family protein', 98, 'insulin'), ('GO_0008152', 'metabolic process', 132, 'metabolized'), ('CHEBI_17270', 'glycerol 2-phosphate', 155, 'glycerol-3-phosphate'), ('CHEBI_17855', 'triglyceride', 180, 'triglyceride'), ('GO_0009057', 'macromolecule catabolic process', 193, 'synthesis'), ('CHEBI_15351', 'acetyl-CoA', 206, 'acetyl- CoA'), ('CHEBI_35366', 'fatty acid', 230, 'fatty acid'), ('GO_0006633', 'fatty acid biosynthetic process', 230, 'fatty acid synthesis')]
PMC4311629	1/2015	S72-PMC4311629	['as mentioned above, Bat is the Effector Organ of non-Shivering Thermogenesis (both cold and diet-induced) that, by utilizing large quantities of Glucose and Lipids from the circulation, can promote negative energy balance.']	N/A	N/A	[('UBERON_0001348', 'brown adipose tissue', 20, 'BAT'), ('CHEBI_35224', 'effector', 31, 'effector'), ('UBERON_0000062', 'organ', 40, 'organ'), ('GO_0031051', 'scnRNA processing', 53, 'shivering'), ('GO_0031649', 'heat generation', 63, 'thermogenesis'), ('CHEBI_17234', 'glucose', 145, 'glucose'), ('CHEBI_18059', 'lipid', 157, 'lipids')]
PMC4311629	1/2015	S77-PMC4311629	['Bat Activation by cold exposure, β3-Agonist or Thyroid Hormone treatment was shown to improve Glucose tolerance and Insulin sensitivity (cawthorne et al.,1984; forest et al.,1987; peirce and vidal-puig,2013).']	N/A	N/A	[('UBERON_0001348', 'brown adipose tissue', 0, 'BAT'), ('GO_0045148', 'tripeptide aminopeptidase activity', 4, 'activation'), ('CHEBI_85384', 'GABA reuptake inhibitor', 36, 'agonist'), ('CHEBI_60311', 'thyroid hormone', 47, 'thyroid hormone'), ('UBERON_0002046', 'thyroid gland', 47, 'thyroid'), ('CHEBI_17234', 'glucose', 94, 'glucose'), ('PR_000045358', 'insulin family protein', 116, 'insulin')]
PMC4311629	1/2015	S107-PMC4311629	['Bat transplantation also increased Insulin-stimulated Glucose Uptake in Bat, Wat, and Heart, but not in Skeletal muscle (stanford et al.,2013).']	N/A	N/A	[('UBERON_0001348', 'brown adipose tissue', 0, 'BAT'), ('PR_000045358', 'insulin family protein', 35, 'insulin'), ('CHEBI_17234', 'glucose', 54, 'glucose'), ('GO_0046323', 'glucose import', 54, 'glucose uptake'), ('UBERON_0001348', 'brown adipose tissue', 72, 'BAT'), ('UBERON_0006337', 'distal early tubule', 77, 'WAT'), ('UBERON_0000948', 'heart', 86, 'heart'), ('UBERON_0004288', 'skeleton', 104, 'skeletal')]
PMC4311629	1/2015	S162-PMC4311629	['high fat Feeding of Pregnant or Lactating mothers was shown to induce Glucose intolerance and the development of obesity in the progeny during Adult Life (bayol et al.,2008; samuelsson et al.,2008).']	N/A	N/A	[('GO_0007631', 'feeding behavior', 9, 'feeding'), ('GO_0007565', 'female pregnancy', 20, 'pregnant'), ('GO_0007594', 'puparial adhesion', 32, 'lactating'), ('CHEBI_17234', 'glucose', 70, 'glucose'), ('UBERON_0000113', 'post-juvenile adult stage', 143, 'adult life')]
PMC4311629	1/2015	S178-PMC4311629	['during acute cold exposure, Bat was shown as a significant independent determinant of Plasma Glucose and hba1c levels (matsushita et al.,2014).']	N/A	N/A	[('UBERON_0001348', 'brown adipose tissue', 28, 'BAT'), ('UBERON_0001969', 'blood plasma', 86, 'plasma'), ('CHEBI_17234', 'glucose', 93, 'glucose')]
PMC4314535	10/2014	S18-PMC4314535	['in addition, Postnatally overfed Animals show accelerated and exacerbated weight gain and altered Glucose tolerance when Fed an obesogenic diet[10,12].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 13, 'postnatally'), ('NCBITaxon_33208', 'Metazoa', 33, 'animals'), ('CHEBI_17234', 'glucose', 98, 'glucose'), ('GO_0007631', 'feeding behavior', 121, 'fed')]
PMC4314535	10/2014	S43-PMC4314535	['Blood Glucose levels were measured on p180 after overnight fasting using a glucometer (onetouch ultra, johnson & johnson).']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('CHEBI_17234', 'glucose', 6, 'glucose')]
PMC4314535	10/2014	S94-PMC4314535	['in addition, the fasting Glucose levels were significantly elevated in the Adult sl Mice Fed a Chow diet (figure\xa01h).']	N/A	N/A	[('CHEBI_17234', 'glucose', 25, 'glucose'), ('UBERON_0007023', 'adult organism', 75, 'adult'), ('NCBITaxon_10088', 'Mus <genus>', 84, 'mice'), ('GO_0007631', 'feeding behavior', 89, 'fed'), ('CHEBI_33290', 'food', 95, 'chow')]
PMC4341080	3/2015	S62-PMC4341080	['Serum samples were analysed for gamma glutamyl transferase (ggt; roche diagnostics, basel, switzerland) and Glucose (roche diagnostics, basel, switzerland).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_17234', 'glucose', 108, 'glucose')]
PMC4341080	3/2015	S99-PMC4341080	['the distribution of the Glucose concentration of lambs could not be normalised using mathematical transformations.']	N/A	N/A	[('CHEBI_17234', 'glucose', 24, 'glucose')]
PMC4341080	3/2015	S100-PMC4341080	['therefore, Glucose concentrations were analysed using the non-parametric kruskal-wallis test which contained the fixed effect of either nutritional regimen or bcs.']	N/A	N/A	[('CHEBI_17234', 'glucose', 11, 'glucose')]
PMC4341080	3/2015	S136-PMC4341080	['in addition, Lamb Serum Glucose concentration did not differ between ewe bcs or nutritional regimens (data not shown, p>0.05).']	N/A	N/A	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 13, 'lamb'), ('UBERON_0001977', 'blood serum', 18, 'serum'), ('CHEBI_17234', 'glucose', 24, 'glucose')]
PMC4346113	3/2015	S24-PMC4346113	['caption (table-wrap): table 1\n\nglobal trends in fasting Plasma Glucose and diabetes prevalence (1980 vs. 2008)variables19802008 global fpg (mmol/l)*men5.29**5.50 (5.37–5.63)women5.15**5.42 (5.29–5.54)dm2 prevalence (%)*men8.3 (6.5–10.4)9.8 (8.6–11.2)women7.5 (5.8–9.6)9.2 (8.0–10.5)people with dm2 (million)*men77 (60–97)173 (151–197)women76 (58–97)173 (151–197)\n*age-standardized values.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 56, 'plasma'), ('CHEBI_17234', 'glucose', 63, 'glucose')]
PMC4346113	3/2015	S27-PMC4346113	['fpg: fasting Plasma Glucose.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 13, 'plasma'), ('CHEBI_17234', 'glucose', 20, 'glucose')]
PMC4351952	3/2015	S93-PMC4351952	['Brains were rapidly removed and placed in ice-cold N-Methyl-D-Glucamine (nmdg)-based cutting Solution composed of (in mm): 92 nmdg, 2.5 Kcl, 1.2 Nah2Po4, 30 Nahco3, 20 Hepes, 25 Glucose, 2 Thiourea, 3 Sodium Pyruvate, 5 Ascorbic Acid, 10 Mgso4, and 0.5 Cacl2, equilibrated with 95%O2/5%Co2.']	N/A	N/A	[('UBERON_0000955', 'brain', 0, 'Brains'), ('CHEBI_21553', 'N-acetyl-L-glutamine', 51, 'N-methyl-D-glucamine'), ('CHEBI_75958', 'solution', 93, 'solution'), ('CHEBI_32588', 'potassium chloride', 136, 'KCl'), ('CHEBI_37585', 'sodium dihydrogenphosphate', 145, 'NaH2PO4'), ('CHEBI_32139', 'sodium hydrogencarbonate', 157, 'NaHCO3'), ('CHEBI_46756', 'HEPES', 168, 'HEPES'), ('CHEBI_17234', 'glucose', 178, 'glucose'), ('CHEBI_36956', 'tetrauret', 189, 'thiourea'), ('CHEBI_50144', 'sodium pyruvate', 201, 'sodium pyruvate'), ('CHEBI_35493', 'antipyretic', 220, 'ascorbic'), ('CHEBI_37527', 'acid', 229, 'acid'), ('CHEBI_32599', 'magnesium sulfate', 238, 'MgSO4'), ('CHEBI_3312', 'calcium dichloride', 253, 'CaCl2'), ('CHEBI_15379', 'dioxygen', 281, 'O2'), ('CHEBI_16526', 'carbon dioxide', 286, 'CO2')]
PMC4351952	3/2015	S95-PMC4351952	['after cutting, slices were transferred to 32°c nmdg cutting Solution equilibrated with 95%O2/5%Co2For 15 minutes, then transferred to a room-temperature holding Solution composed of (in mm): 92 Nacl, 2.5 Kcl, 1.2 Nah2Po4, 30 Nahco3, 20 Hepes, 25 Glucose, 2 Thiourea, 3 Sodium Pyruvate, 5 Ascorbic Acid, 1 Mgso4, and 2 Cacl2, equilibrated with 95%O2/5%Co2For 50 minutes before recording.']	N/A	N/A	[('CHEBI_75958', 'solution', 60, 'solution'), ('CHEBI_15379', 'dioxygen', 90, 'O2'), ('CHEBI_86192', 'butyl anthranilate', 95, 'CO2for'), ('CHEBI_75958', 'solution', 161, 'solution'), ('CHEBI_26710', 'sodium chloride', 194, 'NaCl'), ('CHEBI_32588', 'potassium chloride', 204, 'KCl'), ('CHEBI_37585', 'sodium dihydrogenphosphate', 213, 'NaH2PO4'), ('CHEBI_32139', 'sodium hydrogencarbonate', 225, 'NaHCO3'), ('CHEBI_46756', 'HEPES', 236, 'HEPES'), ('CHEBI_17234', 'glucose', 246, 'glucose'), ('CHEBI_36956', 'tetrauret', 257, 'thiourea'), ('CHEBI_50144', 'sodium pyruvate', 269, 'sodium pyruvate'), ('CHEBI_22652', 'ascorbic acid', 288, 'ascorbic acid'), ('CHEBI_32599', 'magnesium sulfate', 305, 'MgSO4'), ('CHEBI_3312', 'calcium dichloride', 318, 'CaCl2'), ('CHEBI_15379', 'dioxygen', 346, 'O2'), ('CHEBI_86192', 'butyl anthranilate', 351, 'CO2for')]
PMC4358904	3/2015	S2-PMC4358904	['the dependent variables assessed in the study were: gdm (was confirmed when two or more values were above the Glucose curve using 100\xa0g Glucose), complications, mode of Delivery and Birth weight.']	N/A	N/A	[('CHEBI_17234', 'glucose', 110, 'glucose'), ('CHEBI_17234', 'glucose', 136, 'glucose'), ('GO_0007567', 'parturition', 169, 'delivery'), ('GO_0007567', 'parturition', 182, 'birth')]
PMC4358904	3/2015	S3-PMC4358904	['macrosomia was defined as a Birth weight of >4000\xa0g. the independent variables assessed were: maternal fasting Glucose per trimester as a continuous variable, divided into three categories, socio-demographic data on the mothers.']	N/A	N/A	[('GO_0007567', 'parturition', 28, 'birth'), ('CHEBI_17234', 'glucose', 111, 'glucose')]
PMC4358904	3/2015	S5-PMC4358904	['results\nthe mean fasting Glucose levels of the women who had gdm were higher in the second Trimester than for those who had no Pregnancy complications (90.5\xa0mg/dl vs. 78.5\xa0mg/dl, p\u2009=\u20090.000).']	N/A	N/A	[('CHEBI_17234', 'glucose', 25, 'glucose'), ('GO_0009294', 'DNA mediated transformation', 91, 'trimester'), ('GO_0007565', 'female pregnancy', 127, 'pregnancy')]
PMC4358904	3/2015	S7-PMC4358904	['women who had a cesarean Delivery had higher fasting Glucose levels in the second (80.4\xa0mg/dl vs. 78\xa0mg/dl, post hoc\u2009=\u20090.034) and third (80.4\xa0mg/dl and 77.1\xa0mg/dl; post hoc\u2009=\u20090.005) trimesters than women who had a normal Delivery.']	N/A	N/A	[('GO_0007567', 'parturition', 25, 'delivery'), ('CHEBI_17234', 'glucose', 53, 'glucose'), ('GO_0007567', 'parturition', 221, 'delivery')]
PMC4358904	3/2015	S15-PMC4358904	['gdm is defined as any degree of Glucose intolerance with onset or first recognition during Pregnancy [2].']	N/A	N/A	[('CHEBI_17234', 'glucose', 32, 'glucose'), ('GO_0007565', 'female pregnancy', 91, 'pregnancy')]
PMC4358904	3/2015	S33-PMC4358904	['of this original total of 846 women, 829 met the inclusion criteria, namely: having received Antenatal Care and/or Given Birth at the maternity unit under study; aged ≥20; singleton Pregnancy; no chronic diseases prior to Pregnancy; Plasma Glucose screened and recorded throughout Pregnancy.']	N/A	N/A	[('GO_0007608', 'sensory perception of smell', 93, 'antenatal care'), ('GO_0046660', 'female sex differentiation', 115, 'given'), ('GO_0007567', 'parturition', 121, 'birth'), ('GO_0007565', 'female pregnancy', 182, 'pregnancy'), ('GO_0007565', 'female pregnancy', 222, 'pregnancy'), ('UBERON_0001969', 'blood plasma', 233, 'plasma'), ('CHEBI_17234', 'glucose', 240, 'glucose'), ('GO_0007565', 'female pregnancy', 281, 'pregnancy')]
PMC4358904	3/2015	S35-PMC4358904	['maternal Plasma Glucose was measured using the Glucose oxidase method, and cases of gdm were identified using the criteria valid during the period in question.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 9, 'plasma'), ('CHEBI_17234', 'glucose', 16, 'glucose'), ('CHEBI_17234', 'glucose', 47, 'glucose')]
PMC4358904	3/2015	S36-PMC4358904	['when a Glucose level of\u2009≥\u2009130\xa0mg/dl was obtained 1\xa0hour after the oral Glucose tolerance test (ogtt) with 50\xa0g (screening test), the Pregnant women were referred to conduct another ogtt with 100\xa0g anhydrous Glucose 1\xa0h, 2\xa0h and 3\xa0h after Ingestion.']	N/A	N/A	[('CHEBI_17234', 'glucose', 7, 'glucose'), ('CHEBI_17234', 'glucose', 71, 'glucose'), ('GO_0007565', 'female pregnancy', 133, 'pregnant'), ('CHEBI_17234', 'glucose', 207, 'glucose'), ('GO_0007631', 'feeding behavior', 238, 'ingestion')]
PMC4358904	3/2015	S43-PMC4358904	['the independent variables assessed were: maternal fasting Glucose per trimester as a continuous variable, divided into three categories: <80\xa0mg/dl, 80-90\xa0mg/dl and 90- 94\xa0mg/dl; socio-demographic data on the mothers (age, education, marital status, basic sanitation conditions, total household income); anthropometric data (pre-Pregnancy bmi and weight, weight gain per trimester, total weight gain); and Antenatal care.']	N/A	N/A	[('CHEBI_17234', 'glucose', 58, 'glucose'), ('GO_0007565', 'female pregnancy', 328, 'pregnancy'), ('GO_0007567', 'parturition', 405, 'antenatal')]
PMC4358904	3/2015	S54-PMC4358904	['women who developed gdm in the second trimester were excluded from the analyses of the mean fasting Glucose levels in the third Trimester of Pregnancy.']	N/A	N/A	[('CHEBI_17234', 'glucose', 100, 'glucose'), ('GO_0009294', 'DNA mediated transformation', 128, 'trimester'), ('GO_0007565', 'female pregnancy', 141, 'pregnancy')]
PMC4358904	3/2015	S72-PMC4358904	['caption (table-wrap): table 1\n\ncharacteristics of the women and their newborns (rio de janeiro, brazil - 1999 and 2008)characteristicn%pre-Pregnancy nutritional status (bmi) underweight (<18.5\xa0kg/m2)8410.9normal weight (18.5 – 24.99\xa0kg/m2)49463.8overweight (25.0 – 29.99\xa0kg/m2)13116.9obese (≥30.0\xa0kg/m2)658.4 total weight gain low20926.9intermediate29838.4high27034.7 mode of Delivery normal28849.6forceps223.8cesarean section27046.6 Gestational age at Birth preterm (<37\xa0weeks)264.7term (≥37\xa0weeks)52795.3 weight at Birth low (<2500\xa0g)334.3normal (2500\xa0g - 3999\xa0g)69591.1high (≥4000\xa0g)354.6 Pregnancy complications none45554.9other34741.9gestational diabetes mellitus273.3\nthe mean fasting Glucose levels in the first, second and third trimesters were 79.1\xa0mg/dl (n\u2009=\u2009337; sd\u2009=\u200910.2), 79.3\xa0mg/dl (n\u2009=\u2009499; sd\u2009=\u200910.8) and 78.8\xa0mg/dl (n\u2009=\u2009414; sd\u2009=\u200910.5), respectively.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 139, 'pregnancy'), ('GO_0007567', 'parturition', 376, 'delivery'), ('GO_0007565', 'female pregnancy', 434, 'Gestational'), ('GO_0007567', 'parturition', 453, 'birth'), ('GO_0007567', 'parturition', 517, 'birth'), ('GO_0007565', 'female pregnancy', 592, 'Pregnancy'), ('CHEBI_17234', 'glucose', 691, 'glucose')]
PMC4358904	3/2015	S80-PMC4358904	['the mean fasting Glucose levels were higher amongst the group who developed gdm (second trimester: 90.5\xa0mg/dl; third trimester: 90\xa0mg/dl) than amongst women who did not have any complications during Pregnancy (second trimester: 78.5\xa0mg/dl; third trimester: 77.8\xa0mg/dl).']	N/A	N/A	[('CHEBI_17234', 'glucose', 17, 'glucose'), ('GO_0007565', 'female pregnancy', 199, 'pregnancy')]
PMC4358904	3/2015	S81-PMC4358904	['caption (table-wrap): table 2\n\nmaternal fasting Plasma Glucose levels per Trimester and Pregnancy complication (rio de janeiro, brazil - 1999 and 2008)complicationfasting plasma Glucose in the first trimester (mg/dl)fasting Plasma Glucose in the second trimester (mg/dl)fasting Plasma Glucose in the third trimester (mg/dl)anmeansdpnmeansdpnmeansdp none19679.39.30.47927078.59.80.00022077.89.60.016gdm186-1890.521.349019.4\nafasting Plasma Glucose in the third trimester.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 48, 'plasma'), ('CHEBI_17234', 'glucose', 55, 'glucose'), ('GO_0009294', 'DNA mediated transformation', 74, 'trimester'), ('GO_0007565', 'female pregnancy', 88, 'pregnancy'), ('CHEBI_17234', 'glucose', 178, 'glucose'), ('UBERON_0001969', 'blood plasma', 224, 'plasma'), ('CHEBI_17234', 'glucose', 231, 'glucose'), ('UBERON_0001969', 'blood plasma', 278, 'plasma'), ('CHEBI_17234', 'glucose', 285, 'glucose'), ('UBERON_0001969', 'blood plasma', 432, 'plasma'), ('CHEBI_17234', 'glucose', 439, 'glucose')]
PMC4358904	3/2015	S86-PMC4358904	['caption (table-wrap): table 3\n\nmaternal fasting Plasma Glucose levels per trimester, Birth weight and mode of Delivery (rio de janeiro, brazil - 1999 and 2008)weight at Birth (kg)fasting Plasma Glucose in the first trimester (mg/dl)fasting Plasma Glucose in the second trimester (mg/dl)fasting Plasma Glucose in the third Trimester (mg/dl)nmeansdpnmeansdpnmeansdp underweight976.110.20.5851578.712.30.005882.614.70.545normal28679.310.341278.89.934278.710.6 high (macrosomia) 15787.62486.219.7218011.6 post-hoc (p) 86.2\u2009>\u200978.8 (0.003) mode of Delivery Vaginal17378.89.40.58224478.09.30.03919477.110.00.007cesarean13979.411.021880.411.519380.410.9forceps1576.612.61877.912.51580.111.4 post-hoc (p) 80.4\u2009>\u200978.0 (0.034)ª80.4\u2009>\u200977.1 (0.005)b\np\u2009=\u2009 post-hoc.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 48, 'plasma'), ('CHEBI_17234', 'glucose', 55, 'glucose'), ('GO_0007567', 'parturition', 85, 'birth'), ('GO_0007567', 'parturition', 110, 'delivery'), ('GO_0007567', 'parturition', 169, 'birth'), ('UBERON_0001969', 'blood plasma', 187, 'plasma'), ('CHEBI_17234', 'glucose', 194, 'glucose'), ('UBERON_0001969', 'blood plasma', 240, 'plasma'), ('CHEBI_17234', 'glucose', 247, 'glucose'), ('UBERON_0001969', 'blood plasma', 294, 'plasma'), ('CHEBI_17234', 'glucose', 301, 'glucose'), ('GO_0009294', 'DNA mediated transformation', 322, 'trimester'), ('GO_0007567', 'parturition', 542, 'delivery'), ('UBERON_0034870', 'stratum lucidum of uncal CA3', 551, 'Vaginal17378')]
PMC4358904	3/2015	S87-PMC4358904	['afasting Plasma Glucose in the second trimester;bfasting Plasma Glucose in the third trimester.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 9, 'plasma'), ('CHEBI_17234', 'glucose', 16, 'glucose'), ('UBERON_0001969', 'blood plasma', 57, 'plasma'), ('CHEBI_17234', 'glucose', 64, 'glucose')]
PMC4358904	3/2015	S90-PMC4358904	['most of the women evaluated in the first Trimester of Pregnancy (53%) had fasting Glucose levels of <80\xa0mg/dl.']	N/A	N/A	[('GO_0009294', 'DNA mediated transformation', 41, 'trimester'), ('GO_0007565', 'female pregnancy', 54, 'pregnancy'), ('CHEBI_17234', 'glucose', 82, 'glucose')]
PMC4358904	3/2015	S91-PMC4358904	['the percentage of the three maternal fasting Glucose concentration ranges in the second trimester were: 58.3% <80\xa0mg/dl, 28.5% 80-90\xa0mg/dl, and 13.2% 90-94\xa0mg/dl.']	N/A	N/A	[('CHEBI_17234', 'glucose', 45, 'glucose')]
PMC4358904	3/2015	S93-PMC4358904	['no association was found between the Plasma Glucose ranges studied and the Pregnancy complications macrosomia and cesarean Delivery for the second Trimester of Pregnancy (table\xa04).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 37, 'plasma'), ('CHEBI_17234', 'glucose', 44, 'glucose'), ('GO_0007565', 'female pregnancy', 75, 'pregnancy'), ('GO_0007567', 'parturition', 123, 'delivery'), ('GO_0009294', 'DNA mediated transformation', 147, 'trimester'), ('GO_0007565', 'female pregnancy', 160, 'pregnancy')]
PMC4358904	3/2015	S94-PMC4358904	['caption (table-wrap): table 4\n\nmaternal fasting Plasma Glucose levels in the second and third Trimesters, divided into three ranges, and outcomes (rio de janeiro, brazil - 1999 and 2008)fasting Glucose (mg/dl)n (%)gdm n (%) or (95% ci)macrosomia n (%) or (95% ci)cesarean section n (%) or (95% ci)2nd trimester<80168 (58.3)6 (3.6)1.010(3.9)1.0110 (40.7)1.080-9082 (28.5)4 (4.9)1.38 (0.38-5.04)8 (5.7)1,33 (0.50-3.51)77 (51.3)1.36 (0.89-2.08)90-9438 (13.2)8(21.1)7.2 (2.33-22.24)6(10.9)2.03 (0.65-6.33)31 (51.7)1.19 (0.66-2.16) 3rd trimester<80140 (62.5)1 (0.7)1.013(6.0)1.0104 (45.2)1.080-9065 (29)2 (3.1)4.4 (0.39-49.56)5 (4.6)0.73 (0.25-2.13)60 (49.6)1.24 (0.77-1.98)90-9419 (8.5)1(5.3)7.7 (0.46-128.9)3 (6.7)0.77 (0.16-3.62)29 (58.0)1.86 (0.95-3.65)\nor: odds ratio; 95% ci: 95% confidence interval.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 48, 'plasma'), ('CHEBI_17234', 'glucose', 55, 'glucose'), ('GO_0043033', 'isoamylase complex', 94, 'trimesters'), ('CHEBI_17234', 'glucose', 194, 'glucose')]
PMC4358904	3/2015	S97-PMC4358904	['in the third Trimester, 62.5% of the women had fasting Plasma Glucose levels of <80\xa0mg/dl; 29% fell into the 80-90\xa0mg/dl category, and 8.5% in the 90–94\xa0mg/dl category.']	N/A	N/A	[('GO_0009294', 'DNA mediated transformation', 13, 'trimester'), ('UBERON_0001969', 'blood plasma', 55, 'plasma'), ('CHEBI_17234', 'glucose', 62, 'glucose')]
PMC4358904	3/2015	S98-PMC4358904	['no association was found between the Plasma Glucose ranges studied and the Pregnancy complications and outcomes studied (gdm, macrosomia, cesarean Delivery) for the third trimester of Pregnancy (table\xa04).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 37, 'plasma'), ('CHEBI_17234', 'glucose', 44, 'glucose'), ('GO_0007565', 'female pregnancy', 75, 'pregnancy'), ('GO_0007567', 'parturition', 147, 'delivery'), ('GO_0007565', 'female pregnancy', 184, 'pregnancy')]
PMC4358904	3/2015	S108-PMC4358904	['for instance, average maternal age, mean fasting Glucose levels at different stages of Pregnancy, and prevalence of pih were all higher in the hapo study [4].']	N/A	N/A	[('CHEBI_17234', 'glucose', 49, 'glucose'), ('GO_0007565', 'female pregnancy', 87, 'pregnancy')]
PMC4358904	3/2015	S111-PMC4358904	['in this study, the mean maternal fasting Glucose levels were calculated for each Trimester of Pregnancy.']	N/A	N/A	[('CHEBI_17234', 'glucose', 41, 'glucose'), ('GO_0009294', 'DNA mediated transformation', 81, 'trimester'), ('GO_0007565', 'female pregnancy', 94, 'pregnancy')]
PMC4358904	3/2015	S114-PMC4358904	['they divided fasting Glucose into seven ranges: <75\xa0mg/dl, 75-79\xa0mg/dl, 80-84\xa0mg/dl, 85-89\xa0mg/dl, 90-95\xa0mg/dl, 95-99\xa0mg/dl, 100-105\xa0mg/dl.']	N/A	N/A	[('CHEBI_17234', 'glucose', 21, 'glucose')]
PMC4358904	3/2015	S116-PMC4358904	['the risk of Gdm, fetal macrosomia, and Delivery by cesarean section was higher for the women whose fasting Glucose was 80-84\xa0mg/dl in the first Trimester [5].']	N/A	N/A	[('GO_0070477', 'endospore core', 12, 'GDM'), ('GO_0007567', 'parturition', 39, 'delivery'), ('CHEBI_17234', 'glucose', 107, 'glucose'), ('GO_0009294', 'DNA mediated transformation', 144, 'trimester')]
PMC4363193	3/2015	S29-PMC4363193	['Rats Fed a high fat palatable diet gave Birth to offspring with greater adiposity, increased Serum Glucose and elevated Lipogenic activity in White Adipose Tissue at Adulthood [10].']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 0, 'Rats'), ('GO_0007631', 'feeding behavior', 5, 'fed'), ('GO_0007567', 'parturition', 40, 'birth'), ('UBERON_0001977', 'blood serum', 93, 'serum'), ('CHEBI_17234', 'glucose', 99, 'glucose'), ('GO_0008610', 'lipid biosynthetic process', 120, 'lipogenic'), ('UBERON_0001347', 'white adipose tissue', 142, 'white adipose tissue'), ('UBERON_0000113', 'post-juvenile adult stage', 166, 'adulthood')]
PMC4363193	3/2015	S210-PMC4363193	['levels of mrna Glut4 , which codes for the major Glucose transporter in Adipocytes [36] were higher in treatment em (2.8 fold increase, p\u2009<\u20090.05) and l offspring (4.6 fold increase, p\u2009<\u20090.001) compared to treatment c offspring (figure\xa02).']	N/A	N/A	[('PR_000015065', 'solute carrier family 2, facilitated glucose transporter member 3', 15, 'GLUT4'), ('CHEBI_17234', 'glucose', 49, 'glucose'), ('CL_0000136', 'fat cell', 72, 'adipocytes')]
PMC4372177	2/2015	S47-PMC4372177	['caption (table-wrap): table 1\n\ntops family study of epigenetics (tfse) cohort characteristicschildren and adolescentsadults(mean\u2009±\u2009sd)(mean\u2009±\u2009sd) overweight and obese32%73%Waist over mets threshold15%52%homa over mets threshold17%32%Hypertriglyceride9%20%Hdl-C over mets threshold51%66%mets prevalencena24%phenotypegirls ( n \u2009=\u200921)boys ( n \u2009=\u200932)female ( n \u2009=\u200985)male ( n \u2009=\u200954)\u2003\u2009weight, kg56.35\u2009±\u200922.9758.53\u2009±\u200925.1582.98\u2009±\u200919.6394.60\u2009±\u200923.36\u2003\u2009height, cm157.81\u2009±\u200913.09159.69\u2009±\u200920.93164.62\u2009±\u20096.87177.31\u2009±\u20096.38\u2003\u2009bmi, kg/m222.10\u2009±\u20097.5021.80\u2009±\u20095.7030.75\u2009±\u20097.6630.04\u2009±\u20096.76\u2003\u2009bmi%55.61\u2009±\u200934.2066.91\u2009±\u200926.16nana\u2003\u2009waist circumference (wc), cm68.15\u2009±\u200914.0575.16\u2009±\u200918.1593.87\u2009±\u200917.89101.58\u2009±\u200916.92\u2003\u2009Subcutaneous fat (subqf), g361.49\u2009±\u2009263.70123.31\u2009±\u200995.00319.34\u2009±\u2009191.59255.94\u2009±\u2009131.42\u2003\u2009Visceral fat (Vf), g78.57\u2009±\u200924.0243.66\u2009±\u200925.27170.84\u2009±\u2009149.50265.24\u2009±\u200994.95\u2003\u2009vf/subqf0.32\u2009±\u20090.200.45\u2009±\u20090.200.56\u2009±\u20090.321.13\u2009±\u20090.40\u2003\u2009total Abdominal Fat (Taf), g440.05\u2009±\u2009287.49166.97\u2009±\u2009114.39490.18\u2009±\u2009300.40521.18\u2009±\u2009204.41\u2003\u2009fasting Glucose (fg), mmol/l82.28\u2009±\u20098.4486.47\u2009±\u20098.5484.26\u2009±\u200913.0786.58\u2009±\u200915.37\u2003\u2009fasting Insulin (fi), pmol/l14.81\u2009±\u20095.5013.73\u2009±\u20095.6916.12\u2009±\u200915.6721.07\u2009±\u200922.91\u2003\u2009Insulin/Glucose (igr)0.18\u2009±\u20090.060.16\u2009±\u20090.070.44\u2009±\u20091.660.52\u2009±\u20091.42\u2003\u2009homeostasis model assessment Insulin resistance (homa-ir)3.03\u2009±\u20091.222.94\u2009±\u20091.323.53\u2009±\u20093.794.69\u2009±\u20095.15\u2003\u2009Triglycerides (Tg), mmol/l78.52\u2009±\u200928.1178.00\u2009±\u200945.44100.07\u2009±\u200952.44117.69\u2009±\u200962.38\u2003\u2009total Cholesterol (tc), mmol/l152.76\u2009±\u200922.71142.66\u2009±\u200925.78193.06\u2009±\u200941.21194.61\u2009±\u200938.77\u2003\u2009ldl-Cholesterol (ldl-c), mmol/l89.29\u2009±\u200924.6285.75\u2009±\u200923.15125.91\u2009±\u200938.39133.82\u2009±\u200936.28\u2003\u2009hdl-Cholesterol (hdl-c), mmol/l46.95\u2009±\u20099.9341.31\u2009±\u20099.5046.29\u2009±\u200913.4637.68\u2009±\u20099.93\u2003\u2009systolic Blood pressure (sbp), mmhg105.50\u2009±\u20095.00107.55\u2009±\u200910.42127.34\u2009±\u200918.56129.61\u2009±\u200913.97\u2003\u2009diastolic Blood pressure (dbp), mmhg66.94\u2009±\u20098.3069.45\u2009±\u20099.5976.79\u2009±\u200910.8981.94\u2009±\u200911.39\u2003\u2009adiponectin, ng/ml14.42\u2009±\u20095.9610.45\u2009±\u20095.019.67\u2009±\u20095.527.95\u2009±\u20096.29\u2003\u2009leptin, ng/ml13.46\u2009±\u200911.266.66\u2009±\u20097.1723.72\u2009±\u200914.159.85\u2009±\u20097.22\n\ncaption (table-wrap): table 2\n\npair-wise relationships within tfse pedigreesnumber of relative pairsfamilial relationshipproportion of Alleles shared ibd 196parent-offspring1/2212siblings1/291grandparent-grandchild1/4439avuncular1/41half siblings1/413great grandparent-grandchild1/8275grand avuncular1/82half avuncular1/8454first cousins1/8598first cousins, 1\xa0rem1/161half first cousins1/16236second cousins1/32\nibd identical by descent.']	N/A	N/A	[('UBERON_0000088', 'trophoblast', 172, 'Waist'), ('CHEBI_5801', 'hydroxychloroquine', 233, 'Hypertriglyceride9'), ('PR_000008530', 'hairy/enhancer-of-split related with YRPW motif-like protein', 255, 'HDL-C'), ('UBERON_0002281', 'vestibular membrane of cochlear duct', 689, 'Subcutaneous'), ('UBERON_0002405', 'immune system', 777, 'Visceral'), ('UBERON_0002824', 'vestibular ganglion', 791, 'VF'), ('UBERON_0007808', 'adipose tissue of abdominal region', 914, 'abdominal fat'), ('UBERON_0003671', 'anterior cruciate ligament of knee joint', 929, 'TAF'), ('CHEBI_17234', 'glucose', 1006, 'glucose'), ('PR_000045358', 'insulin family protein', 1086, 'insulin'), ('PR_000045358', 'insulin family protein', 1158, 'Insulin'), ('CHEBI_17234', 'glucose', 1166, 'glucose'), ('PR_000045358', 'insulin family protein', 1254, 'insulin'), ('CHEBI_17855', 'triglyceride', 1328, 'Triglycerides'), ('CHEBI_17855', 'triglyceride', 1343, 'TG'), ('CHEBI_16113', 'cholesterol', 1416, 'Cholesterol'), ('CHEBI_16113', 'cholesterol', 1502, 'cholesterol'), ('CHEBI_16113', 'cholesterol', 1589, 'cholesterol'), ('UBERON_0000178', 'blood', 1676, 'blood'), ('UBERON_0000178', 'blood', 1769, 'blood'), ('SO_0001023', 'allele', 2111, 'alleles')]
PMC4372177	2/2015	S234-PMC4372177	['clinical phenotypes for all subjects included weight, height, bmi, waist circumference (wc), hip circumference (hc), waist to hip ratio (whr), fasting Glucose (fg), fasting Insulin (fi), Insulin to Glucose ratio (igr), Homeostasis model assessment (homa), plasma Triglycerides (tg), total Cholesterol (tc), low density Lipoprotein Cholesterol (Ldl-C), high density lipoprotein Cholesterol (Hdl-C), systolic and Diastolic Blood pressure (sbp and dbp), and pulse.']	N/A	N/A	[('CHEBI_17234', 'glucose', 151, 'glucose'), ('PR_000045358', 'insulin family protein', 173, 'insulin'), ('PR_000045358', 'insulin family protein', 187, 'insulin'), ('CHEBI_17234', 'glucose', 198, 'glucose'), ('GO_0042592', 'homeostatic process', 219, 'homeostasis'), ('CHEBI_17855', 'triglyceride', 263, 'triglycerides'), ('CHEBI_16113', 'cholesterol', 289, 'cholesterol'), ('CHEBI_24911', 'isopiperitenol', 319, 'lipoprotein cholesterol'), ('PR_000009791', 'LIM/homeobox protein Lhx1', 344, 'LDL-c'), ('CHEBI_16113', 'cholesterol', 377, 'cholesterol'), ('PR_000008530', 'hairy/enhancer-of-split related with YRPW motif-like protein', 390, 'HDL-c'), ('GO_0007586', 'digestion', 411, 'diastolic'), ('UBERON_0000178', 'blood', 421, 'blood')]
PMC4377862	2/2015	S85-PMC4377862	['fasting Blood samples were analysed for fasting Glucose (mmol/l), fasting Insulin (miu/l), glycosylated haemoglobin (hba1c, %), Lipids (Total Cholesterol, ldl, hdl, and Triglycerides, in mmol/l), and C-Reactive Protein (mg/l).']	N/A	N/A	[('UBERON_0000178', 'blood', 8, 'blood'), ('CHEBI_17234', 'glucose', 48, 'glucose'), ('PR_000045358', 'insulin family protein', 74, 'insulin'), ('CHEBI_18059', 'lipid', 128, 'lipids'), ('CHEBI_66254', 'topopyrone C', 136, 'total cholesterol'), ('CHEBI_17855', 'triglyceride', 169, 'triglycerides'), ('CHEBI_18245', 'carboxylato group', 200, 'C'), ('PR_000005890', 'crooked neck-like protein 1', 200, 'C-reactive protein')]
PMC4377862	2/2015	S86-PMC4377862	['homeostatic model assessment (homa-ir) was estimated: (Glucose × Insulin)/22.5.']	N/A	N/A	[('CHEBI_17234', 'glucose', 55, 'glucose'), ('PR_000045358', 'insulin family protein', 65, 'insulin')]
PMC4379362	3/2015	S13-PMC4379362	['the additional predisposing factors include Pregnancy-specific biochemical changes in Urine, with higher amounts of Glucose, Amino Acids and hormone degradation products, which increase Urinary ph [7,8].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 44, 'pregnancy'), ('UBERON_0001088', 'urine', 86, 'urine'), ('CHEBI_17234', 'glucose', 116, 'glucose'), ('CHEBI_33867', 'idonates', 125, 'amino acids'), ('UBERON_0001088', 'urine', 186, 'urinary')]
PMC4383546	4/2015	S44-PMC4383546	['Glucose tolerance tests (gtt) were performed at 16 weeks of age (n = 5–10 per group from ≥ 5 litters) by an i.p.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose')]
PMC4383546	4/2015	S45-PMC4383546	['administration of Glucose (1.5mg/g bodyweight) after overnight fasting, and then the Blood Glucose levels were measured 0, 15, 30, 45, 60, 90, 120, and 150 min following Glucose challenge.']	N/A	N/A	[('CHEBI_17234', 'glucose', 18, 'glucose'), ('UBERON_0000178', 'blood', 85, 'blood'), ('CHEBI_17234', 'glucose', 91, 'glucose'), ('CHEBI_17234', 'glucose', 170, 'glucose')]
PMC4383546	4/2015	S46-PMC4383546	['the incremental (and inverted for itt) area under the Glucose curve (iauc) was calculated using the trapezoidal rule.']	N/A	N/A	[('CHEBI_17234', 'glucose', 54, 'glucose')]
PMC4383546	4/2015	S104-PMC4383546	['i-k : Plasma levels of Tnf-Α ( i ), Glucose ( j ), and Insulin ( k ) in nl and sl Mice at p21 (n = 4–5 per group from ≥ 4 litters).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 6, 'Plasma'), ('PR_000000134', 'tumor necrosis factor alpha', 23, 'TNF-α'), ('CHEBI_17234', 'glucose', 36, 'glucose'), ('PR_000045358', 'insulin family protein', 55, 'insulin'), ('NCBITaxon_10088', 'Mus <genus>', 82, 'mice')]
PMC4383546	4/2015	S123-PMC4383546	['fasting Glucose and Insulin levels were significantly elevated in sl-hfd Mice compared to nl-hfd Animals (fig 3 c –3 d ).']	N/A	N/A	[('CHEBI_17234', 'glucose', 8, 'glucose'), ('PR_000045358', 'insulin family protein', 20, 'insulin'), ('NCBITaxon_10088', 'Mus <genus>', 73, 'mice'), ('NCBITaxon_33208', 'Metazoa', 97, 'animals')]
PMC4383546	4/2015	S124-PMC4383546	['in addition, when exposed to a Glucose challenge, sl-hfd Mice displayed impaired Glucose tolerance as compared to nl-hfd Mice across all time points ( p<0.01;fig 3 a ).']	N/A	N/A	[('CHEBI_17234', 'glucose', 31, 'glucose'), ('NCBITaxon_10088', 'Mus <genus>', 57, 'mice'), ('CHEBI_17234', 'glucose', 81, 'glucose'), ('NCBITaxon_10088', 'Mus <genus>', 121, 'mice')]
PMC4383546	4/2015	S127-PMC4383546	['during the itt, blood Glucose in sl-hfd Mice was statistically significantly higher than nl-hfd Animals at 60, 90, and 120 min post insulin injection ( p<0.001, 0.001, and 0.01, respectively;fig 3 b ); and the mean itt-derived iauc of the sl-hfd group was one-third that of the nl-hfd group ( p<0.001;fig 3 b inset ).']	N/A	N/A	[('CHEBI_17234', 'glucose', 22, 'glucose'), ('NCBITaxon_10088', 'Mus <genus>', 40, 'mice'), ('NCBITaxon_33208', 'Metazoa', 96, 'animals')]
PMC4383546	4/2015	S128-PMC4383546	['in addition, sl Animals exposed to hfd displayed a 2-fold increase in the mean Hepatic Triglyceride content and enhanced Hepatic steatosis compared to nl-hfd Mice ( p<0.01;fig 3 e –3 f ).10.1371/journal.pone.0121954.g003\n\ncaption (fig): fig 3\nneonatal overnutrition perturbs Glucose Homeostasis and causes Hepatic steatosis in diet-induced obesity.']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 16, 'animals'), ('UBERON_0002107', 'liver', 79, 'hepatic'), ('CHEBI_17855', 'triglyceride', 87, 'triglyceride'), ('UBERON_0002107', 'liver', 121, 'hepatic'), ('NCBITaxon_10088', 'Mus <genus>', 158, 'mice'), ('CHEBI_17234', 'glucose', 275, 'glucose'), ('GO_0042593', 'glucose homeostasis', 275, 'glucose homeostasis'), ('UBERON_0002107', 'liver', 306, 'hepatic')]
PMC4383546	4/2015	S129-PMC4383546	['a-b : Glucose and ( a ) Insulin ( b ) tolerance tests and incremental area under the curves/inverted incremental area under the curves of Adult sl and nl Mice Fed a Chow or a high-fat diet (hfd) ( n = 4–10 per group from ≥ 4 litters).']	N/A	N/A	[('CHEBI_17234', 'glucose', 6, 'Glucose'), ('PR_000045358', 'insulin family protein', 24, 'insulin'), ('UBERON_0007023', 'adult organism', 138, 'adult'), ('NCBITaxon_10088', 'Mus <genus>', 154, 'mice'), ('GO_0007631', 'feeding behavior', 159, 'fed'), ('CHEBI_33290', 'food', 165, 'chow')]
PMC4383546	4/2015	S130-PMC4383546	['c-e : Plasma levels of Glucose ( c ), Insulin ( d ), and Hepatic Triglyceride content ( e ) of Adult sl and nl Mice Fed a Chow or a hfd ( n = 5–11 per group from ≥ 5 litters).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 6, 'Plasma'), ('CHEBI_17234', 'glucose', 23, 'glucose'), ('PR_000045358', 'insulin family protein', 38, 'insulin'), ('UBERON_0002107', 'liver', 57, 'hepatic'), ('CHEBI_17855', 'triglyceride', 65, 'triglyceride'), ('UBERON_0007023', 'adult organism', 95, 'adult'), ('NCBITaxon_10088', 'Mus <genus>', 111, 'mice'), ('GO_0007631', 'feeding behavior', 116, 'fed'), ('CHEBI_33290', 'food', 122, 'chow')]
PMC4388824	4/2015	S11-PMC4388824	['introduction\nGestational diabetes mellitus (gdm) is characterised as any degree of Glucose intolerance with first recognition during Pregnancy.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 13, 'Gestational'), ('CHEBI_17234', 'glucose', 83, 'glucose'), ('GO_0007565', 'female pregnancy', 133, 'pregnancy')]
PMC4388824	4/2015	S44-PMC4388824	['Adipose Tissue was obtained from the following groups: (i) normal Glucose tolerant (ngt) women who entered Pregnancy lean (bmi between 18-<25 kg/m2; n = 6 patients); (ii) ngt women who entered Pregnancy obese (bmi ≥30 kg/m2; n = 6 patients); (iii) women with gdm were managed by diet alone (n = 6 lean and n = 6 obese); and (iv) women with gdm were managed by Insulin in addition to diet (n = 6 lean and n = 6 obese).']	N/A	N/A	[('UBERON_0001013', 'adipose tissue', 0, 'Adipose tissue'), ('CHEBI_17234', 'glucose', 66, 'glucose'), ('GO_0007565', 'female pregnancy', 107, 'pregnancy'), ('GO_0007565', 'female pregnancy', 193, 'pregnancy'), ('PR_000045358', 'insulin family protein', 360, 'insulin')]
PMC4388824	4/2015	S46-PMC4388824	['women were controlled by diet if their fasting Glucose readings were maintained below 5.5 mmol/l over a 2 week period post diagnosis.']	N/A	N/A	[('CHEBI_17234', 'glucose', 47, 'glucose')]
PMC4388824	4/2015	S47-PMC4388824	['women with fasting Glucose readings greater than 5.5 mmol/l were placed on Insulin for optimal Glucose Control.']	N/A	N/A	[('CHEBI_17234', 'glucose', 19, 'glucose'), ('PR_000045358', 'insulin family protein', 75, 'insulin'), ('CHEBI_17234', 'glucose', 95, 'glucose'), ('GO_0065007', 'biological regulation', 103, 'control')]
PMC4390148	4/2015	S10-PMC4390148	['exercise significantly reduced Insulin concentrations in males (ce/fe versus cs/fs), with reduced Glucose in male fe pups.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 31, 'insulin'), ('CHEBI_17234', 'glucose', 98, 'glucose')]
PMC4390148	4/2015	S11-PMC4390148	['in males, maternal obesity significantly decreased Muscle Myogenic Differentiation 1 (Myod1) and Glucose Transporter Type 4 (Glut4) mrna Expressions (fs vs cs); these were normalized by exercise.']	N/A	N/A	[('PR_000010155', 'mitogen-activated protein kinase 15', 51, 'muscle myogenic differentiation 1'), ('PR_000010827', 'myosin-3', 86, 'MYOD1'), ('CHEBI_17234', 'glucose', 97, 'glucose'), ('PR_000015060', 'solute carrier family 2, facilitated glucose transporter member 11', 97, 'glucose transporter type 4'), ('PR_000015065', 'solute carrier family 2, facilitated glucose transporter member 3', 125, 'GLUT4'), ('GO_0010467', 'gene expression', 137, 'expressions')]
PMC4390148	4/2015	S63-PMC4390148	['Blood was collected via Cardiac puncture for Glucose (accu-check Glucose monitor, roche diagnostics australia), Plasma Triglycerides and hormone analysis.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('UBERON_0000948', 'heart', 24, 'cardiac'), ('CHEBI_17234', 'glucose', 45, 'glucose'), ('CHEBI_17234', 'glucose', 65, 'glucose'), ('UBERON_0001969', 'blood plasma', 112, 'plasma'), ('CHEBI_17855', 'triglyceride', 119, 'triglycerides')]
PMC4390148	4/2015	S78-PMC4390148	['weekly body weight and Glucose tolerance test of dams were analyzed by two-way mixed anova with repeated measures followed by post hoc least significance differences (lsd) test.']	N/A	N/A	[('CHEBI_17234', 'glucose', 23, 'glucose')]
PMC4390148	4/2015	S79-PMC4390148	['final body weight, Blood Glucose, Plasma Insulin, Triglycerides and Organ weights were analyzed by two-way anova (maternal diet x maternal activity), followed by post hoc lsd.']	N/A	N/A	[('UBERON_0000178', 'blood', 19, 'blood'), ('CHEBI_17234', 'glucose', 25, 'glucose'), ('UBERON_0001969', 'blood plasma', 34, 'plasma'), ('PR_000045358', 'insulin family protein', 41, 'insulin'), ('CHEBI_17855', 'triglyceride', 50, 'triglycerides'), ('UBERON_0000062', 'organ', 68, 'organ')]
PMC4390148	4/2015	S100-PMC4390148	['there was no significant difference in blood Glucose level at 4 weeks Postpartum across groups (table 1).']	N/A	N/A	[('CHEBI_17234', 'glucose', 45, 'glucose'), ('GO_0007565', 'female pregnancy', 70, 'postpartum')]
PMC4390148	4/2015	S118-PMC4390148	['**p < .01 maternal hfd effect;††p < .01 maternal exercise effect.10.1371/journal.pone.0120980.t002\n\ncaption (table-wrap): table 2\noffspring body weight, Visceral fat, total fat, muscle mass, Blood Glucose, Plasma Insulin and Triglyceride concentrations at pnd19.malefemalecs (17)ce (14)fs (16)fe (12)cs (18)ce (13)fs (21)fe (12)body weight (g)33.4 ± 1.030.0 ± 0.649.7 ± 2.7**49.8 ± 2.6**31.5 ± 0.928.9 ± 0.547.3 ± 1.4*46.8 ± 1.4*Visceral fat (mg)125.4 ± 5.3107.5 ± 3.9†229.0 ± 17.3**250.0 ± 13.1**106.7 ± 6.390.3 ± 7.1234.6 ± 10.8*213.5 ± 13.7*total Wat (mg)283.6 ± 24.8223.1 ± 19.5675.6 ± 66.9**713.9 ± 41.6**143.5 ± 8.8122.3 ± 7.8385.8 ± 2.4**387.0 ± 22.9**total muscle (mg)161.9 ± 7.6137.3 ± 4.4221.8 ± 19.6**236.3 ± 23.9**149.0 ± 7.0141.8 ± 10.4197.7 ± 14.4**209.7 ± 15.9**Blood Glucose (mmol.l-1)7.6 ± 0.37.8 ± 0.28.7 ± 0.3**7.9 ± 0.4†7.6 ± 0.17.6 ± 0.18.5 ± 0.2**8.2 ± 0.2**Plasma Insulin (ng.ml-1)1.8 ± 0.21.3 ± 0.1†1.7 ± 0.21.0 ± 0.1†0.6 ± 0.10.7 ± 0.12.1 ± 0.2**2.1 ± 0.2**Plasma tg (mmol.l-1)26.6 ± 2.720.8 ± 2.6†27.1 ± 3.432.7 ± 4.7*16.1 ± 1.215.0 ± 2.922.6 ± 2.321.9 ± 1.9\nbody weight, Visceral fat, total Wat, muscle mass, Blood Glucose, Plasma Insulin and Triglyceride concentrations in male and female offspring at pnd19.']	N/A	N/A	[('UBERON_0002075', 'viscus', 153, 'visceral'), ('UBERON_0000178', 'blood', 191, 'blood'), ('CHEBI_17234', 'glucose', 197, 'glucose'), ('UBERON_0001969', 'blood plasma', 206, 'plasma'), ('PR_000045358', 'insulin family protein', 213, 'insulin'), ('CHEBI_17855', 'triglyceride', 225, 'triglyceride'), ('UBERON_0002405', 'immune system', 429, 'Visceral'), ('UBERON_0006337', 'distal early tubule', 550, 'WAT'), ('UBERON_0000178', 'blood', 777, 'Blood'), ('CHEBI_17234', 'glucose', 783, 'glucose'), ('UBERON_0001969', 'blood plasma', 880, 'Plasma'), ('PR_000045358', 'insulin family protein', 887, 'insulin'), ('UBERON_0001969', 'blood plasma', 982, 'Plasma'), ('UBERON_0002075', 'viscus', 1098, 'visceral'), ('UBERON_0006337', 'distal early tubule', 1118, 'WAT'), ('UBERON_0000178', 'blood', 1136, 'blood'), ('CHEBI_17234', 'glucose', 1142, 'glucose'), ('UBERON_0001969', 'blood plasma', 1151, 'plasma'), ('PR_000045358', 'insulin family protein', 1158, 'insulin'), ('CHEBI_17855', 'triglyceride', 1170, 'triglyceride')]
PMC4390148	4/2015	S136-PMC4390148	['Glut4 is the Glucose transporter found primarily in the muscle and fat.']	N/A	N/A	[('PR_000015065', 'solute carrier family 2, facilitated glucose transporter member 3', 0, 'GLUT4'), ('CHEBI_17234', 'glucose', 13, 'glucose')]
PMC4390148	4/2015	S163-PMC4390148	['voluntary exercise by obese dams during Pregnancy also improved Glucose Homeostasis in their offspring, with decreased Plasma Glucose and Insulin concentrations in male pups at pnd19.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 40, 'pregnancy'), ('CHEBI_17234', 'glucose', 64, 'glucose'), ('GO_0042593', 'glucose homeostasis', 64, 'glucose homeostasis'), ('UBERON_0001969', 'blood plasma', 119, 'plasma'), ('CHEBI_17234', 'glucose', 126, 'glucose'), ('PR_000045358', 'insulin family protein', 138, 'insulin')]
PMC4390148	4/2015	S167-PMC4390148	['in male offspring, exercise during Pregnancy was able to decrease the Metabolic risk conferred by maternal obesity by improving Insulin and Glucose Metabolism.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 35, 'pregnancy'), ('GO_0008152', 'metabolic process', 70, 'metabolic'), ('PR_000045358', 'insulin family protein', 128, 'insulin'), ('CHEBI_17234', 'glucose', 140, 'glucose'), ('GO_0006006', 'glucose metabolic process', 140, 'glucose metabolism')]
PMC4390148	4/2015	S216-PMC4390148	['modest voluntary exercise by obese dams prior to and during Pregnancy had benefits in normalizing their Blood Glucose concentrations during the Lactation window.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 60, 'pregnancy'), ('UBERON_0000178', 'blood', 104, 'blood'), ('CHEBI_17234', 'glucose', 110, 'glucose'), ('GO_0007595', 'lactation', 144, 'lactation')]
PMC4392553	3/2015	S93-PMC4392553	['[18] furthermore, Pancreatic Insulin content was only 63% of control levels, and Insulin Release following Glucose administration was also reduced.']	N/A	N/A	[('UBERON_0001264', 'pancreas', 18, 'pancreatic'), ('PR_000045358', 'insulin family protein', 29, 'insulin'), ('GO_0006880', 'intracellular sequestering of iron ion', 81, 'insulin release'), ('PR_000045358', 'insulin family protein', 81, 'insulin'), ('CHEBI_17234', 'glucose', 107, 'glucose')]
PMC4407308	4/2015	S114-PMC4407308	['Allantoic Fluid is also a reservoir for both Glucose and Fructose in the Sheep, and both concentrations and total levels of Fructose are much greater than that of Glucose and change significantly with day of Gestation [32].']	N/A	N/A	[('UBERON_0010230', 'eyeball of camera-type eye', 0, 'Allantoic fluid'), ('CHEBI_17234', 'glucose', 45, 'glucose'), ('CHEBI_28757', 'fructose', 57, 'fructose'), ('NCBITaxon_10088', 'Mus <genus>', 73, 'sheep'), ('CHEBI_28757', 'fructose', 124, 'fructose'), ('CHEBI_17234', 'glucose', 163, 'glucose'), ('GO_0007565', 'female pregnancy', 208, 'gestation')]
PMC4407308	4/2015	S125-PMC4407308	['as the Fetus Grows, so does its rate of absolute Glucose utilization and thereby the Placental rate of Glucose Transfer must increase accordingly.']	N/A	N/A	[('UBERON_0000312', 'inner cambium layer of periosteum', 7, 'fetus'), ('GO_0040007', 'growth', 13, 'grows'), ('CHEBI_17234', 'glucose', 49, 'glucose'), ('UBERON_0001987', 'placenta', 85, 'placental'), ('CHEBI_17234', 'glucose', 103, 'glucose'), ('GO_0006094', 'gluconeogenesis', 103, 'glucose transfer')]
PMC4407308	4/2015	S126-PMC4407308	['changes in maternal Glucose levels and/or rate of Placental Transfer require the fetus to adapt Metabolically to maintain consistent levels for its trajectory of development [83].']	N/A	N/A	[('CHEBI_17234', 'glucose', 20, 'glucose'), ('GO_0001966', 'thigmotaxis', 50, 'placental transfer'), ('UBERON_0001987', 'placenta', 50, 'placental'), ('GO_0008152', 'metabolic process', 96, 'metabolically')]
PMC4407308	4/2015	S155-PMC4407308	['in the case of Lactating dairy Cows, Blood Glucose levels are lower in comparison to their non-Lactating contemporaries [112].']	N/A	N/A	[('GO_0007594', 'puparial adhesion', 15, 'lactating'), ('NCBITaxon_33208', 'Metazoa', 31, 'cows'), ('UBERON_0000178', 'blood', 37, 'blood'), ('CHEBI_17234', 'glucose', 43, 'glucose'), ('GO_0007594', 'puparial adhesion', 95, 'lactating')]
PMC4410178	4/2015	S40-PMC4410178	['two days before sacrifice, systolic Blood pressure and Heart rate were measured by noninvasive Tail-Cuff plethysmography (hugo-sachs elektronik, freiburg, germany) and one day before sacrifice oral Glucose tolerance test was performed.']	N/A	N/A	[('UBERON_0000178', 'blood', 36, 'blood'), ('UBERON_0000948', 'heart', 55, 'heart'), ('UBERON_0002415', 'tail', 95, 'tail'), ('UBERON_0003124', 'chorion', 100, 'cuff'), ('CHEBI_17234', 'glucose', 198, 'glucose')]
PMC4410178	4/2015	S41-PMC4410178	['after overnight fasting with Water or Coca-Cola available ad libitum , Rats were administered 2 g/kg body weight of Glucose dissolved in 0.5 ml of Water via gavage.']	N/A	N/A	[('CHEBI_15377', 'water', 29, 'water'), ('CHEBI_15579', '(25S)-5beta-spirostan-3beta-yl beta-D-glucoside', 38, 'Coca-Cola'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 71, 'rats'), ('CHEBI_17234', 'glucose', 116, 'glucose'), ('CHEBI_15377', 'water', 147, 'water')]
PMC4410178	4/2015	S42-PMC4410178	['Blood Glucose levels were measured using standard Glucose meter in Blood from the Tail, before Glucose administration and 15, 30, 60, 90 and 120 minutes thereafter.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('CHEBI_17234', 'glucose', 6, 'glucose'), ('CHEBI_17234', 'glucose', 50, 'glucose'), ('UBERON_0000178', 'blood', 67, 'blood'), ('UBERON_0002415', 'tail', 82, 'tail'), ('CHEBI_17234', 'glucose', 95, 'glucose')]
PMC4410178	4/2015	S56-PMC4410178	['homeostatic model assessment of Insulin resistance (homa-ir) was calculated using the formula: fasting Insuline (μiu/ml)\u2009×\u2009fasting Plasma Glucose (mmol/l)/22.5.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 32, 'insulin'), ('PR_000045358', 'insulin family protein', 103, 'insuline'), ('UBERON_0001969', 'blood plasma', 131, 'plasma'), ('CHEBI_17234', 'glucose', 138, 'glucose')]
PMC4410178	4/2015	S57-PMC4410178	['area under Glucose curve was calculated from the ogtt data.']	N/A	N/A	[('CHEBI_17234', 'glucose', 11, 'glucose')]
PMC4410178	4/2015	S79-PMC4410178	['Glucose Metabolism\nfasting Glucose levels were significantly higher in both mrp+ groups than in mrps- groups.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('GO_0006006', 'glucose metabolic process', 0, 'Glucose metabolism'), ('CHEBI_17234', 'glucose', 27, 'glucose')]
PMC4410178	4/2015	S83-PMC4410178	['caption (fig): figure 3\n\nfasting Glucose levels were increased by Prenatal Maillard Reaction products (mrp) diet and by its combination with coca-cola Intake.']	N/A	N/A	[('CHEBI_17234', 'glucose', 33, 'glucose'), ('GO_0007565', 'female pregnancy', 66, 'prenatal'), ('CHEBI_6673', 'malvalic acid', 75, 'Maillard'), ('GO_0008152', 'metabolic process', 75, 'Maillard reaction'), ('GO_0007631', 'feeding behavior', 151, 'intake')]
PMC4421033	4/2015	S14-PMC4421033	['Pregnancy alters the maternal Metabolic profile away from the normal preference for Glucose as an energy source and towards the use of Fatty Acids, conserving Glucose and amino Acids for the Growing fetus.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnancy'), ('GO_0008152', 'metabolic process', 30, 'metabolic'), ('CHEBI_17234', 'glucose', 84, 'glucose'), ('CHEBI_35366', 'fatty acid', 135, 'fatty acids'), ('CHEBI_17234', 'glucose', 159, 'glucose'), ('CHEBI_37527', 'acid', 177, 'acids'), ('GO_0040007', 'growth', 191, 'growing')]
PMC4421033	4/2015	S51-PMC4421033	['Gestational diabetes (a clinical diagnosis based on 2 or more abnormal Glucose tolerance tests) and abnormal Glucose tolerance (a single recorded abnormal test without a Gestational diabetes diagnosis) were abstracted from hospital charts.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_17234', 'glucose', 71, 'glucose'), ('CHEBI_17234', 'glucose', 109, 'glucose'), ('GO_0007565', 'female pregnancy', 170, 'gestational')]
PMC4421033	4/2015	S96-PMC4421033	['treated Gestational diabetes did not significantly contribute to the risk of Delivering a lga infant, but a single abnormal Glucose tolerance test during Pregnancy, without a clinical diagnosis of Gestational diabetes, did (or = 2.84, p< 0.01).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 8, 'gestational'), ('GO_0006900', 'vesicle budding from membrane', 77, 'delivering'), ('CHEBI_17234', 'glucose', 124, 'glucose'), ('GO_0007565', 'female pregnancy', 154, 'pregnancy'), ('GO_0007565', 'female pregnancy', 197, 'gestational')]
PMC4427001	4/2015	S50-PMC4427001	['gdm screening was carried out using ogtt with 75\u2009g of Glucose performed between 24th and 30th weeks of Pregnancy.']	N/A	N/A	[('CHEBI_17234', 'glucose', 54, 'glucose'), ('GO_0007565', 'female pregnancy', 103, 'pregnancy')]
PMC4427001	4/2015	S51-PMC4427001	['gdm diagnosis was established according to the who criteria recommended by the czech diabetes society at that time of recruitment (2012): fpg ≥ 5.6\u2009mmol/l, 1\u2009hr after load Glucose ≥ 8.9\u2009mmol/l, and 2\u2009hr after load Glucose ≥ 7.7\u2009mmol/l (any one of the three above cut-off values qualified for the gdm diagnosis).']	N/A	N/A	[('CHEBI_17234', 'glucose', 172, 'glucose'), ('CHEBI_17234', 'glucose', 214, 'glucose')]
PMC4427001	4/2015	S52-PMC4427001	['Postpartum diagnosis of diabetes/prediabetes was based on the who criteria for nonpregnant subjects: fpg ≥ 7\u2009mmol/l alone or 2\u2009hr after load Glucose ≥ 11.1\u2009mmol/l for diabetes mellitus and fpg 5.6–6.9\u2009mmol/l or 2\u2009hr after load Glucose 7.8–11.0\u2009mmol/l for prediabetes.']	N/A	N/A	[('GO_0007567', 'parturition', 0, 'Postpartum'), ('CHEBI_17234', 'glucose', 141, 'glucose'), ('CHEBI_17234', 'glucose', 227, 'glucose')]
PMC4427001	4/2015	S78-PMC4427001	['based on the results of ogtt repeated up to maximum 12 months Postpartum the Glucose abnormality was detected in 7 women (14.9%) with history of gdm.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 62, 'postpartum'), ('CHEBI_17234', 'glucose', 77, 'glucose')]
PMC4430416	5/2015	S4-PMC4430416	['a subset of 348 women provided fasting Serum samples for Glucose and Lipid measurements.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 39, 'serum'), ('CHEBI_17234', 'glucose', 57, 'glucose'), ('CHEBI_18059', 'lipid', 69, 'lipid')]
PMC4430416	5/2015	S35-PMC4430416	['of them a subset of 348 women provided fasting Blood samples for Glucose and Lipid measurements, due to the timing of enrollment in the study.']	N/A	N/A	[('UBERON_0000178', 'blood', 47, 'blood'), ('CHEBI_17234', 'glucose', 65, 'glucose'), ('CHEBI_18059', 'lipid', 77, 'lipid')]
PMC4430416	5/2015	S39-PMC4430416	['maternal fasting Glucose and Lipid levels in early Pregnancy\nwe measured Lipids [total Cholesterol (tc), Triglycerides (tg), high-density lipoprotein Cholesterol (hdl-c)] and Glucose by standard enzymatic methods (medicon, greece) on an automatic analyzer (au5400 high-volume chemistry analyzer; olympus america, inc., melville, new york).']	N/A	N/A	[('CHEBI_17234', 'glucose', 17, 'glucose'), ('CHEBI_18059', 'lipid', 29, 'lipid'), ('GO_0007565', 'female pregnancy', 51, 'pregnancy'), ('CHEBI_18059', 'lipid', 73, 'lipids'), ('CHEBI_16113', 'cholesterol', 87, 'cholesterol'), ('CHEBI_17855', 'triglyceride', 105, 'triglycerides'), ('CHEBI_16113', 'cholesterol', 150, 'cholesterol'), ('CHEBI_17234', 'glucose', 175, 'glucose')]
PMC4430416	5/2015	S45-PMC4430416	['maternal hyperglycemia in early Pregnancy was defined as a maternal fasting Blood Glucose level ≥92 mg/dl [27].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 32, 'pregnancy'), ('UBERON_0000178', 'blood', 76, 'blood'), ('CHEBI_17234', 'glucose', 82, 'glucose')]
PMC4430416	5/2015	S81-PMC4430416	['there were no significant differences in socio- demographic characteristics between women who provided fasting Blood samples and those who did not (s2 table).10.1371/journal.pone.0126327.t001\n\ncaption (table-wrap): table 1\nmother- child characteristics by pre-Pregnancy overweight/obesity status, rhea Pregnancy cohort, crete, greece.pre-Pregnancy obesity statusno excess weightoverweight/obese p - valuea(n = 409)(n = 209) maternal characteristics \xa0\xa0\xa0\xa0maternal age at Delivery (yr), mean (sd) 29.87 (0.2)29.98 (0.3)0.891\xa0\xa0\xa0\xa0education, n (%)<0.001\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 low 49 (12.0)54 (25.8)\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 medium 208 (50.9)102 (48.8)\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 high 152 (37.2)53 (25.4)greek origin, n (%) 384 (93.9)199 (95.2)0.499primiparous, n (%) 194 (47.4)70 (33.5)0.001smoking during Pregnancy, n (%) 126 (30.8)70 (33.5)0.497gestational diabetes, n (%) 32 (8.4)18 (9.2)0.758gestational hypertension, n (%) 15 (4.0)14 (7.1)0.106gestational weight gain (kg), n (%)<0.001\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 inadequate 114 (27.9)15 (7.2)\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 adequate 155 (37.9)81 (38.8)\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 excessive 140 (34.2)113 (54.1)\xa0\xa0\xa0\xa0caesarian section, n (%) 195 (48.0)115 (55.0)0.100 Metabolic profile in early Pregnancy (n = 348) Glucose (mg/dl), mean (sd) 74.93 (0.7)76.10 (1.2)0.341insulin (mg/dl), mean (sd) 9.33 (0.9)12.75 (1.5)<0.001tc (mg/dl), mean (sd) 195.49 (2.3)203.87 (3.7)0.025ldl-C (mg/dl), mean (sd) 113.87 (1.8)123.14 (3.0)0.008hdl-C (mg/dl), mean (sd) 60.18 (0.9)55.42 (1.3)0.007tg (mg/dl), mean (sd) 108.04 (2.8)126.23 (4.8)<0.001sbp (mmhg), mean (sd) 105.06 (0.5)109.92 (0.8)<0.001dbp (mmhg), mean (sd) 69.27 (0.5)71.31 (0.7)0.013 child characteristics in infancy \xa0\xa0\xa0\xa0sex, girl, n (%) 201 (49.1)93 (44.5)0.274\xa0\xa0\xa0\xa0Birth weight (kg), mean (sd) 3.20 (0.02)3.21 (0.03)0.887\xa0\xa0\xa0\xa0Gestational age (weeks), mean (sd) 38.32 (0.07)38.08 (0.11)0.123\xa0\xa0\xa0\xa0duration of breastfeeding (months), mean (sd) 4.69 (0.2)3.44 (0.3)<0.001\xa0\xa0\xa0\xa0day care attendance in the first 2 years of Life, n (%) 79 (19.5)36 (17.3)0.518 child characteristics at 4 years of age bmi (kg/m2), mean (sd) 16.11 (0.08)16.93 (0.15)<0.001overweight/obese, n (%) 74 (18.1)60 (28.7)0.002waist circumference (cm), mean (sd) 52.90 (0.2)54.66 (0.4)<0.001waist circumference ≥90th pct, n (%) 35 (8.7)37 (17.9)<0.001sum of Skinfolds (mm), mean (sd) 37.78 (0.7)43.29 (1.1)<0.001tc (mg/dl), mean (sd) 156.39 (1.5)158.97 (2.0)0.247Ldl-C (mg/dl), mean (sd) 69.98 (27.4)69.58 (26.7)0.856hdl-C (mg/dl), mean (sd) 47.17 (0.6)47.78 (0.8)0.518tg (mg/dl), mean (sd) 69.69 (1.5)70.40 (2.1)0.690time spent watching tv (hours/day), n (%) 0.019\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 almost never 124 (30.5)52 (25.0)\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 1–2 hours/day 251 (61.8)126 (60.6)\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 more than 3 hours/day 31 (7.6)30 (14.4)energy Intake (kcals/day), mean (sd) 1583.5 (23.0)1594.3 (32.1)0.752\nbmi, body mass index; tc, total Cholesterol; Ldl-C, low density Lipoprotein Cholesterol; Hdl-C, high density\nLipoprotein Cholesterol; tg, Triglyceride; crp, C-Reactive Protein; sbp, systolic Blood pressure; dbp, diastolic Blood pressure; pct, percentile\nap -values obtained by mann-whitney u test for two independent samples, and χ2test or fisher exact test with monte-carlo correction.']	N/A	N/A	[('UBERON_0000178', 'blood', 111, 'blood'), ('GO_0007565', 'female pregnancy', 260, 'pregnancy'), ('GO_0007565', 'female pregnancy', 302, 'pregnancy'), ('GO_0007565', 'female pregnancy', 338, 'pregnancy'), ('GO_0007567', 'parturition', 469, 'delivery'), ('GO_0007565', 'female pregnancy', 750, 'pregnancy'), ('GO_0008152', 'metabolic process', 1103, 'Metabolic'), ('GO_0007565', 'female pregnancy', 1130, 'pregnancy'), ('CHEBI_17234', 'glucose', 1150, 'Glucose'), ('PR_000000037', 'BMP receptor type-2', 1312, '-C'), ('PR_000000037', 'BMP receptor type-2', 1366, '-C'), ('GO_0007567', 'parturition', 1651, 'Birth'), ('GO_0007565', 'female pregnancy', 1711, 'Gestational'), ('UBERON_0000104', 'life cycle', 1899, 'life'), ('UBERON_0009007', 'superficial inguinal lymph node', 2206, 'skinfolds'), ('PR_000010755', 'metaxin-1', 2308, '247LDL-C'), ('PR_000000037', 'BMP receptor type-2', 2368, '-C'), ('GO_0007631', 'feeding behavior', 2652, 'intake'), ('CHEBI_16113', 'cholesterol', 2746, 'Cholesterol'), ('PR_000009780', 'legumain', 2759, 'LDL-C'), ('CHEBI_39015', 'apolipoprotein', 2778, 'Lipoprotein'), ('CHEBI_16113', 'cholesterol', 2790, 'Cholesterol'), ('PR_000008530', 'hairy/enhancer-of-split related with YRPW motif-like protein', 2803, 'HDL-C'), ('CHEBI_39015', 'apolipoprotein', 2823, 'Lipoprotein'), ('CHEBI_16113', 'cholesterol', 2835, 'Cholesterol'), ('CHEBI_17855', 'triglyceride', 2852, 'Triglyceride'), ('PR_000005890', 'crooked neck-like protein 1', 2871, 'C-reactive protein'), ('UBERON_0000178', 'blood', 2905, 'Blood'), ('UBERON_0000178', 'blood', 2936, 'Blood')]
PMC4446764	5/2015	S151-PMC4446764	['if exogenous Insulin-Like Growth Factor-1 is administered to the dam, there is increased Glucose and Amino Acid Uptake by both fetal and maternal Tissues [87].']	N/A	N/A	[('PR_000008953', 'insulin-like growth factor-binding protein 7', 13, 'insulin-like growth factor-1'), ('CHEBI_17234', 'glucose', 89, 'glucose'), ('GO_0007369', 'gastrulation', 89, 'glucose ...'), ('GO_0043090', 'amino acid import', 101, 'amino acid uptake'), ('UBERON_0000479', 'tissue', 146, 'tissues')]
PMC4452737	6/2015	S3-PMC4452737	['methods\nin this observational study, fasting Glucose, Sorbitol and Fructose concentrations were measured using gas-chromatography-liquid mass spectroscopy in Cerebrospinal Fluid (Csf), maternal Plasma, and Venous Cord Blood collected from 25 Pregnant women (6 lean, 10 overweight/obese, and 9 t2dm/Gestational dm) undergoing Spinal anesthesia and elective cesarean section.']	N/A	N/A	[('CHEBI_17234', 'glucose', 45, 'glucose'), ('CHEBI_30911', 'glucitol', 54, 'sorbitol'), ('CHEBI_28757', 'fructose', 67, 'fructose'), ('UBERON_0001359', 'cerebrospinal fluid', 158, 'cerebrospinal fluid'), ('UBERON_0001359', 'cerebrospinal fluid', 179, 'CSF'), ('UBERON_0001969', 'blood plasma', 194, 'plasma'), ('UBERON_0005487', 'vitelline vein', 206, 'venous cord'), ('UBERON_0000178', 'blood', 218, 'blood'), ('GO_0007565', 'female pregnancy', 242, 'pregnant'), ('GO_0007565', 'female pregnancy', 298, 'gestational'), ('UBERON_0001130', 'vertebral column', 325, 'spinal')]
PMC4452737	6/2015	S8-PMC4452737	['there were no differences in Plasma, Csf, and Cord Blood Glucose, Fructose, or Sorbitol levels between groups.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 29, 'plasma'), ('UBERON_0001359', 'cerebrospinal fluid', 37, 'CSF'), ('UBERON_0002240', 'spinal cord', 46, 'cord'), ('UBERON_0000178', 'blood', 51, 'blood'), ('CHEBI_17234', 'glucose', 57, 'glucose'), ('CHEBI_28757', 'fructose', 66, 'fructose'), ('CHEBI_30911', 'glucitol', 79, 'sorbitol')]
PMC4452737	6/2015	S12-PMC4452737	['in Rats, Intraventricular Glucose infusion into the Brain decreases Feeding, whereas infusion of Fructose promotes Feeding [3].']	N/A	N/A	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 3, 'rats'), ('UBERON_0006250', 'infundibular recess of 3rd ventricle', 9, 'intraventricular'), ('CHEBI_17234', 'glucose', 26, 'glucose'), ('UBERON_0000955', 'brain', 52, 'brain'), ('GO_0007631', 'feeding behavior', 68, 'feeding'), ('CHEBI_28757', 'fructose', 97, 'fructose'), ('GO_0007631', 'feeding behavior', 115, 'feeding')]
PMC4452737	6/2015	S17-PMC4452737	['fructose can be converted from Glucose via the polyol pathway (Glucose → Sorbitol → Fructose), an alternate Glucose pathway that bypasses the Control points of hexokinase and phosphofructokinase [8,9].']	N/A	N/A	[('CHEBI_17234', 'glucose', 31, 'glucose'), ('CHEBI_17234', 'glucose', 63, 'glucose'), ('CHEBI_30911', 'glucitol', 73, 'sorbitol'), ('CHEBI_28757', 'fructose', 84, 'fructose'), ('CHEBI_17234', 'glucose', 108, 'glucose'), ('GO_0065007', 'biological regulation', 142, 'control')]
PMC4452737	6/2015	S18-PMC4452737	['both aldose reductase (which reduces Glucose to Sorbitol) and Sorbitol dehydrogenase (which oxidizes Sorbitol to Fructose), are present throughout the body including in the Brain [10,11] and Placenta [8,12].']	N/A	N/A	[('CHEBI_17234', 'glucose', 37, 'glucose'), ('CHEBI_30911', 'glucitol', 48, 'sorbitol'), ('CHEBI_30911', 'glucitol', 62, 'sorbitol'), ('CHEBI_30911', 'glucitol', 101, 'sorbitol'), ('CHEBI_28757', 'fructose', 113, 'fructose'), ('UBERON_0000955', 'brain', 173, 'brain'), ('UBERON_0001987', 'placenta', 191, 'placenta')]
PMC4452737	6/2015	S20-PMC4452737	['in Dogs, peripheral Glucose infusion increases levels of Fructose and Sorbitol in the Cerebrospinal Fluid (Csf) [13,14].']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 3, 'dogs'), ('CHEBI_17234', 'glucose', 20, 'glucose'), ('CHEBI_28757', 'fructose', 57, 'fructose'), ('CHEBI_30911', 'glucitol', 70, 'sorbitol'), ('UBERON_0001359', 'cerebrospinal fluid', 86, 'cerebrospinal fluid'), ('UBERON_0001359', 'cerebrospinal fluid', 107, 'CSF')]
PMC4452737	6/2015	S37-PMC4452737	['two subjects had >5 Rbcs per high-power field in their Csf; however, there were no differences in Csf Fructose, Glucose, or Sorbitol levels and those subjects were included in the analysis.']	N/A	N/A	[('CL_0000232', 'erythrocyte', 20, 'RBCs'), ('UBERON_0001359', 'cerebrospinal fluid', 55, 'CSF'), ('UBERON_0001359', 'cerebrospinal fluid', 98, 'CSF'), ('CHEBI_28757', 'fructose', 102, 'fructose'), ('CHEBI_17234', 'glucose', 112, 'glucose'), ('CHEBI_30911', 'glucitol', 124, 'sorbitol')]
PMC4452737	6/2015	S42-PMC4452737	['Glucose levels were measured enzymatically with Glucose oxidase (ysi, yellow springs, oh, usa).']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('CHEBI_17234', 'glucose', 48, 'glucose')]
PMC4452737	6/2015	S46-PMC4452737	['Glucose was normally distributed and one-way anova was used for across group comparisons and t-test for post-hoc analysis.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose')]
PMC4452737	6/2015	S49-PMC4452737	['Glucose data are reported as mean ± se; Fructose and Sorbitol data are reported as both median and mean.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('CHEBI_28757', 'fructose', 40, 'fructose'), ('CHEBI_30911', 'glucitol', 53, 'sorbitol')]
PMC4452737	6/2015	S53-PMC4452737	['no differences were observed in fasting Plasma Glucose levels between the groups (p = 0.61).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 40, 'plasma'), ('CHEBI_17234', 'glucose', 47, 'glucose')]
PMC4452737	6/2015	S61-PMC4452737	['no correlation was detected between Csf Glucose and csf Sorbitol levels (fig 2c, ρ 0.24, p = 0.2).10.1371/journal.pone.0128582.t002\n\ncaption (table-wrap): table 2\nGlucose, Fructose and Sorbitol levels for all subjects.all subjectslean (n = 6)obese (n = 10)dm (n = 9)p * Plasma Glucose 4.3 ± 0.14.3 ± 0.24.2 ± 0.24.5 ± 0.20.61 Csf Glucose 2.5 ± 0.12.5 ± 0.12.6 ± 0.12.5 ± 0.10.65 Csf:Plasma ratio 0.6 ± 0.040.6 ± 0.030.7 ± 0.10.6 ± 0.020.30 Cord Glucose 3.2 ± 0.33.9 ± 0.22.5 ± 0.63.7 ± 0.20.58 Plasma fructose\u2003mean 0.01 ± 0.0010.008 ± 0.0040.012 ± 0.0010.007 ± 0.0020.22 \u2003median (iqr) 0.009 (0.003, 0.015)0.006 (0.003, 0.016)0.01 (0.01, 0.015)0.003 (0.003, 0.014) Csf fructose\u2003mean 0.17 ± 0.010.18 ± 0.020.18 ± 0.020.14 ± 0.010.16 \u2003median (iqr) 0.17 (0.11, 0.19)0.19 (0.12, 0.21)0.18 (0.13, 0.20)0.14 (0.11, 0.18) Csf:Plasma ratio\u2003mean 27 ± 534 ± 1416 ± 434 ± 70.47 \u2003median (iqr) 17 (11, 47)32 (9, 60)13 (12, 17)39 (10, 55) Cord Fructose\u2003mean 0.009 ± 0.0010.01 ± 0.0040.008 ± 0.0010.009 ± 0.0010.65 \u2003median (iqr) 0.009 (0.006, 0.01)0.01 (0.005, 0.01)0.007 (0.006, 0.01)0.009 (0.007, 0.01) Plasma Sorbitol\u2003mean 0.02 ± 0.000.03 ± 0.010.02 ± 0.010.02 ± 0.000.97 \u2003median (iqr) 0.02 (0.01, 0.03)0.02 (0.01, 0.04)0.02 (0.01, 0.03)0.02 (0.015, 0.02) csf Sorbitol\u2003mean 0.17 ± 0.020.15 ± 0.020.17 ± 0.020.14 ± 0.020.89 \u2003median (iqr) 0.15 (0.12, 0.17)0.15 (0.10, 0.18)0.15 (0.12, 0.19)0.15 (0.11, 0.17) Csf:Plasma ratio\u2003mean 9.6 ± 19.8 ± 6.110.5 ± 2.48.5 ±4.30.92 \u2003median (iqr) 8.5 (5, 15)8.2 (6, 16)8.2 (4, 17)8.7 (5, 12) Cord Sorbitol\u2003mean 0.13 ± 0.020.08 ± 0.030.17 ± 0.040.12 ± 0.020.48 \u2003median (iqr) 0.12 (0.08, 0.16)0.11 (0.00, 0.13)0.14 (0.09, 0.25)0.13 (0.08, 0.16)\n* p values across groups; Glucose, Fructose, and Sorbitol in mmol/l; unless otherwise noted, data presented as mean ± se10.1371/journal.pone.0128582.g001\n\ncaption (fig): fig 1\ncsf to Plasma ratios of Glucose, Sorbitol, and Fructose.']	N/A	N/A	[('UBERON_0001359', 'cerebrospinal fluid', 36, 'CSF'), ('CHEBI_17234', 'glucose', 40, 'glucose'), ('CHEBI_30911', 'glucitol', 56, 'sorbitol'), ('CHEBI_17234', 'glucose', 163, 'Glucose'), ('CHEBI_28757', 'fructose', 172, 'fructose'), ('CHEBI_30911', 'glucitol', 185, 'sorbitol'), ('UBERON_0001969', 'blood plasma', 270, 'Plasma'), ('CHEBI_17234', 'glucose', 277, 'Glucose'), ('UBERON_0001359', 'cerebrospinal fluid', 326, 'CSF'), ('CHEBI_17234', 'glucose', 330, 'glucose'), ('UBERON_0001359', 'cerebrospinal fluid', 379, 'CSF'), ('UBERON_0001969', 'blood plasma', 383, 'plasma'), ('CHEBI_33252', 'atomic nucleus', 440, 'Cord'), ('UBERON_0000948', 'heart', 440, 'Cord'), ('CHEBI_17234', 'glucose', 445, 'glucose'), ('UBERON_0001969', 'blood plasma', 494, 'Plasma'), ('UBERON_0001359', 'cerebrospinal fluid', 664, 'CSF'), ('UBERON_0001359', 'cerebrospinal fluid', 814, 'CSF'), ('UBERON_0001969', 'blood plasma', 818, 'plasma'), ('UBERON_0000948', 'heart', 924, 'Cord'), ('CHEBI_28757', 'fructose', 929, 'fructose'), ('UBERON_0001969', 'blood plasma', 1089, 'Plasma'), ('CHEBI_30911', 'glucitol', 1096, 'sorbitol'), ('CHEBI_30911', 'glucitol', 1247, 'sorbitol'), ('UBERON_0001359', 'cerebrospinal fluid', 1393, 'CSF'), ('UBERON_0001969', 'blood plasma', 1397, 'plasma'), ('CHEBI_33252', 'atomic nucleus', 1513, 'Cord'), ('UBERON_0000948', 'heart', 1513, 'Cord'), ('CHEBI_30911', 'glucitol', 1518, 'sorbitol'), ('CHEBI_17234', 'glucose', 1690, 'Glucose'), ('CHEBI_28757', 'fructose', 1699, 'fructose'), ('CHEBI_30911', 'glucitol', 1713, 'sorbitol'), ('UBERON_0001969', 'blood plasma', 1847, 'plasma'), ('CHEBI_17234', 'glucose', 1864, 'glucose'), ('CHEBI_30911', 'glucitol', 1873, 'sorbitol'), ('CHEBI_28757', 'fructose', 1887, 'fructose')]
PMC4462496	8/2013	S35-PMC4462496	['increased Serum Glucose levels of the mother, free Fatty Acids and Amino Acids produce permanent alterations in the Regulation Of the Appetite, the Neuronal and Endocrine systems and the energetic Metabolism Of the Foetus, thus determining obesity and a high risk of Metabolic syndrome in the subsequent Life of the Individual [7].']	N/A	N/A	[('UBERON_0001977', 'blood serum', 10, 'serum'), ('CHEBI_17234', 'glucose', 16, 'glucose'), ('CHEBI_35366', 'fatty acid', 51, 'fatty acids'), ('CHEBI_33867', 'idonates', 67, 'amino acids'), ('GO_2000615', 'regulation of histone H3-K9 acetylation', 116, 'regulation of ... appetite'), ('CL_0000540', 'neuron', 148, 'neuronal'), ('UBERON_0002049', 'vasculature', 161, 'endocrine'), ('GO_0008150', 'biological_process', 197, 'metabolism of ... foetus'), ('GO_0008152', 'metabolic process', 267, 'metabolic'), ('UBERON_0000104', 'life cycle', 304, 'life'), ('NCBITaxon_1', 'root', 316, 'individual')]
PMC4462496	8/2013	S45-PMC4462496	['we calculated the body mass index (bmi) for the children and the mothers\nthe laboratory tests performed were: fasting Glucose level, oral Glucose tolerance test, fasting Insulin level, total Cholesterol, hdl Cholesterol, Triglycerides.']	N/A	N/A	[('CHEBI_17234', 'glucose', 118, 'glucose'), ('CHEBI_17234', 'glucose', 138, 'glucose'), ('PR_000045358', 'insulin family protein', 170, 'insulin'), ('CHEBI_16113', 'cholesterol', 191, 'cholesterol'), ('CHEBI_16113', 'cholesterol', 208, 'cholesterol'), ('CHEBI_17855', 'triglyceride', 221, 'triglycerides')]
PMC4463828	5/2015	S47-PMC4463828	['taqman real-time pcr was performed for Il-1 Β , tnf α , Cd68, lipoprotein Lipase (Lpl), Cd36, Glucose transporter (glut)1, Glut4, system n/a amino acid transporter (Snat)2, Snat4 and Delta Homolog (dlk)1 using pre-developed assay Reagent Kits.']	N/A	N/A	[('PR_000001383', 'interleukin-22', 39, 'IL-1 β'), ('PR_000001309', 'CD70 molecule', 56, 'CD68'), ('PR_000009875', 'E3 ubiquitin-protein ligase LNX', 74, 'lipase'), ('PR_000009880', 'Lon protease, mitochondrial', 82, 'LPL'), ('PR_000002060', 'lysosome-associated membrane glycoprotein 1', 88, 'CD36'), ('CHEBI_17234', 'glucose', 94, 'glucose'), ('PR_000015065', 'solute carrier family 2, facilitated glucose transporter member 3', 123, 'GLUT4'), ('PR_000015209', 'sodium/calcium exchanger 3', 165, 'SNAT ... 2'), ('PR_000015190', 'sodium- and chloride-dependent glycine transporter 2', 173, 'SNAT4'), ('PR_000006602', 'dynamin-1-like protein', 183, 'delta homolog ...'), ('CHEBI_33893', 'reagent', 230, 'Reagent'), ('PR_000009329', 'killer cell immunoglobulin-like receptor 2DL3', 238, 'Kits')]
PMC4463828	5/2015	S102-PMC4463828	['caption (fig): figure 5\n\nPlacental Glucose Transporter Gene Expression: Placental mrna Expression of (a) Glut1, (b) Glut4 was analyzed by rt-pcr (* p \xa0<\xa00.05 w.r.t cd; n \xa0=\xa06 males; n \xa0=\xa06 females from independent litters).']	N/A	N/A	[('UBERON_0001987', 'placenta', 25, 'Placental'), ('CHEBI_17234', 'glucose', 35, 'glucose'), ('GO_0006094', 'gluconeogenesis', 35, 'glucose transporter'), ('GO_0010467', 'gene expression', 55, 'gene expression'), ('SO_0000704', 'gene', 55, 'gene'), ('UBERON_0001987', 'placenta', 72, 'Placental'), ('GO_0010467', 'gene expression', 87, 'expression'), ('PR_000015065', 'solute carrier family 2, facilitated glucose transporter member 3', 105, 'GLUT1'), ('PR_000015065', 'solute carrier family 2, facilitated glucose transporter member 3', 116, 'GLUT4')]
PMC4463828	5/2015	S155-PMC4463828	['Expression of system a sodium dependant Glucose transporters, Snat2 and Snat4 was also measured.']	N/A	N/A	[('GO_0010467', 'gene expression', 0, 'Expression'), ('CHEBI_17234', 'glucose', 40, 'glucose'), ('PR_000015209', 'sodium/calcium exchanger 3', 62, 'SNAT2'), ('PR_000015190', 'sodium- and chloride-dependent glycine transporter 2', 72, 'SNAT4')]
PMC4473145	12/2014	S6-PMC4473145	['Lipid and Glucose Metabolism was disturbed in mhfd offspring, with altered Regulation of Cluster Of Differentiation 36 (Cd36) ( p \xa0<\xa00·001), Fatty Acid synthase ( p \xa0<\xa00·05) and Glut1 ( p \xa0<\xa00·05) Gene Expression in Skeletal muscle.']	N/A	N/A	[('CHEBI_18059', 'lipid', 0, 'Lipid'), ('GO_0036339', 'lymphocyte adhesion to endothelial cell of high endothelial venule', 0, 'Lipid ...'), ('CHEBI_17234', 'glucose', 10, 'glucose'), ('GO_0006006', 'glucose metabolic process', 10, 'glucose metabolism'), ('GO_0065007', 'biological regulation', 75, 'regulation'), ('PR_000005190', 'cell division cycle protein 23', 89, 'cluster of differentiation 36'), ('PR_000002060', 'lysosome-associated membrane glycoprotein 1', 120, 'CD36'), ('CHEBI_35366', 'fatty acid', 141, 'fatty acid'), ('PR_000015065', 'solute carrier family 2, facilitated glucose transporter member 3', 178, 'GLUT1'), ('GO_0010467', 'gene expression', 197, 'gene expression'), ('SO_0000704', 'gene', 197, 'gene'), ('UBERON_0004288', 'skeleton', 216, 'skeletal')]
PMC4488777	5/2015	S170-PMC4488777	['in the same study, patients with the highest concentrations of vd2had the lowest Glucose concentration in Follicular Fluid ( p = 0.003) [61].']	N/A	N/A	[('CHEBI_17234', 'glucose', 81, 'glucose'), ('UBERON_0000038', 'follicular fluid', 106, 'follicular fluid')]
PMC4490503	6/2015	S91-PMC4490503	['universal screening for gdm is common in most developed nations [45], using a variety of tests including an oral Glucose tolerance test (ogtt) at 24–28 weeks Gestation for diagnosis.']	N/A	N/A	[('CHEBI_17234', 'glucose', 113, 'glucose'), ('GO_0007565', 'female pregnancy', 158, 'gestation')]
PMC4490503	6/2015	S193-PMC4490503	['Adiponectin is an Insulin-sensitizing, anti-inflammatory and anti-atherogenic adipokine that stimulates Glucose Uptake in Skeletal muscle and reduces Hepatic Glucose Production through amp-activated protein kinases [26,42,95].']	N/A	N/A	[('PR_000004070', 'anthrax toxin receptor-like', 0, 'Adiponectin'), ('PR_000045358', 'insulin family protein', 18, 'insulin'), ('CHEBI_17234', 'glucose', 104, 'glucose'), ('GO_0046323', 'glucose import', 104, 'glucose uptake'), ('UBERON_0004288', 'skeleton', 122, 'skeletal'), ('UBERON_0002107', 'liver', 150, 'hepatic'), ('CHEBI_17234', 'glucose', 158, 'glucose'), ('GO_0006094', 'gluconeogenesis', 158, 'glucose production')]
PMC4490503	6/2015	S258-PMC4490503	['[86] reported higher Plasma Visfatin in gdm women compared to controls with normal Glucose tolerance, but there was no relationship with fasting Plasma Glucose, Insulin, Insulin resistance or bmi.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 21, 'plasma'), ('CHEBI_9945', 'Ventinone A', 28, 'visfatin'), ('CHEBI_17234', 'glucose', 83, 'glucose'), ('UBERON_0001969', 'blood plasma', 145, 'plasma'), ('CHEBI_17234', 'glucose', 152, 'glucose'), ('PR_000045358', 'insulin family protein', 161, 'insulin'), ('PR_000045358', 'insulin family protein', 170, 'insulin')]
PMC4490503	6/2015	S326-PMC4490503	['[137] performed a prospective study of 150 women looking at maternal Lipids including Serum tg, Cholesterol, free Fatty Acids (ffa), Glycerol, Insulin and Glucose in maternal Serum and Cord Blood during the third trimester.']	N/A	N/A	[('CHEBI_18059', 'lipid', 69, 'lipids'), ('UBERON_0001977', 'blood serum', 86, 'serum'), ('CHEBI_16113', 'cholesterol', 96, 'cholesterol'), ('CHEBI_35366', 'fatty acid', 114, 'fatty acids'), ('CHEBI_17754', 'glycerol', 133, 'glycerol'), ('PR_000045358', 'insulin family protein', 143, 'insulin'), ('CHEBI_17234', 'glucose', 155, 'glucose'), ('UBERON_0001977', 'blood serum', 175, 'serum'), ('UBERON_0002240', 'spinal cord', 185, 'cord'), ('UBERON_0000178', 'blood', 190, 'blood')]
PMC4490503	6/2015	S359-PMC4490503	['we progressed this work in those identified at high gdm risk in the clinical prediction tool, measured and examined fasting biochemical markers (Glucose, Lipids) at 12–15 weeks Gestation and gdm diagnosis at 28 weeks Gestation in our cohort [52].']	N/A	N/A	[('CHEBI_17234', 'glucose', 145, 'glucose'), ('CHEBI_18059', 'lipid', 154, 'lipids'), ('GO_0007565', 'female pregnancy', 177, 'gestation'), ('GO_0007565', 'female pregnancy', 217, 'gestation')]
PMC4490503	6/2015	S361-PMC4490503	['fasting Glucose at 14–16 weeks was the strongest predictor for gdm and incrementally improved the tool with sensitivity and specificity of 97% and 94.8% respectively for adips-diagnosed gdm (auc 0.79) and 94% and 92.4% for iadpsg-diagnosed gdm (auc 0.83) [52].']	N/A	N/A	[('CHEBI_17234', 'glucose', 8, 'glucose')]
PMC4492644	6/2015	S8-PMC4492644	['it is defined by the national institutes of health (nih) by having at least three of the following conditions: central obesity, elevated Triglycerides, low high-density lipoprotein Cholesterol, hypertension or elevated fasting Plasma Glucose.']	N/A	N/A	[('CHEBI_17855', 'triglyceride', 137, 'triglycerides'), ('CHEBI_16113', 'cholesterol', 181, 'cholesterol'), ('UBERON_0001969', 'blood plasma', 227, 'plasma'), ('CHEBI_17234', 'glucose', 234, 'glucose')]
PMC4492644	6/2015	S53-PMC4492644	['elevated maternal Blood Glucose triggers the Production Of Reactive Oxygen Species.']	N/A	N/A	[('UBERON_0000178', 'blood', 18, 'blood'), ('CHEBI_17234', 'glucose', 24, 'glucose'), ('GO_1903409', 'reactive oxygen species biosynthetic process', 45, 'production of reactive oxygen species'), ('CHEBI_26523', 'reactive oxygen species', 59, 'reactive oxygen species')]
PMC4509429	7/2015	S10-PMC4509429	['gdm is defined as Glucose intolerance with onset or initial diagnosis during Pregnancy, which includes previously undetected type 1 or 2 diabetes mellitus or first presentation of diabetes during Pregnancy [1,2].']	N/A	N/A	[('CHEBI_17234', 'glucose', 18, 'glucose'), ('GO_0007565', 'female pregnancy', 77, 'pregnancy'), ('GO_0007565', 'female pregnancy', 196, 'pregnancy')]
PMC4509429	7/2015	S26-PMC4509429	['overview of monitoring and general management\nas with screening and diagnostic recommendations, Glucose testing and treatment goals differ among guidelines (table 3).']	N/A	N/A	[('CHEBI_17234', 'glucose', 96, 'glucose')]
PMC4509429	7/2015	S39-PMC4509429	['the primary outcome was achievement of desired Glucose Control and secondary outcomes were assessment of maternal and fetal complications.']	N/A	N/A	[('CHEBI_17234', 'glucose', 47, 'glucose'), ('GO_0046323', 'glucose import', 47, 'glucose control')]
PMC4509429	7/2015	S40-PMC4509429	['there were no significant differences in the primary endpoint, which included fasting, pre- and postprandial, and mean Blood Glucose levels as well as a1c.']	N/A	N/A	[('UBERON_0000178', 'blood', 119, 'blood'), ('CHEBI_17234', 'glucose', 125, 'glucose')]
PMC4509429	7/2015	S110-PMC4509429	['there is one rct (n=15) in which women with gdm who were uncontrolled with diet and exercise were given a standard meal on three subsequent days, and Glucose, Insulin, and c-peptide levels were measured before the administration of Insulin and after regular Insulin and aspart administration [42].']	N/A	N/A	[('CHEBI_17234', 'glucose', 150, 'glucose'), ('PR_000045358', 'insulin family protein', 159, 'insulin'), ('PR_000045358', 'insulin family protein', 232, 'insulin'), ('PR_000045358', 'insulin family protein', 258, 'insulin')]
PMC4509429	7/2015	S119-PMC4509429	['ninety-six women with gdm were allocated to receive aspart (n=31), lispro (n=33), or regular Insulin (n=32) in conjunction with nph Insulin, if needed to Control fasting Glucose [44].']	N/A	N/A	[('PR_000045358', 'insulin family protein', 93, 'insulin'), ('PR_000045358', 'insulin family protein', 132, 'insulin'), ('GO_0065007', 'biological regulation', 154, 'control'), ('CHEBI_17234', 'glucose', 170, 'glucose')]
PMC4509429	7/2015	S136-PMC4509429	['maternal Glucose levels were significantly lower at 1 hour after Eating (lispro 108.4 mg/dl vs regular 121.0 mg/dl, p<0.01) as expected.']	N/A	N/A	[('CHEBI_17234', 'glucose', 9, 'glucose'), ('GO_0051318', 'G1 phase', 65, 'eating')]
PMC4509429	7/2015	S138-PMC4509429	['two hundred and one south indian women with gdm were included in a retrospective observational study in which patients took Lispro before each meal and nph based on fasting plasma Glucose readings greater than 95 mg/dl [52].']	N/A	N/A	[('CHEBI_29785', 'nitro group', 124, 'lispro'), ('CHEBI_17234', 'glucose', 180, 'glucose')]
PMC4509429	7/2015	S139-PMC4509429	['patients met target Blood Glucose goals for gdm, and there were no cases of eclampsia.']	N/A	N/A	[('UBERON_0000178', 'blood', 20, 'blood'), ('CHEBI_17234', 'glucose', 26, 'glucose')]
PMC4509429	7/2015	S191-PMC4509429	['Postpartum management\nfor women with Gestational diabetes, Blood Glucose levels can be variable for both mother and infant in the immediate Postpartum period.']	N/A	N/A	[('GO_0007567', 'parturition', 0, 'Postpartum'), ('GO_0007565', 'female pregnancy', 37, 'gestational'), ('UBERON_0000178', 'blood', 59, 'blood'), ('CHEBI_17234', 'glucose', 65, 'glucose'), ('GO_0007565', 'female pregnancy', 140, 'postpartum')]
PMC4509429	7/2015	S245-PMC4509429	['she reports her fasting Plasma Glucose average as 110 mg/dl and her 2-hour Postprandial Glucose average as 132 mg/dl.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 24, 'plasma'), ('CHEBI_17234', 'glucose', 31, 'glucose'), ('GO_0007567', 'parturition', 75, 'postprandial'), ('CHEBI_17234', 'glucose', 88, 'glucose')]
PMC4512131	8/2015	S15-PMC4512131	['he discussed this in the context of diabetes in Pregnancy leading to excess fuel exposure to the Fetal-Placental Unit, not only from Glucose but also from excess Lipids and Amino Acids (aas).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 48, 'pregnancy'), ('UBERON_0000922', 'embryo', 97, 'fetal'), ('UBERON_0013765', 'digestive system element', 103, 'placental unit'), ('CHEBI_17234', 'glucose', 133, 'glucose'), ('CHEBI_18059', 'lipid', 162, 'lipids'), ('CHEBI_33867', 'idonates', 173, 'amino acids')]
PMC4512131	8/2015	S35-PMC4512131	['Genes for Lipids and Aa Transport are upregulated in the Placenta of women with gdm more than those for Glucose, as are Genes for inflammatory pathways (22,23).']	N/A	N/A	[('SO_0000704', 'gene', 0, 'Genes'), ('CHEBI_18059', 'lipid', 10, 'lipids'), ('GO_0008610', 'lipid biosynthetic process', 10, 'lipids'), ('GO_0043132', 'NAD transport', 21, 'AA transport'), ('UBERON_0001987', 'placenta', 57, 'placenta'), ('CHEBI_17234', 'glucose', 104, 'glucose'), ('SO_0000704', 'gene', 120, 'genes')]
PMC4514967	12/2014	S28-PMC4514967	["by age 2, Blood Flow and Metabolism in the Brain reach Adult levels, while at the end of the first decade of Life Glucose Metabolism and Blood flow are almost twice Adult levels (at a time that the child's Brain-to-body-weight ratio remains several fold higher than in Adults)."]	N/A	N/A	[('UBERON_0000178', 'blood', 10, 'blood'), ('GO_0007601', 'visual perception', 16, 'flow'), ('GO_0008152', 'metabolic process', 25, 'metabolism'), ('UBERON_0000955', 'brain', 43, 'brain'), ('UBERON_0007023', 'adult organism', 55, 'adult'), ('UBERON_0000104', 'life cycle', 109, 'life'), ('CHEBI_17234', 'glucose', 114, 'glucose'), ('GO_0006006', 'glucose metabolic process', 114, 'glucose metabolism'), ('UBERON_0000178', 'blood', 137, 'blood'), ('UBERON_0007023', 'adult organism', 165, 'adult'), ('UBERON_0000955', 'brain', 206, 'brain'), ('UBERON_0007023', 'adult organism', 269, 'adults')]
PMC4538752	8/2015	S79-PMC4538752	['outcomes\nprimary outcomes will be: 1) for mothers: a) adequate weight gain at the end of the Pregnancy based on iom 2009 [30]; b) adequate Glycaemic Control at 24-28 weeks of Pregnancy according to ada 2011 (having fasting Plasma Glucose (fpg) levels <92\xa0mg/dl or\xa02-h values in the oral Glucose tolerance test (ogtt) of <153\xa0mg/dl) [22]; 2) for infants: adequate weight, length and bmi growth during the first year of Life according to who 2006 [31] (table\xa02).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 93, 'pregnancy'), ('GO_0051162', 'L-arabitol metabolic process', 139, 'glycaemic control'), ('GO_0007565', 'female pregnancy', 175, 'pregnancy'), ('UBERON_0001969', 'blood plasma', 223, 'plasma'), ('CHEBI_17234', 'glucose', 230, 'glucose'), ('CHEBI_17234', 'glucose', 287, 'glucose'), ('UBERON_0000104', 'life cycle', 418, 'life')]
PMC4538752	8/2015	S82-PMC4538752	['caption (table-wrap): table 2\n\noutcomes of the interventiongoal\xa0indicatorhealthy weight gain during Pregnancyabased on Pre-Conceptional nutritional status:normal (bmi 18.5-24.9\xa0kg/m2) =11.5-16.0\xa0kgoverweight (bmi 25.0-29.9\xa0kg/m2)\u2009=\u20097.0-11.5\xa0kgobese (bmi ≥30\xa0kg/m2)\u2009=\u20095.0-9.0\xa0kgadequate Glycaemic Control During Pregnancybfasting Plasma Glucose (fpg) levels <92\xa0mg/dl or\xa02-h values in the 75-g Oral Glucose tolerance test (ogtt) of <153\xa0mg/dl at 24-28 weeks of Pregnancyhealthy infant growthcfrom 0-1 yweight-for-age, height-for-age and bmi-for-age z-scores based on who standards (between -2 and +2sd)\nainstitute of medicine (us) and national research council, weight gain during Pregnancy: reexamining the guidelines, 2009\nbdiabetes care, vol.']	N/A	N/A	[('GO_0006412', 'translation', 100, 'PregnancyaBased'), ('GO_0007568', 'aging', 119, 'pre'), ('GO_0007620', 'copulation', 123, 'conceptional'), ('GO_0006009', 'glucose 1-phosphate phosphorylation', 286, 'Glycaemic control during'), ('GO_0016540', 'protein autoprocessing', 311, 'PregnancybFasting'), ('UBERON_0001969', 'blood plasma', 329, 'plasma'), ('CHEBI_17234', 'glucose', 336, 'glucose'), ('UBERON_0000165', 'mouth', 393, 'oral'), ('CHEBI_17234', 'glucose', 398, 'glucose'), ('GO_0040007', 'growth', 398, 'glucose'), ('GO_0006412', 'translation', 460, 'pregnancyHealthy'), ('GO_0007565', 'female pregnancy', 680, 'Pregnancy')]
PMC4539485	8/2015	S160-PMC4539485	['in addition to Micronutrients, tbis require an increased demand for energy in the Brain, creating an increased need for Glucose [11,55].']	N/A	N/A	[('CHEBI_33839', 'macromolecule', 15, 'micronutrients'), ('UBERON_0000955', 'brain', 82, 'brain'), ('CHEBI_17234', 'glucose', 120, 'glucose')]
PMC4545890	8/2015	S22-PMC4545890	['routine analysis for fasting Plasma Glucose (fpg) was undertaken by the pathology labs at the royal devon and exeter nhs foundation trust, uk (women with fpg >5.5 mmol/l were excluded from analysis).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 29, 'plasma'), ('CHEBI_17234', 'glucose', 36, 'glucose')]
PMC4553961	3/2015	S41-PMC4553961	['oral Glucose tolerance test was performed and Gestational diabetes was defined as fasting Glucose ≥7.0\u200ammol/l or 2-hour Glucose ≥11.1\u200ammol/l.']	N/A	N/A	[('CHEBI_17234', 'glucose', 5, 'glucose'), ('GO_0007565', 'female pregnancy', 46, 'gestational'), ('CHEBI_17234', 'glucose', 90, 'glucose'), ('CHEBI_17234', 'glucose', 120, 'glucose')]
PMC4569192	9/2015	S3-PMC4569192	['Serum Insulin, Glucose and leptin were measured in early Pregnancy and at 28 weeks.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('PR_000045358', 'insulin family protein', 6, 'insulin'), ('CHEBI_17234', 'glucose', 15, 'glucose'), ('GO_0007565', 'female pregnancy', 57, 'pregnancy')]
PMC4569192	9/2015	S40-PMC4569192	['at this visit and again at 28 weeks Gestation fasting Serum Glucose, Insulin, and leptin concentrations were measured.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 36, 'gestation'), ('UBERON_0001977', 'blood serum', 54, 'serum'), ('CHEBI_17234', 'glucose', 60, 'glucose'), ('PR_000045358', 'insulin family protein', 69, 'insulin')]
PMC4569192	9/2015	S77-PMC4569192	['additionally female fetuses had higher concentrations of both Cord Blood leptin and Cord Blood c-peptide when compared to male offspring (b = 0.38, p<0.001 and b = 0.31, p = 0.03 respectively).table 3.10.1371/journal.pone.0137215.t001\n\ncaption (table-wrap): table 1\nbaseline characteristics.baseline characteristicoverallfemale fetusmale fetusp-valuebmi (kg/m2)26.78 (4.9)26.35 (4.6)27.17 (5.1)0.05early Pregnancy Glucose (mmol\\l)4.41 (0.3)4.37 (0.3)4.44 (0.3)0.06smoking (n)3114170.7gestation at Delivery (days)281.53 (9.7)281.62 (8.6)281.43 (10.6)0.7\ndata presented as mean and standard deviations or n. bmi is body mass index as calculated at first Antenatal consultation.']	N/A	N/A	[('UBERON_0002240', 'spinal cord', 62, 'cord'), ('UBERON_0000178', 'blood', 67, 'blood'), ('UBERON_0002240', 'spinal cord', 84, 'cord'), ('UBERON_0000178', 'blood', 89, 'blood'), ('GO_0007565', 'female pregnancy', 404, 'pregnancy'), ('CHEBI_17234', 'glucose', 414, 'glucose'), ('GO_0007567', 'parturition', 497, 'delivery'), ('GO_0007567', 'parturition', 652, 'antenatal')]
PMC4586532	8/2015	S40-PMC4586532	['Blood Glucose (Glucometer, precision qid, medisense, oxfordshire, uk) and Serum Insulin (Rat Insulin radio-immunoassay (ria) kit, linco research, st. charles, mo, usa) concentrations were measured.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('CHEBI_17234', 'glucose', 6, 'glucose'), ('CHEBI_24321', 'glutamo group', 15, 'glucometer'), ('UBERON_0001977', 'blood serum', 74, 'serum'), ('PR_000045358', 'insulin family protein', 80, 'insulin'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 89, 'rat'), ('PR_000045358', 'insulin family protein', 93, 'insulin')]
PMC4586532	8/2015	S41-PMC4586532	['the Homeostasis model assessment (homa-Insulin resistance) was calculated (fasting Plasma Glucose (mmol/l) × fasting Serum Insulin (mu/l)/22.5)).']	N/A	N/A	[('GO_0042592', 'homeostatic process', 4, 'Homeostasis'), ('PR_000045358', 'insulin family protein', 39, 'insulin'), ('UBERON_0001969', 'blood plasma', 83, 'plasma'), ('CHEBI_17234', 'glucose', 90, 'glucose'), ('UBERON_0001977', 'blood serum', 117, 'serum'), ('PR_000045358', 'insulin family protein', 123, 'insulin')]
PMC4586532	8/2015	S59-PMC4586532	['Metabolic parameters\nthe hf3 fetuses had higher Glucose concentrations relative to the other fetuses (table 1).']	N/A	N/A	[('GO_0008152', 'metabolic process', 0, 'Metabolic'), ('CHEBI_17234', 'glucose', 48, 'glucose')]
PMC4586532	8/2015	S85-PMC4586532	['during the final week of fetal Life the Endocrine Pancreas differentiates into functional Islet Cells specialized for the maintenance of Glucose Homeostasis.']	N/A	N/A	[('UBERON_0000104', 'life cycle', 31, 'life'), ('UBERON_0002049', 'vasculature', 40, 'endocrine'), ('UBERON_0001264', 'pancreas', 50, 'pancreas'), ('CL_0000129', 'microglial cell', 90, 'islet cells'), ('CHEBI_17234', 'glucose', 137, 'glucose'), ('GO_0042593', 'glucose homeostasis', 137, 'glucose homeostasis')]
PMC4591141	10/2015	S79-PMC4591141	['women were given the questionnaire by a health service provider during their Prenatal Glucose challenge appointment.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 77, 'prenatal'), ('CHEBI_17234', 'glucose', 86, 'glucose')]
PMC4613350	9/2015	S95-PMC4613350	['legend: ( 1 ) Activin-A; ( 2 ) Adam-12; ( 3 ) Α Fetoprotein; ( 4 ) α-1-macroglobulin; ( 5 ) anti-Cd63 (Gp53, Lysosomal secretion); ( 6 ) Chemerin; ( 7 ) C-Reactive Protein; ( 8 ) cystatin C; ( 9 ) Endoglin; ( 10 ) E-Selectin; ( 11 ) fetal dna; ( 12 ) fetal hemoglobin (ratio); ( 13 ) Fibronectin; ( 14 ) free Β-Hcg; ( 15 ) free leptin index; ( 16 ) Grp78 (Glucose Regulated Protein) ratio c-term/full length; ( 17 ) Htr-A1 (High-Temperature Requirement A1); ( 18 ) Inhibin-A; ( 19 ) Ngal (Neutrophil Gelatinase-Associated Lipocalin); ( 20 ) Papp-A; ( 21 ) Pbmc (Peripheral Blood Mononuclear Cell) Mirna; ( 22 ) Plgf; ( 23 ) Pp-13; ( 24 ) P-Selectin; ( 25 ) soluble endoglin; ( 26 ) Sflt/Plgf ratio; ( 27 ) Sflt-1; ( 28 ) Svegfr-1 (Vascular Endothelial Growth Factor); ( 29 ) Tnf-R1 (Tumor Necrosis Factor Receptor).']	N/A	N/A	[('PR_000000210', 'activin receptor type-2B isoform ActR-IIBtrunc', 14, 'activin-A'), ('PR_000003719', 'disintegrin and metalloproteinase domain-containing protein 23', 31, 'ADAM-12'), ('PR_000003593', 'ankyrin repeat and BTB/POZ domain-containing protein 2', 46, 'α fetoprotein'), ('PR_000001309', 'CD70 molecule', 97, 'CD63'), ('PR_000001509', 'probable G-protein coupled receptor 146', 103, 'GP53'), ('GO_0005764', 'lysosome', 109, 'lysosomal'), ('CHEBI_23103', 'chitodextrin', 137, 'chemerin'), ('PR_000005399', 'glutathione-specific gamma-glutamylcyclotransferase 2', 137, 'chemerin'), ('PR_000005890', 'crooked neck-like protein 1', 153, 'C-reactive protein'), ('PR_000004900', 'complement C3', 188, 'C'), ('PR_000007090', 'glycerophosphocholine cholinephosphodiesterase ENPP6', 197, 'endoglin'), ('PR_000001447', 'cadherin-1', 214, 'E-selectin'), ('PR_000007500', 'fibroblast growth factor 9', 284, 'fibronectin'), ('PR_000000035', 'BMP receptor type-1A', 309, 'β-hCG'), ('PR_000008210', 'glutathione peroxidase 1', 349, 'GRP78'), ('CHEBI_17234', 'glucose', 356, 'glucose'), ('PR_000007989', 'ARF GTPase-activating protein GIT1', 356, 'glucose regulated protein'), ('GO_0065007', 'biological regulation', 364, 'regulated'), ('PR_000008820', 'heat shock protein beta-8', 416, 'Htr-A1'), ('PR_000008441', 'hydroxyacid oxidase 1', 424, 'High-Temperature Requirement A1'), ('PR_000009070', 'integrator complex subunit 3', 465, 'inhibin-A'), ('PR_000010960', 'N-acetyl-D-glucosamine kinase', 483, 'NGAL'), ('CL_0000775', 'neutrophil', 489, 'neutrophil'), ('PR_000011041', 'nuclear receptor coactivator 2', 489, 'neutrophil gelatinase-associated lipocalin'), ('PR_000012271', 'pappalysin-2', 541, 'PAPP-A'), ('CL_0002246', 'peripheral blood stem cell', 556, 'PBMC'), ('CL_0000111', 'peripheral neuron', 562, 'peripheral blood mononuclear cell'), ('UBERON_0000178', 'blood', 573, 'blood'), ('GO_0031097', 'medial cortex', 579, 'mononuclear'), ('SO_0000276', 'miRNA', 597, 'miRNA'), ('PR_000012611', 'N-acetylmuramoyl-L-alanine amidase', 611, 'PlGF'), ('PR_000013440', 'protein tyrosine phosphatase type IVA 1', 624, 'PP-13'), ('PR_000001245', 'rhodopsin', 638, 'P-selectin'), ('PR_000014791', 'protein O-mannose kinase', 682, 'sFLT'), ('PR_000012611', 'N-acetylmuramoyl-L-alanine amidase', 687, 'PlGF'), ('PR_000014793', 'inactive tyrosine-protein kinase PRAG1', 706, 'sFlt-1'), ('PR_000015699', 'alpha-2,8-sialyltransferase 8E', 721, 'sVEGFR-1'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 731, 'vascular endothelial growth factor'), ('UBERON_0001986', 'endothelium', 740, 'endothelial'), ('PR_000001958', 'tumor necrosis factor receptor superfamily member 1A', 775, 'TNF-R1'), ('PR_000001959', 'tumor necrosis factor receptor superfamily member 1B', 783, 'tumor necrosis factor receptor')]
PMC4619070	10/2015	S14-PMC4619070	['background\nGestational diabetes (gdm) is a frequent medical condition during Pregnancy and was historically defined as ‘any degree of Glucose intolerance with onset or first recognition during Pregnancy’ [1].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 11, 'Gestational'), ('GO_0007565', 'female pregnancy', 77, 'pregnancy'), ('CHEBI_17234', 'glucose', 134, 'glucose'), ('GO_0007565', 'female pregnancy', 193, 'pregnancy')]
PMC4619070	10/2015	S18-PMC4619070	['initial treatment of gdm involves diet modification, Glucose monitoring and moderate exercise [7].']	N/A	N/A	[('CHEBI_17234', 'glucose', 53, 'glucose')]
PMC4619070	10/2015	S38-PMC4619070	['to uniform the initiation for Insulin therapy as much as possible, the ‘weekly average glycaemia’ (wag) is calculated based on the self-monitoring values of the blood Glucose (fasting and Postprandial) during the first weeks after the diagnosis.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 30, 'insulin'), ('CHEBI_17234', 'glucose', 167, 'glucose'), ('GO_0007567', 'parturition', 188, 'postprandial')]
PMC4619070	10/2015	S50-PMC4619070	['the Insulin sensitivity index of matsuda is defined as 10 000/√ [(fpg x fasting plasma Insulin) x (mean Glucose during ogtt x mean Insulin during ogtt)] [16].']	N/A	N/A	[('PR_000045358', 'insulin family protein', 4, 'insulin'), ('PR_000045358', 'insulin family protein', 87, 'insulin'), ('CHEBI_17234', 'glucose', 104, 'glucose'), ('PR_000045358', 'insulin family protein', 131, 'insulin')]
PMC4619070	10/2015	S53-PMC4619070	['Beta-Cell function was assessed by the Insulin secretion sensitivity index (issi-2), an ogtt-derived measure that is analogous to the disposition index obtained from the frequently sampled Intravenous Glucose tolerance test [18,19].']	N/A	N/A	[('CL_0000944', 'Be2 cell', 0, 'Beta-cell'), ('UBERON_0000164', 'primitive urogenital sinus', 0, 'Beta-cell'), ('PR_000045358', 'insulin family protein', 39, 'insulin'), ('UBERON_0034986', 'sacral nerve plexus', 189, 'intravenous'), ('CHEBI_17234', 'glucose', 201, 'glucose')]
PMC4619070	10/2015	S54-PMC4619070	['glycaemia was assessed by the area under the Glucose curve (auc Glucose) during the ogtt, calculated using the trapezoidal rule [18,19].']	N/A	N/A	[('CHEBI_17234', 'glucose', 45, 'glucose'), ('CHEBI_17234', 'glucose', 64, 'glucose')]
PMC4619070	10/2015	S55-PMC4619070	['issi-2 is defined as the product of 1) Insulin secretion measured by the ratio of the auc Insulin to the auc Glucose and 2) Insulin sensitivity measured by the Insulin sensitivity index of matsuda [18,19].']	N/A	N/A	[('PR_000045358', 'insulin family protein', 39, 'insulin'), ('PR_000045358', 'insulin family protein', 90, 'insulin'), ('CHEBI_17234', 'glucose', 109, 'glucose'), ('PR_000045358', 'insulin family protein', 124, 'insulin'), ('PR_000045358', 'insulin family protein', 160, 'insulin')]
PMC4619070	10/2015	S59-PMC4619070	['in both centers Plasma Glucose was measured by an automated colorimetric-enzymatic method (hexokinase-Glucose-6-Phosphate-dehydrogenase, application 668) on a hitachi/roche-modular p analyzer.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 16, 'plasma'), ('CHEBI_17234', 'glucose', 23, 'glucose'), ('CHEBI_14314', 'D-glucose 6-phosphate', 102, 'glucose-6-phosphate')]
PMC4619070	10/2015	S86-PMC4619070	['caption (table-wrap): table 1\n\nthe general characteristics and the differences between both centers of the cohort of women with gdmgeneral cohort n \u2009=\u2009−601university hospital n \u2009=\u2009269 (44.8\xa0%)non-university hospital n \u2009=\u2009332 (55.2\xa0%) p -valuemean age (years)31.9\u2009±\u20094.832.0\u2009±\u20094.831.5\u2009±\u20094.8 0.028 % first degree relative with diabetes18.3\xa0% (109)14.9\xa0% (40)21.1\xa0% (69) <0.0001 % second degree relative with diabetes21.8\xa0% (130)8.2\xa0% (22)33.0\xa0% (108) <0.0001 % with a history of gdm13.1\xa0% (78)12.3\xa0% (33)13.8\xa0% (45) 0.023 % overweight32.2\xa0% (158)34.2\xa0% (89)30.0\xa0% (69)0.317% obese22.9\xa0% (112)22.3\xa0% (58)23.5\xa0% (54)0.758% excessive weight gain19.7\xa0% (103)22.0\xa0% (55)17.5\xa0% (48)0.197% emb24.5\xa0% (146)37.2\xa0% (100)14.1\xa0% (46) <0.0001 fasting glycaemia at ogtt in mg/dl (mmol/l)90.0\u2009±\u200913.4 (5.0\u2009±\u20090.7)93.6\u2009±\u200915.6 (5.5\u2009±\u20090.9)87.3\u2009±\u200910.8 (4.8\u2009±\u20090.6) <0.0001 hba1c, mean in % (mmol/mol)5.3\u2009±\u20090.5 (34\u2009±\u20096)5.4\u2009±\u20090.5 (36\u2009±\u20096)5.1\u2009±\u20090.4 (32\u2009±\u20095) <0.0001 % Insulin use24.1\xa0% (145)27.2\xa0% (73)21.8\xa0% (72)0.291% macrosomia8.7\xa0% (52)7.5\xa0% (20)9.7\xa0% (32)0.329% lga16.9\xa0% (101)16.8\xa0% (45)17.1\xa0% (56)0.927% Preterm Delivery13.0\xa0% (187)18.3\xa0% (49)8.8\xa0% (29) <0.0001 % cesarean section31.2\xa0% (187)36.6\xa0%(98)26.96\xa0% (89) 0.011 % Shoulder dystocia1.2\xa0% (7)2.2\xa0% (6)0.3\xa0% (1) 0.029 % admission nicu9.6\xa0% (57)16.4\xa0% (44)4.0\xa0% (13) <0.0001\ngdm Gestational diabetes, emb ethnic minority background, ogtt oral Glucose tolerance test, lga large-for-Gestational age infants, nicu Neonatal Intensive Care Unit, p-values in bold are significant values\ntable\xa02gives an overview of the differences in Pregnancy outcomes of the whole cohort between the Insulin- and diet-treated women gdm.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 940, 'Insulin'), ('GO_0007128', 'meiotic prophase I', 1083, 'Preterm'), ('GO_0007567', 'parturition', 1091, 'delivery13'), ('UBERON_0001467', 'shoulder', 1202, 'shoulder'), ('GO_0007565', 'female pregnancy', 1313, 'gestational'), ('CHEBI_17234', 'glucose', 1377, 'glucose'), ('GO_0007565', 'female pregnancy', 1415, 'gestational'), ('UBERON_0001759', 'vagus nerve', 1445, 'neonatal'), ('UBERON_0011933', 'vibrissa unit', 1454, 'intensive care unit'), ('GO_0007565', 'female pregnancy', 1562, 'pregnancy'), ('CHEBI_66075', 'inflexin', 1613, 'insulin'), ('PR_000045358', 'insulin family protein', 1613, 'insulin')]
PMC4619070	10/2015	S95-PMC4619070	['caption (table-wrap): table 3\n\nthe differences in characteristics between the Insulin- and diet-treated women with gdmdiet n \u2009=\u2009456 (75.9\xa0%)Insulin n \u2009=\u2009145 (24.1\xa0%) p -value*adjusted p -valueage, mean (y)31.8\u2009±\u20094.832.5\u2009±\u20094.70.109gestational age, mean (y)39.3\u2009±\u200916.838.0\u2009±\u20091.60.352mean bmi (kg/m2) at first Prenatal visit26.8\u2009±\u200912.929.1\u2009±\u200920.20.149% overweight32.4\xa0% (121)31.6\xa0% (36)0.877% obese21.4\xa0% (80)27.2\xa0% (31)0.196% exessive weight gain18.5\xa0% (73)22.7\xa0% (29)0.306% emb21.6\xa0% (97)33.3\xa0% (48) 0.004 0.939% first degree relative with diabetes16.7\xa0% (75)22.9\xa0% (33)0.107% second degree relative with diabetes23.1\xa0% (104)17.4\xa0% (25)0.107% history of gdm10.4\xa0% (47)21.5\xa0% (31) 0.002 0.142% multiparous47.6\xa0% (216)59.3\xa0% (86) 0.044 0.998% primigravida36.0\xa0% (163)23.4\xa0% (34) 0.020 0.260week of gct, mean25.4\u2009±\u20093.323.6\u2009±\u20094.9 <0.0001 0.203value of gct, mean in mg/dl (mmol/l)166.7\u2009±\u200919.6 (9.3\u2009±\u20091.1)179.0\u2009±\u200940.0 (9.9\u2009±\u20092.2) <0.0001 0.304week of gdm diagnosis mean27.1\u2009±\u20093.725.3\u2009±\u20094.9 <0.0001 0.278fasting glycaemia at ogtt in mg/dl (mmol/l)87.7\u2009±\u200910.3 (4.9\u2009±\u20090.6)97.6\u2009±\u200918.8 (5.4\u2009±\u20091.0) <0.0001<0.0001 1-hour glycaemia at ogtt in mg/dl (mmol/l)184.5\u2009±\u200925.8 (10.2\u2009±\u20091.4)194.7\u2009±\u200930.1 (10.8\u2009±\u20091.7) <0.0001 0.4172-hour glycaemia at ogtt in mg/dl (mmol/l)175.0\u2009±\u200922.8 (9.7\u2009±\u20091.3)185.2\u2009±\u200928.5 (10.3\u2009±\u20091.6) <0.0001 0.3423-hour glycaemia at ogtt in mg/dl (mmol/l)145.4\u2009±\u200927.6 (8.1\u2009±\u20091.5)152.7\u2009±\u200933.4 (8.5\u2009±\u20091.8) 0.013 0.238% ≥3 abnormal values on the ogtt37.8\xa0% (161)58.1\xa0% (75) <0.0001 0.915% ≥4 abnormal values at ogtt7.7\xa0% (33)24.8\xa0% (32) <0.0001 0.756hba1c, mean in % (mmol/mol)5.2\u2009±\u20090.5 (33\u2009±\u20096)5.5\u2009±\u20090.6 (37\u2009±\u20096) <0.0001 0.496% treatment with corticoïds2.4\xa0% (11)11.0\xa0% (16) <0.0001\ny years, bmi body mass index, emb ethnic minority background, gct Glucose challenge test, ogtt oral Glucose tolerance test, gdm Gestational diabetes *adjusted p -value: clinical variables that were identified as most significantly associated with the need for Insulin use were included in the multivariable logistic regression, p-values in bold are significant values\ntable\xa04gives an overview of the differences in Insulin sensitivity and Beta-Cell function between the Insulin- and diet-treated women with gdm attending the university hospital.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 78, 'insulin'), ('PR_000045358', 'insulin family protein', 140, 'Insulin'), ('GO_0007565', 'female pregnancy', 307, 'prenatal'), ('CHEBI_17234', 'glucose', 1746, 'glucose'), ('CHEBI_17234', 'glucose', 1780, 'glucose'), ('GO_0007565', 'female pregnancy', 1808, 'gestational'), ('PR_000045358', 'insulin family protein', 1940, 'insulin'), ('PR_000045358', 'insulin family protein', 2095, 'insulin'), ('CL_0000349', 'extraembryonic cell', 2119, 'beta-cell'), ('UBERON_0000922', 'embryo', 2119, 'beta-'), ('PR_000045358', 'insulin family protein', 2150, 'insulin')]
PMC4630792	11/2015	S29-PMC4630792	['no significant differences were observed in body weight, fasting Glucose concentration or in Organ weights between control and recuperated groups at either 3 months or 6 months of age (table 1).']	N/A	N/A	[('CHEBI_17234', 'glucose', 65, 'glucose'), ('UBERON_0000062', 'organ', 93, 'organ')]
PMC4630792	11/2015	S124-PMC4630792	['fasting blood Glucose levels were determined using a glucometer (hemocue, angelholm, sweden).']	N/A	N/A	[('CHEBI_17234', 'glucose', 14, 'glucose')]
PMC4632418	10/2015	S63-PMC4632418	['seven different criteria were used to diagnose gdm and five assay techniques were used to measure Serum 25(Oh)D level.nutrients-07-05398-t001_table 1\n\ncaption (table-wrap): table 1\n\ncharacteristics of observational studies included in this meta-analysis.author and yearlocationstudy typeparticipants( n )gdm( n )gdm criteria *assay methodmean 25(Oh)D nmol/l (sd)prevalencesignificantadjustments**gdmngtmaghbooli (2008) [22]irancross-sectional57952c&cria16.5(10.4)22.9(18.3)70.60%yesa, bclifton-bligh (2008) [23]australiacross-sectional30781adpslc–ms48.6(24.9)55.3(23.3)48%yesa, b, czhang (2008) [24]usnested-case-control17157adaelisa60.4(21.22)75.13(24.21)19.80%yesa, b, c, dfarrant (2009) [16]indiacross-sectional55939c&cria49.3(31.2)46.4(30.9)66%noa, b, e, fsoheilykhah (2010) [25]irancase-control16554c&celisa24.01(20.62)32.2(35.74)78.40%yesnrbaker (2012) [15]usnested-case-control18060nddglc–ms97.0(29.0)86.0(22.0)7.20%yesa, b, e, hmakgoba (2011) [26]ukcase-control24890wholc–ms47.2(26.7)47.6 (26.7)58.80%noa, b, c, d, e, gparlea (2012) [27]canadanested-case-control337118nddgclia56.3(19.4)62.0(21.6)nryesh, ifernandez-alonso (2012) [28]spaincross-sectional46636adaeclianrnr23.40%nrnrparildar (2013) [29]turkeycase-control12244iadpsgclia48.67(23.21)57.16(24.96)43.40%nonrwang (2012) [30]chinanested-case-control400200adaelisa22.4(10.7)25.9(12.3)96.25%yesa, d, jburris (2012) [31]uscross-sectional115568adaclianrnr33.10%nra, b, c, e, h, k, l, m, n, o, p, tperez-ferre (2012) [32]spaincross-sectional26649adaclianrnr59.02%nra, c, d, gzuhur (2013) [33]turkeycross-sectional402234iadpsgeclia30.8(16.3)36.0(16.2)84.30%yesa, b, d, gbener (2013) [34]qatariprospective cohort1873260whorianrnr48.40%nrnrlacroix (2014) [35]canadacross-sectional65554iadpsglc–ms57.5(17.2)63.5(18.9)26.70%yesa, c, d, e, g, r, s, t, umcmanus (2014) [36]canadacase-control7336cdaria77.3(24.3)93.2(19.2)6.85%yesa, bpark (2014) [37]koreaprospective cohort52323c&ceclia49.4(19.4)48(24.8)88.90%noa, b, e, h, g, varnold (2015) [38]usnested-case-control652135adalc–ms59.7(23.5)66.6(22)25.61%yesa, b, c, d, epleskacova (2015) [39]czechcase-control7647whoeiasa28(3.76)31.85(4.62)94.7%nob\nnote: nr, not reported; prevalence: prevalence of Vitamin D deficiency; significant: significant difference in Serum 25(Oh)d between Gestational diabetes mellitus (gdm) & normal Glucose tolerance (ngt).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 98, 'serum'), ('CHEBI_71657', 'versiconol acetate', 104, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 104, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 343, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 2203, 'vitamin D'), ('UBERON_0001977', 'blood serum', 2264, 'serum'), ('CHEBI_30778', 'gallic acid', 2270, '25(OH)'), ('GO_0007565', 'female pregnancy', 2286, 'gestational'), ('CHEBI_17234', 'glucose', 2331, 'glucose')]
PMC4632418	10/2015	S112-PMC4632418	['first, 1,25(Oh)2D3, the active form of Vitamin D, Regulates circulating Glucose levels by binding to Vitamin D Receptor of Pancreatic β-Cell and Modulating Insulin secretion [41,42].']	N/A	N/A	[('CHEBI_72779', '11-trans-LTE4', 7, '1,25(OH)2D3'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('GO_0065007', 'biological regulation', 50, 'regulates'), ('CHEBI_17234', 'glucose', 72, 'glucose'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('PR_000001683', 'vasopressin V2 receptor', 101, 'vitamin D receptor'), ('UBERON_0001264', 'pancreas', 123, 'pancreatic'), ('CL_0000622', 'acinar cell', 135, '-cell'), ('GO_0065007', 'biological regulation', 145, 'modulating'), ('PR_000045358', 'insulin family protein', 156, 'insulin')]
PMC4632418	10/2015	S113-PMC4632418	['second, 1,25(Oh)2D3Promotes Insulin sensitivity by stimulating the Expression of Insulin receptors and enhancing Insulin responsiveness for Glucose transport [43].']	N/A	N/A	[('CHEBI_37958', 'dye', 8, '1,'), ('CHEBI_77861', 'cincreasin', 10, '25(OH)2D3promotes'), ('PR_000045358', 'insulin family protein', 28, 'insulin'), ('GO_0010467', 'gene expression', 67, 'expression'), ('PR_000045358', 'insulin family protein', 81, 'insulin'), ('PR_000045358', 'insulin family protein', 113, 'insulin'), ('CHEBI_17234', 'glucose', 140, 'glucose')]
PMC4661500	11/2014	S342-PMC4661500	['administered 16.2\xa0mmol to Adult patients aiming at an improvement of Glucose handling[76].']	N/A	N/A	[('UBERON_0007023', 'adult organism', 26, 'adult'), ('CHEBI_17234', 'glucose', 69, 'glucose')]
PMC4661500	11/2014	S520-PMC4661500	['their study relied on parameters such as Glucose tolerance, Insulin response to Glucose, resting Heart rate, resting and maximal vo2, and maximal power output[184].']	N/A	N/A	[('CHEBI_17234', 'glucose', 41, 'glucose'), ('PR_000045358', 'insulin family protein', 60, 'insulin'), ('CHEBI_17234', 'glucose', 80, 'glucose'), ('UBERON_0000948', 'heart', 97, 'heart')]
PMC4663588	11/2015	S9-PMC4663588	['introduction\nMetabolic syndrome is a cluster of Metabolic disorders and it is defined as a combination of central obesity and Insulin resistance plus any two of the following four factors: raised Triglycerides, reduced hdl, raised Blood pressure and raised fasting Plasma Glucose [1].']	N/A	N/A	[('GO_0008152', 'metabolic process', 13, 'Metabolic'), ('GO_0008152', 'metabolic process', 48, 'metabolic'), ('PR_000045358', 'insulin family protein', 126, 'insulin'), ('CHEBI_17855', 'triglyceride', 196, 'triglycerides'), ('UBERON_0000178', 'blood', 231, 'blood'), ('UBERON_0001969', 'blood plasma', 265, 'plasma'), ('CHEBI_17234', 'glucose', 272, 'glucose')]
PMC4663588	11/2015	S171-PMC4663588	['however, impaired Glucose tolerance occurs by 15 months of age [84] and diabetes at 17 months of age [85].']	N/A	N/A	[('CHEBI_17234', 'glucose', 18, 'glucose')]
PMC4663588	11/2015	S186-PMC4663588	['fetuses of dams’ sows Fed a hp-lc diet had 50% less Glucose concentration in the Umbilical Vessels compared with maternal concentrations.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 22, 'fed'), ('CHEBI_17234', 'glucose', 52, 'glucose'), ('UBERON_0010366', 'conjunctival vasculature', 81, 'umbilical vessels')]
PMC4663588	11/2015	S266-PMC4663588	['excessive Glucocorticoids during the third semester of Pregnancy (3rd week) resulted in hyperglycemia, Glucose intolerance, and hyperinsulinemia in Adult Life in Rats [110].']	N/A	N/A	[('CHEBI_36597', 'phthalazine', 10, 'glucocorticoids'), ('GO_0007565', 'female pregnancy', 55, 'pregnancy'), ('CHEBI_17234', 'glucose', 103, 'glucose'), ('UBERON_0000113', 'post-juvenile adult stage', 148, 'adult life'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 162, 'rats')]
PMC4663588	11/2015	S337-PMC4663588	['moreover, Casomorphins decrease Insulin secretion in the absence of elevated Glucose levels but have no effect on Glucose stimulation of Insulin [156].']	N/A	N/A	[('PR_000000094', 'decorin', 10, 'casomorphins'), ('PR_000045358', 'insulin family protein', 32, 'insulin'), ('CHEBI_17234', 'glucose', 77, 'glucose'), ('CHEBI_17234', 'glucose', 114, 'glucose'), ('PR_000045358', 'insulin family protein', 137, 'insulin')]
PMC4663588	11/2015	S396-PMC4663588	['Insulin treatment on a daily basis between 8 and 11 days after Birth also increased body weight gain, impaired Glucose tolerance, chronic hyperinsulinemia, and hypertension in later life.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 0, 'Insulin'), ('GO_0007567', 'parturition', 63, 'birth'), ('CHEBI_17234', 'glucose', 111, 'glucose')]
PMC4663588	11/2015	S416-PMC4663588	['Insulin release from fetal Β-Cells is initially more responsive to Amino Acids than Glucose.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 0, 'Insulin'), ('CL_0002200', 'oxyphil cell of thyroid', 27, 'β-cells'), ('CHEBI_33867', 'idonates', 67, 'amino acids'), ('CHEBI_17234', 'glucose', 84, 'glucose')]
PMC4663588	11/2015	S417-PMC4663588	['however, during Pregnancy and through Apoptosis the original Β-Cells will be replaced by new Islet Cells that are more sensitive to Glucose and response during the acute first phase of Insulin Release [195].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 16, 'pregnancy'), ('GO_0006915', 'apoptotic process', 38, 'apoptosis'), ('CL_0002200', 'oxyphil cell of thyroid', 61, 'β-cells'), ('CL_0000129', 'microglial cell', 93, 'islet cells'), ('UBERON_0002533', 'post-anal tail bud', 93, 'islet'), ('CHEBI_17234', 'glucose', 132, 'glucose'), ('GO_0006880', 'intracellular sequestering of iron ion', 185, 'insulin release'), ('PR_000045358', 'insulin family protein', 185, 'insulin')]
PMC4663588	11/2015	S430-PMC4663588	['in addition, a reduction in Insulin secretory response to both Glucose and amino Acids of Islets was observed from 3-mo-old offspring [203].']	N/A	N/A	[('PR_000045358', 'insulin family protein', 28, 'insulin'), ('CHEBI_17234', 'glucose', 63, 'glucose'), ('CHEBI_37527', 'acid', 81, 'acids'), ('CL_0000125', 'glial cell', 90, 'islets'), ('UBERON_0000029', 'lymph node', 90, 'islets')]
PMC4663588	11/2015	S491-PMC4663588	['high protein diet : when dams were Fed a high protein (40% of total calorie) compared to normal protein (20% of total calorie) diet during Pregnancy and Lactation, no effect of maternal diet on Birth weight, energy expenditure, Glucose tolerance, and Plasma Lipid levels of the offspring was observed.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 35, 'fed'), ('GO_0007565', 'female pregnancy', 139, 'pregnancy'), ('GO_0007595', 'lactation', 153, 'lactation'), ('GO_0007567', 'parturition', 194, 'birth'), ('CHEBI_17234', 'glucose', 228, 'glucose'), ('UBERON_0001969', 'blood plasma', 251, 'plasma'), ('CHEBI_18059', 'lipid', 258, 'lipid')]
PMC4663588	11/2015	S501-PMC4663588	['dams’ Soy protein-based diet resulted in higher fasting Glucose, Glucose response to Glucose preloads and the homa-ir index, which are indicators of insulin resistance, in male offspring compared with dams’ casein-based diet [23,24], while had no effect in females at week 14 after weaning [25].']	N/A	N/A	[('CHEBI_29922', 'sulfo group', 6, 'soy'), ('CHEBI_17234', 'glucose', 56, 'glucose'), ('CHEBI_17234', 'glucose', 65, 'glucose'), ('CHEBI_17234', 'glucose', 85, 'glucose')]
PMC4663588	11/2015	S526-PMC4663588	['female offspring Fed a high fat Postnatal diet also showed lower Insulin sensitivity, unchanged metabolic clearance rate (mcr), and higher rate of appearance (ra) of Glucose compared with offspring Fed a low fat diet.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 17, 'fed'), ('GO_0007567', 'parturition', 32, 'postnatal'), ('PR_000045358', 'insulin family protein', 65, 'insulin'), ('CHEBI_17234', 'glucose', 166, 'glucose'), ('GO_0007631', 'feeding behavior', 198, 'fed')]
PMC4663595	11/2015	S160-PMC4663595	['Prenatal Alcohol exposure resulted in increases of Histone deacetylase and the reduction of acetylation in foxo1 and Pepck with Glucose intolerance [55].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_30879', 'alcohol', 9, 'alcohol'), ('CHEBI_15358', 'histone', 51, 'histone'), ('PR_000043452', 'core histone', 51, 'histone'), ('PR_000012564', 'peroxisomal biogenesis factor 3', 117, 'PEPCK'), ('CHEBI_17234', 'glucose', 128, 'glucose')]
PMC4672086	12/2015	S38-PMC4672086	['they are predisposed toward a higher risk of developing neuropsychiatric disorders such as schizophrenia, depression, bipolar disorder, diabetes, obesity, hypertension, and Glucose intolerancy.']	N/A	N/A	[('CHEBI_17234', 'glucose', 173, 'glucose')]
PMC4673623	11/2015	S31-PMC4673623	['the control group had continuous access to the southwest national regional primate research center biscuits (purina monkey diet and monkey diet jumbo, purina labdiets, st louis, mo) containing 12% energy from fat, 0.29% from Glucose, 0.32% from Fructose, and a metabolizable energy content of 3.07\xa0kcal/g.']	N/A	N/A	[('CHEBI_17234', 'glucose', 225, 'glucose'), ('CHEBI_28757', 'fructose', 245, 'fructose')]
PMC4673623	11/2015	S32-PMC4673623	['the hf-hed group had continuous access to both the control diet and the hf-hed regimen containing 45% energy from fat, 4.6% from Glucose, 5.6% from Fructose, and a Metabolizable energy content of 4.03\xa0kcal/g as described previously (maloyan et\xa0al.2013).']	N/A	N/A	[('CHEBI_17234', 'glucose', 129, 'glucose'), ('CHEBI_28757', 'fructose', 148, 'fructose'), ('GO_0008152', 'metabolic process', 164, 'metabolizable')]
PMC4689556	12/2015	S28-PMC4689556	['eligible participants were women presenting at 27 weeks Gestation for routine Glucose challenge test from the following ethnic groups: indian asian, middle eastern, afro-caribbean and caucasian.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 56, 'gestation'), ('CHEBI_17234', 'glucose', 78, 'glucose')]
PMC4692114	1/2016	S1-PMC4692114	['forty-five Pregnant women with gdm (last Trimester mean hba1c\u2009=\u200933.9\u2009mmol/mol) and 42 (nondiabetic) control Pregnant women were enrolled after their routine 75\u2009g oral Glucose tolerance test (ogtt) between the 24th and 28th Gestational week (with expected differences in their mean routine clinical characteristics: plasma Glucose at ogtt: 0′\u2009=\u20095.07 vs. 4.62\u2009mm, 120′\u2009=\u20098.9 vs. 5.76\u2009mm, age\u2009=\u200935.07 vs. 31.66 years, Prepregnancy body mass index\u2009=\u200927.9 vs. 23.9\u2009kg/m2, gdm vs. control, respectively) on a voluntary basis after signing the informed consent.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 11, 'pregnant'), ('GO_0009294', 'DNA mediated transformation', 41, 'trimester'), ('GO_0007565', 'female pregnancy', 108, 'pregnant'), ('CHEBI_17234', 'glucose', 167, 'glucose'), ('GO_0007565', 'female pregnancy', 223, 'gestational'), ('CHEBI_17234', 'glucose', 322, 'glucose'), ('GO_0007565', 'female pregnancy', 415, 'prepregnancy')]
PMC4692114	1/2016	S41-PMC4692114	['clinical characteristics of the Pregnant populations studied\xa0 Plasma Glucose values at 75\u2009g ogtt (24–28\u2009gw, mm) \xa0\xa0\xa0\xa0\xa0 mean (95% ci)Prepregnancy bmi (kg/m2)age at Delivery (years)weight gain during Pregnancy (kg)hba1c % [ifcc unit, mmol/mol] in the Third Trimesterstudy group0′120′mean (95% ci)mean (95% ci)mean (95% ci)mean (95% ci) gdm ( n \u2009=\u200945)5.07 (4.85–5.29)8.9 (8.58–9.21)27.9 (25.55–30.16)35.07 (33.69–36.43)7.58 (5.43–9.72)5.24 (5.08–5.4) [33.9 (32.15–35.64)]control ( n \u2009=\u200942)4.62 (4.42–4.83)5.76 (5.41–6.11)23.9 (22.74–25.01)31.66 (29.9–33.42)14.16 (12.62–15.69)na p value0.0036<0.00010.00240.0025<0.0001\xa0\nbmi, body mass index; 95% ci, 95% confidence interval; gdm, Gestational diabetes mellitus; ogtt, oral Glucose tolerance test.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 32, 'Pregnant'), ('UBERON_0001969', 'blood plasma', 62, 'Plasma'), ('CHEBI_17234', 'glucose', 69, 'glucose'), ('GO_0007565', 'female pregnancy', 131, 'Prepregnancy'), ('GO_0007567', 'parturition', 162, 'delivery'), ('GO_0007565', 'female pregnancy', 197, 'pregnancy'), ('UBERON_0005451', 'segment of manus', 248, 'third trimesterStudy'), ('GO_0007565', 'female pregnancy', 676, 'gestational'), ('CHEBI_17234', 'glucose', 718, 'glucose')]
PMC4700169	12/2015	S17-PMC4700169	['Tpn is a form of nutritional support that contains Lipid emulsions, Amino acids, utilizable nitrogen, and nonprotein calorie sources such as Glucose, electrolytes, and minerals.']	N/A	N/A	[('PR_000016585', 'tripeptidyl-peptidase 1', 0, 'TPN'), ('CHEBI_18059', 'lipid', 51, 'lipid'), ('CHEBI_48310', 'apiitol', 68, 'amino'), ('CHEBI_17234', 'glucose', 141, 'glucose')]
PMC4701853	1/2016	S22-PMC4701853	['fetal Glucose, Amino Acids, and Placental Insulin/Igf 1 Signaling act as upstream regulators of the Mammalian Target Of Rapamycin (mtor), which is central to Energy Sensing and can be reset by maternal obesity and gdm (25) through phosphorylation mechanisms.']	N/A	N/A	[('CHEBI_17234', 'glucose', 6, 'glucose'), ('CHEBI_33867', 'idonates', 15, 'amino acids'), ('UBERON_0001987', 'placenta', 32, 'placental'), ('GO_0030502', 'negative regulation of bone mineralization', 42, 'insulin ... signaling'), ('PR_000045358', 'insulin family protein', 42, 'insulin'), ('PR_000008954', 'insulin-like growth factor-binding protein-like 1', 50, 'IGF 1'), ('NCBITaxon_40674', 'Mammalia', 100, 'mammalian'), ('PR_000016297', 'protein-glutamine gamma-glutamyltransferase 6', 110, 'target of rapamycin'), ('GO_0090505', 'epiboly involved in wound healing', 158, 'energy sensing')]
PMC4701853	1/2016	S59-PMC4701853	['Plasma Glucose and Triglycerides were measured enzymatically (modular analytics evo, roche), whereas Serum leptin concentrations measured by elisa (biosource kap 2281).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_17234', 'glucose', 7, 'glucose'), ('CHEBI_17855', 'triglyceride', 19, 'triglycerides'), ('UBERON_0001977', 'blood serum', 101, 'serum')]
PMC4701853	1/2016	S92-PMC4701853	["women with obesity gained less weight up to 34 weeks' Gestation compared to those of normal weight and Glucose tolerance (table 1)."]	N/A	N/A	[('GO_0007565', 'female pregnancy', 54, 'gestation'), ('CHEBI_17234', 'glucose', 103, 'glucose')]
PMC4701853	1/2016	S109-PMC4701853	['close to Delivery, maternal blood Glucose was elevated in women with gdm irrespective of bmi (table 4).']	N/A	N/A	[('GO_0007567', 'parturition', 9, 'delivery'), ('CHEBI_17234', 'glucose', 34, 'glucose')]
PMC4701853	1/2016	S114-PMC4701853	['Maternal, Placental, and Cord Blood Metabolic characteristics: n, ow, o, gdmn, and gdmo Pregnant womenmaternal Blood at termn (n = 59)ow (n = 29)o (n = 22)Gdmn (n = 14)Gdmo (n = 11)Glucose (mmol/liter)4.3 ± 1.34.6 ± 1.35.3 ± 2.3a6.0 ± 2.2c6.1 ± 1.9ctriglyceride (mmol/liter)11.7 ± 3.913.2 ± 4.212.8 ± 4.311.6 ± 3.912.3 ± 3.3leptin (μg/liter)16.0 ± 13.624.2 ± 23.533.9 ± 21.9b21.1 ± 16.436.6 ± 19.9bmonocyte count (×109/liter)0.5 ± 0.20.6 ± 0.20.6 ± 0.20.6 ± 0.30.40 ± 0.2cord Blooddn (n = 33)ow (n = 18)o (n = 16)Gdn (n = 10)Gdo (n = 7)Glucose (mmol/liter)3.8 ± 1.23.6 ± 1.23.3 ± 1.33.9 ± 0.74.3 ± 1.0triglyceride (mmol/liter)2.7 ± 1.12.5 ± 0.82.5 ± 1.42.5 ± 1.32.5 ± 1.2leptin (μg/liter)19.7 ± 17.932.7 ± 19.662.3 ± 69.0a42.6 ± 31.5a36.6 ± 19.9monocyte count (×109/liter)1.0 ± 0.41.1 ± 0.41.4 ± 0.6a1.2 ± 0.81.1 ± 0.4placental Tissuen (n = 59)ow (n = 29)o (n = 22)Gdn (n = 14)Gdo (n = 11)total Placental tg (mg/g) per Placental weight (g)19.9 ± 10.022.0 ± 10.923.9 ± 12.819.7 ± 10.628.3 ± 16.5arelative Placental Tbars1.0 ± 0.30.9 ± 0.30.8 ± 0.21.0 ± 0.31.0 ± 0.3\nabbreviations: gdmn, Gestational diabetic normal weight; gdmo, Gestational diabetic mellitus obese; n, normal weight; o, obese; ow, overweight; tbars, Thiobarbituric Acid reactive substance; tg, Triglyceride.']	N/A	N/A	[('UBERON_0000976', 'humerus', 0, 'Maternal'), ('UBERON_0001987', 'placenta', 10, 'Placental'), ('UBERON_0000948', 'heart', 25, 'Cord'), ('UBERON_0000178', 'blood', 30, 'Blood'), ('GO_0008152', 'metabolic process', 36, 'Metabolic'), ('GO_0007565', 'female pregnancy', 88, 'Pregnant'), ('UBERON_0000178', 'blood', 111, 'Blood'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 155, 'GDMN'), ('CHEBI_74612', "Ins-1-P-Cer B/B' 34:0(1-)", 168, 'GDMO'), ('CHEBI_17234', 'glucose', 181, 'Glucose'), ('UBERON_0000178', 'blood', 476, 'BlooddN'), ('CHEBI_16038', 'phosphatidylethanolamine', 513, 'GDN'), ('CHEBI_37038', "purine ribonucleoside 5'-diphosphate", 525, 'GDO'), ('CHEBI_17234', 'glucose', 536, 'Glucose'), ('UBERON_0000479', 'tissue', 828, 'TissueN'), ('CHEBI_16038', 'phosphatidylethanolamine', 865, 'GDN'), ('CHEBI_37038', "purine ribonucleoside 5'-diphosphate", 877, 'GDO'), ('UBERON_0001987', 'placenta', 895, 'placental'), ('UBERON_0001987', 'placenta', 919, 'placental'), ('UBERON_0001987', 'placenta', 1004, 'placental'), ('PR_000016139', 'TATA box-binding protein-like 2', 1014, 'TBARS1'), ('GO_0007565', 'female pregnancy', 1086, 'gestational'), ('GO_0007565', 'female pregnancy', 1128, 'gestational'), ('CHEBI_9592', 'tiglic acid', 1216, 'thiobarbituric acid'), ('CHEBI_17855', 'triglyceride', 1260, 'triglyceride')]
PMC4714725	1/2016	S54-PMC4714725	['fasting is defined as no caloric Intake for at least 8 h.*or2-h Plasma Glucose ≥200 mg/dl (11.1 mmol/l) during an ogtt.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 33, 'intake'), ('UBERON_0001969', 'blood plasma', 64, 'plasma'), ('CHEBI_17234', 'glucose', 71, 'glucose')]
PMC4714725	1/2016	S58-PMC4714725	['*orin a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random Plasma Glucose ≥200 mg/dl (11.1 mmol/l).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 89, 'plasma'), ('CHEBI_17234', 'glucose', 96, 'glucose')]
PMC4714725	1/2016	S66-PMC4714725	['ifg, impaired fasting Glucose; igt, impaired Glucose tolerance.']	N/A	N/A	[('CHEBI_17234', 'glucose', 22, 'glucose'), ('CHEBI_17234', 'glucose', 45, 'glucose')]
PMC4714725	1/2016	S207-PMC4714725	['a\nconsider educating Individuals with type 1 diabetes on matching prandial Insulin doses to Carbohydrate intake, premeal blood Glucose levels, and anticipated physical activity.']	N/A	N/A	[('NCBITaxon_1', 'root', 21, 'individuals'), ('PR_000045358', 'insulin family protein', 75, 'insulin'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 92, 'carbohydrate'), ('CHEBI_17234', 'glucose', 127, 'glucose')]
PMC4714725	1/2016	S211-PMC4714725	['a\nconsider initiating Insulin therapy (with or without additional Agents) in patients with newly diagnosed type 2 diabetes who are symptomatic and/or have markedly elevated blood Glucose levels or a1c.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 22, 'insulin'), ('CHEBI_33250', 'atom', 66, 'agents'), ('CHEBI_17234', 'glucose', 179, 'glucose')]
PMC4714725	1/2016	S291-PMC4714725	['e\noptimize Glucose Control to prevent or delay the development of neuropathy in patients with type 1 diabetes a and to slow the progression of neuropathy in patients with type 2 diabetes.']	N/A	N/A	[('CHEBI_17234', 'glucose', 11, 'glucose'), ('GO_0046323', 'glucose import', 11, 'glucose control')]
PMC4714725	1/2016	S375-PMC4714725	['dyslipidemia\n\nrecommendations\n\nobtain a fasting Lipid profile on children ≥10 years of age soon after diabetes diagnosis (after Glucose Control has been established).']	N/A	N/A	[('CHEBI_18059', 'lipid', 48, 'lipid'), ('CHEBI_17234', 'glucose', 128, 'glucose'), ('GO_0065007', 'biological regulation', 136, 'control')]
PMC4714725	1/2016	S430-PMC4714725	['monitor blood Glucose every 4–6 hours while a patient is npo, and dose with short-acting Insulin as needed with a target of 80–180 mg/dl (4.4–10.0 mmol/l).']	N/A	N/A	[('CHEBI_17234', 'glucose', 14, 'glucose'), ('PR_000045358', 'insulin family protein', 89, 'insulin')]
PMC4728621	1/2016	S28-PMC4728621	['in brief; the primary outcome was Birthweight which was not reduced and the secondary outcomes were Gestational weight gain and Glucose intolerance which were both reduced in the intervention group.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 34, 'birthweight'), ('GO_0007565', 'female pregnancy', 100, 'gestational'), ('CHEBI_17234', 'glucose', 128, 'glucose')]
PMC4728621	1/2016	S72-PMC4728621	['variables examined included macro- and micro-Nutrient intake for each trimester, maternal height, weight and bmi during Pregnancy and maternal weight and bmi at 6 months Postpartum , Gestational weight gain, change in weight from late Pregnancy to 6 months Postpartum , reported maternal physical activity, smoking and Alcohol intake during Pregnancy and at 6 months Postpartum , maternal ethnicity, maternal age at Delivery, marital/partner status, fasting Glucose and oral Glucose challenge test results during Pregnancy and glycaemic index and load status during Pregnancy.']	N/A	N/A	[('CHEBI_33284', 'nutrient', 45, 'nutrient'), ('GO_0007565', 'female pregnancy', 120, 'pregnancy'), ('GO_0007565', 'female pregnancy', 170, 'postpartum'), ('GO_0007565', 'female pregnancy', 183, 'gestational'), ('GO_0007565', 'female pregnancy', 235, 'pregnancy'), ('GO_0007565', 'female pregnancy', 257, 'postpartum'), ('CHEBI_30879', 'alcohol', 319, 'alcohol'), ('GO_0007565', 'female pregnancy', 341, 'pregnancy'), ('GO_0007565', 'female pregnancy', 367, 'postpartum'), ('GO_0007567', 'parturition', 416, 'delivery'), ('CHEBI_17234', 'glucose', 458, 'glucose'), ('CHEBI_17234', 'glucose', 475, 'glucose'), ('GO_0007565', 'female pregnancy', 513, 'pregnancy'), ('GO_0007565', 'female pregnancy', 566, 'pregnancy')]
PMC4728639	1/2016	S30-PMC4728639	['specific Placental Nutrient transporters, namely Glucose Transporter (Glut) 1 and Sodium-Coupled Neutral Amino Acid Transporter (Snat) 2, are up-regulated in response to a high fat diet (hfd) [13].']	N/A	N/A	[('UBERON_0001987', 'placenta', 9, 'placental'), ('CHEBI_33284', 'nutrient', 19, 'nutrient'), ('CHEBI_17234', 'glucose', 49, 'glucose'), ('PR_000015064', 'solute carrier family 2, facilitated glucose transporter member 2', 49, 'glucose transporter ...'), ('PR_000015065', 'solute carrier family 2, facilitated glucose transporter member 3', 70, 'GLUT ... 1'), ('CHEBI_52632', 'potassium-39 atom', 82, 'sodium'), ('PR_000015170', 'sodium/myo-inositol cotransporter', 82, 'sodium-coupled neutral amino acid transporter ...'), ('CHEBI_82880', 'N-acyltetradecaphytosphingosine', 105, 'amino acid'), ('PR_000015209', 'sodium/calcium exchanger 3', 129, 'SNAT ... 2')]
PMC4728639	1/2016	S55-PMC4728639	['determination of Blood Glucose and Serum Insulin concentrations and Lipid profiles\nBlood Glucose (Glucometer, precision qid, medisense, cambridge, uk) and Serum Insulin (Rat Insulin ria kit, linco research, st. charles, mo, usa) concentrations were measured.']	N/A	N/A	[('UBERON_0000178', 'blood', 17, 'Blood'), ('CHEBI_17234', 'glucose', 23, 'Glucose'), ('UBERON_0001977', 'blood serum', 35, 'Serum'), ('PR_000045358', 'insulin family protein', 41, 'Insulin'), ('CHEBI_18059', 'lipid', 68, 'Lipid'), ('UBERON_0000178', 'blood', 83, 'Blood'), ('CHEBI_17234', 'glucose', 89, 'glucose'), ('CHEBI_24321', 'glutamo group', 98, 'glucometer'), ('UBERON_0001977', 'blood serum', 155, 'serum'), ('PR_000045358', 'insulin family protein', 161, 'insulin'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 170, 'rat'), ('PR_000045358', 'insulin family protein', 174, 'insulin')]
PMC4728639	1/2016	S56-PMC4728639	['Homeostasis model assessment (homa)-Insulin resistance ((fasting Plasma Glucose (mmol/l) x fasting Serum Insulin (mu/l))/22.5)) was calculated.']	N/A	N/A	[('GO_0042592', 'homeostatic process', 0, 'Homeostasis'), ('PR_000045358', 'insulin family protein', 36, 'insulin'), ('UBERON_0001969', 'blood plasma', 65, 'plasma'), ('CHEBI_17234', 'glucose', 72, 'glucose'), ('UBERON_0001977', 'blood serum', 99, 'serum'), ('PR_000045358', 'insulin family protein', 105, 'insulin')]
PMC4728659	1/2016	S59-PMC4728659	['oral Glucose tolerance test and Tissue sampling\nfour days before the end of the study, Rats were fasted overnight and an oral Glucose tolerance test (ogtt) performed.']	N/A	N/A	[('CHEBI_17234', 'glucose', 5, 'Glucose'), ('UBERON_0000479', 'tissue', 32, 'Tissue'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 87, 'rats'), ('CHEBI_17234', 'glucose', 126, 'glucose')]
PMC4728659	1/2016	S60-PMC4728659	['Blood was sampled from the Tip Of the Tail in conscious Rats followed by an oral Glucose gavage (2 g/kg).']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('UBERON_0010162', 'post-anal tail tip', 27, 'tip of ... tail'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 56, 'rats'), ('CHEBI_17234', 'glucose', 81, 'glucose')]
PMC4728659	1/2016	S61-PMC4728659	['at 15, 30, 60 and 90 min post-Glucose gavage, additional Blood was sampled from the Tail and immediately analyzed using a Blood Glucose meter (accu-chek Blood Glucose meter, laval, qc, canada).']	N/A	N/A	[('CHEBI_17234', 'glucose', 30, 'glucose'), ('UBERON_0000178', 'blood', 57, 'blood'), ('UBERON_0002415', 'tail', 84, 'tail'), ('UBERON_0000178', 'blood', 122, 'blood'), ('CHEBI_17234', 'glucose', 128, 'glucose'), ('UBERON_0000178', 'blood', 153, 'Blood'), ('CHEBI_17234', 'glucose', 159, 'Glucose')]
PMC4728659	1/2016	S69-PMC4728659	['Plasma analysis\na milliplex Rat Gut Hormone kit (millipore, st. charles, mo, usa) and luminex instrument (eve technologies, calgary, ab, canada) were used to measure Ghrelin (active), Insulin, amylin (active), leptin, Glucose-Dependent Insulinotropic polypeptide (gip) (total) and peptide tyrosine tyrosine (pyy) (total).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('NCBITaxon_10088', 'Mus <genus>', 28, 'Rat'), ('UBERON_0001555', 'digestive tract', 32, 'Gut'), ('CHEBI_5762', 'hordatine A', 36, 'Hormone'), ('PR_000007988', 'gastric inhibitory polypeptide receptor', 166, 'ghrelin'), ('PR_000045358', 'insulin family protein', 184, 'insulin'), ('CHEBI_17234', 'glucose', 218, 'glucose'), ('PR_000006264', 'dapper homolog 2', 226, 'dependent insulinotropic')]
PMC4728659	1/2016	S73-PMC4728659	['homeostasis model assessment of Insulin resistance (homa-ir) was calculated from fasting Insulin and fasting Glucose.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 32, 'insulin'), ('PR_000045358', 'insulin family protein', 89, 'insulin'), ('CHEBI_17234', 'glucose', 109, 'glucose')]
PMC4728659	1/2016	S117-PMC4728659	['Plasma satiety hormones and Blood Glucose\nin males, fasting Insulin was lower in hf1 and hp1 compared to c1 (table 3).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('UBERON_0000178', 'blood', 28, 'Blood'), ('CHEBI_17234', 'glucose', 34, 'Glucose'), ('PR_000045358', 'insulin family protein', 60, 'insulin')]
PMC4728659	1/2016	S120-PMC4728659	['gip, Glucose-dependent insulinotropic polypeptide; pyy, peptide tyrosine tyrosine; Glp-1, Glucagon-Like Peptide-1; homa-ir, Homeostasis model assessment of Insulin resistance; tg, Triglycerides.']	N/A	N/A	[('CHEBI_17234', 'glucose', 5, 'glucose'), ('PR_000008050', 'glutaredoxin-related protein 5', 83, 'GLP-1'), ('PR_000008080', 'guanine nucleotide-binding protein subunit alpha-11', 90, 'glucagon-like peptide-1'), ('GO_0042592', 'homeostatic process', 124, 'homeostasis'), ('PR_000045358', 'insulin family protein', 156, 'insulin'), ('CHEBI_17855', 'triglyceride', 180, 'triglycerides')]
PMC4728659	1/2016	S126-PMC4728659	['serial concentrations of Glucose over the course of the ogtt are presented infigure 6.']	N/A	N/A	[('CHEBI_17234', 'glucose', 25, 'glucose')]
PMC4728659	1/2016	S128-PMC4728659	['caption (fig): figure 4\n\narea under the curve for Glucose ( a ), Insulin ( b ), amylin ( c ) and leptin ( d ) over a 90 min oral Glucose tolerance test (ogtt) at 28 weeks.']	N/A	N/A	[('CHEBI_17234', 'glucose', 50, 'glucose'), ('PR_000045358', 'insulin family protein', 65, 'insulin'), ('CHEBI_17234', 'glucose', 129, 'glucose')]
PMC4728659	1/2016	S132-PMC4728659	['caption (fig): figure 6\n\nBlood Glucose concentrations during an Oral Glucose tolerance test in male ( a ) and female ( b ) offspring.']	N/A	N/A	[('UBERON_0000178', 'blood', 25, 'Blood'), ('CHEBI_17234', 'glucose', 31, 'glucose'), ('UBERON_0000165', 'mouth', 64, 'oral'), ('CHEBI_17234', 'glucose', 69, 'glucose')]
PMC4728659	1/2016	S156-PMC4728659	['c1 Rats had higher fasting Glucose than r and h Rats ( p = 0.001) and greater Glucose auc ( p< 0.001) and Amylin auc ( p< 0.001) than r Rats.']	N/A	N/A	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 3, 'rats'), ('CHEBI_17234', 'glucose', 27, 'glucose'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 48, 'rats'), ('CHEBI_17234', 'glucose', 78, 'glucose'), ('CHEBI_22678', 'avenic acid A', 106, 'amylin'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 136, 'rats')]
PMC4728659	1/2016	S190-PMC4728659	['Glp-1 is an incretin hormone with Glucose-lowering properties, Secreted from Thel-Cells Of the distal Small Intestine and proximal Colon [30].']	N/A	N/A	[('PR_000008050', 'glutaredoxin-related protein 5', 0, 'GLP-1'), ('CHEBI_17234', 'glucose', 34, 'glucose'), ('GO_0046903', 'secretion', 63, 'secreted'), ('CL_0000589', 'cochlear inner hair cell', 77, 'thel-cells of ...'), ('UBERON_0002108', 'small intestine', 102, 'small intestine'), ('UBERON_0001155', 'colon', 131, 'colon')]
PMC4730616	1/2016	S76-PMC4730616	['furthermore, Cord Blood will be used for the assessment of Plasma Lipids (Cholesterol, hdl, ldl, Triglycerides, Apolipoprotein a and B), Glucose, leptin and Thyroid function (tsh, ft4).']	N/A	N/A	[('UBERON_0002240', 'spinal cord', 13, 'cord'), ('UBERON_0000178', 'blood', 18, 'blood'), ('UBERON_0001969', 'blood plasma', 59, 'plasma'), ('CHEBI_18059', 'lipid', 66, 'lipids'), ('CHEBI_16113', 'cholesterol', 74, 'cholesterol'), ('CHEBI_17855', 'triglyceride', 97, 'triglycerides'), ('CHEBI_39015', 'apolipoprotein', 112, 'Apolipoprotein'), ('PR_000000037', 'BMP receptor type-2', 133, 'B'), ('CHEBI_17234', 'glucose', 137, 'glucose'), ('UBERON_0002046', 'thyroid gland', 157, 'thyroid')]
PMC4732175	3/2016	S38-PMC4732175	['Blood was collected by Cardiac puncture following euthanasia for measurement of fasting Plasma Glucose (accu-check; roche, mannheim, germany) and total Plasma Lipids by gas chromatography [31].']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('UBERON_0000948', 'heart', 23, 'cardiac'), ('UBERON_0001969', 'blood plasma', 88, 'plasma'), ('CHEBI_17234', 'glucose', 95, 'glucose'), ('UBERON_0001969', 'blood plasma', 152, 'plasma'), ('CHEBI_18059', 'lipid', 159, 'lipids')]
PMC4732175	3/2016	S47-PMC4732175	['the Cremaster Muscle was exteriorized as described previously [33] and perfusion switched to krebs Solution (Nacl (118\u200ammol/l); Kcl (4.7\u200ammol/l); Cacl2(2.52\u200ammol/l); Mgso4.7H2O (1.18\u200ammol/l); Kh2Po4(1.18\u200ammol/l), Nahco3(25\u200ammol/l), Glucose (9\u200ammol/l) buffered to ph 7.4\u200a±\u200a0.05) containing Bovine Serum Albumin (10\u200amg/ml) at a rate of 0.5\u200aml/min.']	N/A	N/A	[('UBERON_0008488', 'cremaster muscle', 4, 'cremaster muscle'), ('CHEBI_75958', 'solution', 99, 'solution'), ('CHEBI_26710', 'sodium chloride', 109, 'NaCl'), ('CHEBI_32588', 'potassium chloride', 128, 'KCl'), ('CHEBI_3312', 'calcium dichloride', 146, 'CaCl2'), ('CHEBI_32599', 'magnesium sulfate', 166, 'MgSO4'), ('CHEBI_15377', 'water', 172, '7H2O'), ('CHEBI_63036', 'potassium dihydrogen phosphate', 192, 'KH2PO4'), ('CHEBI_32139', 'sodium hydrogencarbonate', 213, 'NaHCO3'), ('CHEBI_17234', 'glucose', 232, 'glucose'), ('NCBITaxon_33208', 'Metazoa', 289, 'bovine'), ('PR_000003918', 'albumin', 296, 'serum albumin'), ('UBERON_0001977', 'blood serum', 296, 'serum')]
PMC4732175	3/2016	S62-PMC4732175	['quantification of Endothelial Expression of intermediate-conductance calcium-activated potassium channel and small-conductance calcium-activated potassium channel in Third-Order Cremaster Arterioles and Mesenteric Arteries\nthe entire Cremaster Muscle was dissected in physiological saline solution (pss, mmol/l: 119 Nacl, 4.7 Kcl, 1.17 Mgso4, 1.18 Kh2Po4, 25 Nahco3, 0.027 edta, 5.5 Glucose) and fixed in 4% paraformaldehyde overnight at 4°c.']	N/A	N/A	[('UBERON_0001986', 'endothelium', 18, 'endothelial'), ('GO_0010467', 'gene expression', 30, 'expression'), ('UBERON_0018284', 'lower premolar 1', 166, 'third-order'), ('UBERON_0004006', 'cerebellum intermediate zone', 178, 'cremaster arterioles'), ('UBERON_0000080', 'mesonephros', 203, 'mesenteric'), ('UBERON_0001637', 'artery', 214, 'arteries'), ('UBERON_0008488', 'cremaster muscle', 234, 'cremaster muscle'), ('CHEBI_26710', 'sodium chloride', 316, 'NaCl'), ('CHEBI_32588', 'potassium chloride', 326, 'KCl'), ('CHEBI_32599', 'magnesium sulfate', 336, 'MgSO4'), ('CHEBI_63036', 'potassium dihydrogen phosphate', 348, 'KH2PO4'), ('CHEBI_32139', 'sodium hydrogencarbonate', 359, 'NaHCO3'), ('CHEBI_17234', 'glucose', 383, 'glucose')]
PMC4732175	3/2016	S124-PMC4732175	['(e) fasting Plasma Glucose from a subset of offspring (mean\u200a±\u200a95% confidence interval) (c/c, n \u200a=\u200a6; hf/c, c/hf, n \u200a=\u200a5; n \u200a=\u200a7; hf/hf, n \u200a=\u200a5).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 12, 'plasma'), ('CHEBI_17234', 'glucose', 19, 'glucose')]
PMC4740094	2/2016	S4-PMC4740094	['after sacrifice, biochemical markers of obesity and Insulin resistance including oral Glucose tolerance test, adiponectin, leptin, and Retinol Binding Protein-4 (Rbp4) were measured.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 52, 'insulin'), ('CHEBI_17234', 'glucose', 86, 'glucose'), ('CHEBI_26536', 'retinoic acid', 135, 'retinol'), ('PR_000014000', 'telomere-associated protein RIF1', 135, 'retinol binding protein-4'), ('PR_000013819', 'retinol-binding protein 2', 162, 'RBP4')]
PMC4740094	2/2016	S56-PMC4740094	['Rats were initially fasted overnight prior to oral Glucose tolerance test via intragastric gavage using a Glucose Solution (2 g/kg body weight).']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 0, 'Rats'), ('CHEBI_17234', 'glucose', 51, 'glucose'), ('CHEBI_17234', 'glucose', 106, 'glucose'), ('CHEBI_75958', 'solution', 114, 'solution')]
PMC4740094	2/2016	S70-PMC4740094	['caption (table-wrap): table 2\n\nGene names, accession numbers and sequences of Primers for multiplex pcrgene descriptionaccession no.Primer sequence (with universal tags) Ipf1 nm_022852f: aggtgacactatagaataacatctccccatacgaagr: gtacgactcactatagggaaaataagaattccttctccag B2M A,bnm_012512f: aggtgacactatagaataatgcttgcagagttaaacar: gtacgactcactatagggatgcataaaatatttaaggtaaga actb anm_031144f: aggtgacactatagaataaactacattcaattccatcar: gtacgactcactatagggataaaacgcagctcagtaac glut2 nm_012879f: aggtgacactatagaatacagtacattgcggacttcr: gtacgactcactatagggagactttcctttggtttctg hprt1 anm_012583f: aggtgacactatagaatatcctcatggactgattatgr: gtacgactcactatagggactggtcattacagtagctctt kanr c\nIpf1 : Insulin Promoter Factor 1; B2M : Beta-2-Microglobulin; actb : Beta Actin; Glut2 : Glucose Transporter 2; Hprt1 : Hypoxanthine-guanine phosphoribosyltransferase; kanr : Kanamycin resistant.']	N/A	N/A	[('SO_0000704', 'gene', 31, 'Gene'), ('SO_0000112', 'primer', 78, 'primers'), ('SO_0000112', 'primer', 132, 'Primer'), ('PR_000009020', "Golgi-resident adenosine 3',5'-bisphosphate 3'-phosphatase", 170, 'IPF1'), ('PR_000004597', 'UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7', 267, 'B2m a'), ('PR_000009020', "Golgi-resident adenosine 3',5'-bisphosphate 3'-phosphatase", 670, 'IPF1'), ('PR_000008959', 'immunoglobulin heavy constant gamma 1', 677, 'insulin promoter factor 1'), ('SO_0000167', 'promoter', 685, 'promoter'), ('PR_000004806', 'bromodomain-containing protein 2', 704, 'B2m'), ('PR_000004591', 'beta-1,4-glucuronyltransferase 1', 710, 'beta-2-microglobulin'), ('PR_000004691', 'B-cell lymphoma/leukemia 11B', 739, 'beta actin'), ('PR_000015065', 'solute carrier family 2, facilitated glucose transporter member 3', 751, 'GLUT2'), ('CHEBI_17234', 'glucose', 759, 'glucose'), ('PR_000015060', 'solute carrier family 2, facilitated glucose transporter member 11', 759, 'glucose transporter 2'), ('PR_000005089', 'chromobox protein homolog 8', 782, 'Hprt1'), ('CHEBI_17138', 'glyceraldehyde 3-phosphate', 790, 'Hypoxanthine'), ('CHEBI_6104', 'kanamycin', 845, 'kanamycin')]
PMC4740094	2/2016	S89-PMC4740094	['Oral Glucose tolerance test\nafter administration of Glucose load in the mothers, Blood Glucose levels of all the groups, except n, peaked at 30 min (fig.']	N/A	N/A	[('UBERON_0000978', 'leg', 0, 'Oral'), ('CHEBI_17234', 'glucose', 5, 'glucose'), ('CHEBI_17234', 'glucose', 52, 'glucose'), ('UBERON_0000178', 'blood', 81, 'blood'), ('CHEBI_17234', 'glucose', 87, 'glucose')]
PMC4740094	2/2016	S92-PMC4740094	['at 120 min, the hfd group had the highest Blood Glucose concentration of 9.60±0.57 mmol/l.']	N/A	N/A	[('UBERON_0000178', 'blood', 42, 'blood'), ('CHEBI_17234', 'glucose', 48, 'glucose')]
PMC4740094	2/2016	S94-PMC4740094	['in offspring, Blood Glucose levels of all the groups except hfd, peaked at 30 min.']	N/A	N/A	[('UBERON_0000178', 'blood', 14, 'blood'), ('CHEBI_17234', 'glucose', 20, 'glucose')]
PMC4740094	2/2016	S98-PMC4740094	['2\n\nOral Glucose tolerance profiles of (a) mothers and offspring (b).']	N/A	N/A	[('UBERON_0000978', 'leg', 3, 'Oral'), ('CHEBI_17234', 'glucose', 8, 'glucose')]
PMC4740094	2/2016	S153-PMC4740094	['5\n\nHepatic mrna levels of Insulin Promoter Factor-1 (Ipf1) in mothers (a) and offsprings (b), and Hepatic mrna levels of Glucose transporter 2 in mothers (c) and offsprings (d).']	N/A	N/A	[('UBERON_0002107', 'liver', 3, 'Hepatic'), ('PR_000009158', 'inositol 1,4,5-trisphosphate receptor type 1', 26, 'insulin promoter factor-1'), ('SO_0000167', 'promoter', 34, 'promoter'), ('PR_000009020', "Golgi-resident adenosine 3',5'-bisphosphate 3'-phosphatase", 53, 'IPF1'), ('UBERON_0002107', 'liver', 98, 'Hepatic'), ('CHEBI_17234', 'glucose', 121, 'glucose')]
PMC4778858	3/2016	S4-PMC4778858	['healthy Pregnant women underwent measures of height, weight, and a 75-g fasting Oral Glucose tolerance test (ogtt) at approximately 28 weeks Gestation.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 8, 'pregnant'), ('UBERON_0000165', 'mouth', 80, 'oral'), ('CHEBI_17234', 'glucose', 85, 'glucose'), ('GO_0007565', 'female pregnancy', 141, 'gestation')]
PMC4778858	3/2016	S9-PMC4778858	['maternal fasting Plasma Glucose, Insulin sensitivity, and presence of gdm were not associated with maternal Serum 25-Ohd level when adjusted for maternal bmi.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 17, 'plasma'), ('CHEBI_17234', 'glucose', 24, 'glucose'), ('PR_000045358', 'insulin family protein', 33, 'insulin'), ('UBERON_0001977', 'blood serum', 108, 'serum'), ('CHEBI_72765', 'verruculogen', 114, '25-OHD')]
PMC4778858	3/2016	S42-PMC4778858	['maternal Plasma Glucose and c-peptide levels were previously analyzed at the central laboratory of the Hapo study [16], as described [19].']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 9, 'plasma'), ('CHEBI_17234', 'glucose', 16, 'glucose'), ('CHEBI_17883', 'hydrogen chloride', 103, 'HAPO')]
PMC4778858	3/2016	S43-PMC4778858	['briefly, the central laboratory used a “vitros 750” analyzer for Glucose analysis (oxidase/peroxidase method); calibration was verified against Plasma samples previously measured by the hexokinase reference method at ortho-clinical diagnostics company headquarters (rochester, new york).']	N/A	N/A	[('CHEBI_17234', 'glucose', 65, 'glucose'), ('UBERON_0001969', 'blood plasma', 144, 'plasma')]
PMC4778858	3/2016	S49-PMC4778858	['this formula incorporates maternal Glucose and c-peptide at 0 and 60 minutes of the ogtt.']	N/A	N/A	[('CHEBI_17234', 'glucose', 35, 'glucose')]
PMC4778858	3/2016	S62-PMC4778858	['unadjusted regression models for maternal 25-Ohd and maternal bmi, Insulin sensitivity, fasting Plasma Glucose, and gdm were initially examined.']	N/A	N/A	[('CHEBI_72765', 'verruculogen', 42, '25-OHD'), ('PR_000045358', 'insulin family protein', 67, 'insulin'), ('UBERON_0001969', 'blood plasma', 96, 'plasma'), ('CHEBI_17234', 'glucose', 103, 'glucose')]
PMC4778858	3/2016	S63-PMC4778858	['models were then adjusted for maternal age and field center, with additional adjustment for maternal bmi in models for Insulin sensitivity, fasting Glucose and gdm.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 119, 'insulin'), ('CHEBI_17234', 'glucose', 148, 'glucose')]
PMC4778858	3/2016	S70-PMC4778858	['based on fasting, 1-hr and 2-hr Plasma Glucose levels from the 75-g ogtt, 16.4% of the women in this cohort would be classified as having Gestational diabetes mellitus according to the international association of diabetes and Pregnancy study groups (iadpsg) consensus panel [23].10.1371/journal.pone.0150221.t001\n\ncaption (table-wrap): table 1\nmaternal and neonatal characteristics.mean (sd) or n (%) maternal characteristics n = 360age (years)32.5 (4.6)Gestational age at ogtt and bmi measurement (wks)27.8 (1.4)bmi (kg/m2)28.5 (5.3)normal weight (<28.5)216 (60.0%)overweight (28.5–33)75 (20.8%)obese (>33)69 (19.2%)Serum 25-Ohd (ng/ml)37.2 (11.2)fasting Plasma Glucose (mg/dl)82.6 (6.6)Insulin sensitivity3.7 (1.4)Gestational diabetes mellitus^59 (16.4%)field centerchicago, il112 (31.1%)cleveland, oh118 (32.8%)toronto, on130 (36.1%) neonatal characteristics n = 360gestational age (wks)40.1 (0.7)Birth weight (g)3582.3 (429.2)adiposity (% fat)12.3 (3.3)Cord Blood 25-Ohd (ng/ml)23.4 (9.2)Birth seasonwinter181 (50.3%)summer179 (49.7%)\n^international association of diabetes and Pregnancy study groups consensus panel [23]\nMaternal and Cord Blood mean levels of 25-Ohd are displayed infig 1according to field center with the corresponding latitude.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 32, 'plasma'), ('CHEBI_17234', 'glucose', 39, 'glucose'), ('GO_0007565', 'female pregnancy', 138, 'gestational'), ('GO_0007565', 'female pregnancy', 227, 'Pregnancy'), ('GO_0007565', 'female pregnancy', 455, 'Gestational'), ('UBERON_0001977', 'blood serum', 618, 'Serum'), ('CHEBI_72765', 'verruculogen', 624, '25-OHD'), ('PR_000004775', 'BMP-binding endothelial regulator protein', 626, '-OHD'), ('UBERON_0001969', 'blood plasma', 657, 'Plasma'), ('CHEBI_17234', 'glucose', 664, 'Glucose'), ('PR_000045358', 'insulin family protein', 689, 'Insulin'), ('GO_0007565', 'female pregnancy', 717, 'Gestational'), ('GO_0007567', 'parturition', 901, 'Birth'), ('UBERON_0000948', 'heart', 958, 'Cord'), ('UBERON_0000178', 'blood', 963, 'blood'), ('CHEBI_72765', 'verruculogen', 969, '25-OHD'), ('GO_0007567', 'parturition', 993, 'Birth'), ('GO_0007565', 'female pregnancy', 1083, 'Pregnancy'), ('UBERON_0000976', 'humerus', 1127, 'Maternal'), ('UBERON_0002240', 'spinal cord', 1140, 'cord'), ('UBERON_0000178', 'blood', 1145, 'blood'), ('CHEBI_72765', 'verruculogen', 1166, '25-OHD')]
PMC4778858	3/2016	S80-PMC4778858	['maternal fasting Plasma Glucose and gdm presence were not significantly associated with maternal Serum 25-Ohd level in either unadjusted or adjusted models.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 17, 'plasma'), ('CHEBI_17234', 'glucose', 24, 'glucose'), ('UBERON_0001977', 'blood serum', 97, 'serum'), ('CHEBI_72765', 'verruculogen', 103, '25-OHD')]
PMC4778858	3/2016	S82-PMC4778858	['additional adjustment for season at the time of ogtt and maternal Blood collection in the model for maternal 25-Ohd level did not appreciably change the results (data not shown).10.1371/journal.pone.0150221.t002\n\ncaption (table-wrap): table 2\nlinear regression analysis of the relationship between maternal Serum 25-Ohd at ogtt and maternal factors.univariate modeladjusted model^beta estimate (95% ci)p valuebeta estimate (95% ci)p valuebmi (kg/m2) at ogtt (27.8 wks)-0.48 (-0.71, -0.25)<0.001-0.40 (-0.62, -0.17)<0.001fasting Plasma Glucose (mg/dl)-0.02 (-0.22, 0.17)0.830.05 (-0.14, 0.25)0.59insulin sensitivity1.29 (0.40, 2.19)0.0050.40 (-0.60, 1.39)0.43gdm (yes v. no)0.18 (-3.20, 3.56)0.920.74 (-2.57, 4.04)0.66\n^all models were adjusted for maternal age and field center; fasting Plasma Glucose, Insulin sensitivity and gdm models were additionally adjusted for maternal bmi.']	N/A	N/A	[('UBERON_0000178', 'blood', 66, 'blood'), ('CHEBI_72765', 'verruculogen', 109, '25-OHD'), ('UBERON_0001977', 'blood serum', 307, 'serum'), ('CHEBI_72765', 'verruculogen', 313, '25-OHD'), ('UBERON_0001969', 'blood plasma', 528, 'plasma'), ('CHEBI_17234', 'glucose', 535, 'glucose'), ('UBERON_0001969', 'blood plasma', 787, 'plasma'), ('CHEBI_17234', 'glucose', 794, 'glucose'), ('PR_000045358', 'insulin family protein', 803, 'insulin')]
PMC4785305	3/2016	S82-PMC4785305	['aub-mc clinical chemistry laboratory partakes in the quality assurance, evaluation and accreditation by the college of american pathologists43and is a participant in the Vitamin D external quality assurance surveillance (deqas) programme.44\n\ncaption (table-wrap): table\xa01\n\ntrial events and outcomes measurestrial event and outcomes measures11–13\u2005weeks (screening visit)15–18\u2005weeks (visit 1)20\u2005weeks24–28\u2005weeks28–32\u2005weeks (visit 2)37–42\u2005weeks delivery (visit 3)1\u2005month post Partum (visit 4)maternal height✓maternal weight, Blood pressure✓✓✓maternal health and diet assessment✓✓✓maternal 25(Oh)D, crea, ca×××maternal Cell count, ph, mg, alb, Tsh, 1,25(Oh)2D×pth××maternal Glucose (1\u2005h)✓maternal 24\u2005h (or spot) Urine collection for calcium and creatinine××maternal Vitamin D Binding Protein××maternal Genetic pathways of Vitamin D Metabolism×fetal us:\nCrown -Rump✓fetal us:\nFemur length\nabdominal circumference\nHead circumference\nbiparietal diameter✓newborn weight, length, Knee to Heel length apgar score✓Placental weight×Placental studies×newborn 25(Oh)D, ca, pth (Cord Blood)×newborn Genetic pathways of Vitamin D Metabolism×infant bone/fat mass×infant weight and length✓infant health and diet assessment✓\n✓test performed for clinical purpose.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 170, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 170, 'Vitamin D'), ('GO_0007567', 'parturition', 473, 'partum'), ('UBERON_0000178', 'blood', 522, 'blood'), ('CHEBI_71657', 'versiconol acetate', 586, '25(OH)D'), ('CL_0000573', 'retinal cone cell', 615, 'cell'), ('CHEBI_17855', 'triglyceride', 640, 'TSH'), ('CHEBI_17996', 'chloride', 646, ','), ('CHEBI_66212', "5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone", 647, '25(OH)2D'), ('CHEBI_17234', 'glucose', 670, 'glucose'), ('UBERON_0001088', 'urine', 708, 'urine'), ('CHEBI_27300', 'vitamin D', 762, 'vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 762, 'vitamin D binding protein'), ('SO_0000704', 'gene', 798, 'genetic'), ('CHEBI_27300', 'vitamin D', 818, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 818, 'vitamin D metabolism'), ('UBERON_0002943', 'lingual gyrus', 849, 'crown -rump✓'), ('UBERON_0000981', 'femur', 871, 'Femur'), ('UBERON_0000033', 'head', 908, 'Head'), ('UBERON_0001465', 'knee', 971, 'knee'), ('UBERON_0015875', 'heel', 979, 'heel'), ('UBERON_0001987', 'placenta', 1003, 'Placental'), ('UBERON_0001987', 'placenta', 1020, 'Placental'), ('CHEBI_71657', 'versiconol acetate', 1046, '25(OH)D'), ('UBERON_0009472', 'axilla', 1064, 'cord blood'), ('SO_0000704', 'gene', 1084, 'genetic'), ('CHEBI_27300', 'vitamin D', 1104, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 1104, 'vitamin D metabolism')]
PMC4789467	3/2016	S96-PMC4789467	['regulation of Placental transport function by the maternal environment\nalong with oxygen, Glucose, Amino Acids and Fatty Acids represent essential Nutrients for fetal growth.']	N/A	N/A	[('UBERON_0001987', 'placenta', 14, 'placental'), ('CHEBI_17234', 'glucose', 90, 'glucose'), ('CHEBI_33867', 'idonates', 99, 'amino acids'), ('CHEBI_35366', 'fatty acid', 115, 'fatty acids'), ('CHEBI_33284', 'nutrient', 147, 'nutrients')]
PMC4789467	3/2016	S99-PMC4789467	['Glucose and Lactate are transported down their concentration gradient by facilitated diffusion using transporter proteins embedded in the Plasma Membrane, without a requirement for additional energy.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('CHEBI_24996', 'lactate', 12, 'lactate'), ('GO_0005886', 'plasma membrane', 138, 'plasma membrane')]
PMC4789467	3/2016	S104-PMC4789467	['the maternal environment modifies Placental Glucose transport capacity (table1).']	N/A	N/A	[('UBERON_0001987', 'placenta', 34, 'placental'), ('CHEBI_17234', 'glucose', 44, 'glucose')]
PMC4789467	3/2016	S105-PMC4789467	['trans-Placental Transfer Of Glucose in vivo is unaltered by under-nourishing Pregnant Mice to 80% of the ad libitum daily Intake.']	N/A	N/A	[('UBERON_0001987', 'placenta', 6, 'placental'), ('GO_0006098', 'pentose-phosphate shunt', 16, 'transfer of glucose'), ('CHEBI_17234', 'glucose', 28, 'glucose'), ('GO_0007565', 'female pregnancy', 77, 'pregnant'), ('NCBITaxon_10088', 'Mus <genus>', 86, 'mice'), ('GO_0007631', 'feeding behavior', 122, 'intake')]
PMC4789467	3/2016	S113-PMC4789467	['for instance in Mice, materno-fetal Clearance Of Glucose is increased near term by diets high in fat alone, as well as on day 16 of Gestation in those also Consuming excess Sugar (jones et al.,2008; sferruzzi-perri et al.,2013).']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 16, 'mice'), ('GO_0043254', 'regulation of protein-containing complex assembly', 36, 'clearance of glucose'), ('CHEBI_17234', 'glucose', 49, 'glucose'), ('GO_0007565', 'female pregnancy', 132, 'gestation'), ('GO_0007631', 'feeding behavior', 156, 'consuming'), ('CHEBI_24870', 'ion', 173, 'sugar')]
PMC4794442	3/2016	S39-PMC4794442	['her White Blood Cell count was 23.1 k/µl (range, 3.8–10.5 k/µl) and her Finger-stick Glucose was 113 mg/dl.']	N/A	N/A	[('CL_0000738', 'leukocyte', 4, 'white blood cell'), ('UBERON_0000178', 'blood', 10, 'blood'), ('UBERON_0002389', 'manual digit', 72, 'finger'), ('CHEBI_17234', 'glucose', 85, 'glucose')]
PMC4807004	3/2016	S95-PMC4807004	['these included modified Glucose tolerance test (mgtt), Urine full examination/microscopic examination (feme), Blood Sugar profile (bsp), haemoglobin a1c or glycated haemoglobin test for diabetes (hba1c), full Blood picture (fbp), iron studies and haemoglobin electrophoresis.']	N/A	N/A	[('CHEBI_17234', 'glucose', 24, 'Glucose'), ('UBERON_0001088', 'urine', 55, 'urine'), ('UBERON_0000178', 'blood', 110, 'blood'), ('CHEBI_24870', 'ion', 116, 'sugar'), ('UBERON_0000178', 'blood', 209, 'blood')]
PMC4807004	3/2016	S160-PMC4807004	['the 69% of low-risk women tested were all negative.10.1371/journal.pone.0152167.t005\n\ncaption (table-wrap): table 5\nadditional laboratory tests performed among low- and high-risk women in public-sector health clinics of selangor state (n = 522).all women (n = 522)low-risk (n = 375)high-risk (n = 147)additional tests, n (%)testedtestedtestedmgtt376 (72.0)258 (68.8)118 (80.3)Urine feme66 (29.9)105 (28.0)51 (34.7)bsp86 (16.5)3 (0.8)83 (56.5)hba1c51 (9.8)0 (0.0)51 (34.7)Fbp33 (6.3)10 (2.7)23 (15.6)iron studies28 (5.4)8 (2.1)20 (13.6)hb analysis (electrophoresis)19 (3.6)7 (1.9)12 (8.2)\nmodified Glucose tolerance test (mgtt), Urine full examination/microscopic examination (feme), Blood Sugar profile (bsp), haemoglobin a1c or glycated haemoglobin test (hba1c), full Blood picture (fbp), haemoglobin electrophoresis (hb analysis).']	N/A	N/A	[('UBERON_0001088', 'urine', 376, 'urine'), ('PR_000007395', 'F-box only protein 22', 471, 'FBP33'), ('CHEBI_17234', 'glucose', 597, 'glucose'), ('UBERON_0001088', 'urine', 628, 'urine'), ('UBERON_0000178', 'blood', 683, 'blood'), ('CHEBI_24870', 'ion', 689, 'sugar'), ('UBERON_0000178', 'blood', 769, 'blood')]
PMC4825101	10/2015	S64-PMC4825101	['or percentagea19972011bage (years)36.0 (7.76)50.0 (7.77)weight (kg)55.9 (9.18)61.5 (13.2)height (cm)161.2 (6.94)163.7 (6.84)bmi (kg/m2)21.5 (3.08)22.9 (4.50)***overweight/obese (%)6.86/1.1418.9/6.29***fat mass (kg)na18.1 (9.10)Trunk fat mass (kg)na8.97 (4.87)systolic Blood pressure (mmhg)106.5 (10.5)116.7 (17.5)***diastolic Blood pressure (mmhg)69.7 (7.68)71.3 (10.2)***hypertensive (%)13.1%31.6%***Glucose t0c(mmol/l)5.31 (5.23, 5.38)5.30 (5.19, 5.43)Glucose t30 (mmol/l)7.41 (7.22, 7.61)7.36 (7.07, 7.67)Glucose t120 (mmol/l)5.05 (5.28, 6.15)5.46 (5.20, 5.74)**Insulin t0 (pg/ml)d4.05 (4.03, 5.75)5.98 (5.46, 6.55)***Insulin T30(pg/ml)39.7 (36.6, 43.1)48.2 (43.2, 53.8)***Insulin t120 (pg/ml)13.2 (11.6, 15.0)20.2 (18.0, 22.7)***impaired Glucose tolerance (%)0.577.43***type 2 diabetes mellitus (%)02.86*\ndata presented for the 175 Individuals seen in 1997, who were traced in 2011.']	N/A	N/A	[('UBERON_0002100', 'trunk', 227, 'Trunk'), ('UBERON_0000178', 'blood', 268, 'blood'), ('UBERON_0000178', 'blood', 326, 'blood'), ('CHEBI_17234', 'glucose', 401, 'Glucose'), ('CHEBI_17234', 'glucose', 454, 'Glucose'), ('CHEBI_17234', 'glucose', 508, 'Glucose'), ('PR_000045358', 'insulin family protein', 565, 'Insulin'), ('PR_000002270', 'Bcl-2-like protein 11 isoform 16', 621, 'Insulin T30'), ('PR_000045358', 'insulin family protein', 676, 'Insulin'), ('CHEBI_17234', 'glucose', 742, 'glucose'), ('NCBITaxon_1', 'root', 836, 'individuals')]
PMC4825101	10/2015	S66-PMC4825101	['* p<0.05, ** p<0.01, *** p<0.001\nt0 – baseline (fasting); t30–30 minutes post-Glucose load; t120–120 minutes post-Glucose load.']	N/A	N/A	[('CHEBI_17234', 'glucose', 78, 'glucose'), ('CHEBI_17234', 'glucose', 114, 'glucose')]
PMC4825101	10/2015	S68-PMC4825101	['at follow-up, 7.4% of the subjects had impaired Glucose tolerance (igt; 2 h Plasma Glucose level >7.78–11.0 mmol/l22) and 5 (2.9%) had a provisional diagnosis of type 2 diabetes mellitus (2 h Glucose ⩾11.1 mmol/l).']	N/A	N/A	[('CHEBI_17234', 'glucose', 48, 'glucose'), ('UBERON_0001969', 'blood plasma', 76, 'plasma'), ('CHEBI_17234', 'glucose', 83, 'glucose'), ('CHEBI_17234', 'glucose', 192, 'glucose'), ('CHEBI_24870', 'ion', 200, '⩾')]
PMC4825102	2/2016	S56-PMC4825102	['Glucose Homoeostasis Regulation\ngdm is defined as Carbohydrate intolerance during Pregnancy(1).']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('GO_0042067', 'establishment of ommatidial planar polarity', 0, 'Glucose homoeostasis regulation'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 50, 'carbohydrate'), ('GO_0007565', 'female pregnancy', 82, 'pregnancy')]
PMC4825102	2/2016	S94-PMC4825102	['2\n\ncrosstalk among signalling pathways in Regulating Glucose Metabolism.']	N/A	N/A	[('GO_0065007', 'biological regulation', 42, 'regulating'), ('CHEBI_17234', 'glucose', 53, 'glucose'), ('GO_0006006', 'glucose metabolic process', 53, 'glucose metabolism')]
PMC4825102	2/2016	S97-PMC4825102	['from Lps-treated raw264·7 Macrophages)(144)Resveratrol (0·1–1 µm) for 24 hprevents hyperpermeability; ↑No Production; ↑Enos activityhigh-Glucose-treated baec(145)36 % fat supplemented with 0·37 % Resveratrol↑Placental Dha uptake; ↑ha u activity; ↑mrna Expression of Dha receptorshigh-fat diet (36 % fat supplementated with 0·37 % Resveratrol) in Pregnant Non-Human Primates(193)Tyr (0·1–10 µm) for 1 h pretreatment↑adiponectin; ↑Ppar γ activity; ↓jnk activationhuman Adipocytes tnf α treated(149)Tyr, or ol, or ht, or tax (50 µmeach) for 24 h↓Proliferation and migration; ht and tax↓Vegfr2, Erk1/2 and jnk phosphorylationvegf-treated huvec(150)\n↑, increases; ↓, decreases; nod, non-obese diabetic; Jnk, C-Jun n -terminal kinase; Foxo1, Forkhead Box Protein O1; Gsis, Glucose-stimulated Insulin secretion; Camp, Cyclic Amp; Pka, protein kinase a; Egcg, Epigallocatechin-3-Gallate; Irs1/2, Insulin Receptor Substrate 1/2; ampk, amp-activated protein kinase; c3g, cyanidin-3-Glucoside; sirt-1, Sirtuin 1; stz, Streptozotocin; Pdx1, Pancreatic and Duodenal Homeobox-1; pca, Protocatechuic Acid; t2d, type 2 diabetes; Akt, Protein Kinase B; Ins-1, Insulin 1; gk, Glycerol kinase; P38 Mapk, P38 Mitogen-activated protein kinase; hba1c, glycated Hb; pi3k, Phosphatidylinositol-3-Kinase; Erk1/2, Extracellular Signal-Regulated Kinase; Lps, Lipopolysaccharides; No, Nitric Oxide; Enos, Endothelial no synthase; baec, Bovine Artery Endothelial Cells; tyr, tyrosol; ol, Oleuropein; ht, Hydroxytyrosol; Tax, Taxifolin; Vegfr2, Vascular Endothelial Growth Factor Receptor 2; Vegf, Vascular Endothelial Growth Factor; huvec, Human Umbilical Vein Endothelial Cells.']	N/A	N/A	[('CHEBI_16412', 'lipopolysaccharide', 5, 'LPS'), ('CL_0000235', 'macrophage', 26, 'macrophages'), ('CHEBI_27881', 'resveratrol', 43, 'Resveratrol'), ('GO_0032902', 'nerve growth factor production', 103, 'NO production'), ('PR_000007020', 'ETS-related transcription factor Elf-1', 119, 'eNOS'), ('CHEBI_17234', 'glucose', 137, 'glucose'), ('CHEBI_27881', 'resveratrol', 196, 'resveratrol'), ('UBERON_0001987', 'placenta', 208, 'Placental'), ('CHEBI_17874', 'dihydrozeatin', 218, 'DHA'), ('GO_0010467', 'gene expression', 252, 'expression'), ('CHEBI_17874', 'dihydrozeatin', 266, 'DHA'), ('CHEBI_27881', 'resveratrol', 330, 'resveratrol'), ('GO_0007565', 'female pregnancy', 346, 'pregnant'), ('NCBITaxon_10088', 'Mus <genus>', 355, 'non'), ('NCBITaxon_9606', 'Homo sapiens', 359, 'human'), ('NCBITaxon_33208', 'Metazoa', 365, 'primates'), ('CHEBI_9754', 'tris', 378, 'Tyr'), ('PR_000013057', 'peroxisome proliferator-activated receptor delta', 429, 'PPAR'), ('CL_0000136', 'fat cell', 467, 'adipocytes'), ('CHEBI_9754', 'tris', 496, 'Tyr'), ('GO_0008283', 'cell proliferation', 543, 'Proliferation'), ('PR_000017279', 'testis-specific basic protein Y 1', 583, 'VEGFR2'), ('PR_000007164', 'general transcription and DNA repair factor IIH helicase subunit XPD', 591, 'ERK1'), ('PR_000009211', 'lysine-specific demethylase 3A', 698, 'JNK'), ('PR_000004968', 'calretinin', 703, 'c-Jun'), ('PR_000017653', 'zinc finger protein ZFPM2', 729, 'Foxo1'), ('PR_000007620', 'forkhead box protein E3', 736, 'forkhead box protein O1'), ('PR_000008294', 'glutathione S-transferase A1', 761, 'GSIS'), ('CHEBI_17234', 'glucose', 767, 'glucose'), ('PR_000045358', 'insulin family protein', 786, 'insulin'), ('CHEBI_17489', "3',5'-cyclic AMP", 805, 'cAMP'), ('CHEBI_27840', '2,4-dimethylaniline', 811, 'cyclic AMP'), ('PR_000012724', 'phosphatidylinositol 3-kinase regulatory subunit alpha', 823, 'PKA'), ('CHEBI_42298', 'HEPPS', 846, 'EGCG'), ('CHEBI_75272', 'splitomicin', 852, 'epigallocatechin-3-gallate'), ('PR_000009158', 'inositol 1,4,5-trisphosphate receptor type 1', 880, 'IRS1'), ('PR_000008959', 'immunoglobulin heavy constant gamma 1', 888, 'insulin receptor substrate 1'), ('CHEBI_35435', "4'-aminobiphenyl-4-ol", 970, '3-glucoside'), ('PR_000015711', 'STAM-binding protein', 991, 'sirtuin 1'), ('CHEBI_9288', 'streptozocin', 1007, 'streptozotocin'), ('PR_000012525', 'pyridoxal phosphate phosphatase', 1023, 'PDX1'), ('PR_000014700', 'serpin B9', 1029, 'pancreatic'), ('UBERON_0001264', 'pancreas', 1029, 'pancreatic'), ('PR_000006629', 'docking protein 2', 1044, 'duodenal homeobox-1'), ('UBERON_0001245', 'anus', 1044, 'duodenal'), ('CHEBI_15425', 'proclavaminic acid', 1070, 'protocatechuic acid'), ('PR_000003908', 'aflatoxin B1 aldehyde reductase member 2', 1113, 'Akt'), ('PR_000013504', 'periodic tryptophan protein 1', 1118, 'protein kinase B'), ('PR_000009020', "Golgi-resident adenosine 3',5'-bisphosphate 3'-phosphatase", 1136, 'INS-1'), ('PR_000009078', 'integrator complex subunit 9', 1143, 'insulin 1'), ('CHEBI_17754', 'glycerol', 1158, 'glycerol'), ('PR_000001440', 'galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1', 1175, 'p38 MAPK'), ('PR_000000123', 'ribosomal protein S6 kinase beta-1', 1185, 'p38 mitogen'), ('CHEBI_52290', 'mitogen', 1189, 'mitogen'), ('PR_000008609', 'hexokinase-2', 1239, 'Hb'), ('CHEBI_28874', 'phosphatidylinositol', 1249, 'phosphatidylinositol'), ('PR_000013390', '26S proteasome non-ATPase regulatory subunit 8', 1249, 'phosphatidylinositol-3'), ('CHEBI_37972', 'phosphorus-32 atom', 1270, '3'), ('PR_000009210', 'Jun dimerization protein 2', 1272, 'kinase'), ('PR_000007164', 'general transcription and DNA repair factor IIH helicase subunit XPD', 1280, 'ERK1'), ('GO_0005576', 'extracellular region', 1288, 'extracellular'), ('PR_000007140', 'epsin-3', 1288, 'extracellular signal-regulated kinase'), ('CHEBI_16412', 'lipopolysaccharide', 1327, 'LPS'), ('CHEBI_16412', 'lipopolysaccharide', 1332, 'lipopolysaccharides'), ('CHEBI_16382', 'iodide', 1353, 'NO'), ('CHEBI_16480', 'nitric oxide', 1357, 'nitric oxide'), ('PR_000007020', 'ETS-related transcription factor Elf-1', 1371, 'eNOS'), ('UBERON_0001986', 'endothelium', 1377, 'endothelial'), ('CL_1001578', 'vagina squamous cell', 1408, 'bovine artery endothelial cells'), ('NCBITaxon_33208', 'Metazoa', 1408, 'bovine'), ('UBERON_0001637', 'artery', 1415, 'artery'), ('UBERON_0001986', 'endothelium', 1422, 'endothelial'), ('CHEBI_31963', 'Paramethasone acetate', 1459, 'oleuropein'), ('CHEBI_68888', 'benarthin', 1475, 'hydroxytyrosol'), ('PR_000016933', 'transmembrane O-methyltransferase', 1491, 'Tax'), ('PR_000016288', 'homeobox protein TGIF1', 1496, 'taxifolin'), ('PR_000017279', 'testis-specific basic protein Y 1', 1507, 'VEGFR2'), ('PR_000001949', 'tumor necrosis factor ligand superfamily member 4', 1515, 'vascular endothelial growth factor receptor 2'), ('UBERON_0001986', 'endothelium', 1524, 'endothelial'), ('PR_000017279', 'testis-specific basic protein Y 1', 1562, 'VEGF'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 1568, 'vascular endothelial growth factor'), ('UBERON_0001986', 'endothelium', 1577, 'endothelial'), ('NCBITaxon_9606', 'Homo sapiens', 1611, 'human'), ('CL_0010002', 'epithelial cell of umbilical artery', 1617, 'umbilical vein endothelial cells'), ('UBERON_0002066', 'umbilical vein', 1617, 'umbilical vein'), ('UBERON_0001986', 'endothelium', 1632, 'endothelial')]
PMC4825102	2/2016	S100-PMC4825102	['ampk is an Energy-Sensing enzyme recognised as a master regulator of whole-body energy homoeostasis; its activation increases Glut4 Expression and Membrane Translocation in Skeletal muscle, thereby improving Glucose Uptake(93).']	N/A	N/A	[('GO_0090505', 'epiboly involved in wound healing', 11, 'energy-sensing'), ('PR_000015065', 'solute carrier family 2, facilitated glucose transporter member 3', 126, 'GLUT4'), ('GO_0010467', 'gene expression', 132, 'expression'), ('GO_0016020', 'membrane', 147, 'membrane'), ('GO_0055086', 'nucleobase-containing small molecule metabolic process', 147, 'membrane translocation'), ('UBERON_0004288', 'skeleton', 173, 'skeletal'), ('CHEBI_17234', 'glucose', 208, 'glucose'), ('GO_0046323', 'glucose import', 208, 'glucose uptake')]
PMC4825102	2/2016	S111-PMC4825102	['Caffeic Acid, Naringenin and Quercetin (10−6µmfor 72 h each), present in many Plants, enhance gsis and Glucose sensitivity in Rat Pancreatic ins-1e cells(101).']	N/A	N/A	[('CHEBI_28616', 'carbamic acid', 0, 'Caffeic acid'), ('CHEBI_27669', 'neoastilbin', 14, 'naringenin'), ('CHEBI_16243', 'quercetin', 29, 'quercetin'), ('NCBITaxon_10088', 'Mus <genus>', 78, 'plants'), ('CHEBI_17234', 'glucose', 103, 'glucose'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 126, 'rat'), ('UBERON_0001264', 'pancreas', 130, 'pancreatic')]
PMC4825102	2/2016	S118-PMC4825102	['similarly, administration of 0·1 ml of bayberry fruit extracts (containing 150 μg of c3g)/10 g of body weight twice per day for 30 d significantly reduced Blood Glucose and improved Glucose tolerance in streptozotocin-induced diabetic Mice(97).']	N/A	N/A	[('UBERON_0000178', 'blood', 155, 'blood'), ('CHEBI_17234', 'glucose', 161, 'glucose'), ('CHEBI_17234', 'glucose', 182, 'glucose'), ('NCBITaxon_10088', 'Mus <genus>', 235, 'mice')]
PMC4825102	2/2016	S139-PMC4825102	['the activation of these pathways results in Fa Oxidation (fao) and Glucose Uptake in Skeletal muscle, and in the inhibition of Gluconeogenesis in the Liver(121).']	N/A	N/A	[('CHEBI_30751', 'formic acid', 44, 'FA'), ('GO_0019395', 'fatty acid oxidation', 44, 'FA oxidation'), ('CHEBI_17234', 'glucose', 67, 'glucose'), ('GO_0046323', 'glucose import', 67, 'glucose uptake'), ('UBERON_0004288', 'skeleton', 85, 'skeletal'), ('GO_0006094', 'gluconeogenesis', 127, 'gluconeogenesis'), ('UBERON_0002107', 'liver', 150, 'liver')]
PMC4825102	2/2016	S160-PMC4825102	['the high-Glucose-induced Nitric Oxide (No) reduction was reverted by Rsv (0·1–10 μmfor 24 h) incubation in Bovine artery Endothelial Cells, because of enhanced Endothelial no synthase mrna and activity(145).']	N/A	N/A	[('CHEBI_17234', 'glucose', 9, 'glucose'), ('CHEBI_16480', 'nitric oxide', 25, 'nitric oxide'), ('CHEBI_16382', 'iodide', 39, 'NO'), ('NCBITaxon_10088', 'Mus <genus>', 69, 'RSV'), ('NCBITaxon_33208', 'Metazoa', 107, 'bovine'), ('CL_0000115', 'endothelial cell', 121, 'endothelial cells'), ('UBERON_0001986', 'endothelium', 121, 'endothelial'), ('UBERON_0001986', 'endothelium', 160, 'endothelial')]
PMC4825102	2/2016	S172-PMC4825102	['naringin (80 µmpretreatment for 2 h) incubation down-regulated the high-Glucose-induced leptin Expression and inhibited leptin-induced activation of the P38 Mapk pathway in h9c2 Cardiac Cells(153).']	N/A	N/A	[('CHEBI_17234', 'glucose', 72, 'glucose'), ('GO_0010467', 'gene expression', 95, 'expression'), ('GO_0033238', 'regulation of cellular amine metabolic process', 153, 'p38 MAPK'), ('PR_000001440', 'galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1', 153, 'p38 MAPK'), ('CL_0000138', 'chondrocyte', 178, 'cardiac cells'), ('UBERON_0000948', 'heart', 178, 'cardiac')]
PMC4829879	2/2016	S97-PMC4829879	['an aliquot of whole Blood was analyzed for Glucose and Lipid profile (total Cholesterol, high-density lipoprotein Cholesterol, and Triglycerides) with cholestech ldx (alere, san diego, ca).']	N/A	N/A	[('UBERON_0000178', 'blood', 20, 'blood'), ('CHEBI_17234', 'glucose', 43, 'glucose'), ('CHEBI_18059', 'lipid', 55, 'lipid'), ('CHEBI_16113', 'cholesterol', 76, 'cholesterol'), ('CHEBI_16113', 'cholesterol', 114, 'cholesterol'), ('CHEBI_17855', 'triglyceride', 131, 'triglycerides')]
PMC4835505	4/2016	S68-PMC4835505	['intact (non-permeabilized) Neurons suspended in pbs supplemented with 10 mm Glucose were used for evaluation of oxygen consumption followed by sequential additions of 5 μg/ml Oligomycin and 20 μm Fccp (napoli et al.,2011).']	N/A	N/A	[('CL_0000540', 'neuron', 27, 'neurons'), ('CHEBI_17234', 'glucose', 76, 'glucose'), ('CHEBI_25675', 'oligomycin', 175, 'oligomycin'), ('CHEBI_32035', 'potassium hydroxide', 196, 'FCCP')]
PMC4835505	4/2016	S177-PMC4835505	['deficits in bioenergetics in Brain Regions from young ki Mice\ndifferent segments of the Electron Transport Chain from Brain Mitochondria (hippocampus, Cerebellum, and Cortex) were tested for their capacity to generate atp in wt and ki Mice: nadh oxidase (using nad-linked substrates such as Glucose and comprising Complex I, iii, iv, and v), succinate oxidase (using fad-linked substrates such as Fatty Acids and comprising Complex Ii, iii, iv, and v), as well as citrate synthase activity as a normalizing marker of Mitochondrial mass.']	N/A	N/A	[('UBERON_0002616', 'regional part of brain', 29, 'brain regions'), ('NCBITaxon_10088', 'Mus <genus>', 57, 'mice'), ('CHEBI_10545', 'electron', 88, 'electron'), ('GO_0045251', 'electron transfer flavoprotein complex', 88, 'electron transport chain'), ('UBERON_0000955', 'brain', 118, 'brain'), ('GO_0005739', 'mitochondrion', 124, 'mitochondria'), ('UBERON_0002037', 'cerebellum', 151, 'cerebellum'), ('UBERON_0001851', 'cortex', 167, 'cortex'), ('NCBITaxon_10088', 'Mus <genus>', 235, 'mice'), ('CHEBI_17234', 'glucose', 291, 'glucose'), ('GO_0030964', 'NADH dehydrogenase complex', 314, 'Complex I'), ('CHEBI_35366', 'fatty acid', 397, 'fatty acids'), ('GO_0030964', 'NADH dehydrogenase complex', 424, 'Complex II'), ('GO_0005739', 'mitochondrion', 517, 'mitochondrial')]
PMC4835505	4/2016	S223-PMC4835505	['caption (table-wrap): table 2\n\nMitochondrial coupling and Respiratory capacity in intact, isolated Neurons from wt and ki Mice at pnd0 .outcomeshippocampuscerebellumcortex(% basal rate)Oxygen Consumption rateswtkiwtkiwtki Oligomycin-sensitive90 ± 185 ± 1**89 ± 380 ± 684 ± 277 ± 3oligomycin-resistant0.33 ± 0.336.9 ± 0.5***−0.22 ± 0.220.9 ± 0.2*3 ± 519 ± 3*spare Respiratory capacity128 ± 1262 ± 2**102 ± 3074 ± 42110 ± 1767 ± 12 couplinghippocampuscerebellumcortex rcru11 ± 23.4 ± 0.8*9 ± 11.7 ± 0.4**7 ± 10.9 ± 0.3***\noxygen consumption rates under basal conditions (in the presence of Glucose only) were not statistically significant different between wt and ki in any of the Brain Regions [average of wt and ki = 6.5 ± 0.7; 3.4 ± 0.9; and 3.1 ± 0.5 nmol oxygen consumed × (min × 106cells)−1for Cortex, Cerebellum and hippocampus, respectively].']	N/A	N/A	[('GO_0005739', 'mitochondrion', 31, 'Mitochondrial'), ('GO_0045333', 'cellular respiration', 58, 'respiratory'), ('CL_0000540', 'neuron', 99, 'neurons'), ('NCBITaxon_10088', 'Mus <genus>', 122, 'mice'), ('CHEBI_33309', 'noble gas atom', 185, 'Oxygen'), ('GO_0007631', 'feeding behavior', 192, 'consumption'), ('CHEBI_7765', 'Oligouronides', 222, 'Oligomycin'), ('GO_0045333', 'cellular respiration', 363, 'respiratory'), ('UBERON_0001004', 'respiratory system', 363, 'respiratory'), ('CHEBI_17234', 'glucose', 588, 'glucose'), ('UBERON_0002616', 'regional part of brain', 679, 'brain regions'), ('UBERON_0001851', 'cortex', 798, 'cortex'), ('UBERON_0002037', 'cerebellum', 806, 'cerebellum')]
PMC4846845	4/2016	S134-PMC4846845	['the 5698 Genes were enriched in pathways related to Autoimmune, Pancreas, and Glucose Metabolism disorder [86].']	N/A	N/A	[('SO_0000704', 'gene', 9, 'genes'), ('UBERON_0001442', 'skeleton of manus', 52, 'autoimmune'), ('UBERON_0001264', 'pancreas', 64, 'pancreas'), ('CHEBI_17234', 'glucose', 78, 'glucose'), ('GO_0006006', 'glucose metabolic process', 78, 'glucose metabolism')]
PMC4848989	4/2016	S6-PMC4848989	['at 15 and 30 min, Sugar levels were higher in the Dexamethasone plus high-fat diet (Dhf) group than the vehicle plus high-fat diet (vhf) group in the Intraperitoneal Glucose tolerance test (ipgtt).']	N/A	N/A	[('CHEBI_24870', 'ion', 18, 'sugar'), ('CHEBI_41879', 'dexamethasone', 50, 'dexamethasone'), ('CHEBI_42098', 'digoxigenin', 84, 'DHF'), ('UBERON_2001932', 'sensory canal tubular ossicle', 150, 'intraperitoneal'), ('CHEBI_17234', 'glucose', 166, 'glucose')]
PMC4848989	4/2016	S26-PMC4848989	[', Insulin resistance, and insufficient Response Of Β-Cell to Glucose stimuli.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 2, 'insulin'), ('GO_0051776', 'detection of redox state', 39, 'response of β ... cell'), ('CL_0000623', 'natural killer cell', 51, 'β-cell'), ('CHEBI_17234', 'glucose', 61, 'glucose')]
PMC4848989	4/2016	S37-PMC4848989	['Intraperitoneal Glucose tolerance test (ipgtt) and Insulin tolerance test (itt)\nsugar levels at 15 and 30 min were higher in the Dhf group than in the vhf group and at 15 min in the Dhf group than in the vsd group (figure 2a).']	N/A	N/A	[('UBERON_0007158', 'lumen of anal canal', 0, 'Intraperitoneal'), ('CHEBI_17234', 'glucose', 16, 'Glucose'), ('PR_000045358', 'insulin family protein', 51, 'Insulin'), ('CHEBI_42098', 'digoxigenin', 129, 'DHF'), ('CHEBI_42098', 'digoxigenin', 182, 'DHF')]
PMC4848989	4/2016	S38-PMC4848989	['the Glucose area under curve (auc) was larger in the Dhf group than in the vhf group (figure 2b).']	N/A	N/A	[('CHEBI_17234', 'glucose', 4, 'glucose'), ('CHEBI_42098', 'digoxigenin', 53, 'DHF')]
PMC4848989	4/2016	S39-PMC4848989	['Serum Insulin levels at 15, 30 and 60 min after Intraperitoneal Glucose injection were significantly higher in the vhf group than in the vsd group (figure 2c).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('PR_000045358', 'insulin family protein', 6, 'insulin'), ('UBERON_2001932', 'sensory canal tubular ossicle', 48, 'intraperitoneal'), ('CHEBI_17234', 'glucose', 64, 'glucose')]
PMC4848989	4/2016	S40-PMC4848989	['the Glucose level at 60 min during the itt was higher in the Dhf group than the other three groups (figure 2d).']	N/A	N/A	[('CHEBI_17234', 'glucose', 4, 'glucose'), ('CHEBI_42098', 'digoxigenin', 61, 'DHF')]
PMC4848989	4/2016	S56-PMC4848989	['Glucocorticoids can promote Gluconeogenesis in the Liver and decrease Glucose Uptake and Utilization in the Skeletal muscle and White Adipose Tissue.']	N/A	N/A	[('CHEBI_5439', 'Glutethimide', 0, 'Glucocorticoids'), ('GO_0006094', 'gluconeogenesis', 28, 'gluconeogenesis'), ('UBERON_0002107', 'liver', 51, 'liver'), ('CHEBI_17234', 'glucose', 70, 'glucose'), ('GO_0046323', 'glucose import', 70, 'glucose uptake'), ('GO_0008355', 'olfactory learning', 89, 'utilization'), ('UBERON_0004288', 'skeleton', 108, 'skeletal'), ('UBERON_0001347', 'white adipose tissue', 128, 'white adipose tissue')]
PMC4848989	4/2016	S84-PMC4848989	['Glucose injection was significantly higher in the Dhf group than in the vhf group.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'glucose'), ('CHEBI_42098', 'digoxigenin', 50, 'DHF')]
PMC4848989	4/2016	S85-PMC4848989	['the Glucose level was higher at 60 min during the itt in the Dhf group than in the other three groups.']	N/A	N/A	[('CHEBI_17234', 'glucose', 4, 'glucose'), ('CHEBI_42098', 'digoxigenin', 61, 'DHF')]
PMC4848989	4/2016	S97-PMC4848989	['in addition, Insulin Signaling is required for Insulin to act both, directly and indirectly, on Hepatic Glucose Production.']	N/A	N/A	[('GO_0031129', 'inductive cell-cell signaling', 13, 'insulin signaling'), ('PR_000045358', 'insulin family protein', 13, 'insulin'), ('PR_000045358', 'insulin family protein', 47, 'insulin'), ('UBERON_0002107', 'liver', 96, 'hepatic'), ('CHEBI_17234', 'glucose', 104, 'glucose'), ('GO_0006094', 'gluconeogenesis', 104, 'glucose production')]
PMC4848989	4/2016	S99-PMC4848989	['Insulin resistance in obesity and type 2 diabetes is characterized by fewer Insulin stimulated Glucose transport and less Metabolism in Skeletal muscle and Adipocytes.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 0, 'Insulin'), ('PR_000045358', 'insulin family protein', 76, 'insulin'), ('CHEBI_17234', 'glucose', 95, 'glucose'), ('GO_0008152', 'metabolic process', 122, 'metabolism'), ('UBERON_0004288', 'skeleton', 136, 'skeletal'), ('CL_0000136', 'fat cell', 156, 'adipocytes')]
PMC4848989	4/2016	S132-PMC4848989	['Glucose tolerance test (ipgtt) and Insulin tolerance test (itt)\nafter an 8-h fast at pd 110, Blood samples were collected at five time points: before injection and at 15, 30, 60, and 120 min after the i.p.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('PR_000045358', 'insulin family protein', 35, 'Insulin'), ('UBERON_0000178', 'blood', 93, 'blood')]
PMC4848989	4/2016	S133-PMC4848989	['injection of Glucose (2 g/kg body weight).']	N/A	N/A	[('CHEBI_17234', 'glucose', 13, 'glucose')]
PMC4848989	4/2016	S134-PMC4848989	['Plasma Glucose levels were immediately measured using the enzymatic (hexokinase) method with a Glucose assay kit.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_17234', 'glucose', 7, 'glucose'), ('CHEBI_17234', 'glucose', 95, 'glucose')]
PMC4848989	4/2016	S137-PMC4848989	['we measured blood Glucose levels before and 15, 30, 60, and 120 min after Insulin injection using methods as described above.']	N/A	N/A	[('CHEBI_17234', 'glucose', 18, 'glucose'), ('PR_000045358', 'insulin family protein', 74, 'insulin')]
PMC4865384	5/2016	S20-PMC4865384	['(4), in 1992, compared pre- and Postprandial Blood Glucose levels to fetal macrosomia in patients with Pregestational diabetes.']	N/A	N/A	[('GO_0007567', 'parturition', 32, 'postprandial'), ('UBERON_0000178', 'blood', 45, 'blood'), ('CHEBI_17234', 'glucose', 51, 'glucose'), ('GO_0007565', 'female pregnancy', 103, 'pregestational')]
PMC4865384	5/2016	S44-PMC4865384	['lower-Carbohydrate diets yielded lower Postprandial Glucose levels.']	N/A	N/A	[('CHEBI_16730', 'chloramphenicol 3-acetate', 6, 'carbohydrate'), ('GO_0007567', 'parturition', 39, 'postprandial'), ('CHEBI_17234', 'glucose', 52, 'glucose')]
PMC4865384	5/2016	S62-PMC4865384	['they used a higher percentage of more Nutrient-dense Carbohydrate using the choice (choosing healthy options in Carbohydrate energy) diet (60% Carbohydrate, 45% fat, and 15% protein) with continuous Glucose monitoring to determine mean Blood Glucose.']	N/A	N/A	[('CHEBI_33284', 'nutrient', 38, 'nutrient'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 53, 'carbohydrate'), ('CHEBI_16646', 'carbohydrate', 112, 'Carbohydrate'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 143, 'carbohydrate'), ('CHEBI_17234', 'glucose', 199, 'glucose'), ('UBERON_0000178', 'blood', 236, 'blood'), ('CHEBI_17234', 'glucose', 242, 'glucose')]
PMC4865386	5/2016	S5-PMC4865386	['participants tested their Blood Glucose four times daily.']	N/A	N/A	[('UBERON_0000178', 'blood', 26, 'blood'), ('CHEBI_17234', 'glucose', 32, 'glucose')]
PMC4865386	5/2016	S18-PMC4865386	['increased maternal Glucose levels cross the Placenta and result in increased fetal Glucose levels and augmented secretion of fetal Insulin.']	N/A	N/A	[('CHEBI_17234', 'glucose', 19, 'glucose'), ('UBERON_0001987', 'placenta', 44, 'placenta'), ('CHEBI_17234', 'glucose', 83, 'glucose'), ('PR_000045358', 'insulin family protein', 131, 'insulin')]
PMC4865386	5/2016	S20-PMC4865386	['with Plasma Glucose levels just one standard deviation (sd) above the mean for fasting, 1-hour, and 2-hour Postprandial periods, the odds ratios for infant Birth weight above the 90th percentile were 1.38 (95% ci 1.32–1.44), 1.46 (1.39–1.53), and 1.38 (1.32–1.44), respectively.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 5, 'plasma'), ('CHEBI_17234', 'glucose', 12, 'glucose'), ('GO_0007567', 'parturition', 107, 'postprandial'), ('GO_0007567', 'parturition', 156, 'birth')]
PMC4865386	5/2016	S36-PMC4865386	['one-hour ( p<0.01) and 2-hour ( p<0.001) Postprandial Blood Glucose levels were lower on the lc/hf diet than on the hc/lf (choice) diet.']	N/A	N/A	[('GO_0007567', 'parturition', 41, 'postprandial'), ('UBERON_0000178', 'blood', 54, 'blood'), ('CHEBI_17234', 'glucose', 60, 'glucose')]
PMC4865386	5/2016	S37-PMC4865386	['Glucose area under the curve (auc) was measured via a 24-hour continuous Glucose monitoring system, and 24-hour profiles were 6% lower with the lc/hf diet ( p = 0.02).']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('CHEBI_17234', 'glucose', 73, 'glucose')]
PMC4865386	5/2016	S45-PMC4865386	['potential participants were screened with a 50-g oral Glucose tolerance test (ogtt) at 24–28 weeks’ Gestation without regard to time of day or interval since their last meal (13).']	N/A	N/A	[('CHEBI_17234', 'glucose', 54, 'glucose'), ('GO_0007565', 'female pregnancy', 100, 'gestation')]
PMC4865386	5/2016	S46-PMC4865386	['women whose 1-hour screening test Plasma Glucose result was ≥135 mg/dl underwent a 100-g ogtt and were diagnosed with gdm based on the carpenter-coustan criteria (24–26).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 34, 'plasma'), ('CHEBI_17234', 'glucose', 41, 'glucose')]
PMC4865386	5/2016	S60-PMC4865386	['participants in both groups were instructed in self-Monitoring of Blood Glucose (smbg) with portable reflectance Memory meters (onetouch ultra, lifescan, milipitas, calif., or ascencia countour, bayer healthcare, whippany, n.j.).']	N/A	N/A	[('GO_0065007', 'biological regulation', 52, 'monitoring'), ('UBERON_0000178', 'blood', 66, 'blood'), ('CHEBI_17234', 'glucose', 72, 'glucose'), ('GO_0007613', 'memory', 113, 'memory')]
PMC4865386	5/2016	S62-PMC4865386	['participants were asked to bring their blood Glucose and Food logs or meter records to their Prenatal care appointments so their providers could review their results.']	N/A	N/A	[('CHEBI_17234', 'glucose', 45, 'glucose'), ('CHEBI_33290', 'food', 57, 'food'), ('GO_0007565', 'female pregnancy', 93, 'prenatal')]
PMC4865386	5/2016	S75-PMC4865386	['participants who did not complete Food logs were questioned orally about diet adherence during review of their Blood Glucose records with their care provider.']	N/A	N/A	[('CHEBI_33290', 'food', 34, 'food'), ('UBERON_0000178', 'blood', 111, 'blood'), ('CHEBI_17234', 'glucose', 117, 'glucose')]
PMC4865386	5/2016	S88-PMC4865386	['fasting blood Glucose was not significantly different between the two groups.']	N/A	N/A	[('CHEBI_17234', 'glucose', 14, 'glucose')]
PMC4865386	5/2016	S93-PMC4865386	['means and percentages of maternal characteristics by study groupmaternal characteristicslower-Carbohydrate diet group ( n = 37)usual Pregnancy diet group ( n = 31) p mean ± sd2hppbg (mg/dl)111.56 ± 14.45113.91 ± 16.180.61fasting Blood Glucose (mg/dl)90.52 ± 8.5391.97 ± 12.080.65bmi (kg/m2)33.84 ± 8.8431.80 ± 8.680.34total Pregnancy weight gain (lb)27.24 ± 16.0225.68 ±17.080.71age at Delivery (years)30.09 ± 6.1529.63 ± 5.190.74weight change from study entry to Birth (Lb)4.75 ± 6.204.41 ± 6.240.85weeks of Gestation at study entry29.17 ± 2.7830.50 ± 2.850.032weeks of Gestation at Delivery37.78 ± 1.6637.76 ± 1.740.96 percentage (%) need for Insulin therapy8.86.30.69oral Medication use:32.434.40.98before enrollment2.93.1after enrollmentincidence of induction of labor35.334.40.94incidence of primary cesarean section29.440.60.34composite maternal complications0.81\u2003none52.050.0\u2003≥147.150.0\ntables 1and2illustrate that there were no differences in individual or composite maternal comorbidities or neonatal complications between the intervention and control groups.']	N/A	N/A	[('CHEBI_16646', 'carbohydrate', 94, 'Carbohydrate'), ('GO_0007565', 'female pregnancy', 133, 'Pregnancy'), ('UBERON_0000178', 'blood', 229, 'blood'), ('CHEBI_17234', 'glucose', 235, 'glucose'), ('GO_0007565', 'female pregnancy', 324, 'pregnancy'), ('GO_0007567', 'parturition', 386, 'delivery'), ('GO_0007567', 'parturition', 464, 'birth'), ('UBERON_0000118', 'lung bud', 471, 'lb'), ('GO_0007565', 'female pregnancy', 509, 'gestation'), ('GO_0007565', 'female pregnancy', 571, 'gestation'), ('GO_0008206', 'bile acid metabolic process', 584, 'delivery37'), ('PR_000045358', 'insulin family protein', 645, 'insulin'), ('CHEBI_60211', 'compound Z', 675, 'medication')]
PMC4865386	5/2016	S116-PMC4865386	['there were significantly different results between the two study sites; site b had a lower mean postprandial blood Glucose level and a lower composite rate of infant complications.']	N/A	N/A	[('CHEBI_17234', 'glucose', 115, 'glucose')]
PMC4865387	5/2016	S3-PMC4865387	['in Pregnancy, a prevailing Maternal Metabolic Adaptation is the shift in Glucose Metabolism from Insulin sensitivity to Insulin resistance, exemplified by higher circulating Lipids, heightened postprandial Glucose, and increased Β-Cell demand/response (1,2).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 3, 'pregnancy'), ('GO_0007618', 'mating', 27, 'maternal'), ('GO_0051238', 'sequestering of metal ion', 36, 'metabolic adaptation'), ('CHEBI_17234', 'glucose', 73, 'glucose'), ('GO_0006006', 'glucose metabolic process', 73, 'glucose metabolism'), ('PR_000045358', 'insulin family protein', 97, 'insulin'), ('PR_000045358', 'insulin family protein', 120, 'insulin'), ('CHEBI_18059', 'lipid', 174, 'lipids'), ('CHEBI_17234', 'glucose', 206, 'glucose'), ('CL_0000623', 'natural killer cell', 229, 'β-cell')]
PMC4865387	5/2016	S78-PMC4865387	['it is now understood that maternal Glucose, Lipids (Triglycerides, ffas), and Amino Acids are all potent fuels for fetal growth.']	N/A	N/A	[('CHEBI_17234', 'glucose', 35, 'glucose'), ('CHEBI_18059', 'lipid', 44, 'lipids'), ('CHEBI_17855', 'triglyceride', 52, 'triglycerides'), ('CHEBI_33867', 'idonates', 78, 'amino acids')]
PMC4865387	5/2016	S85-PMC4865387	['Insulin is a hormone with many functions beyond Glucose Control.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 0, 'Insulin'), ('CHEBI_17234', 'glucose', 48, 'glucose'), ('GO_0046323', 'glucose import', 48, 'glucose control')]
PMC4865392	5/2016	S31-PMC4865392	['self-monitoring of Blood Glucose records were downloaded at each session and discussed.']	N/A	N/A	[('UBERON_0000178', 'blood', 19, 'blood'), ('CHEBI_17234', 'glucose', 25, 'glucose')]
PMC4865392	5/2016	S39-PMC4865392	['ada, american diabetes association; hands, health access nurturing development services; pp, Postpartum; smbg, self-monitoring of Blood Glucose; u/s, ultrasonography.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 93, 'postpartum'), ('UBERON_0000178', 'blood', 130, 'blood'), ('CHEBI_17234', 'glucose', 136, 'glucose')]
PMC4865392	5/2016	S79-PMC4865392	['all patients in the intervention group received education from a nurse educator regarding the risk factors for gdm and general nutrition and exercise in Pregnancy, including Carbohydrate awareness and the Metabolic benefits of exercise (e.g., improvement of Glucose utilization and decrease in Hepatic Glucose output) (17).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 153, 'pregnancy'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 174, 'carbohydrate'), ('GO_0008152', 'metabolic process', 205, 'metabolic'), ('CHEBI_17234', 'glucose', 258, 'glucose'), ('UBERON_0002107', 'liver', 294, 'hepatic'), ('CHEBI_17234', 'glucose', 302, 'glucose')]
PMC4882683	5/2016	S39-PMC4882683	['women underwent an oral Glucose tolerance test (ogtt) at study entry (<20 weeks Gestation).']	N/A	N/A	[('CHEBI_17234', 'glucose', 24, 'glucose'), ('GO_0007565', 'female pregnancy', 80, 'gestation')]
PMC4892656	6/2016	S3-PMC4892656	['at 2½ years of age (Adulthood), Plasma Metabolite profiles during fasting, Glucose, Insulin and Propionate (in Fed and fasted states) tolerance tests were examined.']	N/A	N/A	[('UBERON_0000113', 'post-juvenile adult stage', 20, 'adulthood'), ('UBERON_0001969', 'blood plasma', 32, 'plasma'), ('CHEBI_39382', 'flufenoxuron', 39, 'metabolite'), ('CHEBI_17234', 'glucose', 75, 'glucose'), ('PR_000045358', 'insulin family protein', 84, 'insulin'), ('CHEBI_17272', 'propionate', 96, 'propionate'), ('GO_0007631', 'feeding behavior', 111, 'fed')]
PMC4892656	6/2016	S20-PMC4892656	['in sprague dawley Rats, a high-fat cafeteria diet for 5-week before Mating and throughout Gestation and Lactation led to adiposity, Glucose intolerance, hyperlipidaemia and reduced Hypothalamic Neuropeptide Y and increased proopiomelanocortin mrna Expression in offspring, and this was amplified by Postnatal Overnutrition [9].']	N/A	N/A	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 18, 'rats'), ('GO_0007618', 'mating', 68, 'mating'), ('GO_0007565', 'female pregnancy', 90, 'gestation'), ('GO_0007595', 'lactation', 104, 'lactation'), ('CHEBI_17234', 'glucose', 132, 'glucose'), ('UBERON_0001898', 'hypothalamus', 181, 'hypothalamic'), ('PR_000011469', 'high affinity nerve growth factor receptor', 194, 'neuropeptide Y'), ('GO_0010467', 'gene expression', 248, 'expression'), ('GO_0007567', 'parturition', 299, 'postnatal'), ('GO_0006704', 'glucocorticoid biosynthetic process', 309, 'overnutrition')]
PMC4892656	6/2016	S22-PMC4892656	['in Rats, pups weaned to high-multivitamin or high-Folate diets were prevented from developing the obesogenic phenotype (higher Food Intake, body weight and glucose response to a Glucose load) induced by maternal exposure to a high-multivitamin diet during Pregnancy [10].']	N/A	N/A	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 3, 'rats'), ('CHEBI_30863', '5-azaorotic acid', 50, 'folate'), ('CHEBI_33290', 'food', 127, 'food'), ('GO_0007631', 'feeding behavior', 127, 'food intake'), ('CHEBI_17234', 'glucose', 178, 'glucose'), ('GO_0007565', 'female pregnancy', 256, 'pregnancy')]
PMC4892656	6/2016	S55-PMC4892656	['in vivo tolerance tests with acute intravenous bolus injections of Glucose (conducted in the morning prior to Feeding the morning meal in overnight fasted Sheep; gtt), Insulin (conducted at mid-day appr.']	N/A	N/A	[('CHEBI_17234', 'glucose', 67, 'glucose'), ('GO_0007631', 'feeding behavior', 110, 'feeding'), ('NCBITaxon_10088', 'Mus <genus>', 155, 'sheep'), ('PR_000045358', 'insulin family protein', 168, 'insulin')]
PMC4892656	6/2016	S57-PMC4892656	['laboratory analyses\nGlucose, non-esterified Fatty Acids (nefa), Triglycerides (tg), Blood Urea nitrogen (bun), creatinine, lactate, Β-Hydroxy-butyrate (bohb), γ-glutamyl transferase (ggt) and Cholesterol levels were determined in Plasma samples as previously described [4,5].']	N/A	N/A	[('CHEBI_17234', 'glucose', 20, 'Glucose'), ('CHEBI_35366', 'fatty acid', 44, 'fatty acids'), ('CHEBI_17855', 'triglyceride', 64, 'triglycerides'), ('UBERON_0000178', 'blood', 84, 'blood'), ('CHEBI_16199', 'urea', 90, 'urea'), ('CHEBI_43141', '3-hydroxypropoxy group', 132, 'β-hydroxy'), ('CHEBI_16113', 'cholesterol', 192, 'cholesterol'), ('UBERON_0001969', 'blood plasma', 230, 'plasma')]
PMC4892656	6/2016	S124-PMC4892656	['(a) Glucose (b) Glucose (c) lactate (d) lactate (e) creatinine (f) creatinine.']	N/A	N/A	[('CHEBI_17234', 'glucose', 4, 'glucose'), ('CHEBI_17234', 'glucose', 16, 'glucose')]
PMC4892656	6/2016	S139-PMC4892656	['female Sheep had higher Plasma levels of Lactate (gtt, ptt-fast), bun (itt), creatinine (itt), Cholesterol (in all except gtt), tg (in all tests), nefa (gtt, ptt-fast) Glucose (in all except itt), bohb (gtt, ptt-fast) and ggt (itt, ptt-fast and -Fed) than in males ( p< 0.05 for all with or without ec).']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 7, 'sheep'), ('UBERON_0001969', 'blood plasma', 24, 'plasma'), ('CHEBI_24996', 'lactate', 41, 'lactate'), ('CHEBI_16113', 'cholesterol', 95, 'cholesterol'), ('CHEBI_17234', 'glucose', 168, 'glucose'), ('GO_0007631', 'feeding behavior', 246, 'fed')]
PMC4892656	6/2016	S219-PMC4892656	['(a) Glucose (b) lactate (c) creatinine (d) nefa (non-esterified Fatty Acids) (e) bohb (β-Hydroxy-Butyrate).']	N/A	N/A	[('CHEBI_17234', 'glucose', 4, 'glucose'), ('CHEBI_35366', 'fatty acid', 64, 'fatty acids'), ('CHEBI_15361', 'pyruvate', 89, 'hydroxy-butyrate')]
PMC4892656	6/2016	S224-PMC4892656	['(a) area under the curve (auc) for Plasma Glucose (auc Glucose; Glucose tolerance test) (b) area over the curve (aoc) for Plasma Glucose (Insulin tolerance test) (c) auc for Plasma Glucose (Propionate tolerance test after 68 hours of fasting) (d) auc for Plasma Glucose (Propionate tolerance test in the Fed state).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 35, 'plasma'), ('CHEBI_17234', 'glucose', 42, 'glucose'), ('CHEBI_17234', 'glucose', 55, 'glucose'), ('CHEBI_17234', 'glucose', 64, 'glucose'), ('UBERON_0001969', 'blood plasma', 122, 'plasma'), ('CHEBI_17234', 'glucose', 129, 'glucose'), ('PR_000045358', 'insulin family protein', 138, 'insulin'), ('UBERON_0001969', 'blood plasma', 174, 'plasma'), ('CHEBI_17234', 'glucose', 181, 'glucose'), ('CHEBI_17272', 'propionate', 190, 'propionate'), ('UBERON_0001969', 'blood plasma', 255, 'plasma'), ('CHEBI_17234', 'glucose', 262, 'glucose'), ('CHEBI_17272', 'propionate', 271, 'propionate'), ('GO_0007631', 'feeding behavior', 304, 'fed')]
PMC4892656	6/2016	S228-PMC4892656	['caption (supplementary-material): s4 fig\n\nchanges in Plasma Metabolites during Glucose (panels to the left; a, c, e) and Insulin (panels to the right; b, d, f) tolerance tests .']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 53, 'plasma'), ('CHEBI_25212', 'metabolite', 60, 'metabolites'), ('CHEBI_17234', 'glucose', 79, 'glucose'), ('PR_000045358', 'insulin family protein', 121, 'insulin')]
PMC4892656	6/2016	S229-PMC4892656	['(a) Glucose (b) Glucose (c) creatinine (d) creatinine (e) bohb (Β-Hydroxy-Butyrate) (f) bohb.']	N/A	N/A	[('CHEBI_17234', 'glucose', 4, 'glucose'), ('CHEBI_17234', 'glucose', 16, 'glucose'), ('CHEBI_16723', '4-methylthio-2-oxobutanoate', 64, 'β-hydroxy-butyrate')]
PMC4896250	4/2016	S2364-PMC4896250	['Blood tests on admission showed hemoglobin 16.1 g/dl, total Leukocyte count 5265 /ul (Neutrophils 78.7%, Lymphocytes 11.2%, Eosinophils 4.9%), ast 47 iu/l, alt 49 iu/l, Serum Bilirubin 0.55 mg/dl, serum creatinine 0.91 mg/dl and Blood Glucose 95 mg/dl.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('CL_0000738', 'leukocyte', 60, 'leukocyte'), ('CL_0000775', 'neutrophil', 86, 'neutrophils'), ('CL_0000542', 'lymphocyte', 105, 'lymphocytes'), ('CL_0000771', 'eosinophil', 124, 'eosinophils'), ('UBERON_0001977', 'blood serum', 169, 'serum'), ('CHEBI_16990', 'bilirubin IXalpha', 175, 'bilirubin'), ('UBERON_0000178', 'blood', 229, 'blood'), ('CHEBI_17234', 'glucose', 235, 'glucose')]
PMC4905827	1/2016	S38-PMC4905827	['Blood samples were collected from the Jugular Veins of 60 Cows (mild: 12, moderate: 20 and severe: 28) at the first examination and were evaluated for the Blood Urea nitrogen (bun), aspartate transaminase (ast), alanine aminotransferase (alt), alkaline phosphatase (alp), γ-glutamyl transpeptidase (γ-gtp), total Bilirubin (t-bil), Glucose (glu), Triglyceride (tg), non-esterified Fatty Acids (nefa), total Cholesterol (t-Cho) and total protein (tp) levels.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('UBERON_0034981', 'superior bulb of internal jugular vein', 38, 'jugular veins'), ('NCBITaxon_33208', 'Metazoa', 58, 'cows'), ('UBERON_0000178', 'blood', 155, 'blood'), ('CHEBI_16199', 'urea', 161, 'urea'), ('CHEBI_16990', 'bilirubin IXalpha', 313, 'bilirubin'), ('UBERON_0004058', 'biliary ductule', 313, 'bilirubin'), ('CHEBI_17234', 'glucose', 332, 'glucose'), ('CHEBI_17855', 'triglyceride', 347, 'triglyceride'), ('CHEBI_35366', 'fatty acid', 381, 'fatty acids'), ('CHEBI_16113', 'cholesterol', 407, 'cholesterol'), ('CHEBI_33290', 'food', 422, 'Cho')]
PMC4910255	6/2016	S164-PMC4910255	['[47]Waist: Fefol\u2009+\u2009vita a, 51.27\xa0cm; Mmn, 51.22\xa0cmsystolic: Fefol\u2009+\u2009vit a, 95.2\xa0mmhg; Mmn, 95.5\xa0mmhg; calculated difference, 0.29\xa0mmhg (95\xa0% ci, –0.65 to 1.23)ddiastolic: Fefol\u2009+\u2009vit a, 63.9\xa0mmhg; Mmn, 64.4\xa0mmhg; calculated difference, 0.56\xa0mmhg (95\xa0% ci, –0.38 to 1.50)dnon-fasting Glucose: Fefol\u2009+\u2009vit a, 3.91\xa0mmol/l; mmn, 3.86\xa0mmol/l; ldl: Fefol\u2009+\u2009vit a, 1.89\xa0mmol/l; mmn, 1.84\xa0mmol/l; hdl: Fefol\u2009+\u2009vit a, 0.72\xa0mmol/l; mmn, 0.70\xa0mmol/l; at risk for Metabolic syndrome: Fefol\u2009+\u2009vit a, 12.2\xa0%; mmn, 11.9\xa0%\nresults are unadjusted differences unless otherwise stated.']	N/A	N/A	[('UBERON_0000088', 'trophoblast', 4, 'Waist'), ('CHEBI_4998', 'fenarimol', 11, 'FeFol'), ('UBERON_0003109', 'parapophysis', 37, 'MMN'), ('CHEBI_4998', 'fenarimol', 60, 'FeFol'), ('UBERON_0003109', 'parapophysis', 86, 'MMN'), ('CHEBI_4998', 'fenarimol', 171, 'FeFol'), ('UBERON_0003109', 'parapophysis', 197, 'MMN'), ('CHEBI_17234', 'glucose', 283, 'glucose'), ('CHEBI_4998', 'fenarimol', 292, 'FeFol'), ('CHEBI_4998', 'fenarimol', 343, 'FeFol'), ('CHEBI_4998', 'fenarimol', 394, 'FeFol'), ('GO_0008152', 'metabolic process', 452, 'metabolic'), ('CHEBI_4998', 'fenarimol', 472, 'FeFol')]
PMC4919374	6/2016	S93-PMC4919374	['patients with t1dm have insufficient Insulin, causing higher maternal Glucose levels.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 37, 'insulin'), ('CHEBI_17234', 'glucose', 70, 'glucose')]
PMC4919374	6/2016	S94-PMC4919374	['the excess Glucose from the maternal circulation results in elevated Glucose levels in the fetal circulation, which in turn causes excess fetal Adipose growth and increases the risk for large for Gestational age (lga) or macrosomia in infants, especially when the mother is obese [50].']	N/A	N/A	[('CHEBI_17234', 'glucose', 11, 'glucose'), ('CHEBI_17234', 'glucose', 69, 'glucose'), ('UBERON_2000251', 'adipose fin', 144, 'adipose'), ('GO_0007565', 'female pregnancy', 196, 'gestational')]
PMC4919374	6/2016	S95-PMC4919374	['in addition, excessive fuel to the fetus results in increased risk of obesity [51] and impaired Glucose tolerance [52,53] in children of diabetic mothers.']	N/A	N/A	[('CHEBI_17234', 'glucose', 96, 'glucose')]
PMC4919374	6/2016	S98-PMC4919374	['csii necessitates commitment to frequent Glucose monitoring, Carbohydrate counting, and rapid implementation of sick day rules in the setting of pump malfunction or illness.']	N/A	N/A	[('CHEBI_17234', 'glucose', 41, 'glucose'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 61, 'carbohydrate')]
PMC4919374	6/2016	S117-PMC4919374	['hyperglycemia\ndka occurs at lower Glucose levels because Pregnancy is a Ketosis-prone state [68,69].']	N/A	N/A	[('CHEBI_17234', 'glucose', 34, 'glucose'), ('GO_0007565', 'female pregnancy', 57, 'pregnancy'), ('GO_0001818', 'negative regulation of cytokine production', 72, 'ketosis')]
PMC4919374	6/2016	S123-PMC4919374	['neonatal macrosomia, hypoglycemia, and Respiratory distress can be decreased when average antepartum Glucose levels are <110\xa0mg/dl [61].']	N/A	N/A	[('UBERON_0001004', 'respiratory system', 39, 'respiratory'), ('CHEBI_17234', 'glucose', 101, 'glucose')]
PMC4933662	4/2016	S135-PMC4933662	['furthermore, Rats considered small for their Gestational age (deng et\xa0al .,2014) and Humans with low Birth weight (ozanne et\xa0al .,2005) can also develop Insulin resistance and Glucose intolerance.']	N/A	N/A	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 13, 'rats'), ('GO_0007565', 'female pregnancy', 45, 'gestational'), ('NCBITaxon_9606', 'Homo sapiens', 85, 'humans'), ('GO_0007567', 'parturition', 101, 'birth'), ('PR_000045358', 'insulin family protein', 153, 'insulin'), ('CHEBI_17234', 'glucose', 176, 'glucose')]
PMC4933662	4/2016	S173-PMC4933662	['the cells derived from active Humans displayed an improved ability to uptake Glucose and were somewhat protected from Palmitate‐induced Insulin resistance vs. cells isolated from sedentary Humans (green et\xa0al .,2013; valencia & spangenburg,2013).']	N/A	N/A	[('NCBITaxon_9606', 'Homo sapiens', 30, 'humans'), ('CHEBI_17234', 'glucose', 77, 'glucose'), ('CHEBI_7896', 'hexadecanoate', 118, 'palmitate'), ('PR_000045358', 'insulin family protein', 136, 'insulin'), ('NCBITaxon_9606', 'Homo sapiens', 189, 'humans')]
PMC4934634	11/2015	S117-PMC4934634	['after nine weeks of supplementation of Vitamin D or placebo, the Vitamin D supplemented group had reductions in Serum Insulin, fasting Plasma Glucose levels, high sensitivity c-Reactive Protein (Hs-Crp), and Blood pressure compared to the placebo group.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('UBERON_0001977', 'blood serum', 112, 'serum'), ('PR_000045358', 'insulin family protein', 118, 'insulin'), ('UBERON_0001969', 'blood plasma', 135, 'plasma'), ('CHEBI_17234', 'glucose', 142, 'glucose'), ('PR_000004806', 'bromodomain-containing protein 2', 176, '-reactive protein'), ('PR_000006060', 'CWF19-like protein 1', 195, 'hs-CRP'), ('UBERON_0000178', 'blood', 208, 'blood')]
PMC4935697	7/2016	S59-PMC4935697	['this susceptibility to Glucose intolerance is exacerbated by subsequent catch-up growth in early childhood, which elevates adiposity and promotes Insulin resistance (50–52).']	N/A	N/A	[('CHEBI_17234', 'glucose', 23, 'glucose'), ('PR_000045358', 'insulin family protein', 146, 'insulin')]
PMC4935697	7/2016	S91-PMC4935697	['caption (fig): figure 5\n\nassociations between Plasma Glucose levels 120\u2009min after administration of an oral Glucose load, a marker of Glucose intolerance, with height adjusted for weight, and weight adjusted for height in an urban indian population at the age of 21\u2009years .']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 46, 'plasma'), ('CHEBI_17234', 'glucose', 53, 'glucose'), ('CHEBI_17234', 'glucose', 108, 'glucose'), ('CHEBI_17234', 'glucose', 134, 'glucose')]
PMC4935697	7/2016	S306-PMC4935697	['in addition, they have a reduced capacity to tolerate this load, given their low average Birth weight and their reduced ability to clear Glucose, deriving from the lower lean mass.']	N/A	N/A	[('GO_0007567', 'parturition', 89, 'birth'), ('CHEBI_17234', 'glucose', 137, 'glucose')]
PMC4939564	8/2015	S97-PMC4939564	['offspring whose mothers had been exposed to famine in the second or third trimester had reduced Glucose tolerance, shown by increased two-hour Plasma Glucose concentrations [52].']	N/A	N/A	[('CHEBI_17234', 'glucose', 96, 'glucose'), ('UBERON_0001969', 'blood plasma', 143, 'plasma'), ('CHEBI_17234', 'glucose', 150, 'glucose')]
PMC4939564	8/2015	S98-PMC4939564	['those Individuals who had smaller Birth weights had increased two-hour Plasma Glucose concentrations.']	N/A	N/A	[('NCBITaxon_1', 'root', 6, 'individuals'), ('GO_0007567', 'parturition', 34, 'birth'), ('UBERON_0001969', 'blood plasma', 71, 'plasma'), ('CHEBI_17234', 'glucose', 78, 'glucose')]
PMC4939564	8/2015	S118-PMC4939564	['during fasting, circulating Glucose levels fall, leading to a decrease in Insulin secretion.']	N/A	N/A	[('CHEBI_17234', 'glucose', 28, 'glucose'), ('PR_000045358', 'insulin family protein', 74, 'insulin')]
PMC4939564	8/2015	S121-PMC4939564	['Oxidation Of Fatty Acids generates Ketones that can be used as fuel by Skeletal and Cardiac Muscle, Liver, Kidney, and Adipose Tissue, thus sparing Glucose for continued utilization by Brain and Erythrocytes [64].']	N/A	N/A	[('GO_0035193', 'larval central nervous system remodeling', 0, 'Oxidation of fatty acids'), ('CHEBI_35366', 'fatty acid', 13, 'fatty acids'), ('CHEBI_17087', 'ketone', 35, 'ketones'), ('UBERON_0001442', 'skeleton of manus', 71, 'skeletal ...'), ('UBERON_0001133', 'cardiac muscle tissue', 84, 'cardiac muscle'), ('UBERON_0002107', 'liver', 100, 'liver'), ('UBERON_0002113', 'kidney', 107, 'kidney'), ('UBERON_0001013', 'adipose tissue', 119, 'adipose tissue'), ('CHEBI_17234', 'glucose', 148, 'glucose'), ('UBERON_0000955', 'brain', 185, 'brain'), ('CL_0000232', 'erythrocyte', 195, 'erythrocytes')]
PMC4939564	8/2015	S180-PMC4939564	['300 g Cho/d (50%)1200 kcal improved (randomized) Glucose; elevated Ketonesknopp 1991 [91]6 overweight gdm (randomized)1600–1800 (30%–33% restriction) vs .']	N/A	N/A	[('CHEBI_17883', 'hydrogen chloride', 6, 'CHO'), ('CHEBI_17234', 'glucose', 49, 'glucose'), ('CHEBI_74960', 'homoeriodictyol', 67, 'ketonesKnopp')]
PMC4939564	8/2015	S182-PMC4939564	['300 g Cho/d (50%)1600–1800 kcal restriction improved Glucose and trig with no marked ketonuriaalgert 1985 [94]22 obese (non-randomized)1700–1800 kcal; 212–225 g cho/d (50%–60%)lower weight gain, higher; mean Birth weight, no ketonuriamagee 1990 [92]12 obese (randomized)1200 kcal (50% restriction) vs .']	N/A	N/A	[('CHEBI_17883', 'hydrogen chloride', 6, 'CHO'), ('CHEBI_17234', 'glucose', 53, 'glucose'), ('GO_0007567', 'parturition', 208, 'birth')]
PMC4939564	8/2015	S184-PMC4939564	['300 g Cho/d) (50%)1.200 kcal lowered mean Glucose, no change in fasting Plasma Glucose, increased ketonemiarae 2000 [93]66 intervention vs .']	N/A	N/A	[('CHEBI_17883', 'hydrogen chloride', 6, 'CHO'), ('CHEBI_17234', 'glucose', 42, 'glucose'), ('UBERON_0001969', 'blood plasma', 72, 'plasma'), ('CHEBI_17234', 'glucose', 79, 'glucose')]
PMC4944979	7/2016	S52-PMC4944979	['Tissue was immersed in low-Glucose (1.0 g/l) dubelcco’s modified eagle’s Serum (dmem) supplemented with Msc growth factors (mscgm;lonza, walkersville, md, usa).']	N/A	N/A	[('UBERON_0000479', 'tissue', 0, 'Tissue'), ('CHEBI_17234', 'glucose', 27, 'glucose'), ('UBERON_0001977', 'blood serum', 73, 'Serum'), ('CL_0000186', 'myofibroblast cell', 104, 'MSC')]
PMC4944979	7/2016	S59-PMC4944979	['briefly, on day 0 growth media was replaced with Adipogenic induction media (aim) consisting of low-Glucose dmem supplemented with 5% fetal Bovine Serum (fbs), 0.01%-strep, 1.0 um Dexamethasone (Dex), 0.2 mm Indomethasone (indo), and 170 pm Insulin [14].']	N/A	N/A	[('GO_0060612', 'adipose tissue development', 49, 'adipogenic'), ('CHEBI_17234', 'glucose', 100, 'glucose'), ('NCBITaxon_33208', 'Metazoa', 140, 'bovine'), ('UBERON_0001977', 'blood serum', 147, 'serum'), ('CHEBI_41879', 'dexamethasone', 180, 'dexamethasone'), ('CHEBI_4450', 'desmopressin', 195, 'DEX'), ('CHEBI_36823', 'pseudohalo group', 208, 'indomethasone'), ('PR_000045358', 'insulin family protein', 241, 'insulin')]
PMC4944979	7/2016	S60-PMC4944979	['after 3 days of aim, media was changed to Adipogenic maintenance media (amm) consisting of low-Glucose dmem, 5% fbs, 10 units/ml:10 ug/ml Pen:strep, and 170 nm Insulin and incubated for 3 days.']	N/A	N/A	[('GO_0060612', 'adipose tissue development', 42, 'adipogenic'), ('CHEBI_17234', 'glucose', 95, 'glucose'), ('PR_000012527', 'Na(+)/H(+) exchange regulatory cofactor NHE-RF4', 138, 'PEN'), ('PR_000045358', 'insulin family protein', 160, 'insulin')]
PMC4946587	7/2016	S32-PMC4946587	['it leads to Glucose Uptake and Consumption by body Tissues and decreases Protein Breakdown.']	N/A	N/A	[('CHEBI_17234', 'glucose', 12, 'glucose'), ('GO_0006099', 'tricarboxylic acid cycle', 12, 'glucose uptake ... consumption'), ('UBERON_0000479', 'tissue', 51, 'tissues'), ('GO_0030163', 'protein catabolic process', 73, 'protein breakdown')]
PMC4949006	7/2016	S184-PMC4949006	['Foods with a high-gi value cause a big rise in Blood Glucose, and Foods with a low-gi value cause a smaller rise.']	N/A	N/A	[('CHEBI_33290', 'food', 0, 'Foods'), ('UBERON_0000178', 'blood', 47, 'blood'), ('CHEBI_17234', 'glucose', 53, 'glucose'), ('CHEBI_33290', 'food', 66, 'foods')]
PMC4954778	7/2016	S4-PMC4954778	['Glucose response to a Glucose load was measured at 18 weeks post-weaning.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('CHEBI_17234', 'glucose', 22, 'glucose')]
PMC4954778	7/2016	S6-PMC4954778	['results\nhv or hfol pup diets increased Brain and Plasma Folate concentrations and prevented the increase in Food Intake (5%, p=0.03), body weight (8%, p=0.0006) and Glucose response to a Glucose load (36%, p=0.02) found in those Fed the rv diet.']	N/A	N/A	[('UBERON_0000955', 'brain', 39, 'brain'), ('UBERON_0001969', 'blood plasma', 49, 'plasma'), ('CHEBI_30863', '5-azaorotic acid', 56, 'folate'), ('CHEBI_33290', 'food', 108, 'food'), ('GO_0007631', 'feeding behavior', 108, 'food intake'), ('CHEBI_17234', 'glucose', 165, 'glucose'), ('CHEBI_17234', 'glucose', 187, 'glucose'), ('GO_0007631', 'feeding behavior', 229, 'fed')]
PMC4954778	7/2016	S37-PMC4954778	['Food intake, weight gain and Oral Glucose tolerance test\nfigure 1boutlines the study protocol.']	N/A	N/A	[('CHEBI_33290', 'food', 0, 'Food'), ('UBERON_0000978', 'leg', 29, 'Oral'), ('CHEBI_17234', 'glucose', 34, 'Glucose')]
PMC4954778	7/2016	S40-PMC4954778	['Glucose response to Glucose gavage (0.375 g Glucose ml−1, 5 g of Glucose per kg body weight) was measured at 18 weeks post-weaning.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('CHEBI_17234', 'glucose', 20, 'glucose'), ('CHEBI_17234', 'glucose', 44, 'glucose'), ('CHEBI_17234', 'glucose', 65, 'glucose')]
PMC4954778	7/2016	S41-PMC4954778	['the Rats were fasted overnight for 10 h before Glucose gavage.']	N/A	N/A	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 4, 'rats'), ('CHEBI_17234', 'glucose', 47, 'glucose')]
PMC4954778	7/2016	S42-PMC4954778	['a Blood sample was withdrawn from the Tail Vein and baseline Glucose was immediately assayed using a commercial Glucometer (medisense precision xtra, abbott laboratories, abbott park, il, usa).']	N/A	N/A	[('UBERON_0000178', 'blood', 2, 'blood'), ('UBERON_0003481', 'tail vein', 38, 'tail vein'), ('CHEBI_17234', 'glucose', 61, 'glucose'), ('CHEBI_24321', 'glutamo group', 112, 'glucometer')]
PMC4954778	7/2016	S43-PMC4954778	['upon the Glucose gavage, Blood Glucose concentrations were determined 15 and 60 min later and the incremental area under the curve (iauc) was calculated.']	N/A	N/A	[('CHEBI_17234', 'glucose', 9, 'glucose'), ('UBERON_0000178', 'blood', 25, 'blood'), ('CHEBI_17234', 'glucose', 31, 'glucose')]
PMC4954778	7/2016	S66-PMC4954778	['the means at each time point and for Hypothalamic Gene Expression, Folate status and Glucose response were compared by one-way analysis of variance using the proc glm followed by a tukey’s post-hoc test.']	N/A	N/A	[('UBERON_0001898', 'hypothalamus', 37, 'hypothalamic'), ('GO_0010467', 'gene expression', 50, 'gene expression'), ('SO_0000704', 'gene', 50, 'gene'), ('CHEBI_30863', '5-azaorotic acid', 67, 'folate'), ('CHEBI_17234', 'glucose', 85, 'glucose')]
PMC4954778	7/2016	S69-PMC4954778	['results\n\nFood intake, weight gain and Glucose response\nthere was no difference in body weight at Birth and weaning between the offspring Born to dams on the hv diet compared to those Born to dams on a rv diet.']	N/A	N/A	[('CHEBI_33290', 'food', 9, 'Food'), ('CHEBI_17234', 'glucose', 38, 'Glucose'), ('GO_0007567', 'parturition', 97, 'birth'), ('GO_0007567', 'parturition', 137, 'born'), ('GO_0007567', 'parturition', 183, 'born')]
PMC4954778	7/2016	S70-PMC4954778	['male offspring from the hv dams weaned to the rv diet had 5% higher 72 h Food Intake (diet: p=0.03, time: p<0.0001, diet*time interaction: p=0.4), 8% higher weight gain (diet: p=0.0006, time: p<0.0001, diet*time interaction: p=0.3) and 36% higher Glucose response to Glucose gavage (p=0.02) compared to those from the rv dams at 29 weeks post-weaning (figure 2,3,4).']	N/A	N/A	[('CHEBI_33290', 'food', 73, 'food'), ('GO_0007631', 'feeding behavior', 73, 'food intake'), ('CHEBI_17234', 'glucose', 247, 'glucose'), ('CHEBI_17234', 'glucose', 267, 'glucose')]
PMC4974775	8/2016	S48-PMC4974775	['session and content is based on healthy diet, exercise, healthy lifestyle, and Blood Glucose level monitoring.']	N/A	N/A	[('UBERON_0000178', 'blood', 79, 'blood'), ('CHEBI_17234', 'glucose', 85, 'glucose')]
PMC4974775	8/2016	S50-PMC4974775	['questionnaire\nthe questionnaire included health questionnaires developed/adapted by the authors and used in previous studies of australian women [25], which included demographic information, health, knowledge of gdm, knowledge of testing blood Glucose level, knowledge of Food Choice and self-managing gdm.']	N/A	N/A	[('CHEBI_17234', 'glucose', 244, 'glucose'), ('CHEBI_33290', 'food', 272, 'food'), ('GO_0009407', 'toxin catabolic process', 272, 'food choice')]
PMC4974775	8/2016	S73-PMC4974775	['the four modules covered: (1) Healthy Food choices, (2) healthy habits/healthy lifestyle, (3) emotions, family and Food, and (4) testing Blood Glucose level.']	N/A	N/A	[('GO_0010453', 'regulation of cell fate commitment', 30, 'healthy'), ('CHEBI_33290', 'food', 38, 'food'), ('CHEBI_33290', 'food', 115, 'food'), ('UBERON_0000178', 'blood', 137, 'blood'), ('CHEBI_17234', 'glucose', 143, 'glucose')]
PMC4974775	8/2016	S121-PMC4974775	['most participants in both groups had an excellent understanding of fruits and vegetables (98.2\xa0% and 98.3\xa0%), and the majority of participants in both groups understood how exercise in gdm helps to Control blood Glucose and improve baby’s health (98.2\xa0% and 98.3\xa0%).']	N/A	N/A	[('GO_0065007', 'biological regulation', 198, 'control'), ('CHEBI_17234', 'glucose', 212, 'glucose')]
PMC4974775	8/2016	S126-PMC4974775	['a normal 2\xa0h post-prandial (after meals) Blood Glucose level was also reported correctly in both groups (91.1\xa0% and 90\xa0%).']	N/A	N/A	[('UBERON_0000178', 'blood', 41, 'blood'), ('CHEBI_17234', 'glucose', 47, 'glucose')]
PMC4974775	8/2016	S127-PMC4974775	['the majority of women in both groups knew what they needed to do if their Blood Glucose level was high on one occasion (80.4\xa0% and 80\xa0%) and if it was high in two occasions in one week (60.7\xa0% and 60\xa0%).']	N/A	N/A	[('UBERON_0000178', 'blood', 74, 'blood'), ('CHEBI_17234', 'glucose', 80, 'glucose')]
PMC4974775	8/2016	S128-PMC4974775	['both groups had a good understanding of testing blood Glucose level if they were sick (94.6\xa0% and 95\xa0%) (table\xa03).']	N/A	N/A	[('CHEBI_17234', 'glucose', 54, 'glucose')]
PMC4974775	8/2016	S129-PMC4974775	['significant differences were reported in “time of testing blood Glucose level” p \u2009=\u20090.026 as more women in the control group (86.7\xa0%) reported correct answers compared to women in the intervention group (69.6\xa0%).']	N/A	N/A	[('CHEBI_17234', 'glucose', 64, 'glucose')]
PMC4974775	8/2016	S134-PMC4974775	['caption (table-wrap): table 4\n\nmanagement of Gestational diabetes mellitusgroups p valueaintervention n (%)control n (%)you should check your Blood Glucose levelsᅟ- correct54 (96.4)58 (96.7)0.944ᅟ- incorrect2 (3.6)2 (3.3)Controlling your Blood Glucose levels:ᅟ- correct49 (87.5)52(86.7)0.894ᅟ- incorrect7 (12.5)8(13.3)if there is a social occasion, such as a party, you should:ᅟ- correct40 (71.4)51 (85)0.076ᅟ- incorrect16 (28.6)9 (15)when your Blood Glucose levels are high:ᅟ- correct47 (83.9)51 (85)0.873ᅟ- incorrect9 (16.1)9 (15)to Control Blood Glucose effectively you shouldᅟ- correct35 (62.5)44 (73.3)0.211ᅟ- incorrect21 (37.5)16 (26.7)gdm can be Controlled by:ᅟ- correct48 (85.7)58 (96.7)0.036bᅟ- incorrect8 (14.3)2 (3.3)when you are hungry in between meals:ᅟ- correct32 (57.1)48 (80)0.008bᅟ- incorrect24 (42.9)12 (20)\nachi-square test and chi-square exact test\nbp \u2009≤\u20090.05 was considered statistically significant\nin addition, the majority (76.8\xa0%) of women in the intervention group understood that they should get a follow up Glucose test at 6\xa0weeks set up compared to control group (81.7\xa0%).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 45, 'gestational'), ('UBERON_0000178', 'blood', 142, 'blood'), ('CHEBI_17234', 'glucose', 148, 'glucose'), ('GO_0065007', 'biological regulation', 221, 'Controlling'), ('UBERON_0000178', 'blood', 238, 'blood'), ('CHEBI_17234', 'glucose', 244, 'glucose'), ('UBERON_0000178', 'blood', 445, 'blood'), ('CHEBI_17234', 'glucose', 451, 'glucose'), ('GO_0065007', 'biological regulation', 535, 'control'), ('UBERON_0000178', 'blood', 543, 'blood'), ('CHEBI_17234', 'glucose', 549, 'glucose'), ('GO_0065007', 'biological regulation', 653, 'controlled'), ('CHEBI_17234', 'glucose', 1035, 'glucose')]
PMC4974775	8/2016	S141-PMC4974775	['more women with tertiary education reported correct answers for “time to test blood Glucose level” (62.1\xa0% vs 16.4\xa0%, p \u2009=\u20090.007) and “pricking Fingers for Blood Glucose test” (42.2\xa0% vs 22.4\xa0%, p \u2009=\u20090.009), compared to women with lower education level.']	N/A	N/A	[('CHEBI_17234', 'glucose', 84, 'glucose'), ('UBERON_0002389', 'manual digit', 144, 'fingers'), ('UBERON_0000178', 'blood', 156, 'blood'), ('CHEBI_17234', 'glucose', 162, 'glucose')]
PMC4974775	8/2016	S178-PMC4974775	['a statistically significant difference was reported on questions regarding pricking Fingers for testing Blood Glucose ( p \u2009<\u20090.05).']	N/A	N/A	[('UBERON_0002389', 'manual digit', 84, 'fingers'), ('UBERON_0000178', 'blood', 104, 'blood'), ('CHEBI_17234', 'glucose', 110, 'glucose')]
PMC4977046	3/2016	S105-PMC4977046	['trained study staff also conducted a medical record review to collect results of Gestational Blood Glucose testing.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 81, 'gestational'), ('UBERON_0000178', 'blood', 93, 'blood'), ('CHEBI_17234', 'glucose', 99, 'glucose')]
PMC4977046	3/2016	S106-PMC4977046	['as part of routine Prenatal care, women typically completed a nonfasting Glucose challenge test (gct) between 24 and 28 weeks Gestation, where Blood was sampled 1 hr after Ingestion of 50 g of Glucose.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 19, 'prenatal'), ('CHEBI_17234', 'glucose', 73, 'glucose'), ('GO_0007565', 'female pregnancy', 126, 'gestation'), ('UBERON_0000178', 'blood', 143, 'blood'), ('GO_0007631', 'feeding behavior', 172, 'ingestion'), ('CHEBI_17234', 'glucose', 193, 'glucose')]
PMC4977046	3/2016	S107-PMC4977046	['for those with a 1-hr gct result of 140–199 mg/dl an additional, fasting Oral Glucose tolerance test (ogtt) was performed, where Blood was sampled hourly for 3 hr after Ingesting 100 g of Glucose.']	N/A	N/A	[('UBERON_0000165', 'mouth', 73, 'oral'), ('CHEBI_17234', 'glucose', 78, 'glucose'), ('UBERON_0000178', 'blood', 129, 'blood'), ('GO_0007567', 'parturition', 169, 'ingesting'), ('CHEBI_17234', 'glucose', 188, 'glucose')]
PMC4977046	3/2016	S110-PMC4977046	['specifically, Gestational diabetes mellitus (gdm) was defined as a 1-hr gct result ≥ 200 mg/dl or failing the 1-hr gct (140–199 mg/dl) with two or more high values on the ogtt based on the american diabetes association criteria for a normal ogtt (committee on practice bulletins—obstetrics 2013) of Blood Glucose ≤ 95 mg/dl at baseline, ≤ 180 mg/dl at 1 hr, ≤ 155 mg/dl at 2 hr, and ≤ 140 mg/dl at 3 hr.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 14, 'gestational'), ('UBERON_0000178', 'blood', 299, 'blood'), ('CHEBI_17234', 'glucose', 305, 'glucose')]
PMC4977046	3/2016	S111-PMC4977046	['impaired Glucose tolerance (igt) was defined as failing the 1-hr gct (140–199 mg/dl) and having one high value on the ogtt.']	N/A	N/A	[('CHEBI_17234', 'glucose', 9, 'glucose')]
PMC4977046	3/2016	S132-PMC4977046	['avariableall ( n = 706)normal weight ( n = 406)overweight/obese ( n = 300) p -valuebprepregnancy bmi (kg/m2) (mean ± sd)25.3 ± 4.922.1 ± 1.629.8 ± 4.4< 0.001maternal age (years) (mean ± sd)31.1 ± 4.731.4 ± 4.730.6 ± 4.70.03education level [ n (%)]cless than 11th grade8 (1.1)3 (0.7)5 (1.7)0.01high school graduate or equivalent68 (9.7)34 (8.4)34 (11.4)junior college graduate, or some college or technical school153 (21.8)77 (19.1)76 (25.4)college graduate275 (39.1)157 (38.9)118 (39.5)postgraduate schooling199 (28.3)133 (32.9)66 (22.1)previous Pregnancies [ n (%)]d0281 (39.9)172 (42.6)109 (36.3)0.041271 (38.5)151 (37.4)120 (40.0)296 (13.6)58 (14.4)38 (12.7)≥ 356 (8.0)23 (5.7)33 (11.0)smoking status [ n (%)]never624 (88.4)357 (87.9)267 (89.0)0.58evere45 (6.4)29 (7.1)16 (5.3)current37 (5.2)20 (4.9)17 (5.7)maternal Gestational weight gain (lbs) (mean ± sd)f32.0 ± 12.133.8 ± 9.629.5 ± 14.5< 0.001maternal Gestational hyperglycemia [ n (%)]gnormal566 (83.0)332 (84.7)234 (80.7)0.37igt70 (10.3)37 (9.4)33 (11.4)gdm46 (6.7)23 (5.9)23 (7.9)1-hr Blood Glucose challenge test resultsg(mg/dl) (mean ± sd)113 ± 28112 ± 27114 ± 290.29home Water Arsenic concentration (μg/l) [median (iqr)]0.5 (0.1–2.7)0.5 (0.1–2.6)0.5 (0.1–2.8)0.94any Seafood in 2 days before Urine collection [ n (%)]112 (15.9)69 (17.0)43 (14.3)0.39any rice in 2 days before Urine collection [ n (%)]163 (23.1)102 (25.1)61 (20.3)0.16urinary Arsenic concentration (μg/l) [median (iqr)]Inorganic Arsenic (Ias)0.3 (0.1–0.5)0.2 (0.1–0.5)0.3 (0.1–0.5)0.49monomethylarsonic Acid (Mma)0.3 (0.1–0.5)0.3 (0.1–0.5)0.3 (0.1–0.6)0.41Dimethylarsinic Acid (Dma)2.8 (1.4–4.9)2.5 (1.3–4.8)2.9 (1.4–5.1)0.27total Arsenic (Ias + Mma + Dma)3.4 (1.7–6.0)3.3 (1.6–5.7)3.6 (1.8–6.1)0.34primary methylation index (Mma/ias)1.0 (0.5–1.8)1.0 (0.5–1.8)1.0 (0.5–1.8)0.84secondary methylation index (dma/Mma)10.4 (7.6–18.3)10.3 (7.6–17.7)10.6 (7.5–18.6)0.68infant Delivery mode [ n (%)]vaginal472 (66.9)291 (71.7)181 (60.3)< 0.01cesarean section234 (33.1)115 (28.3)119 (39.7)infant Birth outcomesgestational age (weeks) (mean ± sd)39.5 ± 1.639.6 ± 1.539.3 ± 1.70.02head circumference (cm) (mean ± sd)34.7 ± 1.734.5 ± 1.834.9 ± 1.7< 0.01birth length (cm) (mean ± sd)50.9 ± 2.750.9 ± 2.650.9 ± 2.80.92birth weight (g) (mean ± sd)3,462 ± 516.83,435 ± 488.63,499 ± 551.50.11ponderal index (kg/m3) (mean ± sd)26.3 ± 3.426.1 ± 3.326.6 ± 3.60.07birth weight status [ n (%)]hsmall for Gestational age37 (5.2)24 (5.9)13 (4.3)0.02average for Gestational age600 (85.0)353 (87.0)247 (82.3)large for Gestational age69 (9.8)29 (7.1)40 (13.3)anormal weight defined as Prepregnancy bmi 18.5–24.9 kg/m2and overweight/obese defined as Prepregnancy bmi ≥ 25 kg/m2; 25 underweight mothers (bmi < 18.5 kg/m2) excluded from analysis.bcalculated from an unpaired, 2-tailed t -test with an equal variance assumption to analyze the difference in means, a chi-square test to analyze the difference in proportions, or a wilcoxon–mann–whitney test to analyze the difference in medians by maternal weight status.ceducation data missing for 3 participants.dparity data missing for 2 participants.eparticipants who reported ever smoking but did not report smoking during Pregnancy or had missing data for smoking during Pregnancy were classified as ever smokers.fdata for Gestational weight gain available for a subset of 639 women.gmaternal hyperglycemia measured as part of usual Prenatal care.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 546, 'pregnancies'), ('GO_0007565', 'female pregnancy', 820, 'gestational'), ('GO_0007565', 'female pregnancy', 910, 'gestational'), ('UBERON_0000178', 'blood', 1046, 'blood'), ('CHEBI_17234', 'glucose', 1052, 'glucose'), ('CHEBI_15377', 'water', 1135, 'water'), ('CHEBI_27563', 'arsenic atom', 1141, 'arsenic'), ('CHEBI_34973', 'Selfotel', 1231, 'seafood'), ('UBERON_0001088', 'urine', 1256, 'urine'), ('UBERON_0001088', 'urine', 1339, 'urine'), ('CHEBI_27563', 'arsenic atom', 1405, 'arsenic'), ('CHEBI_5939', 'Interferon gamma-1b', 1448, 'Inorganic'), ('CHEBI_27563', 'arsenic atom', 1458, 'arsenic'), ('CHEBI_24870', 'ion', 1467, 'iAs'), ('CHEBI_37527', 'acid', 1532, 'acid'), ('CHEBI_34840', 'methyl methacrylate', 1538, 'MMA'), ('CHEBI_17549', '5-aminolevulinic acid', 1583, '41Dimethylarsinic acid'), ('CHEBI_17874', 'dihydrozeatin', 1607, 'DMA'), ('CHEBI_85195', '9,10-epoxyoctadecanoate', 1660, 'Arsenic'), ('CHEBI_24870', 'ion', 1669, 'iAs'), ('CHEBI_34840', 'methyl methacrylate', 1675, 'MMA'), ('CHEBI_17874', 'dihydrozeatin', 1681, 'DMA'), ('CHEBI_34840', 'methyl methacrylate', 1755, 'MMA'), ('CHEBI_34840', 'methyl methacrylate', 1839, 'MMA'), ('GO_0007567', 'parturition', 1899, 'delivery'), ('GO_0007567', 'parturition', 2017, 'birth'), ('GO_0007565', 'female pregnancy', 2412, 'gestational'), ('GO_0007565', 'female pregnancy', 2467, 'gestational'), ('GO_0007565', 'female pregnancy', 2522, 'gestational'), ('GO_0007565', 'female pregnancy', 2588, 'prepregnancy'), ('GO_0007565', 'female pregnancy', 2652, 'prepregnancy'), ('GO_0007565', 'female pregnancy', 3175, 'pregnancy'), ('GO_0007565', 'female pregnancy', 3224, 'pregnancy'), ('GO_0007565', 'female pregnancy', 3276, 'gestational'), ('GO_0007565', 'female pregnancy', 3386, 'prenatal')]
PMC4977046	3/2016	S133-PMC4977046	['results for 1-hr Blood Glucose screening and igt status available for a subset of 680 women; data on gdm status available for a subset of 682 women.hage- and sex-adjusted Birth weight percentiles were used to classify infants’ size-for-Gestational age, which included small (≤ 10th percentile) (sga), average (11–89th percentile) (aga), and large-for-Gestational age (≥ 90th percentile) (lga) (fenton et al.']	N/A	N/A	[('UBERON_0000178', 'blood', 17, 'blood'), ('CHEBI_17234', 'glucose', 23, 'glucose'), ('GO_0007567', 'parturition', 171, 'birth'), ('GO_0007565', 'female pregnancy', 236, 'gestational'), ('GO_0007565', 'female pregnancy', 351, 'gestational')]
PMC4977046	3/2016	S149-PMC4977046	['in addition, 25 women were missing data on gdm status, and 27 women were missing data on igt and their 1-hr Blood Glucose screening.']	N/A	N/A	[('UBERON_0000178', 'blood', 108, 'blood'), ('CHEBI_17234', 'glucose', 114, 'glucose')]
PMC4977047	2/2016	S86-PMC4977047	['information on Maternal Pregnancy health and Prenatal care such as Glucose challenge test results was obtained from medical records.']	N/A	N/A	[('GO_0007618', 'mating', 15, 'maternal'), ('GO_0007565', 'female pregnancy', 24, 'pregnancy'), ('GO_0007565', 'female pregnancy', 45, 'prenatal'), ('CHEBI_17234', 'glucose', 67, 'glucose')]
PMC4977047	2/2016	S130-PMC4977047	['caption (table-wrap): table 1\n\ncharacteristics of mother–infant pairs [ n (%) or mean ± sd].characteristicincluded participants ( n = 622)aexcluded participants ( n = 91)bmaternalage at Delivery (years)24.5 ± 5.524.5 ± 5.2prepregnancy bmi (kg/m2)26.9 ± 6.428.8 ± 7.0weight gain during Pregnancy (kg)13.1 ± 7.213.6 ± 7.7marital statusmarried or living with partner391 (64.1)64 (73.6)never married/separated/divorced219 (35.9)23 (26.4)race/ethnicitywhite408 (67.2)58 (67.4)native american143 (23.6)24 (27.9)other (including hispanic)56 (9.2)4 (4.7)education< 12th grade159 (25.6)25 (28.1)≥ 12th grade462 (74.4)64 (71.9)annual household income< $20,000188 (47.5)45 (60.0)$20,000–$40,000134 (33.8)19 (25.3)$40,000–$70,00061 (15.4)7 (9.3)> $70,00013 (3.3)4 (5.3)impaired Glucose tolerance, 24–28 weeks Gestation< 140 mg/dl508 (87.1)65 (84.4)≥ 140 mg/dl75 (12.9)12 (15.6)primiparousyes243 (39.1)32 (35.6)no378 (60.9)58 (64.4)smoked during Pregnancy*yes224 (36.0)22 (24.4)no398 (64.0)68 (75.6)any smokers in householdyes134 (38.0)32 (40.5)no219 (62.0)47 (59.5)Prenatal vitamin use*yes397 (63.8)32 (35.2)no225 (36.2)59 (64.8)anemia at Deliverycyes156 (25.3)19 (22.4)no460 (74.7)66 (77.6)hemoglobin at Delivery (g/dl)11.8 ± 1.411.7 ± 1.2infantbirth weight (g)3370.2 ± 474.53245.6 ± 462.3gestational age at Birth (week)39.1 ± 1.338.7 ± 1.9length at Birth (cm)50.0 ± 2.650.8 ± 2.4head circumference at Birth (cm)34.5 ± 1.834.1 ± 1.3male sex340 (54.7)46 (51.7)aof included participants, data were missing for Prepregnancy bmi ( n = 63), weight gain during Pregnancy ( n = 63), marital status ( n = 12), race/ethnicity ( n = 15), education ( n = 1), household income ( n = 226), impaired Glucose tolerance ( n = 39), primiparous ( n = 1), any smokers in household ( n = 269), anemia at Delivery ( n = 6), hemoglobin at Delivery ( n = 6), length at Birth ( n = 10), and Head circumference at Birth ( n = 24).bof excluded participants, data were missing for age at Delivery ( n = 3), Prepregnancy bmi ( n = 6), weight gain during Pregnancy ( n = 5), marital status ( n = 4), race/ethnicity ( n = 5), education ( n = 2), household income ( n = 16), impaired Glucose tolerance ( n = 14), primiparous ( n = 1), smoked during Pregnancy ( n = 1), any smokers in household ( n = 12), anemia ( n = 6), hemoglobin at Delivery ( n = 6), Birth weight ( n = 3), Gestational age at Birth ( n = 6), length at Birth ( n = 6), Head circumference at Birth ( n = 7), and male sex ( n = 2).canemia is defined as hemoglobin < 11.0 g/dl at Delivery, which is based on definition from cdc (1998; during 3rd Trimester), who (1968; during Pregnancy), and the american congress of obstetricians and gynecologists (2008; in 1st and 3rd Trimesters).']	N/A	N/A	[('GO_0007567', 'parturition', 186, 'delivery'), ('GO_0007565', 'female pregnancy', 285, 'pregnancy'), ('CHEBI_17234', 'glucose', 766, 'glucose'), ('GO_0007565', 'female pregnancy', 797, 'gestation'), ('GO_0007565', 'female pregnancy', 933, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1053, 'Prenatal'), ('GO_0048513', 'animal organ development', 1127, 'deliverycYes156'), ('GO_0007567', 'parturition', 1193, 'delivery'), ('GO_0007567', 'parturition', 1297, 'birth'), ('GO_0007567', 'parturition', 1339, 'birth'), ('GO_0007567', 'parturition', 1391, 'birth'), ('GO_0007565', 'female pregnancy', 1497, 'prepregnancy'), ('GO_0007565', 'female pregnancy', 1544, 'pregnancy'), ('CHEBI_17234', 'glucose', 1675, 'glucose'), ('GO_0007567', 'parturition', 1773, 'delivery'), ('GO_0007567', 'parturition', 1806, 'delivery'), ('GO_0007567', 'parturition', 1835, 'birth'), ('UBERON_0000033', 'head', 1856, 'head'), ('GO_0007567', 'parturition', 1878, 'birth'), ('GO_0007567', 'parturition', 1950, 'delivery'), ('GO_0007565', 'female pregnancy', 1969, 'prepregnancy'), ('GO_0007565', 'female pregnancy', 2015, 'pregnancy'), ('CHEBI_17234', 'glucose', 2142, 'glucose'), ('GO_0007565', 'female pregnancy', 2207, 'pregnancy'), ('GO_0007567', 'parturition', 2294, 'delivery'), ('GO_0007567', 'parturition', 2313, 'birth'), ('GO_0007565', 'female pregnancy', 2336, 'gestational'), ('GO_0007567', 'parturition', 2355, 'birth'), ('GO_0007567', 'parturition', 2381, 'birth'), ('UBERON_0000033', 'head', 2397, 'head'), ('GO_0007567', 'parturition', 2419, 'birth'), ('GO_0007567', 'parturition', 2505, 'delivery'), ('GO_0009294', 'DNA mediated transformation', 2571, 'trimester'), ('GO_0007565', 'female pregnancy', 2601, 'pregnancy'), ('GO_0043033', 'isoamylase complex', 2696, 'trimesters')]
PMC4995781	8/2016	S3-PMC4995781	['an overnight fasted Intravenous Glucose tolerance test (500\xa0mg Glucose/kg body weight) was performed on chronically cannulated non-Pregnant and 20-day Pregnant Rats.']	N/A	N/A	[('UBERON_0034986', 'sacral nerve plexus', 20, 'intravenous'), ('CHEBI_17234', 'glucose', 32, 'glucose'), ('CHEBI_17234', 'glucose', 63, 'glucose'), ('GO_0007565', 'female pregnancy', 131, 'pregnant'), ('GO_0007565', 'female pregnancy', 151, 'pregnant'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 160, 'rats')]
PMC4995781	8/2016	S4-PMC4995781	['indices of Insulin secretion (β) and Insulin sensitivity (s) were calculated from the Plasma Glucose and Insulin responses.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 11, 'insulin'), ('PR_000045358', 'insulin family protein', 37, 'insulin'), ('UBERON_0001969', 'blood plasma', 86, 'plasma'), ('CHEBI_17234', 'glucose', 93, 'glucose'), ('PR_000045358', 'insulin family protein', 105, 'insulin')]
PMC4995781	8/2016	S32-PMC4995781	['cannulas were inserted in the Right and Left Jugular Veins to infuse Glucose and withdraw Blood during the Intravenous Glucose tolerance test [16].']	N/A	N/A	[('UBERON_0002078', 'right cardiac atrium', 30, 'right ...'), ('UBERON_0006195', 'renal sinus of left kidney', 40, 'left jugular veins'), ('CHEBI_17234', 'glucose', 69, 'glucose'), ('UBERON_0000178', 'blood', 90, 'blood'), ('UBERON_0034986', 'sacral nerve plexus', 107, 'intravenous'), ('CHEBI_17234', 'glucose', 119, 'glucose')]
PMC4995781	8/2016	S40-PMC4995781	['Intravenous Glucose tolerance test (ivgtt)\nat the end of 5 d post-cannulation (day 20 of Pregnancy for Pregnant Rats), Rats were fasted overnight and allowed at least 30\xa0min acclimatization in testing cages prior to the test.']	N/A	N/A	[('UBERON_3000713', 'epichordal', 0, 'Intravenous'), ('CHEBI_17234', 'glucose', 12, 'glucose'), ('GO_0007565', 'female pregnancy', 89, 'pregnancy'), ('GO_0007565', 'female pregnancy', 103, 'pregnant'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 112, 'rats'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 119, 'rats')]
PMC4995781	8/2016	S41-PMC4995781	['immediately after taking a baseline Blood sample (400\xa0μl), Rats received an Intravenous bolus of 1\xa0ml/kg body weight Glucose (50\xa0%\xa0w/v) over a 10-s interval.']	N/A	N/A	[('UBERON_0000178', 'blood', 36, 'blood'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 59, 'rats'), ('UBERON_0034986', 'sacral nerve plexus', 76, 'intravenous'), ('CHEBI_17234', 'glucose', 117, 'glucose')]
PMC4995781	8/2016	S43-PMC4995781	['Plasma were stored at -20\xa0°c for not more than one month until assayed for Glucose and Insulin concentrations.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_17234', 'glucose', 75, 'glucose'), ('PR_000045358', 'insulin family protein', 87, 'insulin')]
PMC4995781	8/2016	S48-PMC4995781	['biochemical analyses\nPlasma Glucose and Insulin were measured in duplicates using commercially available assay kits from roche (mannheim, germany) and emd millipore (st charles, mo) respectively.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 21, 'Plasma'), ('CHEBI_17234', 'glucose', 28, 'glucose'), ('PR_000045358', 'insulin family protein', 40, 'insulin')]
PMC4995781	8/2016	S57-PMC4995781	['Insulin secretion and Insulin sensitivity indices\nthe submaximal sensitivity of Insulin secretion to Glucose (β) was calculated from the areas under the curves (aucs) of the plasma Glucose and Insulin responses to the ivgtt as insulinauc0-30/glucoseauc0-30[20].']	N/A	N/A	[('PR_000045358', 'insulin family protein', 0, 'Insulin'), ('PR_000045358', 'insulin family protein', 22, 'insulin'), ('PR_000045358', 'insulin family protein', 80, 'insulin'), ('CHEBI_17234', 'glucose', 101, 'glucose'), ('CHEBI_17234', 'glucose', 181, 'glucose'), ('PR_000045358', 'insulin family protein', 193, 'insulin')]
PMC4995781	8/2016	S59-PMC4995781	['under the conditions tested (fasting, Glucose clamp, ivgtt) any two of glycemia, the Glucose-sensitivity of Insulin secretion, and Insulin sensitivity can be used to calculate the third using the following equation:\\documentclass[12pt]{minimal} \\usepackage{amsmath} \\usepackage{wasysym} \\usepackage{amsfonts} \\usepackage{amssymb} \\usepackage{amsbsy} \\usepackage{mathrsfs} \\usepackage{upgreek} \\setlength{\\oddsidemargin}{-69pt} \\begin{document}$$ g=\\frac{r_{in}}{\\beta \\kern0.5em \\cdotp \\kern0.5em s} $$\\end{document}g=rinβ·swhere g \u2009=\u2009Glucose concentration, rin\u2009=\u2009the rate of Entry Of Glucose into the system, β\u2009=\u2009the Glucose-sensitivity of Insulin secretion, and s \u2009=\u2009the Insulin sensitivity of Glucose disposal.']	N/A	N/A	[('CHEBI_17234', 'glucose', 38, 'glucose'), ('CHEBI_17234', 'glucose', 85, 'glucose'), ('PR_000045358', 'insulin family protein', 108, 'insulin'), ('PR_000045358', 'insulin family protein', 131, 'insulin'), ('CHEBI_17234', 'glucose', 535, 'glucose'), ('GO_0050886', 'endocrine process', 576, 'entry of glucose'), ('CHEBI_17234', 'glucose', 585, 'glucose'), ('CHEBI_17234', 'glucose', 618, 'glucose'), ('PR_000045358', 'insulin family protein', 641, 'insulin'), ('PR_000045358', 'insulin family protein', 673, 'insulin'), ('CHEBI_17234', 'glucose', 696, 'glucose')]
PMC4995781	8/2016	S77-PMC4995781	['caption (table-wrap): table 1\n\nbody weight and biochemical analyses ( n \u2009=\u20097–8 per group)chown-3n-6 p -valuenon-Pregnantpregnantnon-Pregnantpregnantnon-Pregnantpregnantpregnancydietinteractionbefore dietary interventions\u2003weight [g]241\u2009±\u20093242\u2009±\u20092245\u2009±\u20093242\u2009±\u20091246\u2009±\u20093246\u2009±\u20094nsnsnsafter dietary interventions\u2003weight [g]265\u2009±\u20093303\u2009±\u20095284\u2009±\u20092319\u2009±\u20094287\u2009±\u20093319\u2009±\u20092<0.001< 0.001ns\u2003fasting Glucose [mmol/l]5.78\u2009±\u20090.254.41\u2009±\u20090.126.54\u2009±\u20090.523.91\u2009±\u20090.336.83\u2009±\u20090.536.01\u2009±\u20090.34< 0.001< 0.01ns\u2003fasting Insulin [pmol/l]161\u2009±\u200926280\u2009±\u200952189\u2009±\u200936116\u2009±\u200919162\u2009±\u200928305\u2009±\u200945< 0.05ns< 0.01\u2003Ivgtt Glucose auc[min*mmol/l]a270\u2009±\u200920183\u2009±\u20096300\u2009±\u200923219\u2009±\u200912325\u2009±\u200918260\u2009±\u200912< 0.001< 0.01ns\u2003Ivgtt Insulin auc[min*nmol/l]a11.9\u2009±\u20091.427.2\u2009±\u20093.910.3\u2009±\u20090.79.4\u2009±\u20091.117.0\u2009±\u20092.718.9\u2009±\u20092.9< 0.01< 0.001< 0.01\u2003Liver Triglycerides [mmol/mg]8.30\u2009±\u20090.697.79\u2009±\u20090.566.45\u2009±\u20090.896.13\u2009±\u20090.7010.7\u2009±\u20090.898.31\u2009±\u20091.00ns< 0.001ns\naivgtt Intravenous Glucose tolerance test, auc area under the curve\n\nGlucose Homeostasis\nfasting circulating levels of Glucose and Insulin did not differ between diet groups in non-Pregnant Rats (fig.']	N/A	N/A	[('GO_0006412', 'translation', 112, 'pregnantPregnantNon'), ('GO_0006412', 'translation', 132, 'pregnantPregnantNon'), ('GO_0048206', 'vesicle targeting, cis-Golgi to rough endoplasmic reticulum', 152, 'pregnantPregnantPregnancyDietInteractionBefore'), ('CHEBI_17234', 'glucose', 383, 'glucose'), ('PR_000045358', 'insulin family protein', 489, 'insulin'), ('GO_0080088', 'spermidine hydroxycinnamate conjugate biosynthetic process', 568, 'IVGTT'), ('CHEBI_17234', 'glucose', 574, 'glucose'), ('GO_0080088', 'spermidine hydroxycinnamate conjugate biosynthetic process', 661, 'IVGTT'), ('PR_000045358', 'insulin family protein', 667, 'insulin'), ('UBERON_0002107', 'liver', 770, 'Liver'), ('CHEBI_17855', 'triglyceride', 776, 'triglycerides'), ('UBERON_0034986', 'sacral nerve plexus', 884, 'intravenous'), ('CHEBI_17234', 'glucose', 896, 'glucose'), ('CHEBI_17234', 'glucose', 946, 'Glucose'), ('GO_0043062', 'extracellular structure organization', 946, 'Glucose homeostasis'), ('CHEBI_17234', 'glucose', 996, 'glucose'), ('PR_000045358', 'insulin family protein', 1008, 'insulin'), ('GO_0007565', 'female pregnancy', 1058, 'pregnant'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 1067, 'rats')]
PMC4995781	8/2016	S99-PMC4995781	['Insulin secretion (β; a ) and Insulin sensitivity (s; b ) indices were calculated from the area under the curves of plasma Glucose and Insulin concentrations during the intravenous Glucose tolerance test.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 0, 'Insulin'), ('PR_000045358', 'insulin family protein', 30, 'insulin'), ('CHEBI_17234', 'glucose', 123, 'glucose'), ('PR_000045358', 'insulin family protein', 135, 'insulin'), ('CHEBI_17234', 'glucose', 181, 'glucose')]
PMC4995781	8/2016	S155-PMC4995781	['N-3-enriched diet acted to improve overall Glucose Homeostasis in Pregnancy.']	N/A	N/A	[('PR_000011510', 'nuclear pore complex protein Nup160', 0, 'N-3'), ('CHEBI_17234', 'glucose', 43, 'glucose'), ('GO_0042593', 'glucose homeostasis', 43, 'glucose homeostasis'), ('GO_0007565', 'female pregnancy', 66, 'pregnancy')]
PMC4997411	8/2016	S69-PMC4997411	['meanwhile, fetal Ovary Tissues were also used to analyze Alpha-1-Antitrypsin ( aat ), alpha-fetoprotein ( afp ), 78-kda Glucose-regulated protein ( Grp78 ), Gelsolin ( gen ), Lim Homeobox Protein 8 ( lhx8 ), Newborn Ovary Homeobox Gene ( nobox ) and Spermatogenesis and Oogenesis-specific Basic Helix-loop-Helix 2 ( sohlh2 ).']	N/A	N/A	[('UBERON_0000992', 'ovary', 17, 'ovary'), ('UBERON_0000479', 'tissue', 23, 'tissues'), ('PR_000003890', 'A-kinase anchor protein 3', 57, 'alpha-1-antitrypsin'), ('CHEBI_17234', 'glucose', 120, 'glucose'), ('PR_000008210', 'glutathione peroxidase 1', 148, 'grp78'), ('PR_000008060', 'glycine N-acyltransferase-like protein 1', 157, 'gelsolin'), ('PR_000009796', 'LIM/homeobox protein Lhx8', 175, 'LIM homeobox protein 8'), ('PR_000011271', 'NACHT, LRR and PYD domains-containing protein 3', 208, 'newborn ovary homeobox'), ('UBERON_0000992', 'ovary', 216, 'ovary'), ('SO_0000704', 'gene', 231, 'gene'), ('GO_0007283', 'spermatogenesis', 250, 'spermatogenesis'), ('GO_0048477', 'oogenesis', 270, 'oogenesis'), ('CHEBI_22695', 'base', 289, 'basic'), ('SO_0001114', 'peptide_helix', 295, 'helix'), ('SO_0001114', 'peptide_helix', 306, 'helix')]
PMC4997411	8/2016	S145-PMC4997411	['the neonatal (one day) Glucose level had increased in the hfd compared to con (+66%).']	N/A	N/A	[('CHEBI_17234', 'glucose', 23, 'glucose')]
PMC4999868	8/2016	S47-PMC4999868	['the Cytotrophoblast Cells were then isolated by a discontinuous percoll gradient and diluted to 3\u2009×\u2009106cells/ml in cell culture media made up of a 1:1 Mixture of dulbecco’s modified eagle’s medium (dmem) containing 25\u2009mm Glucose and ham’s f-12 Nutrient Mixture containing 10\u2009mm Glucose plus 10% fetal Bovine Serum (fbs), 50\u2009μg/ml gentamicin, 60\u2009μg/ml Benzylpenicillin, and 100\u2009μg/ml Streptomycin.']	N/A	N/A	[('CL_0000722', 'cystoblast', 4, 'cytotrophoblast cells'), ('CHEBI_60004', 'mixture', 151, 'mixture'), ('CHEBI_17234', 'glucose', 221, 'glucose'), ('CHEBI_33284', 'nutrient', 244, 'Nutrient'), ('CHEBI_60004', 'mixture', 253, 'Mixture'), ('CHEBI_17234', 'glucose', 278, 'glucose'), ('NCBITaxon_33208', 'Metazoa', 301, 'bovine'), ('UBERON_0001977', 'blood serum', 308, 'serum'), ('CHEBI_18208', 'benzylpenicillin', 351, 'benzylpenicillin'), ('CHEBI_17076', 'streptomycin', 383, 'streptomycin')]
PMC4999868	8/2016	S58-PMC4999868	['in brief, Transport experiments were performed in a buffer with the following composition (in mm): 150 Nacl, 10 Hepes ( N -2-Hydroxyethylpiperazine- N ′-2-Ethanesulfonic Acid) and 5.6d(+) Glucose (ph 7.4).']	N/A	N/A	[('GO_0006809', 'nitric oxide biosynthetic process', 10, 'transport'), ('CHEBI_26710', 'sodium chloride', 103, 'NaCl'), ('CHEBI_46756', 'HEPES', 112, 'HEPES'), ('CHEBI_46844', 'N-acylpiperazine', 120, 'N -2-hydroxyethylpiperazine'), ('CHEBI_83507', 'N-ethylperfluorooctane sulfonamidoacetic acid', 149, 'N ′-2-ethanesulfonic acid'), ('CHEBI_29103', 'potassium(1+)', 184, '(+)'), ('CHEBI_17234', 'glucose', 188, 'glucose')]
PMC5019390	9/2016	S58-PMC5019390	['Glucose (gtt) tolerance test\nmale Rats were fasted for 4hrs (09:00am to 01:00pm).']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 34, 'rats')]
PMC5019390	9/2016	S59-PMC5019390	['a Glucose load of 1.5 g/kg was administered i.p.']	N/A	N/A	[('CHEBI_17234', 'glucose', 2, 'glucose')]
PMC5019390	9/2016	S60-PMC5019390	['Blood samples were collected by Tail nicking for further analyses of Plasma Glucose and Insulin concentrations.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('UBERON_0002415', 'tail', 32, 'tail'), ('UBERON_0001969', 'blood plasma', 69, 'plasma'), ('CHEBI_17234', 'glucose', 76, 'glucose'), ('PR_000045358', 'insulin family protein', 88, 'insulin')]
PMC5019390	9/2016	S61-PMC5019390	['Plasma measurements\nPlasma Glucose was measured by the Glucose oxidase method (glu, roche diagnostics gmbh, rotkreuz, switzerland).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('UBERON_0001969', 'blood plasma', 20, 'Plasma'), ('CHEBI_17234', 'glucose', 27, 'glucose'), ('CHEBI_17234', 'glucose', 55, 'glucose')]
PMC5019390	9/2016	S145-PMC5019390	['as can be seen onfig 5a, hfduring the Perinatal Period significantly altered Glucose tolerance in wistar Rats at 15 and 30 min.']	N/A	N/A	[('GO_0036268', 'swimming', 38, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 38, 'perinatal period'), ('CHEBI_17234', 'glucose', 77, 'glucose'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 105, 'rats')]
PMC5019390	9/2016	S146-PMC5019390	['after the Glucose load (f(5, 132)= 29.30, p<0.0001).']	N/A	N/A	[('CHEBI_17234', 'glucose', 10, 'glucose')]
PMC5019390	9/2016	S147-PMC5019390	['moreover, the areas under the curves (aucs) of the Glycemia, 120 minutes after the Glucose load was significantly higher in phf wistar compared to psd Rats (p<0.01) (fig 5b).']	N/A	N/A	[('GO_0007601', 'visual perception', 51, 'glycemia'), ('CHEBI_17234', 'glucose', 83, 'glucose'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 151, 'rats')]
PMC5019390	9/2016	S149-PMC5019390	['no alteration of Glucose tolerance or of Insulin secretion was observed in lou/c Rats.10.1371/journal.pone.0162517.g005\n\ncaption (fig): fig 5\neffect of a Perinatal hf diet on Glucose tolerance in 3-month old wistar and lou/c male Rats under a standard diet.']	N/A	N/A	[('CHEBI_17234', 'glucose', 17, 'glucose'), ('PR_000045358', 'insulin family protein', 41, 'insulin'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 81, 'rats'), ('GO_0036268', 'swimming', 154, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 154, 'perinatal'), ('CHEBI_17234', 'glucose', 175, 'glucose'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 230, 'rats')]
PMC5019390	9/2016	S150-PMC5019390	['a) evolution of delta glycemia (mm) at 0, 15, 30, 60 and 120 min after acute Glucose injection (1.5 g/kg, i.p.).']	N/A	N/A	[('CHEBI_17234', 'glucose', 77, 'glucose')]
PMC5019390	9/2016	S151-PMC5019390	['b) areas under the curves (aucs) of glycemia (mmol/l x min) over 120 minutes following the Glucose load.']	N/A	N/A	[('CHEBI_17234', 'glucose', 91, 'glucose')]
PMC5019390	9/2016	S152-PMC5019390	['c) areas under the curves (aucs) of Insulin (ng/ml x min) over the 60 minutes following the Glucose load.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 36, 'insulin'), ('CHEBI_17234', 'glucose', 92, 'glucose')]
PMC5019390	9/2016	S184-PMC5019390	['no change in any of these parameters was observed in lou/c Rats.10.1371/journal.pone.0162517.g007\n\ncaption (fig): fig 7\neffect of a Perinatal hf diet on Glucose tolerance in 4-month old wistar and lou/c male Rats under a high fat diet.']	N/A	N/A	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 59, 'rats'), ('GO_0036268', 'swimming', 132, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 132, 'perinatal'), ('CHEBI_17234', 'glucose', 153, 'glucose'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 208, 'rats')]
PMC5019390	9/2016	S185-PMC5019390	['a) evolution of delta glycemia (mm) at 0, 15, 30, 60 and 120 min after acute Glucose injection (1.5 g/kg, i.p.).']	N/A	N/A	[('CHEBI_17234', 'glucose', 77, 'glucose')]
PMC5019390	9/2016	S186-PMC5019390	['b) areas under the curves (aucs) of glycemia (mmol/l x min) over 120 minutes following the Glucose load.']	N/A	N/A	[('CHEBI_17234', 'glucose', 91, 'glucose')]
PMC5019390	9/2016	S229-PMC5019390	['in lou/c Rats, no deleterious impact of the phf diet on Glucose tolerance or diet-induced obesity was observed at Adulthood.']	N/A	N/A	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 9, 'rats'), ('CHEBI_17234', 'glucose', 56, 'glucose'), ('UBERON_0000113', 'post-juvenile adult stage', 114, 'adulthood')]
PMC5019390	9/2016	S235-PMC5019390	['moreover, as previously described [1,4–6,34,41,42], Perinatal hf diet alters Glucose tolerance in Adult wistar Rats under a standard diet, and increases the susceptibility to develop diet-induced obesity.']	N/A	N/A	[('GO_0036268', 'swimming', 52, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 52, 'perinatal'), ('CHEBI_17234', 'glucose', 77, 'glucose'), ('UBERON_0007023', 'adult organism', 98, 'adult'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 111, 'rats')]
PMC5025055	9/2016	S34-PMC5025055	['prior to each assay run, cells were washed with xf assay medium modified dmem (seahorse bioscience, 102365–100) which was supplemented with 2 mm Sodium Pyruvate and 25 mm Glucose and adjusted to ph 7.4.']	N/A	N/A	[('CHEBI_52632', 'potassium-39 atom', 145, 'sodium'), ('CHEBI_15361', 'pyruvate', 152, 'pyruvate'), ('CHEBI_17234', 'glucose', 171, 'glucose')]
PMC5025055	9/2016	S243-PMC5025055	['rapidly dividing cells also utilize more Glucose thereby increasing their Glycolytic rate with concomitant decrease in Mitochondrial Oxidative Phosphorylation [23].']	N/A	N/A	[('CHEBI_17234', 'glucose', 41, 'glucose'), ('GO_0006096', 'glycolytic process', 74, 'glycolytic'), ('GO_0005739', 'mitochondrion', 119, 'mitochondrial'), ('GO_0006119', 'oxidative phosphorylation', 133, 'oxidative phosphorylation')]
PMC5025983	8/2015	S134-PMC5025983	['on the 21st day of Gestation, compared to the standard diet group, the high fat diet group was 20\xa0% heavier, Consumed more energy, and had twice Insulin, 34\xa0% more Glucose, and 68\xa0% more Triglycerides in their Blood.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 19, 'gestation'), ('GO_0007631', 'feeding behavior', 109, 'consumed'), ('PR_000045358', 'insulin family protein', 145, 'insulin'), ('CHEBI_17234', 'glucose', 164, 'glucose'), ('CHEBI_17855', 'triglyceride', 187, 'triglycerides'), ('UBERON_0000178', 'blood', 210, 'blood')]
PMC5025983	8/2015	S149-PMC5025983	['the offspring from mothers Fed saturated fats exhibited low numbers of Pancreatic Islets and a rapid, high Insulin response on the Oral Glucose tolerance test.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 27, 'fed'), ('CL_0002079', 'pancreatic ductal cell', 71, 'pancreatic islets'), ('UBERON_0000006', 'islet of Langerhans', 71, 'pancreatic islets'), ('PR_000045358', 'insulin family protein', 107, 'insulin'), ('UBERON_0000165', 'mouth', 131, 'oral'), ('CHEBI_17234', 'glucose', 136, 'glucose')]
PMC5025983	8/2015	S179-PMC5025983	['additionally, maternal obesity and increased Food Intake disrupt Glucose Metabolism, and raise Insulin resistance in the offspring; this increases the risks of adiposity and obesity [8,73].']	N/A	N/A	[('CHEBI_33290', 'food', 45, 'food'), ('GO_0007631', 'feeding behavior', 45, 'food intake'), ('CHEBI_17234', 'glucose', 65, 'glucose'), ('GO_0006006', 'glucose metabolic process', 65, 'glucose metabolism'), ('PR_000045358', 'insulin family protein', 95, 'insulin')]
PMC5030620	9/2016	S243-PMC5030620	['(2014)*/†\u2002nutrition:\u2002\u2002high fat dietmouse ratoral (diet) (60% fat)pre-Conception (maternal) \u2002to Lactation early Adulthoodadulthood f0-f1generationsweight-, Glucose- and Lipid- \u2002related Metabolic and Food \u2002Preference abnormalitiesdna Methylation mirnasbaselga-escudero et\xa0al.']	N/A	N/A	[('GO_0007620', 'copulation', 69, 'conception'), ('GO_0007595', 'lactation', 95, 'lactation'), ('UBERON_0000113', 'post-juvenile adult stage', 111, 'adulthoodAdulthood'), ('CHEBI_17234', 'glucose', 155, 'glucose'), ('GO_0061610', 'glycerol to glycerone phosphate metabolic process', 155, 'glucose- ... lipid- ...'), ('CHEBI_18059', 'lipid', 168, 'lipid'), ('GO_0008152', 'metabolic process', 184, 'metabolic ...'), ('CHEBI_33290', 'food', 198, 'food'), ('GO_0009408', 'response to heat', 198, 'food  preference'), ('GO_0032258', 'cytoplasm to vacuole transport by the Cvt pathway', 232, 'methylation')]
PMC5031324	9/2016	S5-PMC5031324	['participants received web lessons, self-tracking of weight and Glucose, automated feedback and access to a message board for peer support.']	N/A	N/A	[('CHEBI_17234', 'glucose', 63, 'glucose')]
PMC5031324	9/2016	S43-PMC5031324	['goodmoms was designed to promote self-Management and Self-Regulation in weight and Glucose Control, including i) Pregnancy and Postpartum web lessons, ii) a web-based self-monitoring diary for participants to record their daily weight, exercise and Glucose levels during Pregnancy and weight, calories, and exercise during the Postpartum period, iii) weekly healthy recipes and tips about maintaining a healthy lifestyle, iv) an online message board for peer support and to pose questions or concerns for the study’s interventionist and v) weekly text messages.']	N/A	N/A	[('GO_0016358', 'dendrite development', 37, '-management'), ('GO_0051923', 'sulfation', 53, 'self-regulation'), ('CHEBI_17234', 'glucose', 83, 'glucose'), ('GO_0046323', 'glucose import', 83, 'glucose control'), ('GO_0007565', 'female pregnancy', 113, 'pregnancy'), ('GO_0007565', 'female pregnancy', 127, 'postpartum'), ('CHEBI_17234', 'glucose', 249, 'glucose'), ('GO_0007565', 'female pregnancy', 271, 'pregnancy'), ('GO_0007565', 'female pregnancy', 327, 'postpartum')]
PMC5031324	9/2016	S64-PMC5031324	['[it] had the bullet points broken out so you can get the gist of it pretty quickly.”\n\nusefulness of web-based components\nparticipants verbalized that the link to healthy recipes and the “tracking your progress” page to record daily weights, exercise and Blood Glucose levels were the most useful website component.']	N/A	N/A	[('UBERON_0000178', 'blood', 254, 'blood'), ('CHEBI_17234', 'glucose', 260, 'glucose')]
PMC5031324	9/2016	S69-PMC5031324	['we integrated additional cooking tips and recipes into the website and expanded the self-tracking page to show graphic representation of fasting Glucose levels and weekly weights.']	N/A	N/A	[('CHEBI_17234', 'glucose', 145, 'glucose')]
PMC5031324	9/2016	S79-PMC5031324	['each of the recruitment sites screens for gdm between 24 and 28\xa0weeks of Pregnancy using the two-step screening strategy recommended by american college of obstetricians and gynecologists which includes a 50\xa0g, 1-h Glucose challenge test, followed by a 100\xa0g, 3-h Oral Glucose tolerance test in those with a 1-h value\u2009≥\u2009140\xa0mg/dl.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 73, 'pregnancy'), ('CHEBI_17234', 'glucose', 215, 'glucose'), ('UBERON_0000165', 'mouth', 264, 'oral'), ('CHEBI_17234', 'glucose', 269, 'glucose')]
PMC5031324	9/2016	S107-PMC5031324	['participants were asked to login weekly to record their weight and fasting Glucose levels, and to review web lesson, videos and health tips.']	N/A	N/A	[('CHEBI_17234', 'glucose', 75, 'glucose')]
PMC5031324	9/2016	S108-PMC5031324	['participants were also encouraged to post questions, concerns and successful weight or Glucose Control strategies on the program’s message board.']	N/A	N/A	[('CHEBI_17234', 'glucose', 87, 'glucose'), ('GO_0046323', 'glucose import', 87, 'glucose control')]
PMC5031324	9/2016	S144-PMC5031324	['fasting Glucose was measured with the uv-hexokinanse method on a Glucose analyzer (beckman diagnostic) at 6\xa0weeks and 30\xa0weeks Postpartum.']	N/A	N/A	[('CHEBI_17234', 'glucose', 8, 'glucose'), ('CHEBI_17234', 'glucose', 65, 'glucose'), ('GO_0007565', 'female pregnancy', 127, 'postpartum')]
PMC5031324	9/2016	S146-PMC5031324	['Insulin resistance [26] was assessed, as measured by the Homeostasis model of assessment-Insulin resistance (homa-ir\u2009=\u2009Insulin*Glucose/405) [12].']	N/A	N/A	[('PR_000045358', 'insulin family protein', 0, 'Insulin'), ('GO_0042592', 'homeostatic process', 57, 'homeostasis'), ('PR_000045358', 'insulin family protein', 89, 'insulin'), ('PR_000045358', 'insulin family protein', 119, 'insulin'), ('CHEBI_17234', 'glucose', 127, 'glucose')]
PMC5031324	9/2016	S188-PMC5031324	['), mean (sd)31.5 (4.7)race\u2003white16 (70)\u2003african american3 (13)\u2003asian3 (13)\u2003other1(4)\u2003hispanic4 (17)education\u2003high school or less5 (22)\u2003some college/complete college degree12 (52)\u2003graduate/post graduate6 (2.6)marital status\u2003married19 (83)\u2003single4 (17)employed14 (61)\u2003source of medical payment\u2003commercial18 (78)\u2003medicaid2 (9)\u2003self-pay2 (9)\u2003medicare1 (4)parity, n, no prior Delivery11 (48)\u200315 (22)\u20032 or more7 (30)first-degree family history of diabetes5 (22)smoking before Pregnancy23 (100)Gestational age at baseline, (wks), mean (sd)28.9 (3.4)pre-Pregnancy bmia(kg/m2)29.4 (11.2)\u2003normal (18.5–24.9)9 (39)\u2003overweight (25.0–29.9)4 (17)\u2003obese (30–34)10 (43)earliest first trimester weight (kg), mean (sd)71.7 (18.2)weight at enrollment, (kgs), mean (sd)79 (18.8)Gestational weight gain at enrollment (kgs), mean (sd)7 (5)therapy during Pregnancy after gdm diagnosis\u2003diet16 (70)\u2003Glyburide or Metformin6 (26)\u2003Insulin1 (4)internet access at least 4\xa0h per week23 (100)1-h 50-g Glucose challenge test (mg/dl), mean (sd)155 (10)3-h, 100-g ogtt (mg/dl), mean (sd)\u2003fasting100 (5)\u20031-h183 (30)\u20032-h165 (25)\u20033-h145 (15)% dietary Intake at baseline\u2003percent fat (%), mean (sd)36 (5)\u2003fruit and vegetable (servings/day), mean (sd)3.2(1.6)moderate walking in bouts\u2009≥\u200910\xa0min (minutes/week) mean (sd)159 (185.7)\nkg kilograms; data are reported as n (%) unless otherwise indicated\napre-Pregnancy bmi is based on weight and height measured at earliest first trimester visit\n\nclinical outcomes\n\nGestational weight gain\naverage Gestational weight gain for all participants was 19.9 lbs\u2009±\u200913.2.']	N/A	N/A	[('GO_0007567', 'parturition', 371, 'delivery11'), ('GO_0007565', 'female pregnancy', 470, 'pregnancy23'), ('GO_0007565', 'female pregnancy', 487, 'Gestational'), ('GO_0007565', 'female pregnancy', 546, 'pregnancy'), ('GO_0007565', 'female pregnancy', 758, 'Gestational'), ('GO_0007565', 'female pregnancy', 832, 'pregnancy'), ('CHEBI_5441', 'glyburide', 874, 'Glyburide'), ('CHEBI_66689', 'megathyrin A', 887, 'metformin6'), ('PR_000009158', 'inositol 1,4,5-trisphosphate receptor type 1', 903, 'Insulin1'), ('CHEBI_17234', 'glucose', 969, 'glucose'), ('GO_0007631', 'feeding behavior', 1113, 'intake'), ('GO_0007565', 'female pregnancy', 1362, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1469, 'Gestational'), ('GO_0007565', 'female pregnancy', 1501, 'gestational')]
PMC5031324	9/2016	S224-PMC5031324	['we were able to adapt acog [18] and ada [19] guidelines for Glucose and weight management during Pregnancy and the dpp lifestyle intervention [8] to develop a Pregnancy and Postpartum intervention for women with gdm and their offspring.']	N/A	N/A	[('CHEBI_17234', 'glucose', 60, 'glucose'), ('GO_0007565', 'female pregnancy', 97, 'pregnancy'), ('GO_0007565', 'female pregnancy', 159, 'pregnancy'), ('GO_0007565', 'female pregnancy', 173, 'postpartum')]
PMC5035678	4/2016	S4-PMC5035678	['the primary outcomes were fasting Plasma Glucose (fpg), Insulin, 2-h post 75 g Glucose load Plasma Glucose (2-hplg), Homeostasis model assessment of Insulin resistance (homa-ir), hba1c, and 25 Ohd at 6 - 12 weeks after Delivery.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 34, 'plasma'), ('CHEBI_17234', 'glucose', 41, 'glucose'), ('PR_000045358', 'insulin family protein', 56, 'insulin'), ('CHEBI_17234', 'glucose', 79, 'glucose'), ('UBERON_0001969', 'blood plasma', 92, 'plasma'), ('CHEBI_17234', 'glucose', 99, 'glucose'), ('GO_0042592', 'homeostatic process', 117, 'homeostasis'), ('PR_000045358', 'insulin family protein', 149, 'insulin'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 190, '25 OHD'), ('GO_0007567', 'parturition', 219, 'delivery')]
PMC5035678	4/2016	S14-PMC5035678	['women at high risk are the exception to this guideline, and for these patients, the oral Glucose tolerance test (ogtt) is performed at first Prenatal visit.']	N/A	N/A	[('CHEBI_17234', 'glucose', 89, 'glucose'), ('GO_0007565', 'female pregnancy', 141, 'prenatal')]
PMC5035678	4/2016	S22-PMC5035678	['a significant proportion of these patients develop isolated impaired fasting Glucose (ifg) or impaired Glucose tolerance (igt), and 5% - 14% of these cases convert to persistent type 2 diabetes even shortly after Delivery (13,14,15).']	N/A	N/A	[('CHEBI_17234', 'glucose', 77, 'glucose'), ('CHEBI_17234', 'glucose', 103, 'glucose'), ('GO_0007567', 'parturition', 213, 'delivery')]
PMC5035678	4/2016	S35-PMC5035678	['carpenter-coustan criteria were defined as fasting, 1h, 2h, and 3h Plasma Glucose (pg) levels of 95, 180, 155, and 140 mg/dl after administration of 100 g ogtt, with or without a prior Glucose challenge test (gct, n = 99) (17).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 67, 'plasma'), ('CHEBI_17234', 'glucose', 74, 'glucose'), ('CHEBI_17234', 'glucose', 185, 'glucose')]
PMC5035678	4/2016	S56-PMC5035678	['the primary outcomes were maternal fasting Plasma Glucose (fpg), 2-h post 75 g Glucose load Plasma Glucose (2-hplg), fasting Serum Insulin, homeostasis model assessment of Insulin resistance (homa-ir), hba1c, and Serum 25Ohd at 6 - 12 weeks after Delivery.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 43, 'plasma'), ('CHEBI_17234', 'glucose', 50, 'glucose'), ('CHEBI_17234', 'glucose', 79, 'glucose'), ('UBERON_0001969', 'blood plasma', 92, 'plasma'), ('CHEBI_17234', 'glucose', 99, 'glucose'), ('UBERON_0001977', 'blood serum', 125, 'serum'), ('PR_000045358', 'insulin family protein', 131, 'insulin'), ('PR_000045358', 'insulin family protein', 172, 'insulin'), ('UBERON_0001977', 'blood serum', 213, 'serum'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 219, '25OHD'), ('GO_0007567', 'parturition', 247, 'delivery')]
PMC5035678	4/2016	S60-PMC5035678	['after Glucose measurement, the Sera and whole Blood were kept at -80°c and 4°c, respectively, for testing of Lipids, Insulin, and hba1c.']	N/A	N/A	[('CHEBI_17234', 'glucose', 6, 'glucose'), ('UBERON_0001977', 'blood serum', 31, 'sera'), ('UBERON_0000178', 'blood', 46, 'blood'), ('CHEBI_18059', 'lipid', 109, 'lipids'), ('PR_000045358', 'insulin family protein', 117, 'insulin')]
PMC5035678	4/2016	S63-PMC5035678	['Blood Glucose measurement was carried out by the enzymatic (god - Glucose oxidase) method (pars azmun co., tehran, iran), and Hba1C measurement was performed with the enzymatic method (sekisui medical co., osaka, japan).']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('CHEBI_17234', 'glucose', 6, 'glucose'), ('CHEBI_17234', 'glucose', 66, 'glucose'), ('PR_000002010', 'MHC class I histocompatibility antigen B alpha chain', 126, 'HbA1C')]
PMC5035678	4/2016	S87-PMC5035678	['baseline characteristics of the studied groupsvariablesintervention groupcontrol groupp value number 4242 age, mean (sd), y 32.0 (5.5)32.4 (4.7)0.70 pre-Pregnancy bmi, mean (sd), kg/m227.6 (3.9)27.6 (3.8)0.94 weight gain during Pregnancy, mean (sd), kg 8.9 (4.6)6.7 (4.8)0.04 Planning For Pregnancy, n (%) 26 (61)22 (52)0.37 literacy, n (%) less than high school19 (45)16 (38)0.57high school8 (19)12 (28)university15 (36)14 (34) gravidity, n (%) 112 (28)10 (24)0.09≥ 230 (72)32 (76) history, n (%) gdm in patient6 (14)1 (2)0.10atype 2 diabetes in first degree relatives18 (42)14 (33)0.36multivitamin use36 (85)36 (85)1.00ga at gdm diagnosis, mean (sd), week20.8 (7.6)21.3 (7.2)0.78 biochemistry, mean (sd) 25 ohd, ng/ml14.6 (6.3)17.7 (6.1)0.04serum Calcium, mg/dl8.9 (0.6)9.0 (0.5)0.95fpg, mg/dl97 (18)97 (14)0.871h ogtt196 (26)203 (29)0.292h ogtt170 (35)168 (31)0.863h ogtt109 (36)120 (36)0.17hba1c, %5.5 (0.7)5.3 (0.5)0.13hba1c, mmol/mol37 (7)34 (6)0.13\nabbreviations: sd, standard deviation; dm, diabetes mellitus; ga, Gestational age; gdm, Gestational diabetes mellitus; fpg, fasting Plasma Glucose; ogtt, oral Glucose tolerance test.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 153, 'pregnancy'), ('GO_0007565', 'female pregnancy', 228, 'pregnancy'), ('GO_0006276', 'plasmid maintenance', 276, 'Planning for'), ('GO_0007565', 'female pregnancy', 289, 'pregnancy'), ('CHEBI_31341', 'calcium dihydroxide', 749, 'Calcium'), ('GO_0007565', 'female pregnancy', 1022, 'gestational'), ('GO_0007565', 'female pregnancy', 1044, 'gestational'), ('UBERON_0001969', 'blood plasma', 1088, 'plasma'), ('CHEBI_17234', 'glucose', 1095, 'glucose'), ('CHEBI_17234', 'glucose', 1115, 'glucose')]
PMC5035678	4/2016	S119-PMC5035678	['the fasting plasma Glucose, Insulin level, and homa-ir after six weeks of intervention decreased significantly compared to the control group.']	N/A	N/A	[('CHEBI_17234', 'glucose', 19, 'glucose'), ('PR_000045358', 'insulin family protein', 28, 'insulin')]
PMC5035678	4/2016	S131-PMC5035678	['(29) on 179 women with gdm, plasma Glucose level and homa-ir were compared in two groups receiving high dose (5000 iu daily) and low dose (400 iu daily) Vitamin D supplementation.']	N/A	N/A	[('CHEBI_17234', 'glucose', 35, 'glucose'), ('CHEBI_27300', 'vitamin D', 153, 'vitamin D')]
PMC5035678	4/2016	S162-PMC5035678	['this increase persists for several weeks after Delivery, but does not affect fasting Glucose and Insulin levels, Insulin resistance, or clinical outcomes.']	N/A	N/A	[('GO_0007567', 'parturition', 47, 'delivery'), ('CHEBI_17234', 'glucose', 85, 'glucose'), ('PR_000045358', 'insulin family protein', 97, 'insulin'), ('PR_000045358', 'insulin family protein', 113, 'insulin')]
PMC5045149	9/2016	S183-PMC5045149	['in addition to recording his diet and blood Glucose response, he was asked to monitor his Sleep, physical activity, and stress or anxiety symptom occurrences and record this information in the provided log-sheets (examples given in supplementary information).']	N/A	N/A	[('CHEBI_17234', 'glucose', 44, 'glucose'), ('GO_0030431', 'sleep', 90, 'sleep')]
PMC5045149	9/2016	S188-PMC5045149	['trial weeks consisted of first a dietary intervention whereby the results of the Blood Glucose testing were evaluated along with his self-reported dietary record to create a new diet plan, and second an exercise to practice mindful self-exploration of emotional experiences in response to his diet.']	N/A	N/A	[('UBERON_0000178', 'blood', 81, 'blood'), ('CHEBI_17234', 'glucose', 87, 'glucose')]
PMC5054961	9/2015	S4-PMC5054961	['clinical measurements collected included, height, weight, blood Glucose and neonatal outcomes.']	N/A	N/A	[('CHEBI_17234', 'glucose', 64, 'glucose')]
PMC5054961	9/2015	S31-PMC5054961	['anthropometric and biochemical information was collected at approximately 28\xa0weeks of Gestation and included weight, height, fasting and random blood Glucose.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 86, 'gestation'), ('CHEBI_17234', 'glucose', 150, 'glucose')]
PMC5054961	9/2015	S73-PMC5054961	['caption (table-wrap): table 2\n\ncharacteristics of women with ( n \xa0=\xa0635) and without Food cravings ( n \xa0=\xa01004)cravingsno cravings p *valueage at interview (years) (sd)29.7 (5.5)29.7 (5.5)nsgestational age at interview28.9 (1.2)28.9 (1.2)nsyears in education (years)14.7 (2.9)15.1 (2.8)0.037smoking at interview†165 (26%)218 (22%)0.05employed at interview‡453 (72%)785 (78%)0.001previous children§347 (55%)477 (48%)0.002bmi (kg/m²) <16\xa0weeks gest (mean 12.1\xa0weeks\xa0±\xa02.3)25.8 (4.9)25.5 (4.9)nsweight (kg) <16\xa0weeks gest (mean 12.1\xa0weeks\xa0±\xa02.3)68.5 (14)67.5 (13)nsweight (kg) 29\xa0weeks75.8 (14)74.9 (13)nsheight (m) 29\xa0weeks163 (6.3)163 (6.3)nsbmi (kg/m²) 29\xa0weeks28.5 (4.9)28.3 (4.8)nsweight gain <16\xa0weeks – 3rd Trimester (mean 32.8\xa0weeks\xa0±\xa04.5)9.6 (5.4)8.9 (5.5)nsrate of weight gain (kg\xa0week−1)0.5 (0.2)0.4 (0.2)nsfasting Blood Glucose 29\xa0weeks (ogtt) mmol\xa0l−15.2 (1)5.2 (1)nshba1c 29\xa0weeks4.8 (0.4)4.8 (0.3)nsneonatal Birthweight3.5 (0.6)3.5 (0.5)nsbirthweight sds−0.1 (0.9)−0.1 (0.9)nsbirth length sds0.2 (1.1)0.1 (1.2)nshead circumference sds0.3 (1)0.2 (1)nsfemale child √310 (49%)474 (48%)ns\ndata are the mean (sd) or n (%) of subjects *t‐test for independent samples or chi‐squared tests †with cravings, n = 633, and without cravings, n = 998.']	N/A	N/A	[('CHEBI_33290', 'food', 85, 'food'), ('GO_0009294', 'DNA mediated transformation', 711, 'trimester'), ('UBERON_0000178', 'blood', 823, 'blood'), ('CHEBI_17234', 'glucose', 829, 'glucose'), ('GO_0007596', 'blood coagulation', 920, 'birthweight3')]
PMC5054961	9/2015	S77-PMC5054961	['bmi, body mass index; hba1c, glycosylated haemoglobin; ns, not significant; ogtt, oral Glucose tolerance test; sds, standard deviation score.john wiley & sons, ltd\n\nfrequency and type of Food craving\nthe most commonly Craved Foods (calculated as a percentage of the total number) were sweet foods, especially chocolate (35%), fruit and fruit juices (13%), and dairy Foods (8%) (table\xa03).']	N/A	N/A	[('CHEBI_17234', 'glucose', 87, 'glucose'), ('CHEBI_33290', 'food', 187, 'food'), ('GO_0007631', 'feeding behavior', 187, 'food'), ('GO_0006260', 'DNA replication', 218, 'craved'), ('CHEBI_33290', 'food', 225, 'foods'), ('CHEBI_33290', 'food', 366, 'foods')]
PMC5054961	9/2015	S92-PMC5054961	['clinical associations of cravings in Pregnancy\nno differences were observed between groups in measurements of glycosylated haemoglobin (hba1c), fasting, and 1‐ and 2‐h blood Glucose measurements at 29\xa0weeks of Gestation (mean 29.0wks ± 1.24).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 37, 'pregnancy'), ('CHEBI_17234', 'glucose', 174, 'glucose'), ('GO_0007565', 'female pregnancy', 210, 'gestation')]
PMC5069446	10/2016	S179-PMC5069446	['under high Nutrient conditions (amino acid or Glucose sufficient), mtorc1 is activated, and it increases the levels of ubiquitin e3 ligase Mdm2 by a P53-dependent transcriptional and P53-independent post-transcriptional pathway.']	N/A	N/A	[('CHEBI_33284', 'nutrient', 11, 'nutrient'), ('CHEBI_17234', 'glucose', 46, 'glucose'), ('PR_000010123', 'microtubule-associated protein 1S', 139, 'Mdm2'), ('PR_000003035', 'cellular tumor antigen p53', 149, 'p53'), ('PR_000014700', 'serpin B9', 183, 'P53')]
PMC5069446	10/2016	S181-PMC5069446	['under low Nutrient conditions (amino acid starvation or Glucose deprivation), mtorc1 is not active and Mdm2 levels are low.']	N/A	N/A	[('CHEBI_33284', 'nutrient', 10, 'nutrient'), ('CHEBI_17234', 'glucose', 56, 'glucose'), ('PR_000010123', 'microtubule-associated protein 1S', 103, 'Mdm2')]
PMC5069446	10/2016	S203-PMC5069446	['additionally, maternal protein restriction during Gestation increases the Expression of Ccaat/Enhancer-Binding Protein (C/Ebpβ) and Glucose Transporter 4 (Glut4) in female offspring Rat Skeletal muscle through the Regulation Of Histone Modification at their Promoter regions152,153.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 50, 'gestation'), ('GO_0010467', 'gene expression', 74, 'expression'), ('PR_000005255', 'cyclin-dependent kinase 2-associated protein 2', 88, 'CCAAT/enhancer-binding protein'), ('SO_0000165', 'enhancer', 94, 'enhancer'), ('PR_000004967', 'calbindin', 120, 'C/EBPβ'), ('CHEBI_17234', 'glucose', 132, 'glucose'), ('PR_000015064', 'solute carrier family 2, facilitated glucose transporter member 2', 132, 'glucose transporter 4'), ('PR_000015065', 'solute carrier family 2, facilitated glucose transporter member 3', 155, 'GLUT4'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 182, 'rat'), ('UBERON_0004288', 'skeleton', 186, 'skeletal'), ('GO_0007565', 'female pregnancy', 214, 'regulation of'), ('CHEBI_15358', 'histone', 228, 'histone'), ('GO_0016570', 'histone modification', 228, 'histone modification'), ('PR_000043452', 'core histone', 228, 'histone'), ('SO_0000167', 'promoter', 258, 'promoter')]
PMC5085625	9/2016	S33-PMC5085625	['it is defined as Glucose intolerance of any degree, which started or has been newly diagnosed in Pregnancy.']	N/A	N/A	[('CHEBI_17234', 'glucose', 17, 'glucose'), ('GO_0007565', 'female pregnancy', 97, 'pregnancy')]
PMC5085625	9/2016	S136-PMC5085625	['type a1 (corresponding to gdm g1) was defined as abnormal Oral Glucose tolerance test (ogtt), but normal Blood Glucose levels during fasting and one/two hours after a meal; diet modification was sufficient to control Glucose levels.']	N/A	N/A	[('UBERON_0000165', 'mouth', 58, 'oral'), ('CHEBI_17234', 'glucose', 63, 'glucose'), ('UBERON_0000178', 'blood', 105, 'blood'), ('CHEBI_17234', 'glucose', 111, 'glucose'), ('CHEBI_17234', 'glucose', 217, 'glucose')]
PMC5085625	9/2016	S137-PMC5085625	['type a2 (corresponding to gdm g2) was defined as abnormal ogtt compounded by abnormal Glucose levels during fasting and/or after a meal; additional therapy with Insulin or other Medications was required.']	N/A	N/A	[('CHEBI_17234', 'glucose', 86, 'glucose'), ('PR_000045358', 'insulin family protein', 161, 'insulin'), ('CHEBI_25441', 'mycothiols', 178, 'medications')]
PMC5085625	9/2016	S141-PMC5085625	['Gestational diabetes was detected on the basis of a 75 g Glucose tolerance test conducted between 24 and 28 weeks of Gestation.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_17234', 'glucose', 57, 'glucose'), ('GO_0007565', 'female pregnancy', 117, 'gestation')]
PMC5085625	9/2016	S148-PMC5085625	['the control group included 36 women with uncomplicated Pregnancies, normal Arterial Blood pressure and Glucose concentrations.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 55, 'pregnancies'), ('UBERON_0001637', 'artery', 75, 'arterial'), ('UBERON_0000178', 'blood', 84, 'blood'), ('CHEBI_17234', 'glucose', 103, 'glucose')]
PMC5091916	11/2016	S120-PMC5091916	['measurement of Metabolites, Hepatic enzymes and leptin in Plasma\nthe following Plasma Metabolites were measured: basal Glucose, Triglycerides, total Cholesterol, high-density lipoprotein (hdl), Urea, Bilirubin, alkaline phosphatase (alkp), and the Hepatic enzymes alanine aminotransferase (alt), aspartate aminotransferase (ast) and gamma-glutamyltranspeptidase (γgt).']	N/A	N/A	[('CHEBI_25212', 'metabolite', 15, 'metabolites'), ('UBERON_0002107', 'liver', 28, 'hepatic'), ('UBERON_0001969', 'blood plasma', 58, 'plasma'), ('UBERON_0001969', 'blood plasma', 79, 'plasma'), ('CHEBI_25212', 'metabolite', 86, 'metabolites'), ('CHEBI_17234', 'glucose', 119, 'glucose'), ('CHEBI_17855', 'triglyceride', 128, 'triglycerides'), ('CHEBI_16113', 'cholesterol', 149, 'cholesterol'), ('CHEBI_16199', 'urea', 194, 'urea'), ('CHEBI_16990', 'bilirubin IXalpha', 200, 'bilirubin'), ('UBERON_0002107', 'liver', 248, 'hepatic')]
PMC5091916	11/2016	S413-PMC5091916	['additionally, pc females displayed lower levels of leptin, Glucose, total Cholesterol, and ast/alt ratio than pc males (#/###p<0 .']	N/A	N/A	[('CHEBI_17234', 'glucose', 59, 'glucose'), ('CHEBI_16113', 'cholesterol', 74, 'cholesterol')]
PMC5091916	11/2016	S415-PMC5091916	['001 ) (table 1).10.1371/journal.pone.0165432.t001\n\ncaption (table-wrap): table 1\nPlasma leptin, Metabolites and Hepatic transaminases at 5thpostnatal montha.malefemaletwo-way anovacc (n = 6)pc (n = 5)cc (n = 5)pc (n = 5)interactionperinatal dietsex leptin (μg/ml) 5.829±0.88 11.21 ±1.69* 6.07±2.17 4.15±0.89#f1,16= 6.817, p = 0.0189ns f1,16= 5.94, p = 0.0269 Glucose (mg/dl) 187.33±12.11211.40±17.04169.60±15.65 154.80±15.57#nsns f1,17= 7.60, p = 0.013 Triglycerides (mg/dl) 79.50±3.12105.40±9.8482.60±15.96110.40±10.87ns f1,17= 8.241, p = 0.011ns Tcholesterol (mg/dl) 39.00±5.4938.60±2.6137.20±2.53 26.40±4.04#nsnsns hdl (mg/dl) 26.67±3.04 13.80±7.73* 21.60±2.91 2.20±0.82$ $ns f1,17= 17.304, p = 0.001f1,17= 4.617, p = 0.046 ldl (mg/dl) 12.37±2.79 37.36±11.80* 17.01±8.4 40.29±4.76$ns f1,17= 13.144, p = 0.002ns vldl (mg/dl) 15.90±0.6221.08±1.9716.52±3.1922.08±2.17ns f1,17= 8.241, p = 0.011ns Urea (mg/dl) 27.50±2.8926.80±1.2930.40±2.0228.80±4.33nsnsns Bilirubin (mg/dl) 0.13±0.02 0.50±0.19** 0.20±0.050.24±0.06nsf1,17= 5.512, p = 0.031ns Alkp (ui) 73.83±4.5764.60±2.6663.20±7.7968.40±2.08nsnsns γgt (ui) 10.50±1.018.80±1.7812.20±0.9611.40±0.57nsnsns ast (ui) 162.50±33.02108.80±18.26145.00±20.39172.60±27.22nsnsf1,17= 5.152, p = 0.037 alt (ui) 55.00±3.9659.80±6.2670.40±8.3774.60±10.56nsnsns ast/alt 0.39±0.060.57±0.38 4.05±0.24***3.97±0.42###nsns f1,17= 290.791, p<0.001\navalues are expressed as means ± s.e.m.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 81, 'Plasma'), ('CHEBI_25212', 'metabolite', 96, 'metabolites'), ('UBERON_0002107', 'liver', 112, 'hepatic'), ('CHEBI_17234', 'glucose', 359, 'Glucose'), ('CHEBI_17855', 'triglyceride', 453, 'Triglycerides'), ('CHEBI_17027', 'allysine', 548, 'tCholesterol'), ('CHEBI_16199', 'urea', 896, 'Urea'), ('UBERON_0000978', 'leg', 896, 'Urea'), ('CHEBI_16990', 'bilirubin IXalpha', 956, 'Bilirubin'), ('PR_000003939', 'GDP-Man:Man(3)GlcNAc(2)-PP-Dol alpha-1,2-mannosyltransferase', 1042, 'ALKP')]
PMC5091916	11/2016	S676-PMC5091916	['also, pc Animals did not show greater Plasma Glucose than their respective controls.']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 9, 'animals'), ('UBERON_0001969', 'blood plasma', 38, 'plasma'), ('CHEBI_17234', 'glucose', 45, 'glucose')]
PMC5093227	10/2016	S26-PMC5093227	['her a1c value was 8.3% and the fasting Glucose Sugar level was 175 mg/dl.']	N/A	N/A	[('CHEBI_17234', 'glucose', 39, 'glucose'), ('CHEBI_24870', 'ion', 47, 'sugar')]
PMC5093227	10/2016	S43-PMC5093227	['through these efforts and Drug therapy, her Blood Glucose level has been kept near normal.']	N/A	N/A	[('CHEBI_23888', 'drug', 26, 'drug'), ('UBERON_0000178', 'blood', 44, 'blood'), ('CHEBI_17234', 'glucose', 50, 'glucose')]
PMC5093227	10/2016	S51-PMC5093227	['her 1-hour Postprandial Glucose level was elevated to 140–200 mg/dl.']	N/A	N/A	[('GO_0007567', 'parturition', 11, 'postprandial'), ('CHEBI_17234', 'glucose', 24, 'glucose')]
PMC5093227	10/2016	S72-PMC5093227	['when her morning fasting blood Glucose level was high, the Insulin lispro dose was increased by 2 units.']	N/A	N/A	[('CHEBI_17234', 'glucose', 31, 'glucose'), ('PR_000045358', 'insulin family protein', 59, 'insulin')]
PMC5093227	10/2016	S76-PMC5093227	['her morning fasting blood Glucose level was maintained at 95–105 mg/dl.']	N/A	N/A	[('CHEBI_17234', 'glucose', 26, 'glucose')]
PMC5093227	10/2016	S89-PMC5093227	['caption (table-wrap): table 1\nsummary of visitsvisit#1#2#3#4#5#6#7period, wkpreconceptionga 6ga 8ga 10ga 12ga 32after deliveryenergy Intake, kcal1,7741,4741,4309301,7022,0201,500weight, kg60.059.058.056.558.466.967.3weight change during Pregnancy, kg--−1−2.5−0.77.98.3urine Ketones--negative–1+1+–2+negative–tracenegative-a1c, %8.35.45.5--5.2-smbg--fbs < 95 mg/dlfbs < 95 mg/dlfbs < 95 mg/dlfbs 95–105 mg/dlnormal Rangepp1 140–200 mg/Dlpp1 < 140 mg/Dlpp1 < 140 mg/Dlpp1 < 140 mg/dlnutrition interventioneducation for diabetes and Preconception careeducation for diabetes in Pregnancydiet plan on Insulin therapyeducation for weight gain without producing ketonesincreased energy requirement of +340 kcal/day (second trimester)increased energy requirement of +450 kcal/day (third trimester)rearrangement energy requirement +320 kcal/day (Breast feeding), education for Postpartum care\nga, Gestational age; smbg, self-monitoring of Blood Glucose; fbs, fasting Blood Sugar; pp1, Postprandial 1 hour.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 133, 'intake'), ('GO_0007565', 'female pregnancy', 237, 'pregnancy'), ('CHEBI_17087', 'ketone', 274, 'ketones'), ('PR_000013044', 'POU domain, class 5, transcription factor 1', 414, 'rangePP1'), ('PR_000006474', 'ATP-dependent RNA helicase A', 434, 'dLPP1'), ('PR_000006474', 'ATP-dependent RNA helicase A', 449, 'dLPP1'), ('PR_000006474', 'ATP-dependent RNA helicase A', 464, 'dLPP1'), ('GO_0007565', 'female pregnancy', 530, 'preconception'), ('GO_0007565', 'female pregnancy', 574, 'pregnancyDiet'), ('PR_000045358', 'insulin family protein', 596, 'insulin'), ('UBERON_0000310', 'breast', 837, 'breast'), ('GO_0007565', 'female pregnancy', 868, 'postpartum'), ('GO_0007565', 'female pregnancy', 888, 'gestational'), ('UBERON_0000178', 'blood', 930, 'blood'), ('CHEBI_17234', 'glucose', 936, 'glucose'), ('UBERON_0000178', 'blood', 958, 'blood'), ('CHEBI_24870', 'ion', 964, 'sugar'), ('GO_0007567', 'parturition', 976, 'postprandial')]
PMC5093227	10/2016	S91-PMC5093227	['the patient achieved close to normal Glucose levels through effective Preconception counseling and had a successful Pregnancy.']	N/A	N/A	[('CHEBI_17234', 'glucose', 37, 'glucose'), ('GO_0007565', 'female pregnancy', 70, 'preconception'), ('GO_0007565', 'female pregnancy', 116, 'pregnancy')]
PMC5093227	10/2016	S92-PMC5093227	['furthermore, Glycemic Control during Pregnancy was good, with daily Insulin therapy and Glucose monitoring.']	N/A	N/A	[('GO_0006094', 'gluconeogenesis', 13, 'glycemic control'), ('GO_0007565', 'female pregnancy', 37, 'pregnancy'), ('PR_000045358', 'insulin family protein', 68, 'insulin'), ('CHEBI_17234', 'glucose', 88, 'glucose')]
PMC5100620	10/2016	S4-PMC5100620	['their children ( n \u2009=\u20091667) were followed up at 4.5 years with assessment of biomarkers of Lipid and Glucose Metabolism, inflammation and oxidative stress.']	N/A	N/A	[('CHEBI_18059', 'lipid', 91, 'lipid'), ('GO_0006266', 'DNA ligation', 91, 'lipid ...'), ('CHEBI_17234', 'glucose', 101, 'glucose'), ('GO_0006006', 'glucose metabolic process', 101, 'glucose metabolism')]
PMC5100620	10/2016	S6-PMC5100620	['mms supplementation resulted in lower high-density lipoprotein (hdl) (difference -0.028\u2009mmol/l, 95% cl -0.053; -0.002), lower Glucose (difference -0.099\u2009mmol/l, 95% cl -0.179; -0.019) and lower Insulin-Like Growth Factor 1 (Igf-1) (difference on log scale -0.141\u2009µg/l, 95% cl -0.254; -0.028) than 60\u2009mg iron and 400 μg Folic Acid.']	N/A	N/A	[('CHEBI_17234', 'glucose', 126, 'glucose'), ('PR_000008959', 'immunoglobulin heavy constant gamma 1', 194, 'insulin-like growth factor 1'), ('PR_000008929', 'interferon-related developmental regulator 1', 224, 'IGF-1'), ('CHEBI_30751', 'formic acid', 319, 'folic acid')]
PMC5100620	10/2016	S44-PMC5100620	['outcomes\nthe primary outcomes were maternal haemoglobin at 30 weeks of Gestation, Birthweight and infant mortality.24secondary outcomes reported in this paper are Metabolic markers (Lipid and Glucose Metabolism, inflammation, oxidative stress) at 4.5 years of age.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 71, 'gestation'), ('GO_0007596', 'blood coagulation', 82, 'birthweight'), ('GO_0008152', 'metabolic process', 163, 'metabolic'), ('CHEBI_18059', 'lipid', 182, 'lipid'), ('CHEBI_17234', 'glucose', 192, 'glucose'), ('GO_0006006', 'glucose metabolic process', 192, 'glucose metabolism')]
PMC5100620	10/2016	S55-PMC5100620	['Glucose was analysed in whole Blood at the field site health clinics by Hemocue®(hemocue, ängelholm, sweden).']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('UBERON_0000178', 'blood', 30, 'blood'), ('CHEBI_46756', 'HEPES', 72, 'HemoCue')]
PMC5100620	10/2016	S58-PMC5100620	['Insulin resistance was estimated by the Homeostasis model assessment (homa-ir) [homa-ir = fasting Plasma Insulin level (mu/l × fasting plasma Glucose level (mmol/l)/22.5].33the coefficient of variation (cv) was measured at two levels and for the Lipid biomarkers cv was\xa0≤ 3% in all cases.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 0, 'Insulin'), ('GO_0042592', 'homeostatic process', 40, 'homeostasis'), ('UBERON_0001969', 'blood plasma', 98, 'plasma'), ('PR_000045358', 'insulin family protein', 105, 'insulin'), ('CHEBI_17234', 'glucose', 142, 'glucose'), ('CHEBI_18059', 'lipid', 246, 'lipid')]
PMC5100620	10/2016	S85-PMC5100620	['biomarkers were presented in blocks divided into Lipid Metabolism (Apoa1, apob, apob/Apoa1, Cholesterol, hdl, ldl, ldl/hdl, Triglycerides), Glucose Metabolism (Glucose, Insulin, homa-ir), growth factors (Igf-1, Igfbp-1, Igf-1/Igfbp-1), inflammation (crp) and oxidative stress (8-Iso-Pgf2Α).']	N/A	N/A	[('CHEBI_18059', 'lipid', 49, 'lipid'), ('GO_0006629', 'lipid metabolic process', 49, 'lipid metabolism'), ('PR_000004123', 'adenomatous polyposis coli protein 2', 67, 'apoA1'), ('PR_000004123', 'adenomatous polyposis coli protein 2', 85, 'apoA1'), ('CHEBI_16113', 'cholesterol', 92, 'cholesterol'), ('CHEBI_17855', 'triglyceride', 124, 'triglycerides'), ('CHEBI_17234', 'glucose', 140, 'glucose'), ('GO_0006006', 'glucose metabolic process', 140, 'glucose metabolism'), ('CHEBI_17234', 'glucose', 160, 'glucose'), ('PR_000045358', 'insulin family protein', 169, 'insulin'), ('PR_000008929', 'interferon-related developmental regulator 1', 204, 'IGF-1'), ('PR_000008940', 'intraflagellar transport protein 88', 211, 'IGFBP-1'), ('PR_000008929', 'interferon-related developmental regulator 1', 220, 'IGF-1'), ('PR_000008940', 'intraflagellar transport protein 88', 226, 'IGFBP-1'), ('CHEBI_46930', 'N(2)-ornithino group', 278, '-iso'), ('PR_000012644', 'protein Jade-1', 283, 'PGF2α')]
PMC5100620	10/2016	S86-PMC5100620	['normally distributed biomarkers are presented as means with 95 % confidence intervals (all assessed Lipid markers and Glucose).']	N/A	N/A	[('CHEBI_18059', 'lipid', 100, 'lipid'), ('CHEBI_17234', 'glucose', 118, 'glucose')]
PMC5100620	10/2016	S118-PMC5100620	['Metabolic markers by Food and Micronutrient supplementation groups and mean differences between supplementation groupsmaternal Food supplementationmaternal Micronutrient supplementationall childrenearly invitationusual invitationmean difference early- usual (95% ci)mmsfe60ffe30fmean difference mms-fe60 Lipid Metabolism( n \u2009=\u20091335)( n \u2009=\u2009672)( n \u2009=\u2009663)( n \u2009=\u2009435)( n \u2009=\u2009449)( n \u2009=\u2009451) \u2003Apoa1 (g/l)a0.98 (0.97 to 0.99)0.98 (0.97 to 0 .99)0.98 (.97 to 1.00)−0.005 (−0.023 to 0.012)0.97 (0.96 to 0.99)0.99 (0.97 to 1.00)0.98 (0.97 to 1.00)−0.014 (−0.035 to 0.007)\u2003Apob (g/l)0.72 (0.71 to 0.73)0.71 (0.70 to 0.72)0.73 (0.72 to 0.74)−0.017 (−0.033 to -0.001)0.72 (0.70 to 0.73)0.72 (0.71 to 0.74)0.72 (0.70 to 0.73)−0.004 (−0.024 to 0.016)\u2003Apob/Apoa10.74 (0.74 to 0.75)0.74 (0.72 to 0.75)0.75 (0.74 to 0.77)−0.015 (−0.034 to 0.004)0.75 (0.74 to 0.77)0.74 (0.72 to 0.76)0.74 (0.73 to 0.76)0.011 (−0.012 to 0.034)\u2003Cholesterol (mmol/l)3.78 (3.74 to 3.82)3.74 (3.69 to 3.80)3.82 (3.77 to 3.88)−0.079 (−0.156 to -0.003)3.75 (3.68 to 3.82)3.82 (3.75 to 3.88)3.78 (3.71 to 3.85)−0.064 (−0.158 to 0.031)\u2003hdl (mmol/l)0.91 (0.90 to 0.92)0.90 (0.89 to 0.92)0.91 (0.90 to 0.93)−0.007 (−0.027 to 0.014)0.89 (0.87 to 0.87)0.92 (0.90 to 0.94)0.91 (0.90 to 0.93)−0.028 (−0.053 to -0.002)\u2003ldl (mmol/l)2.07 (2.04 to 2.09)2.03 (1.99 to 2.07)2.10 (2.06 to 2.14)−0.068 (−0.126 to -0.011)2.04 (1.99 to 2.09)2.10 (2.05 to 2.15)2.06 (2.01 to 2.11)−0.054 (−0.124 to 0.017)\u2003ldl/hdl2.32 (2.29 to 2.35)2.29 (2.25 to 2.34)2.35 (2.30 to 2.39)−0.054 (−0.117 to 0.008)2.33 (2.28 to 2.39)2.32 (2.27 to 2.38)2.30 (2.25 to 2.35)0.010 (−0.067 to 0.087)\u2003Triglycerides (mmol/l)1.28 (1.26 to 1.31)1.29 (1.25 to 1.33)1.27 (1.24 to 1.31)0.016 (−0.037 to 0.070)1.28 (1.24 to 1.33)1.27 (1.23 to 1.32)1.29 (1.25 to 1.34)0.011 (−0.054 to 0.077) Glucose Metabolism( n\u2009=\u20091351)( n\u2009=\u2009682)( n\u2009=\u2009669)( n\u2009=\u2009439)( n\u2009=\u2009454)( n\u2009=\u2009458) \u2003Glucose (mmol/l)4.75 (4.72 to 4.78)4.73 (4.68 to 4.77)4.78 (4.73 to 4.82)−0.050 (−0.115 to 0.015)4.70 (4.64 to 4.75)4.80 (4.74 to 4.85)4.76 (4.70 to 4.81)−0.099 (−0.179 to -0.019)(n\u2009=\u20091290)(n\u2009=\u2009649)(n\u2009=\u2009641)log mean difference early-usual (95% ci)(n\u2009=\u2009416)(n\u2009=\u2009432)(n\u2009=\u2009442)log mean difference mms- fe60 (95% ci)\u2003Insulin (pmol/l)8.70 (4.56 to 15.00)8.58 (4.56 to 14.40)8.76 (4.53 to 15.60)−0.009 (−0.123 to 0.105)8.10 (4.38 to13.80)8.79 (4.56 to 15.60)9.06 (4.77 to 15.15)−0.071 (−0.212 to 0.069)\u2003homa-ir0.30 (0.16 to 0.54)0.30 (0.16 to 0.52)0.30 (0.16 to 0.56)−0.018 (−0.137 to 0.101)0.28 (0.15 to 0.49)0.31 (0.17 to 0.56)0.30 (0.16 to 0.58)−0.095 (−0.241 to 0.052) growth factorsn\u2009=\u2009529n\u2009=\u2009258n\u2009=\u2009271n\u2009=\u2009162n\u2009=\u2009184n\u2009=\u2009181 \u2003Igf-1 (µg/l)83 (58 to 117)83 (61 to 113)85 (57 to 120)0.001 (−0.091 to 0.093)77 (53 to 106)88 (61 to 122)85 (62 to 124)−0.141 (−0.254 to -0.028)b\u2003Igfbp-1 (µg/l)147 (126 to 171)150 (124 to 170)146 (126 to 172)−0.024 (−0.074 to 0.027)152 (129 to 174)144 (124 to 167)148 (127 to 168)0.063 (0.001 to 0.126)\u2003Igf-1/Igfbp-10.57 (0.37 to 0.86)0.56 (0.39 to 0.82)0.57 (0.35 to 0.87)0.021 (−0.099 to 0.141)0.51 (0.33 to 0.76)0.62 (0.42 to 0.89)0.57 (0.38 to 0.94)−0.199 (−0.347 to -0.051) inflammation( n\u2009=\u20091335)( n\u2009=\u2009672)( n\u2009=\u2009663)( n\u2009=\u2009435)( n\u2009=\u2009449)( n\u2009=\u2009451) \u2003Crp (mg/l)0.48 (0.21 to 1.40)0.48 (0.21 to 1.30)0.48 (0.21 to 1.40)−0.046 (−0.200 to 0.109)0.54 (0.23 to 1.40)0.44 (0.20 to 1.30)0.48 (0.21 to 1.50)0.100 (−0.090 to 0.290)\u2003oxidative stress(n\u2009=\u2009264)(n\u2009=\u2009136)(n\u2009=\u2009128)(n\u2009=\u200977)(n\u2009=\u200984)(n\u2009=\u2009103)\u20038-Iso- Pgf2Α(nmol/mmol Creatinine)0.97 (0.74 to 1.27)0.99 (0.74 to 1.32)0.95 (0.72 to 1.20)0.069 (−0.047 to 0.184)0.97 (0.75 to 1.29)0.96 (0.73 to 1.20)0.97 (0.74 to 1.28)0.058 (−0.091 to 0.206)\nadata are presented as mean (95% ci) and mean difference (95% ci) for normally distributed variables, and median (iqr) and log mean difference (95% ci) for non-normally distributed variables.']	N/A	N/A	[('GO_0008152', 'metabolic process', 0, 'Metabolic'), ('CHEBI_33290', 'food', 21, 'food'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 30, 'micronutrient'), ('CHEBI_33290', 'food', 127, 'food'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 156, 'micronutrient'), ('CHEBI_18059', 'lipid', 304, 'Lipid'), ('GO_0046441', 'D-lysine metabolic process', 304, 'Lipid metabolism'), ('PR_000004155', 'apolipoprotein E', 389, 'ApoA1'), ('PR_000004155', 'apolipoprotein E', 564, 'ApoB'), ('PR_000004155', 'apolipoprotein E', 738, 'ApoB'), ('PR_000004105', 'AP-3 complex subunit beta-2', 743, 'ApoA10'), ('CHEBI_16113', 'cholesterol', 910, 'Cholesterol'), ('CHEBI_17855', 'triglyceride', 1615, 'Triglycerides'), ('CHEBI_17234', 'glucose', 1798, 'Glucose'), ('GO_0006006', 'glucose metabolic process', 1798, 'Glucose metabolism'), ('CHEBI_17234', 'glucose', 1879, 'Glucose'), ('GO_0060206', 'estrous cycle phase', 1879, 'Glucose'), ('PR_000045358', 'insulin family protein', 2192, 'Insulin'), ('PR_000008929', 'interferon-related developmental regulator 1', 2604, 'IGF-1'), ('PR_000008940', 'intraflagellar transport protein 88', 2750, 'IGFBP-1'), ('PR_000008929', 'interferon-related developmental regulator 1', 2907, 'IGF-1'), ('PR_000008940', 'intraflagellar transport protein 88', 2913, 'IGFBP-10'), ('PR_000005890', 'crooked neck-like protein 1', 3158, 'CRP'), ('CHEBI_70351', 'Bussealin D', 3399, '8-iso-'), ('PR_000012644', 'protein Jade-1', 3406, 'PGF2α'), ('CHEBI_16737', 'creatinine', 3422, 'creatinine')]
PMC5100620	10/2016	S121-PMC5100620	['we found no differential effect by timing of Food supplementation groups on markers of Glucose Metabolism (table 2).']	N/A	N/A	[('CHEBI_33290', 'food', 45, 'food'), ('CHEBI_17234', 'glucose', 87, 'glucose'), ('GO_0006006', 'glucose metabolic process', 87, 'glucose metabolism')]
PMC5100620	10/2016	S127-PMC5100620	['allocation to Prenatal Mms supplementation resulted in lower fasting Glucose concentrations in the children compared with the fe60f group (table 2).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 14, 'prenatal'), ('CHEBI_39010', 'MES', 23, 'MMS'), ('CHEBI_17234', 'glucose', 69, 'glucose')]
PMC5100620	10/2016	S135-PMC5100620	['children of women allocated to multiple Micronutrient supplementation (as compared with standard Iron-Folate) had lower levels of fasting Glucose and Insulin-Like Growth Factor 1 and also lower levels of hdl.']	N/A	N/A	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 40, 'micronutrient'), ('CHEBI_24870', 'ion', 97, 'iron'), ('CHEBI_30863', '5-azaorotic acid', 102, 'folate'), ('CHEBI_17234', 'glucose', 138, 'glucose'), ('PR_000008959', 'immunoglobulin heavy constant gamma 1', 150, 'insulin-like growth factor')]
PMC5100627	10/2016	S37-PMC5100627	['characteristics of the seven cohortscharacteristicsnfbc 1986alspac childrenfinn-twinfinn-twinnfbc 1966young finns studyhelsinki Birth cohort studyft12ft16number of Individuals5579287476749554122273890Men [%]50.448.441.251.149.944.743.9age at Blood sampling [years]16.1 (0.4)17.8 (0.4)22.4 (0.6)26.2 (1.3)31.2 (0.4)39.2 (6.1)66.3 (2.9)Birthweight [g]3562 (541)3426 (546)2703 (507)2673 (495)3498 (523)3508 (543)3432 (470)Gestational age [week]39.4 (1.8)39.4 (1.6)36.9 (2.2)36.9 (2.5)40.0 (1.9)38.6 (1.2)40.0 (1.5)Adult body mass index [kg/m2]21.2 (3.4)23.0 (3.9)23.3 (3.9)23.8 (4.0)25.6 (4.1)26.3 (4.9)27.0 (4.1)systolic Blood pressure [mm hg]116 (13)115 (10)––125 (13)119 (14)143 (19)total-c [mmol/l]4.3 (0.8)3.8 (0.7)4.7 (0.9)5.0 (0.9)5.0 (1.0)5.1 (0.9)6.1 (1.0)hdl-c [mmol/l]1.4 (0.3)1.4 (0.2)1.8 (0.4)1.8 (0.4)1.5 (0.4)1.3 (0.3)1.7 (0.4)Triglycerides [mmol/l]0.70.80.91.21.01.11.2[0.6-1.0][0.7-1.0][0.7-1.2][0.9-1.62][0.7-1.4][0.8-1.5][0.9-1.7]Glucose [mmol/l]5.25.04.64.75.05.35.5[4.9-5.4][4.7-5.3][4.3-4.8][4.3-5.2][4.7-5.3][4.9-5.6][5.1-5.8]Insulin [iu/l]9.66.8––7.57.37.4[7.4-12.3][4.9-9.3][6.2-9.4][4.4-11.2][5.2-11.2]\nvalues are mean (sd) and median [interquartile range] for normally distributed and positively skewed variables, respectively.']	N/A	N/A	[('GO_0007567', 'parturition', 128, 'Birth'), ('NCBITaxon_10088', 'Mus <genus>', 164, 'individuals5579287476749554122273890Men'), ('UBERON_0000178', 'blood', 242, 'blood'), ('GO_0007608', 'sensory perception of smell', 334, 'Birthweight'), ('GO_0007565', 'female pregnancy', 419, 'Gestational'), ('UBERON_0007023', 'adult organism', 511, 'Adult'), ('UBERON_0000178', 'blood', 619, 'blood'), ('CHEBI_17855', 'triglyceride', 839, 'Triglycerides'), ('CHEBI_17234', 'glucose', 946, 'Glucose'), ('PR_000045358', 'insulin family protein', 1046, 'Insulin')]
PMC5110566	11/2016	S74-PMC5110566	['offspring from hfd mothers showed alterations in blood Glucose and Insulin levels, with high predisposition to Insulin resistance and Cardiac dysfunction (taylor et al.,2005; wang et al.,2010).']	N/A	N/A	[('CHEBI_17234', 'glucose', 55, 'glucose'), ('PR_000045358', 'insulin family protein', 67, 'insulin'), ('PR_000045358', 'insulin family protein', 111, 'insulin'), ('UBERON_0000948', 'heart', 134, 'cardiac')]
PMC5117700	11/2016	S29-PMC5117700	['Metformin inhibits both Gluconeogenesis and Glycogenolysis, thereby reducing Hepatic Glucose Production, [18] while increasing Insulin mediated Skeletal muscle and Adipocyte Glucose utilisation [19].']	N/A	N/A	[('CHEBI_6801', 'metformin', 0, 'Metformin'), ('GO_0006094', 'gluconeogenesis', 24, 'gluconeogenesis'), ('GO_0005981', 'regulation of glycogen catabolic process', 44, 'glycogenolysis'), ('UBERON_0002107', 'liver', 77, 'hepatic'), ('CHEBI_17234', 'glucose', 85, 'glucose'), ('GO_0006094', 'gluconeogenesis', 85, 'glucose production'), ('PR_000045358', 'insulin family protein', 127, 'insulin'), ('UBERON_0004288', 'skeleton', 144, 'skeletal'), ('CL_0000136', 'fat cell', 164, 'adipocyte'), ('CHEBI_17234', 'glucose', 174, 'glucose')]
PMC5118969	11/2016	S53-PMC5118969	['caption (table-wrap): table 1\n\nlaboratory parameters on admission.parametersvalues hemoglobin (g/dl)15.4hematocrit (%)47platelet count (k/μl)127leucocyte count (k/μl)13.6serum Sodium (meq/l)133serum Potassium (meq/l)2.4serum Chloride (meq/l)77serum bicarbonate (meq/l)30bun (mg/dl)43creatinine (mg/dl)1.1serum Glucose (mg/dl)151total protein (g/dl)8.5serum Albumin (g/dl)4.8aspartate transaminase (unit/l)285alanine aminotransferase (unit/l)549alkaline phosphatase (unit/l)97total Bilirubin (mg/dl)6.1direct bilirubin (mg/dl)4.5lactic acid level (mmol/l)2.6urine analysisnegativeblood culturesnegativeurine culturesnegativeurine toxicologycannabinoids\n\ncaption (table-wrap): table 2\n\nCardiac markers and Thyroid panel during the admission.day 1day 1day 2day 2 Troponin T (ng/ml)1.4103.1903.6003.110creatine kinase (μ/l)1107223629711344creatine kinase mb (ng/ml)66.5981tsh (iu/l)<0.07<0.07<0.07<0.07t3 (ng/dl)377298169149t4 (ug/dl)>24.822.8free Thyroxin (ng/dl)7.777.743.722.89\n\ntreatment\nshe was started on Dexamethasone and loaded with Iodine to achieve euthyroid state.']	N/A	N/A	[('CHEBI_52632', 'potassium-39 atom', 176, 'sodium'), ('CHEBI_22314', 'alkali metal atom', 199, 'potassium'), ('CHEBI_17996', 'chloride', 225, 'chloride'), ('CHEBI_17234', 'glucose', 310, 'glucose'), ('PR_000005908', 'alpha-crystallin B chain', 357, 'albumin'), ('CHEBI_16990', 'bilirubin IXalpha', 481, 'bilirubin'), ('UBERON_0000948', 'heart', 684, 'Cardiac'), ('UBERON_0002046', 'thyroid gland', 704, 'thyroid'), ('CHEBI_80935', 'Plocamene C', 760, 'Troponin T'), ('PR_000016649', 'transcription intermediary factor 1-alpha', 760, 'Troponin T'), ('CHEBI_71941', 'tolmetin', 944, 'thyroxin'), ('CHEBI_41879', 'dexamethasone', 1007, 'dexamethasone'), ('CHEBI_24859', 'iodine atom', 1037, 'iodine')]
PMC5126873	11/2016	S48-PMC5126873	['participants from both arms of the trial had an oral Glucose tolerance test (75\xa0g Glucose load) at 27+0to 28+6weeks Gestation for gdm diagnosis.']	N/A	N/A	[('CHEBI_17234', 'glucose', 53, 'glucose'), ('CHEBI_17234', 'glucose', 82, 'glucose'), ('GO_0007565', 'female pregnancy', 116, 'gestation')]
PMC5165167	12/2016	S6-PMC5165167	['msg-treated Mice developed obesity, Glucose intolerance, Insulin resistance, Pancreatic Islet dysfunction, and higher fat stores.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 12, 'mice'), ('CHEBI_17234', 'glucose', 36, 'glucose'), ('PR_000045358', 'insulin family protein', 57, 'insulin'), ('UBERON_0001264', 'pancreas', 77, 'pancreatic'), ('CL_0000214', 'synovial cell', 88, 'islet'), ('UBERON_0002533', 'post-anal tail bud', 88, 'islet')]
PMC5165167	12/2016	S7-PMC5165167	['maternal flaxseed diet-supplementation decreased n-6/n-3 Pufas ratio in the Brain and Pancreas and blocked Glucose intolerance, Insulin resistance, giis impairment, and obesity development.']	N/A	N/A	[('CHEBI_86926', 'S a S b S', 57, 'PUFAs'), ('UBERON_0000955', 'brain', 76, 'brain'), ('UBERON_0001264', 'pancreas', 86, 'pancreas'), ('CHEBI_17234', 'glucose', 107, 'glucose'), ('PR_000045358', 'insulin family protein', 128, 'insulin')]
PMC5165167	12/2016	S54-PMC5165167	['Intraperitoneal Glucose tolerance test (ipgtt)\nthe ipgtt was performed by Intraperitoneally injecting Glucose (2\u2009g\u2009kg−1) into overnight-fasted Mice.']	N/A	N/A	[('UBERON_0007158', 'lumen of anal canal', 0, 'Intraperitoneal'), ('CHEBI_17234', 'glucose', 16, 'Glucose'), ('UBERON_0000007', 'pituitary gland', 74, 'intraperitoneally'), ('CHEBI_17234', 'glucose', 102, 'glucose'), ('NCBITaxon_10088', 'Mus <genus>', 143, 'mice')]
PMC5165167	12/2016	S56-PMC5165167	['the blood Glucose levels were determined prior (0) to injection and 30, 60, 90, and 120\u2009min after injection.']	N/A	N/A	[('CHEBI_17234', 'glucose', 10, 'glucose')]
PMC5165167	12/2016	S57-PMC5165167	['all Blood samples were obtained from the Tail Vein, and the Plasma was used to measure the Glucose concentration by the Glucose oxidase method.']	N/A	N/A	[('UBERON_0000178', 'blood', 4, 'blood'), ('UBERON_0003481', 'tail vein', 41, 'tail vein'), ('UBERON_0001969', 'blood plasma', 60, 'plasma'), ('CHEBI_17234', 'glucose', 91, 'glucose'), ('CHEBI_17234', 'glucose', 120, 'glucose')]
PMC5165167	12/2016	S61-PMC5165167	['the blood Glucose levels were determined prior (0) to injection and 5, 15, 30, and 45\u2009min after injection.']	N/A	N/A	[('CHEBI_17234', 'glucose', 10, 'glucose')]
PMC5165167	12/2016	S62-PMC5165167	['all Blood samples were obtained and the Plasma Glucose concentration was measured as described above.']	N/A	N/A	[('UBERON_0000178', 'blood', 4, 'blood'), ('UBERON_0001969', 'blood plasma', 40, 'plasma'), ('CHEBI_17234', 'glucose', 47, 'glucose')]
PMC5165167	12/2016	S63-PMC5165167	['the constant rate for Plasma Glucose disappearance ( kitt) was calculated using the formula 0.693( t1/2)−1.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 22, 'plasma'), ('CHEBI_17234', 'glucose', 29, 'glucose')]
PMC5165167	12/2016	S68-PMC5165167	['to adapt the isolated Islets to a baseline Glucose concentration (5.6\u2009mmol\u2009l−1), the Islets (four Islets per well) were preincubated for 60\u2009min with 1\u2009ml of normal krebs-ringer Solution [concentration in mmol\u2009l−1: Nacl, 115; Nahco3, 24; Kcl, 1.6; Mgcl·6H2O, 1; Cacl2·2H2O, 1; and Bovine Serum Albumin, bsa, 15] at ph 7.4 containing 5.6\u2009mmol\u2009l−1glucose.']	N/A	N/A	[('UBERON_0000029', 'lymph node', 22, 'islets'), ('CHEBI_17234', 'glucose', 43, 'glucose'), ('UBERON_0000029', 'lymph node', 85, 'islets'), ('UBERON_0000029', 'lymph node', 98, 'islets'), ('CHEBI_75958', 'solution', 177, 'solution'), ('CHEBI_26710', 'sodium chloride', 214, 'NaCl'), ('CHEBI_32139', 'sodium hydrogencarbonate', 225, 'NaHCO3'), ('CHEBI_32588', 'potassium chloride', 237, 'KCl'), ('CHEBI_6636', 'magnesium dichloride', 247, 'MgCl'), ('CHEBI_17759', 'cholesta-5,7-dien-3beta-ol', 252, '6H2O'), ('CHEBI_3312', 'calcium dichloride', 261, 'CaCl2'), ('CHEBI_37926', 'fluorescein isothiocyanate', 267, '2H2O'), ('NCBITaxon_33208', 'Metazoa', 280, 'bovine'), ('PR_000003918', 'albumin', 287, 'serum albumin'), ('UBERON_0001977', 'blood serum', 287, 'serum')]
PMC5165167	12/2016	S70-PMC5165167	['after the preincubation step, the Islets were incubated with 2 different Glucose concentrations, 5.6 and 16.7\u2009mmol\u2009l−1, for an additional 60\u2009min.']	N/A	N/A	[('CL_0000125', 'glial cell', 34, 'islets'), ('UBERON_0000029', 'lymph node', 34, 'islets'), ('CHEBI_17234', 'glucose', 73, 'glucose')]
PMC5165167	12/2016	S90-PMC5165167	['as showed infigure 2(b), msg-com Mice exhibited a low capacity for Glucose Uptake after Insulin injection.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 33, 'mice'), ('CHEBI_17234', 'glucose', 67, 'glucose'), ('GO_0046323', 'glucose import', 67, 'glucose uptake'), ('PR_000045358', 'insulin family protein', 88, 'insulin')]
PMC5165167	12/2016	S92-PMC5165167	['by contrast, the msg-flax treated Mice displayed an increased Glucose disappearance rate of 155%, p< 0.001.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 34, 'mice'), ('CHEBI_17234', 'glucose', 62, 'glucose')]
PMC5165167	12/2016	S97-PMC5165167	['Glucose concentrations of 16.7\u2009mmol\u2009l−1also induced Insulin oversecretion in Islets isolated from the msg-com Mice, a 2-fold increase in the giis compared to the control-com Mice ( p< 0.001).']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('PR_000045358', 'insulin family protein', 52, 'insulin'), ('CL_0000125', 'glial cell', 77, 'islets'), ('UBERON_0000029', 'lymph node', 77, 'islets'), ('NCBITaxon_10088', 'Mus <genus>', 110, 'mice'), ('NCBITaxon_10088', 'Mus <genus>', 174, 'mice')]
PMC5165167	12/2016	S98-PMC5165167	['Perinatal treatment with the flax-diet caused an 83%, p< 0.01, increase in giis that was stimulated by a high Glucose concentration in the Islets isolated from the control-flax group compared to the control-com group.']	N/A	N/A	[('GO_0036268', 'swimming', 0, 'Perinatal'), ('UBERON_0012101', 'perinatal stage', 0, 'Perinatal'), ('CHEBI_17234', 'glucose', 110, 'glucose'), ('CL_0000125', 'glial cell', 139, 'islets')]
PMC5165167	12/2016	S130-PMC5165167	['dietary supplementation with sunflower oil and golden flaxseed flour as sources of N-6/N-3 Fatty Acids in a 1.2\u2009:\u20091.0 ratio in the maternal diet during Pregnancy and Lactation improved the Metabolism of msg-obese Mice Adult offspring, including a correction of Glucose intolerance, low Insulin sensitivity in peripheral Tissues, high fat Tissue accumulation, and Insulin oversecretion.']	N/A	N/A	[('CHEBI_18320', '1,4-dithiothreitol', 83, 'n-6'), ('CHEBI_30256', 'thiocarbonyl group', 87, 'n-3'), ('CHEBI_35366', 'fatty acid', 91, 'fatty acids'), ('GO_0007565', 'female pregnancy', 152, 'pregnancy'), ('GO_0007595', 'lactation', 166, 'lactation'), ('GO_0008152', 'metabolic process', 189, 'metabolism'), ('NCBITaxon_10088', 'Mus <genus>', 213, 'mice'), ('UBERON_0007023', 'adult organism', 218, 'adult'), ('CHEBI_17234', 'glucose', 261, 'glucose'), ('PR_000045358', 'insulin family protein', 286, 'insulin'), ('UBERON_0000479', 'tissue', 320, 'tissues'), ('UBERON_0000479', 'tissue', 338, 'tissue'), ('PR_000045358', 'insulin family protein', 363, 'insulin')]
PMC5187359	12/2016	S5-PMC5187359	['the female offspring from calorie-restricted dams exhibited higher Plasma levels of ldl and Glucose as well as a reduction in chocolate and caloric Intake at post-weaning periods in the Feeding tests.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 67, 'plasma'), ('CHEBI_17234', 'glucose', 92, 'glucose'), ('GO_0007631', 'feeding behavior', 148, 'intake'), ('GO_0007631', 'feeding behavior', 186, 'feeding')]
PMC5187359	12/2016	S90-PMC5187359	['measurement of Metabolites, Hepatic enzymes, and leptin in Plasma\nthe following Plasma Metabolites and enzymes were measured: basal Glucose, Triglycerides, total Cholesterol, high-density lipoprotein (hdl), Urea, Bilirubin, alkaline phosphatase (alkp), and the Hepatic enzymes alanine aminotransferase (alt), aspartate aminotransferase (ast), and gamma-glutamyl transpeptidase (γgt).']	N/A	N/A	[('CHEBI_25212', 'metabolite', 15, 'metabolites'), ('UBERON_0002107', 'liver', 28, 'hepatic'), ('UBERON_0001969', 'blood plasma', 59, 'plasma'), ('UBERON_0001969', 'blood plasma', 80, 'plasma'), ('CHEBI_25212', 'metabolite', 87, 'metabolites'), ('CHEBI_17234', 'glucose', 132, 'glucose'), ('CHEBI_17855', 'triglyceride', 141, 'triglycerides'), ('CHEBI_16113', 'cholesterol', 162, 'cholesterol'), ('CHEBI_16199', 'urea', 207, 'urea'), ('CHEBI_16990', 'bilirubin IXalpha', 213, 'bilirubin'), ('UBERON_0002107', 'liver', 261, 'hepatic')]
PMC5187359	12/2016	S170-PMC5187359	['the rc females presented an increase in the Plasma levels of Glucose.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 44, 'plasma'), ('CHEBI_17234', 'glucose', 61, 'glucose')]
PMC5241768	1/2017	S29-PMC5241768	['fasting is defined as no caloric Intake for at least 8 h.*or2-h Plasma Glucose ≥200 mg/dl (11.1 mmol/l) during an ogtt.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 33, 'intake'), ('UBERON_0001969', 'blood plasma', 64, 'plasma'), ('CHEBI_17234', 'glucose', 71, 'glucose')]
PMC5241768	1/2017	S33-PMC5241768	['*orin a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random Plasma Glucose ≥200 mg/dl (11.1 mmol/l).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 89, 'plasma'), ('CHEBI_17234', 'glucose', 96, 'glucose')]
PMC5241768	1/2017	S75-PMC5241768	['in a 15-year prospective study of community-dwelling People >60 years of age, the presence of diabetes at baseline significantly increased the age- and sex-adjusted incidence of all-cause dementia, alzheimer’s disease, and vascular dementia compared with rates in those with normal Glucose tolerance.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 53, 'people'), ('CHEBI_17234', 'glucose', 282, 'glucose')]
PMC5241768	1/2017	S243-PMC5241768	['a\nconsider educating Individuals with type 1 diabetes on matching prandial Insulin doses to Carbohydrate intake, premeal blood Glucose levels, and anticipated physical activity.']	N/A	N/A	[('NCBITaxon_1', 'root', 21, 'individuals'), ('PR_000045358', 'insulin family protein', 75, 'insulin'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 92, 'carbohydrate'), ('CHEBI_17234', 'glucose', 127, 'glucose')]
PMC5241768	1/2017	S247-PMC5241768	['b\nconsider initiating Insulin therapy (with or without additional Agents) in patients with newly diagnosed type 2 diabetes who are symptomatic and/or have an a1c ≥10% (86 mmol/mol) and/or Blood Glucose levels ≥300 mg/dl (16.7 mmol/l).']	N/A	N/A	[('CHEBI_66075', 'inflexin', 22, 'insulin'), ('PR_000045358', 'insulin family protein', 22, 'insulin'), ('CHEBI_33250', 'atom', 66, 'agents'), ('UBERON_0000178', 'blood', 188, 'blood'), ('CHEBI_17234', 'glucose', 194, 'glucose')]
PMC5241768	1/2017	S266-PMC5241768	['fbg, fasting blood Glucose; Glp-1 Ra, Glp-1 Receptor Agonist; hypo, hypoglycemia.']	N/A	N/A	[('CHEBI_17234', 'glucose', 19, 'glucose'), ('PR_000008070', 'glia maturation factor beta', 28, 'GLP-1 RA'), ('PR_000007998', 'gap junction beta-2 protein', 38, 'GLP-1 receptor'), ('CHEBI_85384', 'GABA reuptake inhibitor', 53, 'agonist')]
PMC5241768	1/2017	S312-PMC5241768	['b\noptimize Glucose Control to reduce the risk or slow the progression of diabetic Kidney disease.']	N/A	N/A	[('CHEBI_17234', 'glucose', 11, 'glucose'), ('GO_0046323', 'glucose import', 11, 'glucose control'), ('UBERON_0002113', 'kidney', 82, 'kidney')]
PMC5241768	1/2017	S333-PMC5241768	['b\noptimize Glucose Control to prevent or delay the development of neuropathy in patients with type 1 diabetes a and to slow the progression of neuropathy in patients with type 2 diabetes.']	N/A	N/A	[('CHEBI_17234', 'glucose', 11, 'glucose'), ('GO_0046323', 'glucose import', 11, 'glucose control')]
PMC5241768	1/2017	S402-PMC5241768	['dyslipidemia\nrecommendations\nobtain a fasting Lipid profile on children ≥10 years of age soon after diabetes diagnosis (after Glucose Control has been established).']	N/A	N/A	[('CHEBI_18059', 'lipid', 46, 'lipid'), ('CHEBI_17234', 'glucose', 126, 'glucose'), ('GO_0065007', 'biological regulation', 134, 'control')]
PMC5241768	1/2017	S452-PMC5241768	['Glycemic targets in hospitalized patients\n\nstandard definition of Glucose abnormalities\n\nhyperglycemia: >140 mg/dl (7.8 mmol/l)\nhypoglycemia: <54 mg/dl (3.0 mmol/l) or severe Cognitive impairment.']	N/A	N/A	[('CHEBI_30856', 'thiophene', 0, 'Glycemic'), ('GO_0001815', 'positive regulation of antibody-dependent cellular cytotoxicity', 0, 'Glycemic'), ('CHEBI_17234', 'glucose', 66, 'Glucose'), ('GO_0050890', 'cognition', 175, 'cognitive')]
PMC5241768	1/2017	S464-PMC5241768	['monitor blood Glucose every 4–6 hours while a patient is taking nothing by mouth and dose with short-acting Insulin as needed with a target of 80–180 mg/dl (4.4–10.0 mmol/l).']	N/A	N/A	[('CHEBI_17234', 'glucose', 14, 'glucose'), ('PR_000045358', 'insulin family protein', 108, 'insulin')]
PMC5273824	1/2017	S30-PMC5273824	['Vitamin D induces Insulin receptor Expression through Vitamin D receptor (vdr), enhancing Insulin-Dependent Glucose transport.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('PR_000045358', 'insulin family protein', 18, 'insulin'), ('GO_0010467', 'gene expression', 35, 'expression'), ('CHEBI_28384', 'vitamin K', 54, 'Vitamin D'), ('GO_0007631', 'feeding behavior', 90, 'insulin'), ('PR_000045358', 'insulin family protein', 90, 'insulin'), ('GO_0007567', 'parturition', 98, 'dependent'), ('CHEBI_17234', 'glucose', 108, 'glucose')]
PMC5273824	1/2017	S38-PMC5273824	['methods\n\nstudy objects\nPregnant women in middle and late Pregnancy who were diagnosed with gdm by 75-g oral Glucose tolerance test (ogtt) at the outpatient nutrition clinic in peking union medical college hospital from october 2013 to july 2015 were enrolled in this study.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 23, 'Pregnant'), ('GO_0007565', 'female pregnancy', 57, 'pregnancy'), ('CHEBI_17234', 'glucose', 108, 'glucose')]
PMC5273824	1/2017	S39-PMC5273824	['the ogtt diagnostic criteria for gdm was as follows: oral Intake of 83\xa0g Glucose powder; the normal fasting Glucose level was 5.1\xa0mmol/l; 1\xa0h post oral Glucose Intake was 10.0\xa0mmol/l; 2\xa0h post oral Glucose Intake was 8.5\xa0mmol/l; diagnosis of gdm was reached if the Glucose level of more than one time point was high than normal.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 58, 'intake'), ('CHEBI_17234', 'glucose', 73, 'glucose'), ('CHEBI_17234', 'glucose', 108, 'glucose'), ('CHEBI_17234', 'glucose', 152, 'glucose'), ('GO_0007631', 'feeding behavior', 160, 'intake'), ('CHEBI_17234', 'glucose', 198, 'glucose'), ('GO_0007631', 'feeding behavior', 206, 'intake'), ('CHEBI_17234', 'glucose', 265, 'glucose')]
PMC5279975	12/2016	S16-PMC5279975	['introduction\nGestational diabetes is a Glucose tolerance disorder, which is developed or diagnosed during the Pregnancy period (1).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 13, 'Gestational'), ('CHEBI_17234', 'glucose', 39, 'glucose'), ('GO_0007565', 'female pregnancy', 110, 'pregnancy'), ('UBERON_0000970', 'eye', 110, 'pregnancy')]
PMC5283658	1/2017	S17-PMC5283658	['a common trait in the f1 offspring is an age-related loss of Glucose tolerance and development of Insulin resistance [17–20].']	N/A	N/A	[('CHEBI_17234', 'glucose', 61, 'glucose'), ('PR_000045358', 'insulin family protein', 98, 'insulin')]
PMC5295046	12/2016	S64-PMC5295046	['furthermore, oral Glucose tolerance tests were administered and Gestational diabetes mellitus (gdm) was defined based on the 1999 world health organization criteria [35,36].']	N/A	N/A	[('CHEBI_17234', 'glucose', 18, 'glucose'), ('GO_0007565', 'female pregnancy', 64, 'gestational')]
PMC5303734	2/2017	S173-PMC5303734	['in the developing Brain, substantially high energy demand increases the need for Glucose, oxygen and Cerebral Blood flow (hagberg et al.,2014).']	N/A	N/A	[('UBERON_0000955', 'brain', 18, 'brain'), ('CHEBI_17234', 'glucose', 81, 'glucose'), ('UBERON_0001893', 'telencephalon', 101, 'cerebral'), ('UBERON_0000178', 'blood', 110, 'blood')]
PMC5307888	2/2017	S55-PMC5307888	['Cardiometabolic markers\nthe following Cardiometabolic markers were analysed: total Cholesterol, Triglycerides, non-esterified Fatty Acids (nefa), high-density lipoprotein Cholesterol (hdl-c), Insulin, Glucose, leptin, adiponectin and crp.']	N/A	N/A	[('GO_0007129', 'homologous chromosome pairing at meiosis', 0, 'Cardiometabolic'), ('GO_0007599', 'hemostasis', 38, 'cardiometabolic'), ('CHEBI_16113', 'cholesterol', 83, 'cholesterol'), ('CHEBI_17855', 'triglyceride', 96, 'triglycerides'), ('CHEBI_35366', 'fatty acid', 126, 'fatty acids'), ('CHEBI_16113', 'cholesterol', 171, 'cholesterol'), ('PR_000045358', 'insulin family protein', 192, 'insulin'), ('CHEBI_17234', 'glucose', 201, 'glucose')]
PMC5307888	2/2017	S58-PMC5307888	['Glucose, Cholesterol, hdl-c, Triglycerides, nefa and crp were measured using commercial kits (roche diagnostics, australia or wako pure chemical industries, japan for nefa) with all assays performed on the automated hitachi auto 912 analyser or cobas integra 400 plus with appropriate calibrators and quality controls (roche for roche assays; and wako standard and sero qc’s for the Nefa C assay).']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('CHEBI_16113', 'cholesterol', 9, 'cholesterol'), ('CHEBI_17855', 'triglyceride', 29, 'triglycerides'), ('PR_000011111', 'N-terminal EF-hand calcium-binding protein 3', 383, 'NEFA C')]
PMC5307888	2/2017	S142-PMC5307888	['no statistically significant differences were identified between the two treatment groups in Cord Blood Glucose, Insulin and crp [47].']	N/A	N/A	[('UBERON_0002240', 'spinal cord', 93, 'cord'), ('UBERON_0000178', 'blood', 98, 'blood'), ('CHEBI_17234', 'glucose', 104, 'glucose'), ('PR_000045358', 'insulin family protein', 113, 'insulin')]
PMC5325607	2/2017	S7-PMC5325607	['additionally, mhfd offspring +rw exhibited higher Plasma Insulin levels during Glucose tolerance test and an elevated basal Pancreatic Insulin production compared to mlfd offspring.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 50, 'plasma'), ('PR_000045358', 'insulin family protein', 57, 'insulin'), ('CHEBI_17234', 'glucose', 79, 'glucose'), ('UBERON_0001264', 'pancreas', 124, 'pancreatic'), ('GO_0007631', 'feeding behavior', 135, 'insulin'), ('PR_000045358', 'insulin family protein', 135, 'insulin')]
PMC5325607	2/2017	S15-PMC5325607	['furthermore, regular exercise during Pregnancy improved body fat mass development, Glucose tolerance and increased Glucose clearance in various Tissues/Organs of Adult offspring [7–9].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 37, 'pregnancy'), ('CHEBI_17234', 'glucose', 83, 'glucose'), ('CHEBI_17234', 'glucose', 115, 'glucose'), ('UBERON_0000479', 'tissue', 144, 'tissues'), ('UBERON_0000062', 'organ', 152, 'organs'), ('UBERON_0007023', 'adult organism', 162, 'adult')]
PMC5325607	2/2017	S53-PMC5325607	['a four-hour oral Glucose tolerance test (ogtt) was performed in wk 22 and indirect calorimetry (ic) was performed in wk 24.']	N/A	N/A	[('CHEBI_17234', 'glucose', 17, 'glucose')]
PMC5325607	2/2017	S64-PMC5325607	['oral Glucose tolerance test\nafter 16h of fasting, a four-hour ogtt was performed in wk 22.']	N/A	N/A	[('CHEBI_17234', 'glucose', 5, 'glucose')]
PMC5325607	2/2017	S65-PMC5325607	['following oral Glucose application by gavage (2 mg Glucose/g body weight), Glucose concentrations were measured in Tail Vein whole Blood by contourxt Glucose sensor (bayer ag, leverkusen, germany) before Glucose application and 15, 30, 60, 120, and 240 min after gavage.']	N/A	N/A	[('CHEBI_17234', 'glucose', 15, 'glucose'), ('CHEBI_17234', 'glucose', 51, 'glucose'), ('CHEBI_17234', 'glucose', 75, 'glucose'), ('UBERON_0003481', 'tail vein', 115, 'tail vein'), ('UBERON_0000178', 'blood', 131, 'blood'), ('CHEBI_17234', 'glucose', 150, 'glucose'), ('CHEBI_17234', 'glucose', 204, 'glucose')]
PMC5325607	2/2017	S66-PMC5325607	['Plasma Insulin was measured at baseline, 15 min, and 30 min after Glucose administration and determined by Insulin Mouse ultrasensitive elisa (alpco diagnostics, salem, usa).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('PR_000045358', 'insulin family protein', 7, 'insulin'), ('CHEBI_17234', 'glucose', 66, 'glucose'), ('PR_000045358', 'insulin family protein', 107, 'Insulin'), ('NCBITaxon_10088', 'Mus <genus>', 115, 'Mouse')]
PMC5325607	2/2017	S187-PMC5325607	['(a) Glucose tolerance, (b) Insulin sensitivity, (c) Pancreas Insulin content and (d) basal Blood Glucose concentration.']	N/A	N/A	[('CHEBI_17234', 'glucose', 4, 'glucose'), ('PR_000045358', 'insulin family protein', 27, 'insulin'), ('UBERON_0001264', 'pancreas', 52, 'pancreas'), ('PR_000045358', 'insulin family protein', 61, 'insulin'), ('UBERON_0000178', 'blood', 91, 'blood'), ('CHEBI_17234', 'glucose', 97, 'glucose')]
PMC5332602	3/2017	S51-PMC5332602	['caption (fig): fig\xa02\xa0\n\nconcentrations of protein (a), albumin (b), Glucose (c), Selenium (d), Vitamin A (e), and Vitamin E (f) in the Serum of protein-deficient and -sufficient Hifm/Hrv-infected Pigs measured at experiment termination.']	N/A	N/A	[('CHEBI_17234', 'glucose', 67, 'glucose'), ('CHEBI_27568', 'selenium atom', 80, 'selenium'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin E'), ('UBERON_0001977', 'blood serum', 134, 'serum'), ('PR_000008563', 'histidine triad nucleotide-binding protein 3', 177, 'HIFM'), ('NCBITaxon_10088', 'Mus <genus>', 182, 'HRV'), ('NCBITaxon_10088', 'Mus <genus>', 195, 'pigs')]
PMC5332602	3/2017	S52-PMC5332602	['concentrations of protein, Albumin, and Glucose in the Serum of protein-deficient and -sufficient Hifm/Hrv-infected Pigs ( n = 10/group) were determined at marshfield labs (marshfield, wi), and Selenium, Vitamin A and E concentrations in the Serum of protein-deficient and -sufficient hifm/hrv-infected Pigs ( n = 8/group) were measured at the diagnostic center for population and Animal health (michigan state university, east lansing, mi) by high-performance liquid chromatography.']	N/A	N/A	[('PR_000005908', 'alpha-crystallin B chain', 27, 'albumin'), ('CHEBI_17234', 'glucose', 40, 'glucose'), ('UBERON_0001977', 'blood serum', 55, 'serum'), ('PR_000008563', 'histidine triad nucleotide-binding protein 3', 98, 'HIFM'), ('NCBITaxon_10088', 'Mus <genus>', 103, 'HRV'), ('NCBITaxon_10088', 'Mus <genus>', 116, 'pigs'), ('CHEBI_27568', 'selenium atom', 194, 'selenium'), ('CHEBI_27300', 'vitamin D', 204, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 218, 'E'), ('UBERON_0001977', 'blood serum', 242, 'serum'), ('NCBITaxon_10088', 'Mus <genus>', 303, 'pigs'), ('NCBITaxon_33208', 'Metazoa', 381, 'Animal')]
PMC5332602	3/2017	S279-PMC5332602	['the frequencies of cell populations in flow cytometry and Serum Glucose, protein, albumin, Lps, Vitamin A ands E, and Selenium levels were compared among groups with the kruskal-wallis rank sum and mann-whitney (nonparametric) tests.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 58, 'serum'), ('CHEBI_17234', 'glucose', 64, 'glucose'), ('CHEBI_16412', 'lipopolysaccharide', 91, 'LPS'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 111, 'E'), ('CHEBI_27568', 'selenium atom', 118, 'selenium')]
PMC5343397	3/2017	S62-PMC5343397	['caption (table-wrap): table 2\n\navailable Maternal health outcomestrial namelimit [55–57]upbeat [58]rolo [59]lip [60–63]belgian flanders [64]nelli [65]the top study [66]investigatorsdodd, grivell, owenspostonmcauliffevinter, tanvig, jensenbogaerts, devliegerluotorenaulttiming assessment3\xa0years3\xa0years5\xa0years4–7\xa0years5–7\xa0years3\xa0yearsheight✓✓✓✓✓✓✓weight✓✓✓✓✓✓✓weight change✓✓✓✓✓✓✓bmi✓✓✓✓✓✓✓circumferences\u2003-Neck✓\u2003-Waist✓✓\u2003-Hip✓\u2003-Thigh✓\u2003-mid Upper Arm✓\u2003-Wrist✓Sftm\u2003-Subscapular✓✓\u2003-Triceps✓✓\u2003-Biceps✓✓\u2003-Suprailiac✓✓% body fat✓✓dxa✓ subsetbodpod✓bia✓✓dietary intake✓ also 6\xa0months, 18\xa0months✓✓✓physical activity✓ also 6\xa0months, 18\xa0months✓✓✓Metabolic syndrome✓✓✓Glucose intolerance✓ subset✓✓✓at 12\xa0months Postpartuminsulin✓type 2 dm✓ subset✓✓ self report✓ fasting Glucose✓hypertension/bp✓✓✓✓✓✓hyperlipidaemia✓✓✓inflammatory markers✓✓transferrin??']	N/A	N/A	[('GO_0007618', 'mating', 41, 'maternal'), ('UBERON_0002551', 'interstitial nucleus of Cajal', 404, 'Neck'), ('UBERON_0001876', 'amygdala', 408, '✓'), ('UBERON_0000088', 'trophoblast', 411, 'Waist'), ('UBERON_0008894', 'pharyngeal gill precursor', 416, '✓✓'), ('UBERON_0006337', 'distal early tubule', 420, 'Hip'), ('UBERON_0001876', 'amygdala', 423, '✓'), ('UBERON_0000376', 'hindlimb stylopod', 426, 'Thigh'), ('UBERON_0001876', 'amygdala', 431, '✓'), ('UBERON_0004708', 'paired limb/fin', 438, 'upper arm✓'), ('UBERON_0004452', 'carpal region', 450, 'Wrist'), ('UBERON_0001876', 'amygdala', 455, '✓'), ('UBERON_0006333', 'snout', 456, 'SFTM'), ('UBERON_0004029', 'canal of Schlemm', 462, 'Subscapular'), ('UBERON_0008894', 'pharyngeal gill precursor', 473, '✓✓'), ('UBERON_0001509', 'triceps brachii', 477, 'Triceps'), ('UBERON_0008894', 'pharyngeal gill precursor', 484, '✓✓'), ('UBERON_0001530', 'common carotid artery plus branches', 488, 'Biceps'), ('UBERON_0008894', 'pharyngeal gill precursor', 494, '✓✓'), ('UBERON_0010402', 'epidermis suprabasal layer', 498, 'Suprailiac'), ('GO_0008152', 'metabolic process', 634, 'Metabolic'), ('CHEBI_17234', 'glucose', 655, 'Glucose'), ('GO_0007378', 'amnioserosa formation', 698, 'postpartumInsulin'), ('GO_0007567', 'parturition', 715, '✓'), ('CHEBI_17234', 'glucose', 757, 'glucose'), ('CHEBI_24870', 'ion', 764, '✓')]
PMC5343397	3/2017	S79-PMC5343397	['caption (table-wrap): table 4\n\nmaternal outcomes determined from the delphi survey (first round median and iqr in brackets)maternal outcomesmedianiqrmaternal Metabolic syndrome (8.00, 2.00)81maternal Glucose intolerance (8.00, 2.00)81.25maternal type 2 diabetes (8.00, 2.00)82maternal hypertension (8.00, 2.00)7.51maternal physical activity patterns (6.00, 3.00)71maternal weight change (7.00, 3.50)71.25maternal hyperlipidaemia (6.00, 3.00)62maternal dietary patterns (6.00, 3.50)62maternal anxiety/depression (6.00, 2.00)62maternal quality of life (6.00, 2.00)61.25maternal body fat (%) (5.00, 2.00)52maternal elevated crp (4.00, 3.00)4.52maternal Skin Fold thicknesses (5.00, 2.00)4.52\n\ncaption (table-wrap): table 5\n\nchildhood outcomes determined from the delphi survey (first round median and iqr in brackets)child outcomesmedianiqrbmi (7.00, 2.50)72bmi\u2009≥\u200985% (7.00, 1.50)71.25bmi z score (7.00, 2.00)71.25blood pressure-continuous (7.00, 2.00)71.25hypertension (sbp and dbp) (7.00, 2.00)71.25abdominal fat mass (7.00, 3.00)71.25impaired Cardiovascular function (8.00, 2.50)72.25physical activity measures/patterns (7.00, 2.50)72.25sedentary activity measures (7.00, 3.00)72food frequency/Eating–ffq (7.00, 3.00)71.25developmental milestones (7.00, 2.50)72general health (7.00, 1.50)71insulin/Glucose Homeostasis (7.00, 2.50)72cognitive development (new)72.25lipid profile (7.00, 2.50)6.51.25circumferences (6.00, 2.00)61skinfold thicknesses (6.00, 1.00)61calculated fat-free mass (%) (6.00, 1.50)61.25calculated total fat mass (%) (6.00, 1.50)61.25breastfeeding duration (6.00, 2.00)61.25sleep patterns/duration (6.00, 2.00)61leptin/adiponectin (6.00, 2.00)61asthma/allergy (new)61child behaviour (new)62inflammatory markers (6.00, 2.00)52\n\nprimary outcome measures\nthe primary maternal outcome is a diagnosis of maternal Metabolic syndrome.']	N/A	N/A	[('GO_0008152', 'metabolic process', 158, 'metabolic'), ('CHEBI_17234', 'glucose', 200, 'glucose'), ('UBERON_0009007', 'superficial inguinal lymph node', 650, 'skin fold'), ('UBERON_0004535', 'cardiovascular system', 1043, 'cardiovascular'), ('GO_0051318', 'G1 phase', 1194, 'eating'), ('CHEBI_17234', 'glucose', 1298, 'glucose'), ('GO_0042593', 'glucose homeostasis', 1298, 'glucose homeostasis'), ('GO_0008152', 'metabolic process', 1828, 'metabolic')]
PMC5345907	1/2017	S185-PMC5345907	['the neonatal Meconium was enriched for several Microbial pathways including the Pentose Phosphate pathway and the phophotransferase system (pts), which participate in Sequestering and utilizing Glucose for anabolism of Amino Acids and Cell Wall components.']	N/A	N/A	[('UBERON_0007109', 'meconium', 13, 'meconium'), ('NCBITaxon_10088', 'Mus <genus>', 47, 'microbial'), ('CHEBI_25895', 'pentaric acid anion', 80, 'pentose phosphate'), ('GO_0051235', 'maintenance of location', 167, 'sequestering'), ('CHEBI_17234', 'glucose', 194, 'glucose'), ('GO_0040007', 'growth', 194, 'glucose'), ('CHEBI_33867', 'idonates', 219, 'amino acids'), ('GO_0005618', 'cell wall', 235, 'cell wall'), ('GO_0007617', 'mating behavior', 240, 'wall')]
PMC5347102	3/2017	S62-PMC5347102	['both under- and overnutrition of prospective mothers set a trajectory in offspring toward increased adiposity, hyperphagia and dysfunction of Insulin and Glucose responsiveness, and Homeostasis.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 142, 'insulin'), ('CHEBI_17234', 'glucose', 154, 'glucose'), ('GO_0042592', 'homeostatic process', 182, 'homeostasis')]
PMC5347102	3/2017	S70-PMC5347102	['when overfed, obese Ewes were restricted to normal energy intake beginning in early Pregnancy (day 28), deleterious alterations in fetal growth, adiposity, and Glucose and Insulin Metabolism were prevented.']	N/A	N/A	[('UBERON_0000970', 'eye', 20, 'ewes'), ('GO_0007565', 'female pregnancy', 84, 'pregnancy'), ('CHEBI_17234', 'glucose', 160, 'glucose'), ('GO_1901142', 'insulin metabolic process', 172, 'insulin metabolism'), ('PR_000045358', 'insulin family protein', 172, 'insulin')]
PMC5347102	3/2017	S114-PMC5347102	['Umbilical Vein Uptake Of Glucose, Amino Acids, and oxygen were reduced (50–60%), and fetal Insulin and Insulin-Like Growth Factor (Igf) i were likewise reduced.']	N/A	N/A	[('UBERON_0002066', 'umbilical vein', 0, 'Umbilical vein'), ('GO_0046323', 'glucose import', 15, 'uptake of glucose'), ('CHEBI_17234', 'glucose', 25, 'glucose'), ('GO_0019048', 'modulation by virus of host process', 34, 'amino acids'), ('PR_000045358', 'insulin family protein', 91, 'insulin'), ('PR_000008959', 'immunoglobulin heavy constant gamma 1', 103, 'insulin-like growth factor'), ('PR_000008989', 'interleukin-1 family member 7', 131, 'IGF')]
PMC5347102	3/2017	S248-PMC5347102	['among its attributes, colostrum 1 ) provides a Metabolic switch for Glucose Synthesis, 2 ) promotes Thermoregulation, 3 ) provides the first Igg source for systemic passive immunity and Gut barrier function, and 4 ) promotes Intestinal villi growth and/or maturation for Digestion.']	N/A	N/A	[('GO_0008152', 'metabolic process', 47, 'metabolic'), ('CHEBI_17234', 'glucose', 68, 'glucose'), ('GO_0006094', 'gluconeogenesis', 68, 'glucose synthesis'), ('GO_0001659', 'temperature homeostasis', 100, 'thermoregulation'), ('GO_0071735', 'IgG immunoglobulin complex', 141, 'IgG'), ('UBERON_0001555', 'digestive tract', 186, 'gut'), ('UBERON_0000160', 'intestine', 225, 'intestinal'), ('GO_0007586', 'digestion', 271, 'digestion')]
PMC5350159	3/2017	S78-PMC5350159	['Glucose tolerance\nmultiparous dams Fed their respective diets for at least 32\xa0weeks underwent a fasting Glucose tolerance test.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('GO_0007631', 'feeding behavior', 35, 'fed'), ('CHEBI_17234', 'glucose', 104, 'glucose')]
PMC5350159	3/2017	S79-PMC5350159	['Mice were fasted for 6\xa0h, baseline Glucose readings obtained and then they were given an ip injection ofd‐Glucose (2\xa0mg/g body weight).']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 0, 'Mice'), ('CHEBI_17234', 'glucose', 35, 'glucose'), ('CHEBI_17234', 'glucose', 106, 'glucose')]
PMC5350159	3/2017	S80-PMC5350159	['Glucose readings were taken 15, 30, 60, and 120\xa0min after injection.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose')]
PMC5350159	3/2017	S81-PMC5350159	['Glucose was measured using a onetouch ultra mini Glucometer (johnson & johnson, new brunswick, nj) with commercially available unistrip1 test strips (unistrip technologies, charlotte, nc).']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('CHEBI_24321', 'glutamo group', 49, 'glucometer')]
PMC5350159	3/2017	S157-PMC5350159	['dam weight and Glucose tolerance testing\nafter 70\xa0days on diet the mean weight of the dams on hfd ( n \xa0=\xa04) was 22.2\xa0g (sem ±0.73), on the nfd ( n \xa0=\xa04) the mean weight was 22.5\xa0g, (sem ±0.46), the difference was not significant ( p \xa0=\xa00.37).']	N/A	N/A	[('CHEBI_17234', 'glucose', 15, 'glucose')]
PMC5350159	3/2017	S158-PMC5350159	['multiparous dams that had been on hfd for at least 32\xa0weeks had elevated Glucose levels 15 and 30\xa0min after ip Glucose injection.']	N/A	N/A	[('CHEBI_17234', 'glucose', 73, 'glucose'), ('CHEBI_17234', 'glucose', 111, 'glucose')]
PMC5350159	3/2017	S159-PMC5350159	['this altered Glucose Metabolism is also seen in area under the curve calculations (fig.']	N/A	N/A	[('CHEBI_17234', 'glucose', 13, 'glucose'), ('GO_0006006', 'glucose metabolic process', 13, 'glucose metabolism')]
PMC5350159	3/2017	S163-PMC5350159	['Glucose concentrations were taken after a 6\xa0h fast, and 15, 30, 60 and 120\xa0min following anipinjection of Glucose.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('CHEBI_17234', 'glucose', 106, 'glucose')]
PMC5359891	3/2017	S3-PMC5359891	['the primary outcome is maternal Glucose tolerance at 28\xa0weeks’ Gestation following an oral Glucose tolerance test.']	N/A	N/A	[('CHEBI_17234', 'glucose', 32, 'glucose'), ('GO_0007565', 'female pregnancy', 63, 'gestation'), ('CHEBI_17234', 'glucose', 91, 'glucose')]
PMC5359891	3/2017	S6-PMC5359891	['myo-inositol is a Nutrient that enhances Cellular Glucose Uptake.']	N/A	N/A	[('CHEBI_33284', 'nutrient', 18, 'nutrient'), ('GO_0043277', 'apoptotic cell clearance', 41, 'cellular glucose uptake'), ('CHEBI_17234', 'glucose', 50, 'glucose')]
PMC5359891	3/2017	S27-PMC5359891	['Pregnancy represents a state of relative maternal Insulin resistance, which helps to promote the transfer of Nutrients, such as Glucose, Fatty Acids and Amino Acids, to the fetus [16].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnancy'), ('PR_000045358', 'insulin family protein', 50, 'insulin'), ('CHEBI_33284', 'nutrient', 109, 'nutrients'), ('CHEBI_17234', 'glucose', 128, 'glucose'), ('CHEBI_35366', 'fatty acid', 137, 'fatty acids'), ('CHEBI_33867', 'idonates', 153, 'amino acids')]
PMC5359891	3/2017	S36-PMC5359891	['higher Blood Glucose levels in Pregnancy carry risk of Cardiovascular disease for both the mother as well as the child, a risk which increases with each Pregnancy [31].']	N/A	N/A	[('UBERON_0000178', 'blood', 7, 'blood'), ('CHEBI_17234', 'glucose', 13, 'glucose'), ('GO_0007565', 'female pregnancy', 31, 'pregnancy'), ('UBERON_0004535', 'cardiovascular system', 55, 'cardiovascular'), ('GO_0007565', 'female pregnancy', 153, 'pregnancy')]
PMC5359891	3/2017	S64-PMC5359891	['following informed consent at the first Preconception visit, a baseline standard 75-g oral Glucose tolerance test (ogtt) will be conducted, nutritional status, lifestyle, mood, body anthropometry and Metabolic phenotype ascertained and biosampling undertaken, followed by randomisation to the intervention or control drink.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 40, 'preconception'), ('CHEBI_17234', 'glucose', 91, 'glucose'), ('GO_0008152', 'metabolic process', 200, 'metabolic')]
PMC5359891	3/2017	S79-PMC5359891	['abbreviations: pcv Preconception visit, pc Preconception, pgv Pregnancy visit, pdv post-Delivery visit, bia bioelectrical impedance analysis, bp Blood pressure, dm diabetes mellitus, dxa dual-energy x-ray absorptiometry, gdm Gestational diabetes, hiv , human immunodeficiency virus, ifg impaired fasting Glucose, igt impaired Glucose tolerance, ngt normal Glucose tolerance, ogtt oral Glucose tolerance test, uss, ultrasound scan.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 19, 'preconception'), ('GO_0007565', 'female pregnancy', 43, 'preconception'), ('GO_0007565', 'female pregnancy', 62, 'pregnancy'), ('GO_0007567', 'parturition', 88, 'delivery'), ('UBERON_0000178', 'blood', 145, 'blood'), ('GO_0007565', 'female pregnancy', 225, 'gestational'), ('CHEBI_17234', 'glucose', 304, 'glucose'), ('CHEBI_17234', 'glucose', 326, 'glucose'), ('CHEBI_17234', 'glucose', 356, 'glucose'), ('CHEBI_17234', 'glucose', 385, 'glucose')]
PMC5359891	3/2017	S84-PMC5359891	['inclusion criteria are women who meet the following:\naged 18–38 years\nliving in southampton, singapore or auckland\nin southampton and auckland, planning to have future maternity care in southampton and auckland, respectively\nin singapore, willing to Deliver at the national university hospital\nwomen planning to Conceive within 6\xa0months (but Conception up to 12\xa0months after phenotyping will still be included)\nin singapore only women of chinese, malay and indian ethnicity, or of mixed chinese/malay/indian ethnicity will be included\nable to provide written, informed consent\nexclusion criteria are:\nPregnant or Lactating at recruitment (women who are currently breastfeeding will be excluded, but no washout period from the end of breastfeeding will be required before study start)\nassisted fertility apart from those taking Clomiphene or Letrozole alone\nwomen with pre-existing type-1 or type-2 diabetes (fasting Plasma Glucose concentration ≥7.0\xa0mmol/l or post ogtt 2-h Plasma Glucose concentration ≥11.1\xa0mmol/l)\noral or implanted Contraception currently or in the last month, or with an Intrauterine contraceptive device in situ\nmetformin or systemic Steroids currently or in the last month\nAnticonvulsant Medication currently or in the last month\ntreatment for hiv, hepatitis b or c currently or in the last month\nknown serious Food allergy\nwithdrawal criteria are:\nthe participant wishes to discontinue participation in the study\nthe participant is unwilling or unable to comply with the protocol (including attendance at study visits, having study measures and biosampling)\nan overall uptake level of intervention/control Nutritional Drink of less than 60% evidenced by sachet counting\nthe participant is Pregnant before or at Preconception visit 2\nthe participant suffers a Miscarriage (Pregnancy loss before 24\xa0weeks’ Gestation) or ectopic Pregnancy.']	N/A	N/A	[('GO_0007567', 'parturition', 250, 'deliver'), ('GO_0007631', 'feeding behavior', 312, 'conceive'), ('GO_0007620', 'copulation', 342, 'conception'), ('GO_0007565', 'female pregnancy', 601, 'Pregnant'), ('GO_0007594', 'puparial adhesion', 613, 'lactating'), ('CHEBI_3752', 'clomiphene', 827, 'clomiphene'), ('CHEBI_6413', 'letrozole', 841, 'letrozole'), ('UBERON_0001969', 'blood plasma', 916, 'plasma'), ('CHEBI_17234', 'glucose', 923, 'glucose'), ('UBERON_0001969', 'blood plasma', 974, 'plasma'), ('CHEBI_17234', 'glucose', 981, 'glucose'), ('GO_0006936', 'muscle contraction', 1035, 'contraception'), ('UBERON_0022293', 'reproductive gland secretion', 1092, 'intrauterine'), ('CHEBI_35341', 'steroid', 1156, 'steroids'), ('CHEBI_35624', 'azaspiro compound', 1196, 'Anticonvulsant'), ('CHEBI_60211', 'compound Z', 1211, 'medication'), ('CHEBI_33290', 'food', 1334, 'food'), ('CHEBI_7495', 'nefazodone hydrochloride', 1630, 'nutritional'), ('CHEBI_35702', 'diethyl ether', 1642, 'drink'), ('GO_0007565', 'female pregnancy', 1713, 'pregnant'), ('GO_0007565', 'female pregnancy', 1735, 'preconception'), ('GO_0046660', 'female sex differentiation', 1783, 'miscarriage'), ('GO_0007565', 'female pregnancy', 1796, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1828, 'gestation'), ('GO_0007565', 'female pregnancy', 1850, 'pregnancy')]
PMC5359891	3/2017	S120-PMC5359891	['accredited laboratories will be used for measurement of the primary outcome of Plasma Glucose concentrations.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 79, 'plasma'), ('CHEBI_17234', 'glucose', 86, 'glucose')]
PMC5359891	3/2017	S140-PMC5359891	['we will build prognostic models using baseline covariates on the primary outcome of maternal Glucose tolerance in Pregnancy.']	N/A	N/A	[('CHEBI_17234', 'glucose', 93, 'glucose'), ('GO_0007565', 'female pregnancy', 114, 'pregnancy')]
PMC5359891	3/2017	S143-PMC5359891	['a study of 250 Pregnancies with 28-week ogtt data in each group has 89% power to detect a 0.1-mmol/l reduction in fasting Plasma Glucose and 84% power to detect a 0.3-mmol/l reduction in 2-h Plasma Glucose at the 5% level of significance.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 15, 'pregnancies'), ('UBERON_0001969', 'blood plasma', 122, 'plasma'), ('CHEBI_17234', 'glucose', 129, 'glucose'), ('UBERON_0001969', 'blood plasma', 191, 'plasma'), ('CHEBI_17234', 'glucose', 198, 'glucose')]
PMC5359891	3/2017	S145-PMC5359891	['as a further illustration of statistical power, using the distribution of 60-min Plasma Glucose in the Hapo study, a study of 250 participants in each of the two groups has 80% power to detect a difference of ≥0.43\xa0mmol/l in 60-min Glucose at p \u2009<\u20090.05.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 81, 'plasma'), ('CHEBI_17234', 'glucose', 88, 'glucose'), ('CHEBI_17883', 'hydrogen chloride', 103, 'HAPO'), ('CHEBI_17234', 'glucose', 232, 'glucose')]
PMC5359891	3/2017	S146-PMC5359891	['a study of 300 Pregnancies in each arm will have an 80% power to detect a reduction in the mean Plasma Glucose of 0.12, 0.45 and 0.34\xa0mmol/l at fasting, 60\xa0min and 2\xa0h, respectively, with an alpha of 0.017 taking into account multiple testing.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 15, 'pregnancies'), ('UBERON_0001969', 'blood plasma', 96, 'plasma'), ('CHEBI_17234', 'glucose', 103, 'glucose')]
PMC5371275	3/2017	S46-PMC5371275	['women with Gestational diabetes mellitus (gdm) were excluded from further analysis presented for oral Glucose tolerance test (ogtt) at 28Thgestational age.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 11, 'gestational'), ('CHEBI_17234', 'glucose', 102, 'glucose'), ('GO_0043427', 'carbon fixation by 3-hydroxypropionate cycle', 135, '28thgestational')]
PMC5372136	3/2017	S5-PMC5372136	['continuous Glucose monitoring was used to assess diurnal glycemia.']	N/A	N/A	[('CHEBI_17234', 'glucose', 11, 'glucose')]
PMC5372136	3/2017	S6-PMC5372136	['results\nmaternal Glucose levels were 51% lower on the low gl day with lower incremental area under the curve (iauc±sem 549±109 vs 1120±198\u2005mmol/l\u2005min, p=0.015).']	N/A	N/A	[('CHEBI_17234', 'glucose', 17, 'glucose')]
PMC5372136	3/2017	S11-PMC5372136	['low Glycemic index (gi) Foods produce lower Postprandial Blood Glucose spikes compared to high gi Foods.']	N/A	N/A	[('GO_0006096', 'glycolytic process', 4, 'glycemic'), ('CHEBI_33290', 'food', 24, 'foods'), ('GO_0007567', 'parturition', 44, 'postprandial'), ('UBERON_0000178', 'blood', 57, 'blood'), ('CHEBI_17234', 'glucose', 63, 'glucose'), ('CHEBI_33290', 'food', 98, 'foods')]
PMC5372136	3/2017	S26-PMC5372136	['women were eligible if they had at least one of the following risk factors for gdm: Prepregnancy body mass index (bmi) ≥30\u2005kg/m2, age ≥35\u2005years, polycystic Ovarian syndrome, history of gdm or Glucose intolerance, history of a previous Birth >4000\u2005g, family history of type 2 diabetes (first-degree relative), belonging to an ethnic group with a high prevalence of gdm (aboriginal, torres strait islander, polynesian, middle eastern, south asian, south east asian).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 84, 'prepregnancy'), ('UBERON_0000992', 'ovary', 156, 'ovarian'), ('CHEBI_17234', 'glucose', 192, 'glucose'), ('GO_0007567', 'parturition', 235, 'birth')]
PMC5372136	3/2017	S34-PMC5372136	['study protocol\n\ncontinuous Glucose monitors\ncgm systems (medtronic minimed, northridge, california) were used to electrochemically measure subcutaneous Interstitial Glucose concentrations every 5\u2005min, generating 288 measurements per day.']	N/A	N/A	[('CHEBI_17234', 'glucose', 27, 'glucose'), ('UBERON_0005169', 'interstitial tissue', 152, 'interstitial'), ('CHEBI_17234', 'glucose', 165, 'glucose')]
PMC5372136	3/2017	S35-PMC5372136	["the monitors were calibrated four times a day against capillary Blood Glucose measurements, using Blood Glucose meters (accu-check performa; roche) as per the manufacturer's instructions."]	N/A	N/A	[('UBERON_0000178', 'blood', 64, 'blood'), ('CHEBI_17234', 'glucose', 70, 'glucose'), ('UBERON_0000178', 'blood', 98, 'blood'), ('CHEBI_17234', 'glucose', 104, 'glucose')]
PMC5372136	3/2017	S53-PMC5372136	['statistical analysis\nInterstitial Glucose values were obtained by cgms.']	N/A	N/A	[('UBERON_0005169', 'interstitial tissue', 21, 'Interstitial'), ('CHEBI_17234', 'glucose', 34, 'glucose')]
PMC5372136	3/2017	S55-PMC5372136	['the mean amplitude of Glycemic excursion (mage) was determined by calculating the arithmetic mean of the difference between consecutive peaks and nadirs if the difference was >1 sd of the mean Glucose,1920using the automated glyculator algorithm.21the incremental area under the curve (iauc) was calculated across the 24\u2005h, using the trapezoidal rule.']	N/A	N/A	[('GO_0006096', 'glycolytic process', 22, 'glycemic'), ('CHEBI_17234', 'glucose', 193, 'glucose')]
PMC5372136	3/2017	S56-PMC5372136	['the Glucose value at midnight was used as baseline, and all the Interstitial Glucose output from the cgms were used.']	N/A	N/A	[('CHEBI_17234', 'glucose', 4, 'glucose'), ('UBERON_0005169', 'interstitial tissue', 64, 'interstitial'), ('CHEBI_17234', 'glucose', 77, 'glucose')]
PMC5372136	3/2017	S64-PMC5372136	['results were available for the remaining 17 participants, including two full 24\u2005hours (midnight to midnight) Glucose monitoring days.']	N/A	N/A	[('CHEBI_17234', 'glucose', 109, 'glucose')]
PMC5372136	3/2017	S71-PMC5372136	['dietary gl and diurnal Glucose levels\ndiurnal Glucose responses measured by cgms on the high gl day and low gl day are shown infigure 2, and summary results are presented intable 2.']	N/A	N/A	[('CHEBI_17234', 'glucose', 23, 'glucose'), ('CHEBI_17234', 'glucose', 46, 'glucose')]
PMC5372136	3/2017	S72-PMC5372136	['caption (table-wrap): table\xa02\n\naverage maternal Glucose levels (n=17) for the low gl and high gl mealslow glhigh glp valuehighest Glucose value (mmol/l)7.1±0.27.6±0.20.026lowest Glucose value (mmol/l)3.9±0.23.7±0.20.237average (mmol/l)5.3±0.15.4±0.20.352sd average (mmol/l)0.7±0.10.9±0.1<0.001mage (mmol/l)2.1±0.22.7±0.2<0.001iauc (mmol/l\u2009min)549±1091120±1980.015proportion of time (%)\u2003in target (3.9–7.8 mmol/l)95.1±1.787.7±3.20.031\u2003above target0.4±0.24.4±2.80.180\u2003below target4.5±1.77.9±2.20.129\nmean±sem (all such values).']	N/A	N/A	[('CHEBI_17234', 'glucose', 48, 'glucose'), ('CHEBI_17234', 'glucose', 130, 'glucose'), ('CHEBI_17234', 'glucose', 178, 'glucose')]
PMC5372136	3/2017	S73-PMC5372136	['iauc, incremental area under the curve (calculated across the 24\u2005h, using the trapezoidal rule); mage, mean amplitude of glycemic excursions (determined by calculating the arithmetic mean of the difference between consecutive peaks and nadirs if the difference is >1 sd of the mean Glucose).']	N/A	N/A	[('CHEBI_17234', 'glucose', 282, 'glucose')]
PMC5372136	3/2017	S74-PMC5372136	['caption (fig): figure\xa02\n\nmean (±sem) diurnal Glucose levels following low gl meals (gray dots) and high gl meals (black dots).']	N/A	N/A	[('CHEBI_17234', 'glucose', 45, 'glucose')]
PMC5372136	3/2017	S77-PMC5372136	['the peak Glucose concentration was also significantly lower on the low gl day (mean±sem 7.1±0.2\u2005mmol/l vs 7.6±0.2\u2005mmol/l, p=0.026).']	N/A	N/A	[('CHEBI_17234', 'glucose', 9, 'glucose')]
PMC5372136	3/2017	S78-PMC5372136	['time spent within the normal (target) Glucose range was significantly longer on the low gl day, resulting from fewer above and lesser below target values, hence demonstrating less Glucose oscillation (low gl 95.1±1.7% vs high gl 87.7±3.2%, p=0.031).']	N/A	N/A	[('CHEBI_17234', 'glucose', 38, 'glucose'), ('CHEBI_17234', 'glucose', 180, 'glucose')]
PMC5372327	3/2017	S84-PMC5372327	['exclusion criteria for the infants were Nasal continuous positive Airway pressure treatment for more than 1\xa0day, intravenous Glucose infusion, intravenous Postnatal Antibiotic treatment, seizures, duration of phototherapy for more than 3\xa0days, and need for Nasogastric Tube for more than 1\xa0day.']	N/A	N/A	[('UBERON_0000004', 'nose', 40, 'nasal'), ('UBERON_0001005', 'respiratory airway', 66, 'airway'), ('CHEBI_17234', 'glucose', 125, 'glucose'), ('GO_0007567', 'parturition', 155, 'postnatal'), ('CHEBI_33282', 'antibacterial agent', 165, 'antibiotic'), ('UBERON_0001226', 'major calyx', 257, 'nasogastric'), ('UBERON_0000025', 'tube', 269, 'tube')]
PMC5372879	3/2017	S4-PMC5372879	['between 24 and 28 weeks of Gestation, all Pregnant women underwent a scheduled 100 g 3 h oral Glucose tolerance test.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 27, 'gestation'), ('GO_0007565', 'female pregnancy', 42, 'pregnant'), ('CHEBI_17234', 'glucose', 94, 'glucose')]
PMC5372879	3/2017	S13-PMC5372879	['these include complications for mothers, i.e., risk of impaired Glucose tolerance (igt) and type 2 diabetes in the years following Pregnancy, and for offspring, i.e., obesity and developing igt and diabetes in early Adulthood [1].']	N/A	N/A	[('CHEBI_17234', 'glucose', 64, 'glucose'), ('GO_0007565', 'female pregnancy', 131, 'pregnancy'), ('UBERON_0000113', 'post-juvenile adult stage', 216, 'adulthood')]
PMC5372879	3/2017	S40-PMC5372879	['diagnosis of gdm\npregnant women underwent a scheduled 100 g 3 h oral Glucose tolerance test (ogtt) between the 24th–28th weeks of Gestation.']	N/A	N/A	[('CHEBI_17234', 'glucose', 69, 'glucose'), ('GO_0007565', 'female pregnancy', 130, 'gestation')]
PMC5372879	3/2017	S42-PMC5372879	['gdm was defined as the presence of at least two of the following four Plasma Glucose levels, measured while fasting and 1 h, 2 h and 3 h after the oggt: (i) fasting ≥95 mg/dl; (ii) 1 h after ≥180 mg/dl; (iii) 2 h after ≥155 mg/dl; (iv) 3 h after ≥140 mg/dl [20].']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 70, 'plasma'), ('CHEBI_17234', 'glucose', 77, 'glucose')]
PMC5372879	3/2017	S44-PMC5372879	['Serum fasting Glucose concentration was assayed using an enzymatic colorimetric method with the Glucose oxidase technique (pars azmoon inc., tehran, iran).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_17234', 'glucose', 14, 'glucose'), ('CHEBI_17234', 'glucose', 96, 'glucose')]
PMC5372879	3/2017	S45-PMC5372879	['inter- and intra-assay coefficients of variations were both 2.2% for Serum Glucose.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 69, 'serum'), ('CHEBI_17234', 'glucose', 75, 'glucose')]
PMC5385335	4/2017	S67-PMC5385335	['Plasma total Glucose-dependent Insulinotropic peptide (gip) and total pyy were assayed by milliplex mag (Rat Metabolic magnetic bead panel kit, millipore, ma, usa).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_17234', 'glucose', 13, 'glucose'), ('PR_000009000', 'interleukin-22 receptor subunit alpha-2', 31, 'insulinotropic'), ('NCBITaxon_10088', 'Mus <genus>', 105, 'Rat'), ('GO_0008152', 'metabolic process', 109, 'metabolic')]
PMC5387697	2/2017	S107-PMC5387697	['more precisely, ir refers to a holistic reduction of Glucose Uptake in response to physiological Insulin concentrations, primarily in Muscle Tissue.']	N/A	N/A	[('CHEBI_17234', 'glucose', 53, 'glucose'), ('GO_0046323', 'glucose import', 53, 'glucose uptake'), ('PR_000045358', 'insulin family protein', 97, 'insulin'), ('UBERON_0002385', 'muscle tissue', 134, 'muscle tissue')]
PMC5387697	2/2017	S116-PMC5387697	['alternative methods include the Insulin tolerance test (itt), the hyperglycemic clamp, the Insulin-modified or frequently sampled Intravenous Glucose tolerance test (fsigt) and the more frequently used oral Glucose tolerance test (ogtt) (74).']	N/A	N/A	[('PR_000045358', 'insulin family protein', 32, 'insulin'), ('PR_000045358', 'insulin family protein', 91, 'insulin'), ('UBERON_0034986', 'sacral nerve plexus', 130, 'intravenous'), ('CHEBI_17234', 'glucose', 142, 'glucose'), ('CHEBI_17234', 'glucose', 207, 'glucose')]
PMC5387697	2/2017	S132-PMC5387697	['one well-characterized definition requires the presence of three or more factors which can be age-adjusted to define hyperinsulinaemia: overweight, high systolic Blood pressure, hypertriglyceridemia, low hdl-Cholesterol and impaired fasting Plasma Glucose (84).']	N/A	N/A	[('UBERON_0000178', 'blood', 162, 'blood'), ('CHEBI_16113', 'cholesterol', 208, 'cholesterol'), ('UBERON_0001969', 'blood plasma', 241, 'plasma'), ('CHEBI_17234', 'glucose', 248, 'glucose')]
PMC5392925	4/2017	S106-PMC5392925	['prospective nested case–control study of Phenols and gdm risk\n\ngdm case definition and identification\nat kpnc, 96% of Pregnancies are screened for gdm with the 50-g, 1-h Glucose challenge test (gct) at 24–28 weeks of Gestation [20], thus after the second petals research clinic visit at 16–19 weeks.']	N/A	N/A	[('CHEBI_33853', 'phenols', 41, 'phenols'), ('GO_0007565', 'female pregnancy', 118, 'pregnancies'), ('CHEBI_17234', 'glucose', 170, 'glucose'), ('GO_0007565', 'female pregnancy', 217, 'gestation')]
PMC5392925	4/2017	S107-PMC5392925	['if the screening test is abnormal, a diagnostic 100-g, 3-h Oral Glucose tolerance test (ogtt) is performed in the morning after a 12-h fast.']	N/A	N/A	[('UBERON_0000165', 'mouth', 59, 'oral'), ('CHEBI_17234', 'glucose', 64, 'glucose'), ('GO_0040007', 'growth', 64, 'glucose')]
PMC5392925	4/2017	S108-PMC5392925	["Plasma Glucose measurements are performed using the hexokinase method at the kpnc regional laboratory, which participates in the college of american pathologists' accreditation and monitoring program."]	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_17234', 'glucose', 7, 'glucose')]
PMC5392925	4/2017	S109-PMC5392925	['gdm cases are identified by searching the Glucose results from the 50-g, 1-h gct and the 100-g, 3-h ogtt during Pregnancy.']	N/A	N/A	[('CHEBI_17234', 'glucose', 42, 'glucose'), ('GO_0007565', 'female pregnancy', 112, 'pregnancy')]
PMC5392925	4/2017	S131-PMC5392925	['Glucose is measured with an oxidation reaction using a Glucose analyzer (ysi 2300 stat plus; ysi, yellow springs, oh).']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('CHEBI_17234', 'glucose', 55, 'glucose')]
PMC5392925	4/2017	S143-PMC5392925	['caption (table-wrap): table 1\n\noverview of data collection for expected 3350 women in the Pregnancy and environment lifestyle study (petals)Pregnancydeliverydata source10–13 weeks16–19 weeks24–28 weeksmaternal variablesdemographics\u2003agexsurvey\u2003race/ethnicityxsurvey\u2003household sesxsurveymedical historyxxxxsurvey/ehrreproductive historyxsurvey/ehrbehavioral/lifestyle\u2003maternal diet by ffqxsurvey [14]\u2003physical activityxsurvey [16]\u2003sleepxsurvey\u2003smoking and alcoholxsurvey\u2003stress and depressionxsurvey [17,18]/ehranthropometry\u2003pre-Pregnancy weightxehr\u2003weightxcv\u2003heightxcv\u2003waist and hip circumferencesxcv\u2003Gestational weight gainxxxxehrself-reported products usexsurveybiospecimen collection\u2003fasting Bloodxx\u2003Urinexxgdm ascertainmentxehr\u200350-g, 1-h gctxehr\u2003100-g, 3-hour ogttxehrinfant variables\u2003estimated fetal sizexehr\u2003birth size (weight, length)xehr\u2003Gestational age at Deliveryxehr\u2003infant sexxehrmeasurements for the Phenols-gdm case control studya\u2003Urinary Bpa/Bp-3/Tcs levels\u2003Glucose, Insulin, homa-irxaxaserum\u2003total adiponectinxaxaserum\u2003Liver enzymes (alt and ggt)xaxaserum\nalt aminotransferases, Bpa Bisphenol-a, b p-3 Bisphenol-3, cv clinic visit, ehr electronic health record, ffq Food frequency questionnaire, gct Glucose challenge test, ggt gamma-glutamyl transferase, homa-ir Homeostatic model assessment-Insulin resistance, ogtt oral Glucose tolerance test, ses socioeconomic status, tcs triclosan\nameasured among 300 expected gdm cases and 600 controls\n\ninterim results\nbetween october 2013 and february 2016, 2,416 women who initiated Prenatal care with a Gestation age <11\xa0weeks at a kpnc medical center participating in the petals were deemed eligible via telephone interview and enrolled in the study.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 90, 'Pregnancy'), ('GO_0006412', 'translation', 140, 'PregnancyDeliveryData'), ('GO_0007565', 'female pregnancy', 527, 'pregnancy'), ('GO_0007565', 'female pregnancy', 600, 'Gestational'), ('UBERON_0001969', 'blood plasma', 694, 'bloodXX'), ('UBERON_0005906', 'serous sac', 702, 'UrineXXGDM'), ('GO_0007565', 'female pregnancy', 845, 'Gestational'), ('GO_0070983', 'dendrite guidance', 864, 'deliveryXEHR'), ('CHEBI_33853', 'phenols', 912, 'phenols'), ('UBERON_0001088', 'urine', 944, 'Urinary'), ('PR_000004792', 'bisphosphoglycerate mutase', 952, 'BPA'), ('PR_000004793', 'valacyclovir hydrolase', 956, 'BP-3'), ('CHEBI_17855', 'triglyceride', 961, 'TCS'), ('CHEBI_17234', 'glucose', 972, 'Glucose'), ('PR_000045358', 'insulin family protein', 981, 'insulin'), ('UBERON_0002107', 'liver', 1034, 'Liver'), ('CHEBI_34018', '(S)-AMPA', 1094, 'BPA'), ('CHEBI_22901', 'bisphenol', 1098, 'bisphenol'), ('CHEBI_37972', 'phosphorus-32 atom', 1115, '3'), ('CHEBI_22901', 'bisphenol', 1117, 'bisphenol'), ('CHEBI_33290', 'food', 1181, 'food'), ('CHEBI_17234', 'glucose', 1215, 'glucose'), ('GO_0042592', 'homeostatic process', 1279, 'homeostatic'), ('PR_000045358', 'insulin family protein', 1308, 'insulin'), ('CHEBI_17234', 'glucose', 1338, 'glucose'), ('GO_0007565', 'female pregnancy', 1541, 'prenatal'), ('GO_0007565', 'female pregnancy', 1562, 'gestation')]
PMC5420136	5/2017	S48-PMC5420136	['the exceedingly small amount of endogenous Lipids limits Atp Production from these Nutrients in neonatal Pigs, leading to the use of Glucose and Aas as the major Metabolic fuels.']	N/A	N/A	[('CHEBI_18059', 'lipid', 43, 'lipids'), ('GO_0006754', 'ATP biosynthetic process', 57, 'ATP production'), ('CHEBI_33284', 'nutrient', 83, 'nutrients'), ('NCBITaxon_10088', 'Mus <genus>', 105, 'pigs'), ('CHEBI_17234', 'glucose', 133, 'glucose'), ('CHEBI_35088', "p,p'-Methoxychlor olefin", 145, 'AAs'), ('GO_0008152', 'metabolic process', 162, 'metabolic')]
PMC5424401	10/2015	S386-PMC5424401	['Cervical Hps addressed with expectant management, local Kcl or hyperosmolar Glucose injections, extraction with forceps, suction curettage or hysteroscopic resection, with or without subsequent foley tamponade, have resulted in Live Birth.']	N/A	N/A	[('UBERON_0005434', 'cervical region', 0, 'Cervical'), ('UBERON_0002228', 'rib', 9, 'HPs'), ('CHEBI_32588', 'potassium chloride', 56, 'KCl'), ('CHEBI_17234', 'glucose', 76, 'glucose'), ('GO_0006266', 'DNA ligation', 228, 'live'), ('GO_0007567', 'parturition', 233, 'birth')]
PMC5434919	3/2017	S3-PMC5434919	['data were extracted regarding body weight, adiposity, Glucose Homeostasis and lipidaemia.']	N/A	N/A	[('CHEBI_17234', 'glucose', 54, 'glucose'), ('GO_0042593', 'glucose homeostasis', 54, 'glucose homeostasis')]
PMC5434919	3/2017	S63-PMC5434919	['for Glucose levels: non‐fasting, fasting, Oral Glucose tolerance test and Intraperitoneal Glucose tolerance test.']	N/A	N/A	[('CHEBI_17234', 'glucose', 4, 'glucose'), ('UBERON_0000165', 'mouth', 42, 'oral'), ('CHEBI_17234', 'glucose', 47, 'glucose'), ('UBERON_2001932', 'sensory canal tubular ossicle', 74, 'intraperitoneal'), ('CHEBI_17234', 'glucose', 90, 'glucose')]
PMC5434919	3/2017	S70-PMC5434919	['thus, where available, we collected the mean and sd (or sem) of Birthweight, weaning weights (at ~ Postnatal day 21) and endpoint weight, adiposity, Glucose, Insulin, Triglycerides, Cholesterol and leptin for sons and daughters or grouped (i.e.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 64, 'birthweight'), ('GO_0007567', 'parturition', 99, 'postnatal'), ('CHEBI_17234', 'glucose', 149, 'glucose'), ('PR_000045358', 'insulin family protein', 158, 'insulin'), ('CHEBI_17855', 'triglyceride', 167, 'triglycerides'), ('CHEBI_16113', 'cholesterol', 182, 'cholesterol')]
PMC5434919	3/2017	S145-PMC5434919	['caption (fig): figure 3\n\nmeta‐analysis and meta‐regression of Glucose Homeostasis in the male and female offspring of mothers exposed to a high fat diet (hfd) during Gestation and Lactation.']	N/A	N/A	[('CHEBI_17234', 'glucose', 62, 'glucose'), ('GO_0042593', 'glucose homeostasis', 62, 'glucose homeostasis'), ('GO_0007565', 'female pregnancy', 166, 'gestation'), ('GO_0007595', 'lactation', 180, 'lactation')]
PMC5434919	3/2017	S147-PMC5434919	['male Glucose, b. male Insulin, c. female Glucose, d. female Insulin.']	N/A	N/A	[('CHEBI_17234', 'glucose', 5, 'glucose'), ('PR_000045358', 'insulin family protein', 22, 'insulin'), ('CHEBI_17234', 'glucose', 41, 'glucose'), ('PR_000045358', 'insulin family protein', 60, 'insulin')]
PMC5434919	3/2017	S153-PMC5434919	['these included the following: nesting – the use of statistical procedures to account for non‐independence of Animals from the same litter; randomization – the random assignment of Animals to each intervention group; cd:hfd ratio of Macronutrients, fat, Carbohydrate (Cho) and protein; cafeteria diet – the use of choice diet or supplementation of standard diets with palatable energy‐rich Foods; species ; the method by which Glucose–Insulin Homeostasis was assessed; and maternal weight – an approximation for Gestation weight gain taken as the ratio change in weight from pre Mating to post Lactation.']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 109, 'animals'), ('NCBITaxon_33208', 'Metazoa', 180, 'animals'), ('CHEBI_33839', 'macromolecule', 232, 'macronutrients'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 253, 'carbohydrate'), ('CHEBI_17883', 'hydrogen chloride', 267, 'CHO'), ('CHEBI_33290', 'food', 389, 'foods'), ('CHEBI_17234', 'glucose', 426, 'glucose'), ('GO_0042593', 'glucose homeostasis', 426, 'glucose– ... homeostasis'), ('PR_000045358', 'insulin family protein', 434, 'insulin'), ('GO_0007565', 'female pregnancy', 511, 'gestation'), ('GO_0007618', 'mating', 578, 'mating'), ('GO_0007595', 'lactation', 593, 'lactation')]
PMC5434919	3/2017	S174-PMC5434919	['Glucose\ndata were extracted from 82 studies regarding Glucose Homeostasis in male offspring there was no effect of maternal hfd exposure on Glucose levels in male offspring (fig.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('CHEBI_17234', 'glucose', 54, 'glucose'), ('GO_0042593', 'glucose homeostasis', 54, 'glucose homeostasis'), ('CHEBI_17234', 'glucose', 140, 'glucose')]
PMC5434919	3/2017	S325-PMC5434919	['(a) Birthweight, (b) Glucose, (c) weaning weight, (d) Insulin, (e) final body weight, (f) adiposity, (g) Cholesterol, (h) Triglycerides, (i) leptin.']	N/A	N/A	[('GO_0007608', 'sensory perception of smell', 4, 'Birthweight'), ('CHEBI_17234', 'glucose', 21, 'glucose'), ('PR_000045358', 'insulin family protein', 54, 'insulin'), ('CHEBI_16113', 'cholesterol', 105, 'cholesterol'), ('CHEBI_17855', 'triglyceride', 122, 'triglycerides')]
PMC544881	12/2004	S92-PMC544881	['during the first two trimesters of Pregnancy, adipose fat storage, as maternal fuels, occurs in preparation for an active transfer of maternal Glucose, amino acids, and free Fatty Acids (ffa) across the Placenta for accelerate fetal growth in late phase of Gestation [18].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 35, 'pregnancy'), ('CHEBI_17234', 'glucose', 143, 'glucose'), ('CHEBI_35366', 'fatty acid', 174, 'fatty acids'), ('UBERON_0001987', 'placenta', 203, 'placenta'), ('GO_0007565', 'female pregnancy', 257, 'gestation')]
PMC5457543	6/2017	S6-PMC5457543	['the effect of intervention on Glucose Metabolism was a secondary endpoint, measuring Glucose (fasting and 2-h following 75-g Glucose load), Insulin, Homeostatic assessment of Insulin resistance (homa-ir) and leptin levels at Gestational-week 30.']	N/A	N/A	[('CHEBI_17234', 'glucose', 30, 'glucose'), ('GO_0006006', 'glucose metabolic process', 30, 'glucose metabolism'), ('CHEBI_17234', 'glucose', 85, 'glucose'), ('CHEBI_17234', 'glucose', 125, 'glucose'), ('PR_000045358', 'insulin family protein', 140, 'insulin'), ('GO_0042592', 'homeostatic process', 149, 'homeostatic'), ('PR_000045358', 'insulin family protein', 175, 'insulin'), ('GO_0007565', 'female pregnancy', 225, 'gestational')]
PMC5457543	6/2017	S10-PMC5457543	['mean diff -207\xa0pmol/l, p \xa0=\xa00.021) compared to routine care, while Glucose levels were unchanged.']	N/A	N/A	[('CHEBI_17234', 'glucose', 67, 'glucose')]
PMC5457543	6/2017	S21-PMC5457543	['effective Antenatal lifestyle intervention to improve Maternal Glucose Metabolism and reduce gdm risk is in high demand [9].']	N/A	N/A	[('GO_0007567', 'parturition', 10, 'antenatal'), ('GO_0007618', 'mating', 54, 'maternal'), ('CHEBI_17234', 'glucose', 63, 'glucose'), ('GO_0006006', 'glucose metabolic process', 63, 'glucose metabolism')]
PMC5457543	6/2017	S39-PMC5457543	['1\n\ntrial profile for analysis of Glucose Metabolism, norwegian fit for Delivery trial.']	N/A	N/A	[('CHEBI_17234', 'glucose', 33, 'glucose'), ('GO_0006006', 'glucose metabolic process', 33, 'glucose metabolism'), ('GO_0007586', 'digestion', 71, 'Delivery')]
PMC5457543	6/2017	S40-PMC5457543	['Blood tests were collected after fasting and two hours after Glucose challenge at 30\xa0weeks of Gestation.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('CHEBI_17234', 'glucose', 61, 'glucose'), ('GO_0007565', 'female pregnancy', 94, 'gestation')]
PMC5457543	6/2017	S76-PMC5457543	['prior to randomisation, fasting Blood tests were assessed for evidence of pre-existing diabetes (defined as Glucose ≥7.0\xa0mmol/l) [22].']	N/A	N/A	[('UBERON_0000178', 'blood', 32, 'blood'), ('CHEBI_17234', 'glucose', 108, 'glucose')]
PMC5457543	6/2017	S78-PMC5457543	['at Gestational-week 30, Plasma Glucose was measured after overnight fast and again at 2-h after 75\xa0g Glucose load.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 3, 'gestational'), ('UBERON_0001969', 'blood plasma', 24, 'plasma'), ('CHEBI_17234', 'glucose', 31, 'glucose'), ('CHEBI_17234', 'glucose', 101, 'glucose')]
PMC5457543	6/2017	S81-PMC5457543	['Glucose at 2-h was missing for 12 participants (9 intervention, 3 control), primarily due to vomiting.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose')]
PMC5457543	6/2017	S86-PMC5457543	['homa-ir was calculated as: (Insulin(mu/l) x fasting Glucose(mmol/l))/22.5.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 28, 'insulin'), ('CHEBI_17234', 'glucose', 52, 'glucose')]
PMC5457543	6/2017	S110-PMC5457543	['the number of classes attended prior to Glucose-testing varied from 0 to 24, with median 10.']	N/A	N/A	[('CHEBI_17234', 'glucose', 40, 'glucose')]
PMC5457543	6/2017	S116-PMC5457543	['Glucose-testing was performed slightly earlier in the intervention group (29.9 vs. 30.1 Gestational-Weeks, p \xa0=\xa00.036), such that Gestational length at Glucose-testing was included in adjusted analyses.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('GO_0007565', 'female pregnancy', 88, 'gestational'), ('GO_0008215', 'spermine metabolic process', 100, 'weeks'), ('GO_0007565', 'female pregnancy', 130, 'gestational'), ('CHEBI_17234', 'glucose', 152, 'glucose')]
PMC5457543	6/2017	S120-PMC5457543	['mean diff.95% ci p -valuegestational weight gain to term (kg)\u2003from pre-Pregnancya14.416.2615.665.54−1.25−2.28, −0.220.017−1.2−2.2, −0.20.021\u2003from trial Inclusionb12.115.1712.994.68−0.89−1.75, −0.020.044−1.0−1.8,−0.10.025gestational weight gain prior to Glucose testing (kg)\u2003from pre-Pregnancyc9.224.679.864.37−0.64−0.11, 1.400.096−0.52−1.28, 0.200.170\u2003from trial inclusiond6.963.247.182.96−0.22−0.72, 0.300.407−0.24−0.74, 0.270.359\nGestational weight gain analyzed as continuous outcome variable using student’s t-test for unadjusted comparison of intervention and control groups, and multiple regression analysis including age, smoking status, educational level and income at trial inclusion.']	N/A	N/A	[('GO_0007605', 'sensory perception of sound', 71, 'pregnancya14'), ('UBERON_0005355', 'malleus neck', 152, 'inclusionb12'), ('CHEBI_17234', 'glucose', 253, 'glucose'), ('GO_0007565', 'female pregnancy', 283, 'pregnancyc9'), ('GO_0007565', 'female pregnancy', 432, 'Gestational')]
PMC5457543	6/2017	S122-PMC5457543	['caption (table-wrap): table 3\n\neffect of nffd intervention on Glucose Regulationinterventioncontrolintervention effect( n \xa0=\xa0281)( n \xa0=\xa0276)unadjustedadjustedmeansdmeansdmean diff.95% ci p -valueadj.']	N/A	N/A	[('CHEBI_17234', 'glucose', 62, 'glucose'), ('GO_0030430', 'host cell cytoplasm', 62, 'glucose regulationInterventionControlIntervention')]
PMC5457543	6/2017	S131-PMC5457543	['the intervention had no effect on Glucose levels for the group as a whole, either fasting or 2-h after Glucose challenge (table3).']	N/A	N/A	[('CHEBI_17234', 'glucose', 34, 'glucose'), ('CHEBI_17234', 'glucose', 103, 'glucose')]
PMC5457543	6/2017	S135-PMC5457543	['2\n\ninteraction of nffd intervention and pre-Pregnancy bmi on Glucose levels.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 44, 'pregnancy'), ('CHEBI_17234', 'glucose', 61, 'glucose')]
PMC5457543	6/2017	S143-PMC5457543	['or 1.1 (95%ci 0.6, 2.2) p \xa0=\xa00.71), among overweight/obese women there was a significantly larger proportion of intervention participants with elevated Glucose levels (33.7% vs. 13.9% for intervention and control group respectively, adj.']	N/A	N/A	[('CHEBI_17234', 'glucose', 152, 'glucose')]
PMC5457543	6/2017	S148-PMC5457543	['however, overweight/obese intervention participants had increased risk of exceeding iadpg thresholds also after controlling for Glucose levels at inclusion in the adjusted analysis (adj.']	N/A	N/A	[('CHEBI_17234', 'glucose', 128, 'glucose')]
PMC5457543	6/2017	S169-PMC5457543	['leptin is essential in energy Regulation and Glucose Metabolism [27,28], and is Secreted by both maternal Adipocytes and Placental Trophoblasts during Pregnancy [15].']	N/A	N/A	[('GO_0065007', 'biological regulation', 30, 'regulation'), ('CHEBI_17234', 'glucose', 45, 'glucose'), ('GO_0006006', 'glucose metabolic process', 45, 'glucose metabolism'), ('GO_0046903', 'secretion', 80, 'secreted'), ('CL_0000136', 'fat cell', 106, 'adipocytes'), ('UBERON_0001987', 'placenta', 121, 'placental'), ('UBERON_0000088', 'trophoblast', 131, 'trophoblasts'), ('GO_0007565', 'female pregnancy', 151, 'pregnancy')]
PMC5471716	1/2017	S126-PMC5471716	['they lost weight and their Glucose tolerance, Insulin sensitivity, Blood Lipids, and Blood pressure all improved (table\xa03).']	N/A	N/A	[('CHEBI_17234', 'glucose', 27, 'glucose'), ('PR_000045358', 'insulin family protein', 46, 'insulin'), ('UBERON_0000178', 'blood', 67, 'blood'), ('CHEBI_18059', 'lipid', 73, 'lipids'), ('UBERON_0000178', 'blood', 85, 'blood')]
PMC5484502	6/2017	S2-PMC5484502	['eighteen mothers were diagnosed with gdm and 32 had normal Glucose tolerance (ngt).']	N/A	N/A	[('CHEBI_17234', 'glucose', 59, 'glucose')]
PMC5484502	6/2017	S115-PMC5484502	['results\n\ninfant and maternal characteristics\ncharacteristics of infants and their mothers, stratified according to maternal Glucose tolerance status, are summarized intable 1.']	N/A	N/A	[('CHEBI_17234', 'glucose', 124, 'glucose')]
PMC5484502	6/2017	S116-PMC5484502	['eighteen mothers (age range 27 to 42 years) were diagnosed with gdm and 32 mothers (age range 22 to 45 years) had normal Glucose tolerance (ngt) according to iadpsg criteria [36].']	N/A	N/A	[('CHEBI_17234', 'glucose', 121, 'glucose')]
PMC5484502	6/2017	S117-PMC5484502	['numerical results of oral Glucose tolerance test (ogtt) performed in the 24th to 28th week of Pregnancy were available for 40 participants (results for 10 women with Ngt were recorded as "normal").']	N/A	N/A	[('CHEBI_17234', 'glucose', 26, 'glucose'), ('GO_0007565', 'female pregnancy', 94, 'pregnancy'), ('UBERON_0012330', 'nasal-associated lymphoid tissue', 166, 'NGT')]
PMC5484502	6/2017	S123-PMC5484502	['gdm, Gestational diabetes mellitus; n, number of subjects; ngt, normal Glucose tolerance; ogtt, oral Glucose tolerance test; pbmi, pre-Pregnancy body mass inde.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 5, 'gestational'), ('CHEBI_17234', 'glucose', 71, 'glucose'), ('CHEBI_17234', 'glucose', 101, 'glucose'), ('GO_0007565', 'female pregnancy', 135, 'pregnancy')]
PMC5484502	6/2017	S139-PMC5484502	["n, number of subjects; rp, pearson's correlation coefficient; rs, spearman's correlation coefficient; rer, relative Expression ratio.10.1371/journal.pone.0179934.t002\n\ncaption (table-wrap): table 2\nassociation of Placental Slc6A4 methylation with categorical variables of the study population.n Slc6A4 methylation (%)p-valuemeansd infant sex \xa0\xa0\xa0\xa0males1918.59.60.318a\xa0\xa0\xa0\xa0females3115.79.3 maternal Glucose tolerance \xa0\xa0\xa0\xa0gdm1813.56.4 0.037a\xa0\xa0\xa0\xa0ngt3218.610.4 pre-Pregnancy body weightc\xa0\xa0\xa0\xa0normal3016.910.20.665b\xa0\xa0\xa0\xa0overweight1016.08.8\xa0\xa0\xa0\xa0obese1018.18.2 parity \xa0\xa0\xa0\xa002418.410.00.137a\xa0\xa0\xa0\xa0≥12615.28.8 smoking in Pregnancy \xa0\xa0\xa0\xa0no3717.19.60.466a\xa0\xa0\xa0\xa0yes1315.69.0 Alcohol in Pregnancy \xa0\xa0\xa0\xa0no3816.39.60.805a\xa0\xa0\xa0\xa0yes815.79.9 Prenatal Vitamins use \xa0\xa0\xa0\xa0no819.88.20.296a\xa0\xa0\xa0\xa0yes4216.29.6\nsignificant differences between categories are shown in bold."]	N/A	N/A	[('GO_0010467', 'gene expression', 116, 'expression'), ('UBERON_0001987', 'placenta', 213, 'placental'), ('PR_000015190', 'sodium- and chloride-dependent glycine transporter 2', 223, 'SLC6A4'), ('PR_000015190', 'sodium- and chloride-dependent glycine transporter 2', 295, 'SLC6A4'), ('CHEBI_17234', 'glucose', 396, 'glucose'), ('GO_0007565', 'female pregnancy', 459, 'pregnancy'), ('GO_0007565', 'female pregnancy', 604, 'pregnancy'), ('CHEBI_30879', 'alcohol', 652, 'Alcohol'), ('GO_0007565', 'female pregnancy', 663, 'pregnancy'), ('GO_0007565', 'female pregnancy', 710, 'Prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 719, 'vitamins')]
PMC5484502	6/2017	S140-PMC5484502	['n, number of subjects; ngt, normal Glucose tolerance; gdm, Gestational diabetes mellitus; pbmi, pre-Pregnancy body mass index; sd, standard deviation.']	N/A	N/A	[('CHEBI_17234', 'glucose', 35, 'glucose'), ('GO_0007565', 'female pregnancy', 59, 'gestational'), ('GO_0007565', 'female pregnancy', 100, 'pregnancy')]
PMC5484502	6/2017	S147-PMC5484502	['gdm, Gestational diabetes mellitus; ngt, normal Glucose tolerance; rer; relative Expression ratio.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 5, 'gestational'), ('CHEBI_17234', 'glucose', 48, 'glucose'), ('GO_0010467', 'gene expression', 81, 'expression')]
PMC5484502	6/2017	S175-PMC5484502	['we subsequently conducted multiple linear regression analysis with Birth weight as the outcome and Placental Slc6A4 mrna levels along with several covariates (in particular, infants sex and Gestational age, maternal smoking in Pregnancy, Glucose tolerance status and gwg) as predictors (s7 table).']	N/A	N/A	[('GO_0007567', 'parturition', 67, 'birth'), ('UBERON_0001987', 'placenta', 99, 'placental'), ('PR_000015190', 'sodium- and chloride-dependent glycine transporter 2', 109, 'SLC6A4'), ('GO_0007565', 'female pregnancy', 190, 'gestational'), ('GO_0007565', 'female pregnancy', 227, 'pregnancy'), ('CHEBI_17234', 'glucose', 238, 'glucose')]
PMC5484502	6/2017	S203-PMC5484502	['caption (supplementary-material): s5 table\npartial correlation between the Slc6A4 methylation levels and maternal Plasma Glucose concentrations in the 24th to 28th week of Pregnancy.']	N/A	N/A	[('PR_000015190', 'sodium- and chloride-dependent glycine transporter 2', 75, 'SLC6A4'), ('UBERON_0001969', 'blood plasma', 114, 'plasma'), ('CHEBI_17234', 'glucose', 121, 'glucose'), ('GO_0007565', 'female pregnancy', 172, 'pregnancy')]
PMC5484502	6/2017	S209-PMC5484502	['caption (supplementary-material): s1 fig\nPlacental Dna Methylation at individual Slc6A4 loci in infants of mothers with normal Glucose tolerance and mothers with Gestational diabetes mellitus.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 41, 'Placental'), ('UBERON_0001987', 'placenta', 41, 'Placental'), ('GO_0006306', 'DNA methylation', 51, 'DNA methylation'), ('PR_000015190', 'sodium- and chloride-dependent glycine transporter 2', 81, 'SLC6A4'), ('CHEBI_17234', 'glucose', 127, 'glucose'), ('GO_0007565', 'female pregnancy', 162, 'gestational')]
PMC5486026	6/2017	S114-PMC5486026	['gdm was diagnosed between 24 and 28 weeks of Gestation by screening with an oral challenge of 50 g Glucose (o’sullivan test) [32].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 45, 'gestation'), ('CHEBI_17234', 'glucose', 99, 'glucose')]
PMC5486026	6/2017	S115-PMC5486026	['a positive screening result (1 h Plasma Glucose concentration >140 mg/dl) was followed by a 3-h Oral Glucose tolerance test with 100 g of an oral Glucose load.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 33, 'plasma'), ('CHEBI_17234', 'glucose', 40, 'glucose'), ('UBERON_0000165', 'mouth', 96, 'oral'), ('CHEBI_17234', 'glucose', 101, 'glucose'), ('CHEBI_17234', 'glucose', 146, 'glucose')]
PMC5486026	6/2017	S116-PMC5486026	['the test was considered positive if two of the four Serum Glucose values were above the cut off (basal: 105 mg/dl, 1 h: 190 mg/dl, 2 h: 165 mg/dl and 3 h: 145 mg/dl) according to the criteria of the national diabetes data group [19].']	N/A	N/A	[('UBERON_0001977', 'blood serum', 52, 'serum'), ('CHEBI_17234', 'glucose', 58, 'glucose')]
PMC5486026	6/2017	S117-PMC5486026	['Metabolic Control of gdm patients was assessed by the endocrinologist who decided diet or Insulin based on the Glycemic results on fasting Glucose >90 mg/dl and 2 h Postprandial Glucose >120 mg/dl.']	N/A	N/A	[('GO_0008150', 'biological_process', 0, 'Metabolic control'), ('PR_000045358', 'insulin family protein', 90, 'insulin'), ('GO_0006096', 'glycolytic process', 111, 'glycemic'), ('CHEBI_17234', 'glucose', 139, 'glucose'), ('GO_0007567', 'parturition', 165, 'postprandial'), ('CHEBI_17234', 'glucose', 178, 'glucose')]
PMC5486026	6/2017	S130-PMC5486026	['biochemical analysis\nSerum Glucose and Triglycerides (tg) were measured using an automatic analyzer (roche-hitachi modular pyd autoanalyzer, mannheim, germany).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 21, 'Serum'), ('CHEBI_17234', 'glucose', 27, 'glucose'), ('CHEBI_17855', 'triglyceride', 39, 'triglycerides')]
PMC5486026	6/2017	S144-PMC5486026	['cells were cultured at 37 °c in f-12 medium with 10% ( v / v ) fetal Bovine Serum, 4.5 g/l Glucose, 100 mg/ml Streptomycin, 100 iu/Penicillin, 100 iu/glutamine in a standard Tissue atmosphere of 20% O2And 5% Co2.']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 69, 'bovine'), ('UBERON_0001977', 'blood serum', 76, 'serum'), ('CHEBI_17234', 'glucose', 91, 'glucose'), ('CHEBI_17076', 'streptomycin', 110, 'streptomycin'), ('CHEBI_17334', 'penicillin', 131, 'penicillin'), ('UBERON_0000479', 'tissue', 174, 'tissue'), ('CHEBI_29020', 'neral', 199, 'O2and'), ('CHEBI_16526', 'carbon dioxide', 208, 'CO2')]
PMC5514114	7/2017	S15-PMC5514114	['this leads to excess Delivery Of Glucose and Fatty Acids to the fetus12, and ultimately to lifelong alterations in Gene Expression through epigenetic changes13.']	N/A	N/A	[('GO_0043654', 'recognition of apoptotic cell', 21, 'delivery of glucose'), ('CHEBI_17234', 'glucose', 33, 'glucose'), ('CHEBI_35366', 'fatty acid', 45, 'fatty acids'), ('GO_0010159', 'specification of animal organ position', 45, 'fatty acids'), ('GO_0010467', 'gene expression', 115, 'gene expression'), ('SO_0000704', 'gene', 115, 'gene')]
PMC5514114	7/2017	S72-PMC5514114	['at day 100, Insulin sensitivity was assessed by an oral Glucose tolerance test following a 6-hour fast.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 12, 'insulin'), ('CHEBI_17234', 'glucose', 56, 'glucose')]
PMC5514114	7/2017	S73-PMC5514114	['after collection of Tail Blood (at t0), a Glucose load (1\u2009g/kg of body weight) was given by gavage.']	N/A	N/A	[('UBERON_0002415', 'tail', 20, 'tail'), ('UBERON_0000178', 'blood', 25, 'blood'), ('CHEBI_17234', 'glucose', 42, 'glucose')]
PMC5514114	7/2017	S75-PMC5514114	['Glucose was measured at each time point, with Plasma Insulin also measured at t0, t30, t60, t90 and t120.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('UBERON_0001969', 'blood plasma', 46, 'plasma'), ('PR_000045358', 'insulin family protein', 53, 'insulin')]
PMC5514114	7/2017	S76-PMC5514114	['Insulin and Glucose concentrations were used to derive the matsuda index of Insulin sensitivity34, which was the primary outcome of this study.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 0, 'Insulin'), ('CHEBI_17234', 'glucose', 12, 'glucose'), ('PR_000045358', 'insulin family protein', 76, 'insulin')]
PMC5514114	7/2017	S83-PMC5514114	['assays\nduring the oral Glucose tolerance test, Glucose concentration was measured by glucometer (optium xceed; abbott laboratories) from Tail whole Blood, at the time samples were taken.']	N/A	N/A	[('CHEBI_17234', 'glucose', 23, 'glucose'), ('CHEBI_17234', 'glucose', 47, 'glucose'), ('UBERON_0002415', 'tail', 137, 'tail'), ('UBERON_0000178', 'blood', 148, 'blood')]
PMC5514114	7/2017	S85-PMC5514114	['Glucose, Creatinine, alkaline phosphatase (alp), alanine transaminase (alt), aspartate transaminase (ast), free Fatty Acids, Uric Acid, Triglycerides, high-density lipoprotein Cholesterol (Hdl-C), low-density lipoprotein Cholesterol (Ldl-C), and total Cholesterol were measured on a hitachi 902 autoanalyser (hitachi high technologies corporation, tokyo, japan) with all cvs less than 6%.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('CHEBI_16737', 'creatinine', 9, 'creatinine'), ('CHEBI_35366', 'fatty acid', 112, 'fatty acids'), ('CHEBI_27226', 'uric acid', 125, 'uric acid'), ('CHEBI_17855', 'triglyceride', 136, 'triglycerides'), ('CHEBI_16113', 'cholesterol', 176, 'cholesterol'), ('PR_000008530', 'hairy/enhancer-of-split related with YRPW motif-like protein', 189, 'HDL-C'), ('CHEBI_16113', 'cholesterol', 221, 'cholesterol'), ('PR_000009780', 'legumain', 234, 'LDL-C'), ('CHEBI_16113', 'cholesterol', 252, 'cholesterol')]
PMC5514114	7/2017	S98-PMC5514114	['caption (table-wrap): table 3\n\nmaternal weight and Metabolic parameters at key milestones of the study and litter characteristics at Birth, according to the maternal diet (control or high-fat) and the gavage treatment during Pregnancy [fish oil or control (Water)].maternal control dietmaternal high-fat dietcontrolfish oilcontrolfish oiln8998maternal weight (g)\xa0\xa0prior to diet allocation (day -10)301\u2009±\u20096298\u2009±\u200910296\u2009±\u20095303\u2009±\u20096\xa0\xa0Mating (day 1)310\u2009±\u20097307\u2009±\u200910322\u2009±\u20097332\u2009±\u200912\xa0\xa0end of Pregnancy (day 22)434\u2009±\u20096444\u2009±\u200914457\u2009±\u200916445\u2009±\u200917\xa0\xa0end of Lactation (day 40)342\u2009±\u20094359\u2009±\u200913368\u2009±\u20099†360\u2009±\u200911\xa0\xa0Gestational weight gain40\u2009±\u2009245\u2009±\u2009242\u2009±\u2009434\u2009±\u20093\xa0\xa0Retroperitoneal fat (% of body weight at day 40)1.2\u2009±\u20090.21.3\u2009±\u20090.21.6\u2009±\u20090.1†1.2\u2009±\u20090.1#Metabolic parameters (day 40)\xa0\xa0fasting Glucose (mmol/l)4.44\u2009±\u20090.174.56\u2009±\u20090.155.20\u2009±\u20090.32†4.93\u2009±\u20090.18\xa0\xa0fasting Insulin (pmol/l)180\u2009±\u200919323\u2009±\u2009118403\u2009±\u200991332\u2009±\u200958\xa0\xa0homa-ir0.98\u2009±\u20090.091.84\u2009±\u20090.662.58\u2009±\u20090.58‡2.01\u2009±\u20090.37\xa0\xa0Triglycerides (mmol/l)0.52\u2009±\u20090.030.47\u2009±\u20090.020.68\u2009±\u20090.05†0.72\u2009±\u20090.05birth characteristics\xa0\xa0litter size (n)11.8\u2009±\u20091.014.1\u2009±\u20090.913.7\u2009±\u20090.811.9\u2009±\u20091.1\xa0\xa0sex ratio (% male per litter)45\u2009±\u2009542\u2009±\u2009457\u2009±\u20093†50\u2009±\u20094\xa0\xa0weight of pups (g)5.6\u2009±\u20090.35.6\u2009±\u20090.35.4\u2009±\u20090.26.2\u2009±\u20090.4*\xa0\xa0length of pups (mm)47.7\u2009±\u20090.247.4\u2009±\u20090.246.7\u2009±\u20090.448.9\u2009±\u20090.2**\ndata are means\u2009±\u2009standard errors.‡p\u2009<\u20090.06\xa0and\xa0†p\u2009<\u20090.05 for a maternal diet effect among controls;#p\u2009<\u20090.06, *p\u2009<\u20090.05, and **p\u2009<\u20090.01 for an effect of the gavage treatment between groups exposed to the same maternal diet.']	N/A	N/A	[('GO_0008152', 'metabolic process', 51, 'metabolic'), ('GO_0007567', 'parturition', 133, 'birth'), ('GO_0007565', 'female pregnancy', 225, 'pregnancy'), ('CHEBI_15377', 'water', 257, 'water'), ('GO_0007618', 'mating', 429, 'Mating'), ('GO_0007565', 'female pregnancy', 482, 'pregnancy'), ('GO_0007595', 'lactation', 540, 'lactation'), ('GO_0007565', 'female pregnancy', 591, 'Gestational'), ('UBERON_0003693', 'retroperitoneal space', 640, 'Retroperitoneal'), ('GO_0008152', 'metabolic process', 726, 'Metabolic'), ('CHEBI_17234', 'glucose', 765, 'glucose'), ('PR_000045358', 'insulin family protein', 836, 'insulin'), ('CHEBI_17855', 'triglyceride', 941, 'Triglycerides')]
PMC5514114	7/2017	S118-PMC5514114	['caption (table-wrap): table 5\n\nstudy outcomes among Adult male offspring according to the maternal diet (control or high-fat), and gavage treatment during Pregnancy [Fish oil or control (Water)].maternal control dietmaternal high-fat dietcontrolfish oilcontrolfish oiln12121212glucose Homeostasis\xa0\xa0matsuda index1.35\u2009±\u20090.171.27\u2009±\u20090.250.84\u2009±\u20090.09†1.55\u2009±\u20090.26*\xa0\xa0Homa-Ir3.02\u2009±\u20090.413.89\u2009±\u20090.634.57\u2009±\u20090.54†2.66\u2009±\u20090.42*\xa0\xa0fasting Glucose (mmol/l)4.96\u2009±\u20090.145.46\u2009±\u20090.215.03\u2009±\u20090.115.03\u2009±\u20090.21\xa0\xa0Glucose auc (min.mmol/l)847\u2009±\u200925841\u2009±\u200928866\u2009±\u200931818\u2009±\u200929\xa0\xa0fasting Insulin (pmol/l)497\u2009±\u200963556\u2009±\u200974732\u2009±\u200979434\u2009±\u200971*\xa0\xa0Insulin auc (x103\u2009min.pmol/l)76\u2009±\u2009982\u2009±\u200911124\u2009±\u200914†81\u2009±\u20099liver function\xa0\xa0alp (u/l)79\u2009±\u2009466\u2009±\u2009376\u2009±\u2009582\u2009±\u20096\xa0\xa0ast (u/l)144\u2009±\u200913133\u2009±\u20095171\u2009±\u20099160\u2009±\u200914\xa0\xa0alt (u/l)36\u2009±\u2009235\u2009±\u2009238\u2009±\u2009438\u2009±\u20092lipids\xa0\xa0free Fatty Acids (mmol/l)0.83\u2009±\u20090.090.79\u2009±\u20090.070.95\u2009±\u20090.120.83\u2009±\u20090.08\xa0\xa0total Cholesterol (mmol/l)1.70\u2009±\u20090.131.94\u2009±\u20090.111.96\u2009±\u20090.151.81\u2009±\u20090.09\xa0\xa0hdl-c (mmol/l)1.21\u2009±\u20090.091.46\u2009±\u20090.081.37\u2009±\u20090.101.39\u2009±\u20090.06\xa0\xa0ldl-c (mmol/l)0.29\u2009±\u20090.030.25\u2009±\u20090.030.25\u2009±\u20090.020.25\u2009±\u20090.03\xa0\xa0Triglycerides (mmol/l)0.68\u2009±\u20090.070.94\u2009±\u20090.091.23\u2009±\u20090.15†0.87\u2009±\u20090.11other\xa0\xa0Uric Acid (µmol/l)71\u2009±\u2009575\u2009±\u2009273\u2009±\u2009369\u2009±\u20096\xa0\xa0leptin (ng/ml)1.6\u2009±\u20090.34.2\u2009±\u20091.3*5.7\u2009±\u20091.3††4.0\u2009±\u20090.9\xa0\xa0systolic Blood pressure (mmhg)124\u2009±\u20091125\u2009±\u20091136\u2009±\u20091††††135\u2009±\u20091\ndata are means\u2009±\u2009standard errors.†p\u2009<\u20090.05,††p\u2009<\u20090.01, and††††p\u2009<\u20090.0001 for a maternal diet effect among the offspring of dams that received control gavage; *p\u2009<\u20090.05 and **p\u2009<\u20090.01 for an effect of the gavage treatment between groups exposed to the same maternal diet.']	N/A	N/A	[('UBERON_0007023', 'adult organism', 52, 'adult'), ('GO_0007565', 'female pregnancy', 155, 'pregnancy'), ('CHEBI_83324', 'pent-2-enoyl-CoA(4-)', 166, 'fish'), ('CHEBI_15377', 'water', 187, 'water'), ('GO_0042592', 'homeostatic process', 285, 'homeostasis'), ('PR_000008680', 'homer protein homolog 3', 359, 'HOMA-IR3'), ('CHEBI_17234', 'glucose', 422, 'glucose'), ('CHEBI_17234', 'glucose', 484, 'Glucose'), ('PR_000045358', 'insulin family protein', 550, 'insulin'), ('PR_000045358', 'insulin family protein', 601, 'Insulin'), ('CHEBI_35366', 'fatty acid', 796, 'fatty acids'), ('CHEBI_16113', 'cholesterol', 868, 'cholesterol'), ('CHEBI_17855', 'triglyceride', 1054, 'Triglycerides'), ('CHEBI_28895', "3'-UMP", 1128, 'Uric acid'), ('UBERON_0000178', 'blood', 1236, 'blood')]
PMC5526977	7/2017	S65-PMC5526977	['therefore, all control females were placed back in group-housed cages and allowed to recover body weights prior to Glucose and Insulin tolerance testing.']	N/A	N/A	[('CHEBI_17234', 'glucose', 115, 'glucose'), ('PR_000045358', 'insulin family protein', 127, 'insulin')]
PMC5526977	7/2017	S110-PMC5526977	['fasting Glucose levels, an indicator of a diabetic-like state, were not affected by genotype (fig.']	N/A	N/A	[('CHEBI_17234', 'glucose', 8, 'glucose')]
PMC5526977	7/2017	S113-PMC5526977	['Glucose tolerance was determined over 180\u2009min following an ip injection of Glucose (2\u2009g/kg).']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('CHEBI_17234', 'glucose', 75, 'glucose')]
PMC5526977	7/2017	S114-PMC5526977	['Glucose clearance was slower in ko from con-Fed dams compared to wt and kiko females at 60, 90, 120, and 180\u2009min (fig.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('GO_0007631', 'feeding behavior', 44, 'fed')]
PMC5526977	7/2017	S117-PMC5526977	['maternal hfd did not alter Glucose clearance in any genotype (fig.']	N/A	N/A	[('CHEBI_17234', 'glucose', 27, 'glucose')]
PMC5526977	7/2017	S121-PMC5526977	['ko exhibited slower Glucose clearance compared to wt, regardless of diet treatment (p\u2009<\u20090.05, p\u2009<\u20090.01, respectively).']	N/A	N/A	[('CHEBI_17234', 'glucose', 20, 'glucose')]
PMC5526977	7/2017	S123-PMC5526977	['in all genotypes, Insulin-induced Glucose clearance was not altered by maternal hfd (fig.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 18, 'insulin'), ('CHEBI_17234', 'glucose', 34, 'glucose')]
PMC5526977	7/2017	S126-PMC5526977	['caption (fig): figure 3\n\nfasting Glucose levels and Glucose tolerance test (gtt) in Adult females from all genotypes after 20 weeks of Adult Chow diet.']	N/A	N/A	[('CHEBI_17234', 'glucose', 33, 'glucose'), ('CHEBI_17234', 'glucose', 52, 'glucose'), ('UBERON_0007023', 'adult organism', 84, 'adult'), ('UBERON_0007023', 'adult organism', 135, 'adult'), ('CHEBI_33290', 'food', 141, 'chow')]
PMC5526977	7/2017	S127-PMC5526977	['( a ) fasting Glucose levels.']	N/A	N/A	[('CHEBI_17234', 'glucose', 14, 'glucose')]
PMC5526977	7/2017	S201-PMC5526977	['Glucose-6-phosphatase ( g6pc ) Expression, which Controls Hepatic Glucose Production46, was elevated by maternal hfd in wt (p\u2009<\u20090.0001) and kiko (p\u2009<\u20090.05) females (fig.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('GO_0010467', 'gene expression', 31, 'expression'), ('GO_0065007', 'biological regulation', 49, 'controls'), ('GO_0007568', 'aging', 58, 'hepatic'), ('UBERON_0002107', 'liver', 58, 'hepatic'), ('CHEBI_17234', 'glucose', 66, 'glucose'), ('GO_0006094', 'gluconeogenesis', 66, 'glucose production46')]
PMC5526977	7/2017	S210-PMC5526977	['Sterol Regulatory Element-Binding Protein 1 ( Srebp1 ), a regulator of Liver transcription for Glucose, Fatty Acid, and Lipid Production49, was not altered by maternal hfd but was Expressed less in ko than in wt (p\u2009<\u20090.05 for both; fig.']	N/A	N/A	[('CHEBI_15889', 'sterol', 0, 'Sterol'), ('PR_000015890', 'synaptophysin', 0, 'Sterol regulatory element-binding protein 1'), ('GO_0065007', 'biological regulation', 7, 'regulatory'), ('SO_0001678', 'regulatory_promoter_element', 7, 'regulatory element'), ('PR_000015909', 'synaptotagmin-7', 46, 'Srebp1'), ('UBERON_0002107', 'liver', 71, 'liver'), ('CHEBI_17234', 'glucose', 95, 'glucose'), ('GO_0007369', 'gastrulation', 95, 'glucose ...'), ('CHEBI_35366', 'fatty acid', 104, 'fatty acid'), ('GO_0001553', 'luteinization', 104, 'fatty acid ...'), ('CHEBI_18059', 'lipid', 120, 'lipid'), ('GO_0032945', 'negative regulation of mononuclear cell proliferation', 120, 'lipid production49'), ('GO_0010467', 'gene expression', 180, 'expressed')]
PMC5526977	7/2017	S314-PMC5526977	['afterward, a Glucose tolerance test (gtt) was performed on each female.']	N/A	N/A	[('CHEBI_17234', 'glucose', 13, 'glucose')]
PMC5526977	7/2017	S316-PMC5526977	['at the start of the test and 30\u2009min after local anesthetizing of the Tail with Lidocaine, Mice were placed in plexiglass restrainers and Tails were nicked to collect a baseline (time\u2009=\u20090) Glucose reading using a Glucometer (alphatrak2).']	N/A	N/A	[('UBERON_0002415', 'tail', 69, 'tail'), ('CHEBI_70622', 'lippiolide', 79, 'lidocaine'), ('NCBITaxon_10088', 'Mus <genus>', 90, 'mice'), ('UBERON_0002415', 'tail', 137, 'tails'), ('CHEBI_17234', 'glucose', 188, 'glucose'), ('CHEBI_24321', 'glutamo group', 212, 'glucometer')]
PMC5526977	7/2017	S317-PMC5526977	['immediately after baseline, females were injected Intraperitoneally (ip) with a bolus of Glucose (2.0\u2009g/kg body weight) and individually housed in clean cages.']	N/A	N/A	[('UBERON_0000007', 'pituitary gland', 50, 'intraperitoneally'), ('CHEBI_17234', 'glucose', 89, 'glucose')]
PMC5531500	7/2017	S2-PMC5531500	['all women were submitted to a 75g oral Glucose tolerance test in the second and third trimester.']	N/A	N/A	[('CHEBI_17234', 'glucose', 39, 'glucose')]
PMC5531500	7/2017	S3-PMC5531500	['First Trimester fasting Blood Glucose was also obtained from ob women.']	N/A	N/A	[('GO_0046897', 'N-terminal peptidyl-tyrosine methylation', 0, 'First trimester'), ('UBERON_0000178', 'blood', 24, 'blood'), ('CHEBI_17234', 'glucose', 30, 'glucose')]
PMC5531500	7/2017	S75-PMC5531500	['homa-ir was calculated using the following formula: homa-i = (fasting Plasma Insulin (mui/l) ×fasting Blood Glucose (mmol/l))/22.5.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 70, 'plasma'), ('PR_000045358', 'insulin family protein', 77, 'insulin'), ('UBERON_0000178', 'blood', 102, 'blood'), ('CHEBI_17234', 'glucose', 108, 'glucose')]
PMC5531500	7/2017	S167-PMC5531500	['furthermore, as shown elsewhere [15], we observed that Pregnant women with obesity who have normal Glucose tolerance still had a higher Glucose profile (glycemia and hba1c) than Pregnant women of normal weight, thereby exposing the fetus to relative hyperglycemia.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 55, 'pregnant'), ('CHEBI_17234', 'glucose', 99, 'glucose'), ('CHEBI_17234', 'glucose', 136, 'glucose'), ('GO_0007565', 'female pregnancy', 178, 'pregnant')]
PMC5539663	7/2017	S4-PMC5539663	['then, the incidence of gdm was measured in 24–26 weeks of Pregnancy with Glucose tolerance test and compared in three groups.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 58, 'pregnancy'), ('CHEBI_17234', 'glucose', 73, 'glucose')]
PMC5539663	7/2017	S39-PMC5539663	['all participants were under Glucose tolerance test (gtt), and they had positive gtt were also excluded from the study.']	N/A	N/A	[('CHEBI_17234', 'glucose', 28, 'glucose')]
PMC5539663	7/2017	S41-PMC5539663	['at zero time (baseline), Blood sample was drawn; then, the participants were given 75 g of Glucose in Solution to drink within a 5 min time frame.']	N/A	N/A	[('UBERON_0000178', 'blood', 25, 'blood'), ('CHEBI_17234', 'glucose', 91, 'glucose'), ('CHEBI_75958', 'solution', 102, 'solution')]
PMC5539663	7/2017	S49-PMC5539663	['gtt was performed in the following way: blood Glucose was measured at baseline, and then participants were given a 75 g oral Glucose and measurement of blood glucose levels 1 and 2 h later was done.']	N/A	N/A	[('CHEBI_17234', 'glucose', 46, 'glucose'), ('CHEBI_17234', 'glucose', 125, 'glucose')]
PMC5539663	7/2017	S50-PMC5539663	['normal result for the Glucose screening test was fasting Blood Sugar between 100 and 120 mg/dl.']	N/A	N/A	[('CHEBI_17234', 'glucose', 22, 'glucose'), ('UBERON_0000178', 'blood', 57, 'blood'), ('CHEBI_24870', 'ion', 63, 'sugar')]
PMC5539754	8/2017	S3-PMC5539754	['Serum 25Ohd, fasting Glucose, Insulin and Insulin resistance (homa-ir) were measured in early (12\xa0weeks’ Gestation) and late Pregnancy (28\xa0weeks’ Gestation).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 6, '25OHD'), ('CHEBI_17234', 'glucose', 21, 'glucose'), ('PR_000045358', 'insulin family protein', 30, 'insulin'), ('PR_000045358', 'insulin family protein', 42, 'insulin'), ('GO_0007565', 'female pregnancy', 105, 'gestation'), ('GO_0007565', 'female pregnancy', 125, 'pregnancy'), ('GO_0007565', 'female pregnancy', 146, 'gestation')]
PMC5539754	8/2017	S55-PMC5539754	['fasting blood Glucose was measured at both time points, and a Glucose challenge test (1-h post a 50-g Glucose load) was performed at 28\xa0weeks’ Gestation.']	N/A	N/A	[('CHEBI_17234', 'glucose', 14, 'glucose'), ('CHEBI_17234', 'glucose', 62, 'glucose'), ('CHEBI_17234', 'glucose', 102, 'glucose'), ('GO_0007565', 'female pregnancy', 143, 'gestation')]
PMC5539754	8/2017	S78-PMC5539754	['caption (table-wrap): table 1\n\nparticipant characteristicsseason at first Antenatal visitcharacteristictotal group( n \xa0=\xa0334)winter( n \xa0=\xa0166)summer( n \xa0=\xa0168) paage (years)33.0 (3.9)32.8 (3.7)33.2 (4.0)0.409gestation at first Antenatal visit (weeks)12.8 (2.3)12.7 (2.3)12.9 (2.2)0.556bmi at first Antenatal visit\u2003mean (sd), (kg/m2)26.3 (4.5)26.3 (4.4)26.2 (4.7)0.948\u2003underweight (bmi <18.5\xa0kg/m2) [n (%)]2 (0.6)1 (0.6)1 (0.6)0.953\u2003normal (bmi 18.5–24.9\xa0kg/m2) [n (%)]153 (45.8)78 (46.4)75 (45.2)\u2003overweight (bmi 25.0–29.9\xa0kg/m2) [n (%)]125 (37.4)60 (35.7)65 (39.2)\u2003obese (bmi >30.0\xa0kg/m2) [n (%)]52 (15.6)27 (16.1)25 (15.1)smoking at baseline [n (%)]7 (2.1)4 (2.4)3 (1.8)0.697intervention group [n (%)]171 (51.2)84 (50.6)87 (50.9)0.829ethnicity: caucasian [n (%)]331 (99.1)166 (100.0)165 (98.2)0.250achieved 3rd level education [n (%)]177 (53.0)87 (52.6)90 (53.6)0.940birth weight (g)4065.9 (470.0)4043.1 (434.4)4088.4 (503.0)0.382\ndata are presented as mean (sd) unless otherwise stated\nacomparison between winter and summer\n\nparticipant characteristics - 25Ohd, season and markers of Glucose Metabolism\nmedian (iqr) 25Ohd concentrations were 39.2\xa0nmol/l (27.2\xa0nmol/l) and 35.8\xa0nmol/l (27.3\xa0nmol/l) in early and late Pregnancy, respectively.']	N/A	N/A	[('GO_0007567', 'parturition', 74, 'antenatal'), ('GO_0007567', 'parturition', 227, 'antenatal'), ('GO_0007567', 'parturition', 298, 'antenatal'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 1058, '25OHD'), ('CHEBI_17234', 'glucose', 1087, 'glucose'), ('GO_0006006', 'glucose metabolic process', 1087, 'glucose metabolism'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 1119, '25OHD'), ('GO_0007565', 'female pregnancy', 1219, 'pregnancy')]
PMC5539754	8/2017	S85-PMC5539754	['caption (table-wrap): table 2\n\nmaternal 25Ohd and markers of Glucose Metabolism in early and late Pregnancy among the total group and categorised by season of first Antenatal visitseason at first Antenatal visittotal group( n \xa0=\xa0334)winter( n \xa0=\xa0166)summer( n \xa0=\xa0168) Pd25Ohd early <30\xa0nmol/la90 (26.9)64 (38.6)26 (15.5)<0.00125ohd early <50\xa0nmol/La205 (61.4)121 (72.9)84 (50.0)0.00225ohd 28\xa0weeks <30\xa0nmol/la111 (33.2)56 (33.7)55 (32.7)0.66225ohd 28\xa0weeks <50\xa0nmol/la211 (63.2)103 (62.0)107 (63.7)0.999homa-ir Earlyb2.1 (2.6)2.4 (2.8)1.7 (2.0)0.004homa-ir 28\xa0weeksb2.8 (3.15)2.9 (3.4)2.6 (2.6)0.064insulin early (μu/ml)b11.3 (12.3)12.8 (13.1)9.3 (11.1)0.002insulin 28\xa0weeks (μu/ml)b14.4 (15.6)14.6 (16.8)14.1 (11.8)0.108fasting Glucose early (mmol/l)c4.48 (0.35)4.47 (0.33)4.49 (0.37)0.566fasting Glucose 28\xa0weeks (mmol/l)c4.46 (0.46)4.49 (0.45)4.42 (0.46)0.1571-h gct 28\xa0weeks (mmol/l)c6.48 (1.44)6.47 (1.39)6.50 (1.48)0.864\ndata presented asan (%),bmedian (interquartile range),cmean (sd)\ndcomparison between winter and summer\n\nunadjusted analysis – 25Ohd, season and markers of Glucose Metabolism\non unadjusted, simple linear regression, early-Pregnancy 25Ohd <30\xa0nmol/l was not associated with any marker of Glucose Metabolism in early or late Pregnancy (table3[a]).']	N/A	N/A	[('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 40, '25OHD'), ('CHEBI_17234', 'glucose', 61, 'glucose'), ('GO_0006006', 'glucose metabolic process', 61, 'glucose metabolism'), ('GO_0007565', 'female pregnancy', 98, 'pregnancy'), ('GO_0007567', 'parturition', 165, 'antenatal'), ('GO_0007567', 'parturition', 196, 'antenatal'), ('CHEBI_72658', '11-oxo-ent-cassa-12,15-dien-3alpha-ol', 268, 'Pd25OHD'), ('CHEBI_78028', 'mitoguazone hydrochloride', 347, 'La205'), ('UBERON_0003125', 'vitelline membrane', 511, 'earlyb2'), ('CHEBI_17234', 'glucose', 729, 'glucose'), ('CHEBI_17234', 'glucose', 798, 'glucose'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 1053, '25OHD'), ('CHEBI_17234', 'glucose', 1082, 'glucose'), ('GO_0006006', 'glucose metabolic process', 1082, 'glucose metabolism'), ('GO_0007565', 'female pregnancy', 1148, 'pregnancy'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 1158, '25OHD'), ('CHEBI_17234', 'glucose', 1213, 'glucose'), ('GO_0006006', 'glucose metabolic process', 1213, 'glucose metabolism'), ('GO_0007565', 'female pregnancy', 1249, 'pregnancy')]
PMC5539754	8/2017	S87-PMC5539754	['caption (table-wrap): table 3\n\nunadjusted regression analysis: percentage difference in markers of Glucose Metabolism associated with, (a) early-Pregnancy 25Ohd\xa0<\xa030\xa0nmol/l, and (b) first Antenatal visit in extended winter(a) early-Pregnancy 25Ohd <30\xa0nmol/l(b) first Antenatal visit in extended winterdependent variable% ∆ab95% ci p % ∆ab95% ci p homa-Ir early18.5%0.17(−0.04, 0.39)0.11031.1%0.27(0.08, 0.46)0.006homa-ir 28\xa0weeks11.6%0.11(−0.13, 0.39)0.37121.9%0.20(0.00, 0.40)0.051insulin early (μu/ml)16.2%0.15(−0.06, 0.35)0.17330.6%0.27(0.08, 0.45)0.005insulin 28\xa0weeks (μu/ml)7.3%0.07(−0.16, 0.30)0.52819.2%0.18(−0.02, 0.37)0.074fasting Glucose early (mmol/l)0.03(−0.06, 0.12)0.541−0.02(−0.09, 0.05)0.566fasting Glucose 28\xa0weeks (mmol/l)0.09(−0.02, 0.21)0.1120.07(−0.03, 0.17)0.1571-h gct 28\xa0weeks (mmol/l)0.04(−0.32, 0.41)0.824−0.03(−0.34, 0.29)0.864\na% difference in Metabolic marker\n\nadjusted analysis (model 1) – 25Ohd, season and markers of Glucose Metabolism\nmultiple linear regression models (table4) included both 25Ohd <30\xa0nmol/l and extended winter as predictors of the Metabolic markers (model 1), and were also adjusted for confounders (model 2).']	N/A	N/A	[('CHEBI_17234', 'glucose', 99, 'glucose'), ('GO_0006006', 'glucose metabolic process', 99, 'glucose metabolism'), ('GO_0007565', 'female pregnancy', 145, 'pregnancy'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 155, '25OHD'), ('GO_0007567', 'parturition', 188, 'antenatal'), ('GO_0007565', 'female pregnancy', 232, 'pregnancy'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 242, '25OHD'), ('GO_0007567', 'parturition', 268, 'antenatal'), ('PR_000002188', 'DNA fragmentation factor subunit alpha', 352, '-IR'), ('CHEBI_17234', 'glucose', 642, 'glucose'), ('CHEBI_17234', 'glucose', 717, 'glucose'), ('GO_0008152', 'metabolic process', 874, 'metabolic'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 922, '25OHD'), ('CHEBI_17234', 'glucose', 951, 'glucose'), ('GO_0006006', 'glucose metabolic process', 951, 'glucose metabolism'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 1027, '25OHD'), ('GO_0008152', 'metabolic process', 1085, 'metabolic')]
PMC5539754	8/2017	S90-PMC5539754	['neither extended winter nor 25Ohd <30\xa0nmol/l were associated with Glucose in early or late Pregnancy, or the gct in late Pregnancy (model 1, table4).']	N/A	N/A	[('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 28, '25OHD'), ('CHEBI_17234', 'glucose', 66, 'glucose'), ('GO_0007565', 'female pregnancy', 91, 'pregnancy'), ('GO_0007565', 'female pregnancy', 121, 'pregnancy')]
PMC5539754	8/2017	S92-PMC5539754	['caption (table-wrap): table 4\n\nmultiple linear regression analysis and associated percentage difference in markers of Glucose Metabolism (model 1 unadjusted, and model 2 adjusted)model 1 – unadjusted modelmodel 2 – final adjusted modeldependent variableindependent variable (early Pregnancy)% ∆ab95% ci p model p % ∆ab95% ci p model p homa-ir earlywinter32.8%0.28(0.08, 0.49)0.0080.00846.72%0.38(0.15, 0.62)0.001<0.00125ohd <30\xa0nmol/l11.6%0.11(−0.11, 0.32)0.32511.64%0.11(−0.14, 0.36)0.382homa-ir 28\xa0weeks’winter29.7%0.26(0.04, 0.49)0.0240.05153.70%0.43(0.17, 0.69)0.0020.00125ohd <30\xa0nmol/l4.1%0.04(−0.20, 0.28)0.7533.00%0.03(−0.25, 0.31)0.837insulin early (μu/ml)winter32.4%0.28(0.08, 0.48)0.0070.01047.57%0.39(0.16, 0.62)0.001<0.00125ohd <30\xa0nmol/l8.3%0.08(−0.14, 0.29)0.4748.16%0.08(−0.17, 0.32)0.530insulin 28\xa0weeks (μu/ml)winter25.9%0.23(0.01, 0.46)0.0410.10249.53%0.40(0.14, 0.66)0.0030.00225ohd <30\xa0nmol/l1.0%0.01(−0.22, 0.24)0.927−0.17%0.00(−0.28, 0.28)0.991fasting Glucose early (mmol/l)winter−0.02(−0.11, 0.06)0.5830.713−0.04(−0.13, 0.06)0.4350.02125ohd <30\xa0nmol/l0.03(−0.06, 0.13)0.4690.06(−0.04, 0.16)0.257fasting Glucose 28\xa0weeks (mmol/l)winter0.07(−0.04, 0.18)0.1850.1180.13(0.00, 0.26)0.0450.01525ohd <30\xa0nmol/l0.08(−0.04, 0.19)0.2080.15(0.01, 0.29)0.0411-h gct 28\xa0weeks (mmol/l)winter0.04(−0.31, 0.39)0.8060.9460.02(−0.41, 0.45)0.9300.68825ohd <30\xa0nmol/l0.03(−0.35, 0.41)0.8730.02(−0.45, 0.50)0.923\na% difference in Metabolic marker\nmodel 1: model not controlled for confounders.']	N/A	N/A	[('CHEBI_17234', 'glucose', 118, 'glucose'), ('GO_0006006', 'glucose metabolic process', 118, 'glucose metabolism'), ('GO_0007565', 'female pregnancy', 281, 'pregnancy'), ('CHEBI_17234', 'glucose', 975, 'glucose'), ('CHEBI_17234', 'glucose', 1127, 'glucose'), ('GO_0008152', 'metabolic process', 1433, 'metabolic')]
PMC5539754	8/2017	S96-PMC5539754	['adjusted analysis (model 2) – 25Ohd, season and markers of Glucose Metabolism\nthe final adjusted, multiple linear regression model included extended winter at first Antenatal visit, 25Ohd <30\xa0nmol/l, and the following confounders: bmi (kg/m2), education, being part of the rolo study intervention group, Early-Pregnancy energy (kcal), protein (g) and fat (g), physical activity and well-being score (model 2, table4).']	N/A	N/A	[('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 30, '25OHD'), ('CHEBI_17234', 'glucose', 59, 'glucose'), ('GO_0006006', 'glucose metabolic process', 59, 'glucose metabolism'), ('GO_0007567', 'parturition', 165, 'antenatal'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 182, '25OHD'), ('GO_0051318', 'G1 phase', 304, 'early'), ('GO_0007565', 'female pregnancy', 310, 'pregnancy')]
PMC5539754	8/2017	S100-PMC5539754	['sensitivity analysis\nthere were no significant changes in the multiple regression models using different 25Ohd variables as independent variables associated with markers of Glucose Metabolism; early Pregnancy 25ohd (continuous); greater or less than 50\xa0nmol/l (insufficiency), greater or less than 39.2\xa0nmol/l (median) (data not shown).']	N/A	N/A	[('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 105, '25OHD'), ('CHEBI_17234', 'glucose', 173, 'glucose'), ('GO_0006006', 'glucose metabolic process', 173, 'glucose metabolism'), ('GO_0007565', 'female pregnancy', 199, 'pregnancy')]
PMC5539754	8/2017	S102-PMC5539754	['an increase in 25Ohd from early to late Pregnancy was not associated with markers of Glucose Metabolism.']	N/A	N/A	[('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 15, '25OHD'), ('GO_0007565', 'female pregnancy', 40, 'pregnancy'), ('CHEBI_17234', 'glucose', 85, 'glucose'), ('GO_0006006', 'glucose metabolic process', 85, 'glucose metabolism')]
PMC5539754	8/2017	S106-PMC5539754	['furthermore, no interaction effect was observed between season and Vitamin D with regards to Glucose Homeostasis.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('CHEBI_17234', 'glucose', 93, 'glucose'), ('GO_0042593', 'glucose homeostasis', 93, 'glucose homeostasis')]
PMC5539754	8/2017	S122-PMC5539754	['prospectively evaluated 7369 oral Glucose tolerance tests (ogtt) over a 3-year period in australia [24].']	N/A	N/A	[('CHEBI_17234', 'glucose', 34, 'glucose')]
PMC5539754	8/2017	S129-PMC5539754	['we carried out Glucose challenge tests (1-h post 50\xa0g Glucose load) for all women in our population, not ogtt as in the above studies.']	N/A	N/A	[('CHEBI_17234', 'glucose', 15, 'glucose'), ('CHEBI_17234', 'glucose', 54, 'glucose')]
PMC5539754	8/2017	S136-PMC5539754	['fasting Glucose and hba1cwere lowest among greek patients with type 2 diabetes during august and september [23].']	N/A	N/A	[('CHEBI_17234', 'glucose', 8, 'glucose')]
PMC5540678	7/2017	S53-PMC5540678	['as sensitivity analyses, we repeated analyses after exclusion of mothers with implausible energy intakes (<2500 or >25\u200a000\u2005kj·day−1[34]) and after exclusion of mothers with diabetes (whose offspring will have experienced high fetal exposure to Glucose).']	N/A	N/A	[('CHEBI_17234', 'glucose', 244, 'glucose')]
PMC5540678	7/2017	S92-PMC5540678	['Fructose Consumption, in the form of high Fructose corn syrup (ratio of Fructose/Glucose 60/40%), increased from near 0% to near 30% of per capita consumption of Refined Sugars in the usa between 1970 and 2000, whereas the Consumption of Sucrose and Glucose declined or remained constant [3].']	N/A	N/A	[('CHEBI_28757', 'fructose', 0, 'Fructose'), ('GO_0007631', 'feeding behavior', 9, 'consumption'), ('CHEBI_28757', 'fructose', 42, 'fructose'), ('CHEBI_28757', 'fructose', 72, 'fructose'), ('CHEBI_17234', 'glucose', 81, 'glucose'), ('CHEBI_36341', 'boson', 162, 'refined'), ('CHEBI_26822', 'sulfide', 170, 'sugars'), ('GO_0007631', 'feeding behavior', 223, 'consumption'), ('CHEBI_17992', 'sucrose', 238, 'sucrose'), ('CHEBI_17234', 'glucose', 250, 'glucose')]
PMC5543438	8/2017	S77-PMC5543438	['dietitians), Food insecurity - increased access to specialist services through telehealth and allied health outreach visits resulted in enhanced local health professionals’ knowledge.- establishment of nutrition in Pregnancy working group resulted in the development of nutrition education resources.- partnership activities resulted in midwives taking on the role of commencing Blood Glucose Monitoring with the women.']	N/A	N/A	[('CHEBI_33290', 'food', 13, 'food'), ('GO_0007565', 'female pregnancy', 215, 'pregnancy'), ('GO_0002026', 'regulation of the force of heart contraction', 379, 'blood glucose monitoring'), ('UBERON_0000178', 'blood', 379, 'blood'), ('CHEBI_17234', 'glucose', 385, 'glucose')]
PMC5543438	8/2017	S78-PMC5543438	['all nt diabetes services are now able to provide home Blood Glucose Monitoring equipment to women.']	N/A	N/A	[('GO_0002026', 'regulation of the force of heart contraction', 54, 'blood glucose monitoring'), ('UBERON_0000178', 'blood', 54, 'blood'), ('CHEBI_17234', 'glucose', 60, 'glucose')]
PMC5543438	8/2017	S109-PMC5543438	['logistics and access\nthe partnership has also been successful in providing better access to specialist services, including to diabetes education, dietitians and access to Glucose meters (table1).']	N/A	N/A	[('CHEBI_17234', 'glucose', 171, 'glucose')]
PMC5543438	8/2017	S116-PMC5543438	['a memorandum of understanding was also endorsed by the partnership with suppliers of Glucose meters to provide free Glucose metres to women with dip.']	N/A	N/A	[('CHEBI_17234', 'glucose', 85, 'glucose'), ('CHEBI_17234', 'glucose', 116, 'glucose')]
PMC5594587	9/2017	S98-PMC5594587	['the Digestive System and intermediary Metabolism of the ruminants differ from the non-Ruminant Animals, as ruminants ferment most of the dietary Carbohydrates to short-chain volatile Fatty Acids using Microbial activity in the Rumen leaving only little Glucose available for Intestinal absorption [41].']	N/A	N/A	[('GO_0007586', 'digestion', 4, 'digestive'), ('UBERON_0001007', 'digestive system', 4, 'digestive system'), ('GO_0008152', 'metabolic process', 38, 'metabolism'), ('NCBITaxon_33208', 'Metazoa', 86, 'ruminant'), ('NCBITaxon_33208', 'Metazoa', 95, 'animals'), ('CHEBI_16646', 'carbohydrate', 145, 'carbohydrates'), ('CHEBI_35366', 'fatty acid', 183, 'fatty acids'), ('NCBITaxon_10088', 'Mus <genus>', 201, 'microbial'), ('UBERON_0007365', 'rumen', 227, 'rumen'), ('CHEBI_17234', 'glucose', 253, 'glucose'), ('UBERON_0000160', 'intestine', 275, 'intestinal')]
PMC5594587	9/2017	S100-PMC5594587	['in our studies, we have performed in vivo Metabolic and Endocrine tolerance tests to elucidate Glucose-Insulin-axis function in Sheep.']	N/A	N/A	[('GO_0008152', 'metabolic process', 42, 'metabolic'), ('GO_0006397', 'mRNA processing', 56, 'endocrine'), ('CHEBI_17234', 'glucose', 95, 'glucose'), ('PR_000045358', 'insulin family protein', 103, 'insulin'), ('NCBITaxon_10088', 'Mus <genus>', 128, 'sheep')]
PMC5594587	9/2017	S101-PMC5594587	['late Gestation undernutrition (50% of energy and protein requirements) decreased peripheral Insulin sensitivity in young Lambs, but their ability to clear intravenously administered Glucose was maintained due to a compensatory upregulation of Insulin Secretion [44,45].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 5, 'gestation'), ('PR_000045358', 'insulin family protein', 92, 'insulin'), ('NCBITaxon_33208', 'Metazoa', 121, 'lambs'), ('CHEBI_17234', 'glucose', 182, 'glucose'), ('PR_000045358', 'insulin family protein', 243, 'insulin'), ('GO_0046903', 'secretion', 251, 'secretion')]
PMC5594587	9/2017	S105-PMC5594587	['in our studies, Lambs exposed to Overnutrition in late Gestation had increased Postnatal Gluconeogenic ability in response to intravenous Propionate injection [46] and had higher levels of plasma Glucose during 44-h fasting when exposed to an early Postnatal high-fat diet [10], which was not observed in Lambs that had been exposed to undernutrition in late Gestation.']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 16, 'lambs'), ('GO_0006704', 'glucocorticoid biosynthetic process', 33, 'overnutrition'), ('GO_0007565', 'female pregnancy', 55, 'gestation'), ('GO_0007567', 'parturition', 79, 'postnatal'), ('GO_0006094', 'gluconeogenesis', 89, 'gluconeogenic'), ('CHEBI_17272', 'propionate', 138, 'propionate'), ('CHEBI_17234', 'glucose', 196, 'glucose'), ('GO_0007567', 'parturition', 249, 'postnatal'), ('NCBITaxon_33208', 'Metazoa', 305, 'lambs'), ('GO_0007565', 'female pregnancy', 359, 'gestation')]
PMC5594587	9/2017	S176-PMC5594587	['the alterations observed in body fat composition and Glucose-Insulin Homeostasis in young Lambs with a history of foetal overnutrition did not persist into Adulthood [56].']	N/A	N/A	[('CHEBI_17234', 'glucose', 53, 'glucose'), ('GO_0042593', 'glucose homeostasis', 53, 'glucose- ... homeostasis'), ('PR_000045358', 'insulin family protein', 61, 'insulin'), ('NCBITaxon_33208', 'Metazoa', 90, 'lambs'), ('UBERON_0000113', 'post-juvenile adult stage', 156, 'adulthood')]
PMC5594587	9/2017	S182-PMC5594587	['old Lambs[44]\u2003late Gestation undernutrition (from 110 d to term)poor Glucose tolerance in Adult Sheep (1\xa0yr)[59]\u2003late Gestational overnutrition (from 115 d to term)increased leptin Expression in subcutaneous and Perirenal Fat from 1 months old Lamb[7]Reproductive function\u2003early Gestational (0 d to 95 d) undernutrition (50% energy)reduced Ovulation rate in Prenatally undernourished Adult female Sheep (20 mo)[71]\u2003early to mid (0 d to 30 d) or mid to late (31 d to 100 d) Gestational undernutrition (50% requirements)increased number of small follicles in the Ovary (early to mid-Gestation undernutrition); reduced large Corpora Lutea (mid to late Gestation undernutrition) in 10 mo old female Lambs.']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 4, 'lambs'), ('GO_0007565', 'female pregnancy', 19, 'gestation'), ('CHEBI_17234', 'glucose', 69, 'glucose'), ('UBERON_0007023', 'adult organism', 90, 'adult'), ('NCBITaxon_10088', 'Mus <genus>', 96, 'sheep'), ('GO_0007565', 'female pregnancy', 118, 'gestational'), ('GO_0010467', 'gene expression', 181, 'expression'), ('UBERON_0001845', 'perilymph', 212, 'perirenal fat'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 244, 'lamb'), ('GO_0000003', 'reproduction', 251, 'Reproductive'), ('GO_0007565', 'female pregnancy', 279, 'gestational'), ('GO_0030728', 'ovulation', 340, 'ovulation'), ('GO_0019230', 'proprioception', 358, 'prenatally'), ('UBERON_0007023', 'adult organism', 384, 'adult'), ('NCBITaxon_10088', 'Mus <genus>', 397, 'sheep'), ('GO_0007565', 'female pregnancy', 473, 'gestational'), ('UBERON_0000992', 'ovary', 561, 'ovary'), ('GO_0007565', 'female pregnancy', 581, 'gestation'), ('UBERON_0002512', 'corpus luteum', 622, 'corpora lutea'), ('GO_0007565', 'female pregnancy', 649, 'gestation'), ('NCBITaxon_33208', 'Metazoa', 695, 'lambs')]
PMC5626729	10/2017	S2-PMC5626729	['Glycogen accumulation requires prior Cellular Uptake Of Glucose.']	N/A	N/A	[('CHEBI_28087', 'glycogen', 0, 'Glycogen'), ('GO_0043652', 'engulfment of apoptotic cell', 37, 'cellular uptake of glucose'), ('CHEBI_17234', 'glucose', 56, 'glucose')]
PMC5626729	10/2017	S23-PMC5626729	['anaerobic glycolysis critically depends on the availability of Glucose.']	N/A	N/A	[('CHEBI_17234', 'glucose', 63, 'glucose')]
PMC5626729	10/2017	S24-PMC5626729	['a valuable Glucose source is Glycogen, which accumulates in Endometrial Tissue11.']	N/A	N/A	[('CHEBI_17234', 'glucose', 11, 'glucose'), ('CHEBI_24384', 'glycogens', 29, 'glycogen'), ('UBERON_0004214', 'upper leg nerve', 60, 'endometrial tissue11')]
PMC5626729	10/2017	S63-PMC5626729	['electrogenic Glucose Transport Across the Endometrium is lost in Slc5A1-/-Mice\nto elucidate the functional significance of Sglt1, Endometrial Epithelium segments from Slc5A1+/+and Slc5A1−/−Mice were mounted into mini-ussing chambers.']	N/A	N/A	[('CHEBI_17234', 'glucose', 13, 'glucose'), ('GO_0035196', 'production of miRNAs involved in gene silencing by miRNA', 13, 'glucose transport across ... endometrium'), ('UBERON_0001852', 'endolymph', 42, 'endometrium'), ('PR_000014968', 'vesicular acetylcholine transporter', 65, 'Slc5a1'), ('NCBITaxon_10088', 'Mus <genus>', 74, 'mice'), ('PR_000015239', 'SLIT and NTRK-like protein 3', 123, 'Sglt1'), ('UBERON_0011949', 'endometrium luminal epithelium', 130, 'endometrial epithelium'), ('PR_000014968', 'vesicular acetylcholine transporter', 167, 'Slc5a1'), ('PR_000014968', 'vesicular acetylcholine transporter', 180, 'Slc5a1'), ('NCBITaxon_10088', 'Mus <genus>', 189, 'mice')]
PMC5626729	10/2017	S64-PMC5626729	['the electrogenic Glucose transport was determined utilizing electrophysiological analysis.']	N/A	N/A	[('CHEBI_17234', 'glucose', 17, 'glucose')]
PMC5626729	10/2017	S68-PMC5626729	['the isosmotic replacement of Mannitol by Glucose (20\u2009mm) created a lumen-negative shift of the transepithelial potential difference (δvg), without significantly altering the transepithelial resistance.']	N/A	N/A	[('CHEBI_25169', 'mannoside', 29, 'mannitol'), ('CHEBI_17234', 'glucose', 41, 'glucose')]
PMC5626729	10/2017	S69-PMC5626729	['δvg enabled calculation of the Glucose-induced current.']	N/A	N/A	[('CHEBI_17234', 'glucose', 31, 'glucose')]
PMC5626729	10/2017	S72-PMC5626729	['Glucose Uptake Into Human Endometrial Cells was significantly decreased by the removal of Extracellular Na+or by addition of the Sglt1-transport Inhibitor, Phlorizin (supplementary fig.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('GO_0043652', 'engulfment of apoptotic cell', 0, 'Glucose uptake into ... cells'), ('NCBITaxon_9606', 'Homo sapiens', 20, 'human'), ('CL_0000115', 'endothelial cell', 26, 'endometrial cells'), ('UBERON_0001983', 'crypt of Lieberkuhn', 26, 'endometrial'), ('GO_0005576', 'extracellular region', 90, 'extracellular'), ('CHEBI_29101', 'sodium(1+)', 104, 'Na+'), ('PR_000015229', 'solute carrier organic anion transporter family member 4A1', 129, 'SGLT1'), ('CHEBI_35222', 'inhibitor', 145, 'inhibitor'), ('CHEBI_8113', 'phlorizin', 156, 'Phlorizin')]
PMC5626729	10/2017	S74-PMC5626729	['caption (fig): figure 2\n\nSglt1 mediates electrogenic transepithelial Glucose transport in Murine Uterine Epithelium.']	N/A	N/A	[('PR_000015239', 'SLIT and NTRK-like protein 3', 25, 'Sglt1'), ('CHEBI_17234', 'glucose', 69, 'glucose'), ('NCBITaxon_39107', 'Murinae', 90, 'murine'), ('UBERON_0001782', 'pigmented layer of retina', 97, 'uterine epithelium')]
PMC5626729	10/2017	S77-PMC5626729	['( b ) arithmetic means\u2009±\u2009sem (n\u2009=\u20093) of Glucose (20\u2009mm) induced short-circuit current across Uterine Epithelium from Slc5A1+/+(black bar) and Slc5A1−/−Mice (grey bar) .']	N/A	N/A	[('CHEBI_17234', 'glucose', 40, 'glucose'), ('UBERON_0001782', 'pigmented layer of retina', 93, 'uterine epithelium'), ('PR_000014968', 'vesicular acetylcholine transporter', 117, 'Slc5a1'), ('PR_000014968', 'vesicular acetylcholine transporter', 142, 'Slc5a1'), ('NCBITaxon_10088', 'Mus <genus>', 151, 'mice')]
PMC5626729	10/2017	S130-PMC5626729	['at a coupling ratio of 2:1, a Cell Membrane potential of −60 mv, and an Intracellular Na+concentration of 15\u2009mm, the carrier is able to establish a Glucose gradient of 10,000 to 1, i.e.']	N/A	N/A	[('GO_0005886', 'plasma membrane', 30, 'cell membrane'), ('GO_0005622', 'intracellular anatomical structure', 72, 'intracellular'), ('CHEBI_29101', 'sodium(1+)', 86, 'Na+'), ('CHEBI_17234', 'glucose', 148, 'glucose')]
PMC5626729	10/2017	S131-PMC5626729	['an Extracellular Glucose concentration ten thousand times lower than the Intracellular Glucose concentration.']	N/A	N/A	[('GO_0005576', 'extracellular region', 3, 'extracellular'), ('CHEBI_17234', 'glucose', 17, 'glucose'), ('GO_0005622', 'intracellular anatomical structure', 73, 'intracellular'), ('CHEBI_17234', 'glucose', 87, 'glucose')]
PMC5626729	10/2017	S132-PMC5626729	['in contrast to Sglt1, Glut122And its Isoforms accomplish passive Transport without generating a chemical Glucose Gradient Across the Cell Membrane23,24.']	N/A	N/A	[('PR_000015229', 'solute carrier organic anion transporter family member 4A1', 15, 'SGLT1'), ('PR_000015055', 'equilibrative nucleoside transporter 2', 22, 'GLUT122and'), ('SO_0001060', 'sequence_variant', 37, 'isoforms'), ('GO_0006809', 'nitric oxide biosynthetic process', 65, 'transport'), ('CHEBI_17234', 'glucose', 105, 'glucose'), ('GO_0019650', 'glycolytic fermentation to butanediol', 105, 'glucose gradient across ... cell membrane23'), ('GO_0005635', 'nuclear envelope', 133, 'cell membrane23')]
PMC5626729	10/2017	S135-PMC5626729	['Sglt1 deficiency in Mice compromised Cellular Glucose Uptake and Glycogen Storage in Endometrial Tissues.']	N/A	N/A	[('PR_000015239', 'SLIT and NTRK-like protein 3', 0, 'Sglt1'), ('NCBITaxon_10088', 'Mus <genus>', 20, 'mice'), ('GO_0043277', 'apoptotic cell clearance', 37, 'cellular glucose uptake'), ('CHEBI_17234', 'glucose', 46, 'glucose'), ('CHEBI_24384', 'glycogens', 65, 'glycogen'), ('GO_0007275', 'multicellular organism development', 65, 'glycogen storage'), ('UBERON_0005296', 'ovary sex cord', 85, 'endometrial tissues')]
PMC5626729	10/2017	S244-PMC5626729	['for the analysis of electrogenic Epithelial Endometrial Glucose transport, ussing chamber experiments were performed.']	N/A	N/A	[('UBERON_0000483', 'epithelium', 33, 'epithelial'), ('GO_0097186', 'amelogenesis', 44, 'endometrial'), ('UBERON_0001983', 'crypt of Lieberkuhn', 44, 'endometrial'), ('CHEBI_17234', 'glucose', 56, 'glucose')]
PMC5626729	10/2017	S255-PMC5626729	['the Glucose induced current was calculated from the Transepithelial resistance and the voltage deflection upon replacement of Mannitol with Glucose.']	N/A	N/A	[('CHEBI_17234', 'glucose', 4, 'glucose'), ('UBERON_0004819', 'kidney epithelium', 52, 'transepithelial'), ('CHEBI_25169', 'mannoside', 126, 'mannitol'), ('CHEBI_17234', 'glucose', 140, 'glucose')]
PMC5626729	10/2017	S268-PMC5626729	['Cellular Glucose Uptake\nthe fluorescent Glucose analogue 2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-Deoxyglucose (2-Nbd-Glucose; invitrogen, darmstadt, germany) was used to measure the relative Uptake Of Glucose by flow cytometry.']	N/A	N/A	[('GO_0007049', 'cell cycle', 0, 'Cellular'), ('CHEBI_17234', 'glucose', 9, 'glucose'), ('GO_0046323', 'glucose import', 9, 'glucose uptake'), ('CHEBI_17234', 'glucose', 40, 'glucose'), ('CHEBI_33980', 'quinovose', 104, '2-deoxyglucose'), ('CHEBI_72755', 'kanamycin C(4+)', 120, '2-NBD-'), ('CHEBI_17234', 'glucose', 126, 'glucose'), ('GO_0046323', 'glucose import', 200, 'uptake of glucose'), ('CHEBI_17234', 'glucose', 210, 'glucose')]
PMC5626729	10/2017	S269-PMC5626729	['in each condition, cells were incubated with 2-Nbd-Glucose (30\u2009μm) for 1\u2009hour at 37\u2009°c, subsequently washed twice in cold pbs and analyzed by flow cytometry (bd biosciences, heidelberg, germany) in fluorescence channel fl1.']	N/A	N/A	[('CHEBI_72755', 'kanamycin C(4+)', 45, '2-NBD-'), ('CHEBI_17234', 'glucose', 51, 'glucose')]
PMC5626729	10/2017	S270-PMC5626729	['to determine the effect of Sglt1 inhibition on Glucose Uptake, cells were incubated with 1\u2009mm of the Sglt1 Inhibitor, Phlorizin (1\u2009mm; #274313; sigma).']	N/A	N/A	[('PR_000015229', 'solute carrier organic anion transporter family member 4A1', 27, 'SGLT1'), ('CHEBI_17234', 'glucose', 47, 'glucose'), ('GO_0046323', 'glucose import', 47, 'glucose uptake'), ('PR_000015229', 'solute carrier organic anion transporter family member 4A1', 101, 'SGLT1'), ('CHEBI_35222', 'inhibitor', 107, 'inhibitor'), ('CHEBI_8113', 'phlorizin', 118, 'Phlorizin')]
PMC5626729	10/2017	S272-PMC5626729	['the Solutions were composed of (in mm): standard Hepes: 115 Nacl, 5 Kcl, 1 Cacl2, 1.2 Mgso4, 2 Nah2Po410 Glucose, 32.2 Hepes or Sodium free Hepes: 132.8 nmdg Cl, 3 Kcl, 1 Cacl2, 1.2 Mgso4, 2 Kh2Po4, 32.2 Hepes, 10 Mannitol, 10 Glucose.']	N/A	N/A	[('CHEBI_75958', 'solution', 4, 'solutions'), ('CHEBI_46756', 'HEPES', 49, 'Hepes'), ('CHEBI_26710', 'sodium chloride', 60, 'NaCl'), ('CHEBI_32588', 'potassium chloride', 68, 'KCl'), ('CHEBI_3312', 'calcium dichloride', 75, 'CaCl2'), ('CHEBI_32599', 'magnesium sulfate', 86, 'MgSO4'), ('CHEBI_34879', 'NS 1619', 95, 'NaH2PO410'), ('CHEBI_17234', 'glucose', 105, 'glucose'), ('CHEBI_46756', 'HEPES', 119, 'Hepes'), ('CHEBI_52632', 'potassium-39 atom', 128, 'sodium'), ('CHEBI_46756', 'HEPES', 140, 'Hepes'), ('CHEBI_17996', 'chloride', 158, 'Cl'), ('CHEBI_32588', 'potassium chloride', 164, 'KCl'), ('CHEBI_3312', 'calcium dichloride', 171, 'CaCl2'), ('CHEBI_32599', 'magnesium sulfate', 182, 'MgSO4'), ('CHEBI_63036', 'potassium dihydrogen phosphate', 191, 'KH2PO4'), ('CHEBI_46756', 'HEPES', 204, 'Hepes'), ('CHEBI_25169', 'mannoside', 214, 'mannitol'), ('CHEBI_17234', 'glucose', 227, 'glucose')]
PMC5643576	9/2015	S13-PMC5643576	["a study by o'sullivan22showed that the incidence of diabetes in participants who had previous transient Gestational Glucose intolerance was significantly higher for overweight subjects (46.7%) than for those of normal weight (25.6%)."]	N/A	N/A	[('GO_0007565', 'female pregnancy', 104, 'gestational'), ('CHEBI_17234', 'glucose', 116, 'glucose')]
PMC5644668	4/2013	S24-PMC5644668	['women were enrolled at their convenience after a diagnostic 100 g oral Glucose tolerance test (gtt) at 28 weeks Gestation ruled out gdm as part of a larger study on foetal body composition in the third trimester.']	N/A	N/A	[('CHEBI_17234', 'glucose', 71, 'glucose'), ('GO_0007565', 'female pregnancy', 112, 'gestation')]
PMC5648128	10/2017	S56-PMC5648128	['outcomes and data collection\n\nstudy outcomes\nthe primary outcome was to compare the effect of a standard diet versus meddiet, supplemented with evoo and pistachios, on gdm incidence at 24–28 gw, in Pregnant women with a prior normal fasting Glucose (<92 mg/dl) at the first Gestational visit (8–12 gw).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 198, 'pregnant'), ('CHEBI_17234', 'glucose', 241, 'glucose'), ('GO_0007565', 'female pregnancy', 274, 'gestational')]
PMC5648128	10/2017	S58-PMC5648128	['gdm screening\ngdm was diagnosed at 24–28 gw with a single 2-h 75-g oral Glucose tolerance test, applying iadpsg criteria.']	N/A	N/A	[('CHEBI_17234', 'glucose', 72, 'glucose')]
PMC5648128	10/2017	S73-PMC5648128	['the following data were determined: hba1c, standardized by the international federation of clinical chemistry and laboratory medicine (ifcc); Serum Insulin; homa-Insulin resistance (homa-ir), calculated as Glucose (mmol/l) x Insulin (mcui/ml)/22.7; and fbg.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 142, 'serum'), ('PR_000045358', 'insulin family protein', 148, 'insulin'), ('PR_000045358', 'insulin family protein', 162, 'insulin'), ('CHEBI_17234', 'glucose', 206, 'glucose'), ('PR_000045358', 'insulin family protein', 225, 'insulin')]
PMC5648128	10/2017	S116-PMC5648128	['four hundred forty were allocated to the cg and 434 to the ig (table 1).10.1371/journal.pone.0185873.t001\n\ncaption (table-wrap): table 1\ncharacteristics of the clinical trial randomized population by groups.control groupintervention groupalln = 500n = 500 age (years) 32.7 ± 5.333.2 ± 5.0 race/ethnicitycaucasian 339 (67.8)345 (69.0) hispanic 142 (28.4)143 (28.6) others 19 (3.8)12 (2.4) family history oftype 2 diabetes 118 (23.6)134 (26.8) mets (>2 components) 93 (18.6)118 (23.6) previous history of gdm 14 (2.8)14 (2.8) previous history of Miscarriages 160 (32.2)163(32.6) educational statuselementary education 54(10.8)34 (6.8) secondary school 188 (37.6)210 (42.0) university degree 251 (50.2)252 (50.4) unk 7 (1.4)4 (0.8) employment 376 (75.2)390 (78.0) number of Pregnanciesprimiparous 211 (42.2)232 (46.4) second Pregnancy 160 (32.0)160 (32.0) >2 Pregnancies 129 (25.8)108 (21.6) smokernever 274 (54.8)260 (52.0) current 40 (8.0)43 (8.6) Gestational age (weeks) at baseline 12.1 ± 0.612.0 ± 0.3 body weight (kg)Prepregnancy 61.7 ± 11.660.4 ± 10.4 at baseline 63.9 ± 11.962.5 ± 10.5 weigth gain 2.1 ± 3.22.0 ± 2.7 bmi (kg/m2)Prepregnancy 23.3 ± 4.022.9 ± 3.6 at baseline 24.1 ± 4.123.7 ± 3.8 systolic bp(mm hg) 107 ± 10107 ± 11 diastolic bp (mm hg) 65 ± 1166 ± 9 fasting Blood Glucose (mg/dl) 81.7 ± 6.180.0 ± 6.1 Tsh mcui/ml 1.9 ± 1.22.0 ± 1.4 medas score 4.9 ± 1.75.0 ± 1.8 nutrition score 0.5 ± 3.20.2 ± 3.2 physical activity score -1.7 ± 1.0-1.0 ± 1.0\ndata are mean ± sd or number (%) mets, Metabolic syndrome.']	N/A	N/A	[('GO_0042706', 'eye photoreceptor cell fate commitment', 544, 'miscarriages'), ('GO_0035777', 'pronephric distal tubule development', 771, 'pregnanciesPrimiparous'), ('GO_0007565', 'female pregnancy', 822, 'pregnancy'), ('GO_0007565', 'female pregnancy', 856, 'pregnancies'), ('GO_0007565', 'female pregnancy', 947, 'Gestational'), ('GO_0007565', 'female pregnancy', 1020, 'Prepregnancy'), ('GO_0007565', 'female pregnancy', 1133, 'Prepregnancy'), ('UBERON_0000178', 'blood', 1279, 'Blood'), ('CHEBI_17234', 'glucose', 1285, 'Glucose'), ('CHEBI_17855', 'triglyceride', 1322, 'TSH'), ('GO_0008152', 'metabolic process', 1503, 'Metabolic')]
PMC5648128	10/2017	S134-PMC5648128	['compared to the cg, ig had significantly lower levels of fbg (p = 0.001), 2h post Glucose load (p = 0.042), hba1c levels (p = 0.001) and homa-ir (p = 0.045) at 24–28 gw.']	N/A	N/A	[('CHEBI_17234', 'glucose', 82, 'glucose')]
PMC5648128	10/2017	S139-PMC5648128	['there was also a significant decrease in the ig in the episodes of uti (p = 0.001), emer-cs (p = 0.001), Perineal trauma (p = 0.001) as well as a significant reduction in the rates of Prematurity (p = 0.023), newborns lga (p = 0.006) and sga (p = 0.001), (table 3).10.1371/journal.pone.0185873.t003\n\ncaption (table-wrap): table 3\nmaternal Pregnancy and neonatal outcomes.control group (n = 440)intervention group (n = 434)p maternal outcomesgdm 103 (23.4)74 (17.1)0.012 75g-ogtt 24–28 gwfasting Blood Glucose (mg/dl) 85.7 ± 6.684.1 ± 6.60.001 1 h Blood Glucose (mg/dl) 123.7 ± 32.0123.5 ± 30.20.912 2 h Blood Glucose (mg/dl) 110.0 ± 26.3106.3 ± 23.80.042 hba1c (%) 24–28 gw 5.1 ± 0.34.9 ± 0.30.001 hba1c (%) 36–38 gw 5.3 ± 0.35.2 ± 0.20.001 fasting Blood Glucose 36–38 gw (mg/dl) 77.1 ± 7.474 ± 7.70.003 fasting Serum Insulin (mcui/ml)24–28 gw 9.4 ± 5.79.1 ± 6.80.061 36–38 gw 10.5 ± 9.610.0 ± 9.90.085 homa-ir24–28 gw 2.2 ± 2.62.0 ± 1.40.045 36–38 gw 2.3 ± 2.72.0 ± 2.30.055 treatment of gdmnutritional 70 (65.4)60 (81.0) Insulin (total) 33 (32.0)14 (19.0)0.037 bolus 6 (5.8)1 (1.4) basal 23 (22.3)12 (16.2) basal/bolus 4 (3.9)1 (1.4)0.003 weight gain (kg) 12 gw to 24–28 gw 5.6 ± 2.85.2 ± 2.50.052 bmi<25 kg.m-2(330/329) 5.8 ± 2.75.4 ± 2.20.003 25–29.9 (88/85) 5.1 ± 3.04.7 ± 3.40.076 ≥ 30 (22/20) 4.2 ± 3.54.0 ± 4.50.770 weight gain (kg) 12 gw to 36–38 gw 9.4 ± 4.39.9 ± 4.70.116 bmi<25 kg.m-29.9 ± 3.910.6 ± 4.00.096 25–29.9 8.8 ± 4.58.3 ± 6.50.066 ≥ 30 5.6 ± 5.67.2 ± 4.70.583 systolic bp (mm hg) 24–28 gw 105 ± 11105 ± 110.189 diastolic bp (mm hg) 24–28 gw 63 ± 963 ± 100.819 systolic bp (mm hg) 36–38 gw 112 ± 13112 ± 110.193 diastolic bp (mm hg) 36–38 gw 72 ± 973 ± 90.316 Pregnancy-induced hypertension 19 (4.3)13 (3.0)0.195 preeclampsia 11 (2.5)7 (1.6)0.247 albuminuria 6 (1.4)2 (0.5)0.298 Urinary Tract infection 60 (13.6)24 (5.5)0.001 Deliveryvaginal 312 (70.9)316 (75.1) instrumental 68 (15.5)58 (11.1) cesarean section 60 (13.6)60 (13.8)0.678 emergency 31 (51.7)9 (15)0.001 Perineal trauma 48 (10.9)14 (3.2)0.001 neonatal outcomesshoulder dystocia 10n.a.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 105, 'perineal'), ('GO_0007565', 'female pregnancy', 184, 'prematurity'), ('GO_0007565', 'female pregnancy', 339, 'pregnancy'), ('UBERON_0000178', 'blood', 495, 'Blood'), ('CHEBI_17234', 'glucose', 501, 'Glucose'), ('UBERON_0000178', 'blood', 547, 'Blood'), ('CHEBI_17234', 'glucose', 553, 'Glucose'), ('UBERON_0000178', 'blood', 603, 'Blood'), ('CHEBI_17234', 'glucose', 609, 'Glucose'), ('UBERON_0000178', 'blood', 749, 'Blood'), ('CHEBI_17234', 'glucose', 755, 'Glucose'), ('UBERON_0001977', 'blood serum', 812, 'Serum'), ('PR_000045358', 'insulin family protein', 818, 'Insulin'), ('PR_000045358', 'insulin family protein', 1023, 'Insulin'), ('GO_0007565', 'female pregnancy', 1681, 'Pregnancy'), ('UBERON_0001502', 'interosseous muscle of manus', 1800, 'Urinary Tract'), ('GO_0006308', 'DNA catabolic process', 1847, 'DeliveryVaginal'), ('UBERON_0001987', 'placenta', 1988, 'Perineal')]
PMC5651398	9/2017	S85-PMC5651398	['whole‐Blood Glucose was assessed using a Glucometer (true2go; cvs pharmacy, inc., woonsocket, ri, usa).']	N/A	N/A	[('UBERON_0000178', 'blood', 6, 'blood'), ('CHEBI_17234', 'glucose', 12, 'glucose'), ('CHEBI_24321', 'glutamo group', 41, 'glucometer')]
PMC5651398	9/2017	S140-PMC5651398	['(e)Bcaasupplementation, and particularly the combination ofhfdandbcaa, resulted in increased fasting Blood Glucose at p8.']	N/A	N/A	[('CHEBI_76730', 'EC 1.4.* (oxidoreductase acting on donor CH-NH2 group) inhibitor', 3, 'BCAAsupplementation'), ('UBERON_0000178', 'blood', 101, 'blood'), ('CHEBI_17234', 'glucose', 107, 'glucose')]
PMC5652542	10/2017	S4-PMC5652542	['data from standard obstetric care recorded in hospital maternity notes (eg, ultrasound reports, results of oral Glucose tolerance test and Pregnancy outcome data) will also be extracted.']	N/A	N/A	[('CHEBI_17234', 'glucose', 112, 'glucose'), ('GO_0007565', 'female pregnancy', 139, 'pregnancy')]
PMC5652542	10/2017	S74-PMC5652542	['the secondary maternal outcomes are maternal nutritional status (eg, Blood routine, Micronutrient status in Blood), clinical indicators of maternal health (eg, Blood pressure, Glucose tolerance), Gestational\xa0weight gain and outcomes of Pregnancy, including complications\xa0(eg, Gestational diabetes mellitus, Gestational hypertension).']	N/A	N/A	[('UBERON_0000178', 'blood', 69, 'blood'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 84, 'micronutrient'), ('UBERON_0000178', 'blood', 108, 'blood'), ('UBERON_0000178', 'blood', 160, 'blood'), ('CHEBI_17234', 'glucose', 176, 'glucose'), ('GO_0007565', 'female pregnancy', 196, 'gestational'), ('GO_0007565', 'female pregnancy', 236, 'pregnancy'), ('GO_0007565', 'female pregnancy', 276, 'gestational'), ('GO_0007565', 'female pregnancy', 307, 'gestational')]
PMC5678092	11/2017	S6-PMC5678092	['maternal obesity programmed increased adiposity and Liver Triglycerides, with decreased Glucose tolerance, Liver Nad+levels and citrate synthase activity in offspring.']	N/A	N/A	[('UBERON_0002107', 'liver', 52, 'liver'), ('CHEBI_17855', 'triglyceride', 58, 'triglycerides'), ('CHEBI_17234', 'glucose', 88, 'glucose'), ('UBERON_0002107', 'liver', 107, 'liver'), ('CHEBI_15846', 'NAD(+)', 113, 'NAD+')]
PMC5678092	11/2017	S72-PMC5678092	['Glucose tolerance test (gtt)\nat 17 weeks of age Mice were fasted for 5\u2009hours prior to the gtt.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('NCBITaxon_10088', 'Mus <genus>', 48, 'mice')]
PMC5678092	11/2017	S73-PMC5678092	['baseline Blood Glucose was measured by Tail nick at time 0.']	N/A	N/A	[('UBERON_0000178', 'blood', 9, 'blood'), ('CHEBI_17234', 'glucose', 15, 'glucose'), ('UBERON_0002415', 'tail', 39, 'tail')]
PMC5678092	11/2017	S75-PMC5678092	['Glucose bolus (2\u2009g/kg body weight).']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'glucose')]
PMC5678092	11/2017	S76-PMC5678092	['Blood Glucose was measured using accu-chekh Glucose meter (roche diagnostics).']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('CHEBI_17234', 'glucose', 6, 'glucose'), ('CHEBI_17234', 'glucose', 44, 'glucose')]
PMC5678092	11/2017	S130-PMC5678092	['abbreviations: gtt, Glucose tolerance test; auc, area under curve.']	N/A	N/A	[('CHEBI_17234', 'glucose', 20, 'Glucose')]
PMC5678092	11/2017	S173-PMC5678092	['in siblings Consuming hfd, exercise and nmn improved the late phase of the response to Glucose challenge (fig.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 12, 'consuming'), ('CHEBI_17234', 'glucose', 87, 'glucose')]
PMC5678092	11/2017	S223-PMC5678092	['abbreviations: acc: Acetyl Coa carboxylase; cd36 : Cluster Of Differentiation 36 / Fatty Acid translocase; Fasn : Fatty Acid synthase; Pparg : Peroxisome proliferator-activated receptor; Mpc1 : Mitochondrial Pyruvate Career ; sirt1 : silent Mating type information Regulation; pc : Pyruvate carboxylase; Pck1 : Phosphoenolpyruvate carboxykinase; g6pc : Glucose-6-phosphatase.']	N/A	N/A	[('CHEBI_15513', 'acryloyl-CoA', 20, 'Acetyl CoA'), ('PR_000007993', 'gap junction alpha-4 protein', 51, 'Cluster of differentiation 36'), ('CHEBI_35366', 'fatty acid', 83, 'fatty acid'), ('PR_000007706', '3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase FUT3', 107, 'Fasn'), ('CHEBI_35366', 'fatty acid', 114, 'fatty acid'), ('PR_000013343', 'PH and SEC7 domain-containing protein 4', 135, 'Pparg'), ('GO_0005777', 'peroxisome', 143, 'Peroxisome'), ('PR_000010205', 'cartilage matrix protein', 187, 'Mpc1'), ('GO_0005753', 'mitochondrial proton-transporting ATP synthase complex', 194, 'mitochondrial pyruvate career'), ('CHEBI_15361', 'pyruvate', 208, 'pyruvate'), ('GO_0007618', 'mating', 241, 'mating'), ('GO_0065007', 'biological regulation', 265, 'regulation'), ('CHEBI_15361', 'pyruvate', 282, 'Pyruvate'), ('PR_000012433', 'neuroendocrine convertase 1', 304, 'Pck1'), ('CHEBI_15361', 'pyruvate', 311, 'Phosphoenolpyruvate'), ('CHEBI_17234', 'glucose', 353, 'Glucose')]
PMC5684580	10/2017	S3-PMC5684580	['enablers included being taught to test capillary blood Glucose in group settings where the health professional demonstrated this on themselves first (60, 100%); health professionals listening (41, 68%); being reminded to perform blood Glucose testing (33, 55%); and being provided healthy meals by friends and family (28, 47%).']	N/A	N/A	[('CHEBI_17234', 'glucose', 55, 'glucose'), ('CHEBI_17234', 'glucose', 235, 'glucose')]
PMC5684580	10/2017	S18-PMC5684580	['participant selection\nwomen diagnosed with gdm were eligible to participate if they had a singleton Pregnancy, could communicate in english, had been self-monitoring their capillary blood Glucose levels for at least two weeks, and provided written consent.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 100, 'pregnancy'), ('CHEBI_17234', 'glucose', 188, 'glucose')]
PMC5684580	10/2017	S23-PMC5684580	['twenty women, recruited from canterbury district health board (dhb) in the south island, were using less tight Glycaemic treatment targets (fasting Blood Glucose\u2009<\u20095.5\u2009mmol/l, 1 hour postprandial\u2009<\u20098.0\u2009mmol/l, and 2 hours postprandial\u2009<\u20097.0\u2009mmol/l).']	N/A	N/A	[('GO_0006096', 'glycolytic process', 111, 'glycaemic'), ('UBERON_0000178', 'blood', 148, 'blood'), ('CHEBI_17234', 'glucose', 154, 'glucose')]
PMC5684580	10/2017	S24-PMC5684580	['forty women were using tighter Glycaemic treatment targets (fasting blood Glucose\u2009≤\u20095.0\u2009mmol/l, 1 hour postprandial\u2009≤\u20097.4\u2009mmol/l, and 2 hours Postprandial\u2009≤\u20096.7\u2009mmol/l): twenty women recruited from canterbury dhb in the south island and twenty women recruited from counties manukau dhb in the north island.']	N/A	N/A	[('CHEBI_24400', 'glycoside', 31, 'glycaemic'), ('GO_0006096', 'glycolytic process', 31, 'glycaemic'), ('CHEBI_17234', 'glucose', 74, 'glucose'), ('GO_0007567', 'parturition', 142, 'postprandial')]
PMC5684580	10/2017	S25-PMC5684580	['local hospital policies differed for testing of capillary blood Glucose.']	N/A	N/A	[('CHEBI_17234', 'glucose', 64, 'glucose')]
PMC5684580	10/2017	S27-PMC5684580	['women were asked to test their capillary blood Glucose at one hour Postprandial.']	N/A	N/A	[('CHEBI_17234', 'glucose', 47, 'glucose'), ('GO_0007567', 'parturition', 67, 'postprandial')]
PMC5684580	10/2017	S29-PMC5684580	['women were asked to test their capillary blood Glucose two hours Postprandial.']	N/A	N/A	[('CHEBI_17234', 'glucose', 47, 'glucose'), ('GO_0007567', 'parturition', 65, 'postprandial')]
PMC5684580	10/2017	S54-PMC5684580	['at the time of the survey, participants had been checking their daily capillary blood Glucose for an average of 6.8\u2009±\u20092.3 weeks (table 1), with just over half checking their Blood Glucose four times a day (32, 53%) and the other participants six times a day (28, 47%).']	N/A	N/A	[('CHEBI_17234', 'glucose', 86, 'glucose'), ('UBERON_0000178', 'blood', 174, 'blood'), ('CHEBI_17234', 'glucose', 180, 'glucose')]
PMC5684580	10/2017	S69-PMC5684580	['all 60 (100%) women indicated that having a health professional to demonstrate the collection of capillary Blood Glucose on themselves and then watch the participant perform it was helpful (table 3).']	N/A	N/A	[('UBERON_0000178', 'blood', 107, 'blood'), ('CHEBI_17234', 'glucose', 113, 'glucose')]
PMC5684580	10/2017	S77-PMC5684580	['over half of the women (33, 55%) indicated that they found it helpful to be asked about their Capillary blood Glucose levels and to be reminded to do them by their partners, children, extended family members, and work colleagues.']	N/A	N/A	[('UBERON_0001982', 'capillary', 94, 'capillary'), ('CHEBI_17234', 'glucose', 110, 'glucose')]
PMC5684580	10/2017	S102-PMC5684580	['being taught blood Glucose testing in a group setting was considered helpful.']	N/A	N/A	[('CHEBI_17234', 'glucose', 19, 'glucose')]
PMC5690443	12/2015	S75-PMC5690443	['quantitative Insulin sensitivity check index (quicki) has an excellent linear correlation with the Glucose clamp index of Insulin sensitivity[38].']	N/A	N/A	[('PR_000045358', 'insulin family protein', 13, 'insulin'), ('CHEBI_17234', 'glucose', 99, 'glucose'), ('PR_000045358', 'insulin family protein', 122, 'insulin')]
PMC5695448	11/2017	S37-PMC5695448	['Gestational diabetes was determined either through (1) self-reported by the mother or recorded from the medical chart (child), or (2) diagnosed using an oral Glucose tolerance test, self-reported by the mother or recorded from the medical chart (abc, family and start).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_17234', 'glucose', 158, 'glucose')]
PMC5706533	11/2017	S40-PMC5706533	['for Gestational diabetes, we required routine Glucose challenge testing, oral Glucose tolerance test, and/or measurement of hba1cduring follow-up.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 4, 'gestational'), ('CHEBI_17234', 'glucose', 46, 'glucose'), ('CHEBI_17234', 'glucose', 78, 'glucose')]
PMC5708048	11/2017	S39-PMC5708048	['this clinic visit was scheduled at this time point to, after the assessment of diet, also administer the oral Glucose tolerance test, which is commonly administered at 24–28 weeks Gestation.']	N/A	N/A	[('CHEBI_17234', 'glucose', 110, 'glucose'), ('GO_0007565', 'female pregnancy', 180, 'gestation')]
PMC5732505	12/2017	S33-PMC5732505	['exclusion criteria for the newborns were: Nasal continuous positive Airway pressure treatment >one day, intravenous Glucose infusion, seizures, duration of phototherapy >three days and need for Nasogastric tube >one day.']	N/A	N/A	[('UBERON_0000004', 'nose', 42, 'nasal'), ('UBERON_0001005', 'respiratory airway', 68, 'airway'), ('CHEBI_17234', 'glucose', 116, 'glucose'), ('UBERON_0001226', 'major calyx', 194, 'nasogastric')]
PMC5732505	12/2017	S116-PMC5732505	['we observed no association between Pregnancy 25(Oh)D and fasting Plasma Glucose (b -0.00; 95% ci -0.00, 0.00; p\u2009= \xa00.54), 1-h Glucose (b 0.00; 95% ci -0.01, 0.01; p\u2009= \xa00.53) or 2-h Glucose (b -0.00; 95% ci -0.01, 0.01; p \u2009=\u20090.54).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 35, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 45, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 45, '25(OH)D'), ('UBERON_0001969', 'blood plasma', 65, 'plasma'), ('CHEBI_17234', 'glucose', 72, 'glucose'), ('CHEBI_17234', 'glucose', 126, 'glucose'), ('CHEBI_17234', 'glucose', 181, 'glucose')]
PMC5736940	12/2017	S4-PMC5736940	['gdm was diagnosed using a 100-gram, 3-hour Oral Glucose tolerance test.']	N/A	N/A	[('UBERON_0000165', 'mouth', 43, 'oral'), ('CHEBI_17234', 'glucose', 48, 'glucose')]
PMC5736940	12/2017	S31-PMC5736940	['Pregnant women were screened for Gestational diabetes between the 24th and 28th weeks of Gestation with a 50\u2009g, 1\u2009hr Glucose challenge test (gct).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('GO_0007565', 'female pregnancy', 33, 'gestational'), ('GO_0007565', 'female pregnancy', 89, 'gestation'), ('CHEBI_17234', 'glucose', 117, 'glucose')]
PMC5736940	12/2017	S32-PMC5736940	['if the screening test was positive (Blood Glucose greater than 130\u2009mg per ml), diagnostic testing was performed using a 100\u2009g, 3-hour oral Glucose tolerance test (ogtt).']	N/A	N/A	[('UBERON_0000178', 'blood', 36, 'blood'), ('CHEBI_17234', 'glucose', 42, 'glucose'), ('CHEBI_17234', 'glucose', 139, 'glucose')]
PMC5736940	12/2017	S98-PMC5736940	['Pregnancy is characterized by progressive hyperlipidemia, Insulin resistance, and a deterioration of Glucose tolerance as the Pregnancy advances to the third trimester [30].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnancy'), ('PR_000045358', 'insulin family protein', 58, 'insulin'), ('CHEBI_17234', 'glucose', 101, 'glucose'), ('GO_0007565', 'female pregnancy', 126, 'pregnancy')]
PMC5736940	12/2017	S109-PMC5736940	['whole grains are high in insoluble fiber which delay Gastric Emptying and slow Absorption Of Glucose, resulting in a small increment in Insulin levels [6,30].']	N/A	N/A	[('GO_0035483', 'gastric emptying', 53, 'gastric emptying'), ('UBERON_0001844', 'cochlea', 53, 'gastric'), ('GO_0006096', 'glycolytic process', 79, 'absorption of glucose'), ('CHEBI_17234', 'glucose', 93, 'glucose'), ('PR_000045358', 'insulin family protein', 136, 'insulin')]
PMC5758521	1/2018	S49-PMC5758521	['Gestational diabetes was defined according to the 2003 american diabetes association’s 2-hour 75\u2009g oral Glucose tolerance test (ogtt) diagnostic criteria (the then-current clinical diagnostic criteria): Gestational diabetes was diagnosed if the woman had two of three Glucose values exceeding the following cutoffs: fasting 5.3\u2009mmol/l, 1-h 10.0\u2009mmol/l, and 2-h 8.6\u2009mmol/l20.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_17234', 'glucose', 104, 'glucose'), ('GO_0007565', 'female pregnancy', 203, 'gestational'), ('CHEBI_17234', 'glucose', 268, 'glucose')]
PMC5758844	12/2017	S56-PMC5758844	['the following biochemical assays were performed: full Blood count, Liver function tests, Renal function, total Cholesterol, high-density lipoprotein (hdl), low-density lipoprotein (ldl), Triglycerides, Glucose, Insulin, hba1c, Vitamin D, and crp.']	N/A	N/A	[('UBERON_0000178', 'blood', 54, 'blood'), ('UBERON_0002107', 'liver', 67, 'liver'), ('UBERON_0002113', 'kidney', 89, 'renal'), ('CHEBI_16113', 'cholesterol', 111, 'cholesterol'), ('CHEBI_17855', 'triglyceride', 187, 'triglycerides'), ('CHEBI_17234', 'glucose', 202, 'glucose'), ('PR_000045358', 'insulin family protein', 211, 'insulin'), ('CHEBI_27300', 'vitamin D', 227, 'vitamin D')]
PMC5758844	12/2017	S58-PMC5758844	['Insulin resistance was calculated using the Homeostasis model assessment- (homa-) ir score, equation: homa-ir = [mean fasting Insulin (miu/l) × mean fasting Glucose (mmol/l)] ÷ 22.5.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 0, 'Insulin'), ('GO_0042592', 'homeostatic process', 44, 'Homeostasis'), ('PR_000045358', 'insulin family protein', 126, 'insulin'), ('CHEBI_17234', 'glucose', 157, 'glucose')]
PMC5792223	1/2018	S29-PMC5792223	['individuals with Prenatal famine exposure ( n = 348) had a 5.6% (+0.36 sd) higher bmi ( p = 5.7 × 10−7), a 13.5% (+0.23 sd) higher Serum tg ( p = 3.8 × 10−3), and a 3.8% (+0.22 sd) higher fasted Glucose ( p = 0.023) but no difference in Ldl-C ( p> 0.05), as compared with non-exposed controls ( n = 463;table 1).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 17, 'prenatal'), ('UBERON_0001977', 'blood serum', 131, 'serum'), ('CHEBI_17234', 'glucose', 195, 'glucose'), ('PR_000009780', 'legumain', 237, 'LDL-C')]
PMC5792223	1/2018	S39-PMC5792223	['caption (table-wrap): table 1\nphenotypic differences and famine exposure.controlsfamine exposuren 463348age (years) [sd]+58.0 [5.4]58.9 [0.5]***male (%)43.046.0bmi1[sd]27.0 [4.2]28.5 [5.0]***Ldl-C2[sd]3.42 [0.96]3.45 [0.97]Triglycerides2[sd]1.48 [0.86]1.68 [1.30]**Glucose baseline3[sd]5.32 [0.93]5.52 [1.19]*\nnominal p value either * p< 0.05, ** p< 0.01 or *** p< 0.001 from a linear mixed-effects model with the denoted variable as the dependent variable and family identifier as random effect.']	N/A	N/A	[('PR_000009751', 'lymphoid enhancer-binding factor 1', 191, 'LDL-C2'), ('CHEBI_32269', 'tropisetron', 223, 'Triglycerides2'), ('CHEBI_17234', 'glucose', 265, 'Glucose')]
PMC5792223	1/2018	S170-PMC5792223	['a Blood draw was performed at the start of a 75-g Oral Glucose test, and Glucose was quickly assessed in Serum by hexokinase reaction on a modular p800 (roche).']	N/A	N/A	[('UBERON_0000178', 'blood', 2, 'blood'), ('UBERON_0000165', 'mouth', 50, 'oral'), ('CHEBI_17234', 'glucose', 55, 'glucose'), ('CHEBI_17234', 'glucose', 73, 'glucose'), ('UBERON_0001977', 'blood serum', 105, 'serum')]
PMC5792223	1/2018	S198-PMC5792223	['reanalysis of the associations between phenotypes and famine exposure was performed with linear mixed-effects models (lmms) with one of the phenotypes (bmi, tg, Glucose, and Ldl-C) as the dependent variable using the r lme4 package ( 62 ).']	N/A	N/A	[('CHEBI_17234', 'glucose', 161, 'glucose'), ('PR_000009791', 'LIM/homeobox protein Lhx1', 174, 'LDL-c')]
PMC5798031	2/2017	S28-PMC5798031	['when a mother stops Eating, under most conditions her body maintains constant availability of circulating Glucose, which directly benefits the fetus.']	N/A	N/A	[('GO_0051318', 'G1 phase', 20, 'eating'), ('CHEBI_17234', 'glucose', 106, 'glucose')]
PMC5798031	2/2017	S30-PMC5798031	['her muscle also stops responding fully to Insulin, shunting Glucose to the fetus.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 42, 'insulin'), ('CHEBI_17234', 'glucose', 60, 'glucose')]
PMC5804527	8/2016	S101-PMC5804527	['high fat diet induces alterations in Insulin and Glucose Metabolism, energy balance, Cardiovascular function, and adiposity in offspring.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 37, 'insulin'), ('CHEBI_17234', 'glucose', 49, 'glucose'), ('GO_0006006', 'glucose metabolic process', 49, 'glucose metabolism'), ('UBERON_0004535', 'cardiovascular system', 85, 'cardiovascular')]
PMC5837564	4/2017	S78-PMC5837564	['non-urgent referrals (high Glucose level, high Blood pressure, anaemia) are identified via a search function within the Keneba biobank database, and cases are called within a few days for re-testing and clinical evaluation during regular clinics (e.g.']	N/A	N/A	[('CHEBI_17234', 'glucose', 27, 'glucose'), ('UBERON_0000178', 'blood', 47, 'blood'), ('NCBITaxon_10088', 'Mus <genus>', 120, 'Keneba')]
PMC5837564	4/2017	S118-PMC5837564	['analytical tests conducted comprise fasting Glucose, malaria, zinc Protoporphyrin (discontinued in 2014) and full Blood count.']	N/A	N/A	[('CHEBI_17234', 'glucose', 44, 'glucose'), ('CHEBI_15430', 'protoporphyrin', 67, 'protoporphyrin'), ('UBERON_0000178', 'blood', 114, 'blood')]
PMC5837564	4/2017	S121-PMC5837564	['data and samples collected as part of the keneba biobank< 5-year-olds5–18 year olds18-year-oldsquestionnairen/an/aeducation, assets, Medication for diabetes and hypertension received outside the districtphenotypesweight, height, Skinfold thickness, Head circumference, mid upper-Arm circumferenceweight, height, body composition, Blood pressureweight, height, body composition, Blood pressurefield and laboratory analysesmalaria test, znpp, full Blood countznpp, Glucose, Blood pressure, full Blood countznpp, Glucose, Blood pressure, full Blood countbiological samples collectedunfasted Blood (4.0\u2009ml edta, 1.2\u2009ml Serum)fasted Blood (4.9\u2009ml edta, 1.2\u2009ml lh, 4.5\u2009ml Serum) and\u2009∼\u20093\u2009ml Urinefasted Blood (4.9\u2009ml edta, 1.2\u2009ml lh, 4.5\u2009ml Serum) and\u2009∼\u20093\u2009ml Urinebiological sample aliquots bankedwhole Blood, Red Blood Cells, Plasma, Serum, dnawhole Blood, Red Blood Cells, Plasma, Serum, dna; Urine (spun, unspun, Acidified)whole Blood, Red Blood Cells, Plasma, Serum, dna, Urine (spun, unspun, Acidified)\nweight in kg to the nearest 10\u2009g; height, Head circumference and mid upper-Arm circumference (muac) to the nearest 0.1\u2009cm; body composition by tanita bc-418 ma analyser; Blood pressure omron 705-cpii; fasting Glucose accu check (roche diagnostics); malaria rapid test (standard diagnostics); Zinc Protoporphyrin (znpp) by haematoflurometer (aviv biomedical); full Blood count by medonic m-series 3-part haematology analyser (boule medical); acidified Urine samples treated with concentrated Hydrogen Chloride; edta, Ethylenediaminetetraacetic Acid; lh, lithium-Heparin.']	N/A	N/A	[('CHEBI_60211', 'compound Z', 133, 'medication'), ('UBERON_0009007', 'superficial inguinal lymph node', 229, 'skinfold'), ('UBERON_0000033', 'head', 249, 'head'), ('UBERON_0001460', 'arm', 279, 'arm'), ('UBERON_0000178', 'blood', 330, 'blood'), ('UBERON_0000178', 'blood', 378, 'blood'), ('UBERON_0000178', 'blood', 446, 'blood'), ('CHEBI_17234', 'glucose', 463, 'glucose'), ('UBERON_0000178', 'blood', 472, 'blood'), ('UBERON_0000178', 'blood', 493, 'blood'), ('CHEBI_17234', 'glucose', 510, 'glucose'), ('UBERON_0000178', 'blood', 519, 'blood'), ('UBERON_0000178', 'blood', 540, 'blood'), ('UBERON_0000178', 'blood', 588, 'blood'), ('UBERON_0001977', 'blood serum', 615, 'serum'), ('UBERON_0000178', 'blood', 628, 'blood'), ('UBERON_0001977', 'blood serum', 666, 'serum'), ('UBERON_0001286', "Bowman's space", 684, 'urineFasted'), ('UBERON_0000178', 'blood', 696, 'blood'), ('UBERON_0001977', 'blood serum', 734, 'serum'), ('UBERON_0002377', 'muscle of neck', 752, 'urineBiological'), ('UBERON_0000178', 'blood', 796, 'blood'), ('CL_0000232', 'erythrocyte', 803, 'red blood cells'), ('UBERON_0000178', 'blood', 807, 'blood'), ('UBERON_0001969', 'blood plasma', 820, 'plasma'), ('UBERON_0001977', 'blood serum', 828, 'serum'), ('UBERON_0000178', 'blood', 844, 'blood'), ('CL_0000232', 'erythrocyte', 851, 'red blood cells'), ('UBERON_0000178', 'blood', 855, 'blood'), ('UBERON_0001969', 'blood plasma', 868, 'plasma'), ('UBERON_0001977', 'blood serum', 876, 'serum'), ('UBERON_0001088', 'urine', 888, 'urine'), ('CHEBI_34520', 'acephate', 909, 'acidified'), ('UBERON_0000178', 'blood', 925, 'blood'), ('CL_0000232', 'erythrocyte', 932, 'red blood cells'), ('UBERON_0000178', 'blood', 936, 'blood'), ('UBERON_0001969', 'blood plasma', 949, 'plasma'), ('UBERON_0001977', 'blood serum', 957, 'serum'), ('UBERON_0001088', 'urine', 969, 'urine'), ('CHEBI_34520', 'acephate', 990, 'acidified'), ('UBERON_0000033', 'head', 1043, 'head'), ('UBERON_0001460', 'arm', 1076, 'arm'), ('UBERON_0000178', 'blood', 1171, 'blood'), ('CHEBI_17234', 'glucose', 1210, 'glucose'), ('CHEBI_33340', 'zinc group element atom', 1293, 'zinc'), ('CHEBI_15430', 'protoporphyrin', 1298, 'protoporphyrin'), ('UBERON_0000178', 'blood', 1365, 'blood'), ('UBERON_0001088', 'urine', 1452, 'urine'), ('CHEBI_17883', 'hydrogen chloride', 1492, 'hydrogen chloride'), ('CHEBI_42191', 'ethylenediaminetetraacetic acid', 1517, 'ethylenediaminetetraacetic acid'), ('CHEBI_28304', 'heparin', 1562, 'heparin')]
PMC5906686	4/2018	S36-PMC5906686	['1a), paralleled to reduced concentrations of Glucose, total Cholesterol, Progesterone (prog) and E2 in the Blood (fig.']	N/A	N/A	[('CHEBI_17234', 'glucose', 45, 'glucose'), ('CHEBI_16113', 'cholesterol', 60, 'cholesterol'), ('CHEBI_17026', 'progesterone', 73, 'progesterone'), ('CHEBI_37983', 'sulfur-35 atom', 97, 'E2'), ('PR_000006300', 'lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrial', 97, 'E2'), ('UBERON_0000178', 'blood', 107, 'blood')]
PMC5906686	4/2018	S48-PMC5906686	['b – e amount of Glucose, total Cholesterol, Prog and E2 in the Blood of 15.5 dpc Pregnant females in control and starved groups.']	N/A	N/A	[('CHEBI_17234', 'glucose', 16, 'glucose'), ('CHEBI_16113', 'cholesterol', 31, 'cholesterol'), ('PR_000013319', 'neurotrypsin', 44, 'PROG'), ('PR_000006300', 'lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrial', 53, 'E2'), ('UBERON_0000178', 'blood', 63, 'blood'), ('GO_0007565', 'female pregnancy', 81, 'pregnant')]
PMC5924963	4/2018	S28-PMC5924963	['chronic Metabolic conditions induce systemic inflammation and alter the microenvironment, resulting in hypertrophic growth, oxidative stress, hypoxia, and altered Lipid Regulation and Glucose Metabolism (26).']	N/A	N/A	[('GO_0008152', 'metabolic process', 8, 'metabolic'), ('CHEBI_18059', 'lipid', 163, 'lipid'), ('GO_0006264', 'mitochondrial DNA replication', 163, 'lipid regulation'), ('CHEBI_17234', 'glucose', 184, 'glucose'), ('GO_0006006', 'glucose metabolic process', 184, 'glucose metabolism')]
PMC5924963	4/2018	S81-PMC5924963	['maternal Insulin response\nintravenous Glucose tolerance tests were performed on Pregnant Adult females during the third Trimester.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 9, 'Insulin'), ('CHEBI_17234', 'glucose', 38, 'glucose'), ('GO_0007565', 'female pregnancy', 80, 'pregnant'), ('UBERON_0007023', 'adult organism', 89, 'adult'), ('GO_0009294', 'DNA mediated transformation', 120, 'trimester')]
PMC5924963	4/2018	S85-PMC5924963	['a 3–8\u2009ml baseline Blood sample was collected just prior to the Glucose infusion, half of which was placed in a Sodium Heparin tube and stored on ice.']	N/A	N/A	[('UBERON_0000178', 'blood', 18, 'blood'), ('CHEBI_17234', 'glucose', 63, 'glucose'), ('CHEBI_28790', 'serotonin', 111, 'sodium heparin')]
PMC5924963	4/2018	S97-PMC5924963	['Insulin area under the curve (iauc) after exogenous Glucose infusion represented an Individual’s Insulin response, with exaggerated iauc indicating Insulin resistance.']	N/A	N/A	[('PR_000045358', 'insulin family protein', 0, 'Insulin'), ('CHEBI_17234', 'glucose', 52, 'glucose'), ('NCBITaxon_1', 'root', 84, 'individual'), ('PR_000045358', 'insulin family protein', 97, 'insulin'), ('PR_000045358', 'insulin family protein', 148, 'insulin')]
PMC5975263	5/2018	S50-PMC5975263	['oral Glucose tolerance test (ogtt) was routinely examined at 24–28 Gestational weeks, and gdm was defined as diabetes that was first diagnosed during Pregnancy, with 3-h 100\xa0g ogtt results exceeding cut-offs for two or more values: fasting Plasma Glucose ≥5.3\xa0mmol/l, 1-h\u2009≥\u200910.0\xa0mmol/ l, 2-h\u2009≥\u20098.6\xa0mmol/ l and 3-h\u2009≥\u20097.8\xa0mmol/ l).']	N/A	N/A	[('CHEBI_17234', 'glucose', 5, 'glucose'), ('GO_0007565', 'female pregnancy', 67, 'gestational'), ('GO_0007565', 'female pregnancy', 150, 'pregnancy'), ('UBERON_0001969', 'blood plasma', 240, 'plasma'), ('CHEBI_17234', 'glucose', 247, 'glucose')]
PMC6022422	6/2018	S74-PMC6022422	['an increase in maternal Blood Glucose leads to a rise in fetal Blood Glucose, which in turn stimulates fetal Pancreatic Islet Cells, resulting in hyperinsulinemia.']	N/A	N/A	[('UBERON_0000178', 'blood', 24, 'blood'), ('CHEBI_17234', 'glucose', 30, 'glucose'), ('UBERON_0000178', 'blood', 63, 'blood'), ('CHEBI_17234', 'glucose', 69, 'glucose'), ('CL_0000083', 'epithelial cell of pancreas', 109, 'pancreatic islet cells'), ('UBERON_0001264', 'pancreas', 109, 'pancreatic')]
PMC6039335	7/2018	S163-PMC6039335	['Acetate or Glucose is used as a substrate for Fa Synthesis [85].']	N/A	N/A	[('CHEBI_30089', 'acetate', 0, 'Acetate'), ('CHEBI_17234', 'glucose', 11, 'glucose'), ('CHEBI_30751', 'formic acid', 46, 'FA'), ('GO_0009398', 'FMN biosynthetic process', 46, 'FA synthesis')]
PMC6039335	7/2018	S165-PMC6039335	['Glucose can also be used as a substrate for Fa de Novo Synthesis in ruminants.']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('CHEBI_30751', 'formic acid', 44, 'FA'), ('GO_0016093', 'polyprenol metabolic process', 50, 'novo synthesis')]
PMC6039335	7/2018	S166-PMC6039335	['Glucose is derived from either Glucose Synthesis via Gluconeogenesis from Propionate/Lactate or Glucose absorbed from the Small Intestinal Digestion of the Rumen bypass [86].']	N/A	N/A	[('CHEBI_17234', 'glucose', 0, 'Glucose'), ('CHEBI_17234', 'glucose', 31, 'glucose'), ('GO_0006094', 'gluconeogenesis', 31, 'glucose synthesis'), ('GO_0006094', 'gluconeogenesis', 53, 'gluconeogenesis'), ('CHEBI_17272', 'propionate', 74, 'propionate'), ('CHEBI_24996', 'lactate', 85, 'lactate'), ('CHEBI_17234', 'glucose', 96, 'glucose'), ('UBERON_0002108', 'small intestine', 122, 'small intestinal'), ('GO_0007586', 'digestion', 139, 'digestion'), ('UBERON_0007365', 'rumen', 156, 'rumen')]
PMC6039335	7/2018	S167-PMC6039335	['atp citrate and nadp Malate dehydrogenase are two key enzymes utilizing Glucose in the Fa De Novo Synthesis pathway.']	N/A	N/A	[('CHEBI_25147', 'mandelate', 21, 'malate'), ('CHEBI_17234', 'glucose', 72, 'glucose'), ('CHEBI_30751', 'formic acid', 87, 'FA'), ('GO_0007631', 'feeding behavior', 87, 'FA'), ('GO_0046091', 'deoxyadenosine biosynthetic process', 90, 'de novo synthesis')]
PMC6039335	7/2018	S172-PMC6039335	['furthermore, imf has a higher Expression of Glucose Transporter 4, which is responsible for Uptake Of Glucose in Adipose Tissues, compared to Subcutaneous Fat (reviewed in [90]).']	N/A	N/A	[('GO_0010467', 'gene expression', 30, 'expression'), ('CHEBI_17234', 'glucose', 44, 'glucose'), ('PR_000015064', 'solute carrier family 2, facilitated glucose transporter member 2', 44, 'glucose transporter 4'), ('GO_0046323', 'glucose import', 92, 'uptake of glucose'), ('CHEBI_17234', 'glucose', 102, 'glucose'), ('UBERON_0001013', 'adipose tissue', 113, 'adipose tissues'), ('UBERON_0002190', 'subcutaneous adipose tissue', 142, 'subcutaneous fat')]
PMC6039335	7/2018	S178-PMC6039335	['in addition to Fas, a Glycerol “backbone”, mainly supplied by Glucose, is needed for Tg Synthesis.']	N/A	N/A	[('CHEBI_33290', 'food', 15, 'FAs'), ('CHEBI_17754', 'glycerol', 22, 'glycerol'), ('CHEBI_17234', 'glucose', 62, 'glucose'), ('GO_0046049', 'UMP metabolic process', 85, 'TG synthesis')]
PMC6039335	7/2018	S213-PMC6039335	['increasing Digestion of Rumen-bypassed Starch in the Small Intestine helps increase the Glucose supply.']	N/A	N/A	[('GO_0007586', 'digestion', 11, 'digestion'), ('UBERON_0007365', 'rumen', 24, 'rumen'), ('CHEBI_28017', 'starch', 39, 'starch'), ('UBERON_0002108', 'small intestine', 53, 'small intestine'), ('CHEBI_17234', 'glucose', 88, 'glucose')]
PMC6039335	7/2018	S286-PMC6039335	['vitamin c\nvitamin C can be synthesized from Glucose in the Liver of many mammalian species other than guinea pigs, Humans, and other Primates [146].']	N/A	N/A	[('PR_000004900', 'complement C3', 18, 'C'), ('CHEBI_17234', 'glucose', 44, 'glucose'), ('UBERON_0002107', 'liver', 59, 'liver'), ('NCBITaxon_9606', 'Homo sapiens', 115, 'humans'), ('NCBITaxon_33208', 'Metazoa', 133, 'primates')]
PMC6056931	7/2018	S119-PMC6056931	['standard procedures are used for a 2-h 75\xa0g oral Glucose tolerance test (ogtt) between 24 and 28\xa0weeks Gestation to determine development of Gestational diabetes mellitus [47].']	N/A	N/A	[('CHEBI_17234', 'glucose', 49, 'glucose'), ('GO_0007565', 'female pregnancy', 103, 'gestation'), ('GO_0007565', 'female pregnancy', 141, 'gestational')]
